{"version":"https://jsonfeed.org/version/1.1","title":"Bay Area Functional Medicine Clinical Library","home_page_url":"https://sanjosefuncmed.com","feed_url":"https://sanjosefuncmed.com/feed.json","description":"Educational articles written by Dr. Richard Esquivel for Bay Area Functional Medicine on functional medicine, digestive health, immune health, thyroid health and related topics.","authors":[{"name":"Dr. Richard Esquivel","url":"https://sanjosefuncmed.com/about/"}],"items":[{"id":"https://sanjosefuncmed.com/requirements-of-a-healthy-immune-system/","url":"https://sanjosefuncmed.com/requirements-of-a-healthy-immune-system/","title":"Requirements of a Healthy Immune System","summary":"A deeper educational discussion of immune development, metabolic health, gut health, nutrition and lifestyle factors.","content_text":"COVID-19 is forcing us to examine our immune health As I stated in the previous article, very rarely are we put into a challenging situation that forces us to examine our immune health. Unless we get diagnosed with an unusual immune disorder, most of us don’t give much thought to our immune system and what it requires to protect us from pathogens we are exposed to on a daily basis. SARS-COV2 (the coronavirus that causes COVID-19) is forcing us to take a closer look at our immune health and whether it is well-suited to defend against this novel coronavirus. Unfortunately, beyond avoiding potential exposures through social distancing, the use of face masks and sanitizer, most of us don’t give much thought to how our immune system is fighting diligently to protect us from constant bacterial and viral threats. But how do we develop a strong immune system and what do we need to do to maintain it? What makes one person’s immune system able to defend against COVID-19 while another’s cannot rise up to the challenge? This article examines the requirements of a strong and effective immune system. The immune system needs to be trained effectively There are certain things that are important to our immune development that have already been predetermined before we have a say in the matter. We all know that breastfeeding is important to impart major protective components to the infant, including secretory IgA (SIgA) antibodies and lactoferrin. We have all heard that the breastfed infant is better protected against numerous common infections than non-breastfed infants (1). And we all know that natural vaginal childbirth allows the fetus to be exposed to beneficial bacteria through the vaginal canal that play an important role in the development of the fetal immune system (2). But did you know that compared with vaginal delivery, CS delivery is associated with increased risks of a multitude of immune disorders later in life , such as asthma, allergies, autoimmune disorders such as type 1 diabetes, celiac disease and inflammatory bowel diseases, immune deficiencies, and childhood cancers such as leukemia and other malignancies (3)? Did you know that our immune system starts developing in utero shortly after our brain and continues developing after birth and is affected by a number of environmental factors both in the womb and after birth? Studies show that environmental insults during pregnancy, such as infection or malnutrition, seem to dramatically impact brain development (4). The Thymus as Boot Camp for the Soldiers of the Immune System Throughout childhood and puberty, the thymus (critical organ of the developing immune system) serves a vital role in the training and development of T-lymphocytes (or T cells), an extremely important type of white blood cell. T cells, part of the adaptive immune system, defend the body from potentially deadly pathogens such as bacteria, viruses, and fungi. The thymus receives immature T cells from the bone marrow and trains them to attack foreign cells and viruses. The T cells that attack foreign cells and viruses appropriately are selected to survive (positive selection) while the T cells that bind to the body’s own antigens leading to autoimmunity are eliminated (negative selection) (5). In this way, the immune system is effectively trained to differentiate foreign antigen (ie: bacteria, viruses, fungi) from self-antigen (the body’s own tissue). The immune system needs to be strong enough to defend against potential threats There are about 1400 species of human pathogens (disease-causing organisms) that have been identified, including various bacteria, mycobacteria, archaea, viruses, fungi, parasites such as protozoans, worms, and prions. Some of these pathogens are responsible for some of the most deadly diseases the world has ever seen, such as the Black Plague, Spanish Flu, malaria, AIDS, tuberculosis, measles, influenza and now the novel SARS-CoV2 coronavirus. The new species of human pathogenic threats that are emerging are primarily viruses and are mostly associated with animal reservoirs (6). A healthy, robust and resilient immune system will be able to cope with most of the pathogenic challenges it will face during its lifetime. However, a weakened or compromised immune system may not be able to defend against many of these challenges it will face. The immune system needs to be smart enough to avoid autoimmunity One common immune disorder we are seeing more and more frequently is autoimmune disease. According to the National Institutes of Health, up to 23.5 million Americans (more than seven percent of the population) suffer from an autoimmune disease —and the prevalence is rising (7). Autoimmunity occurs when the immune system loses the ability to differentiate self-antigen (protein) from foreign antigen (ie: pathogen protein), one of the hallmarks of the healthy immune system, and starts attacking the body. In autoimmunity, the body’s own defense system becomes so dysregulated that it initiates immune (inflammatory) responses against the tissue it is designed to protect. Once this occurs, there is no going back, as the immune system is now primed to continue these attacks indefinitely. The immune system can become overzealous at times and upregulate these attacks on the person’s tissues and organs when internal or external factors trigger these flare-ups and sometimes multiple tissues simultaneously. Not surprisingly, when it comes across a pathogen that poses a threat, it may not be able to defend against it very efficiently because its resources are being spent in other ways. To make matters worse, many of these autoimmune individuals are on medication to suppress their immune system, making them very vulnerable to new pathogens, such as viruses. Importance of Metabolic Health In the last article, we discussed the science showing those with poor metabolic health have a much harder time defending against this virus. Why is that? Because these metabolic disorders are mediated by chronic inflammation which causes dysregulation to the immune system and makes it less efficient at responding to viral threats. One group of researchers on this topic describes the cross-talk between the immune and metabolic systems as “ pivotal in promoting ‘metabolic health’ throughout the life of an organism ” and plays a fundamental role “in its adaptation to ever-changing environmental makeups and nutritional availability” (8). In other words, the constant communication that occurs between the immune and metabolic systems enable the person to to adapt to changes in their diet and environment. These researchers go on to say “perturbations in this intricate immune-metabolic cross-talk contribute to the tendency to develop altered metabolic states that may culminate in metabolic disorders such as malnutrition, obesity, type 2 diabetes mellitus (T2DM), and other features of the metabolic syndrome”. Basically, it is the breakdown of this communication between the immune and metabolic systems that leads to these chronic metabolic diseases. According to these researchers, key regulators of these immune-metabolic interactions include host genetics, nutritional status, and the intestinal microbiome (8). Importance of Gut Health The gut plays many roles in supporting overall immune health and our gut bacteria (microbiome) lie at the center of these functions. First, our microbiome functions to defend against harmful organisms, helps train the gut immune system to identify friend or foe (yes, the gut has its own immune system) and helps degrade toxic compounds. It also is able to digest certain foods that are not digestible by the human GI tract (ie: fiber such as cellulose) and produce compounds (ie: short chain fatty acids) that help the gut immune system react appropriately to antigens (proteins) and help protect against cancers. The gut bacteria also facilitate the absorption of dietary minerals (ie: magnesium, calcium and iron) and synthesize some essential vitamins (ie: vitamin K and folate) and amino acids (the building blocks of proteins). Usually, we coexist ‘peacefully’ with our commensal microflora (mutualism), which has been established through evolution on both sides. The bacteria benefit from the stable habitat, which is rich in energy sources from the food we ingest and the host benefits from these bacteria in these numerous ways described above (9). However, the intestinal flora are affected by several factors, such as diet, climate changes, stress, illness, aging and medications, such as acid-suppressing and antibiotic medications (10). The gut lining also plays a critical role in immune health, acting as a barrier to the body, protecting it from the toxic compounds found in the gut. Toxins in the gut, including endotoxins from gut bacteria, environmental toxins and pathogens, need to be prevented from entering blood circulation. The gut bacteria play an important role in supporting this barrier function by binding to epithelial cells and inhibiting pathogen binding, enhancing barrier function (11). Any compromise to this gut barrier allows toxins into circulation causing immune disruption and increased workload on the organs of toxification, particularly the liver. Intestinal permeability or ‘leaky gut’ is a very common cause of inflammation in the body and can result from many different types of scenarios, including poor diet, chronic stress, poor sleep, hormone imbalances, blood sugar imbalances and medications. This is probably the most common condition that I see in the clinic that causes major inflammation in the body and is likely the predominant breakdown that leads to autoimmunity , according to the most recent research (12, 13). For more on this topic, you can read this article . Diet and Nutrition Nutrition is a critical part of the immune response and malnutrition is the most common cause of compromised immune health worldwide (14). Undernutrition is well understood to impair immune function and the extent of impairment that results will depend upon the severity of the deficiency, the presence of infection and the person’s age (15). The cells and organs of your immune system, like any other cells and organs of the body, require a variety of macro and micronutrients to function optimally, including a broad range of amino acids, vitamins, minerals, antioxidants and nutrients that support antioxidant enzymes, white blood cells and various immune responses. All antibodies (immunoglobulins), which are critical in cell-mediated immunity, are made of proteins, as is the complement system, secretory IgA and cytokines (inflammatory mediators). Micronutrients such as zinc, selenium, iron, copper, vitamins A, C, D, E, and B vitamins have important influences on immune responses. Some of the key micronutrients for immune function are discussed below in Immune Supporting Nutrients and Herbs. What you put into your mouth eventually is digested into nutrients that either serve a useful purpose in immune health (ie: source of fuel for immune reactions, provide direct or indirect support to immune pathways or immune mediator proteins, or protect the body against toxins and oxidative stress) or cause damage to the body leading to inflammation (ie: toxins, advanced glycated end-products or AGEs, reactive oxygen species, etc.). Remember, inflammation is your body’s response to any tissue damage, toxicity or pathogenic entry. Another way to look at any given food is it either promotes inflammatory or anti-inflammatory responses. The foods that have the latter effect are the foods that are recommended in the anti-inflammatory diets used in the naturopathic and functional medicine circles. These tend to be whole, high-fiber diets, high in fruit, vegetables, plant-based proteins, fish, legumes, nuts, and seeds and healthy fats. Meats can also be part of an anti-inflammatory diet if they are grass-fed and free of hormones and antibiotics. The Mediterranean diet and Paleo diet are examples of these. While some people can handle grains, others can’t and this can be a source of inflammation in these people, particularly in the autoimmune population. Chronic inflammation, as you recall, leads to immune dysregulation and sets you up for failure against viral challenges that require a healthy, robust response from the immune system. Adequate Sleep and Rest Sleep has long been known to play a critical role in immune health. Sleep affects various aspects of immune function and is associated with reduced risk of infection, and has been demonstrated to improve recovery from infections and vaccination responses (16). Prolonged sleep deficiency (ie: short sleep duration, sleep disturbance) can lead to chronic, systemic low-grade inflammation and is associated with diabetes, atherosclerosis, and neurodegeneration, which are all driven by inflammation (17). In a recent study, scientists demonstrated that quality sleep bolsters the function of T cells in your body that fight off viral infection. Good sleep does this by enhancing the ability of T cells to adhere to and destroy cells infected by viruses and other pathogens (18). The sleep-wake cycle and the 24-hour circadian rhythm of adrenal hormones such as cortisol also exerts a strong regulatory influence on immune function. Just like adrenal hormones have a circadian rhythm, recent research demonstrates our immune system also has a circadian rhythm. Certain white blood cells (ie: naïve T cells) and inflammatory cytokines peak during early sleeping hours while others (ie: cytotoxic NK cells) and anti-inflammatory cytokines peak during the day (19). Sleep also appears to play another role in improving the formation of immunological memory T helper cells and antibody production, allowing your immune system to defend more efficiently against future infection (20). Stress Management Ever since the pioneering research performed by Hans Selye in the 1930’s, we have known that chronic stress has profound impacts on the immune system. Chronic stress is now well-known to suppress immune function and increase susceptibility to infections and cancer while acute stress is known to exacerbate asthma, and allergic, autoimmune and inflammatory diseases, most likely by causing immune dysregulation (21). Chronic or long-term stress can suppress immune function by decreasing immune cell count and function and increasing immunosuppressive mechanisms (22). Chronic stressors are associated with decreased cytotoxic T-cell and natural killer (NK) cell activity which are critical in fighting viral infection (23). Chronic stress can also dysregulate immune function by promoting proinflammatory and Th-2 cytokine-driven responses (24). Numerous studies have shown the benefits of relaxation and stress management techniques such as guided imagery , mindfulness meditation , breathing exercises and tai-chi in improving immune health. Social connections have been associated with a strong immune system. Even positive emotions such as happiness can have positive effects on immune health (25-29). Avoidance of Toxins We are living in a world that has changed dramatically just within our lifetimes. We are now exposed to countless chemicals, hybridized foods, genetically-modified foods, all of which are very immune-activating. There are now more than 84,000 different chemicals used in making products such as food, clothes, furniture, electronics and toys that we are potentially exposed to on a daily basis and about 1,500 new chemicals are introduced each year (30). Environmental chemicals are linked with various cancers, obesity, diabetes, heart disease, brain degeneration, neurological disorders and almost every known health issue, largely due to immune dysregulation and the chronic inflammation that develops (31). These links can be difficult to identify and the published data difficult for the average person to understand. Unless there is an acute exposure, exposure to chemical pollutants usually occurs gradually over a long period of time and effects tend to be cumulative in the body. This contributes to what is known as the individual’s ‘toxic burden’, which we pay close attention to in functional medicine. However, environmental toxins are not the only toxins we are exposed to unfortunately. There are also toxins generated endogenously (from within our bodies) that are produced by an imbalanced microbiome, such as lipopolysaccharides (endotoxins) that can enter circulation in conditions of intestinal permeability (leaky gut) and wreak havoc on our immune health. In addition to bacterial overgrowths, yeast or fungal overgrowth or other hidden infections can produce endotoxins which can also wreak havoc on our immune systems. Additionally, excess production of hormones (or decreased capacity to metabolize and clear these hormones by our detoxifying organs) can also lead to inflammation and immune dysregulation and decrease our capacity to clear other toxins. Therefore, in order to have a healthy immune system, we must be active in avoiding unnecessary environmental toxins on a daily basis, support gut health, prevent and treat any pathogenic overgrowths or infection, maintain hormonal balance and support hepatic (liver) detoxification. Immune-Supporting Nutrients and Herbs The immune system, like any other system in the body, requires a wide variety of vitamins, minerals and other nutrients to function optimally. Based on available studies, Vitamin A, vitamin C, vitamin D, N-acetylcysteine or glutathione, zinc, selenium, and essential fatty acids appear to be some of the most important nutrients to maintain immune health and fight viral infection (32). In addition, there are a number of herbs such as licorice root, echinacea, astragalus, elderberry, olive leaf, oregano oil and berberine that have been shown to have antiviral effects by either preventing viral binding to cells, blocking viral replication or having direct antiviral effects. In addition, many herbs have been shown to improve immune responses against viruses, by exhibiting antioxidant or anti-inflammatory effects or promoting cell function in other ways. Here is a list of those nutrients and herbs and the key roles they play to defend against viral infection. Vitamin A Efficacy against a wide-range of bacterial and viral infections (33, 34) Essential for normal immune function, growth, development and maintenance of epithelial cells (GI tract) Subclinical deficiency results in increased susceptibility to common infectious disease (WHO) Vitamin C Potent antiviral agent (35, 36, 37) Important antioxidant and immune stimulant Shortens duration and severity of symptoms of the flu and common cold (38, 39) Breaks down histamine and so has anti-histamine function IV vitamin C used to successfully treat COVID-19 patients in China (40) Vitamin D Enhances vitamin A function (41) Improves gut barrier function (42) Enhances both specific and non-specific innate immunity in a wide range of viral infections including HIV, HPV, hepatitis (43-46) Reduces systemic inflammation, neuroinflammation Improves mitochondrial function and muscle strength Zinc Reduces severity and duration of common cold symptoms (47) Inhibits viral replication by blocking RNA polymerase activity Reduces mortality for a wide range of infectious diseases Provides antioxidant benefits Important for gut barrier function Selenium Functions to reduce viral replication and viral mutation (48) Provides anti-inflammatory and antioxidant effects Increases glutathione (GSH) levels N-Acetyl-Cysteine (NAC) Direct and indirect antioxidant (49) Increases production of glutathione (GSH) Supports phase II conjugation and protects the liver Anti-inflammatory and inhibits replication of influenza A (50) Improves cell-mediated immunity (51) Mucolytic Disrupts biofilms Glutathione (GSH) Critical intracellular antioxidant Regulates both innate and adaptive immune responses Regulates NK cell activity Helps balance Th1 and Th2 activity Colloidal Silver Shown to be effective against a wide variety of viruses, including HIV, HBV, HSV, RSV and monkey pox virus (52) Shown to reduce and prevent infection from HSV and the parainfluenza type 3 virus (53) Significantly protected cells from H3N2 flu infection and prevented viral growth in the lungs Shown to inhibit flu virus’ binding capacity to a cell’s membrane Licorice Root (Glycyrrhiza glabra) Used to treat respiratory tract infections for thousands of years in China (54) Shows activity against a wide variety of RNA and DNA viruses Used intravenously to treat chronic hepatitis B and C infections Directly inhibits replication of SARS-associated coronavirus and inhibits binding and penetration of the virus (55, 56) 2003 Lancet article recommended assessing for treatment of SARS (57) Astragalus (Astragalus membranaceus) Used to treat respiratory infections for thousands of years in China Found to inhibit influenza proliferation Exhibits antiviral properties against infectious bronchitis caused by avian (bird) coronavirus and avian influenza (58, 59) Exhibits anti-inflammatory and antioxidant effects (60, 61) Elderberry (Sambucus nigra) Shortens the length of influenza infection by 4 days (62) Effective in vitro against 10 different influenza strains (63) Inhibits the flu virus’s entry and replication in human cells Inhibits coronavirus activity at the point of infection (64) Can inhibit viral uptake and viral budding (preventing infection) (65) Echinacea (Echinacea purpurea) Has multiple immune-modulatory and broad antiviral effects (66, 67) Prevents influenza A, avian flu, and swine flu and has activity against herpes simplex 1 and 2 in vitro Kills HIV-1 Shows antiviral activity to several strains of influenza viruses, herpes simplex virus, respiratory syncytial virus, and rhinoviruses (68, 69) Modifies the clinical course of flu-like respiratory infection (70) Shown to decrease frequency of common cold Olive Leaf (Olea europaea) Inhibits numerous viruses in vitro , including parainfluenza, herpes, pseudorabies, and some forms of polio Shown to have antiviral effects against enveloped viruses Inhibits replication of HIV (71) Inhibits viral assembly at the cell membrane, stopping viral shedding (72) Six antiviral agents in olives identified to be effective against parainfluenza (73) Oregano Oil (Origanum vulgare) Shown to have broad-range antibacterial and antiviral effects (74, 75) Shown partial efficacy against respiratory syncytial virus, coxsackie virus B3, and HSV1 (76) Effective against acute otitis media caused by H. influenzae (77) Inhibits virus’ ability to translate proteins for viral binding to cells Berberine Decreases production of inflammatory cytokines such as TNF-alpha and IL-6 (78) Reduces inflammation through inhibition of various inflammatory pathways (79) Acts as a protease inhibitor for HIV (80) Reduces viral replication of respiratory syncytial virus (RSV) and reduces IL-6 mRNA (81) Key Takeaways to Promote a Healthy Immune System Optimize metabolic health and exercise regularly Optimize gut health, including intestinal barrier function and gut flora balance Adopt a plant-based diet rich in fruits and vegetables and fish and seafood, avoiding processed meat and all processed foods Ensure adequate sleep and exercise Manage stress with stress-reduction activities (breathing, meditation, etc.) Avoid environmental toxins, cigarettes and heavy metals (including dental amalgams) Optimize intake of immune-support nutrients (vitamins A, C, E, zinc, selenium, NAC, etc.) Consider antiviral herbs for prevention or management of viral infection (consult with herbalist for best results) References https://www.ncbi.nlm.nih.gov/pubmed/12727640 https://www.sciencedaily.com/releases/2018/11/181130094328.htm https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5599043/ https://www.hindawi.com/journals/np/2016/3597209/ https://www.innerbody.com/image_endoov/lymp04-new.html https://www.tandfonline.com/doi/full/10.1080/10408410701647560 https://www.niaid.nih.gov/sites/default/files/adccfinal.pdf https://www.sciencedirect.com/science/article/pii/S1550413117300967 https://www.nature.com/articles/nri1373?cacheBust=1508280662071 https://www.ncbi.nlm.nih.gov/pubmed/22366773 https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2036.2008.03750.x https://www.ncbi.nlm.nih.gov/pubmed/16265432 https://www.ncbi.nlm.nih.gov/pubmed/19538307 https://www.ncbi.nlm.nih.gov/pubmed/9250133 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6723551/ https://journals.physiology.org/doi/full/10.1152/physrev.00010.2018 https://journals.physiology.org/doi/full/10.1152/physrev.00010.2018 https://rupress.org/jem/article/216/3/517/120367/G-s-coupled-receptor-signaling-and-sleep-regulate https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3256323/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3256323/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2790771/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2790771/ https://www.sciencedirect.com/science/article/abs/pii/S1470204504015979 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2790771/ https://www.karger.com/Article/Abstract/288872 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4940234/ https://journals.sagepub.com/doi/abs/10.4278/ajhp.081013-LIT-248 https://www.nature.com/articles/nn.3086 https://www.sciencedirect.com/science/article/abs/pii/S1568997206000279 https://pubmed.ncbi.nlm.nih.gov/23027564/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356139/ https://www.ncbi.nlm.nih.gov/pubmed/11781377 https://www.ncbi.nlm.nih.gov/pubmed/11375434 https://jlb.onlinelibrary.wiley.com/doi/10.1189/jlb.71.1.16 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7110025/ https://www.ncbi.nlm.nih.gov/pubmed/9306475 https://www.ncbi.nlm.nih.gov/pubmed/23700397 https://www.ncbi.nlm.nih.gov/pubmed/7814237 https://www.ncbi.nlm.nih.gov/pubmed/10543583 https://clinicaltrials.gov/ct2/show/NCT04264533 https://jlb.onlinelibrary.wiley.com/doi/10.1189/jlb.71.1.16 https://www.ncbi.nlm.nih.gov/pubmed/22647055 https://news.harvard.edu/gazette/story/2017/02/study-confirms-vitamin-d-protects-against-cold-and-flu/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3166406/ https://doi-org.uws.idm.oclc.org/10.1016/j.gene.2018.08.017 https://doi-org.uws.idm.oclc.org/10.1016/j.jcv.2010.12.006 https://jlb.onlinelibrary.wiley.com/doi/10.1189/jlb.71.1.16 https://jlb.onlinelibrary.wiley.com/doi/10.1189/jlb.71.1.16 https://jlb.onlinelibrary.wiley.com/doi/10.1189/jlb.71.1.16 https://www.ncbi.nlm.nih.gov/pubmed/19732754 https://www.ncbi.nlm.nih.gov/pubmed/9230243 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6264685/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3826769/ https://www.researchgate.net/publica https://onlinelibrary.wiley.com/doi/10.1002/jmv.25707 tion/261442961_Prevention_and_treatment_of_viral_respiratory_infections_by_traditional_Chinese_herbs https://www.ncbi.nlm.nih.gov/pubmed/15715493 https://www.ncbi.nlm.nih.gov/pubmed/15885816 https://www.nature.com/articles/news030609-16 https://www.ncbi.nlm.nih.gov/pubmed/29170045 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3729712/ https://www.ncbi.nlm.nih.gov/pubmed/30586589 https://www.ncbi.nlm.nih.gov/pubmed/32057253 https://www.ncbi.nlm.nih.gov/pubmed/15080016 https://www.ncbi.nlm.nih.gov/pubmed/9395631 https://www.ncbi.nlm.nih.gov/pubmed/31560964 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5610768/ https://www.ncbi.nlm.nih.gov/pubmed/26009695 https://www.ncbi.nlm.nih.gov/pubmed/22131823 https://www.ncbi.nlm.nih.gov/pubmed/22131823 https://www.reliasmedia.com/articles/11276-echinacea-for-upper-respiratory-viral-infections-preparatory-differences-matter https://www.reliasmedia.com/articles/11276-echinacea-for-upper-respiratory-viral-infections-preparatory-differences-matter https://www.ncbi.nlm.nih.gov/pubmed/12878215 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2790717/ https://www.ncbi.nlm.nih.gov/pubmed/11724241 https://www.ncbi.nlm.nih.gov/pubmed/29744941 https://www.ncbi.nlm.nih.gov/pubmed/24779581 https://www.sciencedirect.com/science/article/abs/pii/S0308814613018438 https://www.ncbi.nlm.nih.gov/pubmed/15871121 https://www.ncbi.nlm.nih.gov/pubmed/20161729 https://www.ncbi.nlm.nih.gov/pubmed/30306659 https://www.ncbi.nlm.nih.gov/pubmed/20161729 https://www.ncbi.nlm.nih.gov/pubmed/25939536","date_published":"2020-05-19T21:29:05","date_modified":"2020-05-22T00:33:57","authors":[{"name":"Dr. Richard Esquivel","url":"https://sanjosefuncmed.com/about/"}],"tags":["Immune Health"]},{"id":"https://sanjosefuncmed.com/irritable-bowel-syndrome-ibs/","url":"https://sanjosefuncmed.com/irritable-bowel-syndrome-ibs/","title":"Irritable Bowel Syndrome: A Deeper Review","summary":"An in-depth review of irritable bowel syndrome, digestive function and the wider gut-brain context.","content_text":"Irritable Bowel Syndrome (IBS) Irritable bowel syndrome (IBS) affects as many as 5%-20% of individuals worldwide and has a significant impact on quality of life. IBS symptoms range from diarrhea to constipation, or a combination of the two, with abdominal pain or discomfort and gas or bloating, referred to as “abdominal distension”. The degree of symptoms varies in different patients from tolerable to severe, and the time pattern and discomfort varies immensely from patient to patient. Some patients complain of daily symptoms, while others report intermittent symptoms at intervals of weeks or months. [360,361] There are no biomarkers used in the diagnosis of IBS so diagnosis is based on assessment of symptoms.[362,363] IBS is divided into subtypes, depending on symptoms such as diarrhea-predominant IBS (IBS-D), constipation-predominant IBS (IBS-C) and mixed diarrhea and constipation-predominant IBS (IBS-M).[364,365] IBS is not known to be associated with the development of serious disease or with excess mortality. However, IBS causes a reduced quality of life with the same degree of impairment as major chronic diseases.[366,367] The annual costs in the United States, both direct and indirect, for the management of patients with IBS are estimated at $15-30 billion.[368,369] What Causes IBS? The pathogenesis of IBS seems to be multifactorial, with the following factors most likely playing a central role in the pathogenesis of IBS: genetics, diet, gut flora, low-grade inflammation, and disturbances in the neuroendocrine system (NES) of the gut, which includes the enteric nervous system (ENS).[360,361] One hypothesis published recently in a worldwide gastroenterology journal proposes that the cause of IBS is an altered NES of the gut, which accounts for abnormal GI motility, secretions and sensations.[360] All of these abnormalities are characteristic of IBS. The researchers propose that alterations in the NES could be the result of one or more of the following causative factors of IBS: genetic factors, diet, intestinal flora, or low-grade inflammation.[360] Let’s take a look at each of factors that are believed to contribute to the development of IBS. Heritability and Genetics Genetics appear to play a role in IBS. Up to 33% of patients with IBS had a family history of IBS compared to 2% of the controls in one study.[370] In another study of a family cluster, a significant association was reported between having a first degree family member with bowel symptoms and presenting with IBS. In contrast, those who reported having a spouse with bowel symptoms were no more likely to have IBS symptoms than the general population.[371] It was also shown that the prevalence of IBS was 17% in the relatives of patients compared to 7% in the relatives of spouses.[372] Another study showed that patients with IBS were more likely to present a family history of IBS than controls (33.9% and 12.6%, respectively).[373] Does Diet Play a Role? Most patients with IBS believe that their diet has a significant influence on their symptoms and they are interested in finding out which foods they should avoid.[374-377] There is some evidence supporting dietary influence on IBS symptoms. In one study, about 60% of IBS patients reported a worsening of symptoms following specific food ingestion: 28% within 15 min after eating and 93% within 3 hrs.[377] Many IBS patients report specific foods as triggers, most commonly implicating dairy and wheat products, but other foods as well such as onion, peas and beans, hot spices, cabbage, certain meats, smoked products, fried food and caffeine.[378] The reaction of IBS patients to certain food items has been attributed to a number of short-chain carbohydrates called FODMAPs that are poorly digested and absorbed so that a significant portion of the ingested carbohydrates do not get digested properly and enter the small intestine and colon. Once there, these unabsorbed carbohydrates provide a substrate for bacterial fermentation with the production of gas and distension of the intestinal tract and an increase in intra-abdominal pressure (IAP). This leads to abdominal discomfort or pain. [360] Sound familiar? This is the same mechanism described earlier that lead to GERD and as we will see, also occurs in small intestinal bacterial overgrowth (SIBO). The FODMAPs Diet FODMAPs include fructose, lactose, fructans, galactans and sugar alcohols, such as sorbitol, maltitol, mannitol, xylitol and ismalt. The FODMAPs diet consists of excluding all these foods from the diet. Fructose and lactose are present in apples, pears, watermelon, honey, fruit juices, dried fruits, milk and dairy products. Polyols are used in low calorie food products. Galactans and fructans are present in common dietary food, such as wheat, rye, garlic, onions, legumes, cabbage, artichokes, leeks, asparagus, lentils, inulin, soy, brussel sprouts and broccoli.[379] Fiber A deficiency in dietary fiber was once widely believed to be the primary cause of IBS.[380] Although increasing the amount of dietary fiber continues to be a standard recommendation for patients with IBS, clinical practice has shown that increased fiber intake in these patients increases abdominal pain, bloating and distension.[380] In one study, IBS patients assigned to fiber treatment showed persistent symptoms or no improvement in symptoms after treatment compared to patients taking the placebo or a low-fiber diet but these patients were using common bran types of fiber.[380] It is noteworthy that the role of FODMAPs and fiber on IBS symptoms is associated with the intestinal flora. The presence of gut bacteria that break down FODMAPs and fiber and produce gas, such as Clostridia spp ., can cause distension of the small and large intestine with abdominal discomfort or pain and lead to small intestinal bacterial overgrowth (SIBO).[381,382] IBS and Intestinal Flora Most bacteria in the GI tract exist in the colon. The colon of each individual contains between 300 and 500 different species of bacteria, and each person has his own unique intestinal flora.[360] The intestinal flora is affected by several factors, such as diet, climate changes, stress, illness, aging and medications, such as acid-suppressing medication and antibiotic treatment.[383] The intestinal flora in IBS patients has been found to differ considerably from that of healthy controls, as IBS patients have fewer Lactobacillus and Bifidobacterium spp . than healthy subjects.[384] These bacteria bind to epithelial cells and inhibit pathogen binding as well as enhancing barrier functioning.[385] Furthermore, these bacterial species do not produce gas upon fermenting carbohydrates, which is an effect that would be amplified as they also inhibit the Clostridia spp .[385] Probiotics have been shown to decrease colonic fermentation and stabilize the colonic microbiota, and several studies on probiotics have shown improvements in flatulence and abdominal distension, with a reduction in the composite IBS symptom score.[385-387] A recent systematic review with meta-analysis published in a worldwide gastroenterology journal examined the efficacy of probiotics in the treatment of IBS. A total of 1,793 patients were included in the meta-analysis. Distension, bloating, and flatulence were evaluated using an IBS severity scoring system in three trials (two studies) to compare the effect of probiotic therapy in IBS patients with placebo. The review concluded the following: “Probiotics reduce pain and symptom severity scores. The results demonstrate the beneficial effects of probiotics in IBS patients in comparison with placebo.”[388] IBS and Low-Grade Inflammation Low-grade systemic inflammation appears to play a role in the development of IBS. In a subset of IBS patients, GI symptoms appear following gastroenteritis, with about 25% of patients showing diarrhea-predominant IBS (IBS-D) symptoms 6 months post- infection and approximately 10% developing persistent symptoms.[389-392] Post- infectious (PI)-IBS has been reported after viral, bacterial, protozoa and nematode infections[383], with the incidence of PI-IBS varying between 7% and 31%.[389-392] One study showed that 6% to 17% of sporadic IBS patients believed that their symptoms began with an infection.[383] Following infection, the initial inflammatory response shows an increase in certain types of lymphocytes (white blood cells) and macrophages.[389] These changes rapidly decrease in most subjects but a small number of patients with persistent symptoms continue to have signs of infection.[393] There are several pieces of evidence showing that inflammation and immune cells affect the neuroendocrine system (NES) of the gut, which controls and regulates GI motility and sensitivity. [394] There is also evidence of IBS patients having increased intestinal permeability and gut barrier issues than in the non-IBS population.[395-396] For a more in-depth perspective on the neuroendocrine system (NES) of the gut and the brain-gut axis and how abnormalities of the NES and the brain-gut axis may contribute to IBS, click on: The Neuroendocrine System of the Gut and the Brain-Gut Axis Is SIBO the Culprit? Some researchers now believe that irritable bowel syndrome (IBS) may be caused by bacterial overgrowth in the small intestine (SIBO).[487] An article was published in JAMA in 2004 proposing that small intestinal bacterial overgrowth (SIBO) might explain the symptoms of altered gut motility, visceral hypersensitivity, abnormal brain-gut interaction and immune activation seen in IBS.[487] This is supported by multiple lines of evidence. First, SIBO is found in up to 78%-84% of IBS patients undergoing lactulose breath testing indicating bacterial overgrowth.[488,489] Second, the distribution of inflammatory mediators and/or inflammatory cells have been shown to be disturbed in a percentage of patients with IBS.[490] It is thought that SIBO may contribute to many of the clinical manifestations of IBS through bacterial fermentation and stimulation of a gut immune response, characterized by release of inflammatory mediators (such as interleukins and tumour necrosis factor-α) which may affect motility, secretion and sensation.[487,491] Additionally, postinfectious IBS, which occurs in 4%-31% of patients after an episode of acute gastroenteritis[492], also supports a causative role of bacteria in IBS.[493] Conventional Treatment of IBS “A wide range of medications (prokinetics, antispasmodics, sedatives, tranquilizers, laxatives, fecal bulking agents, probiotics and antibiotics) along with lifestyle and diet modifications have been proposed for this highly prevalent condition; however to date there is no definite effective cure for this state.”[494] Conventional treatment options for IBS include pharmacological drugs aimed at symptomatic relief of the primary symptoms involved in IBS, namely pain, diarrhea and constipation.[494] In addition, antibiotic drugs such as rifaximin are recently being used to treat IBS due to evidence of bacterial overgrowth in this condition.[495] Treatment for abdominal pain include antispasmodics, which encompass several different drug classes (smooth-muscle relaxants, antimuscarinics, anticholinergics) and other agents (pinaverium, trimebutine). The anticholinergic properties of these agents restrict their usefulness in clinical practice.[494] Other drugs used for abdominal pain include opioid receptor agonists (exogenous opioids), GLP-1 (glucagon-like peptide 1) and membrane stabilizers (ketotifen). Membrane stabilizers act by blocking mast cell degranulation.[496] The number of mucosal mast cells has been studied and found positively correlated to abdominal pain.[497] Treatment for diarrhea-predominant IBS (IBS-D) include anti-diarrheals (loperamide), 5-HT3 antagonists or serotonin-blockers (alosetron, cilansetron, ramosetron), anti-inflammatory drugs (mesalamine) and antibiotic drugs (rifaximin). The potential use of antibiotics in IBS treatment has been supported by a growing body of evidence showing the important role that intestinal bacterial overgrowth plays in the development of IBS. Various lines of evidence suggest that small intestinal bacterial overgrowth (SIBO) may lead to many of the symptoms seen in IBS, such as altered gut motility, visceral hypersensitivity, abnormal brain-gut interaction and immune activation seen in IBS.[494,498] The American Task Force systematic review of IBS treatments concludes that rifaximin has shown improvement of global IBS symptoms and bloating in trials included in their analysis.[499] Treatment for constipation-predominant IBS (IBS-C) include laxative-based treatments (osmotic agents, and stool softeners), prokinetics (drugs to stimulate movement of bowels), prosecretory agents (drugs that augment intestinal secretion, thus acting as a stool lubricant and facilitating its evacuation, such as lubiprostone and linaclotide), serotonin-boosting drugs (serotonin receptor modulators and 5-HT4 agonists such as tegaserod) and bile acid modulators (CDC and elobixibat). Bile acid modulators have been used to treat constipation disorders based on the observation of increased incidence of diarrhea in patients taking bile acids for gallstones or cholestatic liver diseases.[500] However, these drugs have limited effects in their use due to their symptomatic approach and risk of various side effects. “Pharmacologic treatments for IBS-C have largely been unsatisfactory, mainly due to the multifaceted and poorly understood pathophysiology of this disorder.”[501] “The multifactorial pathogenesis of the disease and the ill-defined drug targets make the goal of manufacturing a “universal drug” for IBS-C a hard one to attain.”[500] Evidence of the long-term benefit of pharmacological treatment has been sparse, and new drugs that have proven to be effective have raised issues concerning safety.[502,503] These agents have limited usefulness as most of them are directed toward the symptoms of IBS, rather than the underlying causes of this condition, with the possible exception of antibiotic therapy. Alternative therapies, such as cognitive behavioral therapy and gut-directed hypnotherapy, have been used with good results.[504] A more efficient approach would be to address the underlying factors that appear to be related to the development of IBS, such as excess carbohydrate consumption, food sensitivities, insufficient HCl and pancreatic enzyme production, balanced intestinal flora, low-grade intestinal inflammation and the brain-gut axis. This is exactly how we approach IBS in the functional medicine model. Clinical Management of IBS in Functional Medicine Clinical management of IBS in the functional medicine model starts with a thorough evaluation of the gut. This may include a comprehensive stool analysis in addition to a stool microbiology assay, assessing for dysbiosis and ruling out pathogenic bacterial, fungal or parasitic infection. A comprehensive stool analysis can provide a great deal of information about gut function including markers of protein and fat digestion, pancreatic function, and production of short-chain fatty acids such as butyric acid which are important for colon health. A stool analysis can also assess for inflammatory gut conditions such as inflammatory bowel disease (ie: ulcerative colitis and Crohn’s disease) without undergoing intestinal biopsy and rule out GI bleeding. Assessment of related gut conditions, such as intestinal permeability and small intestinal bacterial overgrowth should be considered in conditions involving gas and bloating. Routine blood chemistry is usually done to assess inflammatory markers and assess other organ function that impact the gut such as thyroid function. Food sensitivity testing and nutritional analysis to assess for nutrient deficiencies should be considered as well. Management of IBS can vary greatly from person to person depending on the findings of the stool analysis as well as other conditions that may impact stomach and GI health such as intestinal permeability and food sensitivity. Treatment goals in the functional medicine model are to eliminate pathogenic infection, restore balance to the gut flora, and restore normal function of the stomach and GI tract (normal secretion of HCl and pancreatic enzymes, normal digestion of food and normal motility/movement of the intestines). This can normally be attained through the use of herbal anti-microbial compounds, probiotics and digestive enzyme therapy. Assessment of related organ function (particularly the thyroid, immune system, liver and brain) should be conducted to assess for imbalances in these organ systems as well . Most IBS patients suffer from some degree of dysbiosis, so the use of probiotics and prebiotics are often employed to restore gut flora balance. Several specific bacterial probiotic strains have been shown to improve symptom severity and abdominal pain in IBS patients in numerous studies.[462,466-479] There are some species that in clinical trials appear to be more effective than others, such as Bifidobacterium species ( B. infantis 3564 and B. bifidum MIMBb75) [470,474,476] and Lactobacillus species ( Lactobacillus acidophilus -SDC 2012, 2013, L. paracasei B2106, L. plantarum 299V, and L. rhamnosus GG).[469,473,475] These probiotics appear to be effective in reducing abdominal pain and discomfort in adults and in children. Several studies have also suggested that combinations of different probiotic strains, such as VSL3# or mixtures of Bifidobacterium and Lactobacillus species, are able to decrease abdominal pain and discomfort in patients with IBS.[466,478,479] Addressing low-grade inflammation and intestinal permeability through gut-restorative and anti-inflammatory botanicals as well as dietary intervention is also important in IBS. There are a wide variety of compounds shown to repair the damaged intestinal lining, improve gut barrier integrity and decrease low-grade inflammation in the GI tract as described in the Intestinal Permeability section above . [288-351] Dietary compounds can induce immune responses in the GI tract and contribute to low-grade inflammation, particularly in gut permeability issues, therefore food sensitivity testing can be of value in IBS patients. This involves assessing for levels of IgA and IgG antibodies to various foods in the blood through a lab that offers specialized food sensitivity testing. Elimination of these foods from the diet is important when trying to repair a leaky gut or improve IBS symptoms. Lastly, assessing for small intestinal bacterial overgrowth (SIBO) and implementing a specific-carbohydrate diet (SCD) and/or low FODMAP diet in these cases is also important to reduce bacterial fermentation causing gas, bloating, abdominal discomfort and improve bowel regularity. We will learn more about the assessment of SIBO and how this condition is managed in the next section. Related Articles Hypochlorhydria (Low Stomach Acid) Gastritis Gastroesophageal Reflux Disease (GERD) Intestinal Permeability/Leaky Gut NSAID-Induced Enteropathy Small Intestinal Bacterial Overgrowth The Neuroendocrine System of the Gut and the Brain-Gut Axis References 360. El-Salhy M, Gundersen D, Gilja OH, Hatlebakk JG, Hausken T. Is irritable bowel syndrome an organic disorder? World J Gastroenterol . 2014 Jan 14;20(2):384-400. doi: 10.3748/wjg.v20. i2.384. Review. 361. Magdy El-Salhy. Irritable bowel syndrome: Diagnosis and pathogenesis . World J Gastroenterol. 2012 October 7; 18(37): 5151–5163. Published online 2012 October 7. doi: 10.3748/wjg.v18.i37.5151 362. Barbara G, Stanghellini V. Biomarkers in IBS: when will they replace symptoms for diagnosis and management? Gut . 2009;58:1571–1575. [ PubMed ] 363. Spiller RC. Potential biomarkers . Gastroenterol Clin North Am . 2011;40:121–139. [ PubMed ] 364. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology . 2006;130:1480–1491. [ PubMed ] 365. Spiller R, Aziz Q, Creed F, Emmanuel A, Houghton L, Hungin P, Jones R, Kumar D, Rubin G, Trudgill N, et al. Guidelines on the irritable bowel syndrome: mechanisms and practical management . Gut . 2007;56:1770–1798. [ PMC free article ] [ PubMed ] 366. Whitehead WE, Burnett CK, Cook EW, Taub E. Impact of irritable bowel syndrome on quality of life. Dig Dis Sci. 1996;41:2248–2253. [ PubMed ] 367. Gralnek IM, Hays RD, Kilbourne A, Naliboff B, Mayer EA. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology . 2000;119:654–660. [ PubMed ] 368. Hungin AP, Whorwell PJ, Tack J, Mearin F. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Aliment Pharmacol Ther. 2003;17:643–650. [ PubMed ] 369. Sandler RS, Everhart JE, Donowitz M, Adams E, Cronin K, Goodman C, Gemmen E, Shah S, Avdic A, Rubin R. The burden of selected digestive diseases in the United States. Gastroenterology . 2002;122:1500–1511. [ PubMed ] 370. Whorwell PJ, McCallum M, Creed FH, Roberts CT. Non-colonic features of irritable bowel syndrome. Gut . 1986;27:37–40. [ PMC free article ] [ PubMed ] 371. Locke GR, Zinsmeister AR, Talley NJ, Fett SL, Melton LJ. Familial association in adults with functional gastrointestinal disorders. Mayo Clin Proc . 2000;75:907–912. [ PubMed ] 372. Kalantar JS, Locke GR, Zinsmeister AR, Beighley CM, Talley NJ. Familial aggregation of irritable bowel syndrome: a prospective study. Gut . 2003;52:1703–1707. [ PMC free article ] [ PubMed ] 373. Kanazawa M, Endo Y, Whitehead WE, Kano M, Hongo M, Fukudo S. Patients and nonconsulters with irritable bowel syndrome reporting a parental history of bowel problems have more impaired psychological distress. Dig Dis Sci . 2004;49:1046–1053. [ PubMed ] 374. Heizer WD, Southern S, McGovern S. The role of diet in symptoms of irritable bowel syndrome in adults: a narrative review. J Am Diet Assoc . 2009;109:1204–1214. [ PubMed ] 375. Morcos A, Dinan T, Quigley EM. Irritable bowel syndrome: role of food in pathogenesis and management. J Dig Dis . 2009;10:237–246. [ PubMed ] 376. Austin GL, Dalton CB, Hu Y, Morris CB, Hankins J, Weinland SR, Westman EC, Yancy WS, Drossman DA. A very low-carbohydrate diet improves symptoms and quality of life in diarrhea-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol . 2009;7:706–708.e1. [ PMC free article ] [ PubMed ] 377. Simrén M, Månsson A, Langkilde AM, Svedlund J, Abrahamsson H, Bengtsson U, Björnsson ES. Food-related gastrointestinal symptoms in the irritable bowel syndrome. Digestion . 2001;63:108–115.[ PubMed ] 378. Nanda R, James R, Smith H, Dudley CR, Jewell DP. Food intolerance and the irritable bowel syndrome. Gut . 1989;30:1099–1104. [ PMC free article ] [ PubMed ] 379. Austin GL, Dalton CB, Hu Y, Morris CB, Hankins J, Weinland SR, Westman EC, Yancy WS, Drossman DA. A very low-carbohydrate diet improves symptoms and quality of life in diarrhea-predominant irritable bowel syndrome . Clin Gastroenterol Hepatol . 2009;7:706–708.e1. [ PMC free article ] [ PubMed ] 380. Ford AC, Talley NJ, Spiegel BM, Foxx-Orenstein AE, Schiller L, Quigley EM, Moayyedi P. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis . BMJ . 2008;337:a2313. [ PMC free article ] [ PubMed ] 381. Andrew C. Dukowicz, Brian E. Lacy, Gary M. Levine. Small intestinal bacterial overgrowth: a comprehensive review . Gastroenterology Hepatol (NY). 2007 Feb;3(2):112-122. 382. Amit H. Sachdev, Mark Pimentel. Gastrointestinal bacterial overgrowth : pathogenesis and clinical significance . Ther Adv Chronic Dis . 2013. September; 4(5):223–231. doi:10.1177/ 2040622313496126 383. El-Salhy M, Gundersen D, Hatlebakk JG, Hausken T. Irritable bowel syndrome. New York: Nova scientific Publisher ; 2012. 384. Kassinen A, Krogius-Kurikka L, Mäkivuokko H, Rinttilä T, Paulin L, Corander J, Malinen E, Apajalahti J, Palva A. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology . 2007;133:24–33. [ PubMed ] 385. Spiller R. Review article: probiotics and prebiotics in irritable bowel syndrome. Aliment Pharmacol Ther . 2008;28:385–396. [ PubMed ] 386. Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol. 2009; 104:1033–1049; quiz 1050.[ PubMed ] 387. Levy RL, Linde JA, Feld KA, Crowell MD, Jeffery RW. The association of gastrointestinal symptoms with weight, diet, and exercise in weight-loss program participants . Clin Gastroenterol Hepatol . 2005;3:992–996. [ PubMed ] 388. Didari T, Mozaffari S, Nikfar S, Abdollahi M. Effectiveness of probiotics in irritable bowel syndrome : Updated systematic review with meta-analysis. World J Gastroenterol. 2015 Mar 14;21(10):3072-84. doi: 10.3748/wjg.v21.i10.3072. 389. Spiller RC. Role of infection in irritable bowel syndrome. J Gastroenterol . 2007;42 Suppl 17:41–47.[ PubMed ] 390. Spiller R, Garsed K. Infection, inflammation, and the irritable bowel syndrome . Dig Liver Dis. 2009;41:844–849. [ PubMed ] 391. Spiller R, Garsed K. Postinfectious irritable bowel syndrome . Gastroenterology . 2009; 136:1979–1988.[ PubMed ] 392. Neal KR, Hebden J, Spiller R. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. BMJ . 1997;314:779–782. [ PMC free article ] [ PubMed ] 393. Spiller RC, Jenkins D, Thornley JP, Hebden JM, Wright T, Skinner M, Neal KR. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permea-bility following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut . 2000;47: 804–811.[ PMC free article ] [ PubMed ] 394. Spiller R. Serotonin, inflammation, and IBS: fitting the jigsaw together? J Pediatr Gastroenterol Nutr . 2007;45 Suppl 2:S115–S119. [ PubMed ] 395. Rao AS, Camilleri M, Eckert DJ, et al. Urine sugars for in vivo gut permeability: validation and comparisons in irritable bowel syndrome-diarrhea and controls . Am J Physiol. 2011 Aug 11; [Epub ahead of print] [ PMC free article ] [ PubMed ] 396. Shulman RJ, Eakin MN, Czyzewski DI, et al. Increased gastrointestinal permeability and gut inflammation in children with functional abdominal pain and irritable bowel syndrome . J Pediatr . 2008;153:646–50. [ PMC free article ] [ PubMed ] 487. Lin HC. Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. JAMA . 2004;292:852–858. [ PubMed ] 488. Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol . 2000;95:3503–3506. [ PubMed ] 489. Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2003;98:412–419. [ PubMed ] 490. O’Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, O’Sullivan GC, Kiely B, Collins JK, Shanahan F, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology. 2005;128:541–551. [ PubMed ] 491. Frissora CL, Cash BD. Review article: the role of antibiotics vs. conventional pharmacotherapy in treating symptoms of irritable bowel syndrome. Aliment Pharmacol Ther. 2007;25:1271–1281. [ PubMed ] 492. Connor BA. Sequelae of traveler’s diarrhea: focus on postinfectious irritable bowel syndrome. Clin Infect Dis. 2005;41 Suppl 8:S577–S586. [ PubMed ] 493. Lazaraki G, Chatzimavroudis G, Katsinelos P. Recent advances in pharmacological treatment of irritable bowel syndrome. World J Gastroenterol . 2014 Jul 21;20(27):8867-85. doi: 10.3748/wjg.v20.i27.8867. Review. 494. Lazaraki G, Chatzimavroudis G, Katsinelos P. Recent advances in pharmacological treatment of irritable bowel syndrome. World J Gastroenterol. 2014 Jul 21;20(27):8867-85. doi: 10.3748/wjg.v20.i27.8867. Review. 495. Laterza L, Ianiro G, Scoleri I, et al. Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome. Expert Opin Pharmacother . 2015 Mar;16(4):607-15. doi: 10.1517/14656566.2015.1007951. Epub 2015 Feb 1. 496. Klooker TK, Braak B, Koopman KE, et al. The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut . 2010;59:1213–1221. [ PubMed ] 497. Barbara G, Stanghellini V, De Giorgio R, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology. 2004;126:693–702. [ PubMed ] 498. Lin HC. Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. JAMA. 2004;292:852–858. [ PubMed ] 499. Brandt LJ, Chey WD, Foxx-Orenstein AE, et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol . 2009;104 Suppl 1:S1–S35. [ PubMed ] 500. Iser JH, Sali A. Chenodeoxycholic acid: a review of its pharmacological properties and therapeutic use. Drugs. 1981;21:90–119. [ PubMed ] 501. Jadallah KA, Kullab SM, Sanders DS. Constipation-predominant irritable bowel syndrome: a review of current and emerging drug therapies. World J Gastroenterol. 2014 Jul 21;20(27):8898-909. doi: 10.3748/wjg.v20.i27.8898. Review . 502. Pasricha PJ. Desperately seeking serotonin&#8230; A commentary on the withdrawal of tegaserod and the state of drug development for functional and motility disorders. Gastroenterology. 2007;132:2287–2290.[ PubMed ] 503. Wald A, Rakel D. Behavioral and complementary approaches for the treatment of irritable bowel syndrome. Nutr Clin Pract. 2008;23:284–292. [ PubMed ] 504. Schmulson MJ, Ortiz-Garrido OM, Hinojosa C, Arcila D. A single session of reassurance can acutely improve the self-perception of impairment in patients with IBS. J Psychosom Res. 2006;61:461–467.[ PubMed ]","date_published":"2015-09-23T05:27:36","date_modified":"2024-01-29T12:28:35","authors":[{"name":"Dr. Richard Esquivel","url":"https://sanjosefuncmed.com/about/"}],"tags":["Digestive Health"]},{"id":"https://sanjosefuncmed.com/nsaid-induced-enteropathy/","url":"https://sanjosefuncmed.com/nsaid-induced-enteropathy/","title":"NSAID-Induced Enteropathy","summary":"A deeper look at how NSAID exposure can affect the gastrointestinal tract and why medication history matters in persistent digestive symptoms.","content_text":"NSAID-Induced Enteropathy NSAID-induced enteropathy refers to intestinal damage that occurs from the use of non-steroidal anti-inflammatory drugs (NSAIDs). Examples of NSAIDs include ibuprofen (Advil®, Motrin®), naproxen (Aleve®, Naprosyn), Celebrex® and aspirin. The use of NSAIDs, including aspirin, is common in the treatment of pain, inflammation, and fever. Additionally, low-dose aspirin is used routinely in the prevention of heart attack and stroke. These drugs, both through prescription and over-the-counter (OTC) use, are the most widely used class of medications in the United States.[352] Not surprisingly, NSAID use increases among the elderly. In a survey of people 65 years of age and older, 70% used NSAIDs at least once weekly, and 34% used them at least daily! The prevalence of at least weekly aspirin usage was 60%![353] More than 111 million NSAID prescriptions were written in 2004.[354] Much of this usage comes from pain conditions, such as arthritis and related musculoskeletal complaints. In 1990, the estimated prevalence of self-reported arthritis in the U.S. was 37.9 million cases, or 15% of the population! By 2020, it is projected that 59.4 million will be affected—a 57% increase from 1990![355] As the incidence of arthritis complaints increases, the use of prescription and OTC NSAIDs is also expected to increase.[356] However, the use of NSAIDs does not come without risks. The most common risk of NSAID use is damage to the stomach ( gastropathy ) and intestinal lining ( enteropathy ). Iron-deficient anemia is a common first sign of NSAID-enteropathy (due to internal bleeding), and serious complications can include massive bleeding, perforation and strictures, sometimes leading to death.[357] “The prevalence and clinical significance of NSAID-enteropathy continues to be greatly under-recognized. NSAID-induced enteropathy and bleeding occur more frequently than NSAID induced gastropathy. Significant small intestinal damage and bleeding can be observed in about 70% of chronic NSAID users, and in the majority of patients the injury is sub-clinical.”[357] Wow! Significant damage to the small damage occurs in 70% of chronic NSAID users! This information should be more widely publicized! These medications should be clearly labeled and doctors should be warning their patients about the risks associated with these drugs with every prescription. On top of that, in most cases the injury is subclinical (meaning it does not cause any symptoms or signs )! If the injury is subclinical, it can’t be very serious, right? Unfortunately, that’s not the case. “…even minor and subclinical injury to the intestinal mucosa can result in significant, though delayed, metabolic consequences, which may seriously affect the health of an individual.” [358] “With improvements in the detection of NSAID-induced damage in the small intestine, it is now clear that this injury and the associated bleeding occurs more frequently than that occurring in the stomach and duodenum, and can also be regarded as more dangerous.”[357] It is common practice in primary care and pain management to prescribe acid-suppressing medications (PPIs such as omeprazole) together with NSAIDs in order to protect the intestinal tract and reduce risk of GI adverse effects. However, recent research indicates that this can worsen the damage to the GI tract. “Moreover, recent studies suggest that commonly used drugs for protecting the upper gastrointestinal tract ( i.e ., proton pump inhibitors) can significantly worsen NSAID-induced damage in the small intestine.”[357] “The frequent use of PPIs can exacerbate NSAID-induced small intestinal injury by altering intestinal microbiota. Thus, the use of PPI is considered to be an independent risk factor associated with NSAID-associated enteropathy.”[358] Mechanism of Injury of NSAIDs to Gut Lining How do NSAIDs cause damage to the gut? Let’s take a more in-depth look at how NSAIDs injure the gut lining. This may be a bit technical for some readers but others will find this informative. NSAIDs cause topical injury to the mucosal lining of the GI tract and systemic effects (throughout the body) by inhibiting the COX enzymes resulting in prostaglandin depletion . COX (cyclooxygenase) is an enzyme that is responsible for the production of prostaglandins and thromboxane. Prostaglandins are lipid compounds that have a wide range of hormone-like effects in the body. Tissue prostaglandins are produced via two distinct enzyme-dependent pathways: a COX-1 and a COX-2 pathway. The COX-1 pathway is the predominant constitutive (replenishing) pathway ; prostaglandins derived from this enzyme mediate many effects, most notably aiding in gastroduodenal protection, renal perfusion, and platelet activity . The COX-2 pathway, in contrast, is inducible by inflammatory stimuli and primarily mediates effects through prostaglandins which result in inflammation, pain, and fever . NSAIDs work by blocking these two important enzymes throughout the body. Inhibition of the COX-1 pathway blocks production of prostaglandins that play an important protective role in the stomach by increasing mucosal blood flow, stimulating the synthesis and secretion of mucus critical for the mucosal lining, and promoting proliferation of the epithelial lining. Secretion of mucus and epithelial proliferation are critical aspects to gut health in order to prevent intestinal permeability or leaky gut! The inhibition of these prostaglandins by NSAIDs impairs these protective factors, resulting in a gastric lining that is more susceptible to acid, pepsin, and bile salts and more permeable to toxic intestinal compounds (affect intestinal permeability). A major consequence of prostaglandin depletion is to create an environment that is conducive to peptic ulcer formation, bleeding and serious GI complications. Since prostaglandins are essential to both the maintenance of intact GI defenses and normal platelet function, NSAIDs, including aspirin, promote ulcer formation as well as bleeding.[356] This is why NSAIDs are also considered a major risk factor for intestinal permeability. Selective COX-2 Inhibitors What about the newer class of NSAIDs, known as the selective COX-2 inhibitors or “coxibs”, such as Celebrex®? Aren’t they safer for the gut than the other NSAIDS? In the 1990’s, a tremendous amount of research was focused on understanding the physiology and pharmacology of these two distinct COX enzymes, largely fueled by the interest of several large pharmaceutical companies in the notion that selective inhibitors of COX-2 would provide all of the anti-inflammatory activities of NSAIDs without the major adverse effects on the GI lining.[357] “However, as the science of COX-2 caught up with the marketing of COX-2, it became evident that the delineation of functions of the two COX enzymes was not so clear-cut as had been proposed and heavily promoted. COX-1 contributes significantly to inflammation while COX-2 contributes significantly to many physiological functions, including mucosal defense.”[357] So we now know that these selective COX-2 inhibitor medications, which were touted as safe for the stomach and GI tract by the pharmaceutical companies, are not safe for the gut either. Conventional Management of NSAID-Induced Enteropathy There is no known drug treatment for NSAID-induced enteropathy, other than the withdrawal of use of NSAIDs. Some doctors may still recommend the use of PPIs in these cases, however, as we have seen, recent literature has shown that the use of PPIs increases intestinal damage, rather than alleviates it. “Moreover, recent studies suggest that commonly used drugs for protecting the upper gastrointestinal tract ( i.e ., proton pump inhibitors) can significantly worsen NSAID-induced damage in the small intestine.”[357] Clinical Management of NSAID-Induced Enteropathy in Functional Medicine As we have seen from the previous section on natural compounds used in the treatment of intestinal permeability, various plant compounds, vitamins and minerals have been shown in the literature to have a restorative effect on a damaged intestinal lining.[288-351] Many of the compounds that are used to treat intestinal permeability or gastric and duodenal ulcers are also used to in the treatment for NSAID-induced enteropathy. The reason for this is because these compounds have a restorative effect on the mucosal epithelial lining of the GI tract. In other words, they help the GI tract regenerate healthy epithelial cells which make up the GI lining. As you may have noticed, in addition to NSAID-induced enteropathy, NSAIDs are a risk factor for both gastric and duodenal ulcers and intestinal permeability. This is because NSAIDs cause damage to the epithelial lining that lead to all of these conditions which are closely related. They are all mediated by damage to this epithelial lining. In fact, one of the methods used to study the effects of drug or plant compounds on a damaged gastric or intestinal mucosal lining is to give rats high-dose NSAIDs to induce this mucosal damage.[293-295,299] In addition to these plant compounds used for the treatment of damage to the gastric and intestinal lining, the omega-3 polyunsaturated fatty acids (n-3 PUFAs) found in fish oils (EPA and DHA) have been found to have a significant protective effect on the GI lining against NSAID-induced GI damage.[359] In fact, a large gastroenterology medical journal just recently published an article claiming that, due to the protective effects of these fatty acids, the next generation of NSAIDs will include these omega-3 fatty acids in the drug. “Because n-3 PUFAs have been proven to attenuate cytotoxicity, inhibit lipid-raft-associated harmful signaling, and relieve oxidative stress relevant to NSAIDs, n-3 PUFA based NSAIDs will be next-generation GI-safe NSAIDs.”[359] Related Articles Hypochlorhydria (Low Stomach Acid) Gastritis Gastroesophageal Reflux Disease (GERD) Intestinal Permeability/Leaky Gut Irritable Bowel Syndrome (IBS) Small Intestinal Bacterial Overgrowth The Neuroendocrine System of the Gut and the Brain-Gut Axis References 352. Abraham N.S., El-Serag H.B., Johnson M.L.; National adherence to evidence-based guidelines for the prescription of nonsteroidal anti-inflammatory drugs . Gastroenterology . 129 2005:1171-1178. 353. Talley N.J., Evans J.M., Fleming K.C., Harmsen W.S., Zinsmeister A.R., Melton L.J. III; Nonsteroidal antiinflammatory drugs and dyspepsia in the elderly. Dig Dis Sci. 40 1995:1345-1350. 354. Shaheen N.J., Hansen R.A., Morgan D.R.; The burden of gastrointestinal and liver diseases, 2006 . Am J Gastroenterol . 101 2006:2128-2138. 355. Lawrence R.C., Helmick C.G., Arnett F.C.; Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum . 41 1998:778-799. 356. Deepak L. Bhatt, et al. ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents . J Am Coll Cardiol . 2008;52(18):1502-1517. doi:10.1016/j.jacc.2008.08.002 357. John L Wallace. Mechanisms, prevention and clinical implications of nonsteroidal anti-inflammatory drug-enteropathy . World J Gastroenterol . 2013 March 28; 19(12): 1861–1876. Published online 2013 March 28. doi: 10.3748/wjg.v19.i12.1861 358. Marlicz W 1 , Loniewski I 2 , Grimes DS 3 , Quigley EM 4 . Nonsteroidal anti-inflammatory drugs, proton pump inhibitors, and gastrointestinal injury: contrasting interactions in the stomach and small intestine. Mayo Clin Proc. 2014 Dec;89(12):1699-709. doi: 10.1016/j.mayocp.2014.07.015. Epub 2014 Oct 29. 359. Park JM 1 , Han YM , Jeong M , Kim EH , Ko WJ , Cho JY , Hahm KB . Omega-3 polyunsaturated fatty acids as an angelus custos to rescue patients from NSAID-induced gastroduodenal damage. J Gastroenterol . 2015 Jan 13. [Epub ahead of print]","date_published":"2015-09-21T04:40:02","date_modified":"2024-01-29T12:27:16","authors":[{"name":"Dr. Richard Esquivel","url":"https://sanjosefuncmed.com/about/"}],"tags":["Digestive Health"]},{"id":"https://sanjosefuncmed.com/hypochlorhydria-low-stomach-acid/","url":"https://sanjosefuncmed.com/hypochlorhydria-low-stomach-acid/","title":"Hypochlorhydria (Low Stomach Acid)","summary":"A deeper educational review of gastric acid, protein digestion and symptoms sometimes associated with reduced stomach-acid production.","content_text":"Hypochlorhydria As described in the section Functions of GI System , the stomach receives the food from the esophagus where it meets with stomach enzymes which aid in protein digestion before emptying into the duodenum. The stomach acid sanitizes the bolus that enters the stomach and forms chyme . When the chyme enters the small intestine, it is highly acidic, until it mixes with the bile in the duodenum which makes the chyme more alkaline. The primary stomach enzymes used in protein digestion are hydrochloric acid (HCl) and pepsin. A healthy stomach secretes 2-3 liters of gastric juice per day! But this is not the case with many people in today’s modern world. Many people suffer from a problem of hyposecretion of these gastric enzymes (a common condition called hypochlorhydria ). This is especially common in the elderly.[86] This can lead to incomplete protein digestion which can result in a host of health problems, including symptoms such as gas, bloating, burping after meals, difficulty swallowing pills and almost any type of digestive difficulty. As we will see later on this page, it is the primary cause of acid reflux and heartburn as well. Symptoms of Hypochlorhydria: Gas Bloating Burping after meals Acid reflux or heartburn Difficulty swallowing pills Nausea after taking supplements Prolonged fullness after eating Undigested food in stool Hypochlorhydria has been associated with many abnormal stomach conditions, including acute and chronic gastritis, autoimmune gastritis, GERD, peptic ulcer disease and gastric cancer. How is this possible? Let’s start by looking at the various functions of hydrochloric acid in the stomach. Then we will take a closer look at the mechanisms involved in each of these common stomach conditions. The Functions of Hydrochloric Acid Hydrochloric acid (HCl) functions in a variety of ways in the human body. Why is it that the use of acid-suppressing medications, such as PPIs, is associated with such a wide range of side effects, such as increased risk of vitamin and mineral deficiencies, increased food allergies, GI bacterial infection and osteoporosis-related bone fractures?[87-89] This is directly related to the functions of hydrochloric acid in the stomach. Hydrochloric acid has three very important functions in the stomach: Protein digestion (the breakdown of proteins into peptides and amino acids) Protection against bacterial infection (ie: H. pylori ) Absorption of nutrients (some nutrients require sufficient HCl for proper absorption) Protein Digestion Most protein digestion takes place in the stomach in the presence of hydrochloric acid and pepsin. As discussed above, proteins are broken down into peptides and amino acids prior to absorption. The body needs a large pool of peptides and amino acids in order to build important tissue, such as muscle and bone and signaling agents such as hormones and neurotransmitters for the brain. If the substrates of these products are not available, they cannot be synthesized in adequate amounts. It’s really that simple. Medications that suppress acid production have been associated with increased food allergies, presumably by decreasing gastric protein digestion and increasing sensitization. “By increasing the gastric pH, they (acid-suppressing medications) interfere substantially with the digestive function of the stomach, leading to persistence of labile food protein during gastric transit. Indeed, both murine and human studies reveal that antiulcer medication increases the risk of food allergy induction. Thus anti-ulcer agents impeding gastric protein digestion have a major effect on the sensitization and effector phase of food allergy.”[90] Protein digestion is particularly important in the elderly who are at higher risk of sarcopenia (loss of muscle mass). “It is known that the amino acids, including branched chain amino acids (BCAAs), are necessary for the maintenance of muscle health in the elderly. Food intake stimulates muscle protein synthesis, resulting in a positive protein balance.”[91] “Increasing protein intake in elderly and especially in frail elderly (higher than the recommended 0.8g/kg body weight per day) can minimize the sarcopenic process. Higher protein intake is associated with a significant decrease in lean mass in the elderly.”[92] Protection Against Pathogenic Infection “Gastric acid plays an important part in the prevention of bacterial colonization of the gastrointestinal tract.”[93] Adequate stomach acid is important not only for digestion but equally important in protecting against pathogenic organisms entering the stomach, small intestines and blood circulation.[94] The high acidity of the stomach due to hydrochloric acid inhibits the growth of potentially pathogenic bacteria and prevents them from inoculating the gastrointestinal tract, such as Helicobacter pylori . In other words, high stomach acidity acts as a barrier against pathogenic organisms and prevents them from inhabiting the stomach and small intestine. This barrier function of the stomach is referred to as the “gastric acid barrier” in the literature. “The presence of profuse bacterial flora, including coliforms, found in markedly acid-deficient but not in normal stomachs, correlates well with the absence of bactericidal activity. Thus, the ‘gastric bactericidal barrier’ is primarily p H-hydrochloric acid dependent, with other constituents of gastric juice contributing little, if any, detectable effect on the destruction of microorganisms.”[94] Low stomach acid (a condition called hypochlorhydria ) is associated with increased levels of H. pylori infection, an increase in small intestinal pH (decreased acidity), and small intestinal bacterial overgrowth.[95] One study showed that 82% of patients with acute gastritis and hypochlorydria had H. pylori infection within 12 months of diagnosis vs. only 29% in a control group.[96] The quantity of bacteria in the stomach has been shown to increase when acid secretion is inhibited by acid-suppressing medication, such as PPIs, the standard treatment for GERD.[97] In addition, low stomach acid predisposes the person to infection with a broad range of organisms. “Reduction of gastric acid secretion predisposes to infection with a variety of organisms including those responsible for typhoid and non-typhoid salmonellosis, bacillary dysentery, cholera, brucellosis, giardiasis and strongyloidiasis. In addition, there are isolated reports to suggest that Clostridium difficile infection leading to pseudomembranous colitis, and infection with the fish tapeworm Diphyllobothrium latum are more likely in association with hypochlorhydria.”[97] Nutrient Absorption Another important function of gastric acid is to enhance nutrient absorption. Hypochlorhydria has been associated with decreased absorption of various vitamins and minerals including calcium, and increased risk of osteoporosis.[98] Low stomach acid secretion, which is common in gastric bypass surgeries, also leads to poor digestion and hence poor absorption of vitamin B12 into the body. “Our observations implicate an inadequate release (maldigestion) of dietary vitamin B12 as the cause for the malabsorption in these patients, confirming the requirement for acid/peptic-mediated liberation of dietary vitamin B12 for subsequent absorption.”[99] There is abundant evidence in the literature linking long-term use of proton-pump inhibitors (PPIs) and decreased nutrient absorption. In addition to calcium and vitamin B12 absorption, there is concern over the absorption of other important minerals such as iron and magnesium as well.[100] We will take a closer look at these risks of PPIs commonly used in the treatment of GERD and acid reflux in a later section. Causes of Hypochlorhydria What leads to this condition of low stomach acid we have been discussing in so much detail? There are a number of causes and risk factors of this condition, including H. pylori infection, chronic stress and use of acid-suppressing medications. Increasing age is another risk factor. Let’s look at how each of these factors contributes to hypochlorhydria. Helicobacter Pylori “H. pylori infection is a major cause of hypochlorhydria and has a major role in the progression from gastritis to atrophy and finally to gastric cancer. H. pylori and the associated changes in the stomach alter the ecological niche inhabited by the gastric microbiota.”[101] H. pylori is a bacteria that can infect the stomach causing gastritis (inflammation of stomach lining) and hypochlorhydria . This happens due to the bacteria inducing a strong inflammatory response in the gastric lining and significantly inhibiting acid secretion by the parietal cells of the stomach.[102] Chronic H. pylori infection is considered the main cause of peptic ulcers and can progress to atrophic gastritis, dysplasia (a precancerous condition) and then to stomach cancer.[103] H. pylori infection has also been associated with autoimmune gastritis.[104] H. pylori infection is extremely common and affects approximately 50% of the world’s population.[105] However, only 15% of those infected with H. pylori develop disease, and pathogenesis depends upon strain virulence, host genetic susceptibility, and environmental cofactors.[106] Additionally, hypochlorhydria predisposes to H. pylori infection, therefore hypochlorhydria and chronic H. pylori infections can become a vicious cycle. It is not uncommon for people to have recurrent H. pylori infections after being treated with antibiotics while their hypochlorhydria condition is never addressed. Acid-Suppressing Medication Hypochlorydria can result from short or long-term use of PPI medications as these medications have powerful acid-suppressing effects. “PPIs are associated with several adverse events mechanistically linked to hypochlorhydria. Emerging data illustrate the potential risks associated with both short-and long-term PPI therapy, including Clostridium difficile –associated diarrhea, community-acquired pneumonia, osteoporotic fracture, vitamin B12 deficiency, and inhibition of antiplatelet therapy.”[107] Researchers now believe that these medications are being over-prescribed in various medical settings and putting many patients at increased risk of various side-effects. “The effectiveness of PPIs has led to overutilization in multiple treatment arenas, exposing patients to an increasing number of potential risks.”[108] Chronic Stress Chronic psychological stress has significant impacts on the physiology of the gut and has been linked to alterations in gastrointestinal motility, changes in gastrointestinal secretion, increase in intestinal permeability, negative effects on regenerative capacity of gastro-intestinal mucosa and mucosal blood flow and negative effects on intestinal bacteria.[109,110] Treatment of Hypochlorhydria in Functional Medicine As you can see, having low levels of stomach acid can put you at risk of having a wide range of health problems, such as various pathogenic GI infections, including H. pylori, a number of nutrient absorption problems, (such as vitamin B12, calcium, iron and magnesium) and increased risk of osteoporosis and bone fractures. As we will see in a later section, it is also associated with a condition known as intestinal permeability or “leaky gut” . Fortunately, it is a condition that is easily managed by supplementing with stomach enzymes, such as betaine HCl and pepsin, which help to increase gastric acidity. This is an extremely common problem with a simple solution that is often overlooked in conventional medicine. Betaine HCl supplementation has also been shown to normalize stomach acidity in patients on long-term PPI therapy and improve absorption of other medications without any noticeable side-effects.[111] “Maintaining adequate gastric pH ensures a sufficient sterilizing barrier against enteric pathogens, allows for proper absorption of micronutrients, preserves normal intestinal permeability and prevents hypergastrinemia… therefore, maintaining adequate gastric pH might be a preventive measure. Supplemental HCl has been shown to reduce (acidify) gastric pH in subjects with simulated hypochlorhydria.”[112] Related Articles Gastritis Gastroesophageal Reflux Disease (GERD) Intestinal Permeability/Leaky Gut NSAID-Induced Enteropathy Irritable Bowel Syndrome (IBS) Small Intestinal Bacterial Overgrowth The Neuroendocrine System of the Gut and the Brain-Gut Axis References 86. E Husebye, V Skar, T Høverstad, K Melby. Fasting hypochlorhydria with gram positive gastric flora is highly prevalent in healthy old people. Gut . 1992 October; 33(10): 1331–1337. 87. Tetsuhide Ito, Robert T. Jensen. Association of Long-term Proton Pump Inhibitor Therapy with Bone Fractures and effects on Absorption of Calcium, Vitamin B12, Iron, and Magnesium . Curr Gastroenterol Rep . Author manuscript; available in PMC 2011 December 1. Published in final edited form as: Curr Gastroenterol Rep. 2010 December; 12(6): 448–457. doi: 10.1007/s11894-010-0141-0 88. Laura E. Targownik, Lisa M. Lix, et al. Use of proton pump inhibitors and risk of osteoporosis-related fractures . CMAJ . 2008 August 12; 179(4): 319–326. doi: 10.1503/cmaj.071330 89. Joel J. Heidelbaugh, Kathleen L. Goldberg, John M. Inadomi. Adverse Risks Associated With Proton Pump Inhibitors: A Systematic Review . Gastroenterol Hepatol. (N Y) 2009 October; 5(10): 725–734. 90. Eva Untersmayr, Erika Jensen-Jarolim. The role of protein digestibility and antacids on food allergy outcomes . J Allergy Clin Immunol. Author manuscript; available in PMC 2010 December 9. Published in final edited form as: J Allergy Clin Immunol. 2008 June; 121(6): 1301–1310. doi: 10.1016/j.jaci.2008.04.025 91. Mariangela Rondanelli, Milena Faliva, et al. Novel Insights on Nutrient Management of Sarcopenia in Elderly . Biomed Res Int. 2015; 2015: 524948. Published online 2015 January 29. doi: 10.1155/2015/524948 92. Y. Rolland, S. Czerwinski, et al. Sarcopenia: Its Assessment, Etiology , Pathogenesis , Consequences And Future Perspectives . J Nutr Health Aging . Author manuscript; available in PMC 2014 April 16. Published in final edited form as: J Nutr Health Aging. 2008 Aug-Sep; 12(7): 433–450. 93. Yoshihisa Urita, Toshiyasu Watanabe, et al. Extensive Atrophic Gastritis Increases Intraduodenal Hydrogen Gas . Gastroenterol Res Pract . 2008; 2008: 584929. Published online 2008 June 16. doi: 10.1155/2008/584929 94. R. A. Giannella, S. A. Broitman, N. Zamcheck. Gastric acid barrier to ingested microorganisms in man: studies in vivo and in vitro . Gut . 1972 April; 13(4): 251–256. 95. Kassarjian Z, Russell RM. Hypochlorhydria: a factor in nutrition . Annu Rev Nutr. 1989;9:271-285. 96. W Harford, C Barnett, E Lee, G Perez-Perez, M Blaser, W Peterson. Acute gastritis with hypochlorhydria: report of 35 cases with long term follow up . Gut . 2000 October; 47(4): 467–472. doi: 10.1136/gut.47.4.467 97. C W Howden, R H Hunt. Relationship between gastric secretion and infection. Gut . 1987 January; 28(1): 96–107. 98. Sipponen P, Härkönen M. Hypochlorhydric stomach: a risk condition for calcium malabsorption and osteoporosis? Scand J Gastroenterol . 2010;45(2):133-8. doi: 10.3109/00365520903434117. Review. 99. C D Smith, S B Herkes, K E Behrns, V F Fairbanks, K A Kelly, M G Sarr. Gastric acid secretion and vitamin B12 absorption after vertical Roux-en-Y gastric bypass for morbid obesity. Ann Surg . 1993 July; 218(1): 91–96. 100. Tetsuhide Ito, Robert T. Jensen. Association of Long-term Proton Pump Inhibitor Therapy with Bone Fractures and effects on Absorption of Calcium, Vitamin B12, Iron, and Magnesium . Curr Gastroenterol Rep. Author manuscript; available in PMC 2011 December 1. Published in final edited form as: Curr Gastroenterol Rep. 2010 December; 12(6): 448–457. doi: 10.1007/s11894-010-0141-0 101. Alexander Sheh, James G Fox. The role of the gastrointestinal microbiome in Helicobacter pylori pathogenesis . Gut Microbes . 2013 November 1; 4(6): 505–531. Published online 2013 August 19. doi: 10.4161/gmic.26205 102. Arindam Saha, Charles E Hammond, Craig Beeson, Richard M Peek, Jr, Adam J Smolka. Helicobacter pylori represses proton pump expression and inhibits acid secretion in human gastric mucosa . Gut . Author manuscript; available in PMC 2010 November 14. 103. Smolka AJ, Backert S. How Helicobacter pylori infection controls gastric acid secretion. J Gastroenterol . 2012 Jun;47(6):609-18. doi: 10.1007/s00535-012-0592-1. Epub 2012 May 8. Review. 104. Lea Irene Veijola, Aino Mirjam Oksanen, Pentti Ilmari Sipponen, Hilpi Iris Kaarina Rautelin. Association of autoimmune type atrophic corpus gastritis with Helicobacter pylori infection . World J Gastroenterol . 2010 January 7; 16(1): 83–88. Published online 2010 January 7. doi: 10.3748/wjg.v16.i1.83 105. Traci L Testerman, James Morris. Beyond the stomach: An updated view of Helicobacter pylori pathogenesis, diagnosis, and treatment . World J Gastroenterol . 2014 September 28; 20(36): 12781–12808. Published online 2014 September 28. doi: 10.3748/wjg.v20.i36.12781 106. Atherton JC. The pathogenesis of Helicobacter pylori-induced gastro-duodenal diseases. Annu Rev Pathol . 2006;1:63–96. 107. Joel J. Heidelbaugh, Kathleen L. Goldberg, John M. Inadomi. Adverse Risks Associated With Proton Pump Inhibitors: A Systematic Review . Gastroenterol Hepatol . (N Y) 2009 October; 5(10): 725–734. 108. Joel J. Heidelbaugh, Andrea H. Kim, Robert Chang, Paul C. Walker. Overutilization of proton-pump inhibitors: what the clinician needs to know . Therap Adv Gastroenterol. 2012 July; 5(4): 219–232. doi: 10.1177/1756283X12437358 109. Konturek PC 1 , Brzozowski T , Konturek SJ . Stress and the gut: pathophysiology, clinical consequences, diagnostic approach and treatment options. J Physiol Pharmacol . 2011 Dec;62(6):591-9. 110. Bhatia V 1 , Tandon RK . Stress and the gastrointestinal tract . J Gastroenterol Hepatol . 2005 Mar;20(3):332-9. 111. Marc Anthony R. Yago, Adam R. Frymoyer, et al. Gastric Re-acidification with Betaine HCl in Healthy Volunteers with Rabeprazole-Induced Hypochlorhydria . Mol Pharm . Author manuscript; available in PMC 2014 March 8. Published in final edited form as: Mol Pharm. 2013 November 4; 10(11): 4032–4037. 112. Jonathan E. Prousky. Cobalamin deficiency in elderly patients . CMAJ . 2005 February 15; 172(4): 450–451. doi: 10.1503/cmaj.1041424","date_published":"2015-09-21T03:51:13","date_modified":"2024-01-29T12:28:02","authors":[{"name":"Dr. Richard Esquivel","url":"https://sanjosefuncmed.com/about/"}],"tags":["Digestive Health"]},{"id":"https://sanjosefuncmed.com/intestinal-permeabilityleaky-gut/","url":"https://sanjosefuncmed.com/intestinal-permeabilityleaky-gut/","title":"Intestinal Permeability / Leaky Gut","summary":"An in-depth review of intestinal barrier physiology, intestinal permeability and its wider immune context.","content_text":"Intestinal Permeability/ Leaky Gut In this section we will take a hard look at the most common disorders of the intestinal tract, with a focus on the physiologic mechanisms that lead to these disorders and how they can be corrected with natural compounds and dietary changes . We will start this section by examining the literature on a topic that is gaining a lot of attention in gastroenterology research as well as the field of immunology: intestinal permeability or “leaky gut”. Let’s start by explaining exactly what this condition refers to. What is Leaky Gut? The lining of the gastrointestinal (GI) tract is composed of small epithelial cells that lie side-by-side each other forming tight junctions . These tight junctions act as a barrier between the interior of the body (blood/circulatory system) and the exterior of the body (the lumen of the GI tract). There are two primary functions of the epithelial lining of the GI tract: the first is to absorb small micromolecules , such as digested food particles, which are used as fuel sources and other processes for the body. These micronutrients are absorbed directly into the epithelial cells or between the cells and enter the bloodstream after passing through the gut-associated lymphoid tissue (GALT), the underlying intestinal immune system. The GALT serves as a containment system, preventing potentially harmful antigens from reaching systemic circulation. “A more attentive analysis of the anatomic and functional arrangement of the gastrointestinal tract, however, suggests that another extremely important function of this organ is its ability to regulate the trafficking of macromolecules between the environment and the host through a barrier mechanism.”[275] The second function of the epithelial lining of the GI tract, is to act as a barrier and prevent the absorption of larger macromolecules which should not normally penetrate through the intestinal barrier. When the tight junctions (TJs) of the intestinal mucosa are compromised, they become widened and permeable to large undigested food compounds, toxins and bacteria. This is known as intestinal permeability or “leaky gut”. The larger compounds of absorbed yet undigested proteins are reacted against by the immune system of the gut, called the GALT (gut-associated lymphoid tissue). This reaction then promotes exaggerated immune responsiveness and intestinal inflammation. Think of the cells of your intestinal lining, where absorption of micromolecules takes place, as bricks which sit side by side along the basement membrane. These “bricks” are held together by proteins that form the tight junctions (TJs), which act as the “mortar” between the bricks. Micronutrients are absorbed into the epithelial cells and transported through the cells and basement membrane where they enter the bloodstream. If the “mortar” starts to break down, you get penetration of foreign molecules through the intestinal barrier which can then enter the bloodstream (hence the term “leaky gut”). Sometimes the epithelial cells, or “bricks” themselves, start to break down allowing passage of toxins through the cells (transcellular passage) into the blood. These foreign molecules may include undigested food molecules, toxins or bacteria. Intestinal Permeability Leads to Systemic Inflammation If anything penetrates through this gastrointestinal barrier that is foreign, the immune system is activated to eliminate or destroy these unwelcome molecules. This activation of the immune system leads to an inflammatory response. If you look at the anatomy of the intestinal lining, it is mostly immune cells with a thin layer of epithelial cells protecting it. If that epithelial layer gets breached, there is no question there will be an inflammatory immune response. So it is no surprise to see systemic inflammation and risk of autoimmunity when there is breach of this thin epithelial lining. Increases in inflammatory responses increase risk of all chronic disease, including depression and neurodegenerative diseases, cardiovascular disease, bone loss, autoimmune disease, inflammatory bowel disease and chronic pain. A person’s intestinal barrier integrity will influence their inflammatory load and their potential for deteriorating mechanisms throughout the body. Health Conditions Associated with Leaky Gut Syndrome The following conditions have been associated with leaky gut syndrome: Autoimmune disorders Multiple food sensitivities Multiple chemical sensitivities Chronic fatigue syndrome Heart failure Depression Chronic inflammatory conditions Chronic pain Inflammatory bowel disease (IBD) Chronic yeast overgrowth syndromes Brain fog Intestinal Permeability and Autoimmune Disease There is a growing amount of evidence establishing the connection between intestinal permeability and the development of autoimmune disease. This review paper was published in 2009 in the prestigious Annals of New York Academy of Science. This journal is one of the top-rated most powerful scientific journals available: “There is growing evidence that increased intestinal permeability plays a pathogenic role in various autoimmune diseases. Therefore, we hypothesize that loss of intestinal barrier function is necessary to develop autoimmunity.”[276] Basically, what this paper is saying, is that the research is pointing to intestinal permeability, or leaky gut, as a precondition for the development of all autoimmune disease , such as type I diabetes, rheumatoid arthritis (RA), lupus (SLE), multiple sclerosis (MS), Lou Gehrig’s disease (ALS), Hashimoto’s hypothyroidism, Grave’s disease, Crohn’s disease, ulcerative colitis, Celiac disease, and hundreds of other diseases. Here’s another paper supporting this discovery: “Together with the gut-associated lymphoid tissue and the neuroendocrine network, the intestinal epithelial barrier, with its intercellular tight junctions, controls the equilibrium between tolerance and immunity to non-self antigens. When the finely-tuned trafficking of macromolecules is dysregulated in individuals, both intestinal and extraintestinal autoimmune disorders can occur.”[275] One of the hallmarks of a healthy immune system is immune tolerance to self-tissue . This prevents our immune system from attacking one’s own tissue of the body. We are born with an immune system that is able to differentiate self-tissue from foreign pathogens and does not attack self-tissue under normal circumstances. One of the things the research is showing is once these tight junction proteins get compromised, there is such immune zealousness and activation, this whole immune self-tolerance is lost and the immune system is prone to attacking self-tissue. When this occurs, any tissue is up for grabs for autoimmune destruction. The type of tissue that is targeted for destruction determines the type of autoimmune disease that develops. Symptoms of Intestinal Permeability Symptoms of intestinal permeability vary significantly and have a varied presentation. There is a spectrum of severity of intestinal permeability from mild to severe forms. Here is a list of the most common symptoms associated with intestinal permeability: Bloating Poor Digestion Inflammation Food Sensitivities Chronic Pain Brain Fog/Poor Memory Depression Fatigue People with intestinal permeability will often react to certain types of foods, especially common food allergens such as wheat and dairy. Gluten sensitivity is very common with these people. Digestive abnormalities such as gas, bloating and food sensitivities are common symptoms of leaky gut. On the other side of the scale are people who never have intestinal symptoms but have other symptoms of chronic inflammation such as chronic pain, depression, brain fog or fatigue. They are too tired or in too much pain to go to the gym and exercise on a regular basis. When we see patients that present with these symptoms, we have to consider intestinal permeability issues. Common Imbalances Associated with Leaky Gut There are a number of common imbalances that often occur together with leaky gut. These include: Malabsorption/malnutrition Bacterial/yeast overgrowth/dysbiosis (imbalance of beneficial and pathogenic bacteria) Intestinal lining degeneration/impaired intestinal immune integrity Immune activation/immune dysregulation/autoimmunity Food sensitivities Mechanisms Leading to Leaky Gut There are many different environmental and dietary factors that may damage the epithelial lining of the GI tract, including a diet high in refined sugar, intake of food allergens, such as wheat and dairy, alcohol use, use of medications such as antibiotics or NSAIDs, such as ibuprofen and aspirin, stress, chronic infections, nutrient deficiencies, hormonal deficiencies (thyroid, estrogen or testosterone) and metabolic disturbances, such as diabetes or pre-diabetes.[277-286] All of these factors have been shown to contribute to intestinal permeability. Alterations in intestinal physiology may affect the integrity of the intestinal epithelium tight junction protein structures. These mechanisms basically include physiological shifts that induce greater ongoing catabolism (breakdown) versus anabolism (buildup) of the epithelial mucosa. Additionally, systemic inflammation, which occurs in autoimmune conditions, promotes leaky gut. So this becomes a vicious cycle of leaky gut , leading to systemic inflammation, leading to further leaky gut. What are the Causes of Leaky Gut? Diet (refined sugar, wheat, dairy, etc.) Medication (antibiotics, NSAIDs, etc.) Infection (bacterial, viral, parasitic) Stress Hormonal Imbalances (thyroid, estrogen, testosterone, etc.) Neurologic Issues (stroke, brain injury, etc.) Metabolic Issues (diabetes, pre-diabetes, etc.) Autoimmunity Assessment of Intestinal Permeability: Intestinal Permeability Antigenic Screen The Cyrex Labs Array 2 Intestinal Permeability Antigenic Screen is the most accurate intestinal barrier permeability test available and is currently the only lab that measures the immunological response against the intestinal barrier and accepted markers of permeability. The profile includes actin/myosin network IgG, occludin/zonulin IgG, IgA, IgM and lipopolysaccharides (LPS) IgG, IgA, and IgM . Measurements of these antibodies can be used as markers for intestinal permeability. Elevations of occludin/zonulin antibodies indicate breakdown of the intestinal barrier integrity through paracellular (tight junction) pathways . Elevations of actomyosin antibodies indicate breakdown of the intestinal barrier integrity through transcellular (across the intestinal cells) pathways and may also suggest possible autoimmunity against mucosal epithelium and other tissues that contain the actomyosin cytoskeleton. Elevations of LPS antibodies indicate excess penetration of LPS into the bloodstream (leakiness) . Conventional Management of Intestinal Permeability There is currently no drug available to treat intestinal permeability and most doctors have not even heard of it. However, this may change in the near future because drug companies are now working on drugs that modulate gut permeability. There is currently a tight junction regulator being developed, intended for the treatment of patients with celiac disease which has just recently passed Phase IIb human drug trial development and will start Phase III clinical trials for the assessment of the oral drug’s efficacy and safety.[287] Once this drug is approved, doctors, or at least gastroenterologists, will become more familiar with intestinal permeability. However, at present, these drugs appear to be limited to approval for the treatment of this one particular intestinal autoimmune disorder (celiac disease). So patients with intestinal permeability with diagnoses of other autoimmune conditions (or any other condition) will not be able to get drug treatments for the foreseeable future. Clinical Management of Intestinal Permeability in Functional Medicine Fortunately, intestinal permeability usually responds very well to dietary and supplement intervention and can often be well-managed through these interventions alone. The treatment of leaky gut should include an aggressive program designed to break the vicious cycle of leaky gut. This involves a restricted dietary regimen and nutritional supplements that have been shown to help reduce intestinal inflammation and help repair the intestinal lining. The dietary program may need to be conducted for an extended period of time for more progressed cases, depending on the factors involved in promoting leaky gut. One of the things that will create variables for how long this will take are the mechanisms involved that are causing the leaky gut. If the person is still consuming alcohol or consuming inflammatory foods or has hormonal deficiencies or has blood sugar issues, this will take longer to correct. There will be some people that will have chronic leaky gut for the rest of their life, such as severe autoimmune conditions and people with systemic inflammatory conditions. Intestinal Permeability Dietary Restrictions As discussed above, it is important to avoid foods that tend to aggravate or worsen intestinal permeability when trying to repair the gut barrier and decrease autoimmune responses. Sugars and high glycemic foods can create more damage to the intestinal lining and increase permeability. Gluten (and other grains that cross-react with gluten), dairy and soy can also cause additional inflammation and lead to further damage to the epithelial lining of the GI tract. Lectins (found in grains, legumes, nightshade plants and dairy) have also been shown to damage this epithelial ling. It is important to implement an aggressive and complete dietary program to break the vicious cycle of leaky gut and minimize autoimmune reactions. Here is a list of foods shown to aggravate or worsen intestinal permeability as well as the foods that are generally safely tolerated in individuals with this condition. Foods to Avoid Sugars: including corn syrup, high fructose corn syrup, molasses, honey, chocolate candy, etc. High glycemic fruits: watermelon, mango, pineapple, raisins and canned fruit Grains: including gluten, wheat, oats, rice, barley, buckwheat, soy, corn, wheat germ, spelt, amaranth, kamut, millet, and quinoa, etc. Gluten-containing compounds: including processed salad dressings, ketchup, soy sauce, barbecue sauce, condiments, modified starches, etc. Dairy: including milk, whey, eggs, cheeses, creams, and mayonnaise, etc. Soy: including soy milk, soy sauce, soy protein, etc. Alcohol: including beer, wine, sake, cognac, liquors, etc. Lectins: including nuts, beans, soy, potatoes, tomato, eggplant, pepper, peanut oil, soy oil, etc. Coffee Processed foods Canned foods Foods to Eat Most vegetables (except tomato, potatoes and mushrooms): including asparagus, spinach, lettuce, broccoli, beets, cauliflower, carrots, celery artichokes, garlic, onions, zucchini, squash, rhubarb, cucumbers, turnips, watercress, etc. Fermented foods: including sauerkraut, kimchi, pickled ginger, mixed pickle, coconut yogurt, kombucha tea, etc. Meats: including fish, chicken, beef, lamb, organ meats, etc. Low glycemic foods: apricot, plum apple, peach, pear, cherries, berries, etc. Coconut: including coconut oil, coconut bitter, coconut milk, etc. Herbal teas Olives and olive oil Nutritional Compounds Shown to Repair the Intestinal Lining There are various plant compounds, vitamins and minerals that have been shown in the literature to have a restorative effect on a damaged intestinal barrier. These include the following: L-glutamine [288-292], deglycyrrhinized licorice [293-303], N-acetyl glucosamine [304-307], aloe leaf extract [308-312], spanish moss [313-317], marshmallow extract [318-321], methylsulfonylmethane (MSM) [322-325], gamma oryzanol [326-330], slippery elm bark [331-334], german chamomile [335-337], marigold flower extract [338-341], glutathione [342-347], zinc carnosine [348], vitamin D [349-351]. “Regarding intestinal permeability, zinc carnosine caused an approximate threefold increase in gut integrity and repair”[348] “VDR (vitamin D receptor) plays a critical role in mucosal barrier homeostasis by preserving the integrity of junction complexes and the healing capacity of the colonic epithelium. Therefore, vitamin D deficiency may compromise the mucosal barrier, leading to increased susceptibility to mucosal damage and increased risk of IBD (inflammatory bowel disease).”[349] “There is growing appreciation of the importance of the pleiotropic hormone vitamin D in the development of tolerance, immune system defenses, and epithelial barrier integrity” [350] “1,25(OH)2D3 (vitamin D) may play a protective role in mucosal barrier homeostasis by maintaining the integrity of junction complexes and in healing capacity of the colon epithelium. 1,25(OH)2D3 may represent an attractive and novel therapeutic agent for the adjuvant therapy of IBD (inflammatory bowel disease).”[351] References 275. Mechanisms of disease: the role of intestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases. Nat Clin Pract Gastroenterol Hepatol. 2005 Sep;2(9): 416-22 276. Tight junctions, intestinal permeability, and autoimmunity: celiac disease and type 1 diabetes paradigms. Ann N Y Acad Sci. 2009 May;1165:195-205. 277. van Ampting MT, Schonewille AJ, Vink C, et al. Intestinal barrier function in response to abundant or depleted mucosal glutathione in Salmonella-infected rats. BMC Physiol. 2009 Apr 17;9:6. 278. Lammers KM, Lu R, Brownley J, et al. Gliadin induces an increase in intestinal permeability and zonulin release by binding to the chemokine receptor CXCR3. Gastroenterology . 2008 Jul;135(1):194-204.e3. 279. Machowska A, Brzozoweski T, Sliwowski Z, et al. Gastric secretion , proinflammatory cytokines and epidermal growth factor (EGF) in the delayed healing of lingual and gastric ulcerations by testosterone. Inflammopharmacology . 2008 Feb;16(1):40-47. 280. Money SR, Cheron RG, Jaffe BM, Zinner MJ. The effects of thyroid hormones on the formation of stress ulcers in the rat. J Surg Res . 1986 Feb;40(2):176-180. 281. Braniste V, Leveque M, et al. Oestradiol decreases colonic permeability through oestrogen receptor beta-mediated up-regulation of occludin and junctional adhesion molecule-A in epithelial cells. J Physiol . 2009 Jul 1;587(Pt 13):3317-3328. 282. Drago F, Montoneri C, Varga C, Laszlo F. Dual effect of female sex steroids on drug-induced gastoduodenal ulcers in the rat. Life Sci . 1999;64(25):2341-2350. 283. Gareau MG, Silva MA, Perdue MH. Pathophysiological mechanisms of stress-induced intestinal damage. Curr Mol Med. 2008 Jun;8(4):274-281. 284. Zen K, Chen CX, Chen YT, et al. Receptor for advanced glycation endproducts mediates neutrophil migration across intestinal epithelium. J Immunol. 2007 Feb 15;178(4): 2483-2490. 285. Korenaga K, Micci MA, Taglialatela G, Pasricha PJ. Suppression of nNOS expression in rat enteric neurons by the receptor for advanced glycation end-products. Neurogastroenterol Motil. 2006 May;18(5):392-400. 286. Purohit V, Bode JC, Bode C, et al. Alcohol, intestinal bacterial growth, intestinal permeability to endotoxin and medical consequences: summary of a symposium. Alcohol. 2008 Aug;42(5):349-361. 287. http://www.prnewswire.com/news-releases/alba-therapeutics-announces-positive-results-of-phase-iib-trial-in-celiac-disease-244877451.html 288. Noyer CM, Simon D, Borczuk A, Brandt LJ, Lee MJ, Nehra V. A double-blind placebo-controlled pilot study of glutamine therapy for abnormal intestinal permeability in patients with AIDS. Am J Gastroenterol . 1998 Jun;93(6):972-5. 289. Klimberg VS, Souba WW, Dolson DJ, Salloum RM, Hautamaki RD, Plumley DA, Mendenhall WM, Bova FJ, Khan SR, Hackett RL, et al. Prophylactic glutamine protects the intestinal mucosa from radiation injury. Cancer . 1990 Jul 1;66(1):62-8. 290. Chamorro S, de Blas C, Grant G, Badiola I, Menoyo D, Carabaño R. Effect of dietary supplementation with glutamine and a combination of glutamine-arginine on intestinal health in twenty-five-day-old weaned rabbits. J Anim Sci . 2010 Jan;88(1):170-80. 291. Amasheh M, Andres S, Amasheh S, Fromm M, Schulzke JD. Barrier effects of nutritional factors. Ann N Y Acad Sci . 2009 May;1165:267-73 292. Kul M, Vurucu S, Demirkaya E, Tunc T, Aydinoz S, Meral C, Kesik V, Alpay F. Enteral glutamine and/or arginine supplementation have favorable effects on oxidative stress parameters in neonatal rat intestine. J Pediatr Gastroenterol Nutr . 2009 Jul;49(1):85-9. 293. Russell RI, Morgan RJ, Nelson LM. Studies on the protective effect of deglycyrrhinised liquorice against aspirin (ASA) and ASA plus bile acidinduced gastric mucosal damage, and ASA absorption in rats. Scand J Gastroenterol Suppl . 1984;92:97-100. 294. Bennett A. Gastric mucosal formation of prostanoids and the effects of drugs. Acta Physiol Hung . 1984;64(3-4):215-7. 295. Morgan RJ, Nelson LM, Russell RI, Docherty C. The protective effect of deglycyrrhi-nized liquorice against aspirin and aspirin plus bile acid-induced gastric mucosal damage, and its influence on aspirin absorption in rats. J Pharm Pharmacol . 1983 Sep;35(9):605-7. 296. Glick L. Deglycyrrhizinated liquorice for peptic ulcer . Lancet . 1982 Oct 9;2(8302):817. 297. van Marle J, Aarsen PN, Lind A, van Weeren-Kramer J. Deglycyrrhizinised liquorice (DGL) and the renewal of rat stomach epithelium. Eur J Pharmacol . 1981 Jun 19;72(2-3):219-25. 298. Datla R, Rao SR, Murthy KJ. Excretion studies of nitrofurantoin and nitrofurantoin with deglycyrrhizinated liquorice. Indian J Physiol Pharmacol . 1981 Jan-Mar;25(1):59-63. 299. Rees WD, Rhodes J, Wright JE, Stamford LF, Bennett A. Effect of deglycyrrhizinated liquorice on gastric mucosal damage by aspirin. Scand J Gastroenterol . 1979;14(5):605-7. 300. Balakrishnan V, Pillai MV, Raveendran PM, Nair CS. Deglycyrrhizinated liquorice in the treatment of chronic duodenal ulcer. J Assoc Physicians India . 1978 Sep;26(9):811-4. 301. D’Imperio N, Giuliani Piccari G, Sarti F, Soffritti M, Spongano P, Benvenuti C, Dal Monte PR. Double-blind trial in duodenal and gastric ulcers. Cimetidine and deglycyrrhizinized liquorice. Acta Gastroenterol Belg . 1978 Jul-Aug;41(7-8):427-34. 302. Bardhan KD, Cumberland DC, Dixon RA, Holdsworth CD. Proceedings: Deglycyrrhizi-nated liquorice in gastric ulcer: a double blind controlled study. Gut . 1976 May;17(5):397. 303. Larkworthy W, Holgate PF. Deglycyrrhizinized liquorice in the treatment of chronic duodenal ulcer. A retrospective endoscopic survey of 32 patients. Practitioner . 1975 Dec;215(1290):787-92. 304. Baldrick P. The safety of chitosan as a pharmaceutical excipient. Regul Toxicol Pharmacol. 2010 Apr;56(3):290-9. 305. Gunn-Moore DA, Shenoy CM. Oral glucosamine and the management of feline idiopathic cystitis. J Feline Med Surg . 2004 Aug;6(4):219-25. 306. Seidman EG, Bernotti S, Levy E. Nutritional modulation of gut inflammation . Nestle Nutr Workshop Ser Clin Perform Programme. 2002;7:41-61; discussion 61-5. 307. Sharma R, Schumacher U. Carbohydrate expression in the intestinal mucosa. Adv Anat Embryol Cell Biol. 2001;160:III-IX, 1-91. 308. Chen W, Lu Z, Viljoen A, Hamman J. Intestinal drug transport enhancement by Aloe vera. Planta Med. 2009 May;75(6):587-95. 309. Pogribna M, Freeman JP, Paine D, Boudreau MD. Effect of Aloe vera whole leaf extract on short chain fatty acids production by Bacteroides fragilis, Bifidobacterium infantis and Eubacterium limosum. Lett Appl Microbiol . 2008 May;46(5):575-80. 310. Rosca-Casian O, Parvu M, Vlase L, Tamas M. Antifungal activity of Aloe vera leaves. Fitoterapia . 2007 Apr;78(3):219-22. 311. Iena IaM. [The therapeutic properties of aloe]. Lik Sprava . 1993 Feb-Mar;(2-3):142-5. 312. t’Hart LA, van den Berg AJ, Kuis L, van Dijk H, Labadie RP. An anticomplementary polysaccharide with immunological adjuvant activity from the leaf parenchyma gel of Aloe vera. Planta Med . 1989 Dec; 55(6):509-12. 313. de Queiroga MA, de Andrade LM, Florêncio KC, de Fátima Agra M, da Silva MS, Barbosa-Filho JM, da-Cunha EV. Chemical constituents from Tillandsia recurvata . Fitoterapia . 2004 Jun;75(3-4):423-5. 314. Arslanian RL, Stermitz FR, Castedo L. 3-Methoxy-5-hydroxyflavonols from Tillandsia purpurea. J Nat Prod . 1986 Nov-Dec;49(6):1177-8. 315. Feurt SD, Fox LE. Effects of oral administration of Spanish moss, Tillandsia usneoides L. Science. 1953 Nov 20;118(3073):626-7. 316. Feurt SD, Fox LE. The pharmacological activity of substances extracted from Spanish moss, Tillandsia usneoides L. J Am Pharm Assoc (Baltim). 1952 Aug;41(8):453-4. 317. Webber MG, Lauter WM, Foote PA. A preliminary phytochemical study of Tillandsia usneoides L. (Spanish moss). J Am Pharm Assoc . 1952 May;41(5):230-5. 318. Hage-Sleiman R, Mroueh M, Daher CF. Pharmacological evaluation of aqueous extract of Althaea officinalis flower grown in Lebanon. Pharm Biol. 2011 Mar;49(3):327-33. 319. Deters A, Zippel J, Hellenbrand N, Pappai D, Possemeyer C, Hensel A. Aqueous extracts and polysaccharides from Marshmallow roots (Althea officinalis L.): cellular internalisa-tion and stimulation of cell physiology of human epithelial cells in vitro. J Ethnopharmacol. 2010 Jan 8;127(1):62-9. 320. Kardosová A, Machová E. Antioxidant activity of medicinal plant polysaccharides. Fitoterapia . 2006 Jul;77(5):367-73. Epub 2006 May 24. 321. Wang DF, Shang JY, Yu QH. [Analgesic and anti-inflammatory effects of the flower of Althaea rosea (L.) Cav.]. Zhongguo Zhong Yao Za Zhi. 1989 Jan;14(1):46-8, 64. 322. Iauk L, Lo Bue AM, Milazzo I, Rapisarda A, Blandino G. Antibacterial activity of medicinal plant extracts against periodontopathic bacteria. Phytother Res. 2003 Jun;17(6):599-604. 323. Satia JA, Littman A, Slatore CG, Galanko JA, White E. Associations of herbal and specialty supplements with lung and colorectal cancer risk in the VITamins and Lifestyle study. Cancer Epidemiol Biomarkers Prev . 2009 May;18(5):1419-28. 324. Brien S, Prescott P, Bashir N, Lewith H, Lewith G. Systematic review of the nutritional supplements dimethyl sulfoxide (DMSO) and methylsulfonylmethane (MSM) in the treatment of osteoarthritis. Osteoarthritis Cartilage. 2008 Nov;16(11):1277-88. 325. Parcell S. Sulfur in human nutrition and applications in medicine. Altern Med Rev. 2002 Feb;7(1):22-44. 326. Jariwalla RJ. Rice-bran products: phytonutrients with potential applications in preventive and clinical medicine. Drugs Exp Clin Res . 2001;27(1):17-26. 327. Sugano M, Tsuji E. Rice bran oil and human health . Biomed Environ Sci . 1996 Sep;9(2-3):242-6. 328. Hirose M, Ozaki K, Takaba K, Fukushima S, Shirai T, Ito N. Modifying effects of the naturally occurring antioxidants gamma-oryzanol, phytic acid, tannic acid and n-tritriacontane-16, 18-dione in a rat wide-spectrum organ carcinogenesis model. Carcinogenesis . 1991 Oct;12(10):1917-21. 329. Wheeler KB, Garleb KA. Gamma oryzanol-plant sterol supplementation: metabolic, endocrine, and physiologic effects. Int J Sport Nutr. 1991 Jun;1(2):170-7. 330. Itaya K, Kitonaga J, Ishikawa M. [Studies of gamma-oryzanol. The antiulcerogenic action]. Nippon Yakurigaku Zasshi . 1976 Nov;72(8):1001-11. 331. Brown AC, Hairfield M, Richards DG, McMillin DL, Mein EA, Nelson CD. Medical nutrition therapy as a potential complementary treatment for psoriasis-five case reports. Altern Med Rev . 2004 Sep;9(3):297-307. 332. Choi HR, Choi JS, Han YN, Bae SJ, Chung HY. Peroxynitrite scavenging activity of herb extracts. Phytother Res . 2002 Jun;16(4):364-7. 333. Majchrowicz MA. Essiac. Notes Undergr . 1995 Winter;(no 29):6-7. 334. Gill RE, Hirst EL, Jones JK. Constitution of the mucilage from the bark of Ulmus fulva (slippery elm mucilage); the sugars formed in the hydrolysis of the methylated mucilage . J Chem Soc. 1946 Nov:1025-9. 335. Bezerra SB, Leal LK, Pinto NA, Campos AR. Bisabolol-induced gastroprotection against acute gastric lesions: role of prostaglandins, nitric oxide, and KATP+ channels. J Med Food. 2009 Dec;12(6):1403-6. 336. Moura Rocha NF, Venâncio ET, Moura BA, et al. Gastroprotection of (-)-alphabisa-bolol on acute gastric mucosal lesions in mice: the possible involved pharmacological mechanisms. Fundam Clin Pharmacol. 2009 Aug 3. 337. Pereira RP, Fachinetto R, de Souza Prestes A, et al. Antioxidant effects of different extracts from Melissa officinalis, Matricaria recutita and Cymbopogon citratus . Neurochem Res . 2009 May;34(5):973-83. 338. Madisch A, Holtmann G, Mayr G, Vinson B, Hotz J. Treatment of functional dyspepsia with a herbal preparation. A double-blind, randomized, placebo-controlled, multicenter trial. Digestion . 2004;69(1):45-52. 339. Elango G, Rahuman AA, Kamaraj C, Zahir AA, Bagavan A. Studies on effects of indigenous plant extracts on filarial vector Culex tritaeniorhynchus Giles. Parasitol Res . 2010 Apr 7. 340. Bashir S, Gilani AH. Studies on the antioxidant and analgesic activities of Aztec marigold (Tagetes erecta) flowers. Phytother Res . 2008 Dec;22(12):1692-4. 341. Wang M, Tsao R, Zhang S, Dong Z, Yang R, Gong J, Pei Y. Antioxidant activity, mutagenicity/ anti-mutagenicity, and clastogenicity/anticlastogenicity of lutein from marigold flowers. Food Chem Toxicol . 2006 Sep;44(9):1522-9. 342. Martín-Venegas R, Brufau MT, Guerrero-Zamora AM, Mercier Y, Geraert PA, Ferrer R. The methionine precursor DL-2-hydroxy-(4-methylthio) butanoic acid protects intestinal epithelial barrier function. Food Chem . 2013 Dec 1;141(3):1702-9. 343. Flamant M, Aubert P, Rolli-Derkinderen M, et al. Enteric glia protect against Shigella flexneri invasion in intestinal epithelial cells: a role for S-nitrosoglutathione . Gut . 2011 Apr;60(4):473-84. 344. van Ampting MT, Schonewille AJ, Vink C, Brummer RJ, van der Meer R, Bovee-Oudenhoven IM. Intestinal barrier function in response to abundant or depleted mucosal glutathione in Salmonella-infected rats. BMC Physiol. 2009 Apr 17:9:6 345. Maeda T, Miyazono Y, Ito K, Hamada K, Sekine S, Horie T. Oxidative stress and enhanced paracellular permeability in the small intestine of methotrexate treated rats. Cancer Chemother Pharmacol. 2010 May;65(6):1117-2 346. Savidge TC, Newman P, Pothoulakis C, Ruhl A, Neunlist M, Bourreille A, Hurst R, Sofroniew MV. Enteric glia regulate intestinal barrier function and inflammation via release of S-nitrosoglutathione. Gastroenterology . 2007 Apr;132(4):1344-1358 347. The role of the glutathione antioxidant system in gut barrier failure in a rodent model of experimental necrotizing enterocolitis . Surgery . 2004 Sep;136(3):557-66 348. Mahmood A , FitzGerald AJ , Marchbank T , Ntatsaki E , Murray D , Ghosh S , Playford RJ . Zinc carnosine, a health food supplement that stabilises small bowel integrity and stimulates gut repair processes. Gut . 2007 Feb;56(2):168-75. Epub 2006 Jun 15. 349. Kong J, Zhang Z, Musch MW, Ning G, Sun J, Hart J, Bissonnette M, Li YC. Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal barrier. Am J Physiol Gastroint. Liver Physiol. 2008 Jan; 294(1):G208-16 350. Vassallo MF, Camargo CA Jr. Potential mechanisms for the hypothesized link between sunshine, vitamin D, and food allergy in children. J Allergy Clin Immunol . 2010 Aug;126 (2):217-22 351. Zhao H, Zhang H, Wu H, Li H, Liu L, Guo J, Li C, Shih DQ, Zhang X. Protective role of 1,25(OH)2 vitamin D3 in the mucosal injury and epithelial barrier disruption in DSS-induced acute colitis in mice. BMC Gastroenterol . 2012 May 30;12:57.","date_published":"2015-08-24T04:51:43","date_modified":"2020-05-22T01:05:16","authors":[{"name":"Dr. Richard Esquivel","url":"https://sanjosefuncmed.com/about/"}],"tags":["Digestive & Immune Health"]},{"id":"https://sanjosefuncmed.com/adverse-effects-of-ppis/","url":"https://sanjosefuncmed.com/adverse-effects-of-ppis/","title":"Adverse Effects of PPIs","summary":"A deeper educational review of proton-pump inhibitor use, why these medications are prescribed and issues to discuss with a prescribing clinician.","content_text":"The Untold Perils of Proton Pump Inhibitors (PPIs) As we learned in the last article, gastroesophageal reflux disease (GERD) is an extremely prevalent condition in our society. It has been estimated the prevalence of GERD symptoms in the general population may be up to 30% in the U.S.[125] but other studies show it could be as high as 34% to 40%.[126] The standard treatment for this condition continues to be the use of a powerful class of medications known as proton-pump inhibitors (PPIs). PPIs are block-buster drugs that make the pharmaceutical companies billions of dollars annually . This class of medication represents the third-highest selling class of drugs in the United States, with $13.9 billion in annual sales.[127] Sales of Nexium (the “purple pill” by Astra Zeneca) topped $6.1 billion in 2013 alone, the second highest prescribed medication in the U.S.[128] In this article we take a closer look at the known risks associated with the use of PPIs, according to the most recent literature. PPIs and Nutrient Absorption Since stomach acid plays a role in nutrient absorption, PPIs and other acid suppressing medications have a significant impact on vitamin and mineral absorption. The literature reveals that absorption of various vitamins and minerals are impacted as a result of acid suppression. PPIs and Vitamin B12 Absorption Vitamin B12, also called cobalamin, is a crucial water-soluble vitamin that is used for many functions in the body, including brain function, nerve function, red blood cell production, methylation and liver detoxification. B12 deficiency is associated with a number of chronic diseases, including heart disease and cancer. Our primary source of B12 is our diet, and it is found in animal products such as meat. However, in its dietary form, B12 is bound to animal-derived protein which requires stomach acid to cleave off the protein so that it can be absorbed after it becomes bound to intrinsic factor in the intestines. If stomach acid is insufficient, B12 may not be cleaved off from dietary proteins and lead to absorption problems. “The use of H(2)-receptor antagonists and/or PPIs may impair the absorption of protein-bound dietary vitamin B12 and could contribute to the development of vitamin B12 deficiency with prolonged use.”[189] “The studies reviewed in this article clearly show that omeprazole therapy will decrease the absorption of vitamin B12 by preventing its cleavage from dietary proteins.”[190] A number of studies have shown an association of decreased B12 absorption with prolonged PPI use.[189,190] However, PPIs have been shown to affect B12 absorption in very short periods of time as well.[191,192] One study showed a 72% decrease in B12 absorption on 20 mg of omeprazole (Prilosec) and an 88% decrease in B12 absorption on 40 mg of omeprazole after only 2 weeks of treatment! The authors made the following conclusion: “Omeprazole (PPI) therapy acutely decreased cyanocobalamin (B12) absorption in a dose-dependent manner.”[191] B12 absorption issues worsen in patients with atrophic gastritis, which is a common condition in the elderly. In one study of 359 elderly people aged between 60 and 99 years of age, the prevalence of atrophic gastritis was found to be 31.5% and increased significantly with advancing age. Subjects with atrophic gastritis exhibited a lower mean serum vitamin B12 level, indicating decreased absorption. “It is concluded that…atrophic gastritis is common in an elderly population, and that atrophic gastritis is associated with vitamin B12 deficiency and anemia.”[193] PPIs and Iron Absorption Iron is an essential element for red blood cell production. About 70% of your body’s iron is found in the red blood cells of your blood called hemoglobin and in muscle cells called myoglobin . Hemoglobin is essential for transferring oxygen in your blood from the lungs to the tissues. It has long been known that conditions of low stomach acid (hypochlorhydria) such as atrophic gastritis and partial gastrectomy cause iron-deficiency anemia.[194] Studies have shown that patients who undergo gastric bypass surgeries are at much higher risk of iron deficiency, in fact, iron deficiency is extremely frequent in this patient population.[195] Iron can be found in the heme (ferrous) form or nonheme form but only the ferrous form can be absorbed. Nonheme iron requires gastric acid for conversion to the ferrous form of iron for absorption.[196] 90% of dietary and 100% of oral iron supple-mentation is in the nonheme form.[197] So not surprisingly, several review studies in the literature conclude that PPI use leads to decreased iron absorption.[198,199] In one study, all markers of iron deficiency were decreased among patients on PPI therapy as compared to controls. “Among patients on PPI therapy, all hematologic indices decreased from baseline, including hemoglobin (-0.19 g/dL, P=0.03), hematocrit (-0.63%, P=0.02), and mean corpuscular volume (-0.49 fL, P=0.05). PPI users had significant decreases in mean hemoglobin and hematocrit (P&lt;0.01 for both) compared with matched controls. Among adult patients receiving chronic PPI therapy, there is a significant decrease in hematologic indices from baseline.”[200] Another study looked at the effects of omeprazole on iron supplementation in patients with iron-deficient anemia. It found that: “…the profound hypochlorhydria induced by omeprazole may indeed impair the optimal absorption of orally administered iron in iron-deficient individuals…”[201] In fact, PPI therapy is so reliable in reducing iron absorption from food, it is now being used as a treatment for decreasing iron absorption from food in conditions of excess iron stores in the body called hemochromatosis . “Proton pump inhibitor therapy reduces the absorption of non-heme iron and this effect has been employed in the management of hemochromatosis. It may also retard clinical response to iron supplementation.”[202] PPIs and Calcium Absorption Calcium performs a number of basic functions in your body. Your body uses 99% of its calcium to keep your bones and teeth strong, thereby supporting skeletal structure and function. The rest of the calcium in your body plays key roles in cell signaling, blood clotting, muscle contraction and nerve function but calcium levels for these functions is usually tightly-regulated. So anything that effects calcium absorption from food will likely have a negative impact on bone density, primarily. Numerous human studies show that gastric acid secretion aid in calcium absorption and that acid suppressants such as PPIs can decrease calcium absorption and decrease bone density.[203-210] An acidic environment in the stomach facilitates the release of ionized calcium from calcium salts, which is important for calcium absorption.[203-210] A number of conditions that cause hypochlorhydria are associated with an increased occurrence of osteoporosis and bone fracture, and it is assumed that this is secondary to the effect of low gastric acid levels on calcium absorption.[203-210] There were two large, case control studies from 2006 which led to considerable concern that chronic PPI use could lead to an increase in bone fractures and speculation of the possible mechanisms involved. Both of these studies associated long-term use of PPIs with bone fractures with one of them showing the risks were particularly increased with high-dose PPI use and the risk progressively increased with the duration of PPI treatment.[205,211] These studies and others led the U.S. Food and Drug Administration to issue a warning in 2010 of the “possible increased risk of fractures of the hip, wrist, and spine with high doses or long-term use of a class of medications called proton pump inhibitors.” (U.S. FDA News Release, May 25, 2010). Since then, PPIs and other acid-suppressing medications have been shown in numerous studies to decrease calcium absorption [208, 212-214] with omeprazole causing a 41% decrease in one study [208] and long-term PPI usage has been increasingly associated with an increased occurrence of bone fractures. [210,211,215-217] The most widely-assumed mechanism is that long-term PP I use leads to decreased intestinal absorption of calcium resulting in increased osteoporosis, increased bone loss and increased fractures. [205,206, 210,212,218-220] A large retrospective analysis done in 2008 matched 15,792 cases of osteoporosis-related fractures with 47,289 controls during an 8 year period between 1996 and 2004. The researchers concluded the following: “Use of proton pump inhibitors for 7 or more years is associated with a significantly increased risk of an osteoporosis-related fracture. There is an increased risk of hip fracture after 5 or more years exposure.”[221] PPIs and Magnesium Absorption Magnesium is needed for more than 300 biochemical reactions in the body. It helps to maintain normal nerve and muscle function, supports a healthy immune system, keeps the heart beat steady, and helps bones remain strong. It also helps regulate blood glucose levels and aids in the production of energy and protein. So anything that impacts magnesium, can potentially cause a wide range of symptoms related to the muscles, nerves, brain, heart, bone and the immune system. Hypomagnesemia (low magnesium levels in the blood) was reported for the first time in the medical literature as a potential side effect of proton-pump inhibitors (PPIs) in 2006. Since then, numerous studies have shown that magnesium deficiency associated with the use of PPIs results in a wide variety of serious disorders affecting multiple organ systems.[222-229] In 2011, the U.S. Food and Drug Administration released a warning about low serum magnesium levels associated with long-term use of PPIs. Symptoms include seizures, arrhythmias, low blood pressure, severe muscle contraction (tetany), and death.[230] In a recent review of 10 cases, the elderly patients had been taking PPIs for an average of 8.3 yrs.[226] They suffered from severe symptoms of low magnesium and there was significant morbidity related to fatigue, unsteadiness, severe muscle contraction, seizures, cardiac arrhythmias, and multiple hospitalizations. The low magnesium condition promptly resolved when the PPI therapy was stopped and recurred if the PPI therapy was reintroduced. “There were 18 emergency hospital admissions with severe hypomagnesemia (low magnesium). Oral and parenteral magnesium supplements were relatively ineffective at correcting the problem, but stopping PPI therapy lead to prompt resolution of the hypomagnesemia (within 2 weeks in five carefully monitored patients), with symptomatic benefit. Hypomagnesemia recurred if PPI therapy was re-introduced…”[226] Another recent review of 4 cases examined the clinical consequences and mechanisms of electrolyte disorders that resulted from the elderly patients taking a PPI for a period of 1 to 13 years.[227] They developed severe low magnesium levels with low calcium levels, hypoparathyroidism (low parathyroid hormone), and extremely low urinary calcium and magnesium excretion. One patient developed encephalopathy (brain dysfunction) after a collapse likely caused by cardiac arrhythmia. The others had cardiac abnormalities identified by electrocardiogram. Low potassium levels were considered the cause for these arrhythmias. The low potassium levels were believed to be due to excess potassium excretion by the body resulting from the low magnesium. “This series of PPI-induced hypomagnesemia shows that this is a generic effect. It also indicates that hypomagnesemia may occur within 1 year of PPI therapy initiation and can have serious clinical consequences…”[227] At present the mechanism of the PPI-induced low magnesium levels is not known. It was concluded in one study that it is not specific to a given PPI, but is a generic problem with the PPI class of drugs, because it recurs even when PPIs are interchanged.[82] It is believed that low magnesium levels resulting from PPI use is likely due to gastrointestinal malabsorption of magnesium secondary to hypochlorhydria.[222] Summary of PPIs and Nutrient Absorption As you can see, the evidence supporting the risk of critical vitamin and mineral malabsorption secondary to acid suppression by PPI use is alarming and unfortunately often overlooked by doctors and patients. In addition to risk of vitamin B12, calcium, iron and magnesium malabsorption, there is evidence that acid suppression by PPIs increases risk of malabsorption of other important vitamins and minerals as well, including vitamin C, zinc and folic acid.[231- 235] “Proton pump inhibitor therapy lowers the concentration of vitamin C in gastric juice and the proportion of the vitamin in its active antioxidant form i.e., ascorbic acid. There is also some evidence that proton pump inhibitors may reduce the bioavailability of ingested vitamin C.” [231] “Zinc absorption decreased (about 42%) after omeprazole (Prilosec) administration compared with pre-omeprazole values. Suppression of gastric acid secretion by omeprazole reduces intestinal absorption of zinc.”[232] “This study indicates that intragastric pH and salt solubility-dissolution are important in the oral absorption of zinc.”[233] “Further, in vitro studies have confirmed the dependency of folate absorption on intraluminal pH.”[235] In one study, when folate was given to achlorhydric patients (with no stomach acid) along with an HCl supplement, absorption of folate increased by 54%.[235] Although there is currently no available research on PPI risk of malabsorption of other nutrients, given that gastrointestinal pH plays an important role in absorption of various vitamins and minerals, one has to consider the probability that the absorption of other nutrients are affected as well. PPIs and SIBO Small intestinal bacterial overgrowth (SIBO) commonly occurs in patients on omeprazole (PPI) and in atrophic gastritis (a condition leading to very low stomach acid).[183] “SIBO…occurs significantly more frequently among long term PPI users than patients with IBS or control subjects.”[184] Considering that low stomach acid is an important risk factor for the development of SIBO, recent research has focused on the mechanism by which PPIs lead to SIBO. The mechanism appears to be related to a shift in the balance of the intestinal bacteria that occurs in PPI use. This should not be surprising, given the important role that acid plays in preventing bacterial infection. “Use of proton pump inhibitors (PPIs) could predispose individuals to small intestinal bacterial overgrowth (SIBO) by altering the intraluminal environment and bacterial flora.”[185] “ In conclusion, omeprazole is associated with a microbiota shift and functional change in the distal gut in patients with compensated cirrhosis that could set the stage for bacterial overgrowth.”[186] PPIs and Colonic Infections PPIs have also been shown to increase risk of Clostridium difficile (known as C. diff ) infection, which is commonly seen in patients on long-term antibiotic therapy. “Omeprazole treatment decreases the expression of genes that have important functions in colonocyte integrity. Such impairment in colonocyte function may promote Clostridium difficile infection (CDI).”[236] PPIs and Immune Responses PPIs have also been shown to affect normal immune responses and clotting mechanisms. “One potential toxicity mechanism of PPIs as suggested from this systematic PPI-specific gene expression analysis is that PPIs are enriched in acidic organelles where they are activated and inhibit V-ATPases and acid hydrolases, and consequently block the pathways of antigen presentation, the synthesis and secretion of cytokines, and complement component proteins and coagulation factors.”[237] Related Articles Hypochlorhydria (Low Stomach Acid) Gastritis Gastroesophageal Reflux Disease (GERD) Intestinal Permeability/Leaky Gut NSAID-Induced Enteropathy Irritable Bowel Syndrome (IBS) Small Intestinal Bacterial Overgrowth The Neuroendocrine System of the Gut and the Brain-Gut Axis References 189. Ruscin JM 1 , Page RL 2nd , Valuck RJ . Vitamin B(12) deficiency associated with histamine(2)-receptor antagonists and a proton-pump inhibitor . Ann Pharmacother . 2002 May;36(5):812-6. 190. Bradford GS 1 , Taylor CT . Omeprazole and vitamin B12 deficiency . Ann Pharmacother. 1999 May;33(5):641-3. 191. Marcuard SP 1 , Albernaz L , Khazanie PG . Omeprazole therapy causes malabsorption of cyanocobalamin (vitamin B12). Ann Intern Med. 1994 Feb 1;120(3):211-5. 192. Schenk BE 1 , Festen HP , Kuipers EJ , Klinkenberg-Knol EC , Meuwissen SG . Effect of short- and long-term treatment with omeprazole on the absorption and serum levels of cobalamin. Aliment Pharmacol Ther. 1996 Aug;10(4):541-5. 193. Krasinski SD , Russell RM , Samloff IM , Jacob RA , Dallal GE , McGandy RB , Hartz SC . Fundic atrophic gastritis in an elderly population. Effect on hemoglobin and several serum nutritional indicators. J Am Geriatr Soc. 1986 Nov;34(11):800-6. 194. Annibale B, Capurso G, Delle Fave G. The stomach and iron deficiency anaemia: a forgotten link. Dig Liver Dis . 2003;35:288–295. 195. Gesquiere I, Lannoo M, Augustijns P, Matthys C, Van der Schueren B, Foulon V. Iron deficiency after Roux-en-Y gastric bypass: insufficient iron absorption from oral ironsupplements. J Lab Clin Med . 1978 Jul;92(1):108-16. 196. Bezwoda W , Charlton R , Bothwell T , Torrance J , Mayet F . The importance of gastric hydrochloric acid in the absorption of nonheme food iron. Obes Surg . 2014 Jan;24(1):56-61. doi: 10.1007/s11695-013-1042-8. 197. Tempel M, Chawla A, Messina C, Celiker MY. Effects of omeprazole on iron absorption: preliminary study. Turk J Haematol . 2013 Sep;30(3):307-10. doi: 10.5152/tjh.2013.0042. Epub 2013 Sep 5. 198. Wilhelm SM, Rjater RG, Kale-Pradhan PB. Perils and pitfalls of long-term effects of proton pump inhibitors. Expert Rev Clin Pharmacol . 2013 Jul;6(4):443-51. doi: 10.1586/17512433.2013.811206. Review. 199. Ito T, Jensen RT. Association of long-term proton pump inhibitor therapy with bone fractures and effects onabsorption of calcium, vitamin B12, iron, and magnesium. Curr Gastroenterol Rep . 2010 Dec;12(6):448-57. doi: 10.1007/s11894-010-0141-0. Review. 200. Sarzynski E, Puttarajappa C, Xie Y, Grover M, Laird-Fick H. Association between proton pump inhibitor use and anemia: a retrospective cohort study. Dig Dis Sci . 2011 Aug;56(8):2349-53. doi: 10.1007/s10620-011-1589-y. Epub 2011 Feb 12. 201. Sharma VR, Brannon MA, Carloss EA. Effect of omeprazole on oral iron replacement in patients with iron deficiency anemia. South Med J . 2004 Sep;97(9):887-9. 202. McColl KE . Effect of proton pump inhibitors on vitamins and iron. Am J Gastroenterol . 2009 Mar;104 Suppl 2:S5-9. doi: 10.1038/ajg.2009.45. 203. Tetsuhide Ito, Robert T. Jensen. Association of Long-term Proton Pump Inhibitor Therapy with Bone Fractures and effects on Absorption of Calcium, Vitamin B12, Iron, and Magnesium . Curr Gastroenterol Rep. 2010 December; 12(6): 448–457. 204. Lodato F, Azzaroli F, Turco L, et al. Adverse effects of proton pump inhibitors. Best Pract Res Clin Gastroenterol. 2010;24:193–201. [ PubMed ] 205. Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA . 2006;296:2947–2953. [ PubMed ] 206. Insogna KL. The effect of proton pump-inhibiting drugs on mineral metabolism . Am J Gastroenterol. 2009;104 (Suppl 2):S2–S4. [ PubMed ] 207. Fournier MR, Targownik LE, Leslie WD. Proton pump inhibitors, osteoporosis, and osteoporosis-related fractures . Maturitas . 2009;64:9–13. [ PubMed ] 208. O’Connell MB, Madden DM, Murray AM, et al. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med. 2005;118:778–781. [ PubMed ] 209. Sipponen P, Harkonen M. Hypochlorhydric stomach: a risk condition for calcium malabsorption and osteoporosis? Scand J Gastroenterol . 2010;45:133–138. [ PubMed ] 210. Yu EW, Blackwell T, Ensrud KE, et al. Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int . 2008;83:251–259. [ PMC free article ] [ PubMed ] 211. Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int. 2006;79:76–83. 212. Wright MJ, Proctor DD, Insogna KL, Kerstetter JE. Proton pump-inhibiting drugs, calcium homeostasis, and bone health. Nutr Rev . 2008;66:103–108. [ PubMed ] 213. Recker RR. Calcium absorption and achlorhydria . N Engl J Med . 1985;313:70–73. [ PubMed ] 214. Graziani G, Como G, Badalamenti S, et al. Effect of gastric acid secretion on intestinal phosphate and calcium absorption in normal subjects. Nephrol Dial Transplant. 1995;10: 1376–1380. [ PubMed ] 215. Gray SL, LaCroix AZ, Larson J, et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women’s Health Initiative. Arch Intern Med . 2010;170:765–771. [ PMC free article ] [ PubMed ] 216. Johnson DA. Safety of proton pump inhibitors: current evidence for osteoporosis and interaction with antiplatelet agents. Curr Gastroenterol Rep. 2010;12:167–174. [ PubMed ] 217. Corley DA. Proton pump inhibitor, H2 antagonists, and risk of hip fracture: a large population-based study . Gastroenterology . 2009;136:A70. 218. Moayyedi P, Cranney A. Hip fracture and proton pump inhibitor therapy: balancing the evidence for benefit and harm. Am J Gastroenterol . 2008;103:2428–2431. [ PubMed ] 219. Targownik LE, Lix LM, Leung S, Leslie WD. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology . 2010;138:896–904. [ PubMed ] 220. Laine L. Proton pump inhibitors and bone fractures? Am J Gastroenterol . 2009;104: S21–S26. [ PubMed ] 221. Laura E. Targownik, Lisa M. Lix, Colleen J. Metge, Heather J. Prior, Stella Leung, William D. Leslie. Use of proton pump inhibitors and risk of osteoporosis-related fractures . CMAJ . 2008 August 12; 179(4): 319–326. doi: 10.1503/cmaj.071330 222. Tetsuhide Ito, Robert T. Jensen. Association of Long-term Proton Pump Inhibitor Therapy with Bone Fractures and effects on Absorption of Calcium, Vitamin B12, Iron, and Magnesium . Curr Gastroenterol Rep . 2010 December; 12(6): 448–457. 223. Cundy T, Dissanayake A. Severe hypomagnesaemia in long-term users of proton-pump inhibitors. Clin Endocrinol (Oxf). 2008;69:338–341. [ PubMed ] 224. Kuipers MT, Thang HD, Arntzenius AB. Hypomagnesaemia due to use of proton pump inhibitors&#8211;a review. Neth J Med . 2009;67:169–172. [ PubMed ] 225. Shabajee N, Lamb EJ, Sturgess I, Sumathipala RW. Omeprazole and refractory hypomagnesaemia. BMJ . 2008;337:a425. [ PMC free article ] [ PubMed ] 226. Mackay JD, Bladon PT. Hypomagnesaemia due to proton-pump inhibitor therapy: a clinical case series. QJM . 2010;103:387–395. A recent report of the characteristic of 10 cases of PPI induce hypomagnesemia emphasizing the refractoriness of it, severity of its manifestations, and disappearance when the PPI is stopped. [ PubMed ] 227. Hoorn EJ, van der Hoek J, de Man RA, et al. A Case Series of Proton Pump Inhibitor-Induced Hypomagnesemia. Am J Kidney Dis . 2010 [ PubMed ] 228. Francois M, Levy-Bohbot N, Caron J, Durlach V. Chronic use of proton-pump inhibitors associated with giardiasis: A rare cause of hypomagnesemic hypoparathyroidism? Ann Endocrinol (Paris) . 2008;69:446–448.[ PubMed ] 229. Broeren MA, Geerdink EA, Vader HL, van den Wall Bake AW. Hypomagnesemia induced by several proton-pump inhibitors. Ann Intern Med. 2009;151:755–756. [ PubMed ] 230. Nand B, Bhagat M. Serious and commonly overlooked side effect of prolonged use of PPI. Am J Med . 2014 Sep;127(9):e5. doi: 10.1016/j.amjmed.2014.06.002. Epub 2014 Jun 10 231. McColl KE . Effect of proton pump inhibitors on vitamins and iron. Am J Gastroenterol. 2009 Mar;104 Suppl 2:S5-9. doi: 10.1038/ajg.2009.45. 232. Ozutemiz AO, Aydin HH, Isler M, Celik HA, Batur Y. Effect of omeprazole on plasma zinc levels after oral zinc administration. Indian J Gastroenterol . 2002 Nov-Dec;21(6):216-8. 233. Henderson LM 1 , Brewer GJ , et al. Effect of intragastric pH on the absorption of oral zinc acetate and zinc oxide in young healthy volunteers. JPEN J Parenter Enteral Nutr. 1995 Sep-Oct;19(5):393-7. 234. Farrell CP, Morgan M, et al. Proton pump inhibitors interfere with zinc absorption and zinc body stores. Gastroent Res . 2011;4:243–251. 235. Marcos Pedrosa and Robert Russell. Chronic gastritis and hypochlorhydria in the elderly. Ch.11: Folate and vitamin B12 absorption in atrophic gastritis. 1993 by CRC Press, Inc. 183. Saltzman JR 1 , Kowdley KV , Pedrosa MC , Sepe T , Golner B , Perrone G , Russell RM . Bacterial overgrowth without clinical malabsorption in elderly hypochlorhydric subjects. Gastroenterology . 1994 Mar;106(3):615-23. 184. Lombardo L 1 , Foti M , Ruggia O , Chiecchio A . Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin Gastroenterol Hepatol . 2010 Jun;8(6):504-8. doi: 10.1016/j.cgh.2009.12.022. Epub 2010 Jan 6. 185. Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis. Clin Gastroenterol Hepatol . 2013 May;11(5):483-490. 186. Bajaj JS 1 , Cox IJ 2 , Betrapally NS 3 , et al. Systems biology analysis of omeprazole therapy in cirrhosis demonstrates significant shifts in gut microbiota composition and function. Am J Physiol Gastrointest Liver Physiol. 2014 Nov 15;307(10):G951-7. doi:10.1152/ ajpgi.00268. 2014. Epub 2014 Sep 25. 236. Hegarty JP 1 , Sangster W 1 , Harris LR 3rd 1 , Stewart DB 2 . Proton pump inhibitors induce changes in colonocyte gene expression that may affect Clostridium difficile infection. Surgery . 2014 Oct;156(4):972-8. doi: 10.1016/j.surg.2014.06.074. Epub 2014 Aug 21. 237. Wu D 1 , Qiu T , Zhang Q , Kang H , Yuan S , Zhu L , Zhu R . Systematic Toxicity Mechanism Analysis of Proton Pump Inhibitors: An In Silico Study. Chem Res Toxicol. 2015 Feb 9. [Epub ahead of print]","date_published":"2015-07-27T04:37:58","date_modified":"2024-01-29T12:24:37","authors":[{"name":"Dr. Richard Esquivel","url":"https://sanjosefuncmed.com/about/"}],"tags":["Digestive Health"]},{"id":"https://sanjosefuncmed.com/common-stomach-disorders/","url":"https://sanjosefuncmed.com/common-stomach-disorders/","title":"Gastroesophageal Reflux Disease (GERD): Deeper Education","summary":"An in-depth educational review of gastroesophageal reflux disease (GERD).","content_text":"Gastroesophageal Reflux Disease (GERD) Gastroesophageal reflux disease (GERD) is an extremely prevalent condition in our society as evidenced by the constant television commercials bombarding us with ads for drugs that are supposed to solve all our heartburn problems and lead us to a better life. It has been estimated the prevalence of GERD symptoms in the general population may be up to 30% in the U.S.[125] but other studies show it could be as high as 34% to 40%.[126] Make no mistake about it. These are block-buster drugs that make the pharmaceutical companies billions of dollars annually . Proton-pump inhibitors (PPIs) are the third-highest selling class of drugs in the United States, with $13.9 billion in annual sales.[127] Sales of Nexium (the “purple pill” by Astra Zeneca) topped $6.1 billion in 2013 alone, the second highest prescribed medication in the U.S.[128] Is GERD the Result of Excess Acid Production? The symptoms of GERD include heartburn, chest pain and sour regurgitation. It is commonly believed to result from excess acid production in the stomach. This is what the drug companies want us to believe because this is the mechanism their drugs target. However, most of the medical literature on GERD indicates otherwise. “First, excessive gastric acid secretion is not a major factor in GERD pathogenesis. Second, a substantial proportion of symptom-provoking reflux episodes are not caused by acid reflux.” [129] Excess Acid Production is Not the Underlying Cause of GERD Let’s think about this. We know that as we age, gastric acid production decreases, along with pancreatic enzyme secretion.[130] If excess acid production was really the primary mechanism involved in GERD, we would expect to see young children at their peak of digestive function and enzyme secretion popping the purple pills to treat their heartburn! We would expect to see decreased incidence of GERD as people age. As we know, this is far from the reality and in fact, the opposite is the case. GERD is a much more common condition in the elderly, and the incidence of GERD increases, not decreases, as people age.[130] So obviously something else must be going on here that results in GERD. But of course, the drug companies won’t tell you this. And most doctors continue to prescribe PPIs to treat GERD telling their patients that they suffer from a problem of excess acid production. So what’s really going on in GERD? The Real Cause of GERD I will attempt to summarize a somewhat complex condition in the following section. For a more thorough explanation of GERD and the cause of GERD and bacterial overgrowth, please see my article: The Cause of GERD and Bacterial Overgrowth (coming soon) An important cause of GERD is related to failure of the valve mechanism which exists between the esophagus and the stomach, formed by the lower esophageal sphincter (LES) and the diaphragm, which normally prevents reflux of stomach contents into the esophagus.[135] A decrease in pressure of the LES can allow esophageal reflux of gastric contents. Some patients with GERD have a constantly weak, low-pressure LES, which permits reflux every time the pressure in the stomach exceeds the LES pressure. Periodic relaxation of the LES in normal individuals is called “transient lower esophageal sphincter relaxation” (TLESR). When it becomes more frequent and prolonged, TLESRs are believed to contribute significantly to reflux disease.[144] “Recent studies have suggested that transient lower esophageal sphincter relaxation is the main mecha nism underlying gastroesophageal reflux.”[143] In patients with GERD, TLESRs account for the majority of reflux episodes.[145] Gastric distension (also known as “intra-abdominal pressure” or IAP) has been recognized as a major factor inducing TLESRs.[146-148] “We conclude that gastric distention, by significantly increasing the rate of transient LES relaxations in both normal subjects and patients with gastroesophageal reflux disease, may contribute to the postprandial increase in gastroesophageal reflux.”[146] But the million-dollar question that few people are asking is: “What causes gastric distension or intra-abdominal pressure (IAP) in the first place?” There are several related conditions that lead to IAP, including hypochlorhydria, protein putrefaction, carbohydrate malabsorption and bacterial overgrowth. Let’s briefly take a look at these related conditions. Causes of GERD: Hypochlorhydria and Protein Putrefaction It is well-documented in the scientific literature that indigestion of proteins in the intestines leads to a process known as protein putrefaction which can result in dyspepsia (indigestion), gas, bloating and diarrhea.[150,151] Protein putrefaction is caused by bacterial decomposition of undigested protein and results in production of foul-smelling odors.[152] This can also occur in the stomach.[153] Hydrochloric acid production and activity in the stomach is an important part of protein digestion. HCl partially digests protein so that it is more rapidly and efficiently digested by pancreatic enzymes in the small intestine. Decreased production of HCl (hypochlorhydria) or decreased pancreatic enzymes can lead to decreased protein digestion and increased protein putrefaction in the intestinal tract.[155] In addition, when hypochlorhydria is present, there is usually pancreatic enzyme deficiency present as well, since the acidity of the digested food stimulates the release of pancreatic enzymes. This then leads to carbohydrate malabsorption. “Protein putrefaction is often found alongside that of carbohydrate (malabsorption), though the latter is always the more marked.”[155] Causes of GERD: Carbohydrate Malabsorption and Bacterial Overgrowth In a book called, “Heartburn Cured: The Low-Carb Miracle”, microbiologist Norm Robillard, Ph.D., postulates that carbohydrate malabsorption leads to an increase in intra-abdominal pressure (IAP) resulting in acid reflux.[158] Dr. Robillard points out that intestinal bacteria primarily feed on carbohydrates and that these bacteria will ferment any carbohydrate that is not absorbed. Bacterial fermentation leads to excess gas production . The resulting gas increases IAP, which is the driving force behind loss of LES function, acid reﬂux and GERD. When stomach acid is suﬃcient and carbohydrates are consumed in moderation, they are properly broken down into glucose and rapidly absorbed in the small intestine before they can be fermented by small intestinal bacteria. However, if stomach acid is insu ﬃcient or carbohydrates are consumed in excess, some of the carbohydrate can escape absorption and become available for fermentation by intestinal bacteria. Carbohydrate malabsorption therefore leads to an increase in bacterial fermentation and increased gas production. Dr. Robillard cites a study by Suarez and Levitt, showing that 30 grams of carbohydrate that escapes absorption in a day could produce more than 10,000 mL (ten liters) of hydrogen gas! Additionally, increased undigested carbohydrate in the stomach and intestines allows for bacterial overgrowth since these intestinal bacteria will proliferate with large amounts of undigested food. So his solution to GERD and bacterial overgrowth is simple: decrease carbohydrate intake! Hypochlorhydria: The Primary Cause of Carbohydrate Malabsorption, Bacterial Overgrowth and GERD? Stomach acid (HCl) is primarily involved in protein digestion, however, HCl content can also affect carbohydrate digestion. HCl supports the digestion and absorption of carbohydrates by stimulating the release of pancreatic stimuli such as CCK and secretin, which then stimulate pancreatic secretion of enzymes. If the acidity of the intestinal contents is too low (due to insuﬃcient stomach acid), this can affect the secretion of pancreatic enzymes and can affect carbohydrate digestion. Interestingly, human trials examining the effects of HCl on carbohydrate digestion are unavailable in a thorough search of the literature. However, in vitro studies have shown that carbohydrate digestion of rice, starches and vegetables, is improved in the presence of increased hydrochloric acid (HCl). [167-169] Human studies have also shown improved fat digestion and absorption in the presence of HCl.[170] Does HCl Supplementation Decrease Gastric Distension and GERD? It’s really quite shocking how few studies have been done to investigate the benefits of HCl supplementation in the treatment of GERD. Why is this? The most probable explanation is that there is no profit in carrying out this type of study since drug companies cannot patent HCl. There was one small study performed which examined whether the symptoms of gastric distension (IAP) in a group of 9 people were influenced by gastric infusion of HCl. Not surprisingly, the study concluded that sensations of gastric distension were reduced by adding HCl into the stomach in the study group.[171] A more interesting study, much larger in size and involving over 350 people with GERD, divided the participants into 2 groups. The first group (A) received a supplement that contained a combination of betaine HCl, melatonin, l-tryptophan, vitamins B6, B12 and folic acid and methionine. The other group (B) received 20 mg of omeprazole (PPI). Here’s what the study concluded: “All patients of the group A (100%) reported a complete regression of symptoms after 40 days of treatment. On the other hand, 115 subjects (65.7%) of the omeprazole (PPI) reported regression of symptoms in the same period. There was a statistically significant difference between the groups (P &lt; 0.05). This formulation promotes regression of GERD symptoms with no significant side effects.”[172] Conventional Treatment of GERD Conventional treatment of GERD relies on acid-suppressing medications, primarily PPIs (proton-pump inhibitors) such as omeprazole. However, as discussed, there are several problems with using PPIs or other acid-suppressing medication to treat GERD. First, PPIs do not address the underlying cause of GERD (LES dysfunction due to increased intra-abdominal pressure secondary to hypochlorhydria and carbohydrate malabsorption) and therefore are not very effective in the management of GERD. Second, there are many adverse effects associated with PPIs. Let’s start by briefly reviewing the research on the efficacy of PPIs in the treatment of GERD. We will then take a close look at the research on the various adverse effects associated with this class of medications. PPIs Are Not Effective Against GERD Proton-pump inhibitors (PPIs) are the strongest class of acid-suppressing medications available. They are very effective in inhibiting the production of acid in the stomach. However, as we have seen, excess acid production is not the cause of GERD. Since we now know the cause of GERD is insufficient production of HCl leading to carbohydrate malabsorption, bacterial fermentation and increased intra-abdominal pressure causing dysfunction of the LES, we can see how acid-suppressing medications, such as PPIs, do nothing to address the underlying cause of GERD or reduce the incidence of GERD. This has been shown to be the case by several large studies.[135,173,174] People continue to have the same underlying problems of GERD while on PPIs. The only difference is there is less acid content available in their refluxate to irritate the esophagus.[135,173,174] And like most drugs, once the medication is stopped, the original condition returns. “The simultaneous use of intra-esophageal impedance and pH measurement of acid and non-acid gastroesophageal reflux has clearly shown that treatment with PPIs only changes the pH of the refluxate, without stopping reflux through a functionally or mechanically incompetent LES. Vela et al have shown that during treatment with omeprazole, postprandial reflux still occurs but it becomes predominantly non-acid.”[135] Risks Associated with PPIs “Emerging data illustrate the potential risks associated with both short-and long-term PPI therapy, including Clostridium difficile –associated diarrhea, community-acquired pneumonia, osteoporotic fracture, vitamin B12 deficiency, and inhibition of antiplatelet therapy. Due to these associations, it is recommended that clinicians assess the continuing need for PPI therapy and use the lowest possible dose to achieve the desired therapeutic goals.”[176] “…mounting data demonstrate concerns about the long-term use of PPIs…the collective body of information overwhelmingly suggests an increased risk of infectious complications and nutritional deficiencies.”[175] “The risk of pneumonia was increased 27-39% in short-term use of PPIs in three meta-analyses. C. difficile infections were also associated with the use of PPIs (odds ratio: 2.15; 95% CI: 1.81-2.55; p &lt; 0.00001). This effect appears to be dose related. The U.S. FDA has recently issued a warning regarding fractures and the impaired magnesium absorption associated with the use of PPIs. Thrombocytopenia, iron deficiency, vitamin B12 deficiency, rhabdomyolysis and acute interstitial nephritis have also been reported with the use of PPIs. There is mounting evidence that PPIs are associated with serious adverse effects. Practitioners should be vigilant and counsel patients accordingly.”[177] How Do Proton Pump Inhibitors (PPIs) Work? PPIs act by strongly inhibiting the enzyme in parietal cells that allows for acid production in the stomach.[178] They represent the most powerful class of acid-suppressing medications ever developed. Since stomach acid has three primary functions in the stomach (ie: prevent bacterial infection, aid in digestion of protein and aid in nutrient absorption) it’s not surprising that the risks associated with the use of PPIs or other acid-suppressing medications would be related to these critical functions of stomach acid. Studies have shown both short- and long-term use of these medications have been associated with various side effects, such as decreased absorption of vitamins and minerals, such as calcium, vitamin B12, iron and magnesium and increased risk of bone fractures.[179-182] PPIs are recently being associated with increased risk of bacterial overgrowth in the small intestine (SIBO) due to their acid-suppressing effects, related to the important role that acid plays in preventing bacterial infection and preventing dysbiosis (imbalance of gut bacteria). [183-186] They have also been shown to inhibit digestion of proteins and cause food allergy in an animal model study.[187] PPIs are now routinely used in infants and children who suffer from vomiting attributed to acid reflux but not without adverse effects. One long-term study found that adverse effects have been reported in 34% of children treated with PPIs and include headaches, diarrhea, nausea and constipation.[188] PPIs have also been associated with more severe infections, including hospital-acquired life-threatening infections in immune-suppressed infants and children. “Acid suppression may place immune deficient infants and children or those with indwelling catheters, at risk for the development of lower respiratory infections and nosocomial sepsis.”[188] Summary of GERD and the Treatment of GERD with PPIs: As the current literature makes clear, excess acid production is not the underlying cause of GERD. Recent research has found that GERD results from dysfunction of the lower esophageal sphincter (LES), which allows gastric contents (including stomach acids) to reflux into the esophagus, causing the symptoms associated with acid reflux. The cause of dysfunction of the LES appears to be related to increased intra-abdominal pressure (IAP), which results from incomplete digestion of protein and carbohydrates due to insufficient production of stomach acids. Stomach acid is important in protein digestion and also aids in stimulation of the pancreas to secrete digestive enzymes which are used in carbohydrate digestion and absorption. Dr. Robillard’s pioneering work supports the concept that incomplete carbohydrate digestion and absorption causes increased bacterial fermentation in the intestines leading to increased gas and IAP. According to his research, this is the cause of GERD, which is supported by the literature on this topic, pointing to IAP as the cause of GERD. Acid-suppressing medications such as PPIs have no impact on the frequency or severity of esophageal reflux. The only impact that PPIs have on the symptoms of GERD is making the contents of the refluxate less acidic, thereby decreasing symptoms associated with stomach acid entering the esophagus. However, there are many adverse effects associated with PPI use, including increased risk of bacterial infection, decreased absorption of various vitamins and minerals leading to nutritional deficiencies and osteoporosis-related bone fractures. Worse than that, by suppressing acid production, PPIs lead to decreased protein and carbohydrate digestion and increased risk of malabsorption, intra-abdominal pressure and GERD. One editorial entitled “Evidence That Proton-Pump Inhibitor Therapy Induces the Symptoms it is Used to Treat” commented on an article published in a British gastroenterology journal which came to this very conclusion: “Treating gastroesophageal reflux disease with profound acid inhibition will never be ideal because acid secretion is not the primary underlying defect. Acid secretion is normal in most patients with reflux disease and acid inhibitory therapy makes it abnormally low. It is never ideal to treat one abnormality by creating another, as was the case for many years with management of ulcer disease before the disco- very of H. pylori infection. The pathophysiology of acid reflux concerns the dysfunction of the gastroesophageal barrier and research needs to refocus on ways of restoring its competence rather than merely suppressing gastric acid secretion.”[238] Clinical Management of GERD in Functional Medicine Many functional medicine doctors have found that supplementation with betaine HCl and pepsin has been extremely helpful in managing GERD and its associated symptoms. Some people will experience a “burning” sensation in the stomach when they supplement with HCl. I attribute this to irritation or thinning of the gastric lining that protects the stomach from the acidic HCl. In many cases, when we address the irritated gastric lining, they are able to tolerate HCl supplementation. I believe the evidence is strong enough to warrant the use of HCl and pepsin and the clinical response with minimal side effects further justifies its use in the management of GERD. In addition, zinc carnosine has been shown to be helpful in managing a wide range of gastrointestinal conditions.[239] Zinc has been shown to improve the integrity of gastrointestinal epithelial tight junctions and barrier function and have protective effects of the stomach lining against gastric HCl.[239,240] In the next segment, we will take a closer look at the adverse effects associated with PPIs according to the most current literature. In the following segment, we will continue to examine the most common disorders that result from dysfunction of the stomach, including gastric (peptic) ulcers and duodenal ulcer disease. References 125. Mohammad Bashashati, Reza A Hejazi, Christopher N Andrews, Martin A Storr. Gastroesophageal reflux symptoms not responding to proton pump inhibitor: GERD, NERD, NARD, esophageal hypersensitivity or dyspepsia? Can J Gastroenterol Hepatol . 2014 June; 28(6): 335–341. 126. Huihui Sun, Ying Chen, et al. Abnormal activity of default mode network in GERD patients . BMC Neurosci . 2013; 14: 69. Published online 2013 July 11. doi: 10.1186/1471-2202-14-69 127. http://www.aafp.org/news/clinical-care-research/20100601ppifracture.html 128. http://www.medscape.com/viewarticle/820011 129. Guy Boeckxstaens, Hashem B El-Serag, André J P M Smout, Peter J Kahrilas. Symptomatic reflux disease : the present, the past and the future . Gut . 2014 July; 63(7): 1185–1193. Published online 2014 March 7. doi: 10.1136/gutjnl-2013-306393 130. Britton E, McLaughlin JT. Ageing and the gut . Proc Nutr Soc . 2013 Feb;72(1):173-7. doi: 10.1017/S0029665112002807. Epub 2012 Nov 12. Review. 131. Moraes-Filho J, Cecconello I, Gama-Rodrigues J, Castro L, Henry MA, Meneghelli UG, Quigley E. Brazilian consensus on gastroesophageal reflux disease: proposals for assessment, classification, and management. Am J Gastroenterol. 2002;97:241–248. [ PubMed ] 132. Sabine Roman, John E Pandolfino. Environmental –life style related factors . Best Pract Res Clin Gastroenterol. Author manuscript; available in PMC 2013 February 26. Published in final edited form as: Best Pract Res Clin Gastroenterol. 2010 December; 24(6): 847–859. doi: 10.1016/j.bpg.2010.09.010 133. Fatin R. Polat, Sabriye Polat. The Effect of Helicobacter Pylori on Gastroesophageal Reflux Disease . JSLS. 2012 Apr-Jun; 16(2): 260–263. doi: 10.4293/108680812X134279823-76860 134. B T Johnston, S A Lewis, A H Love. Psychological factors in gastro-oesophageal reflux disease. Gut . 1995 April; 36(4): 481–482. 135. Fernando A Herbella, Marco G Patti. Gastroesophageal reflux disease: From pathophysiology to treatment . World J Gastroenterol . 2010 August 14; 16(30): 3745–3749. Published online 2010 August 14. doi: 10.3748/wjg.v16.i30.3745 136. Tack J, Koek G, Demedts I, Sifrim D, Janssens J. Gastroesophageal reflux disease poorly responsive to single-dose proton pump inhibitors in patients without Barrett’s esophagus: acid reflux, bile reflux, or both? Am J Gastroenterol . 2004;99:981–988.[ PubMed ] 137. Herbella FA, Nipominick I, Patti MG. From sponges to capsules. The history of esophageal pH monitoring. Dis Esophagus . 2009;22:99–103. [ PubMed ] 138. Diener U, Patti MG, Molena D, Fisichella PM, Way LW. Esophageal dysmotility and gastroesophageal reflux disease. J Gastrointest Surg . 2001;5:260–265. [ PubMed ] 139. Patti MG, Perretta S. Gastro-oesophageal reflux disease: a decade of changes. Asian J Surg. 2003;26:4–6.[ PubMed ] 140. Meneghetti AT, Tedesco P, Damani T, Patti MG. Esophageal mucosal damage may promote dysmotility and worsen esophageal acid exposure. J Gastrointest Surg. 2005;9:1313–1317. [ PubMed ] 141. Kahrilas PJ. Anatomy and physiology of the gastroesophageal junction. Gastroenterol Clin North Am. 1997;26:467–486. [ PubMed ] 142. F De Giorgi, M Palmiero, I Esposito, F Mosca, R Cuomo. Pathophysiology of gastro-oesophageal reflux disease . Acta Otorhinolaryngol Ital . 2006 October; 26(5): 241–246. 143. Hirsch DP 1, Tytgat GN , Boeckxstaens GE . Transient lower oesophageal sphincter relaxations&#8211;a pharmacological target for gastro-oesophageal reflux disease? Aliment Pharmacol Ther. 2002 Jan;16(1):17-26. 144. Kessing BF 1 , Conchillo JM , Bredenoord AJ , Smout AJ , Masclee AA . Review article: the clinical relevance of transient lower oesophageal sphincter relaxations in gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2011 Mar;33(6):650-61. doi: 10.1111/j.1365-2036.2010.04565.x. Epub 2011 Jan 10. 145. Mittal RK, McCallum RW. Characteristics and frequency of transient relaxations of the lower esophageal sphincter in patients with reflux esophagitis. Gastroenterology. 1988;95:593-9. [ PubMed ] 146. Holloway RH, Hongo M, Berger K, McCallum RW. Gastric distension: a mechanism for postprandial gastroesophageal reflux. Gastroenterology 1985;89:779-84. [ PubMed ] 147. Straathof JW 1 , van Veen MM , Masclee AA . Provocation of transient lower esophageal sphincter relaxations during continuous gastric distension. Scand J Gastroenterol. 2002 Oct;37(10):1140-3. 148. Scheffer RCH, Akkermans LMA, Bais JE, Roelofs JM, Smout AJ, Gooszen HG. Elicitation of transient lower oesophageal sphincter relaxations in response to gastric distension and meal ingestion. Neurogastroenterol Motil 2002; 14 : 647–55. 149. C P Barham, D C Gotley, R Miller, A Mills, D Alderson. Pressure events surrounding oesophageal acid reflux episodes and acid clearance in ambulant healthy volunteers. Gut . 1993 April; 34(4): 444–449. 150. José M. Rosell. Studies in the Pathology of Digestion: I. Intestinal Fermentation and Putrefaction . Can Med Assoc J . 1929 July; 21(1): 42–46. 151. José M. Rosell. Studies in Digestive Pathology: II. The Mechanism of Fermentation and Putrefaction in the Intestines . Can Med Assoc J . 1929 August; 21(2): 161–168. Appl Microbiol Biotechnol. 2014 Mar;98(6):2779-87. doi: 10.1007/s00253-013-5271-5. Epub 2013 Oct 10. 152. http://en.wikipedia.org/wiki/Putrefaction 153. W. Hale White, M.D. The Royal Society of Medicine, March 10, 1913. A discussion on alimentary toxaemia; its sources, consequences, and treatment. General Survey. 154. Zajac, P; Holbrook, A; Super, ME; Vogt, M (March–April 2013). An overview: Current clinical guidelines for the evaluation, diagnosis, treatment, and management of dyspepsia. Osteopathic Family Physician 5 (2): 79–85. doi : 10.1016/j.osfp.2012.10.005 . 155. Physiology And Pathology With Its Applications To Practical Medicine. Ry Carl Von Noorden Professor of The First University Medical Clinic, Vienna Vol. II.— The Pathology Of Metabolism. By Carl Von Noorden, Fr. Kraus, Ad. Schmidt, W. Weintraud, M. Matthes, H. Strauss. 156. https://www.nfpt.com/blog/biochemistry-nutrition/ 157. Li JV, Ashrafian H, et al. Metabolic surgery profoundly influences gut microbial-host metabolic cross-talk. Gut . 2011 Sep;60(9):1214-23. doi: 10.1136/gut.2010.234708. Epub 2011 May 14. 158. Heartburn Cured: The Low Carb Miracle. Norm Robillard, Ph.D., 2005. www.heartburncured.com 159. Pehl C 1 , Pfeiffer A , Wendl B , Stellwag B , Kaess H . Effect of erythromycin on postprandial gastroesophageal reflux in reflux esophagitis. Dis Esophagus. 1997 Jan;10(1):34-7. 160. Pennathur A 1 , Tran A , Cioppi M , Fayad J , Sieren GL , Little AG . Erythromycin strengthens the defective lower esophageal sphincter in patients with gastroesophageal reflux disease. Am J Surg. 1994 Jan;167(1):169-72; discussion 172-3. 161. Austin GL, Thiny MT, Westman EC, Yancy WS Jr, Shaheen NJ. A very low-carbohydrate diet improves gastroesophageal reflux and its symptoms. Dig Dis Sci . 2006 Aug;51(8):1307-12. Epub 2006 Jul 27. 162. Yancy WS Jr, Provenzale D, Westman EC. Improvement of gastroesophageal reflux disease after initiation of a low-carbohydrate diet : five brief case reports. Altern Ther Health Med . 2001 Nov-Dec;7(6):120, 116-9. 163. Yoshihisa Urita, Toshiyasu Watanabe, et al. Extensive Atrophic Gastritis Increases Intraduodenal Hydrogen Gas . Gastroenterol Res Pract. 2008; 2008: 584929. Published online 2008 June 16. doi: 10.1155/2008/584929 164. Diagnosis and management of small intestinal bacterial overgrowth. Nutr Clin Pract. 2013 Jun;28(3):289-299. 165. Theisen J 1 , Nehra D , et al. S uppression of gastric acid secretion in patients with gastroesophageal reflux disease results in gastric bacterialovergrowth and deconjugation of bile acids. J Gastrointest Surg. 2000 Jan-Feb;4(1):50-4. 166. Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis. Clin Gastroenterol Hepatol. 2013 May;11(5):483-490. 167. Li H, Zhu Y, Jiao A, Zhao J, Chen X, Wei B, Hu X, Wu C, Jin Z, Tian Y. Impact of α-amylase combined with hydrochloric acid hydrolysis on structure and digestion of waxy rice starch. Int J Biol Macromol . 2013 Apr;55:276-81. doi: 10.1016/j.ijbiomac.2013.01.021. Epub 2013 Jan 26. 168. Vallejo F, Gil-Izquierdo A, Pérez-Vicente A, García-Viguera C. In vitro gastrointestinal digestion study of broccoli inflorescence phenolic compounds, glucosinolates, and vitamin C. J Agric Food Chem . 2004 Jan 14;52(1):135-8. 169. Ginette Doué, Micaël Bédikou, Gisèle Koua, Rose-Monde Mégnanou, Sébastien Niamké. Enzymatic and acid conversion of new starches from improved orphan crops: prospects for renewable materials uses in food and non-food industries . Springerplus. 2014; 3: 498. Published online 2014 September 3. doi: 10.1186/2193-1801-3-498 170. Parker Vanamee, Walter Lawrence, Jr., Sam Levin, Ann S. Peterson, Henry T. Randall. Further Observations on Postgastrectomy Steatorrhea: The Effect of High Carbohydrate Intake and of Hydrochloric Acid Administration on Fat Absorption . Ann Surg. 1959 September; 150(3): 517–527. 171. Coffin B 1 , Chollet R , Flourié B , Lémann M , Franchisseur C , Rambaud JC , Jian R . Intraluminal modulation of gastric sensitivity to distension: effects of hydrochloric acid and meal. Am J Physiol Gastrointest Liver Physiol. 2001 May;280(5):G904-9. 172. Pereira Rde S. Regression of gastroesophageal reflux disease symptoms using dietary supplementation with melatonin, vitamins and aminoacids: comparison with omeprazole. J Pineal Res . 2006 Oct;41(3):195-200. 173. Tamhankar AP 1 , Peters JH , Portale G , Hsieh CC , Hagen JA , Bremner CG , DeMeester TR . Omeprazole does not reduce gastroesophageal reflux: new insights using multichannel intraluminal impedance technology. J Gastrointest Surg . 2004 Nov;8(7):890-7; discussion 897-8. 174. Tack J 1 , Koek G , Demedts I , Sifrim D , Janssens J . Gastroesophageal reflux disease poorly responsive to single-dose proton pump inhibitors in patients without Barrett’s esophagus: acid reflux, bile reflux, or both? Am J Gastroenterol. 2004 Jun;99(6):981-8. 175. Ali T, Roberts DN, Tierney WM. Long-term safety concerns with proton pump inhibitors. Am J Med. 2009;122:896–903. 176. Joel J. Heidelbaugh, Kathleen L. Goldberg, John M. Inadomi. Adverse Risks Associated With Proton Pump Inhibitors: A Systematic Review . Gastroenterol Hepatol (N Y) 2009 October; 5(10): 725–734. 177. Wilhelm SM 1 , Rjater RG , Kale-Pradhan PB . Perils and pitfalls of long-term effects of proton pump inhibitors. Expert Rev Clin Pharmacol. 2013 Jul;6(4):443-51. doi: 10.1586/17512433.2013.811206. 178. John Calam, J H Baron. Pathophysiology of duodenal and gastric ulcer and gastric cancer . BMJ . 2001 October 27; 323(7319): 980–982. 179. Tetsuhide Ito, Robert T. Jensen. Association of Long-term Proton Pump Inhibitor Therapy with Bone Fractures and effects on Absorption of Calcium, Vitamin B12, Iron, and Magnesium . Curr Gastroenterol Rep. December; 12(6): 448–457. doi: 10.1007/s11894-010-0141-0 180. Laura E. Targownik, Lisa M. Lix, et al. Use of proton pump inhibitors and risk of osteoporosis-related fractures . CMAJ. 2008 August 12; 179(4): 319–326. doi 10.1503/cmaj .071330 181. Katz PO 1 , Zavala S . Proton pump inhibitors in the management of GERD . J Gastrointest Surg. 2010 Feb;14 Suppl 1:S62-6. doi: 10.1007/s11605-009-1015-3. Epub 2009 Sep 23. 182. Fashner J, Gitu AC. Common gastrointestinal symptoms: risks of long-term proton pump inhibitor therapy. FP Essent. 2013 Oct;413:29-39. Review. 183. Saltzman JR 1 , Kowdley KV , Pedrosa MC , Sepe T , Golner B , Perrone G , Russell RM . Bacterial overgrowth without clinical malabsorption in elderly hypochlorhydric subjects. Gastroenterology . 1994 Mar;106(3):615-23. 184. Lombardo L 1 , Foti M , Ruggia O , Chiecchio A . Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin Gastroenterol Hepatol . 2010 Jun;8(6):504-8. doi: 10.1016/j.cgh.2009.12.022. Epub 2010 Jan 6. 185. Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis. Clin Gastroenterol Hepatol . 2013 May;11(5):483-490. 186. Bajaj JS 1 , Cox IJ 2 , Betrapally NS 3 , et al. Systems biology analysis of omeprazole therapy in cirrhosis demonstrates significant shifts in gut microbiota composition and function. Am J Physiol Gastrointest Liver Physiol. 2014 Nov 15;307(10):G951-7. doi:10.1152/ ajpgi.00268. 2014. Epub 2014 Sep 25. 187. Untersmayr E, Scholl I, Schwoboda I, et al. Antacid medications inhibits digestion of dietary proteins and causes food allergy: A fish allergy model in Balb/c mice. J Allerg Clin Immun. 2003;112:616-623 188. Cohen S 1 , Bueno de Mesquita M , Mimouni FB . Adverse effects reported in the use of gastroesophagal reflux disease treatments in children: a 10 years literature review. Br J Clin Pharmacol. 2015 Mar 5. doi: 10.1111/bcp.12619. [Epub ahead of print] 238. Kenneth E.L. McColl, Derek Gillen. Evidence That Proton-Pump Inhibitor Therapy Induces the Symptoms it is Used to Treat-EDITORIAL . Division of Cardiovascular & Medical Sciences, University of Glasgow, Gardiner Institute, Glasgow, UK. Gastroenterology, published online 01 June 2009. Refers to article: “Proton-Pump Inhibitor Therapy Induces Acid-Related Symptoms in Healthy Volunteers After Withdrawal of Therapy” 13 April 2009. Christina Reimer, Bo Sondergaard, Linda Hilsted, Peter Bytzer. Gastroenterology July 2009 (Vol. 137, Issue 1, Pages 80-87.e1) 239. Sonja Skrovanek, Katherine DiGuilio, et al. Zinc and gastrointestinal disease . World J Gastrointest Pathophysiol . 2014 November 15; 5(4): 496–513. Published online 2014 November 15. 240. Ueda K, Ueyama T, Oka M, Ito T, Tsuruo Y, Ichinose M. Polaprezinc (Zinc L-carnosine) is a potent inducer of anti-oxidative stress enzyme, heme oxygenase (HO)-1 &#8211; a new mechanism of gastric mucosal protection. J Pharmacol Sci . 2009 Jul;110(3):285-94. Epub 2009 Jun 19.","date_published":"2015-06-30T05:27:23","date_modified":"2020-04-22T01:03:09","authors":[{"name":"Dr. Richard Esquivel","url":"https://sanjosefuncmed.com/about/"}],"tags":["Digestive Health"]},{"id":"https://sanjosefuncmed.com/neuroendocrine-system-gut-brain-gut-axis/","url":"https://sanjosefuncmed.com/neuroendocrine-system-gut-brain-gut-axis/","title":"The Neuroendocrine System of the Gut & the Gut-Brain Axis","summary":"An educational review of communication between the gastrointestinal tract, enteric nervous system and brain.","content_text":"The Neuroendocrine System of the Gut The neuroendocrine system (NES) of the gut consists of two parts: the gut endocrine cells, which are located in the gut mucosa, and the peptidergic, serotonergic and nitric oxide-containing nerves of the enteric nervous system (ENS) in the gut wall.[361] This system regulates several functions of the GI tract, such as motility, secretion, absorption, microcirculation in the gut, local immune defense and cell proliferation.[361] The ENS comprises a large variety of neurotransmitters and associated receptors. Almost every known neurotransmitter can be found in the ENS of the gut, and most of the receptors associated with these neurotransmitters are also found in the gut.[361] Gut Endocrine Cells The gut contains a large number of endocrine cells that are dispersed among the epithelial cells of the gut mucosa throughout the entire GI tract except for the esophagus.[397-401] These cells constitute the largest endocrine organ in the body and comprise about 1% of all epithelial cells in the gastrointestinal tract, where they are separated from one another by epithelial cells.[397,398,402-404] These cells have specialized microvilli (tiny finger-like projections) that project into the lumen and function as sensors for the gut contents and respond to luminal stimuli by releasing hormones that, in general, target other parts of the digestive system.[405-414] There are at least 15 different populations of endocrine cells in the gastrointestinal tract.[397-399] Some of them have long slender cytoplasmic processes that project toward neighboring cells, increasing their paracrine effects (effects on surrounding cells).[415] The gut endocrine cells secrete signaling substances into the lamina propria of the gut lining, where they exert their action locally on nearby structures (autocrine/paracrine function) and/or via an endocrine mode of action (by circulating in the blood to reach distant targets).[416] These cells interact in an integrated manner with each other and with the enteric nervous system (ENS) and the afferent and efferent nerve fibers of the central nervous system (CNS), in particular the autonomic nervous system.[399,417,418] These cells regulate several functions of the gastrointestinal tract, including sensation, motility, secretion, absorption, local immune defense, and even food intake (by affecting the appetite).[397-399,418] Abnormalities in Gut Endocrine Cells in IBS Patients Abnormal endocrine/paracrine cells have been found in the stomach, proximal small intestine (duodenum), distal small intestine (ileum), colon and rectum of patients with IBS.[419-428] These gut endocrine cells produce various signaling peptides, such as grehlin, gastric inhibitory polypeptide, somatostatin, secretin, cholecystokinin (CCK), serotonin and polypeptide YY (PYY). Each of these peptides play important roles in secretion and gastric motility. In addition to the abnormalities observed in the endocrine cells, there are alterations in the levels of serotonin transporter (SERT), which appear to be increased in the ileum and decreased in the rectum of IBS patients.[428-430] Additionally, the mucosal 5-HT (serotonin) concentration has also been reported to be low in IBS patients which is significant since serotonin is the primary signaling hormone of the gut.[431] Is an Altered NES the Cause of IBS? In a recent paper published in a world gastroenterology journal, Magdy, El-Salhe, et al. propose that these abnormalities observed in the gut endocrine cells may constitute an anatomical basis for the disturbances in digestion, GI motility and hypersensitivity problems seen in IBS.[360] “In conclusion, there are sufficient grounds to suspect that the abnormalities in the gastrointestinal endocrine cells play a role in the development of visceral hypersensitivity, gastrointestinal dysmotility, and abnormal gastrointestinal secretion (in IBS patients).”[360] What Causes an Altered NES of the Gut? According to Magdy, El-Salhe, et al., the alteration in the NES could be the result of one or more of the following factors: genetic factors, dietary intake, intestinal flora or low-grade inflammation.[360] Genetic differences have been found between IBS patients and healthy subjects in genes controlling the serotonin signalling system and CCK. [422,425,426] Additionally, differences in the diet and the diversity and type of intestinal flora may affect the NES of the gut.[360] The release of different gut hormones depends on the composition and quantity of ingested food and intestinal bacteria present. The type and quantity of carbohydrate and fiber consumed, the amount of HCl and digestive enzymes present to aid in digestion and the subsequent fermentation of these unabsorbed foods by various intestinal bacteria can contribute to intestinal osmotic pressure (IAP). This change in intestinal pressure can stimulate hormonal release, such as the release of serotonin.[361] Likewise, inflammation and the release of secretory products from immune cells effects hormonal release and the proliferation of gut endocrine cells. Serotonin secretion, the predominant signaling hormone of the gut, can be enhanced or attenuated by the secretory products of certain immune cells such as CD4+ T-helper cells.[432] IBS has been associated with increased risk of inflammatory bowel disease (IBD) as well. IBS occurs in 32%-46% of patients with ulcerative colitis (UC) and in 42%-60% of Crohn’s disease patients who are in remission.[433-437] Fecal calprotectin has been found to be significantly elevated in UC and Crohn’s disease patients with IBS, compared to those without IBS-type symptoms, indicating the presence of GI inflammation.[437] The Brain-Gut Axis The NES of the gut is part of a larger system of communication between the brain and the gut that regulates all aspects of bowel activity and is gaining wider attention in the literature, known as the “brain-gut axis”. IBS is being viewed by many researchers in this field as a dysfunction of the brain-gut axis in the recent literature.[438-443] “Alterations in the bi-directional signaling between the enteric nervous system and the central nervous system and consequently between the brain and the gut may play a significant role in the pathophysiology of IBS.”[438] Communication between the brain and gut is complex and involves multiple systems including the brain cortex, hypothalamus, pituitary and adrenal glands. These structures are closely linked either by the peripheral nervous system or through neurohumoral stimuli and distinct responses have been shown in healthy subjects and IBS patients.[444,445] The gastrointestinal (GI) tract has a unique neuronal innervation that includes both an intrinsic neural network called the enteric nervous system (ENS) and an extrinsic neural network with connections to the brain via the spinal cord that provides sympathetic and parasympathetic innervation. The vagus nerve , an important part of the parasympathetic system, and its branches provide an important connection between the brain and the gut and convey both information to (ascending) and from (descending) the brain. These networks play a crucial role in the normal regulation and homeostasis of the GI tract.[438] “There is evidence that interactions within the brain and gut axis (BGA) that involves both the afferent-ascending and the efferent-descending pathways as well as the somatosensory cortex, insula, amygdala, anterior cingulate cortex and hippocampus are deranged in IBS showing both activation and inactivation.”[438] Enteric Nervous System The ENS is an autonomic network that can self-regulate itself and can function without input from the peripheral nervous system or brain.[446] It has been called “the brain of the gut” and “the second brain” based on its size, complexity and similarity to the brain.[447] This network is primarily housed in two nerve plexi and an intrinsic neural network . Its main function is to control movement of gut contents and peristalsis (coordinated muscle contractions of the bowel). It controls transit of intestinal contents through the stomach, small bowel and colon [448] and regulates secretory function and sensory-motor function.[446] These neurons are essential for the regulation of local reflexes that occur in response to various stimuli such as serotonin. Its activation results in motor and/or secretory responses.[449] Extrinsic network The extrinsic nerve supply to the GI tract modulates both secretion and motor function (and can override the neural signals of the ENS) and also establishes sensory communication between the ENS and the CNS. The extrinsic network acts in response to a broad variety of stimuli (thermal, chemical and painful) and via spinal and supra-spinal reflexes.[450] The extrinsic network is also comprised of two pathways: 1) Afferent (ascending): This involves vagal and spinal nerves that are mostly responsible for sensory transmission. 2) Efferent (descending): These pathways connect with both the peripheral and the brain, and provide information that induces both secretion of enzymes and peptides and induces peristalsis.[451] The CNS is a two-way traffic processor and regulator of bodily function. “The interactions between the gut and the CNS are complex and a vital part of normal homeostasis and regulation of GI physiology. This is a delicately balanced and fine-tuned system that allows bidirectional relay of messages between the gut and the brain, both at rest and during provocation such as after a meal or luminal distension and controls movements, reflexes, and sensory perceptions in the gut.”[438] Stress, the HPA and Brain-Gut Axis Stress has been linked to symptom generation in IBS and is associated with an altered response or a lack of adaptability in a subset of IBS patients.[452] Anxiety and depression are reported in 22%-30% of IBS patients and 32% have physical and/or sexual abuse.[453,454] Some IBS patients have a history of physical and/or sexual abuse causing traumatic stress which may lead to abnormal CNS pain processing.[455] There is some evidence showing that peripheral stimuli may activate stress hormones that may be involved in the pathophysiology of stress-sensitization. These types of IBS patients have increased psychological stress and increased severity of IBS symptoms. Treatment directed towards the psychiatric conditions can lead to reduction in symptom severity.[456] Neuroendocrine and autonomic output from the CNS to the periphery is modulated by several brain structures including the periventricular nucleus, amygdala and the pituitary gland.[457] Corticotropin (ACTH) plays a crucial role in regulating the response to stress. The limbic system through the amygdala is involved in the secretion of corticotropin releasing hormone (CRH or CRF), as well as the prefrontal cortex and anterior cingulate cortex.[458] Together they mediate the response to psychological stress through the hypothalamic-pituitary-adrenal (HPA) axis.[459] Studies in IBS patients have shown an impaired HPA axis. Anxiety and depression are also linked to alterations of the HPA axis. Emotion plays a key role in altering autonomic and endocrine function which in turn may derange the emotional circuitry. In healthy neural responses, peripheral stimuli travel through afferent pathways to the brain and they are filtered and evaluated in the subcortical regions before reaching the higher cortical regions of the brain, in order to prevent a circuit overload. When the filtering process is altered, stimuli can reach emotional areas, which in turn may activate deep brain structures leading to aberrant interpretation of symptoms. Consequently, non-noxious stimuli can be misinterpreted as painful or harmful. How this filtering process becomes altered in IBS patients is not yet known.[438] The Microbiota and the Brain-Gut Axis Recent data suggest that the human body is not such a neatly self-sufficient island after all. “The discovery of the size and complexity of the human microbiome has resulted in an ongoing reevaluation of many concepts of health and disease, including diseases affecting the CNS (brain). A growing body of preclinical literature has demonstrated bidirectional signaling between the brain and the gut microbiome, involving multiple neurocrine and endocrine signaling mechanisms.”[460] The role that the intestinal microbiota play in the integrity of the brain-gut axis is recently gaining significant attention in the literature.[460-465] Several researchers are now referring to functional GI disorders (FGIDs), such as IBS, as a dysfunction of the microbiota-brain-gut axis .[461-464] “A dysregulated gut-brain axis may be responsible for the main features of irritable bowel syndrome (IBS). However, the role of the gut microbiota is an underappreciated but critical node in this construct.”[461] Numerous studies have shown an association of dysbiosis (an imbalance of the gut flora) and IBS. One of the key questions that researchers are attempting to answer is whether dysbiosis is a cause of IBS . “Numerous clinical studies have documented various alterations in the composition of the gut microbiota in IBS, indicating defects in stability and diversity of this virtual organ.”[461] “Recently, attention has been focused on the microbiota as a possible factor in the pathogenesis of IBS.”[465] The gut microbiota have been shown to have an influence in several aspects to gut health, including immune responses, intestinal permeability, gut motility and abdominal pain. These are some of the ways that that the gut bacteria may contribute to the development of IBS. “It is clear that the microbiota is altered in IBS and that such alterations could well contribute to the pathogenesis of the disorder through, for example, increased permeability, an altered immune profile, effects on the central nervous system and modulation of gut neuromuscular function.”[465] One of the important recent discoveries was that the symptoms associated with IBS can be improved by improving the flora of the gut. “Manipulation of the gut microbiome influences the symptom profile in IBS and clear mechanisms have been elucidated to explain these interactions.”[464] Several specific bacterial probiotic strains have been shown to improve symptom severity and abdominal pain in IBS patients in numerous studies.[462,466-479] The symptoms that were assessed in the majority of these studies include abdominal pain, abdominal distension and bowel regularity. There are some species that in clinical trials appear to be more effective than others, such as Bifidobacterium species ( B. infantis 3564 and B. bifidum MIMBb75) [470,474,476] and Lactobacillus species ( Lactobacillus acidophilus -SDC 2012, 2013, L. paracasei B2106, L. plantarum 299V, and L. rhamnosus GG).[469,473,475] These probiotics appear to be effective in reducing abdominal pain and discomfort in adults and in children. Several studies have also suggested that combinations of different probiotic strains, such as VSL3# or mixtures of Bifidobacterium and Lactobacillus species, are able to decrease abdominal pain and discomfort in patients with IBS.[466,478,479] “Accumulating data suggest that, in a significant percentage of patients, the microbiota plays an important role in the genesis and maintenance of FGIDs (ie: IBS). Probiotic supplementation appears to be of therapeutic value…”[462] Gut Microbiota and Intestinal Permeability “Alterations in gut barrier function, occurring in response, or in parallel, to changes in the microbiota, have also been widely described and can be seen to play a pivotal role in generating and sustaining host immune responses both within and beyond the gut.”[469] The gut microbiome has been shown to directly affect the epithelial barrier through its regulation of tight junction proteins.[465] Commensal flora also contribute to the production of mucus as the mucus layer is considerably reduced in the gut of germ-free mice, but recovers on exposure to bacterial products.[480,481] This may be important considering the compromised epithelial barrier and alterations in permeability observed in IBS.[482,483] The mechanisms underlying this increased permeability in IBS include alterations in tight junction protein function, changes in the microbiota, presence of active inflammation and/or presence of pro-inflammatory cytokines.[484] In particular, reduction of the tight junction protein occludin-zonulin have been observed in IBS.[485,486] The authors of one article published in a major gastroenterology journal concluded the following regarding the role of the microbiota in IBS: “Moreover, it has been reliably demonstrated that manipulation of the microbiota can influence the key symptoms, including abdominal pain and bowel habit, and other prominent features of IBS. There are clear mechanisms through which the microbiota can produce these effects, both humoral and neural. Taken together, these findings firmly establish the microbiota as a critical node in the gut-brain axis and one which is amenable to therapeutic interventions.”[464] Conclusion An altered neuroendocrine system (NES) and dysregulation of the brain-gut axis appears to play a large role in the development of IBS. This is a new and exciting field of research with interesting theories and a number of potential directions of study. According to Magdy, El-Salhe, et al., the alteration in the gut NES could be the result of one or more of the following factors: genetic factors, dietary intake, intestinal flora or low-grade inflammation. As Magdy points out, the release of different gut hormones depends on the composition and quantity of ingested food. The type and quantity of carbohydrate and fiber consumed, the amount of HCl and digestive enzymes present to aid in digestion and the subsequent fermentation of these unabsorbed foods can contribute to intestinal osmotic pressure (IAP) which can stimulate hormonal release, such as the release of serotonin and contribute to the symptoms of IBS. This is the same mechanism involved in GERD and described in that previous section on GERD. As we will see in the next section on SIBO, there is a high percentage of prevalence of both IBS and bacterial overgrowth of the small intestines (SIBO) in the same individuals. This indicates a possible common mechanism between all three of these conditions. Namely, hypochlorhydria and/or excess carbohydrate intake leading to carbohydrate malabsorption and bacterial fermentation may be involved in all three of these common gut conditions. Gut flora seem to play an important role in gut health and are directly affected by our diet, as the gut bacteria feed on food that is left undigested and unabsorbed. Our diet has changed dramatically in recent years with the emergence and technological advances of the food industry, farming and agricultural changes. We now consume a large percentage of carbohydrates in the average diet and much of these are in the form of refined or processed carbohydrate and sugar, rather than whole grains, fruit and vegetables that may result in significant alterations in the balance of gut flora. In addition, our guts are being exposed to numerous environmental chemicals, hormones, antibiotics, genetically-modified foods and other toxins on a daily basis that may further affect the intestinal flora, intestinal permeability, intestinal inflammation and gut function. In addition to diet, there are other important factors that play an important role as well in IBS, such as genetic factors, intestinal flora and inflammatory responses. There have also been other factors identified in IBS that likely contribute to this condition, including altered stress responses, abnormal levels of hormones involved in stress responses, an altered HPA axis and abnormal conduction and processing of neural stimuli. These factors likely contribute to the dysfunction of the brain-gut axis seen in IBS. “Several mechanisms may be involved in the disruption and impairment of the brain and gut axis (BGA) that includes altered stress response, CRF release and processing, serotonin signaling and release, inflammatory insults and deranged conduction and processing of information”[438] References 397. May CL, Kaestner KH. Gut endocrine cell development . Mol Cell Endocrinol. 2010;323: 70–75.[ PMC free article ] [ PubMed ] 398. Gunawardene AR, Corfe BM, Staton CA. Classification and functions of enteroendocrine cells of the lower gastrointestinal tract. Int J Exp Pathol . 2011;92:219–231. [ PMC free article ] [ PubMed ] 399. El-Salhy M, Seim I, Chopin L, Gundersen D, Hatlebakk JG, Hausken T. Irritable bowel syndrome: the role of gut neuroendocrine peptides. Front Biosci (Elite Ed) 2012;4:2783–2800. [ PubMed ] 400. Tanaka-Shintani M, Watanabe M. Immunohistochemical study of enterochromaffin-like cell in human gastric mucosa. Pathol Int. 2007;57:572–583. [ PubMed ] 401. Lönroth H, Håkanson R, Lundell L, Sundler F. Histamine containing endocrine cells in the human stomach. Gut . 1990;31:383–388. [ PMC free article ] [ PubMed ] 402. Buffa R, Capella C, Fontana P, Usellini L, Solcia E. Types of endocrine cells in the human colon and rectum . Cell Tissue Res. 1978;192:227–240. [ PubMed ] 403. Schonhoff SE, Giel-Moloney M, Leiter AB. Minireview: Development and differentiation of gut endocrine cells. Endocrinology . 2004;145:2639–2644. [ PubMed ] 404. Sjölund K, Sandén G, Håkanson R, Sundler F. Endocrine cells in human intestine: an immunocytochemical study. Gastroenterology . 1983;85:1120–1130. [ PubMed ] 405. Sandström O, El-Salhy M. Ageing and endocrine cells of human duodenum. Mech Ageing Dev. 1999;108:39–48. [ PubMed ] 406. Tolhurst G, Reimann F, Gribble FM. Intestinal sensing of nutrients . Handb Exp Pharmacol. 2012;(209):309–335. [ PubMed ] 407. Parker HE, Reimann F, Gribble FM. Molecular mechanisms underlying nutrient-stimulated incretin secretion. Expert Rev Mol Med . 2010;12:e1. [ PubMed ] 408. Raybould HE. Nutrient sensing in the gastrointestinal tract: possible role for nutrient transporters. J Physiol Biochem . 2008;64:349–356. [ PubMed ] 409. San Gabriel A, Nakamura E, Uneyama H, Torii K. Taste, visceral information and exocrine reflexes with glutamate through umami receptors. J Med Invest . 2009;56 Suppl:209–217. [ PubMed ] 410. Rudholm T, Wallin B, Theodorsson E, Näslund E, Hellström PM. Release of regulatory gut peptides somatostatin, neurotensin and vasoactive intestinal peptide by acid and hyperosmolal solutions in the intestine in conscious rats. Regul Pept . 2009;152:8–12. [ PubMed ] 411. Sternini C, Anselmi L, Rozengurt E. Enteroendocrine cells: a site of ‘taste’ in gastrointestinal chemosensing. Curr Opin Endocrinol Diabetes Obes . 2008;15:73–78. [ PMC free article ] [ PubMed ] 412. Sternini C. Taste receptors in the gastrointestinal tract. IV. Functional implications of bitter taste receptors in gastrointestinal chemosensing. Am J Physiol Gastrointest Liver Physiol. 2007;292:G457–G461. [ PubMed ] 413. Buchan AM. Nutrient Tasting and Signaling Mechanisms in the Gut III. Endocrine cell recognition of luminal nutrients. Am J Physiol . 1999;277:G1103–G1107. [ PubMed ] 414. Montero-Hadjadje M, Elias S, Chevalier L, et al. Chromogranin A promotes peptide hormone sorting to mobile granules in constitutively and regulated secreting cells: role of conserved N- and C-terminal peptides. J Biol Chem.2009;284:12420–12431. [ PMC free article ] [ PubMed ] 415. Sandström O. Age-related changes in the neuroendocrine system of the gut: A possible role in the pathogenesis of gastrointestinal diorders in the elderly. Umeå University Medical Dissertations. Umeå: Umeå; 1999. pp. 1–46. [ PubMed ] 416. Rindi G, Inzani F, Solcia E. Pathology of gastrointestinal disorders . Endocrinol Metab Clin North Am. 2010;39:713–727. [ PubMed ] 417. Gershon MD. 5-Hydroxytryptamine (serotonin) in the gastrointestinal tract. Curr Opin Endocrinol Diabetes Obes. 2013;20:14–21. [ PMC free article ] [ PubMed ] 418. Seim I, El-Salhy M, Hausken T, Gundersen D, Chopin L. Ghrelin and the brain-gut axis as a pharmacological target for appetite control. Curr Pharm Des. 2012;18:768–775. [ PubMed ] 419. El-Salhy M, Wendelbo IH, Gundersen D. Reduced chromogranin A cell density in the ileum of patients with irritable bowel syndrome. Mol Med Rep . 2013;7:1241–1244. [ PubMed ] 420. El-Salhy M, Vaali K, Dizdar V, Hausken T. Abnormal small-intestinal endocrine cells in patients with irritable bowel syndrome. Dig Dis Sci . 2010;55:3508–3513. [ PubMed ] 421. El-Salhy M, Mazzawi T, Gundersen D, Hausken T. Chromogranin A cell density in the rectum of patients with irritable bowel syndrome. Mol Med Rep. 2012;6:1223–1225. [ PMC free article ] [ PubMed ] 422. El-Salhy M, Lomholt-Beck B, Hausken T. Chromogranin A as a possible tool in the diagnosis of irritable bowel syndrome. Scand J Gastroenterol. 2010;45:1435–1439. [ PubMed ] 423. El-Salhy M, Lillebø E, Reinemo A, Salmelid L. Ghrelin in patients with irritable bowel syndrome. Int J Mol Med. 2009;23:703–707. [ PubMed ] 424. El-Salhy M, Gundersen D, Ostgaard H, Lomholt-Beck B, Hatlebakk JG, Hausken T. Low densities of serotonin and peptide YY cells in the colon of patients with irritable bowel syndrome. Dig Dis Sci . 2012;57:873–878. [ PMC free article ] [ PubMed ] 425. Sjölund K, Ekman R, Wierup N. Covariation of plasma ghrelin and motilin in irritable bowel syndrome. Peptides . 2010;31:1109–1112. [ PubMed ] 426. Wang SH, Dong L, Luo JY, Gong J, Li L, Lu XL, Han SP. Decreased expression of serotonin in the jejunum and increased numbers of mast cells in the terminal ileum in patients with irritable bowel syndrome. World J Gastroenterol . 2007;13:6041–6047. [ PMC free article ] [ PubMed ] 427. Park JH, Rhee PL, Kim G, et al. Enteroendocrine cell counts correlate with visceral hypersensitivity in patients with diarrhoea-predominant irritable bowel syndrome. Neurogastroenterol Motil. 2006;18:539–546. [ PubMed ] 428. Coates MD, Mahoney CR, Linden DR, et al. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology . 2004;126:1657–1664. [ PubMed ] 429. El-Salhy M, Wendelbo I, Gundersen D. Serotonin and serotonin transporter in the rectum of patients with irritable bowel disease. Mol Med Rep . 2013;8:451–455. [ PubMed ] 430. Wendelbo I, Mazzawi T, El-Salhy M. Increased serotonin transporter immunoreactivity intensity in the ileum of patients with irritable bowel disease. Mol Med Rep . 2014;9: 180–184; Epub 2013 Nov 8. [ PubMed ] 431. El-Salhy M, Gundersen D, Ostgaard H, Lomholt-Beck B, Hatlebakk JG, Hausken T. Low densities of serotonin and peptide YY cells in the colon of patients with irritable bowel syndrome. Dig Dis Sci .2012;57:873–878. [ PMC free article ] [ PubMed ] 432. Khan WI, Ghia JE. Gut hormones: emerging role in immune activation and inflammation. Clin Exp Immunol . 2010;161:19–27. [ PMC free article ] [ PubMed ] 433. Isgar B, Harman M, Kaye MD, Whorwell PJ. Symptoms of irritable bowel syndrome in ulcerative colitis in remission. Gut . 1983;24:190–192. [ PMC free article ] [ PubMed ] 434. Ansari R, Attari F, Razjouyan H, Etemadi A, Amjadi H, Merat S, Malekzadeh R. Ulcerative colitis and irritable bowel syndrome: relationships with quality of life. Eur J Gastroenterol Hepatol. 2008;20:46–50.[ PubMed ] 435. Simrén M, Axelsson J, Gillberg R, Abrahamsson H, Svedlund J, Björnsson ES. Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors. Am J Gastroenterol . 2002;97:389–396. [ PubMed ] 436. Minderhoud IM, Oldenburg B, Wismeijer JA, van Berge Henegouwen GP, Smout AJ. IBS-like symptoms in patients with inflammatory bowel disease in remission; relationships with quality of life and coping behavior . Dig Dis Sci . 2004;49:469–474. [ PubMed ] 437. Keohane J, O’Mahony C, O’Mahony L, O’Mahony S, Quigley EM, Shanahan F. Irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease: a real association or reflection of occult inflammation? Am J Gastroenterol . 2010;105:1788, 1789–1794; quiz 1795. [ PubMed ] 438. Coss-Adame E, Rao SS. Brain and gut interactions in irritable bowel syndrome: new paradigms and new understandings. Curr Gastroenterol Rep . 2014 Apr;16(4):379. doi: 10.1007/s11894-014-0379-z. Review. 439. Emeran A. Mayer. Gut feelings: the emerging biology of gut–brain communication . Nat Rev Neurosci. Author manuscript; available in PMC 2013 December 2. Published in final edited form as: Nat Rev Neurosci. 2011 July 13; 12(8): 10.1038/nrn3071. Published online 2011 July 13. doi: 10.1038/nrn3071 440. Daulatzai MA. Chronic functional bowel syndrome enhances gut-brain axis dysfunction, neuroinflammation, cognitive impairment, and vulnerability to dementia. Neurochem Res . 2014 Apr;39(4):624-44. doi: 10.1007/s11064-014-1266-6. Epub 2014 Mar 4. Review. 441. Yu Y, Wu S, Li J, Wang R, Xie X, Yu X, Pan J, Xu Y, Zheng L. The effect of curcumin on the brain-gut axis in rat model of irritable bowel syndrome: involvement of 5-HT-dependent signaling. Metab Brain Dis. 2015 Feb;30(1):47-55. doi: 10.1007/s11011-014-9554-z. Epub 2014 May 8. 442. Peter Holzer, Florian Reichmann, Aitak Farzi. Neuropeptide Y, peptide YY and pancreatic polypeptide in the gut–brain axis . Neuropeptides . 2012 December; 46(6): 261–274. doi: 10.1016/j.npep.2012.08.005 443. Hyland NP, O’Mahony SM, O’Malley D, O’Mahony CM, Dinan TG, Cryan JF. Early-life stress selectively affects gastrointestinal but not behavioral responses in a genetic model of brain-gut axis dysfunction. Neurogastroenterol Motil. 2015 Jan;27(1):105-13. doi: 10.1111/nmo.12486. Epub 2014 Dec 2. 444. Mayer EA. The neurobiology of stress and gastrointestinal disease . Gut . 2000;47:861–869.[ PMC free article ] [ PubMed ] 445. Straub RH, Herfarth H, Falk W, et al. Uncoupling of the sympathetic nervous system and the hypothalamic–pituitary–adrenal axis in inflammatory bowel disease? J Neuroimmunol. 2002;126:116–125.[ PubMed ] 446. Hansen MB. The enteric nervous system I: The organization and classification. Pharmacol & Toxicol . 2003;92:105–113. [ PubMed ] 447. Gershon MD. The Second Brain. Harper Collins; New York: 1998. 448. Furness JB. Types of neurons in the enteric nervous system . J Auton Nerv Syst. 2000;81:87–96.[ PubMed ] 449. Langley JN. The Autonomic Nervous System, Part 1 . Cambridge : W. Heffer; 1921. 450. Hansen MD. Neurohumoral control of gastrointestinal motility . Physiol Res. 2003;52(1):1–30. [ PubMed ] 451. Hansen MB. The enteric nervous system II: Gastrointestinal functions. Pharmacol & Toxicol. 2003;92:249–257. [ PubMed ] 452. Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology .2006;130:1377–1390. [ PubMed ] 453. Thijssen AY, Jonkers DM, Leue C, et al. Dysfunctional cognitions, anxiety and depression in irritable bowel syndrome. J Clin Gastroenterol . 2010;44:e236–241. [ PubMed ] 454. Delvaux M, Denis P, Allemand H. Sexual abuse is more frequently reported by IBS patients than by patients with organic digestive diseases or controls. Results of a multicentre inquiry. French Club of Digestive Motility. Eur J Gastroenterol Hepatol. 1997;9:345–352. [ PubMed ] 455. Drossman DA, Leserman J, Nachman G, et al. Sexual and physical abuse in women with functional or organic gastrointestinal disorders. Ann Intern Med . 1990;113:828–833. [ PubMed ] 456. Bennett EJ, Tennant CC, Piesse C, Badcock CA, Kellow JE. Level of chronic life stress predicts clinical outcome in irritable bowel syndrome . Gut . 1998;43:256–261. [ PMC free article ] [ PubMed ] 457. Sternberg EM, Chrousos GP, Wilder RL, Gold PW. The stress response and the regulation of inflammatory disease. Ann Intern Med . 1992;117:854–866. [ PubMed ] 458. Sajdyk TJ, Shekhar A, Gehlert DR. Interactions between NPY and CRF in the amygdala to regulate emotionality. Neuropeptides . 2004;38:225–234. [ PubMed ] 459. Swanson LW, Sawchenko PE, Rivier J, Vale WW. Organization of ovine corticotropin-releasing factor immunoreactive cells and fibers in the rat brain: an immunohistochemical study. Neuroendocrinology .1983;36:165–186. [ PubMed ] 460. Emeran A. Mayer, Rob Knight, Sarkis K. Mazmanian, John F. Cryan, Kirsten Tillisch. Gut Microbes and the Brain: Paradigm Shift in Neuroscience . J Neurosci . 2014 November 12; 34(46): 15490–15496. doi: 10.1523/JNEUROSCI.3299-14.2014 461. Kennedy PJ, Cryan JF, Dinan TG, Clarke G. Irritable bowel syndrome: a microbiome-gut-brain axis disorder? World J Gastroentero l. 2014 Oct 21;20(39):14105-25. doi: 10.3748/wjg.v20.i39.14105. 462. De Palma G, Collins SM, Bercik P. The microbiota-gut-brain axis in functional gastrointestinal disorders. Gut Microbes. 2014 May-Jun;5(3):419-29. doi: 10.4161/gmic.29417. Epub 2014 Jun 12. 463. Peter Holzer, Aitak Farzi. Neuropeptides and the Microbiota-Gut-Brain Axis . Adv Exp Med Biol . Author manuscript; available in PMC 2015 March 15. Published in final edited form as: Adv Exp Med Biol. 2014; 817: 195–219. doi: 10.1007/978-1-4939-0897-4_9 464. Emeran A. Mayer, Tor Savidge, Robert J. Shulman. Brain Gut Microbiome Interactions and Functional Bowel Disorders . Gastroenterology . Author manuscript; available in PMC 2014 July 29. Published in final edited form as: Gastroenterology . 2014 May; 146(6): 1500–1512. Published online 2014 February 28. doi: 10.1053/j.gastro.2014.02.037 465. Hyland NP, Quigley EM, Brint E. Microbiota-host interactions in irritable bowel syndrome: epithelial barrier, immune regulation and brain-gut interactions. World J Gastroenterol . 2014 Jul 21;20(27):8859-66. doi: 10.3748/wjg.v20.i27.8859. Review. 466. Cui S, Hu Y. Multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study . Int J Clin Exp Med. 2012;5:238–44. [ PMC free article ][ PubMed ] 467. Diop L, Guillou S, Durand H. Probiotic food supplement reduces stress-induced gastrointestinal symptoms in volunteers: a double-blind, placebo-controlled, randomized trial. Nutr Res . 2008;28:1–5. doi: 10.1016/j.nutres.2007.10.001. [ PubMed ] [ Cross Ref ] 468. Enck P, Zimmermann K, Menke G, Klosterhalfen S. Randomized controlled treatment trial of irritable bowel syndrome with a probiotic E.-coli preparation (DSM17252) compared to placebo. Z Gastroenterol. 2009;47:209–14. doi: 10.1055/s-2008-1027702. [ PubMed ] [ Cross Ref ] 469. Francavilla R, Miniello V, Magistà AM, De Canio A, Bucci N, Gagliardi F, Lionetti E, Castellaneta S, Polimeno L, Peccarisi L, et al. A randomized controlled trial of Lactobacillus GG in children with functional abdominal pain. Pediatrics . 2010;126:e1445–52. doi: 10.1542/peds.2010-0467. [ PubMed ] [ Cross Ref ] 470. Guglielmetti S, Mora D, Gschwender M, Popp K. Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life&#8211;a double-blind, placebo-controlled study. Aliment Pharmacol Ther . 2011;33:1123–32. doi: 10.1111/j.1365-2036.2011.04633.x. [ PubMed ] [ Cross Ref ] 471. Horvath A, Dziechciarz P, Szajewska H. Meta-analysis: Lactobacillus rhamnosus GG for abdominal pain-related functional gastrointestinal disorders in childhood. Aliment Pharmacol Ther. 2011;33:1302–10. doi: 10.1111/j.1365-2036.2011.04665.x. [ PubMed ] [ Cross Ref ] 472. Hun L. Bacillus coagulans significantly improved abdominal pain and bloating in patients with IBS. Postgrad Med. 2009;121:119–24. doi:10.3810/pgm.2009.03.1984. [ PubMed ] [ Cross Ref ] 473. Niedzielin K, Kordecki H, Birkenfeld B. A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol. 2001;13:1143–7. doi: 10.1097/00042737-200110000-00004. [ PubMed ] [ Cross Ref ] 474. O’Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, O’Sullivan GC, Kiely B, Collins JK, Shanahan F, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles . Gastroenterology. 2005;128:541–51. doi: 10.1053/j.gastro.2004.11.050.[ PubMed ] [ Cross Ref ] 475. Sinn DH, Song JH, Kim HJ, et al. Therapeutic effect of Lactobacillus acidophilus-SDC 2012, 2013 in patients with irritable bowel syndrome. Dig Dis Sci . 2008;53:2714–8. doi: 10.1007/s10620-007-0196-4. [ PubMed ] [ Cross Ref ] 476. Whorwell PJ, Altringer L, Morel J, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol. 2006;101:1581–90. doi: 10.1111/j.1572-0241.2006.00734.x.[ PubMed ] [ Cross Ref ] 477. Williams EA, Stimpson J, Wang D, Plummer S, Garaiova I, Barker ME, Corfe BM. Clinical trial: a multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study. Aliment Pharmacol Ther. 2009;29:97–103. doi: 10.1111/j.1365-2036.2008.03848.x. [ PubMed ] [ Cross Ref ] 478. Yoon JS, Sohn W, Lee OY, Lee SP, Lee KN, Jun DW, Lee HL, Yoon BC, Choi HS, Chung WS, et al. Effect of multispecies probiotics on irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Gastroenterol Hepatol . 2014;29:52–9. doi: 10.1111/jgh.12322. [ PubMed ] [ Cross Ref ] 479. Ki Cha B, Mun Jung S, Hwan Choi C, et al. The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial . J Clin Gastroenterol. 2012;46:220–7. doi: 10.1097/MCG.0b013e31823712b1. [ PubMed ] [ Cross Ref ] 480. Petersson J, Schreiber O, Hansson GC, et al. Importance and regulation of the colonic mucus barrier in a mouse model of colitis. Am J Physiol Gastrointest Liver Physiol. 2011;300:G327–G333. [ PMC free article ] [ PubMed ] 481. Ohland CL, Macnaughton WK. Probiotic bacteria and intestinal epithelial barrier function. Am J Physiol Gastrointest Liver Physiol . 2010;298:G807–G819. [ PubMed ] 482. Natividad JM, Verdu EF. Modulation of intestinal barrier by intestinal microbiota: pathological and therapeutic implications. Pharmacol Res . 2013;69:42–51. [ PubMed ] 483. Dunlop SP, Hebden J, Campbell E, Naesdal J, Olbe L, Perkins AC, Spiller RC. Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes. Am J Gastroenterol . 2006;101:1288–1294. [ PubMed ] 484. Frese SA, Benson AK, Tannock GW, et al. The evolution of host specialization in the vertebrate gut symbiont Lactobacillus reuteri. PLoS Genet . 2011;7:e1001314. [ PMC free article ] [ PubMed ] 485. Bertiaux-Vandaële N, Youmba SB, Belmonte L, et al. The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype. Am J Gastroenterol. 2011;106:2165–2173. [ PubMed ] 486. Martínez C, Lobo B, Pigrau M, et al. Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier. Gut . 2013;62:1160–1168. [ PubMed ]","date_published":"2015-06-10T05:22:48","date_modified":"2020-04-22T00:46:42","authors":[{"name":"Dr. Richard Esquivel","url":"https://sanjosefuncmed.com/about/"}],"tags":["Gut-Brain Health"]},{"id":"https://sanjosefuncmed.com/gut-connections-organs/","url":"https://sanjosefuncmed.com/gut-connections-organs/","title":"The Gut & Connections to Other Organs","summary":"A systems-oriented discussion of the gut’s relationship with immune, brain, liver and thyroid function.","content_text":"Recent research has discovered some fascinating connections between the gut and several other organs of the body. In this segment, we review some of these connections between the gut and the liver, immune system, brain and thyroid that have been recently identified in the literature. For a review of the basic functions of the gastrointestinal system, click here: Functions of the Gastrointestinal System. Introduction One of the things we learn in our medical training is that the body is composed of separate organs and organ systems that operate independently and are not closely related and this often makes us inefficient in managing conditions related to these organ systems. We all learn neurology, immunology, and gastroenterology as separate fields of study that can be studied independently but they really aren’t separate systems that can be fully appreciated if they are studied in isolation. The organ systems of the body are all interconnected and inter-influential. In our current healthcare system, we have various specialists that are highly specialized in their field but for the most part, they don’t communicate with other specialists outside of their field, even when it comes to mutual patients. No one else is allowed to talk about their specialty because they feel they are the specialist in that field. However, the body doesn’t work like that. All the organs of the body communicate and influence other organs and the gut is no exception. In fact, the gut communicates with possibly every other organ in the body. Gut Connections with Other Organs In this segment, we review some of the connections the recent research is showing between the gut and the following organs of the body: Liver Immune system Brain Thyroid Gut-Liver Connection There are several relationships between the GI tract and the liver. It is common knowledge when toxins and xenobiotics are absorbed into the body via food or water, they enter the hepatic portal vein which transports these compounds to the liver before distribution to the body. The liver is the primary organ for detoxification of toxicants in our food and environment and for the majority of detoxification enzymes in the body. The primary mechanism in the body for removing lipid-soluble toxins is the hepatic biotransformation (liver detoxification) system which functions to convert lipid-soluble substances to water-soluble substances so they can be excreted via the urine. Abnormal absorption of nutrients in the small intestine can affect liver function. For example, increased gut permeability leads to increased toxic load on the liver. When the intestinal barrier function becomes disrupted, toxins and undigested food compounds enter the circulation via the hepatic portal vein and lead to increased demands on the liver. This can lead to compromised liver function in its ability to transform toxins and increased toxic load in the body and result in a wide range of symptomology. Clinicians see problems secondary to liver detoxification on a daily basis, whether they recognize them or not. It is a very common problem in modern society where most of our food is contaminated with antibiotics, hormones, pesticides and herbicides. Additionally, malabsorption of nutrients can also affect liver function. The liver relies on many nutrients to perform its various functions, such as B vitamins, antioxidants, cofactors and coenzymes and if these are not being absorbed in the gut, liver function can be compromised. In addition to regulating many complex biochemical reactions involved in carbohydrate, protein and lipid metabolism, the liver synthesizes bile which is important in lipid digestion and absorption. The gall bladder stores this bile which is ejected into the biliary tract and enters the small intestine. As described in part 8a, bile is used to emulsify lipids which allows for absorption into the body in the small intestine. Problems with the production of healthy bile leads to problems with fat digestion and risk of gallstones or biliary obstruction, which can lead to acute pancreatitis. Bile is also important in the elimination of toxins from the body. The liver deposits metabolized hormones, drugs and xenobiotics into the bile which enters the duodenum of the small intestine for elimination from the body through the GI tract. Problems with biliary stasis, unhealthy bile production or bowel transit time can all lead to problems with elimination of toxins from the body. In addition, gut dysbiosis (imbalance of the gut bacteria) can affect the liver’s detoxification capacity. Dysbiosis can increase activity of beta-glucuronidase, an enzyme of the gut, which cleaves off the conjugated portion of the toxins, such as estrogens, that have already been conjugated (detoxified) by the liver. This means the liver’s work in eliminating toxic hormones from the body, such as estrogen and other xenoestrogens, is reversed, and this places increased demands on the liver to perform its job of conjugation of hormones all over again.[63] Glucuronidases liberate toxins and mutagens that have been conjugated (glucuronidated) in the liver and excreted into the gut with the bile. This can lead to high local concentrations of carcinogenic compounds within the gut, thus increasing the risk of carcinogenesis.[63] Gut-Immune Connection As described above, the gut-associated lymphoid tissue is an important part of our immune system which is located in the wall of the gut and protects us from a wide variety of pathogens and potentially harmful compounds. The primary purpose of the GALT is to provide the first line of defense against foreign invaders such as food antigens (which elicit immune responses) and pathogenic bacteria and parasites. The GALT has two layers of defense to a foreign pathogen or antigen: localized secretory IgA (sIgA) responses and the systemic IgE and IgG responses. Together, these two responses account for the majority of the body’s immunoglobulins (Ig) which are important proteins needed for immune responses. The GALT serves as a containment system, preventing potentially harmful antigens from reaching systemic circulation, and induces systemic tolerance against intestinal antigens by a process that involves IgA secretion and the induction of regulatory T-cells. As the predominant immunoglobulin on the surface of the GI mucosa, sIgA cells can effectively prevent infection, neutralize viruses and remove antigens before they can cross the mucosal barrier and reach circulation. Antigens and foreign invaders which escape the sIgA surveillance can enter the mucosal layer where the GALT provides the second layer of defense. The interaction of antigen-specific IgE and IgG induces a systemic immune response in which antibodies are generated, cytokines are produced and the full immune response is engaged. The GALT is also instrumental in the development of immune or oral tolerance to harmless antigens in the diet and commensal gut bacteria. Oral tolerance is an important process in which the body becomes able to recognize food molecules and not respond to them with a full-fledged antibody-immune response. Oral tolerance is also stimulated by the commensal gut bacteria. Gut permeability has a direct impact on systemic immune responses and chronic inflammation. Increased gut permeability (leaky gut) leads to increased antigens penetrating the gut barrier and entering circulation. When there is antigen penetration, there is antibody response to these antigens, causing immune activation and various inflammatory responses. There are many toxic compounds which can enter circulation due to a breached gut barrier which have been identified, such as lipopolysaccharides (LPS). LPS are end-products of intestinal bacteria metabolism that have been well-studied and widely recognized to produce toxic inflammatory effects when they enter circulation.[64-66] If this chronic inflammation continues unabated, the individual becomes at risk for immune dysregulation and autoimmunity.[67-68] The chronic intestinal inflammation leads to further intestinal permeability which becomes a vicious cycle. Gut-Brain Connection Have you ever felt so emotional that you felt something in your stomach? Some people will see something or think of something that makes them so sick that they throw up. Have you ever been on a roller coaster that makes you sick and want to throw up? This is due to regions in the brain firing into the enteric nervous system of the gut. Have you ever experienced eating too late at night or overeating and having nightmares? This is due to stress receptors in the gut firing into the amygdala, the fear centers of the brain that cause nightmares. Have you ever eaten something and your mood changes? These are opioids, cytokines and chemicals being released into the brain. Why is it that almost every child with a learning disorder has poor digestion and a bad gut? All these are examples of the brain-gut connection. The recent literature is showing a strong connection between the brain and the gut which is now being referred to as the “brain-gut axis”. “These results show that this form of early life stress results in an altered brain-gut axis and is, therefore, an important model for investigating potential mechanistic insights into stress-related disorders, including depression and IBS”[69] It is now known that a large percentage of patients with abnormal bowel function often suffer from stress-related disorders or other brain disorders. “50%-90% of IBS patients that seek treatment have psychiatric disorders, including panic disorder, generalized anxiety disorder, social phobia, post-traumatic stress disorder, and major depression.”[70] Poor Brain Function Leads To Poor Gut Function One of the earliest signs of poor brain health is not cognitive, but decreased digestive function. About 90% of the brain’s output enters into a region of the brain called the pontomedullary region located in the lower brainstem and this fires into the vagus nerve which largely controls digestive function. The vagus allows for gut motility, enzyme secretion, and normal bowel activity. When a person loses the ability to fire into the brainstem, they will have decreased vagal output and decreased gut function. If you can’t move your food, you end up with dysbiosis (imbalance of beneficial gut flora), yeast overgrowths, enzyme deficiencies, and inability to contract the gallbladder. This will manifest as abdominal pain or discomfort, constipation, loose stools or diarrhea, gas, bloating, food sensitivities and difficulty digesting meals. “Brain alteration of neurotransmitters leads to abnormal gastric enzyme secretion. Brain neurochemistry is important for regulating enzyme secretion in the brain-gut relationship.”[71] Doctors will often diagnose conditions of abdominal pain and irregular bowel movements, including constipation or diarrhea, as “irritable bowel syndrome” or IBS. We are now discovering that IBS involves dysfunction of the brain and the gut’s enteric nervous system (also referred to as “the second brain”). “IBS is one of the most common functional gastrointestinal disorders worldwide is thought to be the result of disturbed neural function along the brain-gut axis” [72] When a person loses the integrity of their brain-gut axis, it is common to see symptoms of constipation and poor gut motility. They have to use laxatives and drink coffee to have bowel movements. People that lose bowel function tend to drink coffee all the time because coffee produces a cholinergic effect and increases gut motility and blood flow to brain. They are basically trying to rev up their brain-gut axis. But one of the things people with poor brain function have besides constipation and enzyme deficiency is leaky gut . One of the things poor brain function causes is intestinal permeability or “leaky gut”. This is loss of the barrier function of the gut that protects our bodies from large molecules that should normally not enter circulation, such as undigested food proteins, bacteria and other toxins. This can lead to gastritis or intestinal ulcers. When the integrity of the gut barrier becomes compromised, undigested food particles can enter circulation causing immune responses and leading to multiple food sensitivities.[73] “These results indicate that the brain is important for regulating development of intestinal ulcers, and that classical neurotransmitters Ach, NE and 5-HT are involved”[74] Poor Gut Function Leads To Poor Brain Function The combination of intestinal permeability and undigested proteins and toxins entering circulation causes systemic inflammation and releases cytokines which have been shown to cross the blood brain barrier and activate the microglial cells of the brain.[75] The microglial cells, when they get activated, create surrounding neuroinflammation in the brain . The neuroinflammation causes the surrounding neurons to lose their nerve conductance so they don’t fire as fast. The brain has no pain fibers so the chief indication of neuroinflammation is slow brain function or “brain fog”. This is when someone tries to get to a thought but they can’t get to it. They have difficulty thinking clearly and have problems with memory and recall. “When cytokine signals from the peripheral immune system reach the CNS, microglia become activated and propagate the inflammatory response throughout the brain.”[76] If this glial activation is sustained for a long period of time, it will eventually degenerate the brain and the enteric nervous system. When someone has a gut on fire and brain on fire, they will have bloating and food sensitivities with brain fog or poor brain function. Their brain function is affected by food they can’t digest. This leads to a vicious cycle of brain degeneration, leaky gut, increased cytokine activation and further brain degeneration. Once you get this inflammatory response in the gut, there is a consequence of inflammation in the brain. There is now evidence that major depression disorder (MDD) is accompanied by an activation of the inflammatory response system in the brain and that pro-inflammatory cytokines and lipopolysaccharide (LPS) from the gut may induce depressive symptoms. “The results showed that intestinal mucosa dysfunction characterized by an increase translocation of enteric bacteria (leaky gut) plays a role in the inflammatory pathophysiology of depression.”[77] A Mayo Clinic study found the observed prevalence of multiple sclerosis (an autoimmune disease that destroys the central nervous system) at the onset of inflammatory bowel disease was 3.7 times higher than expected.[78] A study published in the Lancet demonstrated that the frequency of focal white-matter lesions in patients with inflammatory bowel disease is almost as high as that in patients with multiple sclerosis.[79] Another study essentially concluded that there is no way to have neurodegeneration in the brain and not have neurodegeneration in the gut.[80] Brain-Gut Peptides During the past few years, several brain-gut peptides have emerged as important mediators of communication in the brain-gut axis. Peptides including substance P, neurotensin and galanin are produced in the brain and enteric nervous system are involved in regulating intestinal infection [81]. Cholesystokinin (CCK) is a brain-gut peptide with broad biological activities and serves as a regulating hormone in the digestive system. It also plays a central role in the central nervous system as a neurotransmitter or a neuromodulator. Recently many reports have demonstrated CCK genetic variations with psychiatric states such as schizophrenia, depressive disorder, suicidal behavior and Parkinson’s disease.[82] The gut hormone and neuropeptide ghrelin affects energy balance and growth hormone release through hypothalamic action in the brain.[83] One paper reported that ghrelin enters the hippocampus and binds to neurons of the hippocampal formation, where it promotes dendritic synapse formation and generation of long-term potentiation to enhance learning and memory processes![83] Neurotensin (NT) , is an endogenous brain-gut peptide which has a close functional relationship with the dopamine system. Emerging research demonstrates it may play a role in psychiatric and neurological disease.[84] Brain Influence on Gut Flora “The brain can influence commensal organisms (enteric microbiota) indirectly via changes in gastrointestinal motility and secretion, and intestinal permeability, or directly, via signaling molecules released into the gut lumen from cells of the lamina propria. “Disruption of the bi-directional interactions between the enteric microbiota and the brain may be involved in the pathophysiology of acute and chronic gastrointestinal disease states, including functional and inflammatory bowel disorders.”[85] Gut Flora Influence on Brain “While bi-directional brain-gut interactions are well known mechanisms for the regulation of gut function in both healthy and diseased states, a role of the enteric flora—including both commensal and pathogenic organisms—in these interactions has only been recognized in the past few years.”[85] “The absence of probiotic bacteria in the gut can have adverse effects not only locally in the gut, but also has been shown to affect central brain hypothalamic-pituitary-adrenal and monoaminergic activity, features that have been implicated in the etiology of depression. “The attenuation of pro-inflammatory immune responses and the elevation of the serotonergic precursor tryptophan by bifidobacteria (probiotic) treatment, provides encouraging evidence in support of the proposition that this probiotic may possess anti-depressant properties.”[86] This paper shows two important discoveries. First, bifidobacteria (an important commensal gut bacteria) actually impacts the serotonergic system. In other words, it impacts your ability to make serotonin, the primary neurotransmitter associated with depression. Secondly, imbalances in gut microflora alone can disrupt the gut-brain axis sufficiently to cause depression. These recent discoveries of the gut-brain axis are making it increasingly clear how interdependent the function of the gut and brain really are. Gut-Thyroid Connection “Thyroid hormones have an effect on the gastrointestinal tract at all levels of organization and clinicians have long recognized the associations that exist between gastrointestinal symptoms and thyroid disease.”[87] Thyroid Influences on the Gut Thyroid hormone has a direct impact on gut motility, gut transit time and risk of various gut disorders, including risk of gallstones. The most common gut-related complaints reported in thyroid diseases are those due to disordered bowel function, in particular, alteration in motility in the gastrointestinal tract and bowel regularity. The motor activity of the gastrointestinal tract is increased in hyperthyroidism and decreased in hypothyroidism. The sluggish motility in hypothyroidism may directly lead to constipation and even intestinal obstruction. Diarrhea and steatorrhea (fat in stool) commonly occur in hyperthyroidism.[87,88] The level of gastric acid secretion has also been reported to vary greatly with both hypo- and hyperthyroid states. Hypo- and hyperthyroidism are frequently associated with gastritis (inflammation of the stomach lining) and hypochlorhydria (diminished acid output).[87,88] This often results in acid reflux or GERD. Gastric emptying and esophageal activity are also prolonged in hypothyroidism.[89] Patients with hypothyroidism may also suffer from rectal prolapse, chronic constipation, colonic dilatation (enlargement), and fecal impaction. Rapid gastric emptying and rapid transit time have been associated with hyperthyroidism. [90] Hypothyroidism is also a major risk factor for intestinal permeability or leaky gut syndrome. “Lack of thyroid hormone stimulation of gastric and intestinal cells leads to ulcerations and intestinal permeability known as “leaky gut syndrome”. Additionally, endoscopic examination of gastric ulcers found low T3, low T4, and abnormal levels of reverse T3 on gastric ulcerative tissues.”[90a] “Both thyroxine (T4) and triiodothyronine (T3) have been shown to protect the intestinal mucosal lining from stress-induced intestinal lining injury.”[90b] For decades, one well-known risk factor for the development of gallstones has been hypothyroidism. Recent studies have reported that the risk in particular for stone formation in the common bile duct (CBD) increases substantially in clinical (and subclinical) hypothyroidism.[91] There are multiple factors that may contribute to the formation and/or accumulation of CBD stones in hypothyroid patients, including altered bile composition, diminished bile secretion, and emptying of the biliary tract.[91] Gut Influences on the Thyroid Thyroid hormones are produced as primarily T4 in the thyroid and have to be converted from T4 to T3 hormone since T3 is the primary active thyroid hormone in the body. Most thyroid responses are due to the binding of T3 to thyroid receptors on the various cells of the body, not T4. 93% of what the thyroid gland produces is T4 while only 7% is T3. This means that the majority of thyroid hormone produced has to be converted to an active form in order to have a thyroid response. The enzyme that converts T4 to T3 is 5’deiodinase which is found in every major tissue, especially the liver. A defect in this enzyme activity causes an underconversion problem . Gut infections or chronic inflammation in the gut can cause elevations in cytokine activity which can negatively impact conversion of T4 to T3 causing low T3 hormone levels and a functional hypothyroid condition. Another way that gut activity influences thyroid hormone levels is through gut enzyme activity acting on T4 hormone. As stated, T4 gets converted to T3 primarily in the liver. But only 60% of T4 gets converted to actual T3 in normal healthy metabolism. About 20% of T4 gets converted to reverse T3 (rT3). RT3 is inactive thyroid hormone and has no potential to become active thyroid hormone (T3) ever again. Certain conditions can increase the amount of rT3 produced such as intestinal permeability or inflammation in the gut, resulting in less potential T3. The remaining 20% of T4 gets converted to T3 sulfate (T3S) or T3 acetic acid (T3AC). But unlike rT3, these inactive forms of thyroid hormone can become active again. This occurs by interacting with normal gut bacteria. Gut bacteria have the ability to convert T3S and T3AC back into active T3! Therefore, normal thyroid hormone levels rely on a healthy gut environment and gut metabolism. Leaky Gut, Lipopolysaccarides and Thyroid Metabolism We know chronic gut issues such as leaky gut and chronic gut infections will impact thyroid conversion of T4 to T3 as discussed. Gastrointestinal microorganisms release toxic compounds such as lipopolysaccharides (LPS) as part of bacterial metabolism which can impact thyroid physiology in several ways. Intestinal permeability (leaky gut) allows LPS to penetrate the intestinal barrier and enter circulation. Once in circulation, LPS has the potential to influence the thyroid at all levels of function, including reducing thyroid hormone levels, impacting conversion of T4 to T3, diminishing the expression of the thyroid receptor sites, increasing inactive RT3 levels, decreasing TSH and promoting AI thyroid conditions.[92-94] In the subsequent articles in this series, we will describe the most common disorders that result from each of the primary organs of the GI tract, including the stomach, small intestine and large intestine. References 63. Dabek M, McCrae SI, Stevens VJ, Duncan SH, Louis P. Distribution of beta -glucosidase and beta-glucuronidase activity and of beta-glucuronidase gene gus in human colonic bacteria . FEMS Microbiol Ecol . 2008 Dec;66(3):487-95. doi: 10.1111/j.1574-6941.2008.00520.x. Epub 2008 Jun 4. 64. Focà A, Liberto MC, Quirino A, Matera G. Lipopolysaccharides : from Erinyes to Charites. Mediators Inflamm . 2012;2012:684274. doi: 10.1155/2012/684274. Epub 2012 May 14. Review. 65. McAleer JP, Vella AT. Understanding how lipopolysaccharide impacts CD4 T-cell immunity. Crit Rev Immunol . 2008;28(4):281-99. Review. 66. Nahra R, Dellinger RP. Targeting the lipopolysaccharides : still a matter of debate? Curr Opin Anaesthesiol . 2008 Apr;21(2):98-104. doi:10.1097/ACO. 0b013e3282f5335c. Review. 67. Borella E, Palma L, et al. The body against self: autoinflammation and autoimmunity . Isr Med Assoc J . 2014 Oct;16(10):608-10. No abstract available. 68. Perricone C, Toubi E, Valesini G, Shoenfeld Y. Autoinflammation and autoimmunity : pathogenic, clinical, diagnostic and therapeutic aspects. Isr Med Assoc J . 2014 Oct;16(10): 601-4. No abstract available. 69. Early life stress alters behavior, immunity, and microbiota in rats: implications for irritable bowel syndrome and psychiatric illnesses . Biol Psychiatry. 2009 Feb 1;65(3):263-7. Epub 2008 Aug 23 70. Irritable bowel syndrome, anxiety and depression: What are the links? J Clin Psychiatry. 2001;62 Suppl 8:38-45; discussion 46-7 71. Brain regulation of gastric acid secretion by neurogastrointestinal peptides. Peptides. 1981;suppl 2:51-5 72. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions . Nat Rev Gastroenterol Hepatol . 2010 Mar;7(3):163-73. Epub 2010 Jan 26 73. Rhee SH, Pothoulakis C, Mayer EA. Principles and clinical implications of the brain -gut-enteric microbiota axis. Nat Rev Gastroenterol Hepatol . 2009 May;6(5):306-14. doi: 10.1038/nrgastro.2009.35. Review. 74. The role of paraventricular nucleus of hypothalamus in stress-ulcer formation in rats. Brain Res. 1997; 761(2):203-9. 75. Vitkovic L, Konsman JP, Bockaert J, Dantzer R, Homburger V, Jacque C. Cytokine signals propagate through the brain. Mol Psychiatry . 2000;5:604–615. [ PubMed ] 76. Heidi A. Jurgens, Rodney W. Johnson. Dysregulated Neuronal-Microglial Cross-Talk during Aging, Stress and Inflammation . Exp Neurol. 2012 January; 233(1): 40–48. Published online 2010 November 24. doi: 10.1016/j.expneurol.2010.11.014 77. Maes M, et al. The brain-gut barrier in major depression: intestinal mucosal dysfunction with an increased translocation of LPS from gram negative enterobacteria (leaky gut) plays a role in the inflammatory pathophysiology of depression. Neuro Endocrinol Lett. 2008 Feb;29(1):117-24 78. Kimura K, et al. Concurrence of inflammatory bowel disease and multiple sclerosis. Mayo Clin Proc. Aug 2000; 75: 802-806 79. Geissler A. et al. Focal white-matter lesions in patients with inflammatory bowel disease. Lancet 1995;345:897-98 80. Neurodegeneration: a key factor in the ageing gut. Neurogastroenterol Motil. 2004 Apr; 16 Suppl 1:19-23 81. The role of neuroenteric hormones in intestinal infectious diseases. Curr Opin Gastroenterol. 2000 Nov; 16(6):536-40 82. The relationship between SNP of cholecystokinin gene and certain mental status and its forensic significance. Fa Yi Xue Za Zhi. 2008 Aug;24(4):284-7 83. Ghrelin controls hippocampal spine synapse density and memory performance. Nat Neurosci. 2006 Mar;9(3):381-8. Epub 2/19/06 84. Neurotensin: role in psychiatric and neurological diseases. Peptides. 2006 Oct;27(10):2385-404. Epub 2006 Aug 4 85. Principles and clinical implications of the brain-gut-enteric microbiota axis. Nat Rev Gastroenterol Hepatol. 2009 May;6(5):306-14 86. The probiotic bifidobacteria in infantis: An assessment of potential antidepressant properties in the rat. J Psychiatr Res. 2008 Dec;43(2):164-74. Epub 2008 May 5. 87. W R Middleton. Thyroid hormones and the gut. Gut . 1971 February; 12(2): 172–177. 88. Ebert EC. The thyroid and the gut. J Clin Gastroenterol . 2010 Jul;44(6):402-6. doi: 10.1097/MCG.0b013e3181d6bc3e. Review. 89. Olga Yaylali, Suna Kirac, et al. Does Hypothyroidism Affect Gastrointestinal Motility? Gastroenterol Res Pract. 2009; 2009: 529802. Published online 2010 March 7. doi: 10.1155/ 2009/529802 90. W R Middleton. Thyroid hormones and the gut. Gut . 1971 February; 12(2): 172–177. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1411539/ 90a. The effects of stress on gastric ulceration, T3, T4, reverse T3 and cortisol in neonatal foals. Equine Vet J. 1992; 24(1):37-40 90b. The effects of thyroid hormones on stress ulcer formation. Anz J Surg. 2002; 72(9):672-5 91. Johanna Laukkarinen, Juhani Sand, Isto Nordback. The Underlying Mechanisms: How Hypothyroidism Affects the Formation of Common Bile Duct Stones—A Review . HPB Surg . 2012; 2012: 102825. Published online 2012 September 19. doi: 10.1155/2012/ 102825 92. van der Poll T, Endert E, Coyle SM, Agosti JM, Lowry SF. Neutralization of TNF does not influence endotoxin-induced changes in thyroid hormone metabolism in humans . M J Physiol. 1999 Feb;276(2 Pt 2):R357-R362. 93. van der Poll T, Van Zee KJ, Endert E, et al. Interleukin-1 receptor blockade does not affect endotoxin-induced changes in plasma thyroid hormone and thyrotropin concentrations in man. J Clin Endocrinol Metabl . 1995 Apr;80(4):1341:1346. 94. Boelen A, Kwakkel J, Platvoet-ter Schiphorst M, et al. Interleukin-18, a proinflammatory cytokine, contributes to the pathogenesis of non-thyroidal illness mainly via the central part of the hypothalamus-pituitary-thyroid axis. Eur J Endocrinol . 2004 Oct;151(4):497-502.","date_published":"2015-05-31T06:42:11","date_modified":"2020-04-22T01:13:36","authors":[{"name":"Dr. Richard Esquivel","url":"https://sanjosefuncmed.com/about/"}],"tags":["Digestive Health"]},{"id":"https://sanjosefuncmed.com/functions-gastrointestinal-system/","url":"https://sanjosefuncmed.com/functions-gastrointestinal-system/","title":"Functions of the Gastrointestinal System","summary":"Foundational education on digestion, absorption, barrier function and the GI tract’s broader role in health.","content_text":"Health and maintenance of the gastrointestinal system is critical for successful aging and disorders of this system can result in various chronic diseases affecting multiple organs of the body. In this first segment of this series, we will review the critical functions of this system in the human body according to the most recent research. “Every living organism has to have two fundamental abilities: to bring in substances which provide energy and sustenance and to remove waste from the organism. We are exposed to innumerable substances in our environment simply by breathing, eating, drinking, working and playing. It is crucial that our bodies identify substances that are necessary to maintain health, absorb these substances into our body and circulate these throughout our circulatory system, where they can nourish all the cells of the bodies while protecting it from harmful substances from entering into circulation. It must also be able to eliminate waste and toxins which result from normal metabolism.”[1] Introduction Over a lifetime, a person will consume over 25 tons of food, providing the body with nutrients through the digestion and absorption process. During this process, the body must maintain protection from innumerable harmful external organisms and toxins that often accompany food. For example, in 1999 alone, over 1 billion pounds of pesticides were applied to U.S. crops and over 5.6 billion pounds were applied worldwide.[2] Pesticides are now a ubiquitous component of our environment and can be found within the home, in home gardens and our food we buy at the grocery store. While eating organic foods can greatly reduce our pesticide exposure, this does not guarantee elimination of pesticides. A 2001 review on toxin exposure indicated that the expense of treating environmentally-related conditions accounts for between $57 billion to $397 billion of the healthcare economy annually in the U.S and Canada.[2] Clearly, the ability to protect ourselves against these harmful compounds relies on a healthy digestive and absorptive system. Unfortunately, pesticides and pollutants are not the only harmful compounds that can accompany our food. Pathogens, such as harmful bacteria and parasites, can also be present in our food, causing various forms of stomach and gastrointestinal complaints. Then there are reactions to food, such as food allergies and sensitivities which are becoming increasingly common and growing at an alarming rate. Food allergies are estimated to affect 8% (almost 1 in 10) children worldwide.[4] Food allergies and intolerances account for a wide range of symptoms, from migraines and skin problems to neurological, inflammatory and gastrointestinal diso rders. Many of these reactions are related to intestinal permeability, discussed in Part 5 of the Successful Aging series . The human digestive system can be divided into the gastrointestinal (GI) tract and the accessory digestive organs. The organs of the GI tract include the oral cavity (mouth), pharynx (throat), esophagus, stomach, small intestine (divided into the duodenum, jejunum and ileum), large intestine (colon), rectum and anus. The accessory digestive organs include the salivary glands, liver, gall bladder and pancreas which aid in digestion and absorption of food and nutrients. As we will see, one of the primary functions of the GI tract is protection and this system protects our bodies from potentially harmful or toxic compounds in several ways. Anatomy of the Gut The GI tract, which is not unlike a long tube which extends from the mouth to the anus, is approximately 30 feet long. The gut wall is not smooth but is rough, with valleys and hills which increase the surface area of the gut. If you were to stretch out the surface area of the gut, it would cover the area of two tennis courts (3,000 sq. ft.)! How is this possible? Because of microscopic finger-like projections called villi which increase the surface area and aid in absorption. The villi contain even smaller projections, called microvilli , which increase the surface area even further. We need this large surface area to maximize nutrient absorption, which takes place primarily in the small intestine. The primary functions of the digestive tract are motility, secretion, digestion, absorption, protection and elimination of waste. Motility and Secretion Motility refers to the movement of food through the GI tract through the process of ingestion (intake of food), mastication (chewing food and mixing with saliva), deglutition (swallowing of food) and peristalsis (the rhythmic wave-like contractions that move food through the GI tract). Secretion refers to the secretion of HCl (hydrochloric acid) and mucus in the stomach, bile (synthesized by the liver), bicarbonate and many pancreatic enzymes into the small intestine that work to digest (breakdown) all the different macronutrients that we consume and aid in absorption. A healthy stomach, for example, secretes two to three liters of gastric juice per day! If there are problems with secretion of these gastric enzymes (a common condition called hypochlorhydria ), this can lead to a host of health problems, including gas, bloating, acid reflux or heartburn (called “GERD”), difficulty swallowing and stomach pain. Digestion The role of the digestive process is to breakdown these food compounds into absorbable micronutrients and separate these individual nutrients from the complex food matrix that enters the body. This process begins with mastication (chewing of food into smaller pieces that can be swallowed) and continues as the ingested food passes through the esophagus to the stomach where the majority of protein digestion takes place by stomach acids such as hydrochloric acid and pepsin. Protein digestion continues in the small intestine due to the secretion of various pancreatic enzymes which enable further protein digestion and where most carbohydrate and lipid (fat) digestion takes place. Protein is broken into polypeptides, then amino acids which can then be absorbed in the small intestine. Carbohydrates get broken down by other pancreatic enzymes into polysaccharides, then into monosaccharides, such as glucose, which can then be absorbed in the small intestine. The digestion of lipids is a bit more complex. The arrival of lipids in the duodenum portion of the small intestine serves as a stimulus for the secretion of bile, produced by the liver and stored by the gall bladder. In a process called emulsification , bile salts contained in the bile, act to break up the fat droplets into smaller triglycerides. Pancreatic lipase enzymes further digest (break up) these triglycerides into free fatty acids and monoglycerides which then combine with micelles of bile salts, lecithin and cholesterol to form “mixed micelles” which can then be absorbed in the small intestine. The secretion of adequate amounts of specific digestive enzymes is essential for healthy digestion and absorption of nutrients. If food compounds are not completely broken down into absorbable nutrients, then the body can suffer from malabsorption and malnutrition which are very common with the modern diet and lifestyle. Lack of any of these necessary digestive enzymes can have local and systemic effects (throughout the body). Pancreatic secretions often decrease with age or with conditions that place additional stress on the pancreas, such as insulin resistance, diabetes or chronic pancreatitis. Pancreatic secretions are also adversely affected by alcohol abuse, cystic fibrosis, gallstones and chronic inflammation. Pancreatic insufficiency requires oral replacement of pancreatic enzymes to aid in digestion.[5] Oral pancreatic enzymes have also been shown to reduce histamine secretion and symptoms associated with food allergies.[6] Absorption Absorption of nutrients into the circulatory system takes place primarily in the small intestine but some nutrient absorption takes place in the stomach. Water-soluble nutrients (carbohydrates, amino acids and water-soluble vitamins) are absorbed in the epithelial cells of the intestinal villi (“finger-like” projections of GI lining) by both passive and active transport systems. These nutrients are secreted into blood capillaries where they enter circulation. After undergoing emulsification, as described above, fat-soluble nutrients ( free fatty acids, monoglycerides and fat-soluble vitamins ) are absorbed into the villi of the intestinal epithelial cells. Once these products enter the cells, triglycerides and phospholipids are resynthesized and combined with proteins to form particles that are secreted into the lymphatic capillaries of the intestinal villi. These absorbed lipids pass through the lymphatic system, eventually entering the venous circulation. How the Quality of Food Impacts Digestion and Absorption The digestive process is influenced by the nature of the food consumed. Whole foods or minimally processed foods are generally digested more slowly than highly processed foods. This slows the release of nutrients and influences the rate at which absorption of both macro and micronutrients takes place. A diet high in sugar and fats will result in rapid absorption of glucose and fatty acids, creating increased demand upon the hormonal nutrient regulatory system and enzymes, including insulin, cortisol and insulin-like growth factor.[7] This is a major problem with the modern diet which relies heavily on fast food, processed foods and foods high in sugar. In addition, the selection of what foods to ingest, determines the quality of the diet (nutrient density) and the ultimate influence these nutrients have on physiological function. Let’s look at the important ways the GI tract provides protection to our bodies. Protection: Gut Barrier “The primary functions of the gastrointestinal tract have traditionally been perceived to be limited to the digestion and absorption of nutrients and to electrolytes and water homeostasis. A more attentive analysis of the anatomic and functional arrangement of the gastrointestinal tract, however, suggests that another extremely important function of this organ is its ability to regulate the trafficking of macromolecules between the environment and the host through a barrier mechanism. Together with the gut-associated lymphoid tissue and the neuroendocrine network, the intestinal epithelial barrier, with its intercellular tight junctions, controls the equilibrium between tolerance and immunity to non-self antigens.”[8] The lining of the GI tract is a mucosal membrane surface composed of epithelial cells that is the largest interface between our internal body and the external world. It covers over 3,000 square feet which is over 200 times the surface area of the skin! The GI mucosal membrane has the function of not only absorbing beneficial nutrients into the body but protecting the body against potentially damaging molecules and pathogenic organisms, such as undigested food particles, bacteria and other toxins that can accompany our food which should not be absorbed . Therefore, an important function of the GI mucosal lining is to provide a barrier between the internal body and the external world. Breakdown of this gut barrier leads to unwelcome molecules and toxic compounds potentially entering the body, a condition known as intestinal permeability or “leaky gut”. Leaky gut syndrome is commonly seen in intestinal inflammation, autoimmune conditions and food allergies and sensitivities. Protection: Gastric Mucosa and Hydrochloric Acid The GI mucosa includes the gastric epithelial layer which covers the stomach and protects it from the damaging stomach acid. This mucosa also protects the stomach from ingested toxins, drugs, alcohol and pathogens such as bacteria and viruses. The mucous gel that coats the stomach is comprised of phospholipids, secreted by gastric epithelial cells, called goblet cells . Parietal cells of the gastric lining secrete hydrochloric acid (HCl). Hydrochloric acid serves a protective function in the stomach as well. The high acidity of the stomach prevents bacteria from food and other sources from entering the body and inhabiting the GI tract, such as Helicobacter pylori (H. pylori). Protection: Gut-Associated Lymphoid Tissue (GALT) Another important protective role of the GI tract relates to the function of the gut-associated lymphoid tissue (GALT). Approximately 60% of the immune system, and more than 80% of the immunoglobulin-producing cells, are located within the mucosa of the GI tract. This complex immune system of the gut is called the gut-associated lymphoid tissue (GALT). The primary purpose of the GALT is to provide the first line of defense against foreign invaders such as food antigens (which elicit immune responses) and pathogenic bacteria and parasites. The GALT has two layers of defense to a foreign pathogen or antigen: localized secretory IgA (sIgA) antibody responses and the systemic IgE and IgG antibody responses. Protection: sIgA Cells Secretory IgA (sIgA) cells are immune cells of the intestinal tract which protect us from bacteria, viruses and other pathogens and remove antigens (immune-stimulating compounds) before they can cross the mucosal barrier and reach circulation.[9,10] Low levels of sIgA have been associated with intestinal permeability and increasing uptake of food antigens, leading to atopic (allergic) reactions.[11] Antigens and foreign invaders which escape the sIgA surveillance can enter the mucosal layer where the GALT provides the second layer of defense. This involves the production of IgE and IgG antibodies which have a systemic immune response (throughout the circulatory system). In this immune response, antibodies are generated, cytokines are produced and the full immune response is engaged. Protection: Gut Microbiome Enteric microbiota (beneficial intestinal bacteria) which make up the gut microbiome play an important role in defense. It is estimated that there are approximately 100 trillion bacteria in the human digestive tract.[12-13] This means there are 10 times more bacterial cells in the gastrointestinal tract than there are cells in the human body! There are at least 1,000 different species of known bacteria with more than 3 million genes (approximately 150 times more bacterial genes than human genes)! [14] Accumulating evidence suggests that these commensal gut bacteria, that reside primarily in the large intestine, have a direct impact on promoting a healthy gut barrier, supporting various immune functions of defense and protecting from a wide variety of chronic diseases related to multiple organs of the body.[15-21] “The study of gut microbiota is a rapidly moving field of research, and the impact of gut microbial communities on human health is widely perceived as one of the most exciting advancements in biomedicine in recent years. The gut microbiota plays a key role in digestion, metabolism and immune function, and has widespread impact beyond the gastrointestinal tract. Changes in the biodiversity of the gut microbiota are associated with far reaching consequences on host health and development.”[20] For example, the production of short-chain fatty acids (SCFA) by these bacteria promotes growth and differentiation of intestinal mucosal cells which protects against intestinal permeability and colon cancer.[22-25] These beneficial flora also play a major role in immune tolerance (as described above) to prevent against allergic diseases such as atopic skin disorders, eczema, and asthma.[26-31] High diversity of these gut flora appears to be protective of many chronic health conditions and loss of this diversity predisposes to a wide variety of chronic conditions such as inflammatory bowel disease [32-36], irritable bowel syndrome (IBS) [37], type 1 and type 2 diabetes [38-41], obesity [42-46], cancer [47-48], cardiovascular disease [49], bone loss [50], and urinary tract infections.[51] Recent research has focused on the gut-brain axis and has discovered an important connection of the microbiome to psychiatric conditions such as anxiety, depression, bipolar disorder, schizophrenia and autism. [52-61] Recent evidence has also shown a connection of the gut microbiota to neurodegenerative diseases as well, such as multiple sclerosis and Alzheimer’s disease.[62] Elimination of waste The final important function of the GI tract is the elimination of waste which occurs primarily in the large intestine. Metabolism of nutrients in the GI tract leads to metabolic by-products which need to be eliminated by the body along with undigested food or toxins. Fecal excretion of the remnants and cellular debris of gut bacteria is also important. It is estimated there are 2-4 pounds of gut bacteria in the digestive tract which comprises 1-3% of our body weight. These organisms have their own natural life cycles and when they die, their cellular debris must be excreted. Enteric bacteria also produce many metabolites that must be detoxified and excreted as secondary metabolites. In the next segment, we will look at various connections between the gastrointestinal system and several key organs of the body, including the thyroid, the immune system, the liver and the brain. References 1. Jones, David, Editor in Chief. Textbook of Functional Medicine , Institute for Functional Medicine, 2006. p.189. 2. Jones, David, Editor in Chief. Textbook of Functional Medicine , Institute for Functional Medicine, 2006. p.189. 3. Muir T, Zegarac M. Societal costs of exposure to toxic substances: economic and health costs of four cases studies that are candidates for environmental causation. Environ Health Perspect. 2001;109(suppl 6):885-903. 4. Fogg MI, Spergel JM. Management of food allergies. Expert Opin Pharmacother. 2003;4:1025-1037. 5. Nakamura T, Takeuchi T, Tando Y. Pancreatic dysfunction and treatment options. Pancreas. 1998;16:329-336. 6. Raithel M, et al. Pancreatic enzymes: a new group of antiallergenic drugs? Inflamm Res. 2002;51(suppl 1):S13-S14. 7. Jones, David, Editor in Chief. Textbook of Functional Medicine , Institute for Functional Medicine, 2006. p.190. 8. Fasano A. Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer. Physiol Rev. 2011 Jan;91(1):151-75. doi: 10.1152/physrev.00003.2008. 9. Lukaczer D. Secretory IgA and gastrointestinal barrier competence . Quarterly Rev Natural Med. 1996;Fall:227-229. 10. Albanese C, Smith S, Watkins S, et al. Effect of secretory IgA on transepithelial passage of bacteria across the intact ileum in vitro. J Am Coll Surg . 1994;179:679-688. 11. Ahmed T, Fuchs GJ. Gastrintestinal allergy to food: a review. J Diarrhoeal Dis Res. 1997;15:211-223. 12. Jean-Christophe Lagier, Matthieu Million, Perrine Hugon, Fabrice Armougom, Didier Raoult. Human Gut Microbiota: Repertoire and Variations . Front Cell Infect Microbiol. 2012; 2: 136. Prepublished online 2012 September 22. Published online 2012 November 2. doi: 10.3389/fcimb.2012.00136 13. Elizabeth A. Grice, Julia A. Segre. The Human Microbiome: Our Second Genome . Annu Rev Genomics Hum Genet. Author manuscript; available in PMC 2013 June 6. Published in final edited form as: Annu Rev Genomics Hum Genet. 2012; 13: 151–170. Published online 2012 June 6. 14. Qin J., Li R., et al. (2010). A human gut microbial gene catalogue established by metagenomic sequencing . Nature. 464, 59–6510.1038/nature08821 [ PMC free article ] [ PubMed ] [ Cross Ref ] 15. Macfarlane GT, Macfarlane S. Bacteria, colonic fermentation, and gastrointestinal health. J AOAC Int . 2012 Jan-Feb;95(1):50-60. Review. 16. Doré J, Blottière H. The influence of diet on the gut microbiota and its consequences for health. Curr Opin Biotechnol . 2015 Jan 20;32C:195-199. doi: 10.1016/j.copbio.2015.01.002. [Epub ahead of print] Review. 17. West CE, Renz H, Jenmalm MC, Kozyrskyj AL, Allen KJ, Vuillermin P, Prescott SL; in-FLAMEMicrobiome Interest Group:; in-FLAME Microbiome Interest Group. The gut microbiota and inflammatory noncommunicable diseases: Associations and potentials for gut microbiota therapies. J Allergy Clin Immunol . 2015 Jan;135(1):3-13. doi: 10.1016/j.jaci.2014.11.012. Review. 18. Shreiner AB, Kao JY, Young VB. The gut microbiome in health and in disease. Curr Opin Gastroenterol. 2015 Jan;31(1):69-75. doi: 10.1097/MOG.0000000000000139. 19. Cénit MC, Matzaraki V, Tigchelaar EF, Zhernakova A. Rapidly expanding knowledge on the role of the gut microbiome in health and disease. Biochim Biophys Acta . 2014 Oct;1842(10):1981-1992. doi: 10.1016/j.bbadis.2014.05.023. Epub 2014 Jun 2. Review 20. Doré J, Simrén M, Buttle L, Guarner F. Hot topics in gut microbiota. United European Gastroenterol J. 2013 Oct;1(5):311-8. doi: 10.1177/2050640613502477. 21. Shanahan F. The colonic microbiota in health and disease. Curr Opin Gastroenterol . 2013 Jan;29(1):49-54. doi: 10.1097/MOG.0b013e32835a3493. Review. 22. Conlon MA, Bird AR. The Impact of Diet and Lifestyle on Gut Microbiota and Human Health. Nutrients . 2014 Dec 24;7(1):17-44. Review. 23. O’Keefe SJ. Nutrition and colonic health: the critical role of the microbiota. Curr Opin Gastroenterol . 2008 Jan;24(1):51-8. Review. 24. Tomasello G, Tralongo P, Damiani P, Sinagra E, Di Trapani B, Zeenny MN, Hajj Hussein I, Jurjus A, Leone A. Dismicrobism in inflammatory bowel disease and colorectal cancer: Changes in response of colocytes. World J Gastroenterol . 2014 Dec 28;20(48):18121-18130. Review. 25. Lin XB, Farhangfar A, Valcheva R, Sawyer MB, Dieleman L, Schieber A, Gänzle MG, Baracos V. The role of intestinal microbiota in development of irinotecan toxicity and in toxicity reduction through dietary fibres in rats. PLoS One . 2014 Jan 14;9(1):e83644. doi: 10.1371/journal.pone.0083644. eCollection 2014. 26. Chistiakov DA, Bobryshev YV, Kozarov E, Sobenin IA, Orekhov AN. Intestinal mucosal tolerance and impact of gut microbiota to mucosal tolerance. Front Microbiol . 2015 Jan 13;5:781. doi: 10.3389/fmicb.2014.00781. eCollection 2014. 27. Tlaskalová-Hogenová H, Stepánková R, et al. Commensal bacteria (normal microflora), mucosal immunity and chronic inflammatory and autoimmune diseases. Immunol Lett . 2004 May 15;93(2-3):97-108. Review. 28. Kim CH, Park J, Kim M. Gut microbiota-derived short-chain Fatty acids, T cells, and inflammation. Immune Netw. 2014 Dec;14(6):277-88. doi: 10.4110/in.2014.14.6.277. Epub 2014 Dec 22. Review. 29. West CE. Gut microbiota and allergic disease: new findings. Curr Opin Clin Nutr Metab Care. 2014 May;17(3):261-6. doi: 10.1097/MCO.0000000000000044. Review. 30. Abrahamsson TR, Jakobsson HE, Andersson AF, Björkstén B, Engstrand L, Jenmalm MC. Low gut microbiota diversity in early infancy precedes asthma at school age. Clin Exp Allergy. 2014 Jun;44(6):842-50. doi: 10.1111/cea.12253. 31. Ismail IH, Oppedisano F, Joseph SJ, Boyle RJ, Licciardi PV, Robins-Browne RM, Tang ML. Reduced gut microbial diversity in early life is associated with later development of eczema but not atopy in high-risk infants. Pediatr Allergy Immunol . 2012 Nov;23(7):674-81. doi: 10.1111/j.1399-3038.2012.01328.x. Epub 2012 Jul 26. 32. Matsuoka K, Kanai T. The gut microbiota and inflammatory bowel disease. Semin Immunopathol . 2015 Jan;37(1):47-55. doi: 10.1007/s00281-014-0454-4. Epub 2014 Nov 25. 33. Hansen JJ, Sartor RB. Therapeutic Manipulation of the Microbiome in IBD: Current Results and Future Approaches. Curr Treat Options. Gastroenterol. 2015 Jan 18. [Epub ahead of print] 34. Cammarota G, Ianiro G, Cianci R, Bibbò S, Gasbarrini A, Currò D. The involvement of gut microbiota in inflammatory bowel disease pathogenesis: Potential for therapy. Pharmacol Ther. 2015 Jan 3. pii: S0163-7258(14)00235-6. doi: 10.1016/j.pharmthera.2014.12.006. [Epub ahead of print] Review. 35. Hold GL, Smith M, Grange C, Watt ER, El-Omar EM, Mukhopadhya I. Role of the gut microbiota in inflammatory bowel disease pathogenesis: what have we learnt in the past 10 years? World J Gastroenterol . 2014 Feb 7;20(5):1192-210. doi: 10.3748/wjg.v20.i5.1192. Review. 36. Tomasello G, Tralongo P, Damiani P, Sinagra E, Di Trapani B, Zeenny MN, Hajj Hussein I, Jurjus A, Leone A. Dismicrobism in inflammatory bowel disease and colorectal cancer: Changes in response of colocytes. World J Gastroenterol . 2014 Dec 28;20(48):18121-18130. Review. 37. Kassinen A., Krogius-Kurikka L., Makivuokko H., Rinttila T., Paulin L., Corander J. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects . Gastroenterology. 2007. 133,24–10.1053/j.gastro.2007.04. 005 [ PubMed ] 38. Gjymishka A, Coman RM, Brusko TM, Glover SC. Influence of host immunoregulatory genes, ER stress and gut microbiota on the shared pathogenesis of inflammatory bowel disease and Type 1 diabetes. Immunotherapy . 2013 Dec;5(12):1357-66. doi: 10.2217/imt.13.130. Review. 39. Tai N, Wong FS, Wen L. The role of gut microbiota in the development of type 1, type 2 diabetes mellitus and obesity. Rev Endocr Metab Disord . 2015 Jan 27. [Epub ahead of print] 40. Moreno-Indias I, Cardona F, Tinahones FJ, Queipo-Ortuño MI. Impact of the gut microbiota on the development of obesity and type 2 diabetes mellitus. Front Microbiol . 2014 Apr 29;5:190. doi: 10.3389/fmicb.2014.00190. eCollection 2014. Review. 41. Han JL, Lin HL. Intestinal microbiota and type 2 diabetes: From mechanism insights to therapeutic perspective. World J Gastroenterol . 2014 Dec 21;20(47):17737-17745. Review. 42. Ley R. E., Turnbaugh P. J., Klein S., Gordon J. I. (2006b). Microbial ecology: human gut microbes associated with obesity . Nature . 444, 1022–02310.1038/4441022a [ PubMed ] 43. Turnbaugh P. J., Backhed F., Fulton L., Gordon J. I. (2008). Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. Cell Host Microbe 3, 213–22310.1016/j.chom.2008.02.015 [ PMC free article ] [ PubMed ] 44. Turnbaugh P. J., Hamady M., Yatsunenko T., Cantarel B. L., Duncan A., Ley R. E. A core gut microbiome in obese and lean twins . Nature . 457, 480–48410.1038/nature07540[ PMC free article ] [ PubMed ] 45. Turnbaugh P. J., Ley R. E., Mahowald M. A., Magrini V., Mardis E. R., Gordon J. I. (2006). An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444, 1027–103110.1038/nature05414 [ PubMed ] 46. Santacruz A., Marcos A., Warnberg J., Marti A., Martin-Matillas M., Campoy C. (2009). Interplay between weight loss and gut microbiota composition in overweight adolescents . Obesity (Silver Spring) 17, 1906–191510.1038/oby.2009.112 [ PubMed ] 47. Zitvogel L, Galluzzi L, Viaud S, Vétizou M, Daillère R, Merad M, Kroemer G. Cancer and the gut microbiota: An unexpected link. Sci Transl Med . 2015 Jan 21;7(271):271ps1. Review. 48. Ohtani N. Semin Immunopathol. Microbiome and cancer. 2015 Jan;37(1):65-72. doi: 10.1007/s00281-014-0457-1. Epub 2014 Nov 18. 49. Ettinger G, MacDonald K, Reid G, Burton JP. The influence of the human microbiome and probiotics on cardiovascular health. Gut Microbes. 2014 Nov 2;5(6):719-28. doi: 10.4161/ 19490976.2014.983775. 50. Ohlsson C, Sjögren K. Effects of the gut microbiota on bone mass. Trends Endocrinol Metab . 2014 Dec 9. pii: S1043-2760(14)00201-X. doi: 10.1016/j.tem.2014.11.004. [Epub ahead of print] Review. 51. Whiteside SA, Razvi H, Dave S, Reid G, Burton JP. The microbiome of the urinary tract-a role beyond infection. Nat Rev Urol . 2015 Jan 20. doi: 10.1038/nrurol.2014.361. [Epub ahead of print] Review. 52. Mayer EA, Knight R, Mazmanian SK, Cryan JF, Tillisch K. Gut microbes and the brain: paradigm shift in neuroscience. J Neurosci. 2014 Nov 12;34(46):15490-6. doi: 10.1523/ JNEUROSCI.3299-14.2014. 53. Gareau MG. Microbiota -gut-brain axis and cognitive function. Adv Exp Med Biol. 2014;817:357-71. doi: 10.1007/978-1-4939-0897-4_16. Review. 54. Sue Grenham, Gerard Clarke, John F. Cryan, Timothy G. Dinan. Brain–Gut–Microbe Communication in Health and Disease . Front Physiol. 2011; 2: 94. Prepublished online 2011 October 13. Published online 2011 December 7. doi: 10.3389/fphys.2011.00094 55. Rhee S. H., Pothoulakis C., Mayer E. A. (2009). Principles and clinical implications of the brain–gut–enteric microbiota axis . Nat. Rev. Gastroenterol. Hepatol. 6, 306–31410.1038/nrgastro.2009.35[ PMC free article ] [ PubMed ] [ Cross Ref ] 56. Dash S, Clarke G, Berk M, Jacka FN. The gut microbiome and diet in psychiatry: focus on depression. Curr Opin Psychiatry. 2015 Jan;28(1):1-6. doi: 10.1097/YCO.0000000000000117. 57. Slyepchenko A, Carvalho AF, Cha DS, Kasper S, McIntyre RS. Gut Emotions-Mechanisms of Action of Probiotics as Novel Therapeutic Targets for Depression and Anxiety Disorders. CNS Neurol Disord Drug Targets. 2014 Nov 30. [Epub ahead of print] 58. Fond G, Boukouaci W, et al. The “psychomicrobiotic”: Targeting microbiota in major psychiatric disorders: A systematic review. Pathol Biol (Paris). 2014 Nov 2. pii: S0369-8114(14)00163-1. doi: 10.1016/j.patbio.2014.10.003. [Epub ahead of print]Review. 59. Severance EG, Yolken RH, Eaton WW. Autoimmune diseases, gastrointestinal disorders and the microbiome in schizophrenia: more than a gut feeling. Schizophr Res. 2014 Jul 14. pii: S0920-9964(14)00319-3. doi: 10.1016/j.schres.2014.06.027. [Epub ahead of print] Review. 60. Catanzaro R, Anzalone MG, et al. The gut microbiota and its correlations with the central nervous system disorders. Panminerva Med. 2014 Nov 12. [Epub ahead of print] 61. Finegold SM. Therapy and epidemiology of autism &#8211; clostridial spores as key elements. Med Hypotheses . 2008;70:508–511. doi:10.1016/j.mehy.2007.07.019. [ PubMed ] 62. Alam MZ, Alam Q, Kamal MA, Abuzenadah AM, Haque A. A possible link of gut microbiota alteration in type 2 diabetes and Alzheimer’s disease pathogenicity: an update. CNS Neurol Disord Drug Targets. 2014 Apr;13(3):383-90. Review.","date_published":"2015-05-26T02:20:05","date_modified":"2024-03-26T08:15:21","authors":[{"name":"Dr. Richard Esquivel","url":"https://sanjosefuncmed.com/about/"}],"tags":["Digestive Health"]},{"id":"https://sanjosefuncmed.com/management-of-autoimmune-disease-in-functional-medicine/","url":"https://sanjosefuncmed.com/management-of-autoimmune-disease-in-functional-medicine/","title":"Management of Autoimmune Disease in Functional Medicine","summary":"An in-depth educational review of functional medicine concepts used in autoimmune care.","content_text":"In this issue, we discuss the strategies used to manage autoimmune disease in functional medicine, including dietary and lifestyle strategies and the use of key supplements targeting the major areas of immune dysfunction and autoimmune reactions as identified by the most current literature and described in part 6. Management of Autoimmune Disease in Functional Medicine: A Different Approach to Autoimmunity When you look at the dysregulation of the immune system that occurs in autoimmunity, we know there are several systems involved in the targeting of self-tissue for destruction. The goal of autoimmune management should be to dampen or decrease the immune attacks against self-tissue. In order to do this, we have to understand these various systems that become dysregulated and ultimately lead to autoimmunity and self-tissue destruction. In functional medicine, we attempt to modulate autoimmunity by regulating these various systems with the use of natural compounds that have been identified in the literature to have an impact on these mechanisms of immune dysfunction. In part 6 of this series, we identified several key mechanisms of immune dysfunction which have been shown to play a role in the development of autoimmune reactivity and autoimmunity. Let’s briefly review these mechanisms and their role in autoimmunity and then look at the evidence in the literature supporting the use of various natural compounds in regulating each of these mechanisms. This information is a bit technical, so for those that are not interested in the following technical information but are interested in learning about how dietary and lifestyle changes can improve autoimmune expression and the progression of autoimmune disease, please skip down to the final sections of this article, Lifestyle Strategies for Autoimmunity and Dietary Strategies for Autoimmunity. For a more thorough review of these various mechanisms and how they are involved in autoimmunity, please refer to part 6 of this series. Major Mechanisms of Immune Dysfunction in Autoimmunity NF-kB activation and dampening Glutathione recycling system Barrier system integrity TH-1 and TH-2 polar shifts TH-3 or regulatory T-cell activation TH-17 activation and dampening Nitric oxide isomer expressions NF-kB Activation In the last segment of this series, we learned that an increasing number of studies indicate that a protein complex known as NF-kB plays an important role in the development and progression of autoimmunity. [1] NF-kB controls the expression of genes encoding the proinflammatory mediators involved in autoimmune disease. NF-kB can become chronically elevated because of its own amplifying loop. [2] This means that elevations in NF-kB can perpetuate further elevations of NF-kB. NF-kB signaling needs to be downregulated in order to maintain tissue homeostasis. [3] If this does not occur, then immune dysregulation takes place that can eventually lead to autoimmunity. Recent data has shown that NF-kB is required for activation of immune cells against self-tissue, and its hyperactivity should be minimized, since it promotes autoimmunity. [4] “NF-kB is a key signaling component in autoimmunity and an attractive target for autoimmune disease therapy” [5] “Since NF-kB represents an important and very attractive therapeutic target for drugs to treat many inflammatory diseases, including arthritis, asthma and the autoimmune diseases, most attention has been paid in the last decade to the identification of compounds that selectively interfere with this pathway” [6] Clinical Strategies to Dampen NF-kB Activation Overall, it appears that the two most potent natural NF-kB minimizers that researchers have discovered are curcumin and resveratrol . Curcumin is the alkaloid derived from turmeric , a spice used in Indian cooking. Resveratrol is a compound found in the skin of red grapes, peanuts and some berries. In recent studies, both curcumin and resveratrol have shown to support healthy numbers of T-cell cytokines (inflammatory messengers). These results suggest the potential use of these select phytochemicals for supporting healthy immune responses. Here is what some recent literature is saying about these compounds: Curcumin “Curcumin, a dietary spice from turmeric, has outstanding anti-inflammation and neuroprotective effects. Herein, we review key features of curcumin involved in biology, pharmacology, and medicinal chemistry and discuss its potential relevance to pathophysiological progress of multiple sclerosis”[7] “Curcumin, a component of turmeric, has been shown to be non-toxic, to have antioxidant activity, and to inhibit such mediators of inflammation as NFkB, cyclooxygenase-2 (COX-2), lipooxygenase (LOX), and inducible nitric oxide synthase (iNOS)”[8] “In a larger, randomized, double-blind, multicenter trial involving patients with quiescent ulcerative colitis, administration of 1 g of curcumin twice daily resulted in both clinical improvement and a statistically significant decrease in the rate of relapse”[9] “Our results indicate that curcumin has the potential to protect against cardiac inflammation… and may provide a novel therapeutic strategy for autoimmune myocarditis” [10] “In various chronic illnesses in which inflammation is known to play a major role, curcumin has been shown to exhibit therapeutic potential. These diseases include Alzheimer’s disease (AD), Parkinson’s disease, multiple sclerosis, epilepsy, cerebral injury, CVDs, cancer, allergy, asthma, bronchitis, colitis, rheumatoid arthritis, renal ischemia, psoriasis, diabetes, obesity, depression, fatigue, and AIDS”[11] “…curcumin has received considerable interest as a potential therapeutic agent for the prevention and/or treatment of various malignant diseases, arthritis, allergies, Alzheimer’s disease, and other inflammatory illnesses. The underlying mechanisms of these effects are diverse and appear to involve the regulation of various molecular targets, including transcription factors (such as nuclear factor-kB)…”[12] Resveratrol Resveratrol has been shown in the literature to have powerful anti-inflammatory effects which involve multiple pathways including inhibiting NF-kB, inhibiting iNOS (inducible-nitric oxide synthase) expression and inhibiting inflammatory cytokines such as IL-6 in various inflammatory conditions, including multiple sclerosis [13], diabetic neuropathy [14], arthritis [15], autoimmune myocarditis [16], colitis [17], and exerts immunomodu-latory effects both in vitro and in vivo lymphocytic leukemia in lymphocytic leukemia. [18] “These studies demonstrate that SRT501 (a pharmaceutical grade formulation of resveratrol) attenuates neuronal damage and neurological dysfunction in experimental autoimmune encephalomyelitis (the animal model of multiple sclerosis) by a mechanism involving SIRT1 activation”[13] “This study confirms the NF-kB inhibitory activity and anti-inflammatory activity of resveratrol, which may contribute to neuroprotection in diabetic neuropathy apart from its antioxidant effect”[14] “In summary, our results suggest that resveratrol suppresses apoptosis and inflammatory signaling through its actions on the NF-kB pathway in human chondrocytes”[15] “Resveratrol significantly ameliorated myocardial injury and preserved cardiac function in a rat model of autoimmune myocarditis” [16] In addition, both curcumin and resveratrol have been shown to reduce the inflammatory mediators that contribute to the low-level, chronic inflammation found in obese individuals and have been linked to the onset of cardiovascular disorders, insulin resistance and type 2 diabetes mellitus. “Curcumin and resveratrol are able to inhibit TNFalpha-activated NF-kappaB signaling in adipocytes and as a result significantly reduce cytokine expression. These data suggest that curcumin and resveratrol may provide a novel and safe approach to reduce or inhibit the chronic inflammatory properties of adipose tissue.”[19] The Role of Glutathione in Autoimmune Modulation In part 6, we learned that glutathione (GSH) appears to be an important antioxidant that helps support regulatory TH-3 cells of the immune system (important immune-regulating cells), protect the intestinal barrier and quench oxidative compounds before they are activated by the NF-kB receptor. Recall that glutathione production occurs in all cells but primarily in hepatocytes (the cells of the liver) which is used in some phase II detox pathways, such as glutathione conjugation. Glutathione is also an important part of phase I detoxification. Some medications (such as acetaminophen or Tylenol™) block the production of glutathione by the liver. This is why glutathione precursors (such as N-acetyl-cysteine or NAC) is used to decrease liver toxicity in acetaminophen overdose. [20] Many studies suggest that intracellular GSH levels in antigen-presenting cells such as macrophages, influence the TH1/TH2 cytokine response patterns which are associated with immune dysregulation and autoimmunity. “Accumulation of evidence suggests that intracellular GSH levels in antigen-presenting cells such as macrophages, influence the TH1/TH2 cytokine response pattern. The observations reported herein show that pro-GSH molecules represent new therapeutic agents to support immune modulation”[21] Low GSH levels have been associated with many autoimmune and inflammatory diseases, including rheumatoid arthritis, systemic lupus erythematosus, Crohn’s disease, multiple sclerosis, psoriasis, and contact dermatitis. [22] Another study suggested that the severity of some autoimmune diseases, such as systemic lupus erythematosus (SLE), correlate with levels of glutathione in the blood, namely, the lower the glutathione levels, the more severe the autoimmune disease. “A significant correlation between plasma glutathione and SLE severity exists that may aid evaluation of the disease severity and usefulness of the management of SLE”[23] In general, high oxidant burdens are a common feature in many immune dysfunctions and GSH plays a major role in quenching these oxidant species, and hence protecting the cell from damage. Therefore, any decrease in GSH may influence the immune system through perpetuating reactive species signaling events and increasing ROS-related damage. [24] Age-related decline in cellular function is thought to result from increasing oxidative damage. Oxidative stress depletes intracellular GSH, so increasing production of glutathione may protect against mitochondrial and cellular damage. [25] Glutathione helps support regulatory T cells, and differentiation of T-cells into their specific types by reducing damage from oxidative stress. This system is absolutely critical for overall modulation of autoimmunity. “These data indicate that glutathione peroxidase-dependent control of intracellular reactive oxygen species accumulation is important not only for regulation of TH-cell proliferation, but also for modulation of differentiation into TH1, TH2 and TH17 cells.”[26] Summary of the Role of Glutathione in Autoimmune Modulation Modulates TH-1 and TH-2 polarization which dampens AI tissue destruction Activates TH-3 regulatory T-cells which dampens AI tissue destruction Dampens TH-17 activity which dampens AI tissue destruction Enhances tissue and intestinal regeneration which enhances AI recovery Protects cell mitochondria which enhances AI recovery Clinical Strategies to Support Glutathione Levels and Glutathione Recycling If you look at the literature, there are several natural compounds that have been shown to help raise intracellular glutathione and support the glutathione recycling system: N-acetyl-cysteine Alpha lipoic acid L-glutamine Selenium Cordyceps Centella asiatica Silybum marianum Broccoli extract N-Acetyl-Cysteine (NAC) N-acetyl-cysteine is a metabolite of the sulfur-containing amino acid, cysteine. It plays a role in the sulfation cycle, acting as a sulfur donor in phase II detoxification and as a methyl donor in the conversion of homocysteine to methionine. N-acetyl cysteine is rapidly metabolized to intracellular glutathione. It is used for acetaminophen overdose and as a nephroprotective agent for radiocontrast. [27-33] Alpha lipoic acid Alpha lipoic acid is an antioxidant that is made by the body and is found in every cell, where it helps turn glucose into energy. Unlike other antioxidants, which work only in water (such as vitamin C) or fatty tissues (such as vitamin E), alpha lipoic acid is both fat- and water-soluble. This means it can work throughout the body. Alpha lipoic acid also plays an important role in the synergism of antioxidants. It directly recycles and extends the metabolic life spans of vitamin C, glutathione, and coenzyme Q10, and it indirectly renews vitamin E, all of which are necessary for glutathione recycling. [34-43] L-Glutamine L-glutamine is important for the generation of glutathione stores since glutamate is unable to be transported into cells. Glutamine is efficiently transported into the cell, converted to glutamate, and readily available for glutathione synthesis. Research has demonstrated that glutamine is important for the generation of glutathione. [44-57] Selenium Selenium is a trace element nutrient that serves as the essential cofactor for the enzyme glutathione peroxidase. Selenium-deficient humans and animals are known to be deficient in glutathione peroxidase activity in their cells and plasma. [58-69] Cordyceps Cordyceps (used in Chinese medicine for thousands of years) has been shown to activate glutathione peroxidase synthesis in the body (the enzymes that increase glutathione) and raise glutathione levels within minutes. Research has demonstrated cordyceps helps protect cells by engaging the glutathione enzyme cycle. [70-73] Centella asiatica (Gotu Kola) Research has clearly demonstrated that oral intake of gotu kola very rapidly and dramatically increases the activity and amount of glutathione peroxidase and quantity of glutathione. [74-84] Silybum marianum Administration of Silybum marianum has shown to significantly increase glutathione, increase superoxide dismutase activity, and have positive influence in the ratios of reduced and oxidized glutathione. [85-101] Broccoli extract Broccoli has a high content of glucosinolates, which are metabolized into isothiocyanates and sulforaphane [102]. These compounds exhibit chemoprotective activity through a mechanism involving inhibition of cytochrome P450 and induction of GST and other enzymes [103,104]. Barrier System Integrity In part 6, we learned when the intestinal mucosa of the digestive tract is inflamed, the tight junctions of the intestinal mucosa are compromised and they become widened and permeable to large, undigested compounds, toxins and bacteria which can then enter the bloodstream. This condition is known as leaky gut. These large undigested proteins that are absorbed are reacted against by the underlying intestinal immune system and promote exaggerated immune responsiveness (inflammation) which leads to further destruction of the intestinal barrier. This creates a vicious cycle of further intestinal inflammation and greater loss of intestinal integrity. As the intestinal tract becomes inflamed from diet, lifestyle, medications, and infections, it promotes further intestinal inflammation and further intestinal permeability. Most importantly, the immune dysregulation from increased permeability has been shown to perpetuate immune overzealousness and loss of ability to regulate self and non-self tolerance, leading to autoimmunity. “A more attentive analysis of the anatomic and functional arrangement of the GI tract however suggests that another extremely important function of this organ is its ability to regulate the trafficking of macromolecules between the environment and the host through a barrier mechanism. Together with the gut-associated lymphoid tissue and the neuroendocrine network, the intestinal epithelial barrier, with its intercellular tight junctions, controls the equilibrium between tolerance and immunity to nonself-antigens. When the finely-tuned trafficking of macromolecules is dysregulated in genetically susceptible individuals, both intestinal and extraintestinal autoimmune disorders can occur.”[105] “There is growing evidence that increased intestinal permeability plays a pathogenic role in various autoimmune diseases. Therefore, we hypothesize that loss of intestinal barrier function is necessary to develop autoimmunity.”[106] Clinical Strategies to Support the Barrier System L-Glutamine L-glutamine is the preferred fuel source for the cells of the small intestine and has been shown in numerous studies to support the regeneration and repair of the intestinal lining. It has also been shown to increase the number of cells in the small intestine, the number of villi on those cells, as well as the height of the villi. Glutamine-reduced permeability of the lining may accompany “leaky gut” patterns that promote intestinal inflammation and the development of delayed food intolerances. [107-128] Deglycyrrhizinated Licorice Deglycyrrhizinated licorice is a popular and substantially studied natural compound that provides flavonoids that help heal the gastric and intestinal lining. Many different mechanisms have been shown with regard to its restorative properties including stimulation and differentiation of glandulars cells, protective mucous formation, protective mucous secretion, increased intestinal blood flow, and growth and regeneration of intestinal lining cells. [129-147] N-Acetyl Glucosamine N-acetyl glucosamine is a monosaccharide derivative of glucose that is used to support the intestinal glycoprotein cover of the mucosa called mucin. It is also a precursor substrate for the repair of the intestinal mucosal cells and provides support of mucosa membrane irritation. [148-151] Aloe Leaf Extract Aloe leaf extract contains natural phytochemicals and powerful antioxidant properties that reduce intestinal inflammation, soothe the intestines, aid in intestinal wound healing, and have an anti-ulcer effect. It also appears to have antifungal properties, supports cholinergic intestinal motility, and reduces intestinal pain and discomfort. [152-161] Spanish Moss Spanish moss is also known as Tillandsia and it has historically been used for intestinal irritation and allergies. Research on the plant has identified rich sources of flavonoids and other phytochemicals that provide antimicrobial activity and free radical scavenging properties. [162-167] Marshmallow Extract Marshmallow extract has high content of mucilage that can soothe and help heal compromised intestinal barrier tissue. It is also rich in antioxidants that can support healing of tissue. It also has properties that inhibit hyaluronidase, which is the enzyme involved in the production of hyaluronic acid that is involved with intestinal tissue destruction. [168-171] Methylsulfonylmethane (MSM) Methylsulfonylmethane (MSM) is a rich source of natural sulfur which helps as a substrate for antioxidant defense systems as well as support substrates for hepatic phase II sulfation pathways. It has antifungal and anti-inflammatory properties that help support the compromised liver-gut axis. [172-176] Gamma Oryzanol Gamma oryzanol is a mixture of plant sterols and ferulic acid esters from rice. It has demonstrated to be a powerful antioxidant. Numerous papers have demonstrated its effectiveness in gastrointestinal complaints, ulcers, irritable bowel syndrome and non-specific gastrointestinal conditions. It has also been shown to modulate and support the enteric nervous system in its ability to activate intestinal motility and secrete digestive enzymes. [177-184] Slippery Elm Bark Slippery elm bark is very high in natural mucilage and helpful in soothing the inflamed intestinal cells. It reduces contact of inflammatory proteins with the intestinal mucosa, thereby enhancing recovery from intestinal barrier compromise and inflammation. [185-188] German Chamomile The chief constituents of German chamomile have been shown to enhance wound-healing time, modulate prostaglandins and nitric oxide activity to provide gastric and intestinal protection. [189-196] Marigold Flower Extract Marigold flower extract constituents include saponins, carotenoids, flavonoids, mucilage, bitter principle, phytosterols, polysaccharides, and resin. It has been used historically for varied gastrointestinal complaints. It provides substrates for digestive enzyme production, helps during inflammation and provides antibacterial activity. [197-204] Glutathione When a person loses their ability to recycle glutathione and glutathione levels become depleted, they are at risk for intestinal lining inflammation which then leads to leaky gut. The glutathione recycling system is one of the main systems that prevents leaky gut onset. Glutathione is suggested to play an important role in gut barrier function and prevention of intestinal inflammation. [205-210] Zinc Carnosine “Regarding intestinal permeability, zinc carnosine caused an approximate threefold increase in gut integrity and repair”[211] Vitamin D “VDR (vitamin D receptor) plays a critical role in mucosal barrier homeostasis by preserving the integrity of junction complexes and the healing capacity of the colonic epithelium. Therefore, vitamin D deficiency may compromise the mucosal barrier, leading to increased susceptibility to mucosal damage and increased risk of IBD (inflammatory bowel disease). ” [212] “There is growing appreciation of the importance of the pleiotropic hormone vitamin D in the development of tolerance, immune system defenses, and epithelial barrier integrity” [213] “1,25(OH)2D3 (vitamin D) may play a protective role in mucosal barrier homeostasis by maintaining the integrity of junction complexes and in healing capacity of the colon epithelium. 1,25(OH)2D3 may represent an attractive and novel therapeutic agent for the adjuvant therapy of IBD (inflammatory bowel disease).”[214] Intestinal Permeability Dietary Restrictions It is important to avoid certain types of food that tend to aggravate or worsen intestinal permeability when trying to repair the gut barrier and decrease autoimmune responses. These self-promoting vicious cycles become difficult to unwind unless aggressive dietary and nutritional strategies are employed. See Intestinal Permeability Dietary Restrictions at the end of this article for a complete list of these foods. TH-1 and TH-2 Polar Shifts As we learned in part 6, the immune system has two major immune responses: T-helper-1 (TH-1) response, which is mediated by T-cells T-helper-2 (TH-2) response, which is mediated by B-cells Both immune responses are important for protecting the body against foreign microbes and invaders. There is a constant interplay and subtle balance of these two immune responses and the regulation of these two responses is extremely important. This is carried out by the TH-3 regulatory system (described below), which acts in many ways like the conductor of a large complex orchestra. In healthy immune responses, there is always a balance in these two systems. In autoimmunity, there is a polar shift or dominance of either the TH-1 or TH-2 system and one side of the system becomes overactive or dominant. Many autoimmune diseases are classified in the immunology literature by their T-helper dominance.[215, 216] Let’s review the TH-3 regulatory system. Regulatory T-Cell (TH-3 Cell) Activation As discussed in part 6, TH-3 cells, or regulatory T-cells , are a subpopulation of T-cells that downregulate the immune system, maintain tolerance to self-antigens and minimize autoimmune disease. Regulatory T-cells are a component of the immune system that suppress immune responses from other cells. This is an important “self-check” mechanism inherent in the immune system to prevent excessive reactions. These cells are involved in shutting down the immune responses after they have successfully eliminated invading organisms and also in preventing autoimmune TH-1 and TH-2 polar shifts. [217, 218] Clinical Strategies to Support Regulatory T-Cell Activation and Balance TH-1 and TH-2 Polar Shifts Two key nutrients have been shown over and over in the literature to support the regulatory T-cells and coordinate TH-1 and TH-2 balance: glutathione and vitamin D . Glutathione Glutathione (GSH) is one of the most critical immune-modulating substances that we know of. Like a conductor of an orchestra, glutathione regulates various aspects of immune balance. As previously discussed, studies show that GSH has a significant impact on the immune system’s ability to activate the appropriate T-helper cell response. [219-220] Because GSH is so important in the immune system’s activation of the appropriate T-helper response, altering its levels may have significant implications in TH1/TH2-related diseases. [221] “Accumulation of evidence suggests that intracellular GSH (glutathione) levels in antigen-presenting cells such as macrophages, influence the TH1/TH2 cytokine response pattern. The observations reported herein show that pro-GSH molecules represent new therapeutic agents to support immune modulation.” [222] “These data indicate that glutathione peroxidase-dependent control of intracellular reactive oxygen species accumulation is important not only for regulation of TH-cell proliferation, but also for modulation of differentiation into TH1, TH2 and TH17 cells.”[223] See the clinical strategies described above for strategies for increasing glutathione levels. Vitamin D Numerous studies have been published establishing the critical immunoregulatory role that vitamin D plays in the prevention of immune dysfunction and the development of autoimmune disease. [224-231] Vitamin D appears to act on a number of different immune cells to promote various regulatory responses by the immune system. Vitamin D deficiency has been associated with many autoimmune disorders including multiple sclerosis, Type 1 diabetes, Crohn’s disease, rheumatoid arthritis as well as others. [232] Studies have shown a significant relation between vitamin D deficiency and allergy and an important role of vitamin D in the pathogenesis and severity of allergic disease, and its capacity to control allergic disease. [233, 234] Vitamin D supplementation has been shown to reduce the occurrence of asthma in most related studies and may be useful in the prevention or adjunct treatment of chronic obstructive pulmonary disease. [235, 236] Here are a few selections from the literature on the role vitamin D plays in immune health: “Increasing evidence demonstrates a strong association between vitamin D signaling and many biological processes that regulate immune responses. The discovery of the vitamin D receptor in multiple immune cell lineages, such as monocytes, dendritic cells, and activated T cells credits vitamin D with a novel role in modulating immunological functions and its subsequent role in the development or prevention of autoimmune diseases.”[237] “It is apparent that vitamin D has significant effects on the immune system and as such may contribute to the pathogenesis of autoimmune disease. Low vitamin D status is reported in many inflammatory rheumatic conditions. In some this extends to an association with disease activity. Vitamin D acts on a number of cells involved in both innate and acquired immunity biasing the adaptive immune system away from Th17 and Th1, towards Th2 and T-regs (T3). Deficiency accordingly could encourage autoimmunity. Vitamin D deficiency may well be an important factor in autoimmune rheumatic disease, including initial disease development and worsening the disease once present.”[238] TH-17 Activation and Dampening As discussed in part 6, T-helper 17 (TH-17) is a subset of T-helper cells producing IL-17. IL-17 is a potent proinflammatory cytokine that amplifies ongoing inflammation in epithelial and endothelial cells. [239-243] TH-17 is important for normal immunity, but it can also become excessively active, especially in those with autoimmunity. TH-17 activity is considered a key marker in the activation and severity of autoimmune flare-ups. TH-17 responses stimulate autoimmunity and TH-17 activation is like “adding fuel to the fire” of autoimmunity. The inhibition or attenuation of TH-17 cells is now considered a therapeutic strategy for the management of autoimmune disease in the literature: “The absence of Th17 cells can lead to a decrease in proinflammatory cytokines. Thus, to achieve the end goal of a balanced immune response, CAM (Complementary and Alternative Medicine) practitioners may target components along the pathway leading from naïve T-cell differentiation to Th17, thereby lowering the levels of Th17 and IL-17.” [244] Clinical Strategies to Dampen TH-17 Activation There are two natural compounds which have shown to inhibit or minimize TH-17 activation in the literature: curcumin and resveratrol . Curcumin There is substantial evidence that curcumin minimizes the activity of TH-17. [8-12] A recent paper entitled, “Curcumin has bright prospects for the treatment of multiple sclerosis,” demonstrated that curcumin supports healthy anti-inflammatory and neurosupportive mechanisms. The researchers concluded that TH-17 cells are key immunological players for the pathophysiological process of multiple sclerosis and curcumin has outstanding effects in dampening this TH-17 system. “ Th17 cells are considered as a key immunological player for the pathophysiological process of MS. Curcumin, a dietary spice from turmeric, has outstanding anti-inflammation and neuroprotective effects. Herein, we review key features of curcumin involved in biology, pharmacology, and medicinal chemistry and discuss its potential relevance to pathophysiological progress of MS”[245] Another study found that providing curcumin supplementation to Lewis rats significantly reduced the clinical severity of experimental autoimmune encephalomyelitis (EAE), and had a dramatic reduction in the number of inflammatory cells that infiltrated the spinal cord by dampening the TH-17 system. “These findings indicated that curcumin amelioration EAE was, to a large extent, due to inhibiting differentiation and development of Th17 cells…and suggest it is useful in the treatment of MS and other Th17 cell-mediated inflammatory diseases.” [246] Resveratrol Resveratrol appears to modulate immunological processes via multiple mechanisms. As we saw above, resveratrol has potent anti-inflammatory effects and has been shown to dampen inflammatory mediators including NF-kB, iNOS (inducible nitric oxide synthase) and various inflammatory cytokines. Several papers have also been published on the role of resveratrol and its ability to modulate TH-17 differentiation and activity as a potential complementary therapy for neuroautoimmune disease such as multiple sclerosis. [247-248] In fact, activation of NF-kB and other inflammatory cytokines has been associated with TH-17 activation and resulting neuroinflammatory processes and tissue destruction. “Therefore, the modulation of NF- κ B and associated cytokines such as IL-1 β , IL6, IL-8 and TNF- α by using one or a combination of different herbal medicines may suppress Th17 and IL-17 production and inhibit neuroinflammation. CAM practitioners may thus consider NF- κ B modulation for therapeutic intervention or maintenance of neuroimmune inflammatory disorders.”[248] Research has pointed to transcription factor aryl hydrocarbon receptor (AHR) as a regulator of T-regulatory cells (T-reg cells) and TH17 cell differentiation. [249] “Thus, AHR regulates both T(reg) and T(H)17 cell differentiation in a ligand-specific fashion, constituting a unique target for therapeutic immunomodulation.” [250] Resveratrol is a natural AHR antagonist. This is one of the mechanisms by which resveratrol is believed to decrease the activity of Th17 cells and has become an attractive therapeutic option for autoimmune disease. “Resveratrol, a polyphenolic compound derived from grapes, suppressed swelling and bone erosion in the paws of mice with CIA (collagen-induced arthritis). This effect was associated with reduced serum levels of proinflammatory cytokines including IL-17 and reduced numbers of Th17 cells”[251] Therefore, it appears that both curcumin and resveratrol impact two major inflammatory pathways in our current understanding of autoimmune physiology: TH-17 activation and NF-kB activation. Nitric Oxide Isomer Expressions As we previously learned, nitric oxide (NO) is an important messenger molecule involved in many physiological and pathological processes as well as a chemical-signalling molecule that is involved with communication in the nervous system, immune system and vascular system. It was proclaimed the “Molecule of the Year” in 1992. [252] Nitic oxide plays both destructive and protective roles in autoimmunity, depending on which of the three enzymes, or synthases, is expressed. The three nitric oxide synthase (NOS) isomers (forms) are neuronal NOS (nNOS), endothelial NOS (eNOS) and inducible NOS (iNOS). nNOS supports nervous tissue, including the brain, and neurological synapses involved in neuronal signaling and brain function. eNOS activity supports blood vessel health by producing dilation of blood vessels, dissolves endothelial plaques, and enhances blood flow. [253, 254] iNOS, however, has destructive effects on tissue. iNOS is activated by TH-17 and produces harmful free radical action and initiates tissue destruction. [254] How these isomers are manipulated or modulated will determine how much destruction of tissue or ability to recover from autoimmune flare-ups a person has. Studies show that nitric oxide (NO) modulates inflammatory and immune responses in multiple ways and plays a protective role in many forms of inflammatory and autoimmune reactions. [255-258] “We conclude that NO (nitric oxide) plays a critical immunoregulatory role and NO modulation may prevent the onset of autoimmune reactions”[259] Research has shown that IL-17 and the TH-17 system activates iNOS and initiates tissue destruction in autoimmunity: “Interleukin-17 is a proinflammatory cytokine involved in autoimmune disorders. The proinflammatory action of IL-17 depends considerably on its ability to trigger the expression of inducible nitric oxide (iNOS). We propose IL-17 and NO modulation could be relevant forms of therapy for autoimmune disorders” [260] “Together, these data indicate that antioxidant modulation of nitric oxide might be a feasible therapeutic tool to interfere with development of autoimmune diabetes” [261] Clinical Strategies to Support the Nitric Oxide System The following compounds have been shown in the literature to modulate nitric oxide isomers: Adenosine 5’-triphosphate Huperzine A Vinpocetine L-alpha-glycerylphosphosphorylcholine Alpha-ketogluteric acid Xanthinol niacinate L-acetylcarnitine ATP (Adenosine 5’-triphosphate) ATP (Adenosine 5’-triphosphate) is the fuel source for all biochemical reactions. ATP can be found inside the cell (intracellular) or outside the cell (extracellular). Research has also clearly demonstrated that supplementation with ATP also increases extracellular and intracellular levels of ATP. [262-264] Extracellular ATP has been found to activate eNOS and nNOS. [265-268] More importantly, ATP does not activate iNOS activity and has even demonstrated suppressive iNOS activity. [269-271] Huperzine A Huperzine A is powerful compound for ideal nitric oxide isomer expression because it enhances acetylcholine activity necessary for eNOS and nNOS and it has powerful iNOS inhibiting properties. [272-273] Huperzine is a potent natural acetylcholine esterase inhibitor, leading to increased acetylcholine activity that is necessary for ideal eNOS and nNOS activity. [274] Not only does Huperzine A inhibit iNOS activity directly, but it also suppresses the same cytokines released during exercise that stimulate iNOS. [275-278] Vinpocetine Vinpocetine is classified as a selective cyclic GMP phosphodiesterase (PDE) balancer and modulates vascular tone and Nitric Oxide release in system circulation. [279-282] The net effect of PDE inhibitors, such as vinpocetine, is to increase eNOS activity, leading to healthy vasodilation and blood delivery to peripheral tissues, such as muscles and brain, important for peak athletic performance and recovery. In addition to vinpocetine’s properties of eNOS activation, the compound has powerful influences on the neurotransmitter acetylcholine. Acetylcholine activity is critical for ideal eNOS receptor site activity. [283-285] Alpha-glycerylphosphorylcholine (Alpha GPC) Alpha-GPC is a phospholipid metabolite that is isolated from lecithin. It is absorbed extremely well by the gastrointestinal tract and is used for the synthesis of acetylcholine. Oral intake of Alpha GPC has been shown to increase acetylcholine levels in the body. [286-287] Acetylcholine activity promotes nitric oxide synthase activity, and nitric oxide promotes acetylcholine activity that is responsible for eNOS vascular dilation and nNOS synaptic activity. [288-293] Alpha-Ketoglutaric Acid (AKG) Alpha-ketoglutaric acid (AKG) is a citric cycle intermediate and can be used to help produce nitric oxide via the urea cycle and metabolize harmful nitrogen out of the body. It is also an intermediate precursor for metabolites that are used by the mitochondria to produce energy. AKG supplementation has been shown to have positive modulating activity on nitric oxide and iNOS. [294] AKG supplementation has been shown to help modulate nitrogen balance and preserve protein synthesis after cell injury. [295-297] Xanthinol Niacinate Xanthinol niacinate has very powerful vascular-enhancing properties and the ability to improve peripheral hemodynamics. [298] It has demonstrated properties to increase eNOS by its nicotinate component activity on the acetylcholine receptors. [299] A human subject study comparing the effects of a placebo and xanthinol niacinate on exercise tolerance found that xainthinol niacinate significantly increased exercise tolerance at 1 hour and 1-9 hours respectively from ingesting the supplement. [300] Clinical research has found that xanthinol niacinate has antioxidant properties that may lead to decreased iNOS activities. Several research studies have found it improves microcirculation and aids in healing. [301-304] Acetyl L-Carnitine (ALCar) Acetyl L-carnitine is composed of acetic acid and L-carnitine bound together and has very close structural similarity to acetylcholine. Research has shown that ALCAR mimics acetylcholine activity and has shown effectiveness in acetycholine mediated pathways. [305-308] Acetylcholine activity promotes nitric oxidesynthase activity, and nitric oxide promotes acetycholine activity that is responsible for eNOS vascular dilation and nNOS synaptic activity. [309-314] Lifestyle Strategies for Autoimmunity If individuals have autoimmunity or are at risk of autoimmunity, they must focus on the proper lifestyle and nutritional strategies to decrease the expression of this condition. Patients with autoimmunity must know they will have bad days. Bad days may be triggered by immune activation from various scenarios, such as stress, lack of sleep, blood glucose fluctuations, food sensitivities, etc. It is important for them to realize what mechanisms can promote their autoimmunity and what mechanisms can dampen their autoimmunity so that they can be empowered to improve their quality of life and slow down self-tissue destruction and the progression of the disease. Lifestyle Factors that Promote TH-17 Responses and Autoimmune Reactions In addition to personal internal stressors, external stressors—such as their job, strict deadlines, unrealistic goals or any environment that places great demands on them—activates their TH-17 pathway, which promotes autoimmunity. The physiologic stress response that occurs from mental or physical stress increases pro-inflammatory cytokines such as IL-2, IL-4, IL-6 and IL-10 which activates the HPA axis and increases production of epinephrine and cortisol and activates the TH-17 pathways that then promote autoimmunity. [315-323] People with autoimmunity must take themselves out of a stressful environment even if it will effect their finances, relationships, commitments, etc. or they are at increased risk of progression of their autoimmune disease. Stress modification is a significant factor of autoimmunity expression, but completely overlooked by both alternative and conventional healthcare professionals today. They must create an environment that is protective and supportive for them so they can focus on their passions and increase opioid activity. This is necessary to break the vicious cycles of ill health they have established and help return them to better health Lifestyle Strategies that Support TH-3 Cells and Dampen Autoimmune Reactions Recall that regulatory T-cells (TH-3 cells) are very important for regulation of proper immune responses. The release of natural opioids by the body activates TH-3 cells and promotes anti-inflammatory responses. [324-328] TH-3 cells are loaded with opioid receptors and as the body releases them, they activate the TH-3 cells that shift autoimmunity into suppression. The best example of opioid release is the feeling people get after they exercise. In order to get the best exercise, the exercise has to be challenging . Just walking on the treadmill passively is not going to get the best opioid response. They must make the exercise challenging enough to get their heart rate up and push themselves when they want to quit—this will create the opioid release. The key is to push themselves hard enough to get the best “exercise high” they can get after their workout, without creating an injury or overtraining. [329-333] Being able to recover quickly after exercise is also very important and sets up the body chemistry to activate TH-3 without activating TH-17, which is critical for a healthy immune response. In addition to creating an “exercise high”, they want to create feelings that make them “high on life”. A positive mental attitude, love, appreciation for life, positive mental reflection, all increase opioids that make a person “high on life”. On the other hand, a negative attitude, violence, poor relationships, internal mental stress, all promote increased production of –pro-inflammatory cytokines which activate the TH-17 pathway and promote autoimmunity. Summary of Lifestyle Modulation of Autoimmunity Adverse Mechanisms which Promote Autoimmunity Excess stress Physical overtraining Lack of sleep Drops in blood glucose Poor social relationships Beneficial Mechanisms which Dampen Autoimmunity Love/appreciation Positive attitude Adequate exercise Adequate sleep Stable blood glucose Social/physical interaction Dietary Strategies for Autoimmunity Here are three common pathophysiologic stress responses that promote autoimmunity: Blood sugar fluctuations Gluten and cross-reactive foods Intestinal permeability In addition to internal and external stressors, people with autoimmunity must decrease their physiologic stress response by optimizing their diet and eating patterns. Maintaining stable glucose levels and avoiding blood sugar spikes is important to minimize inflammatory responses. Autoimmune individuals must also avoid eating gluten or any foods that cross-react with gluten (discussed below). They must also try to improve their leaky gut/intestinal permeability condition by sticking with a low-carb/paleo diet and eating frequently throughout the day. Making the lifestyle and dietary changes as discussed below can lead to significant changes in their overall health and function. These changes will also dampen immune responses and potentially slow down the progression of the autoimmunity. Let’s discuss each of these in a bit more detail. Blood Sugar Fluctuations The most common and significant biochemical stressor today is dysglycemia or poor glucose control from diet and lifestyle. Individuals with autoimmunity need to make sure their blood glucose levels are not going up and down all day like a roller coaster. Numerous studies have shown the effects of oxidative stress and upregulation of pro-inflammatory cytokines when glucose levels fluctuate. [334-338] Studies also show there is a decrease in oxidative stress and inflammation by blunting glucose fluctuations. [339] When blood glucose is low from missing meals or eating meals that are not sufficient in fiber or protein, pro-inflammatory cytokine production (ie: IL-6) increases to raise blood glucose. [340-345] IL-6 not only activates the endocrine system (to produce more adrenal hormones to raise blood glucose) but recall it also stimulates the TH-17 pathways that activate autoimmunity, which we discussed above. [346] Insulin Resistance If they get tired after meals, they are likely eating too much food for their body to handle, particularly excess carbohydrates with insufficient protein and/or are not getting enough exercise. This type of person is often overweight and will often show elevations of fasting blood glucose and triglycerides in their labwork. These are all signs of insulin resistance , as discussed in part 1 of this series. This is an issue of the body’s cells not responding to insulin the way they should. Recall that insulin is the hormone that allows the cells to uptake glucose and lower glucose levels in the blood. Reactive Hypoglycemia If someone gets shaky, lightheaded or irritable when they go too long without eating, this is a sign of their blood glucose levels falling too low. Symptoms are often relieved after eating. If they feel better after they eat, they are either going too long without eating or are not getting enough fiber and protein to stabilize their blood sugar. These people will often show low to normal fasting blood glucose levels and tend to be thinner and often have low blood pressure. Either way, symptoms that improve or worsen after eating meals is not a good sign and indicates some type of blood glucose regulation issue that needs to be addressed to improve autoimmunity. Signs of Blood Glucose Issues and Dietary Needs Low blood sugar Fatigue between meals Eating relieves fatigue Crash in the afternoon Difficulty staying asleep Shaky, lightheaded or irritable between meals Dietary Recommendations High-protein meals Avoid simple sugars Eat every 2-3 hours High blood sugar Fatigue after meals Sugar cravings after meals Need for coffee or stimulants after meals Dietary need Avoid or limit carbohydrates Eat small meal portions Gluten and Cross-Reactive Foods Avoiding food allergens and inflammatory foods is critical to minimizing the triggering of immune responses and tissue destruction in autoimmunity. By far, the most inflammatory food being consumed in the U.S. is gluten. Non-celiac gluten sensitivity has been linked with several types of disease, including autoimmune disease, as we discussed in part 4 of this series [347-353] but it is important to understand that gluten can make any autoimmune disease worse in individuals who are gluten-sensitive because of the inflammatory nature of gluten. [354-358] As we saw in part 4 of this series, gluten sensitivity is extremely common, potentially affecting a much larger percentage of the population than we realize. We do not know exactly how common gluten reactions actually are (because conventional blood testing for this is not reliable since it is only testing for one fraction of wheat seen in celiac disease, as discussed in part 4) but we do know that approximately 30-40% of the normal population have the HLA-DQ2 or DQ8 genotype (the genotype associated with celiac disease) [359] and one estimate is that gluten sensitivity affects 29% of the normal population. [360] We also know that gluten sensitivity presents as a wide variety of symptoms [361], and has been implicated in the development of intestinal permeability or leaky gut syndrome [362]. As we learned in part 5, intestinal permeability is now being theorized to be one of the primary mechanisms in the pathogenesis (development of disease) of autoimmune disease. [363-366] So there is a clear connection between gluten sensitivity, leaky gut and the development and progression of autoimmune disease. “Why am I Not Feeling Better on a Gluten-Free Diet?” Once a patient is diagnosed as Celiac Disease (CD) or showing signs (or suspected of having) gluten sensitivity, he/she is instructed to adhere to a gluten-free diet (GFD). There are many resources that can help the patient with this seemingly difficult process. However, a significant percentage of these patients will continue to have gluten-like complaints even after being on a GFD for months. [367] Why is that? “Gluten-Free” Products are Not Necessarily Gluten-Free Most countries define “gluten-free” products based on the recommendation of the Food and Agricultural Organization of the United Nations and World Health Organization. This codex allows the inclusion of up to 0.3% protein from gluten containing grains in foods labeled “gluten-free.” In some gluten-sensitive individuals who are exposed to 0.3% gluten protein, the immune system can still recognize and react to the protein. [368-369] Hidden Sources of Gluten Wheat/gliadin is commonly added to foods as a “hidden” ingredient in various types of food additives such as soy sauce, food starches, food emulsifiers, malt extract and dextrins. These are often referred to as “natural flavors”, “food starches” or “food stabilizers.” A complete understanding of ‘hidden wheat/gluten’ sources is necessary to have a better outcome with the GFD. Additionally, education of gluten-containing grains, such as rye, barley, Polish wheat and spelt, is also important. Hidden sources of gluten: Soy sauce Salad dressings Food starches Food emulsifiers Food stabilizers Artificial food coloring Malt extract, flavor, syrup Dextrins Cross-Reactivity with Gluten Another major reason for gluten-related symptoms while on a GFD is because there exists antigenic similarity , or cross-reaction , among many grains, and other dietary proteins with gluten. In order to understand this concept of cross-reactivity, let’s review some basic concepts of immunology. Immune responses to food occur when antibodies of the immune system recognize and bind to antigens (specific to that food) made of proteins which are composed of a sequence of amino acids. There are a number of foods that have been identified to have a similar amino acid sequence as gluten, including dairy. In fact, resarch indicates about 50% of patients with celiac disease have problems digesting dairy and may, therefore, contribute to persistent symptoms in patients who are on a GFD. [370] Gluten antibodies can bind to these non-gluten food antigens initiating inflammatory responses similar to those seen with gluten. This type of response is termed “cross-reactivity” and has been clearly-established in the literature. [371-378] This is a big problem for people who are gluten-sensitive because their immune systems “cross-react” to many types of food as if they were consuming gluten and cause major problems for these people, especially if they already have autoimmunity. Research has indicated that identifying these foods appears to be a valuable adjunct in the diagnosis and follow-up of diagnosed celiac disease, both in children and adults. Monitoring these antibodies may be particularly helpful in evaluating the response of patients on a gluten- and cross-reactive food-free diet. [379] The following is a list of foods which have been shown to cross-react with gluten. Gluten Cross-Reactive Foods Cow’s milk Whey protein Soy Oats Yeast Millet Corn Rice Development of Additional Food Sensitivities Additionally, patients who are new to the GFD encounter new foods and/or over-consume old favorites to compensate for the lack of wheat in the diet. Gluten-free cookies, crackers, breads and cakes often contain copious amounts of rice, amaranth, sorghum and other substitutes. Some of these new-to-the-patient foods may illicit an adverse reaction. Other foods that are often introduced to the patient on the GFD are quinoa, buckwheat and hemp. Some patients may turn to the “ancient” grains (Polish wheat, spelt, barley, rye), not knowing that these contain gluten. Another problem patients often face on the GFD is the over-consumption of another starch to make up for the loss of wheat. They turn to potato, rice or corn as a substitute. This can lead to the development of a new sensitivity or the enhancement of old sensitivities. [380-386] Laboratory Testing for Gluten Sensitivity and Gluten Cross-Reactive Foods In part 4 of this series, we discussed the inappropriateness and unreliability of conventional lab testing (anti-gliadin and anti-tissue transglutaminase 2) for gluten sensitivity. This test was designed to detect celiac disease, not all the other types of responses now known to occur in gluten sensitivity. As a result, this test only tests for a limited number of antibody responses and we learned that there are many other types of reactions to gluten as well as other wheat fractions that are not detected in this test that can result in various illnesses. [387] Fortunately, there is a reliable comprehensive gluten sensitivity test available through Cyrex Labs which tests for IgA and IgG antibodies to twelve different reactions to wheat: Array 3x: Wheat/Gluten Proteome Reactivity and Autoimmunity test . In addition to performing reliable testing for gluten sensitivity in individuals where gluten sensitivity is suspected, it is advised to check for immune responses to gluten cross-reactive foods in any individual shown to have gluten sensitivity when symptoms persist after initiation of a gluten-free diet (GFD). Cyrex Labs offers a comprehensive test which tests for immune responses to 24 different cross-reactive foods or foods that patients often develop sensitivity to after initiating a GFD, as discussed above: Array 4: Gluten-Associated Cross-Reactive Foods and Foods Sensitivity test. In my practice, I recommend this test for anyone who is known to have gluten sensitivity but continues to have gluten-related symptoms, even after initiating a GFD. Intestinal Permeability Dietary Restrictions Finally, as discussed above, it is important to avoid foods that tend to aggravate or worsen intestinal permeability when trying to repair the gut barrier and decrease autoimmune responses. Sugars and high glycemic foods can create more damage to the intestinal lining and increase permeability. Gluten (and other grains that cross-react with gluten), dairy and soy can also cause additional inflammation and lead to further damage to the epithelial lining of the GI tract. Lectins (found in grains, legumes, nightshade plants and dairy) have also been shown to damage this epithelial ling. It is important to implement an aggressive and complete dietary program to break the vicious cycle of leaky gut and minimize autoimmune reactions. Here is a list of foods shown to aggravate or worsen intestinal permeability as well as the foods that are generally safely tolerated in individuals with this condition. Foods to Avoid Sugars: including corn syrup, high fructose corn syrup, molasses, honey, chocolate candy, etc. High glycemic fruits: watermelon, mango, pineapple, raisins and canned fruit Grains: including gluten, wheat, oats, rice, barley, buckwheat, soy, corn, wheat germ, spelt, amaranth, kamut, millet, and quinoa, etc. Gluten-containing compounds: including processed salad dressings, ketchup, soy sauce, barbecue sauce, condiments, modified starches, etc. Dairy: including milk, whey, eggs, cheeses, creams, and mayonnaise, etc. Soy: including soy milk, soy sauce, soy protein, etc. Alcohol: including beer, wine, sake, cognac, liquors, etc. Lectins: including nuts, beans, soy, potatoes, tomato, eggplant, pepper, peanut oil, soy oil, etc. Coffee Processed foods Canned foods Foods to Eat Most vegetables (except tomato, potatoes and mushrooms): including asparagus, spinach, lettuce, broccoli, beets, cauliflower, carrots, celery artichokes, garlic, onions, zucchini, squash, rhubarb, cucumbers, turnips, watercress, etc. Fermented foods: including sauerkraut, kimchi, pickled ginger, mixed pickle, coconut yogurt, kombucha tea, etc. Meats: including fish, chicken, beef, lamb, organ meats, etc. Low glycemic foods: apricot, plum apple, peach, pear, cherries, berries, etc. Coconut: including coconut oil, coconut bitter, coconut milk, etc. Herbal teas Olives and olive oil Cyrex Labs Array 2: Intestinal Permeability Antigenic Screen Cyrex Labs offers a reliable intestinal barrier antigenic test which is currently the only commercial lab available that measures the immunological response against the proteins that compose the intestinal barrier and accepted markers of permeability, such as lipopolysaccharides (LPS). The profile includes actin/myosin network IgG, occludin/zonulin IgG, IgA, IgM and lipopolysaccharides (LPS) IgG, IgA, and IgM. Measurements of these antibodies can be used as reliable markers for intestinal permeability. This condition is extremely important to assess in individuals who have autoimmunity or autoimmunity is suspected, or patients that present with common signs or symptoms associated with intestinal permeability as described above and whom the development of autoimmunity is a concern. References Nuclear factor-kB—a pivotal transcription factor in chronic inflammatory diseases. NF-kB Inflammatory Amplifying Loop. N Eng J Med. 1997;336:1066-1071. Nuclear factor-kB—a pivotal transcription factor in chronic inflammatory diseases. NF-kB Inflammatory Amplifying Loop. N Eng J Med. 1997;336:1066-1071. Return to homeostasis: downregulation of NF-kB responses. Nat Immunol. 2011 Jun 19;12(8):709-714 NF-kB in type 1 diabetes . Inflamm Allergy Drug Targets. 2011 Jun;10(3):208-217. NF-kB as a therapeutic target in autoimmune disease. Expert Opin Ther Targets. 2007 Feb;11(2):111-122 Naturally occurring NF-kB inhibitors . Mini Rev Med Chem. 2006 Aug;6(8):945-951. Curcumin has bright prospects for the treatment of multiple sclerosis . Int Immunopharmacol. 2011 Mar;11(3):323-330 Curcumin, an atoxic antioxidant and natural NFkappaB, cyclooxygenase-2, lipooxygenase, and inducible nitric oxide synthase inhibitor: a shield against acute and chronic diseases. Bengmark S. JPEN J Parenter Enteral Nutr. 2006 Jan-Feb;30(1):45-51. Review. Curcumin, an active component of turmeric in the prevention and treatment of ulcerative colitis: preclinical and clinical observations. Baliga MS, Joseph N, Venkataranganna MV, Saxena A, Ponemone V, Fayad R. Food Funct. 2012 Nov;3(11):1109-17. doi: 10.1039/c2fo30097d. Review. Curcumin ameliorates cardiac inflammation in rats with autoimmune myocarditis . Biol Pharm Bull. 2011;34(7):974-979 JPEN J Parenter Enteral Nutr. 2006 Jan-Feb;30(1):45-51. Review. “Spicing up” of the immune system by curcumin. Jagetia GC, Aggarwal BB. J Clin Immunol. 2007 Jan;27(1):19-35. Epub 2007 Jan 9. Review. The targets of curcumin. Curr Drug Targets. 2011 Mar 1;12(3):332-347. Oral resveratrol reduces neuronal damage in a model of multiple sclerosis. J neuroopthalmol. 2010 Dec;30(4):328-339 NF-kB inhibitory action of resveratrol: a probable mechanism of neuroprotection in experimental diabetic neuropathy. Biochem Biophys Res Commun. 2010 Apr 2;394(2):360-365 Resveratrol suppresses IL-1β-induced inflammatory signaling and apoptosis in human articular chondrocytes: potential use for use as a novel nutraceutical for the treatment of osteoarthritis. Biochem Pharmacol. 2008 Dec 1;76(11):1426-39 Resveratrol ameliorates experimental autoimmune myocarditis. Circ J. 2007 Mar;71(3):397-404 Youn J, Lee JS, Na HK, Kundu JK, Surh YJ. Resveratrol and piceatannol inhibit iNOS expression and NF-kappaB activation in dextran sulfate sodium-induced mouse colitis. Nutrition and Cancer . 2009;61(6):847–854. Li T, Fan G-X, Wei W, Li T, Yuan Y-K. Resveratrol induces apoptosis, influences IL-6 and exerts immunomodulatory effect on mouse lymphocytic leukemia both in vitro and in vivo. International Immunopharmacology . 2007;7:1221–1231. Gonzales AM, Orlando RA. Curcumin and resveratrol inhibit nuclear factor-kappaB-mediated cytokine expression in adipocytes. Nutrition and Metabolism . 2008;5(1):17–30. Prescott LF, Park J, Ballantyne A, Adriaenssens P, Proudfoot AT. Treatment of paracetamol (acetaminophen) poisoning with N-acetylcysteine. Lancet 1977;2:432-434. Antiviral and immunomodulatory properties of new pro-glutathione (GSH) molecules. Curr Med Chem. 2006:13(15): 1749-55 Nazzareno Ballatori, Suzanne M. Krance, Sylvia Notenboom, Shujie Shi, Kim Tieu, Christine L. Hammond. Glutathione dysregulation and the etiology and progression of human diseases . Biol Chem. 2009 March; 390(3): 191–214. Correlation of lipid peroxidation and glutathione levels with severity of systemic lupus erythmatosus: a pilot study from single center. J Pharm Pharm Sci. 2008;11(3):30-4 Nazzareno Ballatori, Suzanne M. Krance, Sylvia Notenboom, Shujie Shi, Kim Tieu, Christine L. Hammond. Glutathione dysregulation and the etiology and progression of human diseases . Biol Chem. 2009 March; 390(3): 191–214. Maher P. The effects of stress and aging on glutathione metabolism. Ageing Res Rev 2005;4:288-314. Glutathione peroxidase 1 deficiency attenuates allergen-induced airway inflammation by suppressing TH2 and TH17 cell development. Antioxid Redox Signal. 2010 Jun 6. Odom RY, Dansby MY, Rollins-Hairston AM, Jackson KM, Kirlin WG. Phytochemical induction of cell cycle arrest by glutathione oxidation and reversal by N-acetylcysteine in human colon carcinoma cells. Nutr Cancer. 2009;61(3):332-9. Soghier LM, Brion LP. Cysteine, cystine or N-acetylcysteine supplementation in parenterally fed neonates. Cochrane Database Syst Rev. 2006 Oct 18;(4):CD004869. Badaloo A, Reid M, Forrester T, Heird WC, Jahoor F. Cysteine supplementation improves the erythrocyte glutathione synthesis rate in children with severe edematous malnutrition. Am J Clin Nutr. 2002 Sep;76(3):646-52. 30. Drager LF, Andrade L, Barros de Toledo JF, Laurindo FR, Machado Cesar LA, Seguro AC. Renal effects of N-acetylcysteine in patients at risk for contrast nephropathy: decrease in oxidant stress-mediated renal tubular injury. Nephrol Dial Transplant 2004;19:1803-1807. 31. Shimada K, Murayama T, Yokode M, Kita T, Uzui H, Ueda T, Lee JD, Kishimoto C. N-acetylcysteine reduces the severity of atherosclerosis in apolipoprotein E-deficient mice by reducing superoxide production. Circ J 2009;73:1337-1341. 32. Moldeus P, Cotgreave IA, Berggren M. Lung protection by a thiol-containing antioxidant: N-acetylcysteine. Respiration 1986;50 Suppl 1:31-42. 33. Prescott LF, Park J, Ballantyne A, Adriaenssens P, Proudfoot AT. Treatment of paracetamol (acetaminophen) poisoning with N-acetylcysteine. Lancet 1977;2:432-434. Shay KP, Moreau RF, Smith EJ, Smith AR, Hagen TM. Alpha-lipoic acid as adietary supplement: molecular mechanisms and therapeutic potential. Biochim Biophys Acta. 2009 Oct;1790(10):1149-60. Epub 2009 Aug 4. 35. Kinnunen S, Oksala N, Hyyppä S, Sen CK, Radak Z, Laaksonen DE, Szabó B, Jakus J, Atalay M. Alpha-Lipoic acid modulates thiol antioxidant defenses and attenuates exercise-induced oxidative stress in standardbred trotters. Free Radic Res. 2009 Aug;43(8):697-705. 36. Maczurek A, Hager K, Kenklies M, Sharman M, Martins R, Engel J, Carlson DA, Münch G. Lipoic acid as an anti-infl ammatory and neuroprotective treatment for Alzheimer’s disease. Adv Drug Deliv Rev. 2008 Oct-Nov;60(13-14):1463-70. 37. Suh JH, Moreau R, Heath SH, Hagen TM. Dietary supplementation with (R)-alpha-lipoic acid reverses the age-related accumulation of iron and depletion of antioxidants in the rat cerebral cortex. Redox Rep. 2005;10(1):52-60. 38. Hill AS, Rogers QR, O’Neill SL, Christopher MM. Effects of dietary antioxidant supplementation before and after oral acetaminophen challenge in cats. Am J Vet Res. 2005 Feb;66(2):196-204. 39. Zicker SC, Hagen TM, Joisher N, Golder C, Joshi DK, Miller EP. Safety of long-term feeding of dl-alpha-lipoic acid and its effect on reduced glutathione:oxidized glutathione ratios in beagles. Vet Ther. 2002 Summer;3(2):167-76. 40. Jones W, Li X, Qu ZC, Perriott L, Whitesell RR, May JM. Uptake, recycling, and antioxidant actions of alpha-lipoic acid in endothelial cells. Free Radic Biol Med. 2002 Jul 1;33(1):83-93. 41. Miquel J. Can antioxidant diet supplementation protect against agerelated mitochondrial damage? Ann N Y Acad Sci. 2002 Apr;959:508-16. 42. Khanna S, Atalay M, Laaksonen DE, Gul M, Roy S, Sen CK. Alpha-lipoic acid supplementation: tissue glutathione homeostasis at rest and after exercise. J Appl Physiol. 1999 Apr;86(4):1191-6. 43. Han D, Handelman G, Marcocci L, Sen CK, Roy S, Kobuchi H, Tritschler HJ, Flohé L, Packer L. Lipoic acid increases de novo synthesis of cellular glutathione by improving cystine utilization. Biofactors. 1997;6(3):321-38. 44. Kul M, Vurucu S, Demirkaya E, Tunc T, Aydinoz S, Meral C, Kesik V, Alpay F. Enteral glutamine and/or arginine supplementation have favorable effects on oxidative stress parameters in neonatal rat intestine. J Pediatr Gastroenterol Nutr. 2009 Jul;49(1):85-9. 45. Fan YP, Yu JC, Kang WM, Zhang Q. Effects of glutamine supplementation on patients undergoing abdominal surgery. Chin Med Sci J. 2009 Mar;24(1):55- 46. Todorova V, Vanderpool D, Blossom S, Nwokedi E, Hennings L, Mrak R, Klimberg VS. Oral glutamine protects against cyclophosphamide-induced cardiotoxicity in experimental rats through increase of cardiac glutathione. Nutrition. 2009 Jul-Aug;25(7-8):812-7. 47. Cruzat VF, Tirapegui J. Effects of oral supplementation with glutamine and alanyl-glutamine on glutamine, glutamate, and glutathione status in trained rats and subjected to long-duration exercise. Nutrition. 2009 Apr;25(4):428-35. 48. Kaufmann Y, Todorova VK, Luo S, Klimberg VS. Glutamine affects glutathione recycling enzymes in a DMBA-induced breast cancer model. Nutr Cancer. 2008;60(4):518-25. 49. Xue H, Sawyer MB, Field CJ, Dieleman LA, Murray D, Baracos VE. Bolus oral glutamine protects rats against CPT-11-induced diarrhea and differentially activates cytoprotective mechanisms in host intestine but not tumor. J Nutr. 2008 Apr;138(4):740-6. 50. Mok E, Constantin B, Favreau F, Neveux N, Magaud C, Delwail A, Hankard R. L-glutamine administration reduces oxidized glutathione and MAP kinase signaling in dystrophic muscle of mdx mice. Pediatr Res. 2008 Mar;63(3):268-73. 51. Kaufmann Y, Klimberg VS. Effect of glutamine on gut glutathione fractional release in the implanted tumor model. Nutr Cancer. 2007;59(2):199-206. 52. Belmonte L, Coëffi er M, Le Pessot F, Miralles-Barrachina O, Hiron M, Leplingard A, Lemeland JF, Hecketsweiler B, Daveau M, Ducrotté P, Déchelotte P. Effects of glutamine supplementation on gut barrier, glutathione content and acute phase response in malnourished rats during infl ammatory shock. World J Gastroenterol. 2007 May 28;13(20):2833-40. 53. Jackson AA, Gibson NR, Lu Y, Jahoor F. Synthesis of erythrocyte glutathione in healthy adults consuming the safe amount of dietary protein. Am J Clin Nutr.2004 Jul;80(1):101-7. 54. Melis GC, ter Wengel N, Boelens PG, van Leeuwen PA. Glutamine: recent developments in research on the clinical significance of glutamine. Curr Opin Clin Nutr Metab Care. 2004 Jan;7(1):59-70. 55. Johnson AT, Kaufmann YC, Luo S, Todorova V, Klimberg VS. Effect of glutamine on glutathione, IGF-I, and TGF-beta 1. J Surg Res. 2003 May 15;111(2):222-8. 56. Manhart N, Vierlinger K, Spittler A, Bergmeister H, Sautner T, Roth E. Oral feeding with glutamine prevents lymphocyte and glutathione depletion of Peyer’s patches in endotoxemic mice. Ann Surg. 2001 Jul;234(1):92-7. 57. Le Bricon T. Effect of glutamine supplementation on protein metabolism and glutathione in tumor-bearing rats. Clin Nutr. 1996 Aug;15(4):211. 58. Wichtel JJ, Thompson KG, Williamson NB. Serum glutathione peroxidase activity reflects short-term increases in selenium intake in goats. N Z Vet J. 1996 Aug;44(4):148-50 59. Delmas-Beauvieux MC, Peuchant E, Couchouron A, Constans J, Sergeant C, Simonoff M, Pellegrin JL, Leng B, Conri C, Clerc M. The enzymatic antioxidant system in blood and glutathione status in human immunodeficiency virus (HIV)-infected patients: effects of supplementation with selenium or beta-carotene. Am J Clin Nutr. 1996 Jul;64(1):101-7. Erratum in: Am J Clin Nutr 1996 Dec;64(6):971. 60. Winnefeld K, Schirrmeister W, Thiele R, Sperschneider H, Klinger G. Selenium and antioxidant status in various diseases. Med Klin (Munich). 1995 Jan 15;90 Suppl 1:7-9 61. Bellisola G, Perona G, Galassini S, Moschini G, Guidi GC. Plasma selenium and glutathione peroxidase activities in individuals living in the Veneto region of Italy. J Trace Elem Electrolytes Health Dis. 1993 Dec;7(4):242-4. 62. Bedwal RS, Nair N, Sharma MP, Mathur RS. Selenium&#8211;its biological perspectives . Med Hypotheses. 1993 Aug;41(2):150-9. PubMed 63. Zachara BA, Mikolajczak J, Trafi kowska U. Effect of various dietary selenium (Se) intakes on tissue Se levels and glutathione peroxidase activities in lambs. Zentralbl Veterinarmed A. 1993 May;40(4):310-8. 64. Wilke BC, Vidailhet M, Favier A, Guillemin C, Ducros V, Arnaud J, Richard MJ. Selenium, glutathione peroxidase (GSH-Px) and lipid peroxidation products before and after selenium supplementation. Clin Chim Acta. 1992 Apr 30;207(1-2):137-42. 65. Bellisola G, Galassini S, Moschini G, Poli G, Perona G, Guidi G. Selenium and glutathione peroxidase variations induced by polyunsaturated fatty acids oral supplementation in humans. Clin Chim Acta. 1992 Jan 31;205(1-2):75-85. 66. Pearson DJ, Day JP, Suarez-Mendez VJ, Miller PF, Owen S, Woodcock A. Human selenium status and glutathione peroxidase activity in northwest England. Eur J Clin Nutr. 1990 Apr;44(4):277-83. 67. Michaëlsson G, Edqvist LE. Erythrocyte glutathione peroxidase activity in acne vulgaris and the effect of selenium and vitamin E treatment. Acta Derm Venereol. 1984;64(1):9-14. PubMed PMID: 6203294. 68. Doni MG, Avventi GL, Bonadiman L, Bonaccorso G. Glutathione peroxidase, selenium, and prostaglandin synthesis in platelets. Am J Physiol. 1981 May;240(5):H800-3. 69. Hafeman DG, Sunde RA, Hoekstra WG. Effect of dietary selenium on erythrocyte and liver glutathione peroxidase in the rat. J Nutr. 1974 May;104(5):580-7. 70. Ko WS, Hsu SL, Chyau CC, Chen KC, Peng RY. Compound Cordyceps TCM-700C exhibits potent hepatoprotective capability in animal model. Fitoterapia. 2010 Jan;81(1):1-7. 71. Ji DB, Ye J, Li CL, Wang YH, Zhao J, Cai SQ. Antiaging effect of Cordyceps sinensis extract. Phytother Res. 2009 Jan;23(1):116-22. 72. Wang YH, Ye J, Li CL, Cai SQ, Ishizaki M, Katada M. [An experimental study on anti-aging action of Cordyceps extract]. Zhongguo Zhong Yao Za Zhi. 2004 Aug;29(8):773-6. 73. Liu Y, Wu C, Li C. [Anti-oxidation of Paecilomyces Sinensis (S. Pnov.)]. Zhongguo Zhong Yao Za Zhi. 1991 Apr;16(4):240-2, 256. 74. Haleagrahara N, Ponnusamy K. Neuroprotective effect of Centella asiatica extract (CAE) on experimentally induced parkinsonism in aged Sprague-Dawley rats. J Toxicol Sci.2010;35(1):41-7. 75. Shinomol GK, Ravikumar H; Muralidhara. Prophylaxis with Centella asiatica confers protection to prepubertal mice against 3-nitropropionicacid-induced oxidative stress in brain. Phytother Res. 2009 Nov 26. 76. Shinomol GK, Muralidhara. Prophylactic neuroprotective property of Centella asiatica against 3-nitropropionic acid induced oxidative stress and mitochondrial dysfunctions in brain regions of prepubertal mice. Neurotoxicology. 2008 Nov;29(6):948-57. 77. Shinomol GK, Muralidhara. Effect of Centella asiatica leaf powder on oxidative markers in brain regions of prepubertal mice in vivo and its in vitro efficacy to ameliorate 3-NPA-induced oxidative stress in mitochondria. Phytomedicine. 2008 Jun 5. 78. Flora SJ, Gupta R. Benefi cial effects of Centella asiatica aqueous extract against arsenic-induced oxidative stress and essential metal status in rats. Phytother Res. 2007 Oct;21(10):980-8. 79. Ramanathan M, Sivakumar S, Anandvijayakumar PR, Saravanababu C, Pandian PR. Neuroprotective evaluation of standardized extract of Centella asciatica in monosodium glutamate treated rats. Indian J Exp Biol. 2007 May;45(5):425-31. 80. Gupta R, Flora SJ. Effect of Centella asiatica on arsenic-induced oxidative stress and metal distribution in rats. J Appl Toxicol. 2006 May-Jun;26(3):213-22. 81. Jayashree G, Kurup Muraleedhara G, Sudarslal S, Jacob VB. Antioxidant activity of Centella asiatica on lymphoma-bearing mice. Fitoterapia. 2003 Jul;74(5):431-4. 82. Gupta YK, Veerendra Kumar MH, Srivastava AK. Effect of Centella asiatica on pentylenetetrazole-induced kindling, cognition and oxidative stress in rats. Pharmacol Biochem Behav. 2003 Feb;74(3):579-85. 83. Veerendra Kumar MH, Gupta YK. Effect of different extracts of Centella asiatica on cognition and markers of oxidative stress in rats. J Ethnopharmacol. 2002 Feb;79(2):253-60. 84. Lee MK, Kim SR, Sung SH, Lim D, Kim H, Choi H, Park HK, Je S, Ki YC. Asiatic acid derivatives protect cultured cortical neurons from glutamate-induced excitotoxicity. Res Commun Mol Pathol Pharmacol. 2000 Jul-Aug;108(1-2):75-86. 85. Shaker E, Mahmoud H, Mnaa S. Silymarin, the antioxidant component and Silybum marianum extracts prevent liver damage. Food Chem Toxicol. 2010 Mar;48(3):803-6. 86. Kidd PM. Bioavailability and activity of phytosome complexes from botanical polyphenols: the silymarin, curcumin, green tea, and grape seed extracts. Altern Med Rev. 2009 Sep;14(3):226-46. 87. Kaur G, Athar M, Alam MS. Dietary supplementation of silymarin protects against chemically induced nephrotoxicity, infl ammation and renal tumor promotionresponse. Invest New Drugs. 2009 Jul 10. 88. Lu P, Mamiya T, Lu LL, Mouri A, Zou L, Nagai T, Hiramatsu M, Ikejima T, Nabeshima T. Silibinin prevents amyloid beta peptide-induced memory impairment and oxidative stress in mice. Br J Pharmacol. 2009 Aug;157(7):1270-7. 89. Gharagozloo M, Moayedi B, Zakerinia M, Hamidi M, Karimi M, Maracy M, Amirghofran Z. Combined therapy of silymarin and desferrioxamine in patients with beta-thalassemia major: a randomized double-blind clinical trial. Fundam Clin Pharmacol. 2009 Jun;23(3):359-65. 90. Kim SH, Cheon HJ, Yun N, Oh ST, Shin E, Shim KS, Lee SM. Protective effect of a mixture of Aloe vera and Silybum marianum against carbon tetrachloride-induced acute hepatotoxicity and liver fi brosis. J Pharmacol Sci. 2009 Jan;109(1):119-27. 91. Turgut F, Bayrak O, Catal F, Bayrak R, Atmaca AF, Koc A, Akbas A, Akcay A, Unal D. Antioxidant and protective effects of silymarin on ischemia and reperfusion injury in the kidney tissues of rats. Int Urol Nephrol. 2008;40(2):453-60. 92. Ligeret H, Brault A, Vallerand D, Haddad Y, Haddad PS. Antioxidant and mitochondrial protective effects of silibinin in cold preservation-warm reperfusion liver injury. J Ethnopharmacol. 2008 Feb 12;115(3):507-14. 93. Toklu HZ, Tunali Akbay T, Velioglu-Ogunc A, Ercan F, Gedik N, Keyer-Uysal M, Sener G. Silymarin, the antioxidant component of Silybum marianum, prevents sepsis-induced acute lung and brain injury. J Surg Res. 2008 Apr;145(2):214-22. 94. Song Z, Song M, Lee DY, Liu Y, Deaciuc IV, McClain CJ. Silymarin prevents palmitate-induced lipotoxicity in HepG2 cells: involvement of maintenance of Akt kinase activation. Basic Clin Pharmacol Toxicol. 2007 Oct;101(4):262-8. 95. Toklu HZ, Tunali-Akbay T, Erkanli G, Yüksel M, Ercan F, Sener G. Silymarin, the antioxidant component of Silybum marianum, protects against burn-induced oxidative skin injury. Burns. 2007 Nov;33(7):908-16. 96. Kiruthiga PV, Shafreen RB, Pandian SK, Arun S, Govindu S, Devi KP. Protective effect of silymarin on erythrocyte haemolysate against benzo(a)pyrene and exogenous reactive oxygen species (H2O2) induced oxidative stress. Chemosphere. 2007 Jul;68(8):1511-8. 97. Pradhan SC, Girish C. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Indian J Med Res. 2006 Nov;124(5):491-504. 98. Das SK, Vasudevan DM. Protective effects of silymarin, a milk thistle (Silybium marianum) derivative on ethanol-induced oxidative stress in liver. Indian J Biochem Biophys. 2006 Oct;43(5):306-11. 99. Edwards J, Grange LL, Wang M, Reyes E. Fetoprotectivity of the flavanolignan compound siliphos against ethanol-induced toxicity. Phytother Res. 2000 Nov;14(7):517-21. 100. Täger M, Dietzmann J, Thiel U, Hinrich Neumann K, Ansorge S. Restoration of the cellular thiol status of peritoneal macrophages from CAPD patients by the fl avonoids silibinin and silymarin. Free Radic Res. 2001 Feb;34(2):137-51 101. Valenzuela A, Aspillaga M, Vial S, Guerra R. Selectivity of silymarin on the increase of the glutathione content in different tissues of the rat. Planta Med. 1989 Oct;55(5):420-2. 102. Fahey JW, Talalay P. Antioxidant functions of sulforaphane: a potent inducer of Phase II detoxication enzymes. Food Chem Toxicol 1999;37:973-979. 103. Barcelo S, Gardiner JM, Gescher A, Chipman JK. CYP2E1-mediated mechanism of anti-genotoxicity of the broccoli constituent sulforaphane. Carcinogenesis 1996;17:277-282. 104. Maheo K, Morel F, Langouet S, Kramer H, Le Ferrec E, Ketterer B, Guillouzo A. Inhibition of cytochromes P-450 and induction of glutathione S-transferases by sulforaphane in primary human and rat hepatocytes. Cancer Res 1997;57:3649-3652. 105. Fasano A. Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer. Physiol Rev. 2011;91:151–175. 106. Tight junctions, intestinal permeability, and autoimmunity: celiac disease and type 1 diabetes paradigms Ann N Y Acad Sci. 2009 May;1165:195-205 107. Noyer CM, Simon D, Borczuk A, Brandt LJ, Lee MJ, Nehra V. A double-blind placebo-controlled pilot study of glutamine therapy for abnormal intestinal permeability in patients with AIDS. Am J Gastroenterol. 1998 Jun;93(6):972-5. 108. Klimberg VS, Souba WW, Dolson DJ, Salloum RM, Hautamaki RD, Plumley DA, Mendenhall WM, Bova FJ, Khan SR, Hackett RL, et al. Prophylactic glutamine protects the intestinal mucosa from radiation injury. Cancer. 1990 Jul 1;66(1):62-8. 109. Chamorro S, de Blas C, Grant G, Badiola I, Menoyo D, Carabaño R. Effect of dietary supplementation with glutamine and a combination of glutamine-arginine on intestinal health in twenty-five-day-old weaned rabbits. J Anim Sci. 2010 Jan;88(1):170-80. 110. Amasheh M, Andres S, Amasheh S, Fromm M, Schulzke JD. Barrier effects of nutritional factors. Ann N Y Acad Sci. 2009 May;1165:267-73 111. Kul M, Vurucu S, Demirkaya E, Tunc T, Aydinoz S, Meral C, Kesik V, Alpay F. Enteral glutamine and/or arginine supplementation have favorable effects on oxidative stress parameters in neonatal rat intestine. J Pediatr Gastroenterol Nutr. 2009 Jul;49(1):85-9. 112. Azuma H, Mishima S, Oda J, Homma H, Sasaki H, Hisamura M, Ohta S, Yukioka T. Enteral supplementation enriched with glutamine, fiber, and oligosaccharide prevents gut translocation in a bacterial overgrowth model. J Trauma. 2009 Jan;66(1):110-4. 113. Maes M, Leunis JC. Normalization of leaky gut in chronic fatigue syndrome (CFS) is accompanied by a clinical improvement: effects of age, duration of illness and the translocation of LPS from gram-negative bacteria. Neuro Endocrinol Lett. 2008 Dec;29(6):902-10. 114. Tian J, Hao L, Chandra P, Jones DP, Willams IR, Gewirtz AT, Ziegler TR. Dietary glutamine and oral antibiotics each improve indexes of gut barrier function in rat short bowel syndrome . Am J Physiol Gastrointest Liver Physiol. 2009 Feb;296(2):G348-55. 115. Coëffier M, Claeyssens S, Lecleire S, Leblond J, Coquard A, Bôle-Feysot C, Lavoinne A, Ducrotté P, Déchelotte P. Combined enteral infusion of glutamine, carbohydrates, and antioxidants modulates gut protein metabolism in humans. Am J Clin Nutr. 2008 Nov;88(5):1284-90. 116. Wang WW, Qiao SY, Li DF. Amino acids and gut function. Amino Acids. 2009 May;37(1):105-10. Epub 2008 Aug 1. Review. PubMed PMID:18670730. 117. Xue H, Sawyer MB, Field CJ, Dieleman LA, Murray D, Baracos VE. Bolus oral glutamine protects rats against CPT-11-induced diarrhea and differentially activates cytoprotective mechanisms in host intestine but not tumor. J Nutr. 2008 Apr;138(4):740-6. 118. Vicario M, Amat C, Rivero M, Moretó M, Pelegrí C. Dietary glutamine affects mucosal functions in rats with mild DSS-induced colitis. J Nutr. 2007 Aug;137(8):1931-7. 119. Harsha WT, Kalandarova E, McNutt P, Irwin R, Noel J. Nutritional supplementation with transforming growth factor-beta, glutamine, and short chain fatty acids minimizes methotrexate-induced injury. J Pediatr Gastroenterol Nutr. 2006 Jan;42(1):53-8. 120. Yeh CL, Hsu CS, Yeh SL, Chen WJ. Dietary glutamine supplementation modulates Th1/Th2 cytokine and interleukin-6 expressions in septic mice. Cytokine. 2005 Sep 7;31(5):329-34. 121. Basivireddy J, Jacob M, Balasubramanian KA. Oral glutamine attenuates indomethacin-induced small intestinal damage. Clin Sci (Lond). 2004 Sep;107(3):281-9. 122. Li N, Liboni K, Fang MZ, Samuelson D, Lewis P, Patel R, Neu J. Glutamine decreases lipopolysaccharide-induced intestinal inflammation in infant rats. Am J Physiol Gastrointest Liver Physiol. 2004 Jun;286(6):G914-21. 123. Zhou X, Li YX, Li N, Li JS. Glutamine enhances the gut-trophic effect of growth hormone in rat after massive small bowel resection. J Surg Res. 2001 Jul;99(1):47-52. K60 RepairviteTM 124. Li N, Li J, Li Y. [Nutritional rehabilitation for patients with extreme short bowel]. Zhonghua Wai Ke Za Zhi. 1997 Dec;35(12):707-9. 125. Gismondo MR, Drago L, Fassina MC, Vaghi I, Abbiati R, Grossi E. Immunostimulating effect of oral glutamine. Dig Dis Sci. 1998 Aug;43(8):1752-4. 126. Ameho CK, Adjei AA, Harrison EK, Takeshita K, Morioka T, Arakaki Y, Ito E, Suzuki I, Kulkarni AD, Kawajiri A, Yamamoto S. Prophylactic effect of dietary glutamine supplementation on interleukin 8 and tumour necrosis factor alpha production in trinitrobenzene sulphonic acid induced colitis. Gut. 1997 Oct;41(4):487-93. 127. Elia M, Lunn PG. The use of glutamine in the treatment of gastrointestinal disorders in man. Nutrition. 1997 Jul-Aug;13(7-8):743-7. 128. Wu G, Meier SA, Knabe DA. Dietary glutamine supplementation prevents jejunal atrophy in weaned pigs. J Nutr. 1996 Oct;126(10):2578-84. 129. Marks IN. Site-protective agents. Baillieres Clin Gastroenterol. 1988 Jul;2(3):609-20. Review. 130. Marks IN, Boyd E. Mucosal protective agents in the long-term management of gastric ulcer. Med J Aust. 1985 Feb 4;142(3):S23-5. 131. Russell RI, Morgan RJ, Nelson LM. Studies on the protective effect of deglycyrrhinised liquorice against aspirin (ASA) and ASA plus bile acidinduced gastric mucosal damage, and ASA absorption in rats. Scand J Gastroenterol Suppl. 1984;92:97-100. 132. Bennett A. Gastric mucosal formation of prostanoids and the effects of drugs. Acta Physiol Hung. 1984;64(3-4):215-7. 133. Morgan RJ, Nelson LM, Russell RI, Docherty C. The protective effect of deglycyrrhinized liquorice against aspirin and aspirin plus bile acid-induced gastric mucosal damage, and its influence on aspirin absorption in rats. J Pharm Pharmacol. 1983 Sep;35(9):605-7. 134. Glick L. Deglycyrrhizinated liquorice for peptic ulcer. Lancet. 1982 Oct 9;2(8302):817. 135. van Marle J, Aarsen PN, Lind A, van Weeren-Kramer J. Deglycyrrhizinised liquorice (DGL) and the renewal of rat stomach epithelium. Eur J Pharmacol. 1981 Jun 19;72(2-3):219-25. 136. Datla R, Rao SR, Murthy KJ. Excretion studies of nitrofurantoin and nitrofurantoin with deglycyrrhizinated liquorice. Indian J Physiol Pharmacol. 1981 Jan-Mar;25(1):59-63. 137. Rees WD, Rhodes J, Wright JE, Stamford LF, Bennett A. Effect of deglycyrrhizinated liquorice on gastric mucosal damage by aspirin. Scand J Gastroenterol. 1979;14(5):605-7. 138. Balakrishnan V, Pillai MV, Raveendran PM, Nair CS. Deglycyrrhizinated liquorice in the treatment of chronic duodenal ulcer. J Assoc Physicians India. 1978 Sep;26(9):811-4. 139. D’Imperio N, Giuliani Piccari G, Sarti F, Soffritti M, Spongano P, Benvenuti C, Dal Monte PR. Double-blind trial in duodenal and gastric ulcers. Cimetidine and deglycyrrhizinized liquorice. Acta Gastroenterol Belg. 1978 Jul-Aug;41(7-8):427-34. 140. Bardhan KD, Cumberland DC, Dixon RA, Holdsworth CD. Proceedings: Deglycyrrhizinated liquorice in gastric ulcer: a double blind controlled study. Gut. 1976 May;17(5):397. 141. Larkworthy W, Holgate PF. Deglycyrrhizinized liquorice in the treatment of chronic duodenal ulcer. A retrospective endoscopic survey of 32 patients. Practitioner. 1975 Dec;215(1290):787-92. 142. Aarsen PN. Standardization method of deglycyrrhizinized liquorice on experimental gastric ulcers in rats. Arzneimittelforschung. 1973 Sep;23(9): 1346-8. 143. Engqvist A, von Feilitzen F, Pyk E, Reichard H. Double-blind trial of deglycyrrhizinated liquorice in gastric ulcer. Gut. 1973 Sep;14(9):711-5. 144. Håkanson R, Liedberg G, Oscarson J, Rehfeld JF, Stadil F. Effect of deglycyrrhizinized liquorice on gastric acid secretion, histidine decarboxylase activity and serum gastrin level in the rat. Experientia. 1973 May 15;29(5):570-1. 145. Whiting B, Thomson TJ. Deglycyrrhizinized liquorice in duodenal ulcer. Br Med J. 1971 Oct 2;4(5778):48. 146. Feldman H, Gilat T. A trial of deglycyrrhizinated liquorice in the treatment of duodenal ulcer. Gut. 1971 Jun;12(6):449-51. 147. Andersson S, Bárány F, Caboclo JL, Mizuno T. Protective action of deglycyrrhizinized liquorice on the occurrence of stomach ulcers in pylorus-ligated rats. Scand J Gastroenterol. 1971;6(8):683-6. 148. Baldrick P. The safety of chitosan as a pharmaceutical excipient. Regul Toxicol Pharmacol. 2010 Apr;56(3):290-9. 149. Gunn-Moore DA, Shenoy CM. Oral glucosamine and the management of feline idiopathic cystitis. J Feline Med Surg. 2004 Aug;6(4):219-25. 150. Seidman EG, Bernotti S, Levy E. Nutritional modulation of gut inflammation. Nestle Nutr Workshop Ser Clin Perform Programme. 2002;7:41-61; discussion 61-5. 151. Sharma R, Schumacher U. Carbohydrate expression in the intestinal mucosa. Adv Anat Embryol Cell Biol. 2001;160:III-IX, 1-91. 152. Khan A, Ahmad A, Manzoor N, Khan LA. Antifungal activities of Ocimum sanctum essential oil and its lead molecules. Nat Prod Commun. 2010 Feb;5(2):345-9. 153. Fawole OA, Amoo SO, Ndhlala AR, Light ME, Finnie JF, Van Staden J. Anti-inflammatory, anticholinesterase, antioxidant and phytochemical properties of medicinal plants used for pain-related ailments in South Africa. J Ethnopharmacol. 2010 Feb 3;127(2):235-41. 154. Ozsoy N, Candoken E, Akev N. Implications for degenerative disorders: Antioxidative activity, total phenols, flavonoids, ascorbic acid, betacarotene and beta-tocopherol in Aloe vera. Oxid Med Cell Longev. 2009 Apr;2(2):99-106. 155. Kigondu EV, Rukunga GM, Keriko JM, Tonui WK, Gathirwa JW, Kirira PG, Irungu B, Ingonga JM, Ndiege IO. Anti-parasitic activity and cytotoxicity of selected medicinal plants from Kenya. J Ethnopharmacol. 2009 Jun 25;123(3):504-9. 156. Chen W, Lu Z, Viljoen A, Hamman J. Intestinal drug transport enhancement by Aloe vera. Planta Med. 2009 May;75(6):587-95. 157. Pogribna M, Freeman JP, Paine D, Boudreau MD. Effect of Aloe vera whole leaf extract on short chain fatty acids production by Bacteroides fragilis, Bifidobacterium infantis and Eubacterium limosum. Lett Appl Microbiol. 2008 May;46(5):575-80. 158. Rosca-Casian O, Parvu M, Vlase L, Tamas M. Antifungal activity of Aloe vera leaves. Fitoterapia. 2007 Apr;78(3):219-22. 159. Iena IaM. [The therapeutic properties of aloe]. Lik Sprava. 1993 Feb-Mar;(2-3):142-5. 160. t’Hart LA, van den Berg AJ, Kuis L, van Dijk H, Labadie RP. An anticomplementary polysaccharide with immunological adjuvant activity from the leaf parenchyma gel of Aloe vera. Planta Med. 1989 Dec; 55(6):509-12. 161. Brossat JY, Ledeaut JY, Ralamboranto L, Rakotovao LH, Solar S, Gueguen A, Coulanges P. [Immunostimulating properties of an extract isolated from Aloe vahombe. 2. Protection in mice by fraction F1 against infections by Listeria monocytogenes, Yersinia pestis, Candida albicans and Plasmodium berghei]. Arch Inst Pasteur Madagascar. 1981;48(1):11-34. 162. Delaporte RH, Sarragiotto MH, Takemura OS, Sánchez GM, Filho BP, Nakamura CV. Evaluation of the antioedematogenic, free radical scavenging and antimicrobial activities of aerial parts of Tillandsiastreptocarpa Baker-Bromeliaceae. J Ethnopharmacol. 2004 Dec;95(2-3):229-33. 163. de Queiroga MA, de Andrade LM, Florêncio KC, de Fátima Agra M, da Silva MS, Barbosa-Filho JM, da-Cunha EV. Chemical constituents from Tillandsia recurvata. Fitoterapia. 2004 Jun;75(3-4):423-5. 164. Arslanian RL, Stermitz FR, Castedo L. 3-Methoxy-5-hydroxyflavonols from Tillandsia purpurea. J Nat Prod. 1986 Nov-Dec;49(6):1177-8. 165. FEURT SD, FOX LE. Effects of oral administration of Spanish moss, Tillandsia usneoides L. Science. 1953 Nov 20;118(3073):626-7. 166. FEURT SD, FOX LE. The pharmacological activity of substances extracted from Spanish moss, Tillandsia usneoides L. J Am Pharm Assoc Am Pharm Assoc (Baltim). 1952 Aug;41(8):453-4. 167. WEBBER MG, LAUTER WM, FOOTE PA. A preliminary phytochemical study of Tillandsia usneoides L. (Spanish moss). J Am Pharm Assoc Am Pharm Assoc. 1952 May;41(5):230-5. 168. Hage-Sleiman R, Mroueh M, Daher CF. Pharmacological evaluation of aqueous extract of Althaea officinalis flower grown in Lebanon. Pharm Biol. 2011 Mar;49(3):327-33. 169. Deters A, Zippel J, Hellenbrand N, Pappai D, Possemeyer C, Hensel A. Aqueous extracts and polysaccharides from Marshmallow roots (Althea officinalis L.): cellular internalisation and stimulation of cell physiology of human epithelial cells in vitro. J Ethnopharmacol. 2010 Jan 8;127(1):62-9. 170. Kardosová A, Machová E. Antioxidant activity of medicinal plant polysaccharides. Fitoterapia. 2006 Jul;77(5):367-73. Epub 2006 May 24. 171. Wang DF, Shang JY, Yu QH. [Analgesic and anti-inflammatory effects of the flower of Althaea rosea (L.) Cav.]. Zhongguo Zhong Yao Za Zhi. 1989 Jan;14(1):46-8, 64. 172. Iauk L, Lo Bue AM, Milazzo I, Rapisarda A, Blandino G. Antibacterial activity of medicinal plant extracts against periodontopathic bacteria. Phytother Res. 2003 Jun;17(6):599-604. 173. Satia JA, Littman A, Slatore CG, Galanko JA, White E. Associations of herbal and specialty supplements with lung and colorectal cancer risk in the VITamins and Lifestyle study. Cancer Epidemiol Biomarkers Prev. 2009 May;18(5):1419-28. 174. Marañón G, Muñoz-Escassi B, Manley W, García C, Cayado P, de la Muela MS, Olábarri B, León R, Vara E. The effect of methyl sulphonyl methane supplementation on biomarkers of oxidative stress in sport horses following jumping exercise. Acta Vet Scand. 2008 Nov 7;50:45. 175. Brien S, Prescott P, Bashir N, Lewith H, Lewith G. Systematic review of the nutritional supplements dimethyl sulfoxide (DMSO) and methylsulfonylmethane (MSM)in the treatment of osteoarthritis. Osteoarthritis Cartilage. 2008 Nov;16(11):1277-88. 176. Parcell S. Sulfur in human nutrition and applications in medicine. Altern Med Rev. 2002 Feb;7(1):22-44. 177. Maoka T, Tanimoto F, Sano M, Tsurukawa K, Tsuno T, Tsujiwaki S, Ishimaru K, Takii K. Effects of dietary supplementation of ferulic acid and gammaoryzanol on integument color and suppression of oxidative stress in cultured red sea bream, Pagrus major. J Oleo Sci. 2008;57(2):133-7. 178. Accinni R, Rosina M, Bamonti F, Della Noce C, Tonini A, Bernacchi F, Campolo J, Caruso R, Novembrino C, Ghersi L, Lonati S, Grossi S, Ippolito S, Lorenzano E, Ciani A, Gorini M. Effects of combined dietary supplementation on oxidative and inflammatory status in dyslipidemic subjects. Nutr Metab Cardiovasc Dis. 2006 Mar;16(2):121-7. 179. Sierra S, Lara-Villoslada F, Olivares M, Jiménez J, Boza J, Xaus J. Increased immune response in mice consuming rice bran oil. Eur J Nutr. 2005 Dec;44(8):509-16. 180. Jariwalla RJ. Rice-bran products: phytonutrients with potential applications in preventive and clinical medicine. Drugs Exp Clin Res. 2001;27(1):17-26. 181. Sugano M, Tsuji E. Rice bran oil and human health. Biomed Environ Sci. 1996 Sep;9(2-3):242-6. 182. Hirose M, Ozaki K, Takaba K, Fukushima S, Shirai T, Ito N. Modifying effects of the naturally occurring antioxidants gamma-oryzanol, phytic acid, tannic acid and n-tritriacontane-16, 18-dione in a rat wide-spectrum organ carcinogenesis model. Carcinogenesis. 1991 Oct;12(10):1917-21. 183. Wheeler KB, Garleb KA. Gamma oryzanol-plant sterol supplementation: metabolic, endocrine, and physiologic effects. Int J Sport Nutr. 1991 Jun;1(2):170-7. 184. Itaya K, Kitonaga J, Ishikawa M. [Studies of gamma-oryzanol. (2) The antiulcerogenic action]. Nippon Yakurigaku Zasshi. 1976 Nov;72(8):1001-11. 185. Brown AC, Hairfield M, Richards DG, McMillin DL, Mein EA, Nelson CD. Medical nutrition therapy as a potential complementary treatment for psoriasis-five case reports. Altern Med Rev. 2004 Sep;9(3):297-307. 186. Choi HR, Choi JS, Han YN, Bae SJ, Chung HY. Peroxynitrite scavenging activity of herb extracts. Phytother Res. 2002 Jun;16(4):364-7. 187. Majchrowicz MA. Essiac. Notes Undergr. 1995 Winter;(no 29):6-7. 188. Gill RE, Hirst EL, Jones JK. Constitution of the mucilage from the bark of Ulmus fulva (slippery elm mucilage); the sugars formed in the hydrolysis of the methylated mucilage. J Chem Soc. 1946 Nov:1025-9. 189. Jarrahi M, Vafaei AA, Taherian AA, Miladi H, Rashidi Pour A. Evaluation of topical Matricaria chamomilla extract activity on linear incisional wound healing in albino rats. Nat Prod Res. 2010 May;24(8):697-702. 190. Bezerra SB, Leal LK, Pinto NA, Campos AR. Bisabolol-induced gastroprotection against acute gastric lesions: role of prostaglandins, nitric oxide, and KATP+ channels. J Med Food. 2009 Dec;12(6):1403-6. 191. Moura Rocha NF, Venâncio ET, Moura BA, Gomes Silva MI, Aquino Neto MR, Vasconcelos Rios ER, de Sousa DP, Mendes Vasconcelos SM, de França Fonteles MM, de Sousa FC. Gastroprotection of (-)-alphabisabolol on acute gastric mucosal lesions in mice: the possible involved pharmacological mechanisms. Fundam Clin Pharmacol. 2009 Aug 3. 192. Pereira RP, Fachinetto R, de Souza Prestes A, Puntel RL, Santos da Silva GN, Heinzmann BM, Boschetti TK, Athayde ML, Bürger ME, Morel AF, Morsch VM, Rocha JB. Antioxidant effects of different extracts from Melissa officinalis, Matricaria recutita and Cymbopogon citratus. Neurochem Res. 2009 May;34(5):973-83. 193. Nogueira JC, Diniz Mde F, Lima EO. In vitro antimicrobial activity of plants in Acute Otitis Externa. Braz J Otorhinolaryngol. 2008 Jan-Feb;74(1):118-24. 194. Shikov AN, Pozharitskaya ON, Makarov VG, Kvetnaya AS. Antibacterial activity of Chamomilla recutita oil extract against Helicobacter pylori. Phytother Res. 2008 Feb;22(2):252-3. 195. Capasso R, Savino F, Capasso F. Effects of the herbal formulation ColiMil on upper gastrointestinal transit in mice in vivo. Phytother Res. 2007 Oct;21(10):999-1101. 196. Mahady GB, Pendland SL, Stoia A, Hamill FA, Fabricant D, Dietz BM, Chadwick LR. In vitro susceptibility of Helicobacter pylori to botanical extracts used traditionally for the treatment of gastrointestinal disorders. Phytother Res. 2005 Nov;19(11):988-91. 197. Madisch A, Holtmann G, Mayr G, Vinson B, Hotz J. Treatment of functional dyspepsia with a herbal preparation. A double-blind, randomized, placebo-controlled, multicenter trial. Digestion. 2004;69(1):45-52. 198. Elango G, Rahuman AA, Kamaraj C, Zahir AA, Bagavan A. Studies on effects of indigenous plant extracts on filarial vector Culex tritaeniorhynchus Giles. Parasitol Res. 2010 Apr 7. 199. Aguilar HH, de Gives PM, Sánchez DO, Arellano ME, Hernández EL, Aroche UL, Valladares-Cisneros G. In vitro nematocidal activity of plant extracts of Mexican flora against Haemonchus contortus fourth larval stage. Ann N Y Acad Sci. 2008 Dec;1149:158-60. 200. Bashir S, Gilani AH. Studies on the antioxidant and analgesic activities of Aztec marigold (Tagetes erecta) flowers. Phytother Res. 2008 Dec;22(12):1692-4. 201. Wang M, Tsao R, Zhang S, Dong Z, Yang R, Gong J, Pei Y. Antioxidant activity, mutagenicity/ anti-mutagenicity, and clastogenicity/anticlastogenicity of lutein from marigold flowers. Food Chem Toxicol. 2006 Sep;44(9):1522-9. 202. Wang M, Tsao R, Zhang S, Dong Z, Yang R, Gong J, Pei Y. Antioxidant activity, mutagenicity/anti-mutagenicity, and clastogenicity/anticlastogenicity of lutein from marigold flowers. Food Chem Toxicol. 2006 Sep;44(9):1522-9. 203. Breithaupt DE, Bamedi A, Wirt U. Carotenol fatty acid esters: easy substrates for digestive enzymes? Comp Biochem Physiol B Biochem Mol Biol. 2002 Aug;132(4):721-8. 204. Garg SC, Dengre SL. Antibacterial activity of essential oil of Tagetes erecta Linn. Hindustan Antibiot Bull. 1986 Feb-Nov;28(1-4):27-9. 205. Martín-Venegas R, Brufau MT, Guerrero-Zamora AM, Mercier Y, Geraert PA, Ferrer R. The methionine precursor DL-2-hydroxy-(4-methylthio)butanoic acid protects intestinal epithelial barrier function. Food Chem. 2013 Dec 1;141(3):1702-9. 206. Flamant M, Aubert P, Rolli-Derkinderen M, Bourreille A, Neunlist MR, Mahé MM, Meurette G, Marteyn B, Savidge T, Galmiche JP, Sansonetti PJ, Neunlist M. Enteric glia protect against Shigella flexneri invasion in intestinal epithelial cells: a role for S-nitrosoglutathione. Gut. 2011 Apr;60(4):473-84. 207. van Ampting MT, Schonewille AJ, Vink C, Brummer RJ, van der Meer R, Bovee-Oudenhoven IM. Intestinal barrier function in response to abundant or depleted mucosal glutathione in Salmonella-infected rats. BMC Physiol. 2009 Apr 17:9:6 208. Maeda T, Miyazono Y, Ito K, Hamada K, Sekine S, Horie T. Oxidative stress and enhanced paracellular permeability in the small intestine of methotrexate treated rats. Cancer Chemother Pharmacol.2010 May;65(6):1117-2 209. Savidge TC, Newman P, Pothoulakis C, Ruhl A, Neunlist M, Bourreille A, Hurst R, Sofroniew MV. Enteric glia regulate intestinal barrier function and inflammation via release of S-nitrosoglutathione. Gastroenterology. 2007 Apr;132(4):1344-1358 210. The role of the glutathione antioxidant system in gut barrier failure in a rodent model of experimental necrotizing enterocolitis. Surgery. 2004 Sep;136(3):557-66 211. Mahmood A , FitzGerald AJ , Marchbank T , Ntatsaki E , Murray D , Ghosh S , Playford RJ . Zinc carnosine, a health food supplement that stabilises small bowel integrity and stimulates gut repair processes. Gut. 2007 Feb;56(2):168-75. Epub 2006 Jun 15. 212. Kong J, Zhang Z, Musch MW, Ning G, Sun J, Hart J, Bissonnette M, Li YC. Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal barrier. Am J Physiol Gastroint. Liver Physiol. 2008 Jan; 294(1):G208-16 213. Vassallo MF, Camargo CA Jr. Potential mechanisms for the hypothesized link between sunshine, vitamin D, and food allergy in children. J Allergy Clin Immunol. 2010 Aug;126 (2):217-22 214. Zhao H, Zhang H, Wu H, Li H, Liu L, Guo J, Li C, Shih DQ, Zhang X. Protective role of 1,25(OH)2 vitamin D3 in the mucosal injury and epithelial barrier disruption in DSS-induced acute colitis in mice. BMC Gastroenterol. 2012 May 30;12:57. 215. Romagnani S. Th1 and Th2 in human diseases. Clin Immunol Immunopathol 1996;80:225–35. 216. Kidd P. Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Altern. Med. Rev. 2003;8:223–246. 217. Alla Skapenko, Jan Leipe, Peter E Lipsky, Hendrik Schulze-Koops The role of the T cell in autoimmune inflammation . Arthritis Res Ther. 2005; 7(Suppl 2): S4–S14. 218. Jane M. Rodgers, Stephen D. Miller. Cytokine Control of Inflammation and Repair in the Pathology of Multiple Sclerosis . Yale J Biol Med. 2012 December; 85(4): 447–468. 219. Peterson JD, Herzenberg LA, Vasquez K, Waltenbaugh C. Glutathione levels in antigen-presenting cells modulate Th1 versus Th2 response patterns. Proc Natl Acad Sci U S A. 1998 Mar 17; 95(6):3071-6. 220. Murata Y, Shimamura T, Hamuro J. The polarization of T(h)1/T(h)2 balance is dependent on the intracellular thiol redox status of macrophages due to the distinctive cytokine production. Int Immunol. 2002 Feb; 14(2):201-12. 221. Nazzareno Ballatori, Suzanne M. Krance, Sylvia Notenboom, Shujie Shi, Kim Tieu, Christine L. Hammond. Glutathione dysregulation and the etiology and progression of human diseases . Biol Chem. 2009 March; 390(3): 191–214. 222. Antiviral and immunomodulatory properties of new pro-glutathione (GSH) molecules. Curr Med Chem. 2006:13(15): 1749-55 223. Glutathione peroxidase 1 deficiency attenuates allergen-induced airway inflammation by suppressing TH2 and TH17 cell development. Antioxid Redox Signal. 2010 Jun 6. 224. Venu Lagishetty, Nancy Q. Liu, Martin Hewison. Vitamin D metabolism and innate immunity . Mol Cell Endocrinol. 2011 December 5; 347(1-2): 97–105. 225. Cynthia Aranow. Vitamin D and the Immune System . J Investig Med. 2011 August; 59(6): 881–886 226. Bansal AS, Henriquez F, Sumar N, Patel S. T helper cell subsets in arthritis and the benefits of immunomodulation by 1,25(OH)₂ vitamin D. Rheumatol Int. 2012 Apr;32(4):845-52. 227. Jot Hui Ooi, Jing Chen, Margherita T. Cantorna. Vitamin D regulation of immune function in the gut: Why do T cells have vitamin D receptors? Mol Aspects Med. 2012 February; 33(1): 77–82. 228. Diane L. Kamen, Vin Tangpricha. Vitamin D and molecular actions on the immune system: modulation of innate and autoimmunity . J Mol Med (Berl) 2010 May; 88(5): 441–450. 229. Margherita T. Cantorna. Vitamin D, Multiple Sclerosis and Inflammatory Bowel Disease . Arch Biochem Biophys. 2012 July 1; 523(1): 103–106. 230. Sloka S, Silva C, Wang J, Yong VW. Predominance of Th2 polarization by vitamin D through a STAT6-dependent mechanism. J Neuroinflammation. 2011 May 24;8:56 231. Danny Bruce, Jot Hui Ooi, Sanhong Yu, Margherita T Cantorna. Vitamin D and host resistance to infection? Putting the cart in front of the horse . Exp Biol Med (Maywood) 2010 August; 235(8): 921–927. 232. Székely JI, Pataki Á. Effects of vitamin D on immune disorders with special regard to asthma, COPD and autoimmune diseases: a short review. Expert Rev Respir Med. 2012 Dec;6(6):683-704. Review. 233. Ozkara S, Keles E, Ilhan N, Gungor H, Kaygusuz I, Alpay HC. The relationship between Th1/Th2 balance and 1α,25-dihydroxyvitamin D₃ in patients with nasal polyposis. Eur Arch Otorhinolaryngol. 2012 Dec;269(12):2519-24. 234. Taher YA, van Esch BCAM, Hofman GA, Henricks PAJ, van Oosterhout AJ. 1 α ,25-Dihydroxy-vitamin D 3 potentiates the beneficial effects of allergen immunotherapy in a mouse model of allergic asthma: role for IL-10 and TGF- β 1 . Journal of Immunology . 2008;180(8):5211–5221 235. Székely JI, Pataki Á. Effects of vitamin D on immune disorders with special regard to asthma, COPD and autoimmune diseases: a short review. Expert Rev Respir Med. 2012 Dec;6(6):683-704. Review. 236. Maalmi H, Berraïes A, Tangour E, Ammar J, Abid H, Hamzaoui K, Hamzaoui A. The impact of vitamin D deficiency on immune T cells in asthmatic children: a case-control study. J Asthma Allergy. 2012;5:11-9. 237. Yang CY, Leung PS, Adamopoulos IE, Gershwin ME. The implication of vitamin D and autoimmunity: a comprehensive review. Clin Rev Allergy Immunol. 2013 Oct;45(2):217-26. 238. Gatenby P, Lucas R, Swaminathan A. Vitamin D deficiency and risk for rheumatic diseases: an update. Curr Opin Rheumatol. 2013 Mar;25(2):184-91. Review. 239. M I Koenders, W B van den Berg. Translational Mini-Review Series on Th17 Cells: Are T helper 17 cells really pathogenic in autoimmunity? Clin Exp Immunol. 2010 February; 159(2): 131–136. 240. Jesse M. Damsker, Anna M. Hansen, Rachel R. Caspi. Th1 and Th17 cells: Adversaries and collaborators . Ann N Y Acad Sci. 2010 January; 1183: 211–221. 241. Kiran Nistala, Stuart Adams, Helen Cambrook, Simona Ursu, Biagio Olivito, Wilco de Jager, Jamie G. Evans, Rolando Cimaz, Mona Bajaj-Elliott, Lucy R. Wedderburn. Th17 plasticity in human autoimmune arthritis is driven by the inflammatory environment . Proc Natl Acad Sci U S A. 2010 August 17; 107(33): 14751–14756. 242. Jane M. Rodgers, Stephen D. Miller. Cytokine Control of Inflammation and Repair in the Pathology of Multiple Sclerosis . Yale J Biol Med. 2012 December; 85(4): 447–468. 243. Aristo Vojdani, Jama Lambert. The Role of Th17 in Neuroimmune Disorders: Target for CAM Therapy. Part I . Evid Based Complement Alternat Med. 2011; 2011: 927294. 244. Aristo Vojdani, Jama Lambert, Gottfried Kellermann. The Role of Th17 in Neuroimmune Disorders: A Target for CAM Therapy. Part III . Evid Based Complement Alternat Med. 2011; 2011: 548086. 245. Xie, L, Li XK, Takahara S. Curcumin has bright prospects for the treatment of multiple sclerosis. Int Immunopharmacol. 2011 Mar;11(3):323-330. 246. Amelioration of experimental autoimmune encephalomyelitis by curcumin treatment through inhibition of IL-17 production . Int Immunopharmacol. 2009 May;9(5):575-581 247. Petro TM . Regulatory role of resveratrol on Th17 in autoimmune disease . Int Immunopharmacol. 2011 Mar;11(3):310-318. 248. Aristo Vojdani, Jama Lambert, Gottfried Kellermann. The Role of Th17 in Neuroimmune Disorders: A Target for CAM Therapy. Part III . Evid Based Complement Alternat Med. 2011; 2011: 548086. 249. Veldhoen M, Hirota K, Westendorf AM, Buer J, Dumoutier L, Renauld JC, Stockinger B. The aryl hydrocarbon receptor links T H 17-cell-mediated autoimmunity to environmental toxins. Nature. 2008a;453:106–109. 250. Quintana FJ, Basso AS, Iglesias AH, Korn T, Farez MF, Bettelli E, Caccamo M, Oukka M, Weiner HL. Control of T reg and T H 17 cell differentiation by the aryl hydrocarbon receptor. Nature. 2008;453:65–71. 251. Xuzhu G, Komai-Koma M, Leung BP, Howe HS, McSharry C, McInnes IB, Xu D. Resveratrol modulates murine collagen-induced arthritis by inhibiting Th17 and B-cell function. Ann Rheum Dis 2012;71:129–135. 252. Koshland DE Jr. The molecule of the year. Science. 1992 Dec 18;258(5090):1861. 253. Southan GJ, Szabo C. Selective pharmacological inhibition of distinct nitric oxide synthase isoforms. Biochem Pharmacol. 1996;51(4):383-94. 254.Ulrich Förstermann, William C. Sessa Nitric oxide synthases: regulation and function . Eur Heart J. 2012 April; 33(7): 829–837. 255. Role of nitric oxide in inflammatory conditions. Nephron. 2002 Apr;90(4):373-8. 256. Regulatory role of nitric oxide on monocyte-derived dendritic cell functions. J Interferon Cytokine Res. 2003 Aug;23(8):423-31 257. Role of nitric oxide in the regulation of T-cell functions. Ann Rheum Dis. 2006 Nov;65 Suppl 3:iii37-40 258. Protective role of the cytokine-inducible isoform of nitric oxide synthase induction and nitrosative stress in experimental autoimmune encephalomyelitis of the DA rat. J Neurosci Res. 2003 Jul 15; 73(2):198-205 259. Immunoregulatory role of nitric oxide in Kilham rat virus-induced autoimmune diabetes in DR-BB rats. J Immunol. 2004 Jul 15;173(2):1327-35 260. Inducible nitric oxide synthase activation by interleukin-17. Cytokine Growth Factor Rev. 2004 Feb;15(1):21-32 261. Immunosuppressive and anti-inflammatory action of antioxidants in rat autoimmune diabetes. J Autoimmun. 2004 Jun;22(4):267-76 262. Agretesch HJ, Dagnelie PC, et al. Adensoine triphosphate, established and potential clinical applications. Drugs. 1999;58:211-232. 263. Williams M, Bagwat SS. P2 purinoceptors: a family of novel therapeutic targets. Annual Reports in Medicinal Chemistry. 1996;31:21-30. 264. Haskell CM, Wong M, Williams A, and Leee LY. Phase 1 trial of extracellular adenosine 5’-triphosphate in patients with advanced cancer. Medicinal and Pediatric Oncology. 1996;27:165-173. 265.Mortensen DP, Gonzalez-Alonso J, Bune LT, et al. ATP-induced vasodilation and purinergic receptors in the human leg: roles of nitric oxide, prostaglandins and adenosine. Am J Physiol Regul Integr Comp Physiol. 2009;296:R1140-R1148. 266.Yegutkin GG, Henttiner T, Jalkanen S. Extracellular ATP formation on vascular endothelial cells is mediated by ectonucleotide kinase activities via phosphotransfer reactions. FASEB. 2001;15:251-260. 267. Persechini PM, Bisaggio RC, Alves Neto JL, Coutinho-Silva R. Extracellular ATP in the lymphohematopoiectic system: P2Z purinoceptors and membrane permeabilization. Braz J of Med and Bio Res.1998;31(1):25-34. 268.Silva G, Beierwaltes WH, Garvin JL. Extracellular ATP stimulates NO production in rat thick ascending limb. Hypertension.2006;47(3):563-7. 269.Tongguang W, Guangxiang H, Shuanke W, et al. Effects of extracellular ATP on survival of sensory neurons in the dorsal root ganglia of rats. J Tongi Med Univ. 2001;21(1):44-7. 270.McCullough WT, Collins DM, Ellsworth ML. Arteriolar responses to extracellular ATP in striated muscle. Am J Physiol Heart Cir Physiol. 1997;272:H1886-H1891. 271.Tonetti M, Sturia L, Bistolfi T, Benatti U, De Flora A. Extracellular ATP potentiates nitric oxide synthase expression induced by lipopolysaccharide in RAW 264.7 murine macrophages. Biochem Biophys Res Commun. 1994:203(1):430-5. 272. Li W, Mak M, Jian H, et al. Novel anti-Alzheimer’s dimmer Bis(7)-cognition: cellular and molecular mechanisms of neuroprotection through multiple targets. Neurotherapeutics. 2009: 6(1):187-201. 273.Li J , Wu HM, Zhou RL, Liu GJ, Dong BR. Huperzine A for Alzheimer’s disease. Cochrane Database Sys Rev. 2008:16(2):CD005592. 274.Wang ZF, Tang XC. Huperzine A protects C6 rat glioma cells against oxygen-glucose deprivation –induced injury. FEBS Lett. 2007;581(4):596-602. 275.Zhao HW, Li XY. Ginkgolide A, B, and huperzine A inhibit nitric oxide-induced neurotoxicity. Int Immunopharmacol. 2002;2(11):1551-6. 276.Wang ZF, Tang XC. Huperzine A protects C6 rat glioma cells against oxygen-glucose deprivation–induced injury. FEBS Lett. 2007;581(4):596-602. 277.Pavlov VA, Parrish WR, Rosas-Ballina M. Brain acetylcholinesterase activity controls systemic levels through the cholinergic anti-infl ammatory pathway. Brain Behav Immun. 2009;23(1):41-5. 278.Wang ZF, Wang J, Zhang HY, Tang XC. Huperzine A exhibits anti-infl ammatory and neuroprotective effects in a rat model of transient focal cerebral ischemia . J Neurochem. 2008;106(4):1594-603. 279.Evgenov OV, Busch CJ, Evgenov NV, et al. Inhibition of phosphodiesterase 1 augments the pulmonary vasodilator response to inhaled nitric oxide in awake labs with acute pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2006;290(4):L723-L729. 280.Mancina R, Filippi s, Marini M, et al. Expression and functional activity of phosphodies-terase type 5 in human and rabbit vas deferens. Mol Hum Reprod. 2005;11(2):107-115. 281.Oiu Y, Kraft P, Craig Ec, et al. Identifi cation and functional study of phosphodiesterases in rat urinary bladder. Urol Res. 2001;29(6):388-92. 282.Kim D, Rybalkin SD, Pi X. Upregualtion of phosphodiesterase 1A1 expression is associated with development of nitrate tolerance. Circulation. 2001. 104(19):2263-5. 283.Peyter AC, Muehlethaler V, Liaudet L. Muscarinic receptor M1 phosphodiesterase 1 are key determinants in pulmonary vascular dysfunction following perinatal hypoxia in mice. Am J Physiol Lung Cell Mol Physiol. 2008;295(1):L201-213. 284.Kedia Gt, Ucker T S, Kedia M, Kuczyk MA. Effects of phosphodiesterase inhibitors on contraction induced by endothelin-1 of isolated human prostatic tissue. Urology.2009;73(6):1397-1401. 285. Souness Je, Brazdil R, Diocee BK, Jordan R. Role of selective cyclic GMP phosphodiesterase inhibition in the myorelaxant actions of M&B 22, 948, MY-5455, vinopectine and 1-methyl-3- isobutyl-8-(methylamino)xanthine. Br J Pharmacol. 1989. 98(3):725-34. 286.Lopez Cm, Govoni S, Battaini F, et al. Effect of a new cognition enhancer alphaglycerlphos-phorylcholine, on scopolamine induced amnesia and brain acetylcholine. Pharmacol Biochem Behav 1991;39(4): 835-40. 287. Sigala S, Imperato A , Rizzoneli P, et al. L-alpha glycerylphosphorylcholine antagonizes scopolamine-induced amnesia and enhances hippocampal cholinergic transmission in the rat. Eur J Pharmacol 1992;211(3):351-8. 288.Sterin-Borda L, Echague AV, Leiros CP,et al. Endogenous nitrix oxide signaling system and the cardiac muscarinic acetylcholine receptor-inotropic response. Br J of Pharm. 1995;115:1525-1531. 289.Graves AR, Lewin KA, Lindgren CA. Nitrix oxide, camp and the biphasic muscarinic modulation of Ach release at the lizard neuromuscular junction. J Physiol. 2004;559.2:423-432. 290. Lindgren CA, Younk KM. The inhibition of Ach release by muscarinic agonists at the neuromuscular junction required nitric oxide synthesis. Soc Neurosci Abstr. 2002;28:838.3. 291.Lindgren CA, Graves AR, Lake B. Nitric oxide is necessary but not suffi cient for the biphasic muscarinic modulation of synaptic transmission at the lizard neuromuscular junction. Soc Neurosci Abstr. 2003:29:168.11 292.Zyad Rm, Qazi S, Morton DB, Trimmer, BA. Nicotinic-acetylcholine receptors are functionally coupled to the nitric oxide/cGMP-pathways in insect neruons. J neurochem. 2002;83(2):421-431. 293. Arvalho FA, Martine-Silva J, Mesquirea r, Salanha C. Acetylcholine and choline effects on erthrocyte nitrite and nitrate levels. J Appl Tox.2004:24(6):419-427. 294.Robinson Le, Bussiere FL, Le Boucher J, et al. Amino acid nutrition and immune function in tumorbearing rats: a comparison of glutamine, arginine, and ornithine 2-oxoglutarate-supplmented diets. Clin Sci (Lond).1999:97(6):657-669. 295.Hammarqvist F, Wernerman J, von der Deckern A, Vinnars E. Alpha-ketoglutarate preserves protein synthesis and free glutamine in skeletal muscle after surgery. Surgery. 109(1):28-36. 296.Wernerman J, Hammarkvist F, Ali MR, Vinnars E. Glutamine and ornithine-alpha-ketogluterate but not branched-chain amino acids reduce the loss of muscle glutamine after surgical trauma. Metabolism. 1989:38(8 Suppl 1):63-6. 297. Wernerman J, Hammarqvist F, Vinnars E. Alpha-ketogluterate and postoperative muscle catabolism. Lancet.1990:24;335(8691):701-3. 298. Seiwart H, Winterfeld HJ, Strangeld, et al. Effect of a 3-month interval running exercise in combination with vasodilative therapy on microcirculation of the lower leg in peripheral arterial circulation disorders (stage I and II). ZFA.1983;38(5):377-81. 299.Bieron K, Swies J, Kostka-Trabka E, Gryglewski RJ. Thrombolytic and anti-platelet action of xanithinol nicotinate (Sadmin):possible mechanisms. J Physiol Pharmacol.1998:49(2):241-9. 300. Sharma PL. Comparative effects of placebo and plain and slow-slow release tablets of xanithinol nicotinate on exercise tolerance in normal subjects. Int J Clin Pharmacol Biopharm. 1978;16(1):19-21. 301.Starikov VI. The use of antioxidants and preparations improving the microcirculation in the surgical treatment of cancer of the lung in elderly patients. Klin Khir. 1991;10:4-6. 302.Gomez RD, Rojad HE. Therapeutic results with xanithine derivatives in the intermittent claudication syndrome in diabetic patients. Rev Clin Esp. 1988:182(1):3-6. 303.Janaki S. Pentoxifylline in strokes: a clinical study . J Int Med Res. 1980:8(1):56-62. 304.Mensen H. Rehabilitation course in patients with peripheral and coronary angioorganopathies. Studies with special reference to serum uric acid and cholesterol under xanthinol nicotinate. Ther Ggw. 1977:116(10):1853-81. 305.Spagnolie A, et al. Long-term acetyl-L-carnitine treatment in Alzheimer’s disease. Neurology 1991;41:1726-1732. 306.Bowman B. Acetylcholine and Alzheimer’s disease. Nutr Rev 1992; 50:142-144. 307.Careta A, et al. Acetyl-L-Carntine and Alzheimer’s disease. Pharmacological considerations beyond cholinergic sphere. Ann NY Acad Sci 1993;695:324-326. 308. Pettegrew JW, et al. Clinical and neurochemical effects of acetyl-Lcarnitine in Alzheimer’s disease. Neurobiol Aging 1995;16:1-4. 309.Sterin-Borda L, Echague AV, Leiros CP,et al. Endogenous nitrix oxide signaling system and the cardiac muscarinic acetylcholine receptor-inotropic response. Br J of Pharm. 1995;115:1525-1531. 310.Graves AR, Lewin KA, Lindgren CA. Nitrix oxide, camp and the biphasic muscarinic modulation of Ach release at the lizard neuromuscular junction. J Physiol. 2004;559.2:423-432. 311. Lindgren CA, Younk KM. The inhibition of Ach release by muscarinic agonists at the neuromuscular junction required nitric oxide synthesis. Soc Neurosci Abstr. 2002;28:838.3. 312.Lindgren CA, Graves AR, Lake B. Nitric oxide is necessary but not suffi cient for the biphasic muscarinic modulation of synaptic transmission at the lizard neuromuscular junction. Soc Neurosci Abstr. 2003:29:168.11 313.Zyad Rm, Qazi S, Morton DB, Trimmer, BA. Nicotinic-acetylcholine receptors are functionally coupled to the nitric oxide/cGMP-pathways in insect neruons. J neurochem. 2002;83(2):421-431. 314.Arvalho FA, Martine-Silva J, Mesquirea r, Salanha C. Acetylcholine and choline effects on erthrocyte nitrite and nitrate levels. J Appl Tox.2004:24(6):419-427. 315.Himmerich H, Fischer J, Bauer K, Kirkby KC, Sack U, Krügel U. Stress-induced cytokine changes in rats. Eur Cytokine Netw. 2013 Jun;24(2):97-103. 316.Viktoriya Glovatchcka, Helena Ennes, Emeran A Mayer, Sylvie Bradesi. Chronic stress-induced changes in pro-inflammatory cytokines and spinal glia markers in the rat: a time course study . Neuroimmunomodulation. Author manuscript; available in PMC 2013 October 6. 317.Hannah Gola, Harald Engler, Annette Sommershof, Hannah Adenauer, Stephan Kolassa, Manfred Schedlowski, Marcus Groettrup, Thomas Elbert, Iris-Tatjana Kolassa. Posttraumatic stress disorder is associated with an enhanced spontaneous production of pro-inflammatory cytokines by peripheral blood mononuclear cells . BMC Psychiatry. 2013; 13: 40. 318.Elenkov IJ, Wilder RL, Chrousos GP, Vizi ES. The sympathetic nerve&#8211;an integrative interface between two supersystems: The brain and the immune system. Pharmacol Rev. 2000;52:595–638 319.Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med. 1995;332:1351–1362. 320.Elenkov IJ, Chrousos GP. Stress hormones, proinflammatory and antiinflammatory cytokines, and autoimmunity. Ann N Y Acad Sci. 2002;966:290–303. 321.Anisman H. Cascading effects of stressors and inflammatory immune system activation: Implications for major depressive disorder. J Psychiatry Neurosci. 2009;34:4–20. 322.Frank MG, Baratta MV, Sprunger DB, Watkins LR, Maier SF. Microglia serve as a neuroimmune substrate for stress-induced potentiation of cns pro-inflammatory cytokine responses. Brain Behav Immun. 2007;21:47–59. 323.Maken DS, Weinberg J, Cool DR, Hennessy MB. An investigation of the effects of maternal separation and novelty on central mechanisms mediating pituitary-adrenal activity in infant guinea pigs (cavia porcellus). Behav Neurosci. 2011;124:800–809. 324.M. J. Finley, C. M. Happel, D. E. Kaminsky, T. J. Rogers. Opioid and Nociceptin Receptors Regulate Cytokine and Cytokine Receptor Expression. Cell Immunol. Author manuscript; available in PMC 2009 March 1. 325.Smith EM. Review Opioid peptides in immune cells. Adv Exp Med Biol. 2003; 521():51-68. 326.Carr DJ, Rogers TJ, Weber RJ. Review. The relevance of opioids and opioid receptors on immunocompetence and immune homeostasis. Proc Soc Exp Biol Med.1996 Dec; 213(3):248-57. 327.Walker JS. Anti-inflammatory effects of opioids. Adv Exp Med Biol. 2003;521:148-60. 328.Sacerdote P, Limiroli E, Gaspani L. Experimental evidence for immunomodulatory effects of opioids. Adv Exp Med Biol. 2003;521:106-16. 329.de Oliveira MS, da Silva Fernandes MJ, Scorza FA, Persike DS, Scorza CA, da Ponte JB, de Albuquerque M, Cavalheiro EA, Arida RM. Acute and chronic exercise modulates the expression of MOR opioid receptors in the hippocampal formation of rats. Brain Res Bull.2010 Oct 30;83(5):278-83. 330.Nijs J, Kosek E, Van Oosterwijck J, Meeus M. Dysfunctional endogenous analgesia during exercise in patients with chronic pain: to exercise or not to exercise? Pain Physician. 2012 Jul;15(3 Suppl):ES205-13. Review. 331.T A Howlett, S Tomlin, L Ngahfoong, L H Rees, B A Bullen, G S Skrinar, J W McArthur. Release of beta endorphin and met-enkephalin during exercise in normal women: response to training. Br Med J (Clin Res Ed) 1984 June 30; 288(6435): 1950–1952. 332.Harbach H, Hell K, Gramsch C, Katz N, Hempelmann G, Teschemacher H. Beta-endorphin (1-31) in the plasma of male volunteers undergoing physical exercise. Psychoneuroendocrinology. 2000 Aug;25(6):551-62. 333.Bulbulian R. Endogenous opioid effects on motoneuron pool excitability: potential analgesic effect of acute exercise. J Manipulative Physiol Ther. 2002 May;25(4):209-15. 334.Monnier L, Colette C. Glycemic variability: should we and can we prevent it? Diabetes Care. 2008 Feb;31 Suppl 2:S150-4. doi: 10.2337/dc08-s241. 335.Monnier L, Colette C, Owens DR. Glycemic variability: the third component of the dysglycemia in diabetes. Is it important? How to measure it? J Diabetes Sci Technol. 2008 Nov;2(6):1094-100. 336.Wysocka E, Cofta S, Piorunek T, Dziegielewska-Gesiak S, Bryl W, Torlinski L. Blood antioxidant status, dysglycemia and obstructive sleep apnea. Adv Exp Med Biol. 2013;756:121-9. 337.Standl E. Dysglycemia and abdominal obesity. Curr Vasc Pharmacol. 2012 Nov;10(6):678-9. Review. 338.Hovath EM, Benko R, Kiss L, Muranyi M, Pek T, Fekete K, et al. Rapid glycaemic swings induce oxidative stress, activate poly-(ADP-ribose) polymerase and impair endothelial function in a rat model of diabetes mellitus. Diabetologia. 2009;52:952–61. 339.Maria Rosaria Rizzo, Michelangela Barbieri, Raffaele Marfella, Giuseppe Paolisso. Reduction of Oxidative Stress and Inflammation by Blunting Daily Acute Glucose Fluctuations in Patients With Type 2 Diabetes: Role of dipeptidyl peptidase-IV inhibition . Diabetes Care. 2012 October; 35(10): 2076–2082. 340.Gogitidze Joy N, Hedrington MS, Briscoe VJ, Tate DB, Ertl AC, Davis SN. Effects of acute hypoglycemia on inflammatory and pro-atherothrombotic biomarkers in individuals with type 1 diabetes and healthy individuals. Diabetes Care. 2010 Jul;33(7):1529-35. 341.Razavi Nematollahi L, Kitabchi AE, Stentz FB, Wan JY, Larijani BA, Tehrani MM, Gozashti MH, Omidfar K, Taheri E. Proinflammatory cytokines in response to insulin-induced hypoglycemic stress in healthy subjects. Metabolism. 2009 Apr;58(4):443-8. 342.Dotson S, Freeman R, Failing HJ, Adler GK. Hypoglycemia increases serum interleukin-6 levels in healthy men and women. Diabetes Care. 2008 Jun;31(6):1222-3. 343.Wright RJ, Newby DE, Stirling D, Ludlam CA, Macdonald IA, Frier BM. Effects of acute insulin-induced hypoglycemia on indices of inflammation: putative mechanism for aggravating vascular disease in diabetes. Diabetes Care. 2010 Jul;33(7):1591-7. 344.Ling PR, Bistrian BR. Comparison of the effects of food versus protein restriction on selected nutritional and inflammatory markers in rats. Metabolism. 2009 Jun;58(6):835-42. 345.Ceriello A, Novials A, Ortega E, Canivell S, La Sala L, Pujadas G, Bucciarelli L, Rondinelli M, Genovese S. Vitamin C Further Improves the Protective Effect of Glucagon-like Peptide-1 on Acute Hypoglycemia-Induced Oxidative Stress, Inflammation, and Endothelial Dysfunction in Type 1 Diabetes. Diabetes Care. 2013 Oct 15. 346.Aristo Vojdani, Jama Lambert. The Role of Th17 in Neuroimmune Disorders: Target for CAM Therapy. Part I . Evid Based Complement Alternat Med. 2011; 2011: 927294. 347.Marietta EV, Murray JA. Animal models to study gluten sensitivity. Semin Immunopathol. 2012 Jul;34(4):497-511. Review. 348.Hernández-Lahoz C, Rodrigo L. [Gluten-related disorders and demyelinating diseases]. Med Clin (Barc). 2013 Apr 15;140(7):314-9. Review. Spanish. 349.Sabel’nikova EA. [Intolerance of gluten&#8211;a new disease or undiagnosed celiac disease]. Eksp Klin Gastroenterol. 2012;(3):87-9. Russian. 350.Volta U, Caio G, Tovoli F, De Giorgio R. Non-celiac gluten sensitivity: questions still to be answered despite increasing awareness. Cell Mol Immunol. 2013 Sep;10(5):383-92. 351.Sanders DS, Aziz I. Non-celiac wheat sensitivity: separating the wheat from the chat! Am J Gastroenterol. 2012 Dec;107(12):1908-12 352.Nijeboer P, Mulder C, Bouma G. [Non-coeliac gluten sensitivity: hype, or new epidemic?]. Ned Tijdschr Geneeskd. 2013;157(21):A6168. Review. Dutch. 353.Guan WJ, Liu XJ, Tang BS, Liu YT, Zhou Y, Jiang H, Shen L, Xia K, Wang JL. Gluten ataxia of sporadic and hereditary cerebellar ataxia in patients from mainland China. Neurol India. 2013 May-Jun;61(3):226-30. 354.Fernandez-Jimenez N, Castellanos-Rubio A, Plaza-Izurieta L, Irastorza I, Elcoroaristizabal X, Jauregi-Miguel A, Lopez-Euba T, Tutau C, de Pancorbo MM, Vitoria JC, Bilbao JR. Coregulation and modulation of NFκB-related genes in celiac disease: uncovered aspects of gut mucosal inflammation. Hum Mol Genet. 2013 Oct 31. 355.Eric V. Marietta, Joseph A. Murray. Animal Models to Study Gluten Sensitivity . Semin Immunopathol. Author manuscript; available in PMC 2013 July 1. 356.Tanabe S. Analysis of food allergen structures and development of foods for allergic patients. Biosci Biotechnol Biochem. 2008;72:649–659. doi: 10.1271/bbb.70708. 357.Sapone A, Lammers KM, Mazzarella G, Mikhailenko I, Cartenì M, Casolaro V, Fasano A. Differential mucosal IL-17 expression in two gliadin-induced disorders: gluten sensitivity and the autoimmune enteropathy celiac disease. Int Arch Allergy Immunol. 2010;152:75–80. 358.Molberg O, Uhlen AK, Jemsen T, Flaete NS, Fleckenstein B, Arentz-Hansen H, Raki M, Lundin KE, Sollid LM. Mapping of gluten T-cell epitopes in the bread wheat ancestors: implications for celiac disease. Gastroenterology. 2005;128:393–401. doi: 10.1053/j.gastro.2004.11.003. 359. Daniel DiGiacomo, Antonella Santonicola, Fabiana Zingone, Edoardo Troncone, Maria Cristina Caria, Patrizia Borgheresi, Gianpaolo Parrilli, Carolina Ciacci. Human leukocyte antigen DQ2/8 prevalence in non-celiac patients with gastrointestinal diseases . World J Gastroenterol. 2013 April 28; 19(16): 2507–2513. 360.Fine, Kenneth, “Early Diagnosis of Gluten Sensitivity: Before the Villi are Gone,” Celiac.com, http://www.celiac.com/articles/759/1/Early-Diagnosis-of-Gluten-Sensitivity-Before-the-Villi-are-Gone-By-Kenneth-Fine-MD/Page1.html . 361.Anna Sapone, Julio C Bai, Carolina Ciacci, Jernej Dolinsek, Peter HR Green, Marios Hadjivassiliou, Katri Kaukinen, Kamran Rostami, David S Sanders, Michael Schumann, Reiner Ullrich, Danilo Villalta, Umberto Volta, Carlo Catassi, Alessio Fasano. Spectrum of gluten-related disorders: consensus on new nomenclature and classification . BMC Med. 2012; 10: 13. 362.Fasano A. Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer. Physiol Rev. 2011;91:151–175. 363.Fasano A, Shea-Donohue T. Mechanisms of disease: the role of intestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases. Nat Clin Pract Gastroenterol Hepatol. 2005 Sep;2(9): 416-22 364.Fasano A. Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer. Physiol Rev. 2011;91:151–175. 365.Sapone A, de Magistris L, Pietzak M, Clemente MG, Tripathi A, Cucca F, Lampis R, Kryszak D, Cartenì M, Generoso M, Iafusco D, Prisco F, Laghi F, Riegler G, Carratu R, Counts D, Fasano A. Zonulin upregulation is associated with increased gut permeability in subjects with type 1 diabetes and their relatives. Diabetes. 2006 May;55(5):1443-9. 366. Visser J , Rozing J , Sapone A , Lammers K , Fasano A . Tight junctions, intestinal permeability, and autoimmunity: celiac disease and type 1 diabetes paradigms. Ann N Y Acad Sci. 2009 May;1165:195-205 367.Green P and Cellier C. Celiac Disease. N Engl J Med , 2007; 357:1731-1743. 368.Faulkner-Hogg KB, Selby WS, Loblay RH. Dietary analysis in symptomatic patients with Coeliac disease on a gluten-free diet: the role of trace amounts of gluten and non-gluten food intolerances. Scand J Gastroenterol , 1999; 34:384-389. 369.Sdepanian VL, Scaletsky ICA, Fagundes-Neto U, de Morais MB. Assessment of gliadin in supposedly gluten-free foods prepared and purchased by Celiac patients. J Ped Gastroenterol Nutr , 2001; 32:65-70. 370.Kristjánsson G, Venge P, Hällgren R. Mucosal reactivity to cow’s milk protein in Coeliac disease. Clin Exp Immunol . 2007; 147(3):449-455. 371.Eckman J, Saini SS, Hamilton RG. Diagnostic evaluation of food-related allergic diseases. Allergy Asthma ClinImmunol , 2009; 5(1):2. 372.Wildner G and Diedrichs-Möhring M. Autoimmune uveitis induced by molecular mimicry of peptides from rotavirus, bovine casein and retinal S-antigen. Eur J Immunol , 2003; 33:2577-2587. 373.Zanoni G, Navone R, Lunardi C, et al . In Celiac disease, a subset of autoantibodies against transglutaminase binds to toll-like receptor 4 and induces activation of monocytes. PLoS Med , 2006; 3(9):1637-1653. 374.Blutt SE, Crawford SE, Warfield KL, et al . The VP7 outer capsid protein of rotavirus induces polyclonal B-cell activation. J Virol , 2004; 78:6971-6981. 375.Sollid LM and Gray GM. A role for bacteria in Celiac disease? Am J Gastroenterol , 2004; 99:905-906. 376. Cabrera-Chávez F, Rouzaud-Sández O, Sotelo-Cruz N, et al . Bovine milk caseins and transglutaminase-treated cereal prolamins are differentially recognized by IgA of Celiac disease proteins according to their age. J Agric Food Chem , 2009; 57:3754-3759. 377. Becker CG, Van Hamont N, Wagner M. Tobacco, cocoa, coffee, and ragweed: cross-reacting allergens that activate factor-XII-dependent pathways. Blood , 1981; 58(5):861-867. 378.Vojdani A and Tarash I. Cross-reaction between gliadin and different food and tissue antigens . Food Nutri Sci , 2013; 4:20-32. 379.Scott H, Fausa O, Ek J, Brandtzaeg P. Immune response patterns in Coeliac disease. Serum antibodies to dietary antigens measured by an enzyme linked immunosorbent assay (ELISA). Clin Exp Immunol , 1984; 57(1):25-32. 380.Kristjánsson G, Venge P, Hällgren R. Mucosal reactivity to cow’s milk protein in Coeliac disease. Clin Exp Immunol . 2007; 147(3):449-455. 381.Cyrex Labs Array 4: Gluten-associated cross-reactive foods and foods sensitivity.™ www.cyrexlabs.com Hvatum M, Scott H, Brandtzaeg P. Serum IgG subclass antibodies to a variety of food antigens in patients with Coeliac disease. Gut , 1992; 33(5):632-638. Husby S, Foged N, Oxelius VA, Svehag SE. Serum IgG subclass antibodies to gliadin and other dietary antigens in children with Coeliac disease. Clin Exp Immunol , 1986; 64(3):526-35. 384. Gangur V, Kelly C, Navuluri L. Sesame allergy: a growing food allergy of global proportions? Ann Allergy Asthma Immunol , 2005; 95:4-11. 385.Popa V, Gavrilescu N, Preda N, et al . An investigation of allergy in byssinosis: sensitization to cotton, hemp, flax and jute antigens. Brit J Industr Med , 1969; 26:101-108. 386. Hekkens WT. The determination of prolamins in gluten-free food. Introductory remarks. Panminerva Med , 1991; 33(2):61-64. 387.Kim J-L, Wieslander G, Norbäck D. Allergy/Intolerance to buckwheat and other food products among Swedish subjects with Celiac disease. Proc. 9th Int’l Symp Buckwheat , Prague, 2004; 74:705-709. 388.Anna Sapone, Julio C Bai, Carolina Ciacci, Jernej Dolinsek, Peter HR Green, Marios Hadjivassiliou, Katri Kaukinen, Kamran Rostami, David S Sanders, Michael Schumann, Reiner Ullrich, Danilo Villalta, Umberto Volta, Carlo Catassi, Alessio Fasano. Spectrum of gluten-related disorders: consensus on new nomenclature and classification . BMC Med. 2012; 10: 13.","date_published":"2013-11-11T00:16:06","date_modified":"2020-05-22T00:37:32","authors":[{"name":"Dr. Richard Esquivel","url":"https://sanjosefuncmed.com/about/"}],"tags":["Autoimmune Health"]},{"id":"https://sanjosefuncmed.com/autoimmune-disease-and-the-major-areas-of-immune-dysfunction/","url":"https://sanjosefuncmed.com/autoimmune-disease-and-the-major-areas-of-immune-dysfunction/","title":"Autoimmune Disease & Major Areas of Immune Dysfunction","summary":"An educational discussion of immune-system patterns associated with autoimmune disease.","content_text":"In this issue we look at the prevalence of autoimmune disease, the stages and characteristics of autoimmune disease and discuss the major areas of immune dysfunction involved in the progression of these diseases. Autoimmune Disease and the Major Areas of Immune Dysfunction in Autoimmunity Key points of this issue: The prevalence of autoimmune disease is increasing every year 1 out of 12 women and 1 out of 24 men have an autoimmune disease Autoimmunity results when the body’s immune system loses tolerance to the body’s self-tissue and begins targeting self-tissue for destruction The three stages of autoimmune disease Autoimmune disease is an incurable condition Characteristics of an autoimmune condition The main mechanisms of immune dysfunction in autoimmunity The Autoimmune Epidemic There is an explosion of autoimmune disease taking place worldwide. According to the American Autoimmune Related Disease Association’s current statistics, “ Approximately 50 million Americans, 20 percent of the population or one in five people, suffer from autoimmune diseases.” (1) The National Institutes of Health estimates up to 23.5 million Americans have an autoimmune disease. In comparison, cancer affects up to 9 million and heart disease up to 22 million. These numbers are staggering because they are referring to disease already taking place, not early-stage conditions that lead to autoimmune disease. They also point out that medical education provides minimal learning about autoimmune disease and that specialists are generally unaware of interrelationships among the different autoimmune diseases or advances in treatment outside their own specialty area. (2) Autoimmune Disease in the U.S. Increasing every year Most cases are not diagnosed Most cases continue to progress Conventional healthcare has very little to offer besides steroids and immune-suppressing medications Conventional and alternative healthcare may not fully understand autoimmunity or even immunology Consider the Following Autoimmune Statistics and Facts (www.aarda.org): “The National Institutes of Health estimates up to 23.5 million Americans suffer from autoimmune disease and that the prevalence is rising” “1 out of 12 women and 1 out of 24 men have an autoimmune disease” “Researchers have identified 80-100 different autoimmune diseases and suspect at least 40 additional diseases of having an autoimmune basis. These diseases are chronic and can be life-threatening” “Autoimmune disease is one of the top 10 leading causes of death in female children and women in all age groups up to 64 years of age” “A close genetic relationship exists among autoimmune disease, explaining clustering in individuals and families as well as a common pathway of disease” “Commonly used immunosuppressant treatments lead to devastating long-term side-effects” “The Institute of Medicine reports that the U.S. is behind other countries in research into immune system self-recognition, the process involved in autoimmune disease” “Symptoms cross many specialties and can affect all body organs” “Medical education provides minimal learning about autoimmune disease” “Specialists are generally unaware of interrelationships among the different autoimmune diseases or advances in treatment outside their own specialty area” “Initial symptoms are often intermittent and unspecific until the disease becomes acute” “Research is generally disease-specific and limited in scope. More information-sharing and crossover among research projects on different autoimmune diseases is needed” “The NIH estimates up to 23.5 million Americans have an autoimmune disease. In comparison, cancer affects up to 9 million and heart disease up to 22 million” “According to researchers from the Mayo Clinic, one in 12 women and one in 20 men will develop an autoimmune disease” What is Autoimmune Disease? Autoimmune (AI) disease results when the immune system begins targeting self-tissue of one’s own body causing destruction of that tissue or organ. One of the roles of the immune system is to distinguish between “self” and “non-self”. This means that a healthy immune system can determine when a foreign pathogen, such as a bacteria or virus, enters the body and initiates an immune response against that foreign pathogen to eliminate or destroy it. It does not normally attack the cells or tissue of one’s own body. Normally, self-tissue is “tolerated” by one’s own immune system. However, in some individuals, this tolerance to self-tissue is lost. This is exactly what happens in autoimmune disease. The tissue that gets targeted and destroyed by the immune response defines the type of autoimmune disease one develops. However, all AI disease involves similar mechanisms of immune dysregulation so these seemingly different diseases can be treated similarly by modulating some aspect of the immune response. There are many different AI diseases that have been identified, such as rheumatoid arthritis (RA), multiple sclerosis (MS), lupus (SLE), Hashimoto’s thyroiditis, Crohn’s disease, ulcerative colitis (UC), type I diabetes and Celiac disease (CD). This is because AI disease can affect every organ and tissue in the body. “Autoimmune diseases can affect virtually every site in the body” “At least 15 diseases are known to be the direct result of an autoimmune response, and circumstantial evidence links more than 80 conditions to autoimmunity.” (3) How Does Autoimmunity Happen? Autoimmunity results when the body’s immune system loses tolerance to the body’s self-tissue and begins targeting self-tissue for destruction. The details of precisely how this self-tolerance is lost in susceptible individuals is not yet clearly understood. But there is growing evidence that a variety of factors may play a role in loss of self-tolerance, including genetics, environmental pollutants and toxins, hormonal changes, immunoreactive dietary proteins (from our food), leaky gut, chronic infections, chronic inflammation and stress responses. (For a more detailed explanation of the mediators and modulating factors leading to autoimmune disease, click here .) All of these factors lead to immune dysregulation which leads to loss of self-tolerance and the production of antibodies against self-tissue. These autoantibodies indicate that that specific tissue of the body is being targeted for destruction by the immune system and serve as the hallmark of autoimmune processes in the body and aid in diagnosis of autoimmune disease. “The origins of autoimmune disease are multifactorial. Environmental factors and a genetic predisposition result in tissue injury caused by autoreactive T cells or antibodies.”(4) “Emerging evidence has suggested the involvement of environmental factors such as infections and xenobiotics, and some dietary proteins and their antibodies in the pathogenesis of many autoimmune diseases”(5) “The cause may be due to environmental factors such as bacterial or viral infections, or haptenic toxic chemicals binding to human tissue, causing modification of self-antigens and the subsequent production of autoantibodies”.(6) The Stages of Autoimmunity It is important to keep in mind that the development of autoimmune disease does not occur overnight. The manifestations of the disease occur much later than the initiating factors that lead to the development of autoimmunity. It may take years for the targeting of self tissue by autoantibodies to result in autoimmune disease. During this time, patients are often asymptomatic and unaware that they are laying the groundwork for the development of autoimmune disease. “Autoimmune diseases tend to have long, asymptomatic prodromal periods and the initiating events leading to loss of self tolerance occur long before the disease becomes clinically manifest.”(7) Autoimmunity in general, takes place in several stages: The first stage is called silent autoimmunity and is characterized by the onset of loss of immune self-tolerance without any loss of self-tissue. This stage is identified by elevated autoantibodies but without any other signs or symptoms. The second stage is called autoimmune reactivity and is the stage when the autoimmunity has progressed into tissue destruction and is starting to create noticeable symptoms associated with loss of function but no severe destruction of the tissue. The third stage is called autoimmune disease and this is when there is clear and significant loss of self-tissue that can be identified with imaging studies and other tests, such as nerve conduction studies.(8) Autoimmune Disease is an Incurable Condition There is no known cure for autoimmune disease. The expression of the disease can go into remission but that does not mean the person is cured. Unfortunately, some healthcare providers and patients confuse autoimmune remission with cure . It is clear that once the gene expression of autoimmune disease turns on, there is no “off” switch, but there is a “dimmer switch” that can modulate how active the expression becomes. With the explosion of autoimmunity taking place worldwide, many chronic patients who seek help are either not properly diagnosed or are overlooked and eventually seek the care of alternative medicine practitioners for help. Unfortunately, most alternative healthcare providers are not adequately trained to identify, monitor and manage autoimmune-related conditions. Most autoimmune disease remains undiagnosed. However a healthy diet and lifestyle provide many autoimmune patients with greater function and overall health while remaining undiagnosed. Characteristics of an Autoimmune Condition Incurable condition Relapsing and remitting Chronic and progressive Diagnosed with conditions associated with autoimmunity Hypothyroidism Diabetes Idiopathic neuropathy Inflammatory bowel disease Meniere’s disease Arthritis (systemic) Mechanisms of Autoimmunity There are several mechanisms of immune dysfunction which have been shown to play a role in the development of autoimmune reactivity and autoimmunity. We will discuss each of these mechanisms briefly and show how they play a role in autoimmunity according to the most recent literature in the field of immunology. This section is a bit technical, so if you are not the technical type, then just skip down to the next section. In the next article, we will show how each of these mechanisms are can be modulated with natural compounds in the management of these conditions under the supervision of a functional medicine practitioner. Major Areas of Immune Dysfunction in AI Disease NF-kB activation and dampening Glutathione recycling system Barrier system integrity TH-1 and TH-2 polar shifts TH-3 or regulatory T-cell activation TH-17 activation and dampening Nitric oxide isomer expressions NF-kB Activation and Dampening An increasing number of studies indicate that a protein complex known as NF-kB plays an important role in controlling the expression of genes related to the development of autoimmunity. (9) NF-kB controls the expression of genes encoding the proinflammatory mediators (ie: cytokines, chemokines, and adhesion molecules) involved in autoimmune disease. NF-kB can become chronically elevated because of its own amplifying loop. (10) This means that elevations in NF-kB can perpetuate further elevations of NF-kB. Some activation of NF-kB is essential for a healthy immune response. However, after the pathogen is eliminated, NF-kB signaling needs to be downregulated to maintain tissue homeostasis. (11) If this does not occur, then immune dysregulation takes place leading to autoimmunity. Recent data has shown that NF-kB is required for activation of immune cells against self-tissue, and its hyperactivity should be minimized, since it promotes autoimmunity. (12) The Glutathione Recycling System Glutathione is a tripeptide compound that acts as an immune modulator, antioxidant, and hepatic detoxification substrate. Glutathione is the main protecting antioxidant for cellular mitochondria. Glutathione exists in reduced (GSH) and oxidized (GSSG) states. GSH (reduced glutathione) becomes GSSG (oxidized glutathione) by glutathione peroxidase to support anti-inflammatory response mechanisms. GSH can be regenerated from GSSG by the enzyme glutathione reductase to keep the cycle going. The ability to recycle GSH is critical for a healthy immune response. As long as the enzymes glutathione peroxidase and glutathione reductase are working efficiently, your body is able to maintain this glutathione recycling system and you are fine. When this system fails, you get immune dysregulation and increased risk of autoimmunity. Glutathione appears to be an important antioxidant that helps support regulatory TH-3 cells of the immune system (important immune-regulating cells), protect the intestinal barrier and quench oxidative compounds before they are activated by the NF-kB receptor. Many studies suggest that intracellular GSH levels in antigen-presenting cells such as macrophages, influence the TH1/TH2 cytokine response patterns which are associated with immune dysregulation and autoimmunity. The observations reported in one study showed that pro-GSH molecules represent new therapeutic agents to support immune modulation. (13) Another study suggested that the severity of some autoimmune diseases, such as systemic lupus erythmatosus (SLE), correlate with levels of glutathione in the blood, namely, the lower the glutathione levels, the more severe the autoimmune disease. (14) Glutathione is also suggested to play an important role in gut barrier function and prevention of intestinal inflammation. One study showed that intestinal barrier destruction occurs once glutathione is depleted. It also showed that glutathione depletion aggravated intestinal inflammation after infection. (15) In another study, the researchers concluded that their data support the hypothesis that the GSH antioxidant system plays a crucial role in gut barrier protection. (16) Intestinal Barrier System Integrity When the intestinal mucosa of the digestive tract is inflamed, the tight junctions of the intestinal mucosa are compromised and they become widened and permeable to large, undigested compounds, toxins and bacteria which can then enter the bloodstream. This condition is known as leaky gut. ( What is Leaky Gut? ) These large undigested proteins that are absorbed are reacted against by the underlying intestinal immune system and promote exaggerated immune responsiveness (inflammation) which leads to further destruction of the intestinal barrier. This creates a vicious cycle of further intestinal inflammation and greater loss of intestinal integrity. As the intestinal tract becomes inflamed from diet, lifestyle, medications, and infections, it promotes further intestinal inflammation and further intestinal permeability. It is not uncommon for individuals to suffer from ongoing leaky gut syndrome for several years. After the intestinal mucosa becomes damaged, the damaged cells become unable to properly absorb nutrients and produce the enzymes necessary for digestion and absorption. This leads to malnutrition, further intestinal inflammation, further intestinal permeability and the development of food sensitivities, bacterial overgrowths, yeast overgrowths and impaired intestinal immune integrity. These self-promoting vicious cycles become difficult to unwind unless aggressive dietary and nutritional strategies are employed. Most importantly, the immune dysregulation from increased permeability has been shown to perpetuate immune overzealousness and loss of ability to regulate self and nonself tolerance, leading to autoimmunity. “When the finely-tuned trafficking of macromolecules is dysregulated in genetically susceptible individuals, both intestinal and extraintestinal autoimmune disorders can occur.”(17) This review paper was published in 2009 in the Annals of N.Y. Academy of Science, one of the top-rated most powerful scientific journals available: “There is growing evidence that increased intestinal permeability plays a pathogenic role in various autoimmune diseases. Therefore, we hypothesize that loss of intestinal barrier function is necessary to develop autoimmunity.”(18) TH-1 and TH-2 Polar Shifts The immune system has two major immune responses: T-helper-1 (TH-1) response, which is mediated by T-cells T-helper-2 (TH-2) response, which is mediated by B-cells Both immune responses are important for protecting the body against foreign microbes and invaders. In autoimmunity, there is a polar shift or dominance of either the TH-1 or TH-2 system. Many autoimmune diseases are classified in the immunology literature by their T-helper dominance. The shift in their TH-1 or TH-2 systems remains constant and does not change over the course of the autoimmunity. Identification of the shift may help an individual identify which natural compounds activate their autoimmunity and which natural compounds help potentially dampen their autoimmunity. This identification is helpful in modulating the immune responses seen in autoimmunity. TH-3 Cells or Regulatory T-Cell Activation TH-3 cells, or regulatory T-cells, are a subpopulation of T-cells that downregulate the immune system, maintain tolerance to self-antigens and minimize autoimmune disease. Regulatory T-cells are a component of the immune system that suppress immune responses from other cells. This is an important “self-check” mechanism inherent in the immune system to prevent excessive reactions. These cells are involved in shutting down the immune responses after they have successfully eliminated invading organisms and also in preventing autoimmune TH-1 and TH-2 polar shifts. TH-17 Activation and Dampening T-helper 17 (TH-17) is a subset of T-helper cells producing IL-17. IL-17 is a potent proinflammatory cytokine that amplifies ongoing inflammation by inducing the expression of tumor necrosis factor-α (TNF- α), IL-1β, and IL-6 in epithelial and endothelial cells. TH-17 cells serve a very important function in anti-microbial immunity and are important for immunity and protection from opportunistic infections. Therefore, TH-17 is important for normal immunity, but it can also become excessively active, especially in those with autoimmunity. These cells are considered developmentally distinct from TH-1 and TH-2 cells, and excessive amounts of these cells are thought to play a key role in autoimmune disease activation. TH-17 activity is considered a key marker in the activation and severity of autoimmune flare-ups. Nitric Oxide Isomer Expressions Nitic oxide (NO) is an important messenger molecule involved in many physiological and pathological processes as well as a chemical-signalling molecule that is involved with communication in the nervous system, immune system and vascular system. It was proclaimed the “Molecule of the Year” in 1992. (19) Nitic oxide plays both destructive and protective roles in autoimmunity, depending on which of the three enzymes, or synthases, is expressed. The three nitric oxide synthase (NOS) isomers (forms) are neuronal NOS (nNOS), endothelial NOS (eNOS) and inducible NOS (iNOS). nNOS supports nervous tissue, including the brain, and neurological synapses involved in neuronal signaling and brain function. eNOS activity supports blood vessel health by producing dilation of blood vessels, dissolves endothelial plaques, and enhances blood flow. iNOS, however, has destructive effects on tissue. iNOS is activated by TH-17 and produces harmful free radical action and initiates tissue destruction. How these isomers are manipulated or modulated will determine how much destruction of tissue or ability to recover from autoimmune flare-ups a person has. Studies show that nitric oxide (NO) modulates inflammatory and immune responses in multiple ways and plays a protective role in many forms of inflammatory and autoimmune reactions. (20, 21, 22, 23) “We conclude that NO plays a critical immunoregulatory role and NO modulation may prevent the onset of autoimmune reactions”(24) The Primary Difference Between Conventional vs. Functional Medicine in Management of Autoimmune Conditions The primary medications still being used by conventional medicine to manage autoimmune disease are immune-suppressing medications. Up until recently, the primary class of drugs used to manage most autoimmune disease was oral corticosteroids, such as prednisone, which have powerful anti-inflammatory effects. However, there are many known side-effects of these medications, especially when taken long-term. Some of the known side effects of steroids include immune suppression, bone loss, neurodegenerative impacts on the brain, insulin-related issues and impacts on blood sugar regulation, epithelial thinning, and catabolic states which means these patients have difficulty recovering from flare-ups from their autoimmunity. “Osteoporosis, adrenal suppression, hyperglycemia, dyslipidemia, cardiovascular disease, Cushing’s syndrome, psychiatric disturbances and immunosuppression are among the more serious side effects noted with systemic corticosteroid therapy, particularly when used at high doses for prolonged periods.”(25) The newer class of medications called “biologic therapies” which are more specific in their therapeutic targets of the immune system than previous medications, such as disease-modifying anti-rheumatic drugs (DMARDs) and corticosteroids, still have serious immune-suppressive effects. This is why people are still at risk of developing various types of infection such as tubercolosis. Another major risk of these medications is the induction of autoimmune disease (marked by anti-DNA antibodies) in up to 1/3 of users. (26) They are also extremely expensive and very inconvenient when intravenous administration is required. (27) “Drugs developed by the pharmaceutical industry have thus far been associated with toxicity and side effects, which is why natural substances are of increasing interest”(28) “Current Western therapies for inflammatory diseases are suboptimal; increasingly, patients are turning to complementary and alternative medicine for symptom relief and improved quality of life”(29) Functional medicine treatment of AI disease focuses on removing the triggers promoting the autoimmunity and managing the autoimmunity by modulating the immune response and decreasing tissue destruction. It also emphasizes patient education in order to minimize flare-ups and enhance the patient’s ability to recover from the flare-ups when they occur. “There is emerging evidence that many of these (complementary and alternative) therapies have the ability to modulate the immune system and disrupt the proinflammatory cascade through a variety of mechanisms, including antioxidant effects, alterations in cell signaling (in particular the nuclear factor (NF)-kB pathway), cytokines, proinflammatory mediators, and disruption of bacterial flora”(30) “Finding therapeutic agents which can modulate the inflammatory reaction is the highest priority in medical research today”(31) There is no cure for autoimmune disease. The primary goal in the management of AI conditions in the functional medicine model is to decrease flare ups, decrease destruction of tissue and increase one’s ability to recover from these flare ups. This can have significant impacts on the quality of life of those with AI disease. In the next issue, we will discuss nutritional strategies used to manage autoimmune disease in functional medicine, including dietary and lifestyle strategies and the use of key supplements targeted to the major areas of autoimmunity and autoimmune reactions as identified by the most current literature and described in this article. Stay tuned! Content provided by Datis Kharrazian, D.C., The Gluten, Leaky Gut, Autoimmune Connection. Apex Energetics lecture. Mar. 16, 2013. References: https://www.aarda.org/q_and_a.php https://www.aarda.org/autoimmune_statistics.php NAT CLIN PRAC GASTRO & HEP SEPT 2005 VOL 2 NO 9 Arch Dis Child 1998;79:448-451 Expert Opin. Med. Diagn. (2008) 2(6):1-13 Expert Opin. Med. Diagn. (2008) 2(6):1-13 Arch Dis Child 1998;79:448-451 Kharrazian, D. The Gluten, Leaky Gut, Autoimmune Connection. Apex Energetics lecture. Mar. 16, 2013. Nuclear factor-kB—a pivotal transcription factor in chronic inflammatory diseases. NF-kB Inflammatory Amplifying Loop. N Eng J Med. 1997;336:1066-1071. Nuclear factor-kB—a pivotal transcription factor in chronic inflammatory diseases. NF-kB Inflammatory Amplifying Loop. N Eng J Med. 1997;336:1066-1071. Return to homeostasis: downregulation of NF-kB responses. Nat Immunol. 2011 Jun 19;12(8):709-714 NF-kB in type 1 diabetes. Inflamm Allergy Drug Targets. 2011 Jun;10(3):208-217. Antiviral and immunomodu-latory properties of new pro-glutathione (GSH) molecules. Curr Med Chem. 2006:13(15): 1749-55 Correlation of lipid peroxidation and glutathione levels with severity of systemic lupus erythmatosus: a pilot study from single center. J Pharm Pharm Sci. 2008;11(3):30-4 Intestinal barrier function in response to abundant or depleted mucosal glutathione in Salmonella-infected rats. BMC Physiol. 2009 Apr 17:9:6 The role of the glutathione antioxidant system in gut barrier failure in a rodent model of experimental necrotizing enterocolitis. Surgery. 2004 Sep;136(3):557-66 Mechanisms of disease: the role of intestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases. Nat Clin Pract Gastroenterol Hepatol. 2005 Sep;2(9): 416-22 Tight junctions, intestinal permeability, and autoimmunity: celiac disease and type 1 diabetes paradigms Ann N Y Acad Sci. 2009 May;1165:195-205 Koshland DE Jr. The molecule of the year. Science. 1992 Dec 18;258(5090):1861. Role of nitric oxide in inflammatory conditions. Nephron. 2002 Apr;90(4):373-8. Regulatory role of nitric oxide on monocyte-derived dendritic cell functions. J Interferon Cytokine Res. 2003 Aug;23(8):423-31 Role of nitric oxide in the regulation of T-cell functions. Ann Rheum Dis. 2006 Nov;65 Suppl 3:iii37-40 Protective role of the cytokine-inducible isoform of nitric oxide synthase induction and nitrosative stress in experimental autoimmune encephalomyelitis of the DA rat. J Neurosci Res. 2003 Jul 15; 73(2):198-205 Immunoregulatory role of nitric oxide in Kilham rat virus-induced autoimmune diabetes in DR-BB rats. J Immunol. 2004 Jul 15;173(2):1327-35 Liu D , Ahmet A , Ward L , et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013 Aug 15;9(1):30. [Epub ahead of print] Penn H . Biologic therapies in autoimmune diseases. Clin Med. 2006 Jan-Feb;6(1):105-8. Department of Rheumatology, Royal Free Hospital, London. Rosman Z , Shoenfeld Y , Zandman-Goddard G . Biologic therapy for autoimmune diseases: an update. BMC Med. 2013 Apr 4;11:88. doi: 10.1186/1741-7015-11-88. J OF PAR AND ENT NUTRITION Vol. 30,no.1, 2006,45-51 Nutrition in Clinical Practice 23:4962, Feb 2008 Nutrition in Clinical Practice 23:4962, Feb 2008 J OF PAR AND ENT NUTRITION Vol. 30, no.1, 2006,45-51","date_published":"2013-08-25T06:49:31","date_modified":"2020-05-22T00:52:18","authors":[{"name":"Dr. Richard Esquivel","url":"https://sanjosefuncmed.com/about/"}],"tags":["Autoimmune Health"]},{"id":"https://sanjosefuncmed.com/12-common-endocrine-disruptors-4-notable-environmental-chemicals/","url":"https://sanjosefuncmed.com/12-common-endocrine-disruptors-4-notable-environmental-chemicals/","title":"Common Endocrine Disruptors & Environmental Chemicals","summary":"A deeper educational look at environmental compounds that can interact with endocrine physiology.","content_text":"In this segment, we examine the 12 most common endocrine disruptors according to the Environmental Working Group and 4 other common environmental chemicals we come in contact with daily and review the potential health effects of these compounds according to the most recent research. We review the evidence showing how these compounds may be contributing to various hormonal and reproductive disorders, cognitive and neurological disorders, kidney and liver disease, immunological disorders and cancer. We also make recommendations on how you can protect you and your family against exposure to each of these toxic compounds. In the next segment, we introduce the concept of chemical tolerance and body burden . We introduce the concept of toxicant-induced loss of tolerance (TILT) and examine how this develops and why this may be important for more and more people today. We review common signs and symptoms of loss of chemical tolerance including chemical sensitivity to a wide variety of chemicals in your environment. Key concepts for this issue What are “Endocrine Disruptors”? 12 Common Endocrine Disruptors as Identified by the Environmental Working Group What are “Xenoestrogens”? 4 Other Notable Environmental Chemicals that you Probably Come in Contact with on a Daily Basis What are “Endocrine Disruptors”? From the moment of conception, human growth and development is regulated by tiny amounts of biochemicals called hormones . Our bodies manufacture trace quantities of these chemical messengers, which enter our bloodstream and t ravel throughout our circulatory system, managing our metabolism and controlling the function of specific tissues and organs. Hormones are able to produce an array of sophisticated regulatory signals crucial to human health at part per billion or part per trillion levels in the blood. Disruption of the human hormone (endocrine) system can cause a broad range of illnesses, including reproductive and metabolic disorders and cancer. There are numerous environmental chemicals that we potentially come in contact with on a daily basis that have been shown to disrupt the endocrine system. Chemicals that disrupt the endocrine system are called endocrine disruptors . 12 Common Endocrine Disruptors as Identified by the EWG In October, 2013, the Environmental Working Group (EWG) published a list of 12 common environmental chemicals and toxins that act as endocrine disruptors in human physiology.[1] This means they disrupt hormonal signaling (alter hormonal responses) in the human body. Since hormones act as biochemical messengers and regulators of physiologic function, this can lead to a wide range of physiological problems and it’s interesting to note that most of them impact multiple endocrine organs simultaneously. Here is a list of those chemicals: BPA Dioxin Atrazine Phthalates Perchlorate Fire retardants Lead Arsenic Mercury Perfluorinated chemicals Organophosphate pesticides Glycol Ethers As we did in the previous list of hazardous and toxic compounds, we will take a close look at the most current research on each one of these compounds (not already covered in the last article) and discuss impacts of exposure on human health. 1. Bisphenol A ( BPA) Bisphenol A (BPA) is a plastics chemical currently used in enormous amounts to manufacture hard plastic water bottles and to make epoxy linings of metal food cans, like those for canned infant formula. Another common source of BPA is cash register and credit card receipts, the handling of which have recently been shown to cause elevations in BPA in the blood, as just published by the prestigious Journal of the American Medical Association a couple months ago. [2] How common is BPA exposure? Although its long-time use in consumer products has come with assurances of its safety from industry, studies conducted over the past 20 years now show it to be not only a ubiquitous pollutant in the human body–it contaminates approximately 93% of the population according to the CDC [3]—but also a potent developmental toxin at very low doses . One recent study that examined over 80 published human biomonitoring studies that measured BPA concentrations in human tissues, urine, blood, and other fluids, concluded the following on BPA exposure: “Available data from biomonitoring studies clearly indicate that the general population is exposed to BPA and is at risk from internal exposure to unconjugated BPA.”[4] What are the health effects of BPA exposure? In September, 2008, the National Toxicology Program of NIH determined that BPA may pose risks to human development, raising concerns for early puberty, prostate effects, breast cancer, and behavioral impacts from early-life exposures. [5] But this came after many warnings from consumer environmental groups such as the Environmental Working Group and an accumulation of studies spanning more than 10 years showing that BPA had potentially harmful effects in the human body.[6] A recent review of the most current literature on the health effects of BPA published in December 2013, concluded: “T he growing human literature correlating environmental BPA exposure to adverse effects in humans, along with laboratory studies in many species including primates, provides increasing support that environmental BPA exposure can be harmful to humans, especially in regards to behavioral and other effects in children.”[7] What are “xenoestrogens”? BPA is currently understood to be a xenoestrogen . Xenoestrogens are a type of foreign or synthetic compound (“xeno” means foreign) that imitates estrogen in the human body. This means they stimulate estrogen receptors and produce an estrogenic effect on a living organism even though they differ chemically from the natural estrogenic hormones produced internally by the endocrine system . Synthetic xenoestrogens are widely used industrial compounds, which include BPA , PCBs , and phthalates , among others. Xenoestrogens are clinically significant because they can mimic the effects of endogenous (naturally-produced) estrogen and thus have been implicated in several types of cancer, including breast cancer [8-14], prostate cancer [15-18], and testicular cancer.[19,20] Extensive literature has raised concerns about their impacts on human development, particularly during the developmental states of the brain and nervous system and endocrine system during pregnancy and implications for many endocrine-related disorders such as metabolic disorder, diabetes and obesity [21-29], cardiovascular diseases [30-34], liver and kidney toxicity [35-38], abnormal prostate development [39-42], low sperm count [43-45] and other reproductive disorders.[46-52] “Importantly, many of these studies have reported BPA-related effects at very low doses, e.g., at exposure levels less than 50 μg kg −1 day −1 , the current “safe” dose that is considered acceptable for daily intake by the U.S. Food and Drug Administration (FDA) and that is also the reference dose established by the U.S. Environmental Protection Agency. This suggests that, like endogenous hormones, environmental estrogens can elicit biological effects at extremely low concentrations.”[53] Who are the most vulnerable to the effects of BPA? Many studies indicate that pregnant women and the developing fetus and baby are the most vulnerable to BPA’s toxic effects. [54-59] Unfortunately, they also have the highest BPA exposure of any age group. The federal Food and Drug Administration (FDA) estimates that babies have 12.5 times more BPA exposure than adults.[60] Therefore, it is critical for pregnant mothers to avoid BPA as much as possible. Additionally, a large number of studies have linked BPA exposure with neural development and neurological disorders [61-70], learning and behavioral disorders [71-74] and abnormal growth and development.[75,76] As one recent study concluded regarding the current safety standards for BPA: “We propose that a new risk assessment for BPA is needed based on a) the extensive new literature reporting adverse effects in animals at doses below the current reference dose; b) the high rate of leaching of BPA from food and beverage containers, leading to widespread human exposure; c) reports that the median BPA level in human blood and tissues, including in human fetal blood, is higher than the level that causes adverse effects in mice; and d) recent epidemiologic evidence that BPA is related to disease in women.”[77] How to Avoid Exposure: Go fresh instead of canned – many food cans are lined with BPA – or research which companies don’t use BPA or similar chemicals in their products. Use powdered baby formulas instead of canned. Don’t use polycarbonate plastics for warm food or drinks. Say no to receipts, since thermal paper is often coated with BPA. Avoid plastics marked with a “PC” for polycarbonate or recycling label #7. For more tips, check out: www.ewg.org/bpa Avoiding BPA for Pregnant Mothers and Infants Avoid BPA in formula and baby bottles BPA exposure comes primarily from canned foods and polycarbonate food containers, but baby bottles and baby formula can also contain BPA. Most manufacturers now make BPA-free baby bottles. Glass is the safest and most durable option. Never microwave baby food or drinks in plastic containers. Many parents who have replaced their polycarbonate baby bottles are unaware that BPA contaminates liquid baby formula sold in metal cans. A 1990s test by FDA show BPA leaching from metal cans into all brands of liquid formula. Since formula can make up to 100% of a baby’s diet over her first 6 months of life, parents unable to breast feed should choose a powdered formula if your baby tolerates it. Powdered formula appears to be BPA-free.[78] Avoid BPA in canned foods Almost all canned foods sold in the United States have a BPA-based epoxy liner that leaches BPA into the food. EWG tested 97 canned foods and found detectable levels of BPA in more than half of the foods. The highest concentrations were in canned meats, pasta and soups. Pregnant women and children should limit their consumption of canned foods to avoid BPA. Rinsing canned fruit or vegetables may reduce the amount of BPA you ingest. Avoid BPA in water and food containers Less BPA leaches from plastic water bottles and food containers than from cans into canned foods and baby formula. Nevertheless, it is good to take simple precautions to reduce your exposure. Polycarbonate plastics are rigid, transparent and used for food storage containers and water bottles, among other things. Trace amounts of BPA can migrate from these containers, particularly if used for hot food or liquids. Soft or cloudy-colored plastic does not contain BPA. Avoid putting any plastic containers in microwaves and do not heat up food in plastic containers. Some metal water bottles lined with an epoxy-based enamel coating could leach BPA. Look for stainless steel bottles that do not have a liner.[79] 2. Dioxin Dioxins are major environmental pollutants and are of concern because of their highly toxic potential. They have the dubious distinction of belonging to the “dirty dozen”–a group of dangerous chemicals known as persistent organic pollutants (POPs). In the 1970s, dioxin was identified as a contaminant in Agent Orange, the notorious defoliant deployed by the U.S. during the Vietnam War and blamed for diabetes and other diseases among exposed personnel.[80] Based on animal data and on human epidemiology data, dioxin is classified by IARC as a “known human carcinogen” although the EPA has categorized dioxin as a “ likely human carcinogen” . The name “dioxins” is often used for the family of structurally and chemically related polychlorinated dibenzo para dioxins (PCDDs) and polychlorinated dibenzofurans (PCDFs) . Certain dioxin-like polychlorinated biphenyls (PCBs) with similar toxic properties are also included under the term “dioxins”. Dioxins are found throughout the world in the environment and they accumulate in the food chain, mainly in the fatty tissue of animals, including fish. More than 90% of human exposure is through food, mainly meat and dairy products, fish and shellfish.[81] Sources of dioxin contamination Dioxins are mainly by-products of industrial processes but can also result from natural processes, such as volcanic eruptions and forest fires. Dioxins are unwanted by-products of a wide range of manufacturing processes including smelting, chlorine bleaching of paper pulp and the manufacturing of some herbicides and pesticides. In terms of dioxin release into the environment, uncontrolled waste incinerators (solid waste and hospital waste) are often the worst culprits, due to incomplete burning. Dioxins are found throughout the world in the environment. The highest levels of these compounds are found in some soils, sediments and food, especially dairy products, meat, fish and shellfish. Very low levels are found in plants, water and air.[82] Accumulation of dioxins in animals and the human body Once dioxins have entered the body, they endure a long time because of their chemical stability and their ability to be absorbed by fat tissue, where they are then stored in the body. Their half-life in the body is estimated to be seven to eleven years! In the environment, dioxins tend to accumulate in the food chain. The higher in the animal food chain one goes, the higher the concentration of dioxins. Due to the omnipresence of dioxins, all people have background exposure which contributes to their body burden.[83] Infant exposure to dioxins Again, infants are exposed to the highest amounts and are most vulnerable to exposure. EWG research found that the amount of dioxin a nursing infant ingests daily is up to 77 times higher than the level EPA has proposed to protect the endocrine and immune systems.[84] The fact that both breast milk and formula are contaminated with dioxin highlights the urgent need for EPA to finish its assessment on dioxins. Health effects of dioxin exposure Short-term exposure of humans to high levels of dioxins may result in skin lesions, such as chloracne and patchy darkening of the skin, and altered liver function.[85] Long-term exposure is linked to impairment of the developing immune system [86-92], respiratory system [93-99], nervous system [100-107], endocrine system [108-114] and reproductive functions [115-124] and cause cancer.[125-134] For cancer risk, the situation is concerning: the general public is exposed to up to 1,200 times more dioxin than regulatory agencies typically consider safe.[135] The developing fetus, infants and other vulnerable subgroups The developing fetus is most sensitive to dioxin exposure. The newborn, with rapidly developing organ systems, may also be more vulnerable to certain effects. Some individuals or groups of individuals may be exposed to higher levels of dioxins because of their diets (e.g., high consumers of fish in certain parts of the world) or their occupations (e.g., workers in the pulp and paper industry, in incineration plants and at hazardous waste sites, to name just a few).[136] How to Avoid Exposure: Eat organic foods whenever possible. Products including meat, fish, milk, eggs and butter are most likely to be contaminated, but you can cut down on your exposure by eating fewer animal products and eating organic foods when possible. Trimming fat from meat and consuming low fat dairy products may decrease the exposure to dioxin compounds. Make sure your fish oil supplements are checked for dioxin levels. 3. Atrazine Atrazine , the most heavily used herbicide in the United States but banned in the European Union, is a cancer-causing weed killer applied to 50 million acres of corn each year. After it is applied each spring, it runs off cornfields and through drinking water plants into the tap water of millions of Mid-western homes. While many larger water utilities suppress atrazine levels through special treatments, toxic traces remain in finished water.[137] Atrazine has gained the attention of a number of current researchers. According to amphibian endocrinologist Tyrone Hayes of U.C. Berkeley, exposure to the herbicide Atrazine results in what amounts to chemical castration in frogs.[138] In an interview with Minnesota Public Radio news, Hayes said: “One of the things we discovered is that atrazine chemically castrates the frog, meaning that it causes a reduction in the male hormone, testosterone, which results in things like decreased sperm count, a decrease in the voice box which controls the male’s ability to attract mates.” But Hayes says the enzyme that atrazine activates in frogs is the same one found in humans. It converts testosterone into estrogen. “This same enzyme, or machinery if you will, controls estrogen production in humans. And atrazine is associated in laboratory rodents with development of mammary cancer, or breast cancer, and there are epidemiological studies that associate atrazine exposure to breast cancer in humans.”[139] Atrazine has been linked to delayed puberty and prostate inflammation in animals, and some research has linked it to prostate cancer in men with possible implications for other reproductive cancers.[140-142] Atrazine Continues to Contaminate Surface Water and Drinking Water in the United States The most recent data confirms that atrazine continues to contaminate watersheds and drinking water across the Midwest and Southern United States. Atrazine was found in 80% of drinking water samples taken in 153 public water systems in 2007 to 2008. All twenty watersheds sampled during this time had detectable levels of atrazine, and sixteen had average concentrations above the level that has been shown to harm plants and wildlife.[143] How to Avoid Exposure: Eat organic whenever possible! Drink filtered water certified to remove atrazine. Check out the EWG’s “Shopper’s Guide to Pesticides in Produce” for more information: http://www.ewg.org/foodnews/guide.php?key=40442072 4. Phthalates Phthalates (pronounced “tha–lates”) are a group of chemicals used to soften and increase the flexibility of plastic and vinyl. Polyvinyl chloride (PVC) is made softer and more flexible by the addition of phthalates . Phthalates are used in hundreds of consumer products, including cosmetics and personal care products, perfume, hair spray, soap, shampoo, nail polish, and skin moisturizers. They are used in consumer products such as plastic and vinyl baby toys, shower curtains, wallpaper, vinyl miniblinds, food packaging, and plastic wrap. Phthalates are also used in wood finishes, detergents, adhesives, plastic plumbing pipes, lubricants, medical tubing and fluid bags, solvents , insecticides, medical devices, building materials, and vinyl flooring.[144] How are people exposed to phthalates? You can be exposed to low levels of phthalates through air, water, or food or if you use cosmetics, personal care products, cleaning products, or other plastic and vinyl products that contain them. Exposure to low levels of phthalates may come from eating food packaged in plastic that contains phthalates or breathing dust in rooms with vinyl miniblinds, wallpaper, or recently installed flooring that contain phthalates. You could also be exposed by drinking water that contains phthalates, though it is not known how common that is. Children can be exposed to phthalates by chewing on soft vinyl toys or other products made with them. Children can also be exposed by breathing household dust that contains phthalates or using IV tubing or other medical devices made with phthalates.[145] How much environmental phthalate gets into our bodies? In September, 2000, scientists from the Centers for Disease Control and Prevention (CDC) conducted the first accurate measurements of human phthalate exposures, and reported finding phthalates in every one of 289 people tested, at unexpectedly high levels.[146] Levels of some phthalates in U.S. women of childbearing age have been found to exceed the government’s safe levels set to protect against birth defects, according to another CDC study.[147] Results of phthalate testing in more than 2,500 people ages 6 and above confirmed the CDC’s original findings: phthalate exposures are widespread across the population, and women are exposed at higher levels than men.[148] In a 2007 study of girls age 6 to 8 spearheaded by Mount Sinai School of Medicine, phthalates were found in every one of 90 girls tested.[149] Phthalates are widespread contaminants in the environment as well [150,151). What are the health effects of phthalate exposure? Epidemiological studies of ordinary people have linked high phthalate levels to a wide variety of problems with the male reproductive tract, including reduced sperm motility and concentration, increased damage to sperm DNA, alterations in hormone levels in adult men.[152-154] Exposure to phthalates in the developing fetus and infant boys (through the mother’s breast milk) has been associated with congenital anomalies, decreased testosterone levels and infertility[155-158] which confirmed earlier animal studies.[159-160] Recent studies indicate phthalates may produce non-reproductive health effects in both males and females.[161,162] Phthalate exposure has been associated with a wide range of health effects, including allergies, asthma and atopic dermatitis (eczema) [163-166], pulmonary function [167], alterations in thyroid function [168-171], learning, memory and behavioral problems in children [172-176] and breast cancer.[177-181] How to Avoid Exposure: Avoid plastic food containers, children’s toys (some phthalates are already banned in kids’ products), and plastic wrap made from PVC, which has the recycling label #3. Some personal care products also contain phthalates, so read the labels and avoid products that simply list added “fragrance,” since this catch-all term sometimes means hidden phthalates. Find phthalate-free personal care products with EWG’s Skin Deep Database: www.ewg.org/skindeep/ 5. Perchlorate Perchlorate is the explosive chemical of solid rocket and missile fuel that is produced for and used in rocket fuel, fireworks, ammunition and explosives. The National Resources Defense Council (NRDC) estimates it contaminates the drinking water of more than 20 million Americans.[182] Perchlorate contaminates more than 350 drinking water sources in California alone! Nationally, perchlorate contamination of drinking water has been confirmed by testing in 22 states.[183] Perchlorate contamination of food is also widespread. Perchlorate in our milk and food supply A 2008 Environmental Working Group ( EWG) analysis of FDA data shows that three quarters of 285 commonly consumed foods and beverages are contaminated with perchlorate. That means that every day, the average two-year-old is exposed to more than half of the EPA “safe” dose of perchlorate from food alone. This is especially troubling in the 22 states that also are exposed to perchlorate through contaminated tap water.[184] A 2004 analysis by EWG found that milk from cows raised in some parts of California may expose infants and children to more of a toxic rocket fuel chemical than is considered safe by the U.S. Environmental Protection Agency (EPA). In their study which looked for perchlorate in California supermarket milk, EWG found perchlorate in almost every sample tested: 31 out of 32 samples purchased from grocery stores in Los Angeles and Orange counties. EWG also obtained results of tests for perchlorate in milk by the California Department of Food and Agriculture (CDFA), which found perchlorate in all 32 samples of milk collected from unspecified sources in Alameda, Sacramento, and San Joaquin counties. [185] Our children our most vulnerable to perchlorate exposure EWG’s computer-assisted analysis of federal dietary data shows that by drinking milk contaminated with the levels of perchlorate found in the two studies, 7 percent of women of childbearing age would get a daily dose of rocket fuel larger than the level currently considered safe by the EPA. But children are by far more at risk: Half of all children 1 to 5 would exceed EPA’s provisional daily safe dose just by drinking milk, and more than a third would get twice that dose. One-third of children 6 to 11 would get a larger dose than EPA says is safe, with one-fifth consuming twice as much. These risk estimates assume zero perchlorate exposure from other sources, such as contaminated tap water and foods.[186] Sources of perchlorate Perchlorate occurs both naturally and as a manufactured compound. Natural deposits tend to be of low concentration, except for the high natural perchlorate concentrations found in Chile.[187] Man-made perchlorate sources can be many times more concentrated than most natural sources. Their production and use can lead to releases of perchlorate into the environment. Sites that have been identified with relatively high concentrations of perchlorate contamination involve manufacturing, testing, or disposal of solid rocket propellant; manufacturing of perchlorate compounds; and industrial manufacturing operations where perchlorate compounds were used as reagents. How does perchlorate get into our food? Contamination of perchlorate occurs in the soil and water. Many crop and feed plants, including lettuce, cucumbers, tomatoes and alfalfa, concentrate perchlorate in their tissues when grown with contaminated water. This perchlorate, in turn, can be passed along in cow (or human) milk. A study published in 2009 reported elevated perchlorate levels in powdered infant formula! They also observed that infants given formula reconstituted with perchlorate-contaminated drinking water would be consuming unsafe amounts of the chemical, according to the current EPA standards.[188] What are the health effects of perchlorate exposure? Perchlorate can affect the thyroid gland’s ability to make essential hormones.[189,190] For fetuses, infants and children, disruptions in thyroid hormone levels have been shown to cause lowered IQ, mental retardation, loss of hearing and speech, and motor skill deficits.[191-196] In addition, toddlers are particularly vulnerable because they eat and drink substantial amounts of food and water relative to their small size. Also affected by perchlorate levels are women with low iodine levels , which may account for up to 1/3 of women in the U.S.[197,198] How to Avoid Exposure: You can reduce perchlorate in your drinking water by installing a reverse osmosis filter or buying filtered water. (You can get help finding one at: www.ewg.org/report/ewgs-water-filter-buying-guide ) As for food, it’s almost impossible to avoid perchlorate, but you can reduce exposure by buying organic food, especially milk, and making sure you are getting enough iodine in your diet. Eating iodized salt is one good way. 6. Fire retardants Fire retardants are found in many types of furniture, computers, televisions and other electronics in the home and office. Fire retardants are commonly found in polyurethane foam furniture like couches and upholstered chairs, mattresses and pads, futons and carpet padding and even children’s pajamas. Product studies also find fire retardants in the foam of children’s products including car seats, changing table pads, portable crib mattresses, nap mats, and nursing pillows. Foam products made before 2005 are most hazardous. Older foam items commonly contain PBDEs (polybrominated diphenyl ethers) , a highly toxic fire retardant mixture now removed from the U.S. market. Since 2004 these chemicals have not been manufactured in the U.S. However once PBDEs were withdrawn, other concerning chemicals took their place.[199] How do fire retardants affect health? According to a review published in a scientific journal just a couple months ago: “Plausible outcomes associated with brominated flame retardant (BFR) exposure include diabetes, neurobehavioral and developmental disorders, cancer, reproductive health effects and alteration in thyroid function.”[200] In rodents, repeated exposure to PBDEs results in thyroid hormone disruption, developmental neurotoxicity, some changes of fetal development, and hepatotoxic effects.[201] Very serious health effects are associated with exposure to PBDEs, but toxicity depends on the compound and the amount that one is exposed to. PBDEs are chemically similar to PCBs and, not surprisingly, they show similar health effects as well. They are biomagnified toxic compounds, meaning they accumulate within food chains . Brominated fire retardants are still being studied for health effects but so far have been found to have the following effects in human studies: Thyroid disruption According to an article published in 2005, brominated fire retardants have a striking structural similarity with the thyroid hormones and may constitute a potential health risk by interfering with thyroid hormone homeostasis. The thyroid hormones are essential for normal brain development. Disruption of the hormonal balance may lead to serious and permanent defects of neurological functioning. Brominated flame retardants may interfere with thyroid synthesis, transport, receptor binding, and elimination. The clinical consequences have so far not been firmly established, but results from animal studies suggest that even subtle disturbances of thyroid homeostasis during pregnancy may have serious implications for the developing brain.[202-205] Endocrine disruption Many studies have found some type of endocrine disruption that occurs on exposure to fire retardants. One of the mechanisms that has been identified is that this compound acts as a xenoestrogen in the body as discussed earlier in this article. Xenoestrogens are foreign compounds that mimic estrogen in the body. The potential health impacts of xenoestrogens are still not completely understood.[206-208] Neurobehavioral dysfunction Studies have shown that prenatal exposure to organohalogens, including brominated flame retardants, influences motor, cognitive, and behavioral performance in school-age children. [209, 210] Numerous laboratory studies on mice have shown them to have neurotoxic or neurobehavioral effects[211-213] and in rodents the neurological impacts are more significant if exposure occurs during a specified period of time during neurological development.[214] Reproductive abnormalities Studies have shown an association between fire retardant exposure and reproductive problems such as spontaneous abortion and abnormal uterine tissue and affecting male genitourinary conditions as well.[215-217], Cardiac and metabolic abnormalities Studies have also shown associations with fire retardant exposure and metabolic syndrome in the U.S. and effects on the heart in animal studies.[218, 219] Cancer The International Agency for Research on Cancer (IARC) has determined that PBDEs are possibly carcinogenic to humans.[220] Exposure to PBDEs in breast milk Exposure to PBDEs is nearly impossible to avoid due to their ubiquity in the air, water, food, human fat, and breast milk. The fetus is exposed to the toxins in utero as well as from breast milk, which is where the toxins are transferred from the mother to the baby. A Swedish study published in 2006 found that the concentration of PBDEs in breast milk doubled every five years during the 25-year period that was examined in the study[221] while another showed that higher levels of PBDEs were found in breast milk of women in the U.S. than their European counterparts.[222] How common is exposure to fire retardants? Like PCBs, their long-banned chemical relatives, the brominated fire retardants are persistent in the environment and bioaccumulative , meaning they build up in people’s bodies over a lifetime. There are ubiquitous in our environment, meaning they are found everywhere . As one newspaper writer puts it: “PBDEs: They are everywhere, they accumulate and they spread” .[223] In 2004, the Environmental Working Group (EWG) performed the first nationwide tests for brominated fire retardants in house dust. This study found unexpectedly high levels of these neurotoxic chemicals in every home sampled.[224] EWG’s test results indicate that consumer products, not industrial releases, are the most likely sources of the rapid buildup of PBDEs in people, animals and the environment, which has been documented by tests from Europe to the Arctic. Scientists now recognize that indoor environmental contamination, including contaminants accumulating in household dust, pose a substantial health risk to the population.[225] It is no surprise that American homes are contaminated with PBDEs since these fire retardants are added to thousands of everyday products, including computers, cars, TVs, furniture and clothing. But the EWG study showed the surprising degree to which these chemicals are escaping into the air from consumer products and exposing people, especially children, who continually ingest or inhale dust. How to Avoid Exposure: “Remove old foam (pre-2005) from your home. Clean the dust in your home frequently and regularly, especially if you have infants or children at home.” 7. Lead (previously discussed in last segment) 8. Arsenic (previously discussed in last segment) 9. Mercury (previously discussed in last segment) 10. Perfluorinated chemicals (PFCs) What are PFCs? PFCs are a large group of manufactured compounds that are widely used to make everyday products more resistant to stains, grease, and water. For example, PFCs may be used to keep food from sticking to cookware, to make sofas and carpets resistant to stains, to make clothes and mattresses more waterproof, and may also be used in some food packaging, as well as in some firefighting materials. Because they help reduce friction, they are also used in a variety of other industries, including aerospace, automotive, building and construction, and electronics.[226] PFCs in the environment PFCs break down very slowly in the environment and are considered persistent organic pollutants (POPs) . There is widespread wildlife and human exposure to several PFCs, including perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS). Perfluorochemicals are so widespread and extraordinarily persistent that studies show approximately 99% of Americans have these chemicals in their bodies.[227] Where do they come from? Both PFOA and PFOS are byproducts of other commercial products, meaning they are released into the environment when other products are made, used, or discarded. PFOS is no longer manufactured in the United States, and PFOA production has been reduced and will soon be eliminated. More research is needed to fully understand all sources of human exposure, but people are most likely exposed to these compounds by consuming PFC-contaminated water or food, or by using products that contain PFCs. Are PFCs like other toxins? Unlike many other persistent environmental chemicals, PFCs are not stored in body fat. However, PFCs are similar to other persistent chemicals, because the half-life, or the amount of time it takes for 50% of the chemical to leave the human body, for some of these chemicals, is several years. This slow elimination time makes it difficult to determine how changes in lifestyle, diet, or other exposure-related factors influence blood levels . One particularly notorious compound called PFOA has been shown to be “completely resistant to biodegradation.” In other words, PFOA doesn’t break down in the environment – ever. That means that even though the chemical was banned after decades of use, it will be showing up in people’s bodies for countless generations to come. This is worrisome, since PFOA exposure has been linked to decreased sperm quality, low birth weight, kidney disease, thyroid disease and diabetes, among other health issues.[228] Let’s take a quick look at some of this research on the health effects of exposure to PFCs: Endocrine disruption PFCs are a known endocrine disruptor. Many observational studies suggest that endocrine disruptors contribute to cancer, diabetes, obesity, metabolic syndrome, and infertility.[229] Until recently, most of this data was derived from animal studies but there is growing epidemiologic health data that support associations between adult exposures and outcomes. Recent studies suggest that there are several mechanisms by which PFCs such as PFOA may lead to endocrine disruption.[230] Studies indicate there is disruption in both male and female reproductive physiology. [231] In males, there have been associations with decreased sperm count, semen quality and reproductive hormones. [232] Endocrine disruptors have also been implicated in the development of obesity.[233] Thyroid disruption The thyroid-disrupting effects of PFCs have been documented in many studies, and disruption has been shown to occur with total T3, total T4, and free T4 in the U.S. general population.[234-237] Reduced immune function There is evidence from both epidemiology and laboratory studies that PFCs may be immunotoxic, affecting both cell-mediated and humoral immunity.[238] PFC exposure has also been associated with allergic skin reactions such as atopic dermatitis and pediatric atopy.[239] Multiple organ and tissue effects PFCs can cause adverse effects on multiple organs, including the liver and pancreas and have been shown to cause damage at multiple biological levels including oxidative stress, DNA damage, membrane instability, suppressed filtration rate, and reduced body weight. [240] PFCs have also been associated with osteoarthritis in women.[241] Neurological and neurobehavioral effects PFCs have been shown to be neurotoxic to the brain[242] and cause fetal growth and developmental problems and affect birth outcomes.[243-247] How to Avoid Exposure: Skip non-stick pans as well as stain and water-resistant coatings on clothing, furniture and carpets. Don’t do the Scotchguard®! Stay away from Teflon®, Goretex® or any foreign-sounding names to protect you from stains and water! 11. Organophosphate pesticides “In this century, several hundred billion pounds of pesticides have been produced and released into the global environment. Nearly 5 billion pounds of the insectide DDT alone have been applied both indoors and out since it was introduced in 1939, and DDT is one of nearly 600 pesticides currently registered for use in the world. By 1969, almost 60,000 different products were sold containing some combination of pesticides along with their inert ingredients. As we approach the 21 st century, an additional 5 to 6 billion pounds of insecticides, herbicides, fungicides, rodenticides and other biocides are added to the world’s environment each year, with roughly ¼ of this amount released or sold in the U.S.”[248] Pesticides can be extremely toxic to human health and the environment . U.S. and international government agencies alike have linked pesticides to nervous system toxicity, cancer, hormone system disruption and IQ deficits among children. Studies indicate that children are the most vulnerable to the damaging effects of pesticides. According to one expert on childhood exposure to pesticides: “Children are especially vulnerable to health damage from pesticides. Following conception, a child’s susceptibility changes as organ systems grow and certain functions mature, such as the detoxification potential of the liver or the filtration potential of the kidneys. Children may be especially vulnerable to carcinogens during periods when their cells are normally reproducing most rapidly, generally between conception and age five. They may be more susceptible to loss of brain function if exposed to neurotoxins during critical periods of development.”[249] Neurological effects on children from pesticide exposure Studies show even small amounts of these chemicals add up and can impair a child’s neurological development when they are exposed during the early, critical stages of their development. Numerous studies have been conducted in humans and animals to evaluate the potential effect of myriad exposures, including environmental contaminants, on neurologic development.[250] Neurodevelopmental deficits include a broad spectrum of disorders and dysfunctions such as autism spectrum disorder, attention deficit hyperactivity disorder (ADHD), decreased intelligence, learning disabilities, developmental delays, emotional or behavioral problems, and deficits in gross or fine motor skills. The exact prevalence of these deficits is difficult to ascertain; however, it has been estimated that approximately 3 to 8% of infants and 12% of children are affected by one or more of these conditions.[251] Strong arguments have been made that our government agencies and the science on which policies are based have been insufficient to protect our children against these harmful chemicals.[252] Pregnancy and fetal exposure to pesticides Epidemiological data shows that prenatal exposure to OP pesticides may be associated with an increased risk of pervasive developmental disorders, delays in cognitive development, and attentional deficits. In children, OP exposure has been associated with behavioral problems, poorer short-term memory and motor skills, and longer reaction time.[253] One recent study concluded the following: “These findings support the notion that prenatal exposure to pesticides—at levels not producing adverse health outcomes in the mother—can cause lasting adverse effects on brain development in children. Pesticide exposure therefore may contribute to a “silent pandemic” of developmental neurotoxicity.”[254] Three epidemiological studies published in April, 2011, show a clear link between a mother’s exposure to organophosphate (OP) insecticides during pregnancy and deficits to children’s learning and memory that persist through the ages of 6 to 9. (255) “The risks of dietary exposures to synthetic pesticides, especially organophosphate and pyrethroid insecticides, are greatest during pregnancy and childhood, when the brain and nervous system are most vulnerable. These are two groups that should really avoid eating foods with high levels of pesticide residues.” (256) In an award-winning study published by the journal Environmental Science & Technology in 2009, Payne-Sturges of the EPA’s National Center for Environmental Research analyzed CDC biomonitoring data for organophosphate insecticide exposure in American children. She concluded that two in five American children are exposed to enough organophosphate pesticides to exceed safe amounts! [257] In May 2010, a team led by Maryse F. Bouchard of the Harvard School of Public Health analyzed the same biomonitoring data and found that the children with elevated organophosphate exposure were more likely to be diagnosed with attention deficit-hyperactive disorder.[258] Several studies have also shown that agricultural workers have substantially greater opportunity for pesticide exposure than the population at large.[259-262] “Pesticides, while designed specifically to kill certain organisms, are also associated with a host of very serious health problems in people, including neurological deficits, ADHD, endocrine system disruption and cancer. My advice to consumers is to whenever possible avoid exposure to pesticides, including pesticide residues on food .” –Andrew Weil, MD, Founder and Director, Arizona Center for Integrative Medicine[263] How to Avoid Exposure: Buy organic produce. Consumers can markedly reduce their intake of pesticide residues and their exposure to antibiotic-resistant bacteria by choosing organic produce and meat, according to researchers at Stanford University who reviewed a massive body of scientific studies on the much-debated issue.[264] “Consumers selecting organic produce ingest fewer pesticides. They also eat meats that harbor fewer deadly bacteria. While you still need to take responsibility for eating a varied and healthy diet, you can rest assured that organic food provides a healthier choice for people and the planet.”[265] Use EWG’s Shopper’s Guide to Pesticides in Produce, which can help you find the fruits and vegetables that have the fewest pesticide residues at: www.ewg.org/foodnews/ 12. Glycol Ethers Glycol ethers (GE) are a family of solvents, the use of which has increased dramatically since the 1960’s, in domestic and occupational settings and persist mainly in water-based products, such as paints, inks, varnishes and cleaning agents. There are two subgroups: E series and P series. EGME, among the E series, is the reference substance for most studies. Human and animal studies have shown that glycol ethers can cause adverse reproductive, developmental, and hematological effects through inhalation, dermal absorption, and ingestion. The reproductive organs, nervous system, blood and blood-forming organs are the primary organs affected in acute and chronic intoxications of glycol ethers.[266] Congenital birth defects Studies in multiple countries show that glycol ethers act as human teratogens (substances that cause birth defects) when fetuses are exposed to these chemicals in utero.[267-269] Fertility and reproductive health Glycol ethers are a reprotoxic (toxic to the reproductive system) chemical causing infertility and genital atrophy on both sexes (shrinks the testicles and ovaries) and embryofetal toxicity through maternal exposure (malformation, growth alterations and functional deficits).[270-275] Studies show that glycol ether exposure is related to low motile sperm count in men.[276, 277] Female workers exposed to ethylene glycol in the semiconductor manufacturing industry have been shown to have prolonged menstrual cycles, inhibition of ovulation and prolonged time to pregnancy.[278-281] Hematological effects Studies show that glycol ethers are a hematological toxin in rat studies and leads to anemia in workers exposed to this toxic compound.[282-284] Neurologic effects Overexposure to propylene glycol monomethyl ether (PGME) has been associated with increases in central nervous system depression in rat toxicology studies.[285] It is known that ethylene glycol ethers (EGEs) cross the blood-brain barrier and acute intoxication with these compounds causes disturbances of motor coordination, headaches, permanent cognitive dysfunction, central nervous system (CNS) depression and occasionally convulsions in humans [286]. A recent rat study found that 4-week administration of a mixture of two ethylene glycol ethers (EGEs) decreased total antioxidant capacity and enhanced lipid peroxidation (oxidation of lipids) in the frontal cortex and hippocampus of the rats. These are the same mechanisms involved in neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. The study concluded: “The obtained results suggested that EGEs exerted adverse effects on the central nervous system (CNS) cells and may contribute in pathogenesis of neurodegenerative disorders.”[287] How to Avoid Exposure: Start by checking out EWG’s Guide to Healthy Cleaning ( www.ewg.org/guides/cleaners/ ) and avoid products with ingredients such as 2-butoxyethanol (EGBE) and methoxydiglycol (DEGME). 4 Other Notable Environmental Chemicals that You Should Avoid 1. Perchloroethylene/ Tetrachlorethylene (PERC) Perchloroethylene , also known as tetrachloroethylene , PCE , or PERC , is a chlorinated solvent long used in dry cleaning, industrial cleaning and production of other chemicals and consumer products. Biomonitoring surveys have detected it in the bodies of a significant number of Americans. It has been found in drinking water across the country. The federal Environmental Protection Agency has declared tetrachloroethylene, or PERC, a chemical used by many dry cleaners, a “likely human carcinogen.”[288] Dry cleaners use dangerous chemical solvents that can stick to clothing. Most cleaners in the U.S. still use PERC as a solvent for dry cleaning. A recent study by scientists at Georgetown University, published in 2011, in the journal Environmental Toxicology and Chemistry , found high levels of residual PERC on dry-cleaned wool, cotton and polyester (what do you have on now?). Subsequent dry cleaning cycles intensified these concentrations.[289] When inhaled, even low concentrations of PERC are known to cause respiratory and eye irritation, headache, dizziness and vision problems. Once in the environment, the chemical breaks down into other known human carcinogens, including trichloroethylene (TCE) and vinyl chloride . Health effects of PERCs Based on toxicology, metabolism, animal studies, and human studies, occupational exposure to chlorinated aliphatic solvents (PERCs) has been associated with numerous adverse health effects, including central nervous system, reproductive, liver, and kidney toxicity, and carcinogenicity (initiation of cancer).[290] Cancer Human exposure to PERCs can produce various types of cancer, including esophageal cancer, cervical cancer, non-Hodgkin’s lymphoma, urinary bladder cancer, kidney cancer, leukemia and multiple myeloma (bone marrow cancer).[291-295] Neurotoxicity and mental illness PERC exposure has been found to be toxic to the brain and nervous system and lead to neurobehavioral problems.[296, 297] Studies have also linked prenatal and early childhood exposure to PERC-contaminated drinking water to mental illness, including bipolar disorder and PTSD.[298] Birth defects A 2009 study also linked exposure to PERC-contaminated drinking water to birth defects.[299] How to Avoid Exposure: Ask your cleaners what solvents they use. Watch out for perchloroethylene under any of its names (PERC, PCE, tetrachloroethylene), siloxane and hydrocarbon solvents. Patronize cleaners that use liquid carbon dioxide or the wet-cleaning method. Tetrachloroethylene can remain on clothes and evaporate into the air at home, unnecessarily exposing you and your family. Don’t leave dry cleaned items in the car for a long time because PERC vapors can build up inside the vehicle. Air dry cleaned clothes outdoors.[300] 2. Formaldehyde Formaldehyde is used in a vast array of industrial and consumer products, and there is widespread agreement that consumer exposures must be reduced to protect health.[301] It exists all around us in our homes, office buildings and automobiles and newer construction and material means increased exposure. According to ICIS, an international chemical market research firm , nearly two-thirds of the formaldehyde market is for resins to make construction materials such as plywood, particle board, fiber board, laminate flooring, carpeting , foam underlays, insulation and for vehicle coatings and brake linings. Other major uses include plastics for electronic, automotive and consumer goods, polyurethane foam, and adhesives and sealants for construction and consumer goods, including children’s toys. It is also used as the wet-strength resin added to paper products such as facial tissue, table napkins, and paper towels. Formaldehyde is also a precursor to polyfunctional alcohols which are used to make paints and explosives . The textile industry uses formaldehyde-based resins as finishers to make fabrics crease-resistant.[302a] Formaldehyde-based materials are key to the manufacture of automobiles, and used to make components for the transmission, electrical system, engine block, door panels, axles and brake shoes. There are also compounds known as “ formaldehyde releasers” found in cosmetics and personal care products such as shampoos and conditioners which are known to release formaldehyde into these products, even those intended for children.[302b] The value of sales of formaldehyde and derivative products was over $145 billion in 2003, about 1.2% of the gross domestic product (GDP) of the United States and Canada. Including indirect employment, over 4 million people work in the formaldehyde industry across approximately 11,900 plants in the U.S. and Canada.[303] Health Effects of Formaldehyde Exposure Acute (short-term) and chronic (long-term) exposures have been shown to cause respiratory symptoms and irritation to the skin, eyes, nose, throat and respiratory tract. Human studies have suggested an association between formaldehyde exposure and various cancers, including lung and nasopharyngeal cancer.[304] In 2011, the U.S. National Toxicology Program described formaldehyde as “ known to be a human carcinogen “.[305] But it has also been shown to be toxic to the brain and nervous system, white blood cells (immune system), the lungs, the reproductive system and human DNA.[306] Let’s take a closer look at the various health effects linked to formaldehyde exposure: Effects Due to Acute Exposure Formaldehyde is known to induce acute poisoning and cause irritation, as well as other immunotoxic effects. It is a highly reactive chemical that readily reacts with biological tissues, particularly the mucous tissues lining the respiratory tract and the eyes.[307,308] Acute mucus membrane irritation is the most common adverse effect of formaldehyde exposure, often leading to dry skin, dermatitis, tearing eyes, sneezing, and coughing.[309-312] Skin sensitization and dermal allergic reactions following dermal exposure to formaldehyde has been well documented.[313-318] Short exposures to high level formaldehyde are identified to cause a sudden onset of asthmatic symptoms called reactive airways dysfunction syndrome (RADS) .[319-321] It was reported that the likelihood for the development of allergic asthma increases proportionately with level of indoor formaldehyde concentration, especially when levels exceed 0.08 ppm.[321-327] Effects Due to Chronic Exposure Upper and Lower Respiratory Tract Toxicity Long-term exposure to elevated levels of formaldehyde, especially in the occupational setting, has been designated as the cause of irritation and pain such as upper and lower airway irritation, eye irritation, degenerative diseases, coughing, wheezing, body sores, chest pain, abdominal pain, and loss of appetite.[328-329] Long-term occupational formaldehyde exposure is also reported to be responsible for such chronic health effects as inflammatory and hyperplastic changes of the nasal mucosa, pharyngeal congestion, chronic pharyngitis, chronic rhinitis and loss of olfactory (sense of smell) function.[330-334] Neurotoxicity Chronic exposure to formaldehyde can be responsible for the symptoms of neurasthenia which include headaches, dizziness, sleep disorders, and memory loss. Many reports indicate that chronic exposure to formaldehyde increased the chances of headache and dizziness by 30%–60%.[335-337] Formaldehyde appears to have neurotoxic characteristics with systemic toxic effects. It is thus hypothesized that inhalation of formaldehyde, during the early postnatal period, can cause some neurological diseases with aging.[338] It was also recognized that apart from age and gender, environmental tobacco smoking (ETS) is perhaps the most consistent nongenetic risk factor for amyotrophic lateral sclerosis (ALS).[339, 340] (Recall that formaldehyde is an ingredient of tobacco.) ALS is a fatal, neurodegenerative disease caused by the degeneration of motor neurons system that controls voluntary muscle movement. In an investigation conducted by the American Cancer Society’s Cancer Prevention Study II, more than 1 million individuals were examined over time. Based on this study, it was concluded that individuals who reported formaldehyde exposure in the workplace (e.g., beauticians, pharmacists, morticians, chemists, laboratory technicians, physicians, veterinarians, dentists, firefighters, photographers, printers, and nurses) had a 34% higher rate of ALS than the non-exposure group.[341] Pulmonary Function Damage In repetitive human exposure under occupational (or residential) conditions, formaldehyde has led to symptoms associated with irritation of the upper-respiratory tract and decreased pulmonary function.[342-347] Hematotoxicity Hematotoxicity is defined as toxicity to the blood and hematopoietic (blood-forming) system caused by chemical exposure , often resulting in decreased blood cell counts. It was demonstrated that long-term exposure of formaldehyde can decrease the number of white blood cells (an important part of your immune system).[348-350] A report by Huang et al. revealed that a previously healthy woman experienced lower than normal counts of white blood cells, red blood cells, platelet, and hemoglobin, just after 3 months of moving into a newly remodeled apartment.[351, 352] Reproductive Toxicity The potential role of formaldehyde as a teratogen (substance that causes birth defects) and its impacts on human reproduction are still a matter of scientific controversy. Until recently, very limited research has been conducted to specifically address such aspects of formaldehyde. However, a few studies found menstrual disorder and dysmenorrhea in women who were occupationally exposed to formaldehyde.[354, 355] In a case-control study, a significant association between spontaneous abortion and formaldehyde exposure was found in Finnish women who worked in pathology or histology laboratories for more than 3 days per week.[356] Another study focusing on female wood workers reported significantly decreased frequency of pregnancies in women exposed to high formaldehyde levels.[357] Genotoxicity (Toxicity to the DNA) It was reported that formaldehyde exposure can induce DNA and chromosomal damage in human peripheral blood cells.[358, 359] A line of evidence indicated that formaldehyde is capable of directly reacting with DNA and producing genotoxic effects on portal-of-entry tissues, especially after exceeding liver biotransformation capacities.[360, 361] Chinese workers exposed to formaldehyde showed an increase in DNA damage in peripheral lymphocytes, when measured by single cell gel electrophoresis.[362-367] Carcinogenesis Based on comprehensive research and large-scale human studies conducted internationally, the International Agency for Research on Cancer (IARC) classified formaldehyde as a human carcinogen that can cause nasopharyngeal cancer.[368] According to this classification, formaldehyde is “a probable human carcinogen” under conditions of unusually high or prolonged exposure.[369] The U.S. National Toxicology Program (NTP) reported formaldehyde as a “known human carcinogen” in its 12th Report on Carcinogens.[370] There is sufficient evidence for a linkage between formaldehyde exposure and nasopharyngeal cancer, nasal and paranasal cancer, and leukemias.[371-373] Increased incidences of leukemia have also been reported in several occupational epidemiologic studies.[374-375] How to Avoid Exposure: You cannot avoid formaldehyde exposure completely but there are some steps you can take to avoid unnecessary exposure through products such as cosmetics and skin products. Check the label carefully, both for the ingredient formaldehyde itself and for the seven common “formaldehyde releasers” listed on the following EWG website: http://www.ewg.org/research/exposing-cosmetics-cover/formaldehyde-releasers Or let EWG do the research for you. Check out the products in EWG’s Skin Deep Cosmetics Database ( http://www.ewg.org/skindeep/ ). It contains information on more than 77,000 products and their ingredients. This database highlights toxic substances like formaldehyde — and those insidious formaldehyde releasers. 3. Parabens Parabens are a group of artificial preservatives commonly found in many different cosmetics and body care products which have been in use since the 1920s. Parabens are used to prevent the growth of bacteria and mold in cosmetic products, increasing its shelf life. Studies suggest parabens can cause skin disorders and allergic reactions and act as endocrine disruptors in the human body and have been linked to breast cancer.[376] In 2006, the Centers for Disease Control (CDC) tested urine samples from a group of 100 adults and found parabens in nearly all samples.[377] Cosmetics typically contain mixtures of parabens. Five different parabens are fairly common in cosmetics: methyl-, ethyl-, propyl-, isopropyl-, and butylparaben (measured in combination with isobutylparaben); benzylparaben is less common.[378] How are we exposed to parabens? Parabens are present in a wide variety of cosmetics and body care products, including moisturizers, face and skin cleansers, shampoos, conditioners, sunscreens, deodorants and antiperspirants, shaving gels, toothpastes, makeup, and many others. They are commonly used in sunscreens, in particular. They are also used as preservatives in food and beverages, and in some medications. Daily use of body care products can result in repeated, direct exposure to parabens. Parabens have also been detected in household dust.[379] What are the potential health effects of paraben exposure? Studies show that parabens can cause skin disorders and allergic reactions, act as endocrine disruptors in the human body in both males and females, are toxic to human DNA and have been linked to breast cancer.[380, 381] Let’s take a closer look at this research: Skin and allergic reactions Parabens have been shown to irritate the skin, causing atopic dermatitis and allergic skin reactions.[382-386] Endocrine disruption A wide range of in vitro and in vivo laboratory studies indicate that parabens are estrogenic, meaning they can mimic the hormone estrogen, and act as endocrine disruptors, disrupting normal function of the hormone system.[387-395] A recent study by scientists at the Harvard School of Public Health linked one type of paraben to impaired fertility in women.[396] A study published just this month showed that parabens cross the placenta and enter the fetal circulation of pregnant mothers.[397] Breast cancer There is growing concern in the scientific literature that paraben exposure can increase breast cancer risk.[398-402] In a 2004 study, traces of 5 different parabens were found in the breast cancer tumors of 19 of 20 women examined with methylbarapen (commonly found in sunscreens, deodorants and cosmetics) representing 62% of the total paraben recovered in the extractions.[403] More recent lab studies have since shown that parabens increase proliferation of breast cancer cells.[404-407] A recent study published only two months ago showed that in vitro, parabens can influence not only proliferation but also migratory and invasive properties of human breast cancer cells.[408] Have these chemicals been regulated? The European Union banned use of sodium methylparaben in fragrance because it can strip skin of pigment (SCCPNFP 1999, 2000). While FDA limits the levels of parabens allowed in foods and beverages, it does not regulate these chemicals in cosmetics and body care products.[409] How to Avoid Exposure: Because parabens are found in many everyday products, some exposure may be unavoidable. One way to reduce exposure is to switch to paraben-free cosmetics and body care products. Johnson & Johnson agreed to stop using most parabens in 2012, but they can still be found in numerous cosmetics. Read the labels carefully to spot products that contain parabens, especially the long-chained varieties—propylparaben, isopropylparaben, butylparaben and isobutylparaben.[410] 4. Triclosan Triclosan is an artificial antimicrobial chemical used to kill bacteria on the skin and other surfaces. It is used in a variety of cosmetics and everyday products. Triclosan is the most common active ingredient in “antibacterial” liquid hand soaps, and is also found in toothpastes, deodorants, face and body washes, and acne treatments, among others. Besides cosmetics, triclosan is found in an increasing number of everyday items, such as dishwashing detergent, kitchen tools, toys, trash bags, bedding, bathmats, socks, and footwear.[411] However, a scientific advisory panel to the U.S. Food and Drug Administration (FDA) determined that “antibacterial” soaps, like those containing triclosan, were no better than regular soap and water at killing germs or reducing the spread of infection.[412] The American Medical Association recommends that triclosan and other “antibacterial” products not be used in the home, as they may promote antibiotic resistance in bacteria, because while repeated use kills most bacteria, this can allow resistant strains to flourish.[413] How common is triclosan exposure? Widespread use has led to detection of triclosan in the breast milk, blood, and urine of ordinary people.[414-419] It was found in the urine of 61 percent of 90 girls ages 6 to 8 tested in a 2007 study by Mount Sinai School of Medicine.[420] Urine samples of triclosan have recently been shown to be reliable indicators of exposure.[421] In 2002, scientists found triclosan in 58 percent of 85 streams across the U.S.[422], most likely from discharges of treated wastewater. The amount of triclosan in the wastewater stream is estimated to be as much as 3 to 5 milligrams per person per day from residences alone [423]; in addition, substantial discharges of this antimicrobial agent are expected from laundries, hair salons, medical facilities, and many other commercial and industrial sites. Optimal water treatment can result in degradation and removal of 95 percent of triclosan [424]; however, small amounts may pass through the treatment plants to receiving waters.[425] Triclosan also has been found to contaminate household dust.[426] CDC’s national survey indicates that triclosan contaminates the bodies of 75% of the American population.[427] What are the potential health effects of triclosan exposure? Although the majority of triclosan is eliminated from the blood through the urine, triclosan can accumulate in the liver and fatty tissue and build up in the bodies of people and animals over time. However, it does not have the same potential to accumulate as bisphenyl A.[428] Triclosan has been identified as an endocrine disruptor, therefore, it has the potential to affect the function of numerous organs, such as the thyroid and reproductive organs. It has been associated with dysfunction of the following endocrine organs: Thyroid Human and animal studies have found evidence that exposure to triclosan leads to decreased levels of total triiodothyonine (T3) and thyroxine (T4).[429-434] T3 and T4 are the thyroid hormones used to stimulate the thyroid receptors of all the cells of the body to drive all metabolic processes. Thyroid hormones are critical for normal growth and development of humans and animals; the developing brain of a child is particularly vulnerable to damage caused by disruption of the thyroid system. Studies have shown abnormal development of offspring of animals exposed to triclosan.[435-439] Endocrine disruption and breast cancer Triclosan may also disrupt other critical hormone systems. Recent evidence from various animal studies suggests that triclosan may have previously unrecognized endocrine disrupting properties. Research has predominantly suggested impacts to the reproductive system.[440-446] A 2008 lab study found triclosan to exert both estrogenic and androgenic effects on human breast cancer cells. [447] Immunosuppressive Effects Human natural killer (NK) cells are a first line immune defense against tumor cells and virally infected cells. If their function is impaired, it leaves an individual more susceptible to cancer development or viral infection. The ability of environmental compounds, such as triclosan, to suppress the function of NK cells could contribute to increased risk of cancer development. A 2011 lab study found that triclosan diminished the function of human NK cells’ ability to lyse (kill) cancer cells by 87%![448] A recent review reported that studies support an increase in peanut allergy prevalence in children and exposure to triclosan and having certain genetic mutations associated with food sensitization![449] Cancer Recent evidence suggests that triclosan exposure may alter cancer risk, although human studies are lacking in both number and scope.[450] Three studies have investigated triclosan’s estrogenic action in cultured cancer cells suggesting that triclosan may induce proliferation but also inhibit cell proliferation in the presence of estradiol.[451-453] One of these studies added confirmation that triclosan is intrinsically estrogenic at concentrations consistent with those detected in humans.[454] Triclosan’s actions are similar to other xenoestrogens such as bisphenol A, parabens, and polychlorinated biphenyls in that it is able to bind to estrogen receptors and induce proliferation in cultured estrogen-sensitive breast cancer cells.[455,456] However, whether triclosan raises or lowers risk of cancer through estrogen-related pathways, and possible effect modification by estradiol, have not been examined in human studies. Animal studies of triclosan exposure and cancer development have included long-term studies of its carcinogenicity but observed no increase in carcinogenesis.[457] However, one study did observe the appearance of liver tumors in mice following 18 m onths of exposure to 0–200 mg/kg/day triclosan in diet.[458] Overall, however, the results of animal studies to date have been mixed, showing null, inverse, and positive associations.[459] Recent research shows that triclosan in tap water can react with residual chlorine from standard water disinfecting procedures to form a variety of chlorinated byproducts at low levels, including chloroform, a suspected human carcinogen.[460] A study published in 2007 illustrated that, under some circumstances, triclosan triggered the production of chloroform in amounts up to 40% higher than background levels in chlorine-treated tap water.[461] Triclosan has also been shown to degrade into a form of dioxin, a class of chemicals linked to a broad range of toxicities including cancer.[462] How is Triclosan regulated? Triclosan is regulated by FDA when used in cosmetics and for medical applications, by the U.S. Environmental Protection Agency (EPA) when used as an antibacterial pesticide (in products that make “antibacterial” claims), and by the Consumer Product Safety Commission (CPSC) when used in ordinary consumer products that do not make specific “antibacterial” claims. Current regulations do not take into account concerns regarding hormone disruption or formation of toxic byproducts, nor do they fully account for the potential for multiple exposures through the broad variety of triclosan-treated everyday products.[463] How to Avoid Exposure: Switch to triclosan-free soaps, cosmetics and body care products. Avoid body care products, especially liquid hand soaps, labeled “antibacterial,” and always check the list of ingredients. If you use a skin disinfectant, use an alcohol hand rub or rinse. Avoid “antibacterial” dishwashing detergents, cleaning products, and other items – there is no evidence that these products protect your health. Triclosan is approved for use in over 140 different types of products, and most of these are not required to have ingredient labels. Vague claims such as “protection against mold,” “odor-fighting” or “keeps food fresher, longer,” may also indicate the presence of triclosan. Because triclosan is found in many everyday products, some exposure may be unavoidable. [464] References 1. http://www.ewg.org/research/dirty-dozen-list-endocrine-disruptors 2. Ehrlich S, Calafat AM, Humblet O, Smith T, Hauser R. Handling of thermal receipts as a source of exposure to bisphenol A. JAMA . 2014 Feb 26;311(8):859-60. doi: 10.1001/jama.2013.283735. 3. http://www.niehs.nih.gov/health/assets/docs_a_e/bisphenol-a-factsheet.pdf 4. Laura N. Vandenberg, Ibrahim Chahoud, Jerrold J. Heindel, Vasantha Padmanabhan, Francisco J.R. Paumgartten, Gilbert Schoenfelder. Urinary, Circulating, and Tissue Biomonitoring Studies Indicate Widespread Exposure to Bisphenol A . Environ Health Perspect . 2010 August; 118(8): 1055–1070. Published online 2010 March 24. doi: 10.1289/ehp.0901716 5. http://www.ewg.org/research/timeline-bpa-invention-phase-out 6. http://www.ewg.org/research/timeline-bpa-invention-phase-out 7. Rochester JR. Bisphenol A and human health: a review of the literature. Reprod Toxicol . 2013 Dec;42:132-55. doi: 10.1016/j.reprotox.2013.08.008. Epub 2013 Aug 30. 8. Lazúrová Z, Lazúrová I. [The environmental estrogen bisphenol A and its effects on the human organism]. Vnitr Lek. 2013 Jun;59(6):466-71. Czech. 9. Kang HJ, Hong YB, Yi YW, Cho CH, Wang A, Bae I. Correlations between BRCA1 defect and environmental factors in the risk of breast cancer. J Toxicol Sci. 2013;38(3):355-61. 10. Fernandez SV, Huang Y, Snider KE, Zhou Y, Pogash TJ, Russo J. Expression and DNA methylation changes in human breast epithelial cells after bisphenol A exposure. Int J Oncol . 2012 Jul;41(1):369-77. doi: 10.3892/ijo.2012. 1444. Epub 2012 Apr 20. 11. Sprague BL, Trentham-Dietz A, Hedman CJ, Wang J, Hemming JD, Hampton JM, Buist DS, Aiello Bowles EJ, Sisney GS, Burnside ES. Circulating serum xenoestrogens and mammographic breast density. Breast Cancer Res. 2013 May 27;15(3):R45. [Epub ahead of print] 12. Kristen Weber Lozada, Ruth A. Keri. Bisphenol A Increases Mammary Cancer Risk in Two Distinct Mouse Models of Breast Cancer . Biol Reprod. 2011 September; 85(3): 490–497. Published online 2011 June 2. doi: 10.1095/biolreprod.110.090431 13. Bhan A, Hussain I, Ansari KI, Bobzean SA, Perrotti LI, Mandal SS. Bisphenol-A and diethylstilbestrol exposure induces the expression of breast cancer associated long noncoding RNA HOTAIR in vitro and in vivo. J Steroid Biochem Mol Biol . 2014 Feb 14. pii: S0960-0760(14)00031-4. doi:10.1016/j.jsbmb.2014.02.002. [Epub ahead of print] Carcinogenesis. 2011 Nov;32(11):1724-33. doi: 10.1093/carcin/bgr196. Epub 2011 Sep 1. 14. Soto AM, Sonnenschein C. Environmental causes of cancer: endocrine disruptors as carcinogens. Nat Rev Endocrinol. 2010 Jul;6(7):363-70. doi: 10.1038/nrendo.2010.87. Epub 2010 May 25. Review. 15. Tarapore P, Ying J, Ouyang B, Burke B, Bracken B, Ho SM. Exposure to bisphenol a correlates with early-onset prostate cancer and promotes centrosome amplification and anchorage-independent growth in vitro. PLoS One. 2014 Mar 3;9(3):e90332. doi: 10.1371/journal.pone.0090332. eCollection 2014. 16. Prins GS, Hu WY, Shi GB, Hu DP, Majumdar S, Li G, Huang K, Nelles JL, Ho SM, Walker CL, Kajdacsy-Balla A, van Breemen RB. Bisphenol A promotes human prostate stem-progenitor cell self-renewal and increases in vivo carcinogenesis in human prostate epithelium. Endocrinology . 2014 Mar;155(3):805-17. doi: 10.1210/en.2013-1955. Epub 2014 Jan 1. 17. Prins GS, Birch L, Tang WY, Ho SM. Developmental estrogen exposures predispose to prostate carcinogenesis with aging. Reprod Toxicol . 2007;23:374–382. 18. Bosland MC, et al. Multistage prostate carcinogenesis: the role of hormones. Princess Takamatsu Symp . 1991;22:109–123. 19. Skakkebaek NE, Rajpert-De Meyts E, Main KM. Testicular dysgenesis syndrome: an increasingly common developmental disorder with environmental aspects. Hum Reprod . 2001;16:972–978. 20. Hardell L, Bavel B, Lindstrom G, Eriksson M, Carlberg M. In utero exposure to persistent organic pollutants in relation to testicular cancer risk. Int J Androl . 2006;29:228–234. 21. Rezg R, El-Fazaa S, Gharbi N, Mornagui B. Bisphenol A and human chronic diseases: Current evidences, possible mechanisms, and future perspectives. Environ Int. 2014 Mar;64C:83-90. doi: 10.1016/j.envint.2013.12.007. Epub 2013 Dec 29. Review. 22. Valvi D, Casas M, Mendez MA, Ballesteros-Gómez A, Luque N, Rubio S, Sunyer J, Vrijheid M. Prenatal bisphenol a urine concentrations and early rapid growth and overweight risk in the offspring. Epidemiology . 2013 Nov;24(6):791-9. doi: 10.1097/EDE.0b013e3182a67822. 23. Eng DS, Lee JM, Gebremariam A, Meeker JD, Peterson K, Padmanabhan V. Bisphenol A and chronic disease risk factors in US children. Pediatrics . 2013 Sep;132(3):e637-45. doi: 10.1542/peds.2013-0106. Epub 2013 Aug 19. 24. Lazúrová Z, Lazúrová I. [The environmental estrogen bisphenol A and its effects on the human organism]. Vnitr Lek. 2013 Jun;59(6):466-71. Czech. 25. Bhandari R, Xiao J, Shankar A. Urinary bisphenol A and obesity in U.S. children. Am J Epidemiol . 2013 Jun 1;177(11):1263-70. doi: 10.1093/aje/kws391. Epub 2013 Apr 4. 26. Fenichel P, Chevalier N, Brucker-Davis F. Bisphenol A : an endocrine and metabolic disruptor. Ann Endocrinol (Paris) . 2013 Jul;74(3):211-20. doi: 10.1016/j.ando.2013.04.002. Epub 2013 Jun 21. 27. Chen M, Zhou K, Chen X, Qiao S, Hu Y, Xu B, Xu B, Han X, Tang R, Mao Z, Dong C, Wu D, Wang Y, Wang S, Zhou Z, Xia Y, Wang X. Metabolomic Analysis Reveals Metabolic Changes Caused by Bisphenol A in Rats. Toxicol Sci . 2014 Feb 20. [Epub ahead of print] 28. Frederick S. vom Saal, Susan C. Nagel, Benjamin L. Coe, Brittany M. Angle, Julia A. Taylor. The Estrogenic Endocrine Disrupting Chemical Bisphenol A (BPA) And Obesity . Mol Cell Endocrinol. Author manuscript; available in PMC 2013 May 6. Published in final edited form as: Mol Cell Endocrinol. 2012 May 6; 354(1-2): 74–84. 29. Monica K. Silver, Marie S. O’Neill, MaryFran R. Sowers, Sung Kyun Park. Urinary Bisphenol A and Type-2 Diabetes in U.S. Adults: Data from NHANES 2003-2008 . PLoS One. 2011; 6(10): e26868. Published online 2011 October 26. doi: 10.1371/journal.pone.0026868 30. Khalil N, Ebert JR, Wang L, Belcher S, Lee M, Czerwinski SA, Kannan K. Bisphenol A and cardiometabolic risk factors in obese children. Sci Total Environ . 2014 Feb 1;470-471:726-32. doi: 10.1016/j.scitotenv.2013.09.088. Epub 2013 Oct 30. 31. Kim MJ, Moon MK, Kang GH, Lee KJ, Choi SH, Lim S, Oh BC, Park DJ, Park KS, Jang HC, Park YJ. Chronic Exposure to Bisphenol A can Accelerate Atherosclerosis in High-Fat-Fed Apolipoprotein E Knockout Mice. Cardiovasc Toxicol. 2013 Nov 14. [Epub ahead of print] 32. Zeliger HI. Lipophilic chemical exposure as a cause of cardiovascular disease. Interdiscip Toxicol . 2013 Jun;6(2):55-62. Review. 33. Melzer D, Rice NE, Lewis C, Henley WE, Galloway TS. Association of urinary bisphenol A concentration with heart disease: evidence from NHANES 2003/06. PLoS One . 2010 Jan 13;5(1):e8673. doi: 10.1371/journal.pone.0008673. 34. Melzer D, Osborne NJ, Henley WE, Cipelli R, Young A, Money C, McCormack P, Luben R, Khaw KT, Wareham NJ, Galloway TS. Urinary bisphenol A concentration and risk of future coronary artery disease in apparently healthy men and women. Circulation . 2012 Mar 27;125(12):1482-90. doi: 10.1161/ CIRCULATIONAHA.111.069153. Epub 2012 Feb 21. 35. Yıldız N, Barlas N. Hepatic and renal functions in growing male rats after bisphenol A and octylphenol exposure. Hum Exp Toxicol . 2013 Jul;32(7):675-86. doi: 10.1177/0960327112464796. 36. Jayashree S, Indumathi D, Akilavalli N, Sathish S, Selvaraj J, Balasubramanian K. Effect of Bisphenol-A on insulin signal transduction and glucose oxidation in liver of adult male albino rat. Environ Toxicol Pharmacol . 2013 Mar;35(2):300-10. doi: 10.1016/j.etap.2012.12.016. Epub 2013 Jan 11. 37. Hassan ZK, Elobeid MA, Virk P, Omer SA, ElAmin M, Daghestani MH, AlOlayan EM. Bisphenol A induces hepatotoxicity through oxidative stress in rat model. Oxid Med Cell Longev . 2012;2012:194829. doi: 10.1155/2012/194829. Epub 2012 Jul 24. 38. Moon MK, Kim MJ, Jung IK, Koo YD, Ann HY, Lee KJ, Kim SH, Yoon YC, Cho BJ, Park KS, Jang HC, Park YJ. Bisphenol A impairs mitochondrial function in the liver at doses below the no observed adverse effect level. J Korean Med Sci . 2012 Jun;27(6):644-52. doi: 10.3346/jkms.2012.27.6.644. Epub 2012 May 26. 39. Castro B, Sánchez P, Torres JM, Preda O, del Moral RG, Ortega E. Bisphenol A exposure during adulthood alters expression of aromatase and 5α-reductase isozymes in rat prostate. PLoS One. 2013;8(2):e55905. doi: 10.1371/journal.pone.0055905. Epub 2013 Feb 6. 40. Timms BG, et al. Estrogenic chemicals in plastic and oral contraceptives disrupt development of the fetal mouse prostate and urethra. Proc Natl Acad Sci USA. 2005;102:7014–7019. 41. Timms BG, Peterson RE, vom Saal FS. 2,3,7,8-Tetrachlorodibenzo-p-dioxin interacts with endogenous estradiol to disrupt prostate gland morphogenesis in male rat fetuses. Toxicol Sci. 2002;67:264–274. 42. Huang L, Pu Y, Alam S, Birch L, Prins GS. Estrogenic regulation of signaling pathways and homeobox genes during rat prostate development. J Androl . 2004;25:330–337. 43. Dobrzyńska MM, Jankowska-Steifer EA, Tyrkiel EJ, Gajowik A, Radzikowska J, Pachocki KA. Comparison of the effects of bisphenol A alone and in a combination with X-irradiation on sperm count and quality in male adult and pubescent mice. Environ Toxicol . 2013 Apr 25. doi: 10.1002/tox.21861. [Epub ahead of print] 44. Qiu LL, Wang X, Zhang XH, Zhang Z, Gu J, Liu L, Wang Y, Wang X, Wang SL. Decreased androgen receptor expression may contribute to spermatogenesis failure in rats exposed to low concentration of bisphenol A. Toxicol Lett. 2013 May 23;219(2):116-24. doi: 10.1016/j.toxlet.2013.03.011. Epub 2013 Mar 22. 45. Meeker JD, Ehrlich S, Toth TL, Wright DL, Calafat AM, Trisini AT, Ye X, Hauser R. Semen quality and sperm DNA damage in relation to urinary bisphenol A among men from an infertility clinic. Reprod Toxicol. 2010 Dec;30(4):532-9. doi: 10.1016/j.reprotox.2010.07.005. Epub 2010 Jul 23. 46. Rutkowska A, Rachoń D. Bisphenol A (BPA) and its potential role in the pathogenesis of the polycystic ovary syndrome (PCOS). Gynecol Endocrinol . 2014 Jan 7. [Epub ahead of print] 47. Richter CA, Birnbaum LS, Farabollini F, Newbold RR, Rubin BS, Talsness CE, Vandenbergh JG, Walser-Kuntz DR, Vom Saal FS. In vivo effects of bisphenol A in laboratory rodent studies. Reprod Toxicol 2007; 24: 199–224..224. 48. Vandenberg LN, Maffini MV, Sonnenschein C, Rubin BS, Soto AM. Bisphenol-A and the great divide: a review of controversies in the field of endocrine disruption. Endocr Rev 2009; 30: 75–95..95. 49. Susiarjo M, Hassold TJ, Freeman E, Hunt PA. Bisphenol A exposure in utero disrupts early oogenesis in the mouse. PLoS Genet 2007; 3: e5. 50. Vandenberg LN, Maffini MV, Schaeberle CM, Ucci AA, Sonnenschein C, Rubin BS, Soto AM. Perinatal exposure to the xenoestrogen bisphenol-A induces mammary intraductal hyperplasias in adult CD-1 mice. Reprod Toxicol 2008; 26: 210–219..219. 51. Newbold RR, Jefferson WN, Padilla-Banks E. Long-term adverse effects of neonatal exposure to bisphenol A on the murine female reproductive tract. Reprod Toxicol . 2007 Aug-Sep;24(2):253-8. Epub 2007 Jul 27. 52. Lawson C, Gieske M, Murdoch B, Ye P, Li Y, Hassold T, Hunt PA. Gene expression in the fetal mouse ovary is altered by exposure to low doses of bisphenol A. Biol Reprod . 2011 Jan;84(1):79-86. doi:10.1095/biolreprod.110.084814. Epub 2010 Aug 25. 53. Patricia A. Hunt, Martha Susiarjo, Carmen Rubio, Terry J. Hassold. The Bisphenol A Experience: A Primer for the Analysis of Environmental Effects on Mammalian Reproduction . Biol Reprod. 2009 November; 81(5): 807–813. Published online 2009 May 20. doi: 10.1095/biolreprod.109.077008 54. Alonso-Magdalena P, Vieira E, Soriano S, Menes L, Burks D, Quesada I, Nadal A. Bisphenol A exposure during pregnancy disrupts glucose homeostasis in mothers and adult male offspring. Environ Health Perspect . 2010 Sep;118(9):1243-50. doi: 10.1289/ehp.1001993. Epub 2010 May 7. 55. Markey CM, Rubin BS, Soto AM, Sonnenschein C. Endocrine disruptors: from Wingspread to environmental developmental biology. J Steroid Biochem Mol Biol. 2002 Dec;83(1-5):235-44. Review. 56. Susiarjo M, Hassold TJ, Freeman E, Hunt PA. Bisphenol A exposure in utero disrupts early oogenesis in the mouse. PLoS Genet. 2007 Jan 12;3(1):e5. 57. Richter CA, Taylor JA, Ruhlen RL, Welshons WV, Vom Saal FS. Estradiol and Bisphenol A stimulate androgen receptor and estrogen receptor gene expression in fetal mouse prostate mesenchyme cells. Environ Health Perspect. 2007 Jun;115(6):902-8. Epub 2007 Feb 27. 58. Komada M, Asai Y, Morii M, Matsuki M, Sato M, Nagao T. Maternal bisphenol A oral dosing relates to the acceleration of neurogenesis in the developing neocortex of mouse fetuses. Toxicology . 2012 May 16;295(1-3):31-8. doi: 10.1016/j.tox.2012.02.013. Epub 2012 Mar 7. 59. Braun JM, Hauser R. Bisphenol A and children’s health. Curr Opin Pediatr . 2011 Apr;23(2):233-9. doi: 10.1097/MOP.0b013e3283445675. Review. 60. http://www.ewg.org/research/tips-avoid-bpa-exposure 61. Kajta M, Wójtowicz AK. Impact of endocrine-disrupting chemicals on neural development and the onset of neurological disorders. Pharmacol Rep . 2013;65(6):1632-9. 62. León-Olea M, Martyniuk CJ, Orlando EF, Ottinger MA, Rosenfeld C, Wolstenholme J, Trudeau VL. Current concepts in neuroendocrine disruption. Gen Comp Endocrinol . 2014 Feb 13. pii: S0016-6480(14)00048-3. doi: 10.1016/j.ygcen.2014.02.005. [Epub ahead of print] 63. Elsworth JD, Jentsch JD, Vandevoort CA, Roth RH, Jr DE, Leranth C. Prenatal exposure to bisphenol A impacts midbrain dopamine neurons and hippocampal spine synapses in non-human primates. Neurotoxicology . 2013 Mar;35:113-20. doi: 10.1016/j.neuro.2013.01.001. Epub 2013 Jan 18. 64. Viberg H, Lee I. A single exposure to bisphenol A alters the levels of important neuroproteins in adult male and female mice. Neurotoxicology . 2012 Oct;33(5):1390-5. doi: 10.1016/j.neuro.2012.09.002. Epub 2012 Sep 12. 65. Weiss B. The intersection of neurotoxicology and endocrine disruption. Neurotoxicology . 2012 Dec;33(6):1410-9. doi: 10.1016/j.neuro.2012.05.014. Epub 2012 May 31. Review. 66. Jang YJ, Park HR, Kim TH, Yang WJ, Lee JJ, Choi SY, Oh SB, Lee E, Park JH, Kim HP, Kim HS, Lee J. High dose bisphenol A impairs hippocampal neurogenesis in female mice across generations. Toxicology . 2012 Jun 14;296(1-3):73-82. doi: 10.1016/j.tox.2012.03.007. Epub 2012 Apr 3. 67. Komada M, Asai Y, Morii M, Matsuki M, Sato M, Nagao T. Maternal bisphenol A oral dosing relates to the acceleration of neurogenesis in the developing neocortex of mouse fetuses. Toxicology . 2012 May 16;295(1-3):31-8. doi: 10.1016/j.tox.2012.02.013. Epub 2012 Mar 7. 68. Itoh K, Yaoi T, Fushiki S. Bisphenol A , an endocrine-disrupting chemical, and brain development. Neuropathology . 2012 Aug;32(4):447-57. doi: 10.1111/j.1440-1789.2011.01287.x. Epub 2012 Jan 12. Review. 69. Longnecker MP. Human data on bisphenol A and neurodevelopment. Environ Health Perspect . 2009 Dec;117(12):A531-2. doi: 10.1289/ehp.0901610. No abstract available. 70. Leranth C, Hajszan T, Szigeti-Buck K, Bober J, MacLusky NJ. Bisphenol A prevents the synaptogenic response to estradiol in hippocampus and prefrontal cortex of ovariectomized nonhuman primates. Proc Natl Acad Sci U S A. 2008 Sep 16;105(37):14187-91. doi: 10.1073/pnas.0806139105. Epub 2008 Sep 3. 71. Kundakovic M, Gudsnuk K, Franks B, Madrid J, Miller RL, Perera FP, Champagne FA. Sex-specific epigenetic disruption and behavioral changes following low-dose in utero bisphenol A exposure. Proc Natl Acad Sci U S A. 2013 Jun 11;110(24):9956-61. doi: 10.1073/pnas.1214056110. Epub 2013 May 28. 72. Hong SB, Hong YC, Kim JW, Park EJ, Shin MS, Kim BN, Yoo HJ, Cho IH, Bhang SY, Cho SC. Bisphenol A in relation to behavior and learning of school-age children. J Child Psychol Psychiatry . 2013 Aug;54(8):890-9. doi: 10.1111/jcpp.12050. Epub 2013 Feb 28. 73. Xu X, Hong X, Xie L, Li T, Yang Y, Zhang Q, Zhang G, Liu X. Gestational and lactational exposure to bisphenol-A affects anxiety- and depression-like behaviors in mice. Horm Behav . 2012 Sep;62(4):480-90. 74. Wolstenholme JT, Edwards M, Shetty SR, Gatewood JD, Taylor JA, Rissman EF, Connelly JJ. Gestational exposure to bisphenol A produces transgenerational changes in behaviors and gene expression. Endocrinology . 2012 Aug;153(8):3828-38. doi: 10.1210/en.2012-1195. Epub 2012 Jun 15. 75. Fudvoye J, Bourguignon JP, Parent AS. Endocrine-disrupting chemicals and human growth and maturation: a focus on early critical windows of exposure. Vitam Horm . 2014;94:1-25. doi: 10.1016/B978-0-12-800095-3.00001-8. 76. Beverly S. Rubin, Ana M. Soto. Bisphenol A : Perinatal exposure and body weight . Mol Cell Endocrinol. Author manuscript; available in PMC 2010 February 9. 77. vom Saal FS, Hughes C. An extensive new literature concerning low-dose effects of bisphenol A shows the need for a new risk assessment. Environ Health Perspect 2005; 113: 926–933..933. 78. http://www.ewg.org/research/tips-avoid-bpa-exposure 79. http://www.ewg.org/research/tips-avoid-bpa-exposure 80. http://www.ewg.org/dioxin/analysis 81. http://www.who.int/mediacentre/factsheets/fs225/en/ 82. http://www.who.int/mediacentre/factsheets/fs225/en/ 83. http://www.who.int/mediacentre/factsheets/fs225/en/ 84. http://www.ewg.org/news/news-releases/2010/07/13/infants-ingest-dioxin-77-times-epa%E2%80%99s-safe-threshold 85. Marinković N, Pašalić D, Ferenčak G, Gršković B, Stavljenić Rukavina A. Dioxins and human toxicity. Arh Hig Rada Toksikol. 2010 Dec;61(4):445-53. doi: 10.2478/10004-1254-61-2010-2024. Review. 86. Bethany Winans, Michael C. Humble, B. Paige Lawrence. Environmental toxicants and the developing immune system: a missing link in the global battle against infectious disease? Reprod Toxicol. Author manuscript; available in PMC 2012 April 1. Published in final edited form as: Reprod Toxicol. 2011 April; 31(3): 327–336. Published online 2010 September 22. doi: 10.1016/j.reprotox.2010.09.004 87. Nagayama J, Tsuji H, Iida T, Nakagawa R, Matsueda T, Hirakawa H, et al. Immunologic effects of perinatal exposure to dioxins, PCBs and organochlorine pesticides in Japanese infants. Chemosphere . 2007;67:S393–8. 88. ten Tusscher GW, Steerenberg PA, van Loveren H, Vos JG, Borne AE, Westra M, et al. Persistent hematologic and immunologic disturbances in 8-year-old Dutch children associated with perinatal dioxin exposure. Environ Health Perspect . 2003;111:1519–23. 89. Weisglas-Kuperus N, Sas TC, Koopman-Esseboom C, Zwan CW, De Ridder MA, Beishuizen A, et al. Immunologic effects of background prenatal and postnatal exposure to dioxins and polychlorinated biphenyls in Dutch infants. Pediatr Res. 1995;38:404–10. 90. Weisglas-Kuperus N, Patandin S, Berbers GA, Sas TC, Mulder PG, Sauer PJ, et al. Immunologic effects of background exposure to polychlorinated biphenyls and dioxins in Dutch preschool children. E nvironmental health perspectives. 2000;108:1203. 91. Weisglas-Kuperus N, Vreugdenhil HJ, Mulder PG. Immunological effects of environmental exposure to polychlorinated biphenyls and dioxins in Dutch school children. Toxicol Lett. 2004;149:281–5. 92. Hertz-Picciotto I, Park HY, Dostal M, Kocan A, Trnovec T, Sram R. Prenatal exposures to persistent and non-persistent organic compounds and effects on immune system development. Basic & clinical pharmacology & toxicology. 2008;102:146–54. 93. Gascon M, Morales E, Sunyer J, Vrijheid M. Effects of persistent organic pollutants on the developing respiratory and immune systems: a systematic review. Environ Int. 2013 Feb;52:51-65. doi: 10.1016/j.envint.2012.11.005. Epub 2013 Jan 3. Review. 94. Carpenter DO, Ma J, Lessner L. Asthma and infectious respiratory disease in relation to residence near hazardous waste sites. Ann N Y Acad Sci. 2008 Oct;1140:201-8. doi: 10.1196/annals.1454.000. 95. Kasai T, Saito M, Senoh H, Umeda Y, Aiso S, Ohbayashi H, Nishizawa T, Nagano K, Fukushima S. Thirteen-week inhalation toxicity of 1,4-dioxane in rats. Inhal Toxicol . 2008 Aug;20(10):961-71. doi: 10.1080/08958370802105397 . 96. Wong PS, Vogel CF, Kokosinski K, Matsumura F. Arylhydrocarbon receptor activation in NCI-H441 cells and C57BL/6 mice: possible mechanisms for lung dysfunction. Am J Respir Cell Mol Biol . 2010 Feb;42(2):210-7. doi: 10.1165/rcmb.2008-0228OC. Epub 2009 Apr 16. 97. Kransler KM, McGarrigle BP, Swartz DD, Olson JR. Lung development in the Holtzman rat is adversely affected by gestational exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicol Sci. 2009 Feb;107(2):498-511. doi: 10.1093/toxsci/kfn235. Epub 2008 Nov 6. 98. Walker NJ, Yoshizawa K, Miller RA, Brix AE, Sells DM, Jokinen MP, Wyde ME, Easterling M, Nyska A. Pulmonary lesions in female Harlan Sprague-Dawley rats following two-year oral treatment with dioxin-like compounds. Toxicol Pathol. 2007 Dec;35(7):880-9. 99. ten Tusscher GW, Koppe JG. Perinatal dioxin exposure and later effects&#8211;a review. Chemosphere. 2004 Mar;54(9):1329-36. Review. 100. Fernández-González R, Yebra-Pimentel I, Martínez-Carballo E, Simal-Gándara J. A critical review about the human exposure to polychlorinated dibenzo-p-dioxins (PCDDs), polychlorinated dibenzofurans (PCDFs) and polychlorinated biphenyls (PCBs) through foods. Crit Rev Food Sci Nutr. 2013 Nov 26. [Epub ahead of print] 101. Xu HM, Xie HQ, Tao WQ, Zhou ZG, Li SZ, Zhao B. Dioxin and Dioxin-Like Compounds Suppress Acetylcholinesterase Activity via Transcriptional Downregulations In Vitro. J Mol Neurosci. 2013 Nov 17. [Epub ahead of print] 102. Takeda T, Fujii M, Hattori Y, Yamamoto M, Shimazoe T, Ishii Y, Himeno M, Yamada H. Maternal exposure to dioxin imprints sexual immaturity of the pups through fixing the status of the reduced expression of hypothalamic gonadotropin-releasing hormone. Mol Pharmacol . 2014 Jan;85(1):74-82. doi: 10.1124/mol.113.088575. Epub 2013 Oct 16. 103. Nguyen MN, Nishijo M, Nguyen AT, Bor A, Nakamura T, Hori E, Nakagawa H, Ono T, Nishijo H. Effects of maternal exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin on parvalbumin- and calbindin-immunoreactive neurons in the limbic system and superior colliculus in rat offspring. Toxicology . 2013 Dec 6;314(1):125-34. doi: 10.1016/j.tox.2013.09.005. Epub 2013 Sep 20. 104. Xie HQ, Xu HM, Fu HL, Hu Q, Tian WJ, Pei XH, Zhao B. AhR-mediated effects of dioxin on neuronal acetylcholinesterase expression in vitro. Environ Health Perspect. 2013 May;121(5):613-8. doi: 10.1289/ehp.1206066. Epub 2013 Feb 19. 105. Iida M, Kim EY, Murakami Y, Shima Y, Iwata H. Toxic effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on the peripheral nervous system of developing red seabream (Pagrus major). Aquat Toxicol . 2013 Mar 15;128-129:193-202. doi: 10.1016/j.aquatox.2012.12.009. Epub 2012 Dec 21. 106. Endo T, Kakeyama M, Uemura Y, Haijima A, Okuno H, Bito H, Tohyama C. Executive function deficits and social-behavioral abnormality in mice exposed to a low dose of dioxin in utero and via lactation. PLoS One. 2012;7(12):e50741. doi: 10.1371/journal.pone.0050741. Epub 2012 Dec 12. 107. Tomasini MC, Beggiato S, Ferraro L, Tanganelli S, Marani L, Lorenzini L, Antonelli T. Prenatal exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin produces alterations in cortical neuron development and a long-term dysfunction of glutamate transmission in rat cerebral cortex. Neurochem Int. 2012 Oct;61(5):759-66. doi: 10.1016/j.neuint.2012.07.004. Epub 2012 Jul 10. 108. Fernández-González R, Yebra-Pimentel I, Martínez-Carballo E, Simal-Gándara J. A critical review about the human exposure to polychlorinated dibenzo-p-dioxins (PCDDs), polychlorinated dibenzofurans (PCDFs) and polychlorinated biphenyls (PCBs) through foods. Crit Rev Food Sci Nutr. 2013 Nov 26. [Epub ahead of print] 109. Wong MH, Armour MA, Naidu R, Man M. Persistent toxic substances: sources, fates and effects. Rev Environ Health. 2012;27(4):207-13. doi: 10.1515/reveh-2012-0040. Review . 110. Rysavy NM, Maaetoft-Udsen K, Turner H. Dioxins : diagnostic and prognostic challenges arising from complex mechanisms. J Appl Toxicol . 2013 Jan;33(1):1-8. doi: 10.1002/jat.2759. Epub 2012 May 19. Review . 111. Schug TT, Janesick A, Blumberg B, Heindel JJ. Endocrine disrupting chemicals and disease susceptibility. J Steroid Biochem Mol Biol. 2011 Nov;127(3-5):204-15. doi: 10.1016/j.jsbmb.2011.08.007. Epub 2011 Aug 27. Review . 112. Trnovec T, Jusko TA, Šovčíková E, Lancz K, Chovancová J, Patayová H, Palkovičová L, Drobná B, Langer P, Van den Berg M, Dedik L, Wimmerová S. Relative effect potency estimates of dioxin-like activity for dioxins, furans, and dioxin-like PCBs in adults based on two thyroid outcomes. Environ Health Perspect. 2013 Aug;121(8):886-92. doi: 10.1289/ehp.1205739. Epub 2013 May 1. 113. Rennert A, Wittsiepe J, Kasper-Sonnenberg M, Binder G, Fürst P, Cramer C, Krämer U, Wilhelm M. Prenatal and early life exposure to polychlorinated dibenzo-p-dioxins, dibenzofurans and biphenyls may influence dehydroepiandrosterone sulfate levels at prepubertal age: results from the Duisburg birth cohort study. J Toxicol Environ Health A . 2012;75(19-20):1232-40. 114. Craig ZR, Wang W, Flaws JA. Endocrine -disrupting chemicals in ovarian function: effects on steroidogenesis, metabolism and nuclear receptor signaling. Reproduction . 2011 Nov;142(5):633-46. doi: 10.1530/REP-11-0136. Epub 2011 Aug 23. Review. 115. Balabanič D, Rupnik M, Klemenčič AK. Negative impact of endocrine-disrupting compounds on human reproductive health. Reprod Fertil Dev. 2011;23(3):403-16. doi: 10.1071/RD09300. Review . 116. Fernández-González R, Yebra-Pimentel I, Martínez-Carballo E, Simal-Gándara J. A critical review about the human exposure to polychlorinated dibenzo-p-dioxins (PCDDs), polychlorinated dibenzofurans (PCDFs) and polychlorinated biphenyls (PCBs) through foods. Crit Rev Food Sci Nutr. 2013 Nov 26. [Epub ahead of print] 117. Balabanič D, Rupnik M, Klemenčič AK. Negative impact of endocrine-disrupting compounds on human reproductive health. Reprod Fertil Dev. 2011;23(3):403-16. doi: 10.1071/RD09300. Review. 118. Papadopoulou E, Vafeiadi M, Agramunt S, Mathianaki K, Karakosta P, Spanaki A, Besselink H, Kiviranta H, Rantakokko P, KaterinaSarri, Koutis A, Chatzi L, Kogevinas M. Maternal diet, prenatal exposure to dioxins and other persistent organic pollutants and anogenital distance in children. Sci Total Environ . 2013 Sep 1;461-462:222-9. doi: 10.1016/j.scitotenv.2013.05.005. Epub 2013 May 31. 119. Zawatski W, Lee MM. Male pubertal development: are endocrine-disrupting compounds shifting the norms? J Endocrinol. 2013 Jul 11;218(2):R1-12. doi: 10.1530/JOE-12-0449. Print 2013. Review. 120. Takeda T, Fujii M, Taura J, Ishii Y, Yamada H. Dioxin silences gonadotropin expression in perinatal pups by inducing histone deacetylases: a new insight into the mechanism for the imprinting of sexual immaturity by dioxin. J Biol Chem. 2012 May 25;287(22):18440-50. doi: 10.1074/jbc.M111.335158. Epub 2012 Apr 9. 121. Baker TR, Peterson RE, Heideman W. Using zebrafish as a model system for studying the transgenerational effects of dioxin. Toxicol Sci. 2014 Apr;138(2):403-11. doi: 10.1093/toxsci/kfu006. Epub 2014 Jan 27. 122. Brunnberg S, Andersson P, Poellinger L, Hanberg A. The constitutively active Ah receptor (CA-AhR) mouse as a model for dioxin exposure &#8211; effects in reproductive organs. Chemosphere . 2011 Dec;85(11):1701-6. doi: 10.1016/j.chemosphere.2011.09.015. Epub 2011 Oct 19. 123. Naville D, Rebourcet D, Chauvin MA, Vega N, Jalabert A, Vigier M, Loizon E, Bégeot M, Le Magueresse-Battistoni B. Direct and indirect impact of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) on adult mouse Leydig cells: an in vitro study. Toxicol Lett . 2011 Dec 15;207(3):251-7. doi: 10.1016/j.toxlet.2011.09.019. Epub 2011 Sep 29. 124. Svechnikov K, Izzo G, Landreh L, Weisser J, Söder O. Endocrine disruptors and Leydig cell function. J Biomed Biotechnol . 2010;2010. pii: 684504. doi: 10.1155/2010/684504. Epub 2010 Aug 25. Review. 125. Sankpal UT, Pius H, Khan M, Shukoor MI, Maliakal P, Lee CM, Abdelrahim M, Connelly SF, Basha R. Environmental factors in causing human cancers: emphasis on tumorigenesis. Tumour Biol. 2012 Oct;33(5):1265-74. doi: 10.1007/s13277-012-0413-4. Epub 2012 May 22. Review . 126. Rysavy NM, Maaetoft-Udsen K, Turner H. Dioxins : diagnostic and prognostic challenges arising from complex mechanisms. J Appl Toxicol . 2013 Jan;33(1):1-8. doi: 10.1002/jat.2759. Epub 2012 May 19. Review . 127. Wong MH, Armour MA, Naidu R, Man M. Persistent toxic substances: sources, fates and effects. Rev Environ Health. 2012;27(4):207-13. doi: 10.1515/reveh-2012-0040. Review . 128. Słowińska M, Koter-Michalak M, Bukowska B. [The effect of dioxins on the human organism&#8211;epidemiological studies]. Med Pr. 2011;62(6):643-52. Review . Polish. 129. Bock KW. The human Ah receptor: hints from dioxin toxicities to deregulated target genes and physiological functions. Biol Chem. 2013 Jun;394(6):729-39. doi: 10.1515/hsz-2012-0340. Review . 130. Struciński P, Piskorska-Pliszczyńska J, Góralczyk K, Warenik-Bany M, Maszewski S, Czaja K, Ludwicki JK. [Dioxins and food safety]. Rocz Panstw Zakl Hig. 2011;62(1):3-17. Review . Polish. 131. Jenkins S, Betancourt AM, Wang J, Lamartiniere CA. Endocrine-active chemicals in mammary cancer causation and prevention. J Steroid Biochem Mol Biol . 2012 Apr;129(3-5):191-200. doi:10.1016/j.jsbmb.2011.06.003. Epub 2011 Jun 23. Review . 132. Donato F, Zani C. [Chronic exposure to organochlorine compounds and health effects in adults: cancer, non-Hodgkin lymphoma. Review of literature]. Ann Ig. 2010 Jul-Aug;22(4):357-67. Review . Italian. 133. Papoutsis AJ, Selmin OI, Borg JL, Romagnolo DF. Gestational exposure to the AhR agonist 2,3,7,8-tetrachlorodibenzo-p-dioxin induces BRCA-1 promoter hypermethylation and reduces BRCA-1 expression in mammary tissue of rat offspring: Preventive effects of resveratrol. Mol Carcinog . 2013 Oct 17. doi: 10.1002/mc.22095. [Epub ahead of print] 134. Hoenemeyer LA. Urologic cancer risks for veterans exposed to Agent Orange. Urol Nurs. 2013 Mar-Apr;33(2):87-90, 99. 135. http://www.ewg.org/dioxin/press 136. http://www.who.int/mediacentre/factsheets/fs225/en/ 137. http://www.ewg.org/research/mouths-babes 138. Hayes, Tyrone B.; Anderson, Lloyd L.; Beasley, Val R.; de Solla, Shane R.; Iguchi, Taisen; et al. (2011). Demasculinization and feminization of male gonads by atrazine: Consistent effects across vertebrate classes. The Journal of Steroid Biochemistry and Molecular Biology 127 (1-2): 64–73. doi : 10.1016/j.jsbmb.2011.03.015 139. http://www.mprnews.org/story/2007/01/02/hayesmayo 140. Fan W, Yanase T, Morinaga H, Gondo S, Okabe T, Nomura M, Komatsu T, Morohashi K, Hayes TB, Takayanagi R, Nawata H. Atrazine -induced aromatase expression is SF-1 dependent: implications for endocrine disruption in wildlife and reproductive cancers in humans. Environ Health Perspect. 2007 May;115(5):720-7. Epub 2007 Feb 5. 141. Stanko JP, Enoch RR, Rayner JL, Davis CC, Wolf DC, Malarkey DE, Fenton SE. Effects of prenatal exposure to a low dose atrazine metabolite mixture on pubertal timing and prostate development of male Long-Evans rats. Reprod Toxicol. 2010 Dec;30(4):540-9. doi: 10.1016/j.reprotox.2010.07.006. Epub 2010 Aug 19. Erratum in: Reprod Toxicol. 2011 Jul;32(1):146-7. 142. Stoker TE, Robinette CL, Cooper RL. Maternal exposure to atrazine during lactation suppresses suckling-induced prolactin release and results in prostatitis in the adult offspring. Toxicol Sci. 1999 Nov;52(1):68-79. 143. http://www.nrdc.org/health/atrazine/ 144. http://toxtown.nlm.nih.gov/text_version/chemicals.php?id=24 145. http://www.cdc.gov/biomonitoring/Phthalates_FactSheet.html 146. Blount BC, Silva MJ, Caudill SP, Needham LL, Pirkle JL, Sampson EJ, Lucier GW, Jackson RJ, Brock JW. Levels of seven urinary phthalate metabolites in a human reference population. Environ Health Perspect. 2000 Oct;108(10):979-82. 147. Kohn MC , Parham F , Masten SA , Portier CJ , Shelby MD , Brock JW , Needham LL . Human exposure estimates for phthalates. Environ Health Perspect. 2000 Oct;108(10):A440-2. 148. http://www.cdc.gov/exposurereport/pdf/FourthReport.pdf 149. Wolff MS, Teitelbaum SL, Windham G, Pinney SM, Britton JA, Chelimo C, Godbold J, Biro F, Kushi LH, Pfeiffer CM, Calafat AM. Pilot study of urinary biomarkers of phytoestrogens, phthalates, and phenols in girls. Environ Health Perspect. 2007 Jan;115(1):116-21. 150. Rudel RA 1 , Camann DE , Spengler JD , Korn LR , Brody JG . Phthalates, alkylphenols, pesticides, polybrominated diphenyl ethers, and other endocrine-disrupting compounds in indoor air and dust. Environ Sci Technol. 2003 Oct 15;37(20):4543-53. 151. Kolpin DW, Furlong ET, Meyer MT, Thurman EM, Zaugg SD, Barber LB, Buxton HT. Pharmaceuticals, hormones, and other organic wastewater contaminants in U.S. streams, 1999-2000: a national reconnaissance. Environ Sci Technol. 2002 Mar 15;36(6):1202-11. 152. Hauser R, Meeker JD, Singh NP, Silva MJ, Ryan L, Duty S, Calafat AM. DNA damage in human sperm is related to urinary levels of phthalate monoester and oxidative metabolites. Hum Reprod. 2007 Mar;22(3):688-95. Epub 2006 Nov 7. 153. Hauser R, Meeker JD, Duty S, Silva MJ, Calafat AM. Altered semen quality in relation to urinary concentrations of phthalate monoester and oxidative metabolites. Epidemiology. 2006 Nov;17(6):682-91. 154. Duty SM, Calafat AM, Silva MJ, Ryan L, Hauser R. Phthalate exposure and reproductive hormones in adult men. Hum Reprod. 2005 Mar;20(3):604-10. Epub 2004 Dec 9. 155. Grady R, Sathyanarayana S. An update on phthalates and male reproductive development and function. Curr Urol Rep. 2012 Aug;13(4):307-10. doi: 10.1007/s11934-012-0261-1. 156. Bustamante-Montes LP, Hernández-Valero MA, Flores-Pimentel D, García-Fábila M, Amaya-Chávez A, Barr DB, Borja-Aburto VH. Prenatal exposure to phthalates is associated with decreased anogenital distance and penile size in male newborns. J Dev Orig Health Dis. 2013 Aug;4(4). doi: 10.1017/S2040174413000172. 157. Veeramachaneni DN, Klinefelter GR. Phthalate-Induced Pathology in the Foetal Testis Involves More Than Decreased Testosterone Production. Reproduction . 2013 Nov 26. [Epub ahead of print] 158. Main KM, Mortensen GK, Kaleva MM, Boisen KA, Damgaard IN, Chellakooty M, Schmidt IM, Suomi AM, Virtanen HE, Petersen DV, Andersson AM, Toppari J, Skakkebaek NE. Human breast milk contamination with phthalates and alterations of endogenous reproductive hormones in infants three months of age. Environ Health Perspect. 2006 Feb;114(2):270-6. 159. Howdeshell KL, Rider CV, Wilson VS, Gray LE Jr. Mechanisms of action of phthalate esters, individually and in combination, to induce abnormal reproductive development in male laboratory rats. Environ Res. 2008 Oct;108(2):168-76. Review. 160. Noriega NC, Howdeshell KL, Furr J, Lambright CR, Wilson VS, Gray LE Jr. Pubertal administration of DEHP delays puberty, suppresses testosterone production, and inhibits reproductive tract development in male Sprague-Dawley and Long-Evans rats. Toxicol Sci. 2009 Sep;111(1):163-78. doi:10.1093/toxsci/kfp129. Epub 2009 Jun 15. 161. Pak VM, McCauley LA, Pinto-Martin J. Phthalate exposures and human health concerns: A review and implications for practice. AAOHN J . 2011 May;59(5):228-33; quiz 234-5. doi: 10.3928/08910162-20110426-01. Review. 162. Crinnion WJ. Toxic effects of the easily avoidable phthalates and parabens. Altern Med Rev. 2010 Sep;15(3):190-6. Review. 163. Callesen M, Bekö G, Weschler CJ, Langer S, Brive L, Clausen G, Toftum J, Sigsgaard T, Høst A, Jensen TK. Phthalate metabolites in urine and asthma, allergic rhinoconjunctivitis and atopic dermatitis in preschool children. Int J Hyg Environ Health. 2013 Dec 13. pii: S1438-4639(13)00156-9. doi: 10.1016/j.ijheh.2013.12.001. [Epub ahead of print] 164. He M, Inoue K, Yoshida S, Tanaka M, Takano H, Sun G, Ichinose T. Effects of airway exposure to di-(2-ethylhexyl) phthalate on allergic rhinitis. Immunopharmacol Immunotoxicol. 2013 Jun;35(3):390-5. doi: 10.3109/08923973.2013.787432. 165. Braun JM, Sathyanarayana S, Hauser R. Phthalate exposure and children’s health. Curr Opin Pediatr. 2013 Apr;25(2):247-54. doi: 10.1097/MOP.0b013e32835e1eb6. Review. 166. Hsu NY, Lee CC, Wang JY, Li YC, Chang HW, Chen CY, Bornehag CG, Wu PC, Sundell J, Su HJ. Predicted risk of childhood allergy, asthma, and reported symptoms using measured phthalate exposure in dust and urine. Indoor Air. 2012 Jun;22(3):186-99. doi: 10.1111/j.1600-0668.2011.00753.x. Epub 2011 Nov 16. 167. Park HY, Kim JH, Lim YH, Bae S, Hong YC. Influence of genetic polymorphisms on the association between phthalate exposure and pulmonary function in the elderly. Environ Res. 2013 Apr;122:18-24. doi: 10.1016/j.envres.2012.11.004. Epub 2012 Dec 20. 168. Wu MT, Wu CF, Chen BH, Chen EK, Chen YL, Shiea J, Lee WT, Chao MC, Wu JR. Intake of phthalate-tainted foods alters thyroid functions in Taiwanese children . PLoS One. 2013;8(1):e55005. doi: 10.1371/journal.pone.0055005. Epub 2013 Jan 30. 169. Andra SS, Makris KC. Thyroid disrupting chemicals in plastic additives and thyroid health. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev . 2012;30(2):107-51. doi: 10.1080/10590501.2012.681487. Review. 170. Boas M, Feldt-Rasmussen U, Main KM. Thyroid effects of endocrine disrupting chemicals. Mol Cell Endocrinol. 2012 May 22;355(2):240-8. doi: 10.1016/j.mce.2011.09.005. Epub 2011 Sep 10. Review. 171. Boas M, Feldt-Rasmussen U, Skakkebaek NE, Main KM. Environmental chemicals and thyroid function. Eur J Endocrinol. 2006 May;154(5):599-611. Review. 172. Kobrosly RW, Evans S, Miodovnik A, Barrett ES, Thurston SW, Calafat AM, Swan SH. Prenatal Phthalate Exposures and Neurobehavioral Development Scores in Boys and Girls at 6-10 Years of Age. Environ Health Perspect. 2014 Feb 21. [Epub ahead of print] 173. Szychowski KA, Wójtowicz AK. [Components of plastic disrupt the function of the nervous system] . Postepy Hig Med Dosw (Online). 2013 May 27;67:499-506. Review. Polish. 174. Téllez-Rojo MM, Cantoral A, Cantonwine DE, Schnaas L, Peterson K, Hu H, Meeker JD. Prenatal urinary phthalate metabolites levels and neurodevelopment in children at two and three years of age. Sci Total Environ. 2013 Sep 1;461-462:386-90. doi: 10.1016/j.scitotenv.2013.05.021. Epub 2013 Jun 5. 175. Jurewicz J, Polańska K, Hanke W. Exposure to widespread environmental toxicants and children’s cognitive development and behavioral problems. Int J Occup Med Environ Health. 2013 Apr;26(2):185-204. doi: 10.2478/s13382-013-0099-x. Epub 2013 May 28. Erratum in: Int J Occup Med Environ Health. 2013 Jun;26(3):494. 176. Kim Y, Ha EH, Kim EJ, Park H, Ha M, Kim JH, Hong YC, Chang N, Kim BN. Prenatal exposure to phthalates and infant development at 6 months: prospective Mothers and Children’s Environmental Health (MOCEH) study. Environ Health Perspect . 2011 Oct;119(10):1495-500. doi: 10.1289/ehp.1003178. Epub 2011 Jul 7. 177. Chen FP, Chien MH. Lower concentrations of phthalates induce proliferation in human breast cancer cells . Climacteric. 2013 Dec 27. [Epub ahead of print] 178. Sprague BL, Trentham-Dietz A, Hedman CJ, Wang J, Hemming JD, Hampton JM, Buist DS, Aiello Bowles EJ, Sisney GS, Burnside ES. Circulating serum xenoestrogens and mammographic breast density. Breast Cancer Res. 2013 May 27;15(3):R45. [Epub ahead of print] 179. Wang YC, Chen HS, Long CY, Tsai CF, Hsieh TH, Hsu CY, Tsai EM. Possible mechanism of phthalates-induced tumorigenesis. Kaohsiung J Med Sci. 2012 Jul;28(7 Suppl):S22-7. doi:10.1016/j.kjms.2012.05.006. Epub 2012 Jul 10. Review. 180. Hsieh TH, Tsai CF, Hsu CY, Kuo PL, Lee JN, Chai CY, Wang SC, Tsai EM. Phthalates induce proliferation and invasiveness of estrogen receptor-negative breast cancer through the AhR/HDAC6/c-Myc signaling pathway. FASEB J. 2012 Feb;26(2):778-87. doi: 10.1096/fj.11-191742. Epub 2011 Nov 2. 181. López-Carrillo L, Hernández-Ramírez RU, Calafat AM, Torres-Sánchez L, Galván-Portillo M, Needham LL, Ruiz-Ramos R, Cebrián ME. Exposure to phthalates and breast cancer risk in northern Mexico . Environ Health Perspect. 2010 Apr;118(4):539-44. doi: 10.1289/ehp.0901091. 182. http://www.nrdc.org/living/chemicalindex/perchlorate.asp 183. http://www.ewg.org/research/rocket-fuel-cows-milk-perchlorate 184. http://www.ewg.org/enviroblog/2008/01/perchlorate-you-might-not-know-how-pronounce-it-its-you 185. http://www.ewg.org/research/rocket-fuel-cows-milk-perchlorate 186. http://www.ewg.org/research/rocket-fuel-cows-milk-perchlorate 187. http://yosemite.epa.gov/r10/CLEANUP.NSF/PH/Arkema+Technical+Documents/$FILE/Perchlorate-Sources-Occurance-In-The-Environment.pdf 188. http://www.ewg.org/research/rocket-fuel-cows-milk-perchlorate 189. Steinmaus C 1 , Miller MD , Smith AH . Perchlorate in drinking water during pregnancy and neonatal thyroid hormone levels in California. J Occup Environ Med. 2010 Dec;52(12):1217-524. doi: 10.1097/JOM.0b013e3181fd6fa7. 190. Kirk AB. Environmental perchlorate: why it matters. Anal Chim Acta. 2006 May 10;567(1):4-12. Epub 2006 Mar 27. 191. Pearce EN, Braverman LE. Environmental pollutants and the thyroid. Best Pract Res Clin Endocrinol Metab. 2009 Dec;23(6):801-13. doi: 10.1016/j.beem.2009.06.003. Review. 192. Julvez J, Alvarez-Pedrerol M, Rebagliato M, Murcia M, Forns J, Garcia-Esteban R, Lertxundi N, Espada M, Tardón A, Riaño Galán I, Sunyer J. Thyroxine levels during pregnancy in healthy women and early child neurodevelopment . Epidemiology. 2013 Jan;24(1):150-7. doi: 10.1097/EDE.0b013e318276ccd3. 193. Rivkees SA, Mandel SJ. Thyroid disease in pregnancy. Horm Res Paediatr . 2011;76 Suppl 1:91-6. doi: 10.1159/000329186. Epub 2011 Jul 21. 194. LaFranchi SH, Haddow JE, Hollowell JG. Is thyroid inadequacy during gestation a risk factor for adverse pregnancy and developmental outcomes? Thyroid. 2005 Jan;15(1):60-71. 195. Williams GR. Neurodevelopmental and neurophysiological actions of thyroid hormone. J Neuroendocrinol. 2008 Jun;20(6):784-94. doi: 10.1111/j.1365-2826.2008.01733.x. Review. 196. Morreale de Escobar G, Obregon MJ, Escobar del Rey F. Role of thyroid hormone during early brain development. Eur J Endocrinol . 2004 Nov;151 Suppl 3:U25-37. Review. 197. Richard Dahl. Thyroid Alert: Low Iodine and Perchlorate Effects in Women . Environ Health Perspect. 2006 December; 114(12): A714. 198. Brent GA. Braverman LE. Zoeller RT. Thyroid health and the environment. Thyroid. 2007;17:807–809. 199. http://www.ewg.org/research/healthy-home-tips/tip-4-avoid-fire-retardants 200. Kim YR, Harden FA, Toms LM, Norman RE. Health consequences of exposure to brominated flame retardants: A systematic review. Chemosphere. 2014 Feb 11. pii: S0045-6535(13)01729-3. doi: 10.1016/j.chemosphere.2013.12.064. [Epub ahead of print] Review. 201. Springer C, Dere E, Hall SJ, McDonnell EV, Roberts SC, Butt CM, Stapleton HM, Watkins DJ, McClean MD, Webster TF, Schlezinger JJ, Boekelheide K. Rodent thyroid, liver, and fetal testis toxicity of the monoester metabolite of bis-(2-ethylhexyl) tetrabromophthalate (tbph), a novel brominated flame retardant present in indoor dust. Environ Health Perspect. 2012 Dec;120(12):1711-9. doi: 10.1289/ ehp.1204932. Epub 2012 Sep 26. 202. Gundersen Y 1 , Vaagenes P , Reistad T , Opstad PK . [Brominated flame retardants may cause brain injuries in the fetus and the newborn]. [Article in Norwegian] Tidsskr Nor Laegeforen. 2005 Nov 17;125(22):3098-100. 203. Leijs MM, ten Tusscher GW, Olie K, van Teunenbroek T, van Aalderen WM, de Voogt P, Vulsma T, Bartonova A, Krayer von Krauss M, Mosoiu C, Riojas-Rodriguez H, Calamandrei G, Koppe JG. Thyroid hormone metabolism and environmental chemical exposure. Environ Health. 2012 Jun 28;11 Suppl 1:S10. doi: 10.1186/1476-069X-11-S1-S10. 204. Gill U, Chu I, Ryan JJ, Feeley M. Polybrominated diphenyl ethers: human tissue levels and toxicology. Rev Environ Contam Toxicol. 2004;183:55-97. Review. 205. Wang H, Zhang Y, Liu Q, Wang F, Nie J, Qian Y. Examining the relationship between brominated flame retardants (BFR) exposure and changes of thyroid hormone levels around e-waste dismantling sites. Int J Hyg Environ Health . 2010 Sep;213(5):369-80. doi: 10.1016/j.ijheh.2010.06.004. Epub 2010 Jul 3. 206. Saunders DM, Higley EB, Hecker M, Mankidy R, Giesy JP. In vitro endocrine disruption and TCDD-like effects of three novel brominated flame retardants: TBPH, TBB, &amp; TBCO. Toxicol Lett. 2013 Nov 25;223(2):252-9. doi: 10.1016/j.toxlet.2013.09.009. Epub 2013 Sep 21. 207. Gosavi RA, Knudsen GA, Birnbaum LS, Pedersen LC. Mimicking of estradiol binding by flame retardants and their metabolites: a crystallographic analysis. Environ Health Perspect. 2013 Oct;121(10):1194-9. doi: 10.1289/ehp.1306902. Epub 2013 Aug 13. 208. Johnson PI, Stapleton HM, Mukherjee B, Hauser R, Meeker JD. Associations between brominated flame retardants in house dust and hormone levels in men. Sci Total Environ. 2013 Feb 15;445-446:177-84. doi: 10.1016/j.scitotenv.2012.12.017. Epub 2013 Jan 16. 209. Kiciński M, Viaene MK, Den Hond E, Schoeters G, Covaci A, Dirtu AC, Nelen V, Bruckers L, Croes K, Sioen I, Baeyens W, Van Larebeke N, Nawrot TS. Neurobehavioral function and low-level exposure to brominated flame retardants in adolescents: a cross-sectional study. Environ Health. 2012 Nov 14;11:86. doi: 10.1186/1476-069X-11-86. 210. Roze E, Meijer L, Bakker A, Van Braeckel KN, Sauer PJ, Bos AF. Prenatal exposure to organohalogens, including brominated flame retardants, influences motor, cognitive, and behavioral performance at school age. Environ Health Perspect. 2009 Dec;117(12):1953-8. doi: 10.1289/ehp.0901015. Epub 2009 Aug 31. 211. Dingemans MM, van den Berg M, Westerink RH. Neurotoxicity of brominated flame retardants: (in)direct effects of parent and hydroxylated polybrominated diphenyl ethers on the (developing) nervous system. Environ Health Perspect. 2011 Jul;119(7):900-7. doi: 10.1289/ehp.1003035. Epub 2011 Jan 18. Review. 212. Eriksson P, Fischer C, Fredriksson A. Polybrominated diphenyl ethers, a group of brominated flame retardants, can interact with polychlorinated biphenyls in enhancing developmental neurobehavioral defects. Toxicol Sci. 2006 Dec;94(2):302-9. Epub 2006 Sep 15. 213. Eriksson, P., Jakobsson, E., & Fredriksson, A. Brominated Flame Retardants: A Novel Class of Developmental Neurotoxicants in our Environment? . Environmental Health Perspectives 109(9) , 903-908, 2004. 214. Viberg, H., Fredriksson, A., Jakobsson, E., Orn, U., & Eriksson, P. (2003). Neurobehavioral Derangements in Adult Mice Receiving Decabrominated Diphenyl Ether (PBDE 209) During a Defined Period of Neonatal Brain Development. Toxicol Sci 76(1) , 112-120. 215. Small CM, Murray D, Terrell ML, Marcus M. Reproductive outcomes among women exposed to a brominated flame retardant in utero. Arch Environ Occup Health. 2011;66(4):201-8. doi: 10.1080/19338244.2010.539640. 216. Jamieson DJ, Terrell ML, Aguocha NN, Small CM, Cameron LL, Marcus M. Dietary exposure to brominated flame retardants and abnormal Pap test results. J Womens Health (Larchmt). 2011 Sep;20(9):1269-78. doi: 10.1089/jwh.2010.2275. Epub 2011 Jul 28. 217. Small CM, DeCaro JJ, Terrell ML, Dominguez C, Cameron LL, Wirth J, Marcus M. Maternal exposure to a brominated flame retardant and genitourinary conditions in male offspring. Environ Health Perspect. 2009 Jul;117(7):1175-9. doi: 10.1289/ehp.0800058. Epub 2009 Feb 27. 218. McGee SP, Konstantinov A, Stapleton HM, Volz DC. Aryl phosphate esters within a major PentaBDE replacement product induce cardiotoxicity in developing zebrafish embryos: potential role of the aryl hydrocarbon receptor. Toxicol Sci. 2013 May;133(1):144-56. doi: 10.1093/toxsci/kft020. Epub 2013 Feb 1. 219. Lim JS, Lee DH, Jacobs DR Jr. Association of brominated flame retardants with diabetes and metabolic syndrome in the U.S. population, 2003-2004. Diabetes Care. 2008 Sep;31(9):1802-7. doi: 10.2337/dc08-0850. Epub 2008 Jun 16. 220. http://www.atsdr.cdc.gov/toxfaqs/tf.asp?id=528&tid=94 221. Akutsu K, Hori S. [Polybrominated diphenyl ether flame retardants in foodstuffs and human milk]. Shokuhin Eiseigaku Zasshi . 2004 Aug;45(4):175-83. Review. Japanese. 222. Schmidt, Charles. PBDEs in breast milk: levels higher in United States than in Europe &#8211; Science Selections . Environmental Health Perspectives . Nov 2003. 223. Stiffler, Lisa. “PBDEs: They are everywhere, they accumulate and they spread” . The Seattle Post Intelligentser , March 28, 2007. 224. http://www.ewg.org/research/pbdes-fire-retardants-dust 225. http://www.ewg.org/research/pbdes-fire-retardants-dust 226. http://www.niehs.nih.gov/health/materials/perflourinated_chemicals_508.pdf 227. http://www.ewg.org/research/dirty-dozen-list-endocrine-disruptors 228. http://www.ewg.org/research/dirty-dozen-list-endocrine-disruptors 229. De Coster S, van Larebeke N. Endocrine-disrupting chemicals: associated disorders and mechanisms of action. J Environ Public Health . 2012;2012:713696. Epub 2012 Sep 6. Review. 230. Sally S. White, Suzanne E. Fenton, Erin P. Hines. Endocrine disrupting properties of perfluorooctanoic acid . J Steroid Biochem Mol Biol. Author manuscript; available in PMC 2012 April 24. Published in final edited form as: J Steroid Biochem Mol Biol. 2011 October; 127(1-2): 16–26. Published online 2011 March 21. 231. Kjeldsen LS, Bonefeld-Jørgensen EC. Perfluorinated compounds affect the function of sex hormone receptors. Environ Sci Pollut Res Int. 2013 Nov;20(11):8031-44. doi: 10.1007/s11356-013-1753-3. Epub 2013 Jun 14. 232. Vested A, Ramlau-Hansen CH, Olsen SF, Bonde JP, Kristensen SL, Halldorsson TI, Becher G, Haug LS, Ernst EH, Toft G. Associations of in utero exposure to perfluorinated alkyl acids with human semen quality and reproductive hormones in adult men. Environ Health Perspect . 2013 Apr;121(4):453-8, 458e1-5. doi: 10.1289/ehp.1205118. Epub 2013 Jan 23. 233. Felix Grün, Bruce Blumberg. Endocrine disrupters as obesogens . Mol Cell Endocrinol. Author manuscript; available in PMC 2010 May 25. Published in final edited form as: Mol Cell Endocrinol. 2009 May 25; 304(1-2): 19–29. Published online 2009 March 9. doi: 10.1016/j.mce.2009.02.018 234. Wen LL, Lin LY, Su TC, Chen PC, Lin CY. Association between serum perfluorinated chemicals and thyroid function in U.S. adults: the National Health and Nutrition Examination Survey 2007-2010. J Clin Endocrinol Metab. 2013 Sep;98(9):E1456-64. doi: 10.1210/jc.2013-1282. Epub 2013 Jul 17. 235. Boas M, Feldt-Rasmussen U, Main KM. Thyroid effects of endocrine disrupting chemicals. Mol Cell Endocrinol . 2012 May 22;355(2):240-8. doi: 10.1016/j.mce.2011.09.005. Epub 2011 Sep 10. Review. 236. Marie-Louise Hartoft-Nielsen, Malene Boas, Sofie Bliddal, Åase Krogh Rasmussen, Katharina Main, Ulla Feldt-Rasmussen. Do Thyroid Disrupting Chemicals Influence Foetal Development during Pregnancy? J Thyroid Res. 2011; 2011: 342189. Published online 2011 September 11. doi: 10.4061/2011/342189 237. David Melzer, Neil Rice, Michael H. Depledge, William E. Henley, Tamara S. Galloway. Association between Serum Perfluorooctanoic Acid (PFOA) and Thyroid Disease in the U.S. National Health and Nutrition Examination Survey . Environ Health Perspect. 2010 May; 118(5): 686–692. Published online 2010 January 20. doi: 10.1289/ehp.0901584 238. Corsini E, Luebke RW, Germolec DR, Dewitt JC. Perfluorinated compounds: Emerging POPs with potential immunotoxicity. Toxicol Lett. 2014 Feb 3. pii: S0378-4274(14)00058-7. doi: 10.1016/j.toxlet.2014.01.038. [Epub ahead of print] 239. Wang IJ, Hsieh WS, Chen CY, Fletcher T, Lien GW, Chiang HL, Chiang CF, Wu TN, Chen PC. The effect of prenatal perfluorinated chemicals exposures on pediatric atopy. Environ Res . 2011 Aug;111(6):785-91. doi: 10.1016/j.envres.2011.04.006. Epub 2011 May 23. 240. Liu C, Gin KY, Chang VW. Multi-biomarker responses in green mussels exposed to PFCs: effects at molecular, cellular, and physiological levels. Environ Sci Pollut Res Int. 2014 Feb;21(4):2785-94. doi: 10.1007/s11356-013-2216-6. Epub 2013 Oct 17. 241. Uhl SA, James-Todd T, Bell ML. Association of Osteoarthritis with Perfluorooctanoate and Perfluorooctane Sulfonate in NHANES 2003-2008. Environ Health Perspect. 2013 Apr;121(4):447-52, 452e1-3. doi: 10.1289/ehp.1205673. Epub 2013 Feb 7. 242. Theodore A. Slotkin, Emiko A. MacKillop, Ronald L. Melnick, Kristina A. Thayer, Frederic J. Seidler. Developmental Neurotoxicity of Perfluorinated Chemicals Modeled in Vitro . Environ Health Perspect. 2008 June; 116(6): 716–722. Published online 2008 March 3. doi: 10.1289/ehp.11253 243. Chen Zee E, Cornet P, Lazimi G, Rondet C, Lochard M, Magnier AM, Ibanez G. [Impact of endocrine disrupting chemicals on birth outcomes]. Gynecol Obstet Fertil. 2013 Oct;41(10):601-10. doi: 10.1016/j.gyobfe.2013.08.012. Epub 2013 Oct 9. French. 244. Mei-Huei Chen, Eun-Hee Ha, Ting-Wen Wen, Yi-Ning Su, Guang-Wen Lien, Chia-Yang Chen, Pau-Chung Chen, Wu-Shiun Hsieh. Perfluorinated Compounds in Umbilical Cord Blood and Adverse Birth Outcomes . PLoS One. 2012; 7(8): e42474. Published online 2012 August 3. doi: 10.1371/journal.pone.0042474 245. Fei C, McLaughlin JK, Tarone RE, Olsen J. Perfluorinated chemicals and fetal growth: a study within the Danish National Birth Cohort. Environ Health Perspect . 2007 Nov;115(11):1677-82. 246. De Coster S, van Larebeke N. Endocrine-disrupting chemicals: associated disorders and mechanisms of action. J Environ Public Health . 2012;2012:713696. Epub 2012 Sep 6. Review. 247. Mireia Gascon, Marta Fort, David Martínez, Anne-Elie Carsin, Joan Forns, Joan O. Grimalt, Loreto Santa Marina, Nerea Lertxundi, Jordi Sunyer, Martine Vrijheid. Polybrominated Diphenyl Ethers (PBDEs) in Breast Milk and Neuropsychological Development in Infants . Environ Health Perspect. 2012 December; 120(12): 1760–1765. Published online 2012 September 25. doi: 10.1289/ehp.1205266 248. Wargo, John. Our Children’s Toxic Legacy: How Science and Law Fail to Protect Us from Pesticides. Yale University Press. 2nd edition (1998), page 3. 249. Wargo, John. Our Children’s Toxic Legacy: How Science and Law Fail to Protect Us from Pesticides. Yale University Press. 2nd edition (1998), pages 11-12. 250. Carol J. Burns, Laura J. McIntosh, Pamela J. Mink, Anne M. Jurek, Abby A. Li. Pesticide Exposure and Neurodevelopmental Outcomes: Review of the Epidemiologic and Animal Studies . J Toxicol Environ Health B Crit Rev. 2013 April; 16(3-4): 127–283. Published online 2013 June 18. doi: 10.1080/10937404.2013.783383 251. National Academy of Sciences. Research on children and adolescents with mental, behavioral, and developmental disorders. Washington, DC: National Academy Press; 1988. 252. Wargo, John. Our Children’s Toxic Legacy: How Science and Law Fail to Protect Us from Pesticides. Yale University Press. 2nd edition (1998) 402 pages. 253. Leslie London, Cheryl Beseler, Maryse F. Bouchard, David C. Bellinger, Claudio Colosio, Philippe Grandjean, Raul Harari, Tahira Kootbodien, Hans Kromhout, Francesca Little, Tim Meijster, Angelo Moretto, Diane S. Rohlman, Lorann Stallones. Neurobehavioural and neurodevelopmental effects of pesticide exposures . Neurotoxicology. Author manuscript; available in PMC 2013 August 1. Published in final edited form as: Neurotoxicology. 2012 August; 33(4): 887–896. Published online 2012 January 17. doi: 10.1016/j.neuro.2012.01.004 254. Raul Harari, Jordi Julvez, Katsuyuki Murata, Dana Barr, David C. Bellinger, Frodi Debes, Philippe Grandjean. Neurobehavioral Deficits and Increased Blood Pressure in School-Age Children Prenatally Exposed to Pesticides . Environ Health Perspect. 2010 June; 118(6): 890–896. Published online 2010 February 25. doi: 10.1289/ehp.0901582 255. http://www.ewg.org/news/testimony-official-correspondence/leading-scientists-call-increases-pesticide-testing-childrens 256. http://www.ewg.org/news/news-releases/2012/09/03/organic-produce-reduces-exposure-pesticides-research-confirms 257. Devon Payne-Sturges, Jonathan Cohen, Rosemary Castorina, Daniel A. Axelrad, Tracey J. Woodruff. Evaluating Cumulative OP Pesticide Body Burden of Children: A National Case Study . Environ Sci Technol. Author manuscript; available in PMC 2010 October 15. Published in final edited form as: Environ Sci Technol. 2009 October 15; 43(20): 7924–7930. doi: 10.1021/es900713s 258. Maryse F. Bouchard, David C. Bellinger, Robert O. Wright, Marc G. Weisskopf. Attention deficit/hyperactivity disorder and urinary metabolites of organophosphate pesticides in U.S. children 8–15 years . Pediatrics . Author manuscript; available in PMC 2013 July 9. Published in final edited form as: Pediatrics. 2010 June; 125(6): e1270–e1277. Published online 2010 May 17. doi: 10.1542/peds.2009-3058 259. Curl C. L. Fenske R. A. Kissel J. C. Shirai J. H. Moate T. F. Griffith W. Coronado G. Thompson B. Evaluation of take-home organophosphorus pesticide exposure among agricultural workers and their children. Environ. Health Perspect. 2002;110:A787–A792. 260. Fenske R. A. Lu C. Barr D. Needham L. Children’s exposure to chlorpyrifos and parathion in an agricultural community in central Washington State. Environ. Health Perspect. 2002;110:549–553. 261. Curwin B. D. Hein M. J. Sanderson W. T. Striley C. Heederik D. Kromhout H. Reynolds S. J. Alavanja M. C. Urinary pesticide concentrations among children, mothers and fathers living in farm and non-farm households in Iowa. Ann. Occup. Hyg. 2007;51:53–65. 262. Arcury T. A. Quandt S. A. Barr D. B. Hoppin J. A. Mccauley L. Grzywacz J. G. Robson M. G. Farmworker exposure to pesticides: Methodologic issues for the collection of comparable data. Environ. Health Perspect. 2006;114:923–928. 263. http://www.ewg.org/news/news-releases/2011/06/13/ewgs-2011-shoppers-guide-helps-cut-consumer-pesticide-exposure 264. http://www.ewg.org/news/news-releases/2012/09/03/organic-produce-reduces-exposure-pesticides-research-confirms 265. http://www.ewg.org/news/news-releases/2012/09/03/organic-produce-reduces-exposure-pesticides-research-confirms 266. Starek A, Szabla J. [Ethylene glycol alkyl ethers&#8211;the substances noxious to health] . Med Pr. 2008;59(2): 179-85. Review. Polish. 267. Cordier S, Garlantézec R, Bonvallot N, Multigner L. Glycol ethers and congenital malformations. Epidemiology . 2013 Nov;24(6):940. doi: 10.1097/EDE.0b013e3182a79ac7. No abstract available. 268. El-Zein RA, Abdel-Rahman SZ, Morris DL, Legator MS . Exposure to ethylene glycol monomethyl ether: clinical and cytogenetic findings. Arch Environ Health. 2002 Jul-Aug;57(4):371-6. 269. Cherry N, Moore H, McNamee R, Pacey A, Burgess G, Clyma JA, Dippnall M, Baillie H, Povey A; participating centres of Chaps-UK. Occupation and male infertility: glycol ethers and other exposures. Occup Environ Med . 2008 Oct;65(10):708-14. doi: 10.1136/oem.2007.035824. Epub 2008 Apr 16. 270. Cicolella A. [Glycol ethers reproductive risks] . Gynecol Obstet Fertil. 2006 Oct;34(10):955-63. Epub 2006 Sep 20. Review. French. 271. Jensen TK, Bonde JP, Joffe M. The influence of occupational exposure on male reproductive function. Occup Med (Lond) . 2006 Dec;56(8):544-53. Review. 272. Sheiner EK, Sheiner E, Hammel RD, Potashnik G, Carel R. Effect of occupational exposures on male fertility: literature review. Ind Health . 2003 Apr;41(2):55-62. Review. 273. Massaad C, Entezami F, Massade L, Benahmed M, Olivennes F, Barouki R, Hamamah S. How can chemical compounds alter human fertility? Eur J Obstet Gynecol Reprod Biol. 2002 Jan 10;100(2):127-37. Review. 274. Adedara IA, Farombi EO: Induction of oxidative damage in the testes and spermatozoa and hematotoxicity in rats exposed to multiple doses of ethylene glycol monoethyl ether. Hum Exp Toxicol. 2010, 29, 801–812. 275. Bagchi G, Waxman DJ. Toxicity of ethylene glycol monomethyl ether: impact on testicular gene expression. Int J Androl . 2008, 31, 269–274. 276. Multigner L, Ben Brik E, Arnaud I, Haguenoer JM, Jouannet P, Auger J, Eustache F. Glycol ethers and semen quality: a cross-sectional study among male workers in the Paris Municipality. Occup Environ Med. 2007 Jul;64(7):467-73. Epub 2007 Mar 1. 277. Welch LS, Schrader SM, Turner TW, Cullen MR. Effects of exposure to ethylene glycol ethers on shipyard painters II . Male reproduction. Am J Ind Med . 1988, 14, 509–526. 278. Hsieh GY, Wang JD, Cheng TJ, Chen PC. Prolonged menstrual cycles in female workers exposed to ethylene glycol ethers in the semiconductor manufacturing industry. Occup Environ Med. 2005 Aug;62(8):510-6. 279. Chen PC, Hsieh GY, Wang JD, Cheng TJ. Prolonged time to pregnancy in female workers exposed to ethylene glycol ethers in semiconductor manufacturing. Epidemiology . 2002 Mar;13(2):191-6. Hematological effects 280. Gold EB, Eskenazi B, Hammond SK, Lasley BL, Samuels SJ, O’Neill Rasor M, Hines CJ et al.: Prospectively assessed menstrual cycle characteristics in female wafer-fabrication and nonfabrication semiconductor employees. Am J Ind Med. 1995, 28, 799–815. 281. Davis BJ, Almekinder JL, Flagler N, Travlos G, Wilson R, Maronpot RR. Ovarian luteal cell toxicity of ethylene glycol monomethyl ether and methoxy acetic acid in vivo and in vitro. Toxicol Appl Pharmacol. 1997, 142, 328 – 337. 282. Shih TS, Hsieh AT, Liao GD, Chen YH, Liou SH. Haematological and spermatotoxic effects of ethylene glycol monomethyl ether in copper clad laminate factories. Occup Environ Med. 2000 May;57(5):348-52. 283. Starek A, Szymczak W, Zapor L. Hematological effects of four ethylene glycol monoalkyl ethers in short-term repeated exposure in rats. Arch Toxicol . 2008, 82, 125–136. 284. Starek-OEwiechowicz B, Miranowicz-Dzier¿awska K, SzymczakW, Budziszewska B, Starek A. Hematological effects of exposure to mixtures of selected ethylene glycol alkyl ethers in rats. Pharmacol Rep. 2012, 64, 166–178. 285. R R Miller, E A Hermann, J T Young, T D Landry, L L Calhoun. Ethylene glycol monomethyl ether and propylene glycol monomethyl ether: metabolism, disposition, and subchronic inhalation toxicity studies. Environ Health Perspect. 1984 August; 57: 233–239. 286. MortonW. Occupational phenoxyethanol neurotoxicity: a report of three cases. J Occup Med. 1990, 32, 42–45. 287. Pomierny B, Starek A, Krzyżanowska W, Starek-Swiechowicz B, Smaga I, Pomierny-Chamioło L, Regulska M, Budziszewska B. Potential neurotoxic effect of ethylene glycol ethers mixtures. Pharmacol Rep. 2013;65(5):1415-21. 288. http://www.ewg.org/news/news-releases/2012/02/10/epa-lists-dry-cleaning-chemical-likely-carcinogen 289. http://www.ewg.org/enviroblog/2011/09/dry-cleaning-chemicals-hang-around-your-clothes 290. Ruder AM. Potential health effects of occupational chlorinated solvent exposure. Ann N Y Acad Sci. 2006 Sep;1076:207-27. 291. Diodovich C, Ferrario D, Casati B, Malerba I, Marafante E, Parent-Massin D, Gribaldo L. Sensitivity of human cord blood cells to tetrachloroethylene: cellular and molecular endpoints. Arch Toxicol. 2005 Sep;79(9):508-14. Epub 2005 Jul 12. 292. Vlaanderen J, Straif K, Ruder A, Blair A, Hansen J, Lynge E, Charbotel B, Loomis D, Kauppinen T, Kyyronen P, Pukkala E, Weiderpass E, Guha N. Tetrachloroethylene Exposure and Bladder Cancer Risk: A Meta-Analysis of Dry-Cleaning-Worker Studies. Environ Health Perspect . 2014 Mar 21. [Epub ahead of print] 293. Guyton KZ, Hogan KA, Scott CS, Cooper GS, Bale AS, Kopylev L, Barone S, Makris SL, Glenn B, Subramaniam RP, Gwinn MR, Dzubow RC, Chiu WA. Human health effects of tetrachloroethylene: key findings and scientific issues. Environ Health Perspect. 2014 Apr;122(4):325-34. doi: 10.1289/ehp.1307359. Epub 2014 Feb 11. 294. Calvert GM, Ruder AM, Petersen MR. Mortality and end-stage renal disease incidence among dry cleaning workers. Occup Environ Med. 2011 Oct;68(10):709-16. doi: 10.1136/oem.2010.060665. Epub 2010 Dec 16. 295. Ma J, Lessner L, Schreiber J, Carpenter DO. Association between residential proximity to PERC dry cleaning establishments and kidney cancer in New York City. J Environ Public Health . 2009;2009:183920. doi: 10.1155/2009/183920. Epub 2010 Jan 24. 296. Guyton KZ, Hogan KA, Scott CS, Cooper GS, Bale AS, Kopylev L, Barone S, Makris SL, Glenn B, Subramaniam RP, Gwinn MR, Dzubow RC, Chiu WA. Human health effects of tetrachloroethylene: key findings and scientific issues. Environ Health Perspect . 2014 Apr;122(4):325-34. doi: 10.1289/ehp.1307359. Epub 2014 Feb 11. 297. Grandjean P, Landrigan PJ. Lancet Neurol. 2014 Mar;13(3):330-8. doi: 10.1016/S1474-4422(13)70278-3. Epub 2014 Feb 17. Review. 298. Aschengrau A, Weinberg JM, Janulewicz PA, Romano ME, Gallagher LG, Winter MR, Martin BR, Vieira VM, Webster TF, White RF, Ozonoff DM. Environ Health. 2012 Jan 20;11:2. doi: 10.1186/1476-069X-11-2. 299. Aschengrau A, Weinberg JM, Janulewicz PA, Gallagher LG, Winter MR, Vieira VM, Webster TF, Ozonoff DM. Prenatal exposure to tetrachloroethylene-contaminated drinking water and the risk of congenital anomalies: a retrospective cohort study. Environ Health. 2009 Sep 24;8:44. doi: 10.1186/1476-069X-8-44. 300. http://www.ewg.org/enviroblog/2011/09/dry-cleaning-chemicals-hang-around-your-clothes 301. http://www.ewg.org/news/news-releases/2011/04/08/national-academy-sciences-formaldehyde-causes-cancer 302a. “Formaldehyde in Clothing and Other Textiles” (PDF). Existing Chemicals Information Sheet. Australian National Industrial Chemicals Notification and Assessment Scheme. October 2007. 302b. http://www.ewg.org/enviroblog/2014/01/chemicals-should-disappear-cosmetics 303. Economic Importance , Formaldehyde Council . 2009. 304. http://www.epa.gov/ttn/atw/nata2005/05pdf/sum_results.pdf 305. National Toxicology Program (10 June 2011). “12th Report on Carcinogens” . National Toxicology Program . Retrieved 2011-06-11. 306. Kim KH, Jahan SA, Lee JT. Exposure to formaldehyde and its potential human health hazards. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2011 Oct;29(4):277-99. doi: 10.1080/10590501.2011.629972. Review. 307. Formaldehyde , A CICAD (Concise International Chemical Assessment Document) No. 40. International Programme on Chemical Safety (IPSC). World Health Organization. 2003. 308. “Agency for Toxic Substance & Disease Registry/Environmental Protection Agency”. In Toxicological Profile for Formaldehyde , 468–476. Dept. of Health and Human Services. July 1999. 309. Kulle, T J. 1993. Acute odor and irritation response in healthy nonsmokers with formaldehyde exposure. Inhal Toxicol. , 5: 323–332. 310. Zhang, D Z, Zhang, F L, Jin, S Y and Liu, Y H. 1999. Investigation on the health of workers occupationally exposed to low level of formaldehyde. Chinese J Ind Hyg Occup Dis. , 17(5): 13–14. 311. Kulle, T J. 1993. Acute odor and irritation response in healthy nonsmokers with formaldehyde exposure . Inhal Toxicol. , 5: 323–332. 312. Salonen, H, Pasanen, A L, Lappalainen, S, Riuttala, H, Tuomi, T and Pasanen, P. 2009. Volatile organic compounds and formaldehyde as explaining factors for sensory irritation in office environments. J Occup Environ Hyg , 6(4): 239–247. 313. Cronin, E. 1991. Formaldehyde is a significant allergen in women with hand eczema. Contact Dermatitis , 25(5): 276–282. 314. Meding, B and Swanbeck, G. 1990. Occupational hazard in an industrial city. Contact Dermatitis , 22(1): 13–23. 315. Scheman, A J, Carroll, P A, Brown, K H and Osburn, A H. 1998. Formaldehyde-related textile allergy: An update. Contact Dermatitis , 38(6): 332–336. 316. Rastogi, S C. 1992. A survey of formaldehyde in shampoos and skin creams on the Danish market. Contact Dermatitis , 27(4): 235–240. 317. Su, H and Zheng, R. 1995. Four contact dermatitis cases exposed to phenolic aldehyde resin. J Preven Med , 1: 1–8. 318. Wu, D F and Wu, Y H. 2001. Investigation of dermatitis caused by occupational formaldehyde exposure. J Labour Med , 18(4): 226–227. 319. Brooks, S M, Hammad, Y, Richards, I, Giovonco-Barbas, J and Jenkins, K. 1998. The spectrum of irritant-induced asthma: sudden and not-so sudden onset and the role of allergy. Chest , 113: 42–49. 320. Vandenplas, O, Fievez, P, Delwiche, J P, Boulanger, J and Thimpont, J. 2004. Persistent asthma following accidental exposure to formaldehyde. Allergy , 59: 115–116. 321. Yue, W, Jin, X B, Pan, X C and Ding, J. 2004. Relationship between indoor air formaldehyde exposure and allergic asthma in adults. Chinese J Pub Heal . 20(8): 904–906. 322. Kim, C W, Song, J S, Ahn, Y S, Park, S H, Noh, J H and Hong, C S. 2001. Occupational asthma due to formaldehyde. Yonsei Med J , 42: 440–445. 323. Rumchev, K B, Spickett, J T, Bulsara, M K, Phillips, M R and Stick, S M. 2002. Domestic exposure to formaldehyde significantly increases the risk of asthma in young children. Eur Resp J. , 20(2): 403–408. 324. Casset, A, Marchand, C, Purohit, A, le-Calve, S, Uring-Lambert, B and Donnay, C. 2006. Inhaled formaldehyde exposure: Effect on bronchial response to mite allergen in sensitized asthma patients. Allergy , 61: 1344–1350. 325. McGwin, G, Lienert, J and Kennedy, J I. 2010. Formaldehyde exposure and asthma in children: A systematic review. Environ Health Perspect , 118(3): 313–317. 326. Vandenplas, O, Fievez, P, Delwiche, J P, Boulanger, J and Thimpont, J. 2004. Persistent asthma following accidental exposure to formaldehyde. Allergy , 59: 115–116. 327. Krakowiak, A, Gorski, P, Pazdrak, K and Ruta, U. 1998. Airway response to formaldehyde inhalation in asthmatic subjects with suspected respiratory formaldehyde sensitization. Am J Indus Med. , 33: 274–281. 328. Dai, D and Bao, Z. 1999. Investigative report on formaldehyde occupational workers. Ind Heal Occup Dis. , 1: 43–51. 329. Costa, S, Pina, C, Coelho, P, Costa, C, Silva, SPorto, B. 2011. Occupational exposure to formaldehyde: Genotoxic risk evaluation by comet assay and micronucleus test using human peripheral lymphocytes. J Toxicol Environ Health A , 74: 1040–1051. 330. Li, Z G and Chen, B C. 2002. Effect of low concentration formaldehyde on the health of workers. Chinese J Ind Med. , 15(5): 302–303. 331. Geng, Y, Meng, X, Li, X and Lu, G. 2004. Occupational damage in densified wood board producing field and its effect on workers’ health. Occup Heal. , 20(8): 21–22. 332. Fan, W, Zhou, Y, Jin, F, Du, L and Jin, X. 2006. The health effects of pathologists exposed to formaldehyde. J Occup Environ Med. , 23(6): 466–468. 333. Rager, J E, Smeester, L, Jaspers, I, Sexton, K G and Fry, R C. 2011. Epigenetic changes induced by air toxics: Formaldehyde exposure alters miRNA expression profiles in human lung cells. Environ Health Perspect , 119(4): 494–500. 334. International Agency for Research on Cancer (IARC). 1995. Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Wood Dust and Formaldehyde. Lyon, France: International Association for Research on Cancer. 335. Feng, Y, Wang, W, Jiang, Z, Hu, G, Zhong, S and Zhang, H. 1996. Health status of wood workers exposed to formaldehyde. Anhui J Preven Med. , 2(2): 99–100. 336. Tang, L X and Zhang, Y S . 2003. Health investigation on workers exposed to formaldehyde. Occup Heal. , 19(7): 34–35. 337. Lu, Y, Chen, X J, Yang, X Y and Xue, Z Q. 2007. A survey of the effection to teachers’ health from formaldehyde contact. J Xinjiang Med Uni. , 30(3): 234–237. 338. Songur, A, Ozen, O A and Sarsilmaz, M. 2010. The toxic effects of formaldehyde on the nervous system. Rev Environ Contam Toxicol , 203: 105–118. 339. International Agency for Research on Cancer (IARC). 1995. Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Wood Dust and Formaldehyde. Lyon, France: International Association for Research on Cancer. 340. Armon, C. 2009. Smoking may be considered an established risk factor for sporadic ALS. Neurology , 73: 1693–1698. 341. Weisskopf, M G, Morozova, N, O’Reilly, E J, McCullough, M L, Calle, E E, Thun, M J and Ascherio, A. 2009. Prospective study of chemical exposures and amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. , 80: 558–561. 342. Hong, Z, Tong, Z and Shi, J. 2007. Effects of formaldehyde on respiratory system and pulmonary function of workers. Chinese J Pub Heal. , 23(7): 849–850. 343. Kriebel, D, Sama, S R and Cocanour, B. 1993. Reversible pulmonary responses to formaldehyde. A study of clinical anatomy students. Am Rev Respirat Dis , 148: 1509–1515. 344. Akbar-Khanzadeh, F and Mlynek, J S. 1997. Changes in respiratory function after one and three hours of exposure to formaldehyde in non-smoking subjects. Occup Environ Med , 54: 296–300. 345. Wang, W, Wang, Q and Zhou, Y. 2000. Effects of low concentration of formaldehyde on respiratory system and pulmonary function of workers. Chinese J Ind Med. , 13(2): 115–116. 346. Li, Z G and Chen, B C. 2002. Effect of low concentration formaldehyde on the health of workers. Chinese J Ind Med. , 15(5): 302–303. 347. Fan, W, Zhou, Y, Jin, F, Du, L and Jin, X. 2006. The health effects of pathologists exposed to formaldehyde. J Occup Environ Med. , 23(6): 466–468. 348. Tang, L X and Zhang, Y S. 2003. Health investigation on workers exposed to formaldehyde. Occup Heal. , 19(7): 34–35. 349. Tong, Z M, Zhu, S X and Shi, J. 2007. Effect of formaldehyde on blood component and blood biochemistry of exposed workers. Chinese J Ind Med. , 20(6): 409–410. 350. Yang, W H. 2007. Hemogram of workers exposed to low concentration of formaldehyde. Prac Preven Med. , 14(3): 792–799. 351. Huang, Y, Zou, Z and Deng, H. 2007. An analysis report about peripheral blood anemia induced by excessive formaldehyde in abiding place. Jiangsu Environ Sci Technol , 20: 16–17. 352. Huang, W, Lu, Y, Chang, X, Bai, L, Zhao, H and Liu, W. 2007. Indoor air pollution in newly redecorated rooms. J Environ Heal , 24(2): 101–103. 353. Kuo, H, Jian, G, Chen, C, Liu, C and Lai, J. 1997. White blood cell count as an indicator of formaldehyde exposure. Bull Environ Cont Toxicol , 59(2): 261–267. 354. Xu, S Y, Yi, G L and Li, S H. 2007. Hygienic investigation of the effect of formaldehyde on the workers’ health. Occup Heal. , 23(7): 491–492. 355. Lu, Y, Chen, X J, Yang, X Y and Xue, Z Q. 2007. A survey of the effection to teachers’ health from formaldehyde contact. J Xinjiang Med Uni. , 30(3): 234–237. 356. Taskinen, H K, Kyyronen, P, Hemminki, K, Hoikkala, M, Lajunen, K and Lindbohm, M L. 1994. Laboratory work and pregnancy outcome. J Occup Med. , 36(3): 311–319. 357. Taskinen, H K, Kyyronen, P, Sallmen, M, Virtanen, S V, Liukkonen, T A and Huida, O. 1999. Reduced fertility among female wood workers exposed to formaldehyde. Am J Ind Med. , 36(1): 206–212. 358. Zhang, L, Steinmaus, C, Eastmond, D A, Xin, X K and Smith, M T. 2009. Formaldehyde exposure and leukemia: A new meta-analysis and potential mechanisms. Muta Res , 681: 150–168. 359. Washam, C. 2011. Epigenetics of formaldehyde: Altered microRNAs may be key to adverse effects. Environ Health Perspect , 119: 176–182. 360. IARC. 2006. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol. 88 Formaldehyde, 2-Butoxyethanol and 1-tert-Butoxypropan-2-ol . Available at: http://monographs.iarc.fr/ENG/Monographs/vol88/index.php 361. Yang, Y, Allen, B C, Tan, Y M, Liao, K H and Clewell, H J. 2010. Bayesian analysis of a rat formaldehyde DNA-protein cross-link model. J Toxicol Environ Health A , 73(12): 787–806. 362. Jiang, L. 2006. Mensuration of indoor formaldehyde pollution of Pingdingshan municipal office building. J Pingdingshan Ins Technol. , 15(3): 38–39. 363. Tong, Z M, Shi, J, Zhao, J S, Yang, H, Jiang, R M and Kong, L. 2006. Analysis on genetic toxicity of formaldehyde on occupational exposure population. Chinese J Pub Heal. , 22(7): 783–784. 364. Yu, L Q, Jiang, S F, Leng, S G, Zhang, C Z, Yan, Y J and Niu, Y. 2005. Early genetic effects on workers occupationally exposed to formaldehyde. Chinese J Preven Med. , 39(6): 392–395. 365. Costa, S, Coelho, P, Costa, C, Silva, S, Mayan, O and Santos, L S. 2008. Genotoxic damage in pathology anatomy laboratory workers exposed to formaldehyde. Toxicology , 252: 40–48. 366. Environment Canada/Health Canada. Canadian Environmental Protection Act. 1999. Priority substances list assessment report. Formaldehyde. Government of Canada, Environment Canada, Health Canada. 2001. 367. World Health Organization. 2002. Concise International Chemical Assessment Document 40. Formaldehyde , Geneva: Author. 368. IARC. 2006. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 88 Formaldehyde, 2-Butoxyethanol and 1-tert-Butoxypropan-2-ol Available at: http://monographs.iarc.fr/ENG/Monographs/vol88/index.php 369. Kim KH, Jahan SA, Lee JT. Exposure to formaldehyde and its potential human health hazards. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2011 Oct;29(4):277-99. doi: 10.1080/10590501.2011.629972. Review. 370. 2011. “National Toxicology Program (NTP)”. In Report on Carcinogens , 12th ed, Department of Health and Human Services, Public Health Service, National Toxicology Program. Available at: http://ntp.niehs.nih.gov/go/roc12 371. Integrated Risk Information System. 2010. Formaldehyde , Washington, DC: US Environmental Protection Agency. Available at: http://cfpub.epa.gov/ncea/iris_drafts/recordisplay.cfm?deid=223614 372. Thompson, C M and Grafstrom, R C. 2011. Considerations for the implausibility of leukemia induction by formaldehyde. Toxicol Sci , 120: 230–232. 373. Schwilk, E, Zhang, L, Smith, M T, Smith, A H and Steinmaus, C. 2010. Formaldehyde and leukemia: An updated meta-analysis and evaluation of bias. J Occup Environ Med , 52: 878–886. 374. Pinkerton, L, Hein, M and Stayner, L. 2004. Mortality among a cohort of garment workers exposed to formaldehyde: An update. Occup Environ Med , 61(3): 193–200. 375. Dreyfuss, J H. 2010. Occupational formaldehyde exposure linked to increased risk of myeloid leukemia and death. CA Cancer J Clin , 60(3): 135–136. 376. Crinnion WJ. Toxic effects of the easily avoidable phthalates and parabens. Altern Med Rev. 2010 Sep;15(3):190-6. Review. 377. Ye X, Bishop AM, Reidy JA, Needham LL, Calafat AM. Parabens as urinary biomarkers of exposure in humans. Environ Health Perspect. 2006 Dec;114(12):1843-6. 378. http://www.ewg.org/research/teen-girls-body-burden-hormone-altering-cosmetics-chemicals/cosmetics-chemicals-concern#Parabens 379. Canosa P, Rodríguez I, Rubí E, Cela R. Determination of parabens and triclosan in indoor dust using matrix solid-phase dispersion and gas chromatography with tandem mass spectrometry. Anal Chem. 2007 Feb 15;79(4):1675-81. 380. Crinnion WJ. Toxic effects of the easily avoidable phthalates and parabens. Altern Med Rev. 2010 Sep;15(3):190-6. Review. 381. Darbre PD, Harvey PW. Paraben esters: review of recent studies of endocrine toxicity, absorption, esterase and human exposure, and discussion of potential human health risks. J Appl Toxicol. 2008 Jul;28(5):561-78. doi: 10.1002/jat.1358. Review. 382. Cheng S, Leow YH, Goh CL, Goon A. Contact sensitivity to preservatives in Singapore: frequency of sensitization to 11 common preservatives 2006-2011. Dermatitis . 2014 Mar-Apr;25(2):77-82. doi: 10.1097/DER.0000000000000031. 383. Travassos AR, Claes L, Boey L, Drieghe J, Goossens A. Non-fragrance allergens in specific cosmetic products. Contact Dermatitis. 2011 Nov;65(5):276-85. doi: 10.1111/j.1600-0536.2011.01968.x. Epub 2011, Sep 21. 384. Soni MG, Taylor SL, Greenberg NA, Burdock GA. Evaluation of the health aspects of methyl paraben: a review of the published literature. Food Chem Toxicol. 2002 Oct;40(10):1335-73. Review. 385. Soni MG, Burdock GA, Taylor SL, Greenberg NA. Safety assessment of propyl paraben: a review of the published literature. Food Chem Toxicol . 2001 Jun;39(6):513-32. Review. 386. Mowad CM. Allergic contact dermatitis caused by parabens: 2 case reports and a review. Am J Contact Dermat . 2000 Mar;11(1):53-6. Review. 387. Darbre PD, Harvey PW. Paraben esters: review of recent studies of endocrine toxicity, absorption, esterase and human exposure, and discussion of potential human health risks. J Appl Toxicol. 2008 Jul;28(5):561-78. doi: 10.1002/jat.1358. Review. 388. Ge JH, Chang B. [Estrogenic activities of parabens] . Wei Sheng Yan Jiu . 2006 Sep;35(5):650-2. Review. Chinese. 389. Scialli AR. Reproductive effects of the parabens. Reprod Toxicol. 2011 Jul;32(1):138-40; author reply 141. doi: 10.1016/j.reprotox.2011.03.005. Epub 2011 Mar 31. 390. Boberg J, Taxvig C, Christiansen S, Hass U. Possible endocrine disrupting effects of parabens and their metabolites. Reprod Toxicol. 2010 Sep; 30(2):301-12. Epub 2010 Apr 8. 391. Kim TS, Kim CY, Lee HK, Kang IH, Kim MG, Jung KK, Kwon YK, Nam HS, Hong SK, Kim HS, Yoon HJ, Rhee GS. Estrogenic Activity of Persistent Organic Pollutants and Parabens Based on the Stably Transfected Human Estrogen Receptor-α Transcriptional Activation Assay (OECD TG 455). Toxicol Res. 2011 Sep;27(3):181-4. doi: 10.5487/TR.2011.27.3.181. 392. Vos J.G., Dybing E., Greim H.A., Ladefoged O., Lambre C., Tarazona J.V., Brandt I., Vethaak A.D. Health effects of endocrine-disrupting chemicals on wildlife, with special reference to the European situation. Crit. Rev. Toxicol. (2000);30:71–133. 393. Christiansen S, Kortenkamp A, Axelstad M, Boberg J, Scholze M, Jacobsen PR, Faust M, Lichtensteiger W, Schlumpf M, Burdorf A, Hass U. Mixtures of endocrine disrupting contaminants modelled on human high end exposures: an exploratory study in rats. Int J Androl. 2012 Jun;35(3):303-16. doi: 10.1111/j.1365-2605.2011.01242.x. Epub 2012 Feb 28. 394. Kim SM, Jung EM, An BS, Hwang I, Vo TT, Kim SR, Lee SM, Choi KC, Jeung EB. Additional effects of bisphenol A and paraben on the induction of calbindin-D(9K) and progesterone receptor via an estrogen receptor pathway in rat pituitary GH3 cells. J Physiol Pharmacol. 2012 Oct;63(5):445-55. 395. Ahn HJ, An BS, Jung EM, Yang H, Choi KC, Jeung EB. Parabens inhibit the early phase of folliculogenesis and steroidogenesis in the ovaries of neonatal rats. Mol Reprod Dev . 2012 Sep;79(9):626-36. doi: 10.1002/mrd.22070. Epub 2012 Jul 26. 396. Smith KW, Souter I, Dimitriadis I, Ehrlich S, Williams PL, Calafat AM, Hauser R. Urinary paraben concentrations and ovarian aging among women from a fertility center. Environ Health Perspect. 2013 Nov-Dec;121(11-12):1299-305. doi: 10.1289/ehp.1205350. Epub 2013 Aug 1. 397. Towers CV, Chambers W, Lewis D, Howard B, Chen J, Terry P. Transplacental passage of antimicrobial paraben preservatives. Obstet Gynecol. 2014 May;123 Suppl 1:175S-6S. doi: 10.1097/01. AOG.0000447188.44313.6e. 398. Konduracka E, Krzemieniecki K, Gajos G. Relationship between everyday use cosmetics and female breast cancer. Pol Arch Med Wewn. 2014 Apr 2. pii: AOP_14_026. [Epub ahead of print] 399. Błędzka D, Gromadzińska J, Wąsowicz W. Parabens. From environmental studies to human health. Environ Int. 2014 Jun;67:27-42. doi: 10.1016/j.envint.2014.02.007. Epub 2014 Mar 19. Review. 400. Darbre PD, Harvey PW. Paraben esters: review of recent studies of endocrine toxicity, absorption, esterase and human exposure, and discussion of potential human health risks. J Appl Toxicol. 2008 Jul;28(5):561-78. doi: 10.1002/jat.1358. Review. 401. Darbre PD. Environmental oestrogens, cosmetics and breast cancer. Best Pract Res Clin Endocrinol Metab. 2006 Mar;20(1):121-43. Review. 402. Harvey PW, Darbre P. Endocrine disrupters and human health: could oestrogenic chemicals in body care cosmetics adversely affect breast cancer incidence in women? J Appl Toxicol. 2004 May-Jun;24(3):167-76. Review. 403. Darbre PD, Aljarrah A, Miller WR, Coldham NG, Sauer MJ, Pope GS. Concentrations of parabens in human breast tumours. J Appl Toxicol. 2004 Jan-Feb;24(1):5-13. 404. Charles AK, Darbre PD. Combinations of parabens at concentrations measured in human breast tissue can increase proliferation of MCF-7 human breast cancer cells. J Appl Toxicol . 2013 May;33(5):390-8. doi: 10.1002/jat.2850. Epub 2013 Jan 31. 405. Vo TT 1 , Jeung EB . An evaluation of estrogenic activity of parabens using uterine calbindin-d9k gene in an immature rat model. Toxicol Sci. 2009 Nov;112(1):68-77. doi:10.1093/toxsci/kfp176. Epub 2009 Aug 4. 406. Pugazhendhi D, Pope GS, Darbre PD. Oestrogenic activity of p-hydroxybenzoic acid (common metabolite of paraben esters) and methylparaben in human breast cancer cell lines. J Appl Toxicol . 2005 Jul-Aug;25(4):301-9. 407. Okubo T., Yokoyama Y., Kano K., Kano I. ERdependent estrogenic activity of parabens assessed by proliferation of human breast cancer MCF-7 cells and expression of ERalpha and PR. Food Chem. Toxicol. (2001);39:1225–1232. doi: 10.1016/S0278-6915(01)00073-4. 408. Khanna S, Dash PR, Darbre PD. Exposure to parabens at the concentration of maximal proliferative response increases migratory and invasive activity of human breast cancer cells in vitro. J Appl Toxicol. 2014 Mar 20. doi: 10.1002/jat.3003. [Epub ahead of print] 409. http://www.ewg.org/research/teen-girls-body-burden-hormone-altering-cosmetics-chemicals/cosmetics-chemicals-concern#Parabens 410. http://www.ewg.org/enviroblog/2014/01/chemicals-should-disappear-cosmetics 411. http://www.ewg.org/research/teen-girls-body-burden-hormone-altering-cosmetics-chemicals/cosmetics-chemicals-concern 412. http://www.fda.gov/forconsumers/consumerupdates/ucm205999.htm 413. Tan L , Nielsen NH , Young DC , Trizna Z ; Council on Scientific Affairs, American Medical Association . Use of antimicrobial agents in consumer products. Arch Dermatol. 2002 Aug;138(8):1082-6. 414. Toms LM, Allmyr M, Mueller JF, Adolfsson-Erici M, McLachlan M, Murby J, Harden FA. Triclosan in individual human milk samples from Australia. Chemosphere . 2011 Dec;85(11):1682-6. doi: 10.1016/j.chemosphere.2011.08.009. Epub 2011 Oct 13. 415. Adolfsson-Erici M, Pettersson M, Parkkonen J, Sturve J. Triclosan, a commonly used bactericide found in human milk and in the aquatic environment in Sweden. Chemosphere. 2002 Mar;46(9-10):1485-9. 416. Allmyr M, Adolfsson-Erici M, McLachlan MS, Sandborgh-Englund G. Triclosan in plasma and milk from Swedish nursing mothers and their exposure via personal care products. Sci Total Environ. 2006 Dec 15;372(1):87-93. Epub 2006 Sep 26. 417. Allmyr M, McLachlan MS, Sandborgh-Englund G, Adolfsson-Erici M. Determination of triclosan as its pentafluorobenzoyl ester in human plasma and milk using electron capture negative ionization mass spectrometry. Anal Chem. 2006 Sep 15;78(18):6542-6. 418. Dayan AD . Risk assessment of triclosan [Irgasan] in human breast milk. Food Chem Toxicol. 2007 Jan;45(1):125-9. Epub 2006 Aug 30. 419. Calafat AM, Ye X, Wong LY, Reidy JA, Needham LL. Urinary concentrations of triclosan in the U.S. population: 2003-2004. Environ Health Perspect. 2008 Mar;116(3):303-7. doi: 10.1289/ehp.10768. 420. Wolff MS, Teitelbaum SL, Pinney SM, Windham G, Liao L, Biro F, Kushi LH, Erdmann C, Hiatt RA, Rybak ME, Calafat AM. Investigation of relationships between urinary biomarkers of phytoestrogens, phthalates, and phenols and pubertal stages in girls. Breast Cancer and Environment Research Centers. Environ Health Perspect. 2010 Jul;118(7):1039-46. doi: 10.1289/ehp.0901690. Epub 2010 Mar 22. 421. Bertelsen RJ, Engel SM, Jusko TA, Calafat AM, Hoppin JA, London SJ, Eggesbø M, Aase H, Zeiner P, Reichborn-Kjennerud T, Knudsen GP, Guidry VT, Longnecker MP. Reliability of triclosan measures in repeated urine samples from Norwegian pregnant women. J Expo Sci Environ Epidemiol. 2014 Jan 29. doi: 10.1038/jes.2013.95. [Epub ahead of print] 422. Kolpin DW, Furlong ET, Meyer MT, Thurman EM, Zaugg SD, Barber LB, Buxton HT. Pharmaceuticals, hormones, and other organic wastewater contaminants in U.S. streams, 1999-2000: a national reconnaissance. Environ Sci Technol. 2002 Mar 15;36(6):1202-11. 423. McAvoy DC, Schatowitz B, Jacob M, Hauk A, Eckhoff WS. Measurement of triclosan in wastewater treatment systems. Environ Toxicol Chem. 2002 Jul;21(7):1323-9. 424. Kanda R, Griffin P, James HA, Fothergill J. Pharmaceutical and personal care products in sewage treatment works. J Environ Monit . 2003 Oct;5(5):823-30. 425. http://www.ewg.org/research/down-drain/%C2%BB-triclosan 426. Canosa P, Rodríguez I, Rubí E, Cela R. Determination of parabens and triclosan in indoor dust using matrix solid-phase dispersion and gas chromatography with tandem mass spectrometry. Anal Chem. 2007 Feb 15;79(4):1675-81. 427. Calafat AM, Ye X, Wong LY, Reidy JA, Needham LL. Urinary concentrations of triclosan in the U.S. population: 2003-2004. Environ Health Perspect. 2008 Mar;116(3):303-7. doi: 10.1289/ehp.10768. 428. Geens T, Neels H, Covaci A. Distribution of bisphenol-A, triclosan and n-nonylphenol in human adipose tissue, liver and brain. Chemosphere . 2012 May;87(7):796-802. doi: 10.1016/j.chemosphere. 2012.01.002. Epub 2012 Jan 24. 429. Erika S. Koeppe, Kelly K. Ferguson, Justin A. Colacino, John D. Meeker. Relationship between Urinary Triclosan and Paraben Concentrations and Serum Thyroid Measures in NHANES 2007–2008 . Sci Total Environ. Author manuscript; available in PMC 2014 February 15. Published in final edited form as: Sci Total Environ. 2013 February 15; 445-446: 299–305. Published online 2013 January 20. 430. Katie B. Paul, Joan M. Hedge, Ruby Bansal, R. Thomas Zoeller, Robert Peter, Michael J. DeVito, Kevin M. Crofton. Developmental Triclosan Exposure Decreases Maternal, Fetal, and Early Neonatal Thyroxine: Dynamic and Kinetic Evaluation of a Putative Mode-of-Action . Toxicology . Author manuscript; available in PMC 2013 October 9. Published in final edited form as: Toxicology. 2012 October 9; 300(1-2): 31–45. 431. Axelstad M, Boberg J, Vinggaard AM, Christiansen S, Hass U. Triclosan exposure reduces thyroxine levels in pregnant and lactating rat dams and in directly exposed offspring. Food Chem Toxicol . 2013 Sep;59:534-40. doi: 10.1016/j.fct.2013.06.050. Epub 2013 Jul 4. 432. Crofton KM, Paul KB, Devito MJ, Hedge JM. Short-term in vivo exposure to the water contaminant triclosan: Evidence for disruption of thyroxine. Environ Toxicol Pharmacol. 2007 Sep;24(2):194-7. doi: 10.1016/j.etap.2007.04.008. Epub 2007 Apr 27. 433. Paul KB, Hedge JM, Devito MJ, Crofton KM. Developmental triclosan exposure decreases maternal and neonatal thyroxine in rats. Environ Toxicol Chem. 2010 Dec;29(12):2840-4. doi: 10.1002/etc.339. Epub 2010 Oct 15. 434. Paul KB, Hedge JM, DeVito MJ, Crofton KM. Short-term exposure to triclosan decreases thyroxine in vivo via upregulation of hepatic catabolism in Young Long-Evans rats. Toxicol Sci . 2010 Feb;113(2):367-79. doi: 10.1093/toxsci/kfp271. Epub 2009 Nov 12. 435. Rodríguez PE 1 , Sanchez MS . Maternal exposure to triclosan impairs thyroid homeostasis and female pubertal development in Wistar rat offspring. J Toxicol Environ Health A . 2010;73(24):1678-88. doi: 10.1080/15287394.2010.516241. 436. Zorrilla LM, Gibson EK, Jeffay SC, Crofton KM, Setzer WR, Cooper RL, Stoker TE. The effects of triclosan on puberty and thyroid hormones in male Wistar rats. Toxicol Sci. 2009 Jan;107(1):56-64. doi: 10.1093/toxsci/kfn225. Epub 2008 Oct 21. 437. Marlatt VL, Veldhoen N, Lo BP, Bakker D, Rehaume V, Vallée K, Haberl M, Shang D, van Aggelen GC, Skirrow RC, Elphick JR, Helbing CC. Triclosan exposure alters postembryonic development in a Pacific tree frog (Pseudacris regilla) Amphibian Metamorphosis Assay (TREEMA). Aquat Toxicol. 2013 Jan 15;126:85-94. doi: 10.1016/j.aquatox.2012.10.010. Epub 2012 Oct 29. 438. Fort DJ, Mathis MB, Hanson W, Fort CE, Navarro LT, Peter R, Büche C, Unger S, Pawlowski S, Plautz JR. Triclosan and thyroid-mediated metamorphosis in anurans: differentiating growth effects from thyroid-driven metamorphosis in Xenopus laevis. Toxicol Sci. 2011 Jun;121(2):292-302. doi: 10.1093/toxsci/kfr069. Epub 2011 Mar 23. 439. Veldhoen N, Skirrow RC, Osachoff H, Wigmore H, Clapson DJ, Gunderson MP, Van Aggelen G, Helbing CC. The bactericidal agent triclosan modulates thyroid hormone-associated gene expression and disrupts postembryonic anuran development. Aquat Toxicol. 2006 Dec 1;80(3):217-27. Epub 2006 Sep 29. Erratum in: Aquat Toxicol. 2007 Jun 5;83(1):84. 440. Dann AB, Hontela A. Triclosan: environmental exposure, toxicity and mechanisms of action. J Appl Toxicol. 2011 May;31(4):285-311. doi: 10.1002/jat.1660. Review. 441. Ishibashi H, Matsumara N, Hirano M, Matsuoka M, Shiratsuchi H, Ishibashih Y, Takao Y, Arizono K. Effects of triclosan on the early life stages and reproduction of medaka Oryzias latipes and induction of hepatic vitellogenin. Aquat Toxicol. 2004;67:167–79. 442. Raut SA, Angus RA. Triclosan has endocrine-disrupting effects in male western mosquitofish, Gambusia affinis. Environ Toxicol Chem . 2010;29:1287–91. 443. Torres-Duarte C, Viana MT, Vazquez-Duhalt R. Laccase-mediated transformations of endocrine disrupting chemicals abolish binding affinities to estrogen receptors and their estrogenic activity in zebrafish. Appl Biochem Biotechnol. 2012 Oct;168(4):864-76. doi: 10.1007/s12010-012-9825-2. Epub 2012 Sep 2. 444. Forgacs AL, Ding Q, Jaremba RG, Huhtaniemi IT, Rahman NA, Zacharewski TR. BLTK1 murine Leydig cells: a novel steroidogenic model for evaluating the effects of reproductive and developmental toxicants. Toxicol Sci. 2012 Jun;127(2):391-402. doi: 10.1093/toxsci/kfs121. Epub 2012 Mar 29. 445. Kumar V, Chakraborty A, Kural MR, Roy P. Alteration of testicular steroidogenesis and histopathology of reproductive system in male rats treated with triclosan. Reprod Toxicol. 2009 Apr;27(2):177-85. doi: 10.1016/j.reprotox.2008.12.002. Epub 2008 Dec 11. 446. Foran CM, Bennett ER, Genson WH. Developmental evaluation of a potential non-steroidal estrogen: triclosan. Mar Environ Res. 2000;50:153–6. 447. Gee RH, Charles A, Taylor N, Darbre PD. Oestrogenic and androgenic activity of triclosan in breast cancer cells. J Appl Toxicol . 2008 Jan;28(1):78-91. 448. Felicia Udoji, Tamara Martin, Rachel Etherton, Margaret M. Whalen. Immunosuppressive Effects of Triclosan, Nonylphenol, and DDT on Human Natural Killer Cells In Vitro . J Immunotoxicol. Author manuscript; available in PMC 2011 July 1. 449. Sicherer SH, Leung DY. Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects in 2012. J Allergy Clin Immunol . 2013 Jan;131(1):55-66. doi: 10.1016/j.jaci.2012.11. 007. Epub 2012 Nov 27. Review. 450. Michael T. Dinwiddie, Paul D. Terry, Jiangang Chen. Recent Evidence Regarding Triclosan and Cancer Risk . Int J Environ Res Public Health. 2014 February; 11(2): 2209–2217. Published online 2014 February 21. doi: 10.3390/ijerph110202209 451. Ahn K.C., Zhao B., Chen J., Cherednichenko G., Sanmarti E., Denison M.S., Lasley B., Pessah I.N., Kultz D., Chang D.P., Gee S.J., Hammock B.D. In vitro biologic activities of the antimicrobials triclocarban, its analogs, and triclosan in bioassay screens: Receptor-based bioassay screens. Environ. Health Perspect. 2008;116:1203–1210. doi: 10.1289/ehp.11200. 452. Gee R.H., Charles A., Taylor N., Darbre P.D. Oestrogenic and androgenic activity of triclosan in breast cancer cells. J. Appl. Toxicol . 2008;28:78–91. doi: 10.1002/jat.1316. 453. Henry N.D., Fair P.A. Comparison of in vitro cytotoxicity, estrogenicity and anti-estrogenicity of triclosan, perfluorooctane sulfonate and perfluorooctanoic acid. J. Appl. Toxicol . 2013;33:265–272. doi: 10.1002/jat.1736. 454. Gee R.H., Charles A., Taylor N., Darbre P.D. Oestrogenic and androgenic activity of triclosan in breast cancer cells. J. Appl. Toxicol . 2008;28:78–91. doi: 10.1002/jat.1316. 455. Darbre P.D. Environmental oestrogens, cosmetics and breast cancer. Best Pract. Res. Clin. Endocrinol. Metab. 2006;20:121–143. doi: 10.1016/j.beem.2005.09.007. 456. Recchia A.G., Vivacqua A., Gabriele S., Carpino A., Fasanella G., Rago V., Bonofiglio D., Maggiolini M. Xenoestrogens and the induction of proliferative effects in breast cancer cells via direct activation of oestrogen receptor alpha. Food Add. Contam. 2004;21:134–144. doi: 10.1080/02652030310001641177. 457. Michael T. Dinwiddie, Paul D. Terry, Jiangang Chen. Recent Evidence Regarding Triclosan and Cancer Risk . Int J Environ Res Public Health. 2014 February; 11(2): 2209–2217. Published online 2014 February 21. doi: 10.3390/ijerph110202209 458. Rodricks J.V., Swenberg J.A., Borzelleca J.F., Maronpot R.R., Shipp A.M. Triclosan: A critical review of the experimental data and development of margins of safety for consumer products. Crit. Rev. Toxicol. 2010;40:422–484. doi: 10.3109/10408441003667514. 459. Michael T. Dinwiddie, Paul D. Terry, Jiangang Chen. Recent Evidence Regarding Triclosan and Cancer Risk . Int J Environ Res Public Health. 2014 February; 11(2): 2209–2217. Published online 2014 February 21. doi: 10.3390/ijerph110202209 460. Catherine m. Cooney. Personal care products: triclosan comes under scrutiny . Environ health perspect. 2010 june; 118(6): a242. Doi: 10.1289/ehp.118-a242 461. Fiss EM, et al. Environ Sci Technol . 2007;41(7):2387–2394. 462. Lores M 1 , Llompart M , Sanchez-Prado L , Garcia-Jares C , Cela R . Confirmation of the formation of dichlorodibenzo-p-dioxin in the photodegradation of triclosan by photo-SPME. Anal Bioanal Chem. 2005 Mar;381(6):1294-8. Epub 2005 Feb 9. 463. http://www.ewg.org/research/teen-girls-body-burden-hormone-altering-cosmetics-chemicals/cosmetics-chemicals-concern 464. http://www.ewg.org/research/teen-girls-body-burden-hormone-altering-cosmetics-chemicals/cosmetics-chemicals-concern","date_published":"2014-06-18T05:49:55","date_modified":"2025-12-26T03:54:38","authors":[{"name":"Dr. Richard Esquivel","url":"https://sanjosefuncmed.com/about/"}],"tags":["Environmental Health"]},{"id":"https://sanjosefuncmed.com/brain-master-organ-health-brain-overlooked-medicine-conventional-medicine-offers-neurodegenerative-disorders/","url":"https://sanjosefuncmed.com/brain-master-organ-health-brain-overlooked-medicine-conventional-medicine-offers-neurodegenerative-disorders/","title":"Brain Health & Neurodegenerative Risk","summary":"A library article examining brain health through a broader metabolic, inflammatory and lifestyle lens.","content_text":"“Everything you have ever experienced, felt or conducted in life is due to brain function. The ability to enjoy, perceive, sense and experience life is dictated by the firing rate of your brain. It is impossible for a person to become healthy mentally or physiologically without a healthy brain.”(1) The Brain is the Master Organ Everything you have ever experienced in the past and will ever experience in the future is because you have a brain. Everything you have ever done and will do in the future is directly related to the health of your brain. This includes your ability to eat, taste and smell food, your ability to enjoy being with your loved ones, your ability to appreciate music and poetry, your ability to sing, dance and breathe. All of these things are directly determined by the health of the brain. As the brain deteriorates, you lose all these capacities. Your quality of life becomes dramatically compromised. This is what happens in neurodegenerative disorders, such as Alzheimer’s disease. Do you know anyone with Alzheimer’s disease? Maybe a friend or family member? You can see how their whole quality of life is compromised. They stop appreciating the things in life they used to love and just don’t care about the things they used to care about. They no longer have the capacity to feel the emotions they used to feel. And the worst part is they gradually stop loving their loved ones because they can no longer remember who they are and all the lifetime of experiences that they shared together. Everything you do for them goes unappreciated. Taking care of a loved one with Alzheimer’s disease is one of the hardest things you can do knowing that as their condition progresses, they will become more and more dependent on you and less and less appreciative of all your effort. All this happens due to neurodegeneration (degeneration of the neurons of the brain) . And the worst part is that most doctors don’t consider brain health until advanced stages of degeneration. And the literature shows that there are many natural compounds that support brain function and slow down the progression of these neurodegenerative diseases, even after they have developed. (2, 3, 4, 5, 6, 7, 8, 9) The Health of the Brain is Often Overlooked in Medicine Brain health tends to be ignored in both the conventional and alternative health care systems. Most doctors are focused on their particular specialty, which is understandable. But even primary care doctors tend to focus on all the other organs and metabolic issues before considering the health of the brain. Most doctors don’t make any recommendations on brain health until patients start showing signs of dementia. They often don’t do anything when patients complain of warning signs of neurodegeneration such as mental fatigue, poor memory, poor gastrointestinal function, sleeping disturbances or depression. When patients come in to their office with these problems, they either prescribe medication to address the symptoms or if they recognize early-stage dementia, refer them to a specialist, such as a neurologist or psychiatrist for evaluation. However, it so happens that these are the two specialties of medicine that have the poorest outcomes. Why? Because the brain is so complex, treatment options are limited to pharmaceutical drugs and because the science behind the use of these medications is so tenuous and misguided as you will see. Patients definitely need doctors that can diagnose brain lesions and deal with mental disorders. The problem is we have a large population of patients that are not being served because the options patients have are limited by the pharmaceutical model instead of offering brain activation, brain rehabilitation and brain nutrition therapy. Conventional Medicine Offers Little for Neurodegenerative Disorders There are very few drugs available that have been approved by the FDA to treat neurodegenerative disorders such as Parkinson’s, Alzheimer’s disease or other types of dementias. Most psychotropic drugs only treat the symptoms of neurodegeneration, such as depression, tremors or sleeping disorders. Even then, they don’t do a very good job. A new meta-analysis was recently published in the New England Journal of Medicine which concluded that antidepressants do nothing for mild to moderate depression. (10) They only showed benefit for severe depression. If someone is suicidal, they may be helpful. For the typical patient who has depression, they have been shown to be no more effective than placebo (sugar pills). It’s important to be able to diagnose a patient and identify where the lesion is in the brain but the typical neurodegenerative patient is not being helped very much by the current healthcare system. In functional medicine, we have the ability to improve brain physiology by increasing blood flow to brain (11, 12, 13, 14, 15, 16, 17), by increasing neurotransmitter quantity (18, 19, 20, 21, 22) and by dampening inflammation in the brain (23, 24, 25, 26) which you can’t do with any medications. There are plant compounds that have been shown to help with all of these things but there are no medications currently available that can help with any of them. The next article shows that we really don’t have an evidence-based model of medicine. We will also reveal what people (and doctors) consider “aging” is really neurodegeneration (degeneration of the brain) and what you can do to prevent this from happening and/or progressing! References: Datis Kharrazian, D.C., Brain and Neurotransmitters Seminar, San Francisco, CA, Nov. 22-23, 2008 Wilcock GK, Lelienfeld S, Gaenes, E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer’s disease: multicenter randomized controlled trial. BMJ 2000;321(7274):1445-9. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 2000;54 (12):2269-76. Maelicke A, Samochocki M, Jostorck R, et al. Allosteric sensitizaion of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer’s disease. Biol Psychiatry 2001;49:279-88. Coyle J, Kershew P. Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects of the course of Alzheimer’s disease. Biol Psychiatry 2001;49:289-99. Spagnolie A, et al. Long-term acetyl-L-carnitine treatment in Alzheimer’s disease. Neurology 1991;41:1726-1732. Bowman B. Acetylcholine and Alzheimer’s disease. Nutr Rev 1992; 50:142-144. Careta A, et al. Acetyl-L-Carnitine and Alzheimer’s disease. Pharmacological considerations beyond cholinergic sphere. Ann NY Acad Sci 1993;695:324-326. Pettegrew JW, et al. Clinical and neurochemical effects of acetyl-L-carnitine in Alzheimer’s disease. Neurobiol Aging 1995;16:1-4. JAMA. 2010 Jan 6;303(1):47-53. Antidepressant drug effects and depression severity: a patient-level meta-analysis. Fournier JC , DeRubeis RJ , Hollon SD , Dimidjian S , Amsterdam JD , Shelton RC , Fawcett J . http://www.ncbi.nlm.nih.gov/pubmed/20051569 Ahlemayer B & Krieglstein J. Neuroprotective effects of Ginkgo Biloba extract. Cell Mol Life Sci. 2003;60(9):17779-92. 12. Loew D. Value of Ginkgo biloba in treatment of Alzheimer’s dementia. Wein Med Wochenschr. 2002;152 (15-16):418-22. 13. Jung F, Mroweitz C, Kiesewetter H, Wenzel E. Effect of Ginkgo biloba on fluidity of blood and peripheral microcirculation in volunteers. Arzneimittelforschung. 1990;40(5):589-93. 14. Wu Y, Li S, CUI W, ZU X, DU J, Wang E. Ginkgo biloba extract improves coronary blood flow in healthy elderly adults: role of endothelium-dependant vasodilation. Phytomedicine. 15(3): 164-9. 15. Nevzorova VA, Zakharchuk NV, Plotinokova IV. The state of cerebral blood flow in hypertensive crises and possibilities of its correction. Kardiologia. 2007;47(12):20-3. 16. Miyata N. Yamaura H. Tanaka M, Murmastsu M, Tsuchida K, Okuyma S, Otomo S. Effects of VA-045, a novel apovincaminic acid derivative, on isolated blood vessels: cerebroarterial selectivity. Life Sci. 1993:51(18):PL181-6. 17. Bagoly E, Fehr G, Szapary L. The role of vinpocetine in the treatment of cerebrovascular disease based in human studies. Orb Hetil. 2007; 148(29):1353-8. 18. Sarzi Puttini P, Caruso I. Primary fibromylagia syndrome and 5-hydroxy-L-tryptophan: a 90-day open study. J Int Med Res 1992;20(2):182-9. 19. De Benedittis G, Massei R. Serotonin precursors in chronic primary headache. A double-blind cross-over study with L-5-hydroxytryptophan vs. placebo. Journal of Neurosurgical Sciences 1985;29(3):239-48. 20. Birdsall TC. “5-Hydroxytryptophan: a clinically-effective serotonin precursor Alternative medicine review: a journal of clinical therapeutic 1998;3(4):271-80. 21. Meryer S. Use of neurotransmitter precursors for treatment of depression. Alter Med Rev 2000;5(1):64-71. 22. Turner EH, Loftis JM, Blackwell AD. Serotonin a la carte: supplementation with the serotonin precursor 5-hydroxytryptophan. Pharmacol. Ther2006;109(3):325-38. 23. Rezai-Zaldeh K, Ehrhart J, Bai Y, Sansberg PR, Bickfored P, Tan J, Shytel D. Apigenin and luteolin modulate microgial activation via inhibition of STAT-1 induced CD40 expression. J Neuroinflammation 2008;25(5):41. 24. Elsisi NS, Darling-Reed S, Lee EY, Oriaku ET, Soiman KF. Ibuprofen and apigenin induce apoptosis and cell cycle arrest in activated microglia. Neurosci Lett. 2005;375(2):91-6 25. Chen HO, Jin ZY, Wang XJ, Xu XM, Deng L, Zhao JW. Luteolin protects dopaminergic neurons from inflammation-induced injury through inhibition of microglial activation. Neurosci Lett. 2008;448(2):175-179. 26. Jang S, Kelly KW, Johnson RW. Luteolin reduces IL-6 production in microglia by inhibiting JNK phosphorylation and activation of AP-1. Proc Natl Acad Sci USA. 2008;105(21):7534-7539.","date_published":"2012-06-27T07:34:53","date_modified":"2020-04-19T22:30:59","authors":[{"name":"Dr. Richard Esquivel","url":"https://sanjosefuncmed.com/about/"}],"tags":["Brain Health"]},{"id":"https://sanjosefuncmed.com/chemical-exposure-problem/","url":"https://sanjosefuncmed.com/chemical-exposure-problem/","title":"Chemical Exposure & Health","summary":"A long-form educational discussion of environmental exposure and why the clinical history matters.","content_text":"As we learned in the first part of this series, there are now more than 84,000 different chemicals that we are potentially exposed to on a daily basis and about 1,500 new chemicals are introduced each year.[1] The EPA estimates that in 2002 alone, over 4.7 billion pounds of toxic chemicals were released into the environment in the U.S.[2] We learned that only a quarter of more than 80,000 chemicals have been tested for toxicity.[3] We also learned there are numerous chemicals we are exposed to on a daily basis in our homes and offices, in our cars and even in our bedrooms. Simply sitting at your desk at your home or office while reading this article on your computer exposes you to chemicals used in home and office construction, furniture, and electronics manufacturing. Every time we eat food, drink tap water (or bottled water) or even breathe the air, we are being exposed to chemicals and potential toxins from the soil, food, air and water supplies. The totality of these chemicals in the human body is referred to as your chemical load . Key concepts for this issue What is Your Toxic Load (Toxic Burden)? H ow Do We Defend Ourselves Against These Constant Threats? Why Does Ability to Handle Toxins Vary From Person to Person? When Does Chemical Exposure Become a Problem? What is Toxicant-Induced Loss of Tolerance (TILT)? What Are the Consequences of Loss of Chemical Tolerance? Signs and Symptoms of Loss of Chemical Tolerance How Do We Lose Chemical Tolerance? What is Your Toxic Load? How many chemicals are you exposed to on a daily basis? How many chemicals are in your food? As we found in the previous two segments, food is a common source of chemical exposures. Do you eat 100% organic food? Eating organic is always best whenever possible because it reduces chances of toxic exposure but doesn’t guarantee that your food is toxin-free. Why? Because there are toxins in the air, water and soil which make it into the food supply even though the food may be grown according to organic standards. How about your drinking water? Do you drink bottled water or tap water? We learned that tap water can be contaminated with multiple chemicals, heavy metals, antibiotics and pharmaceuticals. Pharmaceutical residues and other organic wastewater contaminants have been shown to survive conventional water treatment processes and persist in water supplies. A wide range of pharmaceuticals that include antibiotics, sex hormones, and drugs contaminate drinking water supplies of millions of Americans.[4] “Environmental Working Group’s (EWG) studies show that tap water across the U.S. is contaminated with many industrial chemicals, and now we know that millions of Americans are also drinking low-level mixtures of pharmaceuticals with every glass of water.”[5] How about the air we breathe? As we learned in the previous two segments, industrial sources of chemicals permeate the outdoor air we breathe and can lead to a wide variety of health effects, impacting not only our respiratory system but our immune system, endocrine system and nervous system. Industrial air pollution can have significant impacts on the brain and nervous system development. There have been brain changes associated with Alzheimer’s disease discovered in children exposed to outdoor air pollution. In a study published in 2012 in the prestigious Journal of Alzheimer’s Disease , brain changes normally associated with neurodegenerative diseases, such as Alzheimer’s disease, were observed in children exposed to air pollution: “40% of exposed children and young adults exhibit frontal tau hyperphosphorylation. 51% have beta-amyloid plaques compared to 0% in low pollution controls”[6] We also learned that our children are being exposed to hundreds of cancer-causing chemicals and toxins in umbilical cord blood before they are even born: “Of the 287 chemicals we detected in umbilical cord blood, we know that 180 cause cancer in humans or animals, 217 are toxic to the brain and nervous system and 208 cause birth defects or abnormal development in animal tests”[7] And even breast milk of American mothers has been found to be contaminated with toxic fire retardants: “In the first nationwide tests for chemical fire retardants in the breast milk of American women, the EWG found unexpectedly high levels of these little-known neurotoxic chemicals in every participant tested”[8] It is impossible to protect yourself completely from all of these environmental chemicals and potential toxins. You will have exposures to hazardous chemicals during your lifetime and it will affect your health at various levels throughout your lifespan. The questions really are: How much of a chemical load can you handle? How will you manifest symptoms of increased chemical load? How will this impact your health in the long term? Let’s first take a look at how our bodies protect us from toxic exposures. How Do We Defend Ourselves Against These Constant Threats? The body’s ability to defend itself against such an arsenal of immune-producing triggers involves the integrity of our antioxidant systems, our hepatic biotransformation (liver detoxification) potential, the integrity of our barrier system (intestinal, pulmonary and blood-brain barrier) and most importantly our immune system’s ability to maintain chemical tolerance. The Bodies Antioxidant Systems The antioxidant systems of the body are critical for protecting the body from the harmful effects of various chemicals, toxins and heavy metals. These toxic compounds can produce excessive free radical activity leading to damage to important organelles, such as the ATP-producing mitochondria, and cells of various tissues of the body. Our body has the capacity to neutralize a certain amount of this free radical activity to prevent tissue damage. This relies on the antioxidant systems of the body, such as glutathione and superoxide dismutase, and the hepatic biotransformation pathways. However, once these antioxidant systems become overloaded with excessive oxidative stress, then oxidative damage can occur to our tissues and organs, leading to decreased organ function, chronic inflammation, and accelerated biological aging (see Successful Aging parts 1, 2 ). Hepatic Biotransformation (Liver Detoxification) Pathways Hepatic biotransformation refers to the transformation of toxic lipid-soluble compounds and hormones into water-soluble compounds that can be excreted from the body via the urine. This is a process that involves multiple reactions. The first step is known as “phase I” and the second step is known as “phase II”. Phase I reactions involve the cytochrome P450 enzyme which is responsible for converting lipophilic (fat-loving) toxins into biotransformed intermediates that are more water-soluble. In phase II, these biotransformed intermediates undergo further biotransformation in a second series of enzymes called conjugases . These conjugases are enzymes that attach molecules, such as glucuronic acid, sulfate, glutathione, glycine, taurine or methyl groups to the biotransformed intermediates. These phase II pathways are named glucuronidation, sulfation, glutathione conjugation, glycine (amino acid) conjugation, acetylation and methylation. There are an enormous number of toxic compounds that can be handled and detoxified by the human biotransformation pathways. These toxins include not only environmental chemicals that we encounter in our food, air and water supply, medications, alcohol and drugs, but also endogenous compounds produced by the body, such as hormones and other signaling molecules. These endogenous compounds must be eliminated by the body as well, after they have served their purpose acting as signaling and messenger molecules. We now know that endogenously-produced hormones and other signaling molecules are not only detoxified by these enzymes, allowing for elimination, but also are metabolized into other signaling molecules allowing for more variation in the activities of these important substances. An example of this is estrogen metabolism. Estrogen, like all hormones, must be metabolized in the liver once it has served its purpose. There are several variations of these estrogen metabolites that result from metabolism of estrogen in these phase II pathways. Some of these metabolites have been associated with proliferation of tissues, such as seen in cancer, while other metabolites have been shown to be protective of these types of cancers. Main-taining a certain ratio of these metabolites is critical for health and imbalances of these ratios have been associated with breast cancer in women.[9] Having efficient and functional phase I and phase II hepatic biotransformation pathways is crucial to maintaining health. Studies have suggested an association between the ability of the body to adequately transform toxic xenobiotics and metabolites and the etiology of various chronic disease conditions, such as chronic fatigue syndrome (CFS), fibromyalgia (FMG) and multiple chemical sensitivities.[10] Research has also shown a connection between impairment of hepatic biotransformation and chronic neurodegenerative problems, such as Parkinson’s disease [11-13] and various cancers.[14-16] Hepatic Biotransformation Relies on Specific Nutrients How do these enzyme systems work? What do they require to function? Like all metabolic pathways of the body, the enzyme systems involved in hepatic biotransformation require sufficient amounts of vitamins, minerals, coenzymes and cofactors in order to function. Specific detoxification pathways may be induced or inhibited depending on the presence of various available nutrients. For example, methylation conjugation relies on available methyl donors to function, such as vitamin B6, B12 and folic acid. Sulfation conjugation relies on the presence of the sulfur cofactor, which is obtained from precursors in the diet, such as methionine, cysteine and inorganic sulfur. Glutathione conjugation relies on available glutathione to take place, which in turn relies on various dietary cofactors and coenzymes. Besides available nutrients, there are many factors that influence these hepatic transformation pathways and one’s ability to handle toxic exposures, including gender, lifestyle habits, nutritional status, stress and genetics. As we will see, genetic differences in genes that regulate these detox pathways can make a big difference in one’s ability to handle toxic compounds. Why does ability to handle toxins vary from person to person? Why are most people living relatively normal, healthy lives despite all these toxic exposures while other people succumb to toxin-induced illness? The answer to these questions lies in genetic uniqueness of the genes involved in hepatic biotransformation . It is widely known that polymorphisms (genetic variations) exist throughout the human genome that can potentially affect any function related to the protein encoded by that particular gene. Moreover, the genes involved in these detoxification enzymes show a wide variety of polymorphisms which have been identified in the literature.[17] Polymorphisms in enzymes encoding phase I or phase II enzymes have been associated with increased prevalence and/or risk of many conditions including asthma, autism, cancers of the breast, prostate, lungs, esophagus, stomach and pancreas, multiple chemical sensitivity and cardiovascular disease.[18-24] Biochemical Individuality The renowned biochemist, Roger Williams, Ph.D., was the first to use the term “biochemical individuality”. In his 1956 book of the same name, he described how the anatomical and physiological variations among people are related to their varied responses to the environment and to their differing nutritional needs. In 1950, Dr. Williams published an article in The Lancet entitled, “The Concept of Genetotrophic Disease” , in which he proposed a role for nutrients in the prevention of chronic disease.[25] Genetotrophic diseases are those for which genetic uniqueness creates a demand for specific nutrients beyond the average intake to facilitate optimal function and prevent premature disease. He theorized that when those specific needs are not met in a given individual, disease results. He further proposed that the major chronic degenerative diseases of aging are genetotrophic . In other words, the unique genes of each individual require different levels of nutrients for optimal health. The consequences of not meeting these specific needs of the individual are expressed as degenerative disease “of unknown origin”. As our understanding of the interaction of genes and nutrition continues to increase, it appears that Dr. Williams’ theory may very well turn out to be the reality. According to the work of Bruce Ames, Ph.D., biochemistry researcher who has studied the effect of nutrients on oxidative stress and DNA integrity, as many as one-third of all mutations in a gene result in the corresponding enzyme having a decreased affinity for its vitamin cofactor. This results in a lower reaction rate and requires increased amounts of vitamin cofactors in order for the enzyme reaction to take place at a higher rate. According to Dr. Ames, many of these effects can be ameliorated by giving the administration of high doses of the vitamin.[26] When Does Chemical Exposure Become a Problem? Over the years, hundreds of studies have explored the effects of environmental compounds on our health, turning up many disturbing findings. How much of an impact do these toxic compounds have on our health? A 2001 report suggested that between $568 billion and $793 billion is spent per year in the U.S. and Canada on environmentally-caused disease![27] Environmental chemicals are linked with virtually every chronic health disorder including cancers, obesity, diabetes, heart disease, brain degeneration, neurological disorders and other health issues. But these links can be difficult for the average person to identify and our current healthcare system does not allow most doctors to spend much time searching for environmental contributions to their patients’ illness. Unless there is an acute exposure, chemical pollutants do not result in immediate symptoms and are often overlooked, but as we have seen, can have a wide variety of health effects over a period of time, affecting the nervous, immune and endocrine systems in multiple ways. Even small amounts of one toxic compound, such as mercury (still used in influenza vaccinations) can have multiple health effects: “Low concentrations of mercury chloride affect immune function in human cells by dysregulation of cytokine signaling with the potential to influence diverse health outcomes such as susceptibility to infectious disease or risk of autoimmunity”[28] As we learned in part 1 of this series, the prevalence of allergenic-related diseases, food intolerance, and chemical sensitivities in both the pediatric and adult population has increased dramatically over the last two decades, with escalating rates of associated morbidity. A model of toxicity that explains this increase in these types of conditions that has been gaining attention in the literature is the model of toxicant-induced loss of tolerance (TILT). What is Toxicant-Induced Loss of Tolerance (TILT)? Normally, our body’s immune system is able to tolerate (remain non-reactive against) the various foods, chemicals and potential allergens that it comes in contact with on a daily basis. The TILT theory postulates that conditions of acquired allergy, food intolerance and chemical hypersensitivity are frequently the direct result of loss of chemical tolerance in response to a significant initiating toxic exposure. Here is how one researcher describes the development of loss of chemical tolerance and its relationship to the development of chronic disease: “Following the primary toxicant insult, the individuals become sensitive to low levels of diverse and unrelated triggers in their environment, such as commonly encountered chemical, inhalant, or food antigens Among sensitized individuals, exposure to assorted inciting stimuli may precipitate diverse clinical and/or immune sequelae as may be evidenced by clinical symptoms as well as varied lymphocyte, antibody, or cytokine responses in some cases With escalating rates of toxicant exposure and bioaccumulation in the population-at-large, an increasing proportion of contemporary illness is the direct result of toxicant-induced loss of tolerance and ensuing sensitivity-related illness”[29] What Are the Consequences of Loss of Chemical Tolerance? Chemical tolerance is our immune system’s ability to react proportionately to compounds such as toxins, pollutants and dietary proteins. There is no doubt certain toxins will lead to immediate loss of health and even death. However, many chronically ill individuals can no longer tolerate exposure to relatively benign exposures, such as perfume, detergents, jewelry, etc. These individuals have lost their chemical tolerance either from chemical/toxin exposure or from other mechanisms which can lead to loss of tolerance. For people with loss of chemical tolerance, trivial exposures can trigger a long list of conditions, including asthma, migraines, depression, fibromyalgia, fatigue, Gulf War syndrome, brain fog, memory loss, incontinence, neurological dysfunction, rashes, and so on. These people increasingly isolate themselves from the world and other people. They cannot tolerate many indoor places, other people’s scented body products, or clothes laundered in scented detergents. Even the smell of dryer sheets coming from a neighbor’s vent during a walk outside can make them sick. The loss of chemical tolerance is a phenomenon both researchers and clinicians have identified in more than a dozen countries and across diverse groups of people. There was a great paper published on this theoretical model in 2001: “In the late 1800’s, physicians observed that certain illnesses spread from sick, feverish individuals to those contacting them, paving the way for the germ theory of disease. The germ theory served as a crude, but elegant formulation that explained dozens of seemingly unrelated illnesses affecting literally every organ system. Today, we are witnessing another medical anomaly—a unique pattern of illness involving chemically exposed groups in more than a dozen countries, who subsequently report multisystem symptoms and new-onset chemical, food and drug intolerances. These intolerances may be the hallmark of a new disease process or paradigm, just as a fever is a hallmark of infection. The fact that diverse demographic groups, sharing little in common except some initial chemical exposure event, develop these intolerances is a compelling anomaly pointing to a possible new theory of disease, one that has been referred to as “toxicant-induced loss of tolerance” (TILT). TILT has the potential to explain certain cases of asthma, migraine headaches, and depression, as well as chronic fatigue, fibromyalgia and Gulf War syndrome.” [30] According to this theory, the issue is not how many toxins are in your system but whether your immune system reacts to them. This is the mechanism behind chemical intolerance, multiple chemical sensitivities, and toxin-induced brain degeneration mechanisms that are becoming so common today. In the literature, this is called “loss of chemical tolerance” or “toxic-induced loss of tolerance”. When people suffer from TILT, they are not necessarily sick from heavy metals and chemicals, rather, they are sick from their reaction to them. Signs and Symptoms of Loss of Chemical Tolerance Asthma Skin rashes Weak immunity Fatigue Brain fog Depression Chronic pain Multiple chemical sensitivities Multiple food sensitivities Headaches/migraines These are the people who cannot tolerate common chemicals without symptoms. Symptoms may vary but they are triggered by gas fumes, scented body products, laundry detergents, fabric softeners, new carpeting, new construction, the smell of new cars, and so on. For people with loss of chemical tolerance, trivial exposures can trigger a long list of conditions, including asthma, migraines, depression, fibromyalgia, fatigue, Gulf War syndrome, brain fog, memory loss, incontinence, neurological dysfunction, rashes, and so on. These people increasingly isolate themselves from the world and other people. They cannot tolerate many indoor places, other people’s scented body products, or clothes laundered in scented detergents. Even the smell of dryer sheets coming from a neighbor’s vent during a walk outside can make them sick. It is common for them to feel increasingly angry at other people and understandably so. When a scented product triggers a migraine, incontinence or neurological symptoms, the person wearing it can seem cruel and selfish. Summary of Symptoms of Loss of Chemical Tolerance Intolerance to smells Intolerance to jewelry Intolerance to shampoo, lotions, soaps and detergents, etc. Multiple food sensitivities Skin outbreaks How Do We Lose Chemical Tolerance? Loss of chemical tolerance does not happen suddenly and for no reason. Chemical tolerance is dependent upon many overlapping physiological factors that include regulatory T-cell integrity, antioxidant reserves, barrier system integrity and integrity of hepatic biotransformation pathways. There are many ways you can lose self-tolerance or chemical tolerance and enter this vicious cycle: Heavy and ongoing chemical load can lead to depletion of glutathione and/or impaired hepatic biotransformation If you have an ongoing chemical load that depletes glutathione, you will have impaired hepatic biotransformation, you will lose your ability to quench free radicals and oxidative stress, you will lose your ability to regulate T-cells and you will lose the integrity of your barrier systems As you lose your barrier systems, you will have increased inflammation and upregulation of NF-kB (an important inflammatory mediator) and increased expression of iNOS (very destructive to tissues) which creates more demand on glutathione sufficiency and increased loss of barrier systems In summary, loss of chemical tolerance occurs when the following things take place: Depletion of glutathione Regulatory T-cell failure Breakdown of barrier systems Cytokine dysregulation/chronic inflammation Impaired hepatic biotransformation Depletion of Glutathione or Inefficient Glutathione System Depletion of glutathione is a primary cause of loss of chemical intolerance.[31] Glutathione is the body’s master antioxidant and the main antioxidant system in the body is the glutathione system . When there is oxidative stress (free radical activity) glutathione “takes the bullet” for our tissues and neutralizes potential damage from oxidative stress. Glutathione is also a very important regulator of immune responses because it influences regulatory T-cell function. In addition, glutathione is involved in both phase I and phase II hepatic biotransformation pathways and is your body’s primary method of elimination of heavy metals from the body, such as mercury and lead.[32] Excess exposure to environmental chemicals can be a problem but the research shows you do not have an immune response against environmental compounds until glutathione becomes depleted.[33] Even high levels of environmental compounds do not become an immune trigger unless the body’s glutathione levels are depleted. Acute toxic exposures (ie: mercury and other heavy metals) can deplete glutathione levels quickly and many multiple exposures over an extended period of time can also deplete glutathione stores.[34] If you live in a toxic environment, you will have more load to your antioxidant systems and will be at higher risk of glutathione depletion. Here’s a summary of what happens in environmental exposures: Environmental exposures deplete glutathione Glutathione is an antioxidant and “takes the bullet” from the free radical If the glutathione system fails and you don’t have glutathione to take the bullet, then you get immune activation Immune activation then triggers inducible nitric oxide synthase (iNOS) which then causes tissue destruction of self-tissue[35] Regulatory T-cell failure As discussed in previous segments, TH-3 cells, or regulatory T-cells , are a subpopulation of T-cells that downregulate the immune system, maintain tolerance to self-antigens and minimize autoimmune reactions. Regulatory T-cells are a component of the immune system that suppress immune responses from other cells. This is an important “self-check” mechanism inherent in the immune system to prevent excessive reactions. These cells are involved in shutting down the immune responses after they have successfully eliminated invading organisms and in the prevention of autoimmune responses and loss of chemical tolerance.[36] Glutathione depletion causes loss of regulatory T-cell function, as do vitamin D and omega-3 essential fatty acid deficiencies.[37-39] This can lead to dysregulation of immune responses and immune attacks against self-tissue (autoimmunity). Failure of the regulatory T-cells leads to overzealousness of certain aspects of the immune system and depressed in other aspects and has been associated with development of loss of chemical tolerance, multiple chemical sensitivity and autoimmunity.[40,41] Breakdown of Barrier Systems Glutathione depletion is also a major contributing factor to breakdown of the barrier systems, leading to leaky gut (intestinal permeability), compromised blood-brain barrier and breakdown of the pulmonary barrier in the lungs.[42] Many other dietary and lifestyle factors can break down these protective barriers of the body, increasing the risk for both loss of chemical intolerance and autoimmunity, including medications, stress, metabolic imbalances, dysbiosis or chronic inflammation.[43] Loss of one of these barrier systems leads to initiation of an inflammatory cas-cade which places greater demand on the glutathione system and risk of immune dysregulation and autoimmunity.[44] NF-kB Activation and Chronic Inflammation NF-kB activation and chronic inflammation is a major predisposing factor in loss of chemical tolerance. As we learned in earlier segments of this series, NF-kB controls the expression of genes encoding the proinflammatory mediators involved in chronic inflammation and autoimmune disease. NF-kB can become chronically elevated because of its own amplifying loop. [45] This means that elevations in NF-kB can perpetuate further elevations of NF-kB. NF-kB signaling needs to be downregulated in order to maintain tissue homeostasis. [46] Common symptoms of chronic inflammation include: Bloating Skin rashes or eruptions Joint pain Brain fog Depression Anxiety Chronic pain Chronic fatigue Autoimmune flare-ups Impaired Hepatic Biotransformation Environmental compounds and pollutants are metabolized into end-product metabolites by phase I and phase II reactions that can then be excreted by urine, sweat or feces. If hepatic biotransformation pathways are compromised, the pollutants may not be able to be metabolized or are metabolized into more immunoreactive end-products that both increase oxidative stress and further promote the vicious cycle of impaired chemical tolerance. If liver function becomes compromised, it can increase the toxic load and further impair chemical tolerance. Likewise, toxic exposures and the associated inflammation can then hinder liver metabolic function. Summary of mechanisms that may be involved in loss of chemical tolerance: Heavy and ongoing chemical load can lead to depletion of glutathione and/or impaired hepatic biotransformation Depletion of glutathione and impaired hepatic biotransformation, leads to loss of ability to quench free radicals and increased oxidative damage, inability to regulate T-cells and loss of integrity of the barrier systems Loss of barrier systems leads to increased inflammation, upregulation of NF-kB and increased expression of iNOS which creates more demand on glutathione sufficiency and increased loss of barrier systems In the next segment of this series, we will cover the following topics: The Role Chemical Sensitivity Plays in the Development of Autoimmunity Does Chemical Tolerance Vary From Person to Person? Laboratory Evaluation of Immune-Chemical Tolerance Other Factors Besides Chemical Exposure That Impact Chemical Sensitivity Nutritional Management of Loss of Chemical Tolerance Heavy Metal Exposure and Elimination References Moreno MA, Furtner F, Rivara FP. Children’s environmental health. Arch Pediatr Adolesc Med . 2012 Oct;166(10):976. doi: 10.1001/2013.jamapediatrics.8. 2. http://www.epa.gov/All+chemicals&industry 3. The legal failure to prevent subclinical developmental toxicity. Basic Clin Pharmacol Toxicol. 2008 Feb;102(2):267-273 4. http://usatoday30.usatoday.com/news/nation/2008-03-10-drugs-tap-water_N.htm?loc 5. http://www.ewg.org/news/testimony-official-correspondence/pharmaceuticals-pollute-us-tap-water 6. White matter hyperintensities, systemic inflammation, brain growth and cognitive functions in children exposed to air pollution. J Alzheimer’s Dis. 2012;31(1):183-191 7. Houlihan J, et al. Body burden: the pollution in newborns. July 14, 2005. Environmen-tal Working Group.http//www.ewg.org/research/body-burden-pollution-newborns 8. Lunder S, Sharp R. Toxic fire retardants in human breast milk. Sept 23, 2003. Environmental Working Group. http//www.ewg.org/research/mothers-milk-0 9. Santen RJ, Yue W, Wang JP. Estrogen metabolites and breast cancer. Steroids. 2014 Aug 26. pii: S0039-128X(14)00196-2. doi: 10.1016/j.steroids.2014.08.003. [Epub ahead of print] Review. 10. Bland J, Barrager E, Reedy R, Bland K. A medical food-supplemented detoxification program in the management of chronic health problmes. Altern Ther Health Med. 1995 Nov 1;1(5):62-71. 11. Steventon G, Heafield M, Waring R, Williams A. Xenobiotic metabolism in Parkinson’s disease. Neurology. 1989 ;39:883-887. 12. Huang Y, et al. Genetic contributions to Parkinson’s disease. Brain Res Brain Res Rev. 2004;46(1):44-70. 13. Dawson TM, Dawson VL. Molecular pathways of neurodegeneration in Parkinson’s disease. Science. 2003; 302(5646):819-22. 14. Ning B, Wang C, Morel F, et al. Human glutathione S-transferase A2 polymorphisms: variant expression, distribution in prostate cancer cases/controls and a novel form. Pharmacogenetics. 2004;14(1):35-44. 15. Mohrenweiser HW. Genetic variation and exposure related risk estimate: will toxicology enter a new era: DNA repair and cancer as a paradigm. Toxicol Pahtol. 2004;32(Suppl 1):136-45. 16. Chacko P, Joseph T, Mathew BS, et al. Role of xenobiotic metabolizing gene polymorphisms in breast cancer susceptibility and treatment outcome. Mutat Res. 2005;581(1-2):153-63. 17. Textbook of Functional Medicine. Institute of Functional Medicine. 2005. 18. Tamer L, Calikoglu M, Ates NA, et al. Glutathione-S-transferase gene polymorphisms (GSTT1, GSTM1, GSTP1) as increased risk factors for asthma. Respirologoy. 2004;9(4):493-498. 19. Sazci A, Ergul E, Utkan NZ, et al. Catechol-O-methyltransferase Val 108/158 Met polymorphism in premenopausal breast cancer patients. Toxicology. 2004;204(2-3):197-202. 20. Nakazato H, Suzuki K, Matsui H, et al. Association of genetic polymorphisms of glutathione-S-transferase genes (GSTM1, GSTT1, GSTP1) with familial prostate cancer risk in a Japanese population. Anticancer Res. 2003;23(3C):2897-2902. 21. Shi WX, Chen SQ. Frequencies of poor metabolizers of cytochrome P450 2C19 in esophagus cancer, stomach cancer, lung cancer and bladder cancer in Chinese population. Worl J Gastroenterol. 2004;10(13):1961-63 22. Ockenga J, Vogel A, Teich N, et al. UDP glucuronosyltransferase (UGT1A7) gene polymorphisms increase th risk of chronic pancratitis and pancreatic cancer. Gastroenterology. 2003;124(7):1802-8. 23. McKeown-Eyssen G, Baines C, Cole DE, et al. Case-control study of genotypes in multiple chemical sensitivity: C YP2D6, NAT1, NAT2, PON1, PON2 and MTHFR. Int J Epidemiol. 2004;33(5):971-978. 24. Costa LG, Cole TB, Jarvik GP, Furlong CE. Functional genomic of the paraoxonase (PON1) polymporphisms: effects on pesticide sensitivity, cardiovascular disease, and drug metabolism. Annu Rev Med. 2003;54:371-392. 25. Williams RJ, Beerstecher E Jr, Berry LJ. The concept of genetotrophic disease. Lancet. 1950;1(7):287-89 26. Textbook of Functional Medicine. Institute of Functional Medicine. 2005. 27. Muir T, Zegar M. Societal costs of exposure to toxic substances: economic and health costs of four case studies that are candidates for envrironmental causation. Environ Health Perspect. 2001;109 Suppl 6:885-903. 28. Gardner RM, Nyland JF, Evans SL, et al. Mercury induces an unopposed inflammatory resonse in human peripheral blood mononuclear cells in vitro. Environ Health Perspect. 2009 Dec;117(12):1932-38 29. Sensitivity-related illness: the escalating pandemic of allergy, food intolerances and chemical sensitivity . Sci Total Environ. 2010 Nov 15; 408(24):6047-6061. 30. The compelling anomaly of chemical intolerance. Ann NY Acad Sci. 2001 Mar; 933-23 31. Requejo R, Tena M. Influence of glutathione chemical effectors in the response of maize to arsenic exposure. J Plant Physiol. 2012 May 1;169(7):649-656 32. Morris G, Anderson G, Dean O, Berk M, Galecki P, Martin-Subero M, Maes M. The glutathione system: a new drug target in neuroimmune disorders. Mol Neurobiol. 2014 Dec;50(3):1059-84. doi: 10.1007/s12035-014-8705-x. Epub 2014 Apr 22. PMID: 24752591 33. Critical role of hydrogen peroxide in the differential susceptibility of TH1 and TH2 cells to tributyltin-induced apoptosis . Biochem Pharmacol. 2008 Jan 15;75(2):552-61. Epub 2007 Sept 18 34. Carocci A, Rovito N, Sinicropi MS, Genchi G. Mercury toxicity and neurodegenerative effects. Rev Environ Contam Toxicol. 2014;229:1-18. doi: 10.1007/978-3-319-03777-6_1. Review. 35. GSH-dependent iNOS and HO-1 mediated apoptosis of human Jurkat cells induced by nickel (II). Environ Toxicol. 2009 Aug; 24(4):404-14 36. Micovic V, Vojnikovic B, Bulog A, Coklo M, Mlatestinic D, Mrakovcic-Sutic I. Regulatory T cells (Tregs) monitoring in environmental diseases. Coll Antropol. 2009 Sep;33(3):743-746 37. Peterson JD, Herzenberg LA, Vasquez K, Waltenbaugh C. Glutathione levels in antigen-presenting cells modulate Th1 versus Th2 response patterns. Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):3071-6. 38. Mocanu V, Oboroceanu T, Zugun-Eloae F. Current status in vitamin D and regulatory T cells&#8211;immunological implications. Rev Med Chir Soc Med Nat Iasi. 2013 Oct-Dec;117(4):965-73. 39. Issazadeh-Navikas S, Teimer R, Bockermann R. Influence of dietary components on regulatory T cells. Mol Med. 2012 Feb 10;18:95-110. doi: 10.2119/molmed.2011.00311. Review. 40. Winder C. Mechanisms of multiple chemical sensitivity. Toxicol Lett. 2002Mar 10;128(1-3):85-97 41. Alla Skapenko, Jan Leipe, Peter E Lipsky, Hendrik Schulze-Koops. The role of the T cell in autoimmune inflammation . Arthritis Res Ther. 2005; 7(Suppl 2): S4–S14. 42. Intestinal barrier function in response to abundant or depleted mucosal glutathione in Salmonella-infected rats. BMC Physiol. 2009 Apr 17:9:6 43. Stephan C Bischoff, Giovanni Barbara, Wim Buurman, Theo Ockhuizen, Jörg-Dieter Schulzke, Matteo Serino, Herbert Tilg, Alastair Watson, Jerry M Wells. Intestinal permeability – a new target for disease prevention and therapy . BMC Gastroenterol. 2014; 14(1): 189. Published online 2014 November 18. doi: 10.1186/s12876-014-0189-7 44. Stephan C Bischoff, Giovanni Barbara, Wim Buurman, Theo Ockhuizen, Jörg-Dieter Schulzke, Matteo Serino, Herbert Tilg, Alastair Watson, Jerry M Wells. Intestinal permeability – a new target for disease prevention and therapy . BMC Gastroenterol. 2014; 14(1): 189. Published online 2014 November 18. doi: 10.1186/s12876-014-0189-7 45. Nuclear factor-kB—a pivotal transcription factor in chronic inflammatory diseases. NF-kB Inflammatory Amplifying Loop. N Eng J Med. 1997;336:1066-1071. 46. Return to homeostasis: downregulation of NF-kB responses. Nat Immunol. 2011 Jun 19;12(8):709-714","date_published":"2014-12-15T03:23:12","date_modified":"2025-12-26T03:55:18","authors":[{"name":"Dr. Richard Esquivel","url":"https://sanjosefuncmed.com/about/"}],"tags":["Environmental Health"]},{"id":"https://sanjosefuncmed.com/a-patient-shares-her-experience-with-functional-medicine/","url":"https://sanjosefuncmed.com/a-patient-shares-her-experience-with-functional-medicine/","title":"A Patient Shares Her Experience with Functional Medicine","summary":"A patient shares her experience with functional medicine.","content_text":"A patient shares her experience with functional medicine.","date_published":"2012-05-15T19:23:13","date_modified":"2017-04-25T23:35:53","authors":[{"name":"Dr. Richard Esquivel","url":"https://sanjosefuncmed.com/about/"}],"tags":["Functional Medicine"]},{"id":"https://sanjosefuncmed.com/assessing-biological-aging/","url":"https://sanjosefuncmed.com/assessing-biological-aging/","title":"Assessing Biological Aging","summary":"“The mean telomere length serves as a marker for the biological age at the cellular level, with shorter telomeres defining the increased biological age.”1 In ","content_text":"“The mean telomere length serves as a marker for the biological age at the cellular level, with shorter telomeres defining the increased biological age.”1 In part 1 of this series, we discussed the concept of biological aging and how this differs from chronological aging. We examined some of the research of Bruce Ames, Ph.D., and the evidence supporting the view that mitochondrial decay or dysfunction leads to accelerated aging and most of the degenerative diseases we see in the elderly today. We also introduced the concept of genomic stability (the ability to maintain the genome and prevent damage to the DNA) and how this is crucial in maintaining health and preventing chronic disease. In part 2, we will look at some of the clinical tools we have available to assess biological aging in the individual and examine what these specific biomarkers are telling us about what is happening inside the individual’s body. But first, let’s define what we mean by Successful Aging . Successful Aging Means the Avoidance of Chronic Disease We talked about “Successful Aging” in the first article in this series, but we haven’t really addressed what this actually means. What is “Successful Aging”? “Successful Aging” means simply, living a life free of disease until a late age and being physically and mentally active throughout this entire period of life. How common is this? Unfortunately, this is not the norm for most Americans today. Most Americans alive today will suffer from some type of chronic disease during their lifetime although average lifespan continues to increase. This means that more people are suffering with chronic disease and require more care as they age and become more dependent on life-saving surgeries and technology to keep them alive. This is actually where most of our U.S. healthcare dollars are spent. However, this trend in average lifespan is about to come to a halt. For the first time in history, studies indicate that American children will be the first generation to have a shorter lifespan than their parents. Why? Because they are developing chronic disease at an earlier age than their parents. These chronic diseases are closely associated with obesity, physical inactivity and poor nutrition, among other things. As obesity, nutritional deficiencies and lack of physical activity continues to increase, so does chronic disease and shorter lifespan is expected to follow. 2,3 Who would not want a life free of disease until a late age for themselves and their family? We cannot stop the aging process (at least not yet) but there are many things within our control that increase the chance of adding extra years to our life. More importantly, there are a large number of things we can do to improve the quality of life during this time that makes our lives more fulfilling . What is the use of living to 100 years old if you have poor quality of life and are dependent on others throughout your later years? Who wants to spend their later years suffering in chronic pain, bound to a wheelchair or suffering from dementia? Put another way: successful aging means aging gracefully without suffering from chronic disease. Successful Aging vs. Anti-Aging Are we talking about anti-aging? No. We do not know how to stop the aging process. But there is accumulating evidence suggesting that we can slow it down and there is clear evidence that we can decrease our risk of chronic disease significantly by modifying our diet and lifestyle. This means that we have much more influence over whether we live a long healthy life than we previously thought. Are we talking about hormone replacement? The anti-aging movement, which is currently being promoted by some physicians and celebrities who are interested in this field, is often reduced to the use of hormonal therapy to replace low levels of hormones with synthetic (or bioidentical) hormones and return these low levels to youthful levels. This is not one or our goals in functional medicine. Hormone replacement can produce improvement in many different symptoms associated with low hormones and sometimes this is necessary, but there are always tradeoffs in any type of hormone therapy. These include atrophy of glands, decreased sensitization of the hormone receptor sites to the hormones, and loss of feedback loop integration (all hormones are produced by glands which are regulated by feedback mechanisms, just like a thermostat at your home). Whenever you introduce exogenous hormones into the body, you put yourself at risk of all of these things happening to some degree. The more hormones you take and the longer you are on hormone therapy, the bigger risk of developing these problems and the more difficult it is for a practitioner to correct. In other words, hormone therapy can throw a monkey wrench in your physiology . Hormonal therapy should be used judiciously and in the lowest levels possible. How do we assess biological aging? Biological aging has been a subject of scientific research for at least the past 40 years. In the mid-1970’s, a few American researchers discovered regions of the ends of chromosomes (called telomeres ) which became shorter each time the cell divided. It was noticed that chromosomes would stop dividing after about 50 replications. The inability of the cells to continue dividing was later found to be due to the shortening of these telomeres. “Telomere shortening represents a cell-intrinsic mechanism leading to DNA damage accumulation”4 What are Telomeres and Why Are They Important? Telomeres are repeated DNA patterns at the end of chromosomes that function to protect and maintain genomic stability. These telomeres protect the genes from assaults and toxins from our environment. You can think of the telomeres as the plastic ends of shoelaces that protect the DNA strands and prevent them from unraveling. What we now know is that there is a constant battle between agents that damage and shorten telomeres and those that protect them. As people age, the mean length of the telomeres decreases. Telomere shortening has been used in research as a marker of biological aging. “The mean telomere length serves as a marker for the biological age at the cellular level, with shorter telomeres defining the increased biological age.”5 However, mean telomere length of an individual is not a practical tool that can be used easily in a clinical setting to assess biological aging. In the clinic, we need to rely on other easily accessible indicators of biological aging such as the person’s age, vital signs, presenting signs and symptoms and other validated biomarkers from routine blood chemistry or special lab assessments. Formulating Useful Potential Markers of Biological Aging First, we need to be clear that t here is no consensus on reliable biomarkers of aging. The subject is still relatively new and theories of biological aging are still being worked out. However, if we accept the theory presented by Bruce Ames, Ph.D, as described in the first article, then we can draw the same conclusions as he has: namely, that mitochondrial decay and damaged DNA lead to accelerated aging and most of the degenerative diseases we see in the elderly today. The reason why this is such a powerful model is that it means that the same physiologic processes that drive biological aging are the same processes that lead to chronic disease, increased risk of poor quality of life and shorter lifespan. The corollary is that in order to slow down biological aging, we need to reduce our risk of developing chronic disease. Let’s first look at some signs and symptoms which may be associated with chronic disease and then look at some validated disease biomarkers available via routine blood chemistry that are currently used to assess one’s risk of developing chronic disease. We will then consider biomarkers that can be used to assess the internal aging process. Keep in mind that having one or more of these signs or symptoms (or lab markers) does not necessarily indicate chronic disease or the degree of this. However, taken into consideration with other biomarkers, diagnostic tests and one’s signs and symptoms, these may be warning signs or indicators of disease. Laboratory results should always be assessed in conjunction with other lab markers and assessments and provide the clinician with useful information about risk of disease. Signs and Symptoms Which May be Associated with Disease Pain or difficulty moving or difficulty exercising Fatigue or low energy Shortness of breath Chest pain Poor digestion Gas, bloating and abdominal discomfort Constipation Incontinence Difficulty with urination Loss of memory Brain fog Depression Difficulty maintaining balance Shaking or tremors Frequent colds or infections Difficulty recovering from infections Decreased bone density Frequent bone fractures Validated Biomarkers for Assessing Risk of Chronic Disease Cholesterol LDL (“bad” cholesterol): indicator of risk of cardiovascular disease HDL (“good” cholesterol): indicator of protection against cardiovascular disease Triglycerides: strong indicator of insulin resistance, pre-diabetes and fatty liver; insulin resistance is the #1 cause of type 2 diabetes Apo A1:Apo B ratio: strong indicator of heart attack risk Fasting glucose and insulin levels: strong indictors of insulin resistance HbA1C (glycosylated hemoglobin): stable and reliable indicator of prediabetes and diabetes and used to monitor progression of diabetes ALT, AST: indicators of liver disease (hepatitis, fatty liver, etc.) GGT: indicator of alcohol and drug problems, toxicity exposure and risk factor for diabetes CRP or hs-CRP: indicator of systemic inflammation (inflammation throughout the body) and risk factor for heart attack and stroke Homocysteine: risk factor for heart attack, stroke and dementia Uric acid: indicator of metabolic health and risk of gout TSH, T4, T3: markers of thyroid function Antibody profile: ANA, anti-CCP , anti-gliadin, anti-TPO, anti-thyroglobulin; ( strong connection between gluten sensitivity and risk of autoimmune disease) PSA: indicator of prostate health Blood pressure: risk factor for stroke Body composition (BIA): risk factor for many chronic diseases Lp(a): risk factor for heart attack Vitamin D: deficiency is increased risk factor for many types of cancer, cardiac disease and immune dysfunction Risk Factors for Future Cardiovascular Events: World Heart Federation What factors place people at risk for developing cardiovascular disease (heart attack or stroke) as they grow from youth to adulthood? The following blood chemistry markers have been identified with increased risk of cardiovascular events by the World Heart Federation (in order of relative risk of cardiovascular events): Lipoprotein(a) Homocysteine Total cholesterol (TC) LDL-C Apo B TC: HDLC (ratio of TC to HDL cholesterol) HsCRP Now that we have a list of biomarkers used to assess risk of disease, we can start to formulate a list of modifiable characteristics (signs of healthy aging that we have some control over) and some useful potential biomarkers of aging. Modifiable Characteristics of Aging Cardiovascular fitness Muscular strength Flexibility Hearing acuity Skin elasticity and tone Pulmonary function Memory Inflammatory disorders Bone loss Potential Biomarkers of Biological Aging vs. Chronic Disease Evaluation If we accept the work of Bruce Ames, Ph.D, and others who have pioneered the field of biological aging and accept the premise that the same processes that lead to accelerated aging lead to chronic disease, then we find we can use these same biomarkers used to identify chronic disease in the evaluation of risk of biological aging. This is exactly what we do in functional medicine . However, the interpretation of these lab results may be quite different depending on the range being used for comparison. For example, in functional medicine, we use functional ranges as the standard for evaluation of lab markers, which may differ substantially from the lab’s ranges. Lab ranges are pathological ranges used to diagnose disease. Functional ranges are used to assess risk for disease before disease develops. The main difference between the two is the degree of deviation allowed within their normal ranges. Levels outside pathological ranges may indicate disease. Levels outside the functional range usually indicate an imbalance and may indicate risk of developing disease. Functional ranges are science-based ranges. These are ranges derived from the literature which various medical experts and organizations have concluded to be the range of variance for those in ideal health . Functional ranges are basically pathological ranges “tightened up”. At this point, there are no lab ranges for biological aging. However, if we accept Dr. Ames’ model of biological aging, it makes complete sense to use functional ranges to identify risk of biological aging. Those whose lab markers fall within the functional range are in a state of ideal health and have the least risk of accelerated aging and chronic disease. In addition to these markers as identified above, there are other markers which can also provide insight into one’s risk of accelerated aging based on our understanding of how glycosylation, inflammation and low hormone levels increase risk of chronic disease: Glycosylated proteins such as hemoglobin (HbA1C already being used as an indicator of risk of pre-diabetes or diabetes) and albumin (which leads to “crusty proteins”) Increased inflammatory markers (TNfα, IL-6, CRP)(CRP is well-accepted marker of inflammation which is now being correlated with increased risk of almost all chronic disease—a subject we will explore in part 3 of this series) Low anabolic hormone levels (ie: testosterone for men, estrogen for women) and increased stress hormone markers (ie: cortisol) Conclusions What do all these markers tell us about biological aging? How do we know the extent of biological aging by evaluating these markers? These are good questions and we cannot say with certainty that any individual’s biology is aging at any particular rate by examining only these biomarkers. What we do know is that one’s risk of various chronic diseases increases as these biomarkers fall out of the functional and pathological ranges . We also know from the research by Dr. Ames and others, that excess oxygen radical activity or reactive oxygen species (ROS) easily damages the mitochondria and can damage the DNA. Increasing evidence is showing that mitochondrial decay and damage to the DNA drive the biological aging process leading to chronic and degenerative diseases. So we can infer that accelerated aging processes are occurring in individuals who have lab markers that are not within the ideal range or who have (or are developing) signs and symptoms of chronic disease. The Development of “Risk” Over Time A final word about “risk of disease”: risk is a variable concept that occurs on a continuum; it doesn’t happen overnight. Risk can develop suddenly but usually develops gradually over time. Risk factors can vary from weak to strong, depending on the “normal” or “accepted” range. The more risk factors and the longer an individual maintains these risk factors, the higher risk of disease. The earlier you can intervene in an emerging disease pattern, the easier it is to make a change in trajectory of that disease. This is why we take an aggressive preventative approach in the functional medicine model which often includes dietary and lifestyle change and the use of key nutrients when we see signs of an imbalance or risk of developing disease. In parts 3, 4 and 5 of this series, we will focus on the major mechanisms of chronic and degenerative disease, including insulin resistance, inflammation, autoimmunity, food sensitivities (ie: gluten), intestinal permeability, toxicity, hormonal imbalances, gut dysbiosis and gastrointestinal infections. References: 1. Expert Opinion on Therapeutic Targets July 2007, Vol. 11, No. 7, 2. Diab Vasc Dis Res. 2007 Dec;4(4):285-96. Epidemiology of paediatric metabolic syndrome and type 2 diabetes mellitus. De Ferranti SD , Osganian SK . 3. Future Child. 2006 Spring;16(1):47-67. The consequences of childhood overweight and obesity. Daniels SR . 4. Journal of Molecular Medicine Volume 87, Number 12 / December, 2009 5. Expert Opinion on Therapeutic Targets July 2007, Vol. 11, No. 7","date_published":"2013-02-14T06:57:40","date_modified":"2020-04-19T22:02:54","authors":[{"name":"Dr. Richard Esquivel","url":"https://sanjosefuncmed.com/about/"}],"tags":["Functional Medicine"]},{"id":"https://sanjosefuncmed.com/autoimmune-disease-u-s-part-1-6-part-series/","url":"https://sanjosefuncmed.com/autoimmune-disease-u-s-part-1-6-part-series/","title":"Autoimmune Disease in the U.S.- Part 1 in 6-Part Series","summary":"Introduction to autoimmune disease: What is it? How common is it? How is it diagnosed? How is it managed? Main points of this issue: Rates of autoimmune (AI) ","content_text":"Introduction to autoimmune disease: What is it? How common is it? How is it diagnosed? How is it managed? Main points of this issue: Rates of autoimmune (AI) diseases are increasing every year in the U.S. The diagnosis of AI disease is only made after there is degeneration of tissue Most AI cases remain undiagnosed Most AI cases continue to progress over time Most AI patients develop more than one AI disease during their lifetime Conventional healthcare has very little to offer these patients besides steroids Autoimmune Disease in the U.S. One of the things we know for sure is the rates of autoimmune (AI) disease in the U.S. continue to go up for all AI diseases. There is an explosion of AI disease happening now like never before. “Autoimmune diseases are the third leading cause of morbidity and mortality in the industrialized world, surpassed only by cancer and heart disease.” 1 “While many individual autoimmune diseases are rare, collectively they are thought to affect approximately 8 percent of the United States population – 24 million persons.” “To provide a context to evaluate the impact of autoimmune diseases, cancer affected approximately 9 million people and heart disease affected approximately 22 million people in the United States .” 2 What is Autoimmune Disease? Autoimmune disease occurs when the immune system begins targeting self-tissue causing destruction of that tissue or organ. There are many different AI diseases that have been identified, such as rheumatoid arthritis (RA), multiple sclerosis (MS), lupus (SLE), Hashimoto’s thyroiditis, Crohn’s disease, ulcerative colitis (UC), type I diabetes and Celiac disease (CD). AI disease can affect every organ and tissue in the body “Autoimmune diseases can affect virtually every site in the body” “At least 15 diseases are known to be the direct result of an autoimmune response, and circumstantial evidence links more than 80 conditions to autoimmunity.” 3 AI disease is usually progressive over time There is no cure for most AI diseases. AI patients generally suffer more and more symptoms of tissue destruction over time. Conventional treatment is focused on suppressing the immune response and controlling symptoms but little is offered to the patient in regards to modulating the autoimmunity and avoiding triggers that cause flare-ups of the autoimmune response. As a result, AI conditions tend to cause more and more tissue destruction over time, eventually leading to severe tissue destruction and organ failure in many cases. Diagnosis of AI Disease The diagnosis of AI disease is only made after there is degeneration of the tissue. In conventional healthcare, the diagnosis of AI disease is based on destruction of tissue (observable on diagnostic imaging), along with autoantibodies (antibodies against self-tissue) and other markers found in the blood along with clinical findings (signs and symptoms of patient). However, the development of tissue destruction or organ failure does not happen overnight. What about the 5-10 years of suffering the patient had before they are diagnosed with the disease? Autoimmune Reaction versus Autoimmune Disease During the early stages of autoimmunity, the immune system is attacking tissue and initiating an AI reaction (based on the presence of antibodies) but the diagnosis of AI disease is not given until observable destruction of tissue has been identified. An AI reaction is when the immune system starts to attack self-tissue. The presence of autoantibodies indicates that the immune system is initiating an immune response against self-tissue (tissue or cellular components of the body). During an AI reaction , you may or may not have symptoms of that tissue being destroyed. Symptoms will only occur when the tissue destruction is severe enough to lead to a change in physiologic function. The AI reaction isn’t really a concern in the conventional model Our current healthcare system typically waits until the patient shows evidence of tissue destruction before they are given the diagnosis of autoimmune disease. For example, you may have autoantibodies against the cartilage and swelling and pain against your joints, but it isn’t diagnosed as rheumatoid arthritis (RA) until destruction of joints have been seen on X-ray or MRI. Or you may have myelin antibodies but you will not be given the diagnosis of multiple sclerosis (MS) until there are observable changes or lesions in the MRI of the brain or spinal cord. Most AI disease remains undiagnosed. “Collectively autoimmune diseases have been identified in about 24 million people in the U.S., and only 1/3 are diagnosed. That means about 72 million people have an AI disease. It’s not looked for. Our system waits until the signs and symptoms are severe enough with organ failure and irreversible damage before we identify it.”4 Prevalence of Multiple Autoimmune Diseases The other thing we know is that when people have antibodies against one known tissue type, there is likely other antibodies against other tissue as well. In other words, when a person is diagnosed with AI disease, they are at high risk of developing other autoimmune diseases during their lifetime. It is very rare that only one tissue type is targeted by the immune system. When we look at people with AI disease, they may have multiple types of tissue being targeted that have not yet been identified. For example, the literature shows people with thyroid autoimmune disease have over a 50% chance of being affected by another autoimmune disease. 5 Conventional Treatment of AI Disease: Immune-Suppressing Medication People with AI reactions usually don’t get diagnosed and don’t get any management or support until they get diagnosed with AI disease in conventional medicine. Once patients suffer sufficient tissue destruction to be diagnosed with AI disease, what does conventional healthcare have to offer? The standard of care is steroids and other immune-suppressing drugs. Steroids are usually not used in the initial stages because the adverse and damaging effects on the body make it not worth the risks. Some of the side effects of steroids include: immune suppression, bone loss, neurodegeneration, insulin-related issues, epithelial thinning, catabolic states so they cannot recover, etc. So patients aren’t given steroids until their condition has become severe and progressed. If the tissue destruction is severe enough, doctors may use a bone marrow-suppressing drug to shut down the immune system completely or they may take out the thymus in some of the more severe conditions such as myasthenia gravis. There really is little hope in the conventional model of healthcare for these AI patients to have an impact on the progression of their autoimmunity since the focus of treatment is suppression of the immune system. These immuno-suppressive agents come with significant adverse effects. Alternative Treatment for Autoimmune Disease Not Much Better Many of these patients end up seeing an alternative healthcare practitioner. What happens then? If the practitioner doesn’t know it’s an AI reaction, they treat every symptom separately. For example, a person comes in with parietal cell antibodies, cartilage antibodies, myelin antibodies and skin epithelial antibodies and all the symptoms characteristic of each of these diseases. What would be the treatment? Most likely, the alternative practitioner would offer different treatments for each of the symptoms with no consciousness that they really only have one underlying mechanism, which is autoimmunity. They would not consider focusing treatment on the immune system. Nor would they consider focusing on finding the triggers of the autoimmunity. In addition, with many autoimmune people, you can’t just give them any type of treatment because some compounds will actually flare up their autoimmunity. Many of the supplements these patients are already taking are flaring them up and making them worse because they are triggering their AI mechanisms. When you look at alternative medicine, they oversimplify autoimmunity to be due to either nutritional deficiencies or caused by heavy metals, viruses or parasites. This is a very simplistic way of looking at autoimmunity. There is more to autoimmunity than just piling on supplements, hunting for viruses and parasites and eliminating metals. Heavy Metal Chelation? Heavy metal chelation is not a good idea for many of these patients, either. Sometimes doing heavy metal chelation can flare these people up and get them to a place they can never get out of. Alternative practitioners can’t just randomly do these types of therapies because it is not efficient patient management and can actually flare these patients up to a critical condition. Functional Medicine: A Better Option for Autoimmune Disease When you look at the dysregulation of the immune system that occurs in autoimmunity, we know that there are different systems involved in the targeting of tissue for destruction. Autoimmunity is a multi-variant process and the goal should be to calm down the autoimmunity, specifically the immune response against self-tissue. There are several innate regulating systems of immune function that begin to dysregulate in autoimmunity. In functional medicine, we attempt to modulate the autoimmunity by regulating these various systems. Autoimmune Regulation as a Therapeutic Approach When we consider treatment of autoimmunity, there are 3 things we focus on: Finding the triggers causing the autoimmunity to flare up and remove them Modulating the autoimmunity and decrease the tissue destruction Enhancing and supporting their recovery from these flare-ups We are not talking about curing these AI conditions because we don’t know how to do that. But we can improve the quality of life for these patients and empower a person to know how to identify triggers and minimize their flare-ups, manage their autoimmunity and support their recovery. Content provided by Datis Kharrazian, D.C., Autoimmune Regulation of the Nitric Oxide and Glutathione Systems, 11/4/10 In part 2 of this 6-part series , we answer the following questions: What are the different types of autoimmune disease? How common is Hashimoto’s hypothyroidism? What is involved in the development of AI disease? Continue to part 2 of series References: 1. The Journal of Immunology, 2005, 175: 4119–4126. 2. NIH. Autoimmune Diseases Coordinating Comm. Autoimmune Diseases Research Plan. 2006 3. NAT CLIN PRAC GASTRO & HEP SEPT 2005 VOL 2 NO 9 4. Jeffrey S. Bland, Ph.D.; Metagenics Educational Programs. 2006 5. ACTA BIO MEDICA 2003; 74; 9-33","date_published":"2012-06-03T05:10:10","date_modified":"2020-04-17T16:39:54","authors":[{"name":"Dr. Richard Esquivel","url":"https://sanjosefuncmed.com/about/"}],"tags":["Autoimmune Health"]},{"id":"https://sanjosefuncmed.com/autoimmune-disease-u-s-part-2-4-part-series/","url":"https://sanjosefuncmed.com/autoimmune-disease-u-s-part-2-4-part-series/","title":"Autoimmune Disease in the U.S.- Part 2 in 6-Part Series","summary":"What are the different types of autoimmune disease? How common is Hashimoto’s hypothyroidism? What is involved in the development of AI disease? Main points o","content_text":"What are the different types of autoimmune disease? How common is Hashimoto’s hypothyroidism? What is involved in the development of AI disease? Main points of this issue: Autoimmune (AI) disease is characterized by an immune response against self-tissue The most common AI disease in the U.S. is Hashimoto\u001as autoimmune thyroid 8% of the U.S. population has thyroid antibodies 1 out of 10 females in the U.S. has thyroid antibodies 90% of people that become hypothyroid have AI thyroid The presence of autoantibodies indicates current (or future) AI disease Over 50% of people that have autoimmune thyroid have antibodies against other tissues AI disease is characterized by loss of immune tolerance AI disease is characterized by a dominance in either the TH1 or TH2 system In the first issue, we discussed the prevalence of autoimmune (AI) disease in the U.S. and how they are diagnosed. We discussed their progressive nature and the fact that patients who develop one AI disease are at high risk of developing others. We also discussed conventional treatment of AI disease being primarily the use of immune-suppressing medication. In this issue, we will take a deeper look at the nature of autoimmune conditions and their common characteristics. We will look at Hashimoto\u001as autoimmune thyroid as an example of one of these AI conditions and its prevalence. What is autoimmune disease? Let\u001as first take a look at how AI disease is defined: \u001aa condition characterized by a specific humoral or cell-mediated immune response against constituents of the body\u001as own tissues\u001a In any immune response, antibodies are generated by the immune system to help identify and target foreign invaders or harmful substances. In autoimmune diseases, the immune system generates antibodies against the body\u001as own tissue (autoantibodies). The body\u001as own tissue becomes a target of the immune system. There are two general types of autoimmune conditions depending on whether or not they are organ-specific. \u001a Autoimmune disorders can be classified as either organ specific or non-organ specific\u001a \u001aIn organ-specific AI diseases, the autoantibodies are specifically directed against antigens localized in a particular organ and are often detected in circulation.\u001a \u001aExamples of organ-specific autoimmunity include Hashimoto\u001as Thyroiditis, Type 1 Diabetes and Myasthenia Gravis.\u001a \u001aThe non-organ-specific AI disorders are characterized by the presence of autoantibodies directed against ubiquitous antigens (not specific to a particular organ).\u001a \u001aThis is characterized by the presence of specific circulating immune complexes. Non-organ-specific AI includes diseases such as systemic lupus erythematous (SLE), rheumatoid arthritis (RA), and scleroderma.\u001a1 Let\u001as take a look at one example of autoimmune (AI) disease, autoimmune thyroid, which is the most prevalent AI disease in the U.S. today and how it manifests in the affected individual. Autoimmune Thyroid Disease The most common AI disease in the U.S. is Hashimoto\u001as autoimmune thyroid. The thyroid gland is very vulnerable to autoimmune attack and often times thyroid antibodies are the first sign of the development of an autoimmune disease. 8% of the U.S. population has thyroid antibodies. It is estimated that 1 out of 10 females in the U.S. has thyroid antibodies. \u001aThyroid Autoimmune Diseases are the most frequent autoimmune diseases in the population being present on average in 7-8% of the general population, (approximately 24 million people) in the U.S.\u001a2 90% of hypothyroid patients have AI thyroid The most common mechanism for thyroid disorders in the U.S. today is autoimmunity, not iodine deficiency. Most hypothyroid patients actually have antibodies against their thyroid, although this is often overlooked and remains undiagnosed in most cases of hypothyroidism. Current research indicates that approximately 90% of people that become hypothyroid have an autoimmune attack against the thyroid gland.3 These hypothyroid patients are put on thyroid hormone to replace the lack of this hormone in the body but nothing is done for the autoimmune condition itself. What you are really seeing in these thyroid patients is the first expression of an autoimmune disease. Importance of Early Detection of Autoantibodies The presence of thyroid antibodies indicates future thyroid disease. The literature shows if you have thyroid antibodies, at some point, you will have thyroid failure leading to hypothyroidism. In most cases, thyroid antibodies are only discovered after the patient has been diagnosed as hypothyroid. \u001aAlmost all autoimmune disorders are associated with circulating antibodies which bind self protein\u001a4 \u001aThese antibodies appear in the blood years before presentation of symptoms in various disorders\u001a \u001aTherefore, these antibodies may be used as biomarkers for early detection of various diseases\u001a5 Why is early detection of autoantibodies important? Because early detection allows for earlier intervention, possible prevention of the onset of autoimmune disease, potential for slowing down the autoimmune destruction of tissue and better prognosis. \u001aEarly identification might result in earlier treatment, better quality of life and an improved prognosis for these patients\u001a6 Autoantibodies As Predictors of Disease \u001aSince autoantibodies are markers of disease activity, it follows that, under some circumstances, autoantibodies should be able to predict disease\u001a \u001aThe practical value of autoantibodies has not been fully realized in the majority of diseases in which they can be detected. Realizing the clinical potential of autoantibodies could be extremely valuable\u001a 7 \u001aSeveral studies have shown that autoimmune diseases are preceded by a long preclinical phase, and that many autoantibodies can be detected in the serum of asymptomatic subjects years before the diagnosis.\u001a 8 We also know that most people (over 50%) that have autoimmune thyroid have antibodies against other tissues. 9 This is important because as we will see, there are many things we can do to modulate the autoimmune response through diet, lifestyle and nutritional medicine that can decrease your risk of developing other AI diseases. Remember that any tissue is up for grabs for autoimmune destruction in AI disease. Characteristic of Autoimmune Disease: Loss of Immune Tolerance Why would we become allergic to ourselves? Are we really allergic to ourselves? Why would our immune systems attack self-tissue? One of the things we have to have in order to prevent autoimmune disease is immune tolerance. Immune tolerance is the concept that the immune system tolerates (and does not react to) certain antigens in the body, including self-protein markers, and some types of foreign antigens as well, such as heavy metals or toxins. However, when the immune system loses this ability to tolerate a marker, then it initiates an immune response against this antigen or marker. The production of antibodies occurs as part of the immune response. TH1/TH2 Balancing = Immune Tolerance In a healthy immune system, there is a balance between two important aspects of the immune system: TH1 and TH2 responses. When you look at the immune system, there are two types of cells: T cells and B cells. The T cell response is called TH1 response (cell-mediated immunity). The B cell response is called TH2 response (humoral-mediated immunity). When your immune system has to destroy an antigen, it attacks it first (TH1 response), then it makes antibodies so that it can be more efficient in finding it (TH2 response). In a healthy immune response, the TH1 and TH2 systems are somewhat in balance. Autoimmune Disease is Characterized by Polarity in TH1 and TH2 Systems In AI disease, there is a polarity in these TH1 and TH2 systems. There is always a dominance in their TH1 or TH2 systems. AI diseases are promoted by imbalances in the TH1 and TH2 systems. \u001aRegardless of whether autoimmune diseases are caused by too much or too little exposure to micro organisms, it is now generally believed that adaptive immunity and an imbalance between the TH1 and TH2 immune responses are the key elements underlying the pathogenesis of the autoimmune process\u001a10 TH3 System Regulates TH1 and TH2 Response TH3 is the regulatory system that balances the TH1 and TH2 systems. The TH3 system is made up of regulatory T cells that regulate the immune response between the TH1 and TH2 systems. One of the things we want is to have a TH3 system that is as strong as possible for this reason. We will learn later some important compounds that have a powerful effect on the TH3 system, such as vitamin D and glutathione. \u001aThere is a constant state of balanced chronic inflammation present in the gastrointestinal tract. This physiologic inflammation is essential for the maturing of the immune system and development of the normal morphology of the intestinal mucosa.\u001a 11 TH 17 System Activity Leads to Greater Tissue Destruction There is one more important system involved in the immune response: the TH17 system. The TH17 system comes from T helper cells and induces IL-17 production. The more active the TH17 system, the more IL-17 produced and the more tissue destruction you get in the TH1 or TH2 shift. If you have a TH1 system that is dominant and an active TH17 system, then it is more destructive than before. One of our goals is to dampen the TH17 system in order to minimize tissue destruction. Goals of Autoimmune Management In order to manage autoimmune disease, you need to: \u001a Balance TH1 and TH2 systems \u001a Enhance the TH3 regulatory system \u001a Decrease the TH-17 response When we manage the AI patient in functional medicine, we are trying to do 3 things: 1. Decrease the triggers of their AI flare-ups 2. Dampen their AI overzealousness altogether 3. Enhance their recovery In order to accomplish this, we need to be able to answer the following questions: \u001a What systems are involved in flaring them up? \u001a What systems are involved in causing destruction of tissue? \u001a What systems are involved in their recovery? If we can answer these questions, then we can start to ask what interventions we can employ to make the biggest change in these patients. Content provided by Datis Kharrazian, D.C., Autoimmune Regulation of the Nitric Oxide and Glutathione Systems, 11/4/10 In part 3 of this 6-part series , we answer the following questions: What are the mechanisms and mediators involved in autoimmunity? Intestinal permeability promotes autoimmunity. Gluten sensitivity and autoimmunity connection. Continue to part 3 of series References: 1. Clin. Diag. Lab. Immunology, July 2001, p. 678\u001a685 2. Betterele C and Zanchetta R. Update on autoimmune polyendocrine syndromes (APS). Acta Bio Medica. 2003; 74:9-43 3. Baillieres. Autoimmunity and hypothyroidism. Clin Endocrinol Metab. 1998; Aug 2 (3): 591-617 4. Lupus (2006) 15, 183-190 5. Expert Opin. Med. Diagn. (2008) 2(6):1-13 6. Lupus (2006) 15, 183-190 7. Autoimmunity, June 2004 Vol. 37 (4), pp. 253-256 8. Autoimmunity Review 2007; 6: 325-33 9. Betterele C and Zanchetta R. Update on autoimmune polyendocrine syndromes (APS). Acta Bio Medica. 2003; 74:9-43 10. NAT CLIN PRAC GASTRO & HEP SEPT 2005 VOL 2 NO 9 11. Gut. 2002 Feb;50(2):148-9","date_published":"2012-05-25T01:04:23","date_modified":"2020-04-17T16:39:54","authors":[{"name":"Dr. Richard Esquivel","url":"https://sanjosefuncmed.com/about/"}],"tags":["Autoimmune Health"]},{"id":"https://sanjosefuncmed.com/autoimmune-disease-u-s-part-3-5-part-series/","url":"https://sanjosefuncmed.com/autoimmune-disease-u-s-part-3-5-part-series/","title":"Autoimmune Disease in the U.S.- Part 3 in 6-Part Series","summary":"What are the mechanisms and mediators involved in autoimmunity? Intestinal permeability promotes autoimmunity. Gluten sensitivity and autoimmunity connection.","content_text":"What are the mechanisms and mediators involved in autoimmunity? Intestinal permeability promotes autoimmunity. Gluten sensitivity and autoimmunity connection. Main points of this issue: Intestinal permeability promotes autoimmunity Intestinal permeability occurs when the tight junctions of the intestinal mucosa are compromised Intestinal permeability may be a necessary condition for the development of autoimmunity Malabsorption is common in intestinal permeability Autoimmunity itself tends to cause further intestinal permeability Gluten sensitivity has been found to initiate intestinal permeability Celiac disease (CD) is an autoimmune disease resulting from extreme gluten sensitivity Most cases (87.5%) of CD remain undiagnosed CD significantly increases risk of developing other autoimmune diseases Not all cases of gluten sensitivity result in Celiac disease (CD) 2/3 of people with gluten sensitivity do not have GI enteropathy Most gluten sensitivity affects the brain, not the GI tract Gluten sensitivity may manifest in a number of neurological deficits Gluten sensitivity has been linked to several autoimmune diseases, in addition to CD Intestinal permeability promotes autoimmunity We know there are links of intestinal permeability to autoimmunity. When a person develops intestinal permeability, there is a whole list of health problems that take place. Most people in the conventional world don’t know about leaky gut syndrome or intestinal permeability yet. This will change shortly because drug companies are now working on a drug to treat intestinal permeability. Once they develop a drug, everyone will know about it. What is intestinal permeability (or “leaky gut” syndrome)? The lining of the gastrointestinal (GI) tract is made up of small epithelial cells that lie side-by-side each other forming tight junctions. These cells act as a barrier between the interior of the body (blood/circulatory system)and the exterior of the body (the GI tube). There are two primary functions of the intestinal lining of the GI tract: the first is to absorb small, micromolecules, such as digested food particles, which are used as fuel sources for the body. These micronutrients are absorbed directly into the epithelial cells. The second, is to prevent the absorption of larger macromolecules which should not penetrate through the intestinal barrier. When tight junctions of the intestinal mucosa are compromised, they become widened and permeable to large undigested compounds, toxins and bacteria, known as “leaky gut”. The larger compounds of absorbed yet undigested proteins are reacted against by the underlying intestinal immune system. This reaction then promotes exaggerated immune responsiveness and intestinal inflammation. This creates a vicious cycle of further intestinal inflammation and increased intestinal permeability. Paper after paper in the literature is showing that intestinal permeability promotes autoimmune reactions, flare-ups and overzealousness of the immune system: “A more attentive analysis of the anatomic and functional arrangement of the gastrointestinal tract, however, suggests that another extremely important function of this organ is its ability to regulate the trafficking of macromolecules between the environment and the host through a barrier mechanism.”1 “When the finely tuned trafficking of macromolecules is dysregulated in genetically susceptible individuals, both intestinal and extraintestinal autoimmune disorders can occur.”2 “It is now apparent that tight junctions are dynamic structures that are involved in developmental, physiological, and pathological processes. As a result, particular attention is being placed on the role of tight junction dysfunction in the pathogenesis of several diseases, particularly autoimmune diseases.”3 The literature shows a close connection between increased food sensitivities and intestinal permeability: “Intestinal permeability is increased in patients with food allergy, suggesting that the uptake of food antigens is elevated in food-allergic patients.”4 One of the things researchers are finding is once these tight junction proteins get compromised, there is such immune zealousness and activation, this whole immune self-tolerance is lost, resulting in autoimmunity: “In all cases, increased permeability appears to precede disease and causes an abnormality in antigen delivery that triggers the multiorgan process leading to the autoimmune response.”5 “Together with the gut-associated lymphoid tissue and the neuroendocrine network, the intestinal epithelial barrier, with its intercellular tight junctions, controls the equilibrium between tolerance and immunity to non-self antigens. When the finely-tuned trafficking of macromolecules is dysregulated in individuals, both intestinal and extraintestinal autoimmune disorders can occur.”6 A recent article published in a well-respected medical journal hypothesized that intestinal permeability is a necessary condition for the development of autoimmunity: “There is growing evidence that increased intestinal permeability plays a pathogenic role in various autoimmune diseases. Therefore, we hypothesize that loss of intestinal barrier function is necessary to develop autoimmunity Tight junctions, intestinal permeability, and autoimmunity: celiac disease and type 1 diabetes paradigms.”7 Malabsorption is Common in Leaky Gut The other consequence of intestinal permeability is malabsorption of nurients. Many of these leaky gut patients get malabsorption because the inflammation that occurs from the penetration of peptides causes mucus formation. The mucus makes it difficult for small micronutrients to penetrate the intestinal epithelial cells. The larger molecules are able to penetrate because of their greater mass. So you get leaky gut with malabsorption issues. This becomes a serious problem. Autoimmunity Itself Tends to Cause Further Intestinal Permeability We now know autoimmunity also leads to leaky gut. Cytokine explosions from autoimmunity immediately destroy the tight junctions of the intestinal barrier. As the autoimmunity flares up, these patients get increased intestinal permeability. Most people who have autoimmunity feel better until they get a flare up, then they get worse. Whenever they get flare-ups, they are getting some degree of intestinal permeability. The autoimmunity itself tends to perpetuate the leaky gut syndrome and this becomes a vicious cycle. What are Some of the Mediators and Modulating Factors that Contribute to Autoimmunity? Gluten sensitivity Gluten is the protein found in wheat which can be broken down into gliadin and glutenin. Gliadin is the portion of gluten that initiates the immune response in gluten sensitivity. However, recent research indicates that gluten sensitive individuals may react to glutenin as well. Immune responses to gliadin have been found to initiate intestinal permeability via upregulation of zonulin: “Gliadin and its peptides interact with the intestinal epithelium increasing intestinal permeability through the release of zonulin that, in turn, enables paracellular translocation of gliadin and its subsequent interaction with macrophages within the intestinal submucosa (in CD patients).”8 “Therefore, understanding the interactions between the upregulation of zonulin, increased intestinal permeability, and the development of autoimmune diseases may lead to novel preventative and possibly therapeutic strategies for type 1 diabetes.”9 Celiac Disease: An autoimmune disease resulting from extreme gluten sensitivity We know that gluten sensitivity has major impacts on health. One of the most extreme cases of gluten sensitivity results in an autoimmune disease called Celiac disease. In Celiac disease (CD), the immune system’s response to gluten exposure results in chronic inflammation and destruction of the GI tract. This is the only known autoimmune disease which results directly from exposure to a food whose progression can be stopped by avoidance to exposure that food. Most cases of CD remain undiagnosed It is estimated that only the patients with clinically overt celiac disease (12.5%) get diagnosed. This is only the “tip of the iceberg”. The other 87.5% of patients with CD remain undiagnosed with “silent celiac disease”. These patients are asymptomatic but have positive test results. “The current ratio of clinically diagnosed to undetected cases that is “the size of the iceberg” is approximately 1 to 8.” 10 “For every symptomatic patient with CD there are eight patients with CD and no GI symptoms.” 11 Celiac Disease (CD) Significantly Increases Risk of Developing Other Autoimmune Disease The damage to the GI tract in CD can be devastating. However, the GI tract is not the only tissue that may be the target of immune destruction. When a person has full-blown celiac disease type reactions, any other tissue of the body can be attacked. “Associated autoimmune antibodies are frequent in CD and their first-degree relatives, spanning anti-endocrine, anti-gastrointestinal, anti-nuclear, anti-cytoskeleton and anti-neurological antibodies.” “More specifically, in numerous studies, antibodies against thyroid and the endocrine pancreas, anti-gastric and liver, anti-nuclear constituents, anti-reticulin, actin, smooth muscle, calreticulin, desmin, collagens and bone, anti-brain, ganglioside, neuronal and blood vessel were described in sera of the patients.”12 Gluten sensitivity vs. Celiac disease Not all cases of gluten sensitivity result in celiac disease (CD). There are many forms of gluten sensitivity that are unrelated to CD. Gluten sensitivity is defined by having an immune response to gluten. To have celiac disease, you have to have other criteria. With enteropathy (gastrointestinal disease), you need the HLA-DQ2 or DQ8 genes and gliadin antibodies present in the blood. Then you need either positive serum transglutaminase or positive biopsy results, depending on the source. There are still many doctors that are fixated on the celiac-disease model which is focused on intestinal manifestation of gluten sensitivity. There are other cases of enteropathy (GI disease) associated with gluten without the specific genotype. This is known as “non-celiac gluten enteropathy”. Most people with gluten sensitivity do not have gastrointestinal symptoms The other mistake that many doctors make is they associate gluten sensitivity with disease of the intestinal tract. 2/3 of people with gluten sensitivity do not have gastrointestinal symptoms. What other organs does it affect? Once a person has gluten sensitivity without enteropathy, it can destroy any tissue. The most vulnerable tissue is the brain. Most gluten sensitivity affects the brain, not the GI tract. “Patients with an enteropathy (disease of the intestinal tract) represent only a third of patients with neurological manifestations and gluten sensitivity.”13 Gluten sensitivity may manifest in a number of neurological deficits, depending on what part of the brain or nervous system is affected, including numbness and tingling, ataxia (balance problems), migraines, attention-deficit problems or ADHD, “brain fog”, and cognitive deficits.14,15 Gluten sensitivity is now being found to be involved in the pathological processes of neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, supranuclear palsy, and Huntington’s disease: “In this review, we discuss the molecular mechanisms of the transglutaminases involved in the pathological processes responsible for neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, supranuclear palsy, Huntington’s disease, and other recently identified polyglutamine diseases”16 Gluten Sensitivity and Autoimmune Disease: Type I diabetes “These and recent data show that exposure to dietary gluten in offspring of mothers and fathers with type 1 diabetes very early in life is associated with an increased risk of developing islet cell antibodies. These data also suggest that removal of dietary gluten should be tested as early as possible”17 “The frequency of CD in DM (diabetes mellitus) type 1 was 9.71%” 18 Hashimoto’s Autoimmune Thyroid “Our findings demonstrated an increased prevalence of thyroid disorders with CD.” 19 A study of 100 subjects with autoimmune thyroid disease monitored their response after a gluten-free diet or a gluten-containing diet to evaluate the effect of dietary habits on their thyroid function. “Results: The abnormal thyroid serological markers became undetectable 6 months after beginning a gluten-free diet Conclusion: This study indicates that a gluten-free diet may have profound impacts on patients with autoimmune thyroid disease and gluten withdrawal may single-handedly reverse the abnormality, although it does not cure the condition.” 20 This study confirmed that removing gluten from the diet alone had significant impacts on serum markers of autoimmune thyroid disease. Rheumatoid Arthritis “Increased levels of antigliadin antibodies were found in 37% of all RA patients.”21 These studies support the correlation between gluten sensitivity (and especially celiac disease) and increased risk of various autoimmune diseases. Content provided by Datis Kharrazian, D.C., Autoimmune Regulation of the Nitric Oxide and Glutathione Systems, 11/4/10 In part 4 of this 6-part series , we answer the following questions: What role do chronic bacterial and viral infections play in autoimmunity? What role do environmental toxins play? The role of the glutathione and nitric oxide synthase (NOS) systems and development of autoimmunity. Continue to part 4 of series References: 1. NAT CLIN PRAC GASTRO & HEP SEPT 2005 VOL 2 NO 9 2. NAT CLIN PRAC GASTRO & HEP SEPT 2005 VOL 2 NO 9 3. NAT CLIN PRAC GASTRO & HEP SEPT 2005 VOL 2 NO 9 4. GASTROENTEROLOGY 2005;128:1089\u001a1113 5. DIABETES, VOL. 55, MAY 2006 6. Mechanisms of disease: the role of intestinal barrier function in the pathogenesis of gastrointes-tinal autoimmune diseases. Nat Clin Pract Gastroenterol Hepatol. 2005 Sep;2(9): 416-22 7. Ann N Y Acad Sci. 2009 May;1165:195-205 8. The Journal of Immunology, 2006, 176: 2512\u001a2521. 9. DIABETES, VOL. 55, MAY 2006 10. Gut, 2006; 55:1037-1046 11. Gastroenterology, 2001;120:636-651 12. Associated autoantibodies in celiac disease. Autoimmun Rev. 2007 Sep;6(8):559-65 13. Gluten sensitivity as a neurological illness. J Neurol Neurosurg Psychiatry, 2007:72:560-563 14. Association between migraine and Celiac disease: results from a preliminary case-control and therapeutic study. Am J Gastroenterol. 2003 Mar;98(3)625-9. 15. A preliminary investigation of ADHD symptoms in persons with CD. J Atten Disord. 2006 Nov;10(2):200-4 16. Transglutaminase-catalyzed post translational modifications of proteins in the nervous system and their possible involvement in neurodegenerative diseases. CNS Neurol Disord Drug Targets. 2008 Oct; 7(4):370-5. 17. Elimination of dietary gluten and development of type 1 diabetes in high-risk subjects. Rev Diabet. Stud. 2004 Spring;1(1):39-41 18. The role of Celiac disease and type 1 diabetes coexistence. Is CD responsible for diabetic status? Przegl Lek. 2009:66(4): 170-5 19. Thyroid disorders in Brazilian patients with CD. J Clin Gastroenterol. 2006 Jan;40(1):33-6 20. Thyroid-related autoantibodies and celiac disease: a role for a gluten-free diet? J Clin Gastroenterol. 2002 Sep;35(3):245-8 21. Gliadin immune reactivity in patients with RA. Clin Exp Rheumatol. 1995 Sep-Oct;13(5): 603-7","date_published":"2012-05-25T01:14:19","date_modified":"2020-04-17T16:39:54","authors":[{"name":"Dr. Richard Esquivel","url":"https://sanjosefuncmed.com/about/"}],"tags":["Autoimmune Health"]},{"id":"https://sanjosefuncmed.com/autoimmune-disease-u-s-part-4-6-part-series/","url":"https://sanjosefuncmed.com/autoimmune-disease-u-s-part-4-6-part-series/","title":"Autoimmune Disease in the U.S.- Part 4 in 6-Part Series","summary":"What role do chronic bacterial and viral infections play in autoimmunity? What role do environmental toxins play? The role of the glutathione and nitric oxide","content_text":"What role do chronic bacterial and viral infections play in autoimmunity? What role do environmental toxins play? The role of the glutathione and nitric oxide synthase (NOS) systems and development of autoimmunity. Main points of this issue: Evidence shows that chronic bacterial or viral infections play a role in the development of autoimmune disease Various viruses, such as coxsackie virus, herpes simplex 1 virus, Epstein-Barr virus, and adenoviruses have been associated with the development of autoimmune disease Protozoan infections have been linked to intestinal permeability Exposure to persistent organic pollutants (POPs) has been linked to the development of autoimmune diabetes (type I diabetes) Bisphenol A (BPA) is one of the most well-known and toxic POPs BPA is common in plastic food and bevarage containers BPA acts as a potent estrogen in the body and has been linked to several immune-mediated diseases, cancer and infections Environmental compounds activate the immune system only after glutathione levels are depleted Failure of the glatathione system causes immune activation Immune activation triggers inducible nitric oxide synthase (iNOS) which promotes autoimmunity. The origins of autoimmune disease are multifactorial “The origins of autoimmune disease are multifactorial. Environmental factors and a genetic predisposition result in tissue injury caused by autoreactive T cells or antibodies.”1 We know that there are a number of physiologic dysfunctions and overzealous immune responses that are involved in the development of autoimmune disease. We looked at some of these dysfunctions in the last issue, including intestinal permeability and gluten sensitivity. In this issue, we focus on other mediators and modulating factors involved in the development of autoimmunity, including chronic bacterial, viral or parasitic infection and environmental exposures, such as BPA and other persistent organic pollutants. We will also look at the role glutathione plays in protecting us from autoimmunity, and how the glutathione recycling system and the nitric oxide system are so important in preventing autoimmune disease. It is important to keep in mind that the development of autoimmune disease does not occur overnight. The manifestations of the disease occur much later than the initiating factors that lead to the development of autoimmunity. During this time, patients are often asymptomatic and unaware that they are laying the groundwork for the development of autoimmunity (immune response to self-tissue). “Autoimmune diseases tend to have long, asymptomatic prodromal periods and the initiating events leading to loss of self tolerance occur long before the disease becomes clinically manifest.”2 What are Some of the Mediators/Modulating Factors that Contribute to Autoimmunity? Chronic Infection and Chronic Inflammation There is more and more evidence of the role that chronic bacterial or viral infections play in the development of autoimmune disease. “Emerging evidence has suggested the involvement of environmental factors such as infections and xenobiotics, and some dietary proteins and their antibodies in the pathogenesis of many autoimmune diseases”.3 “The cause may be due to environmental factors such as bacterial or viral infections, or haptenic toxic chemicals binding to human tissue, causing modification of self-antigens and the subsequent production of autoantibodies”.4 Coxsackie Virus and Autoimmune Diabetes (Type 1 Diabetes) “Three way molecular mimicry exists between a peptide of carboxypeptidase H (an enzyme expressed within islet cell granules and an autoantigen), and peptides of coxsackie virus coat protein.” “The major peptide determinant of GAD recognized by patients with diabetes has a significant sequence similarity to a 15 amino acid sequence within a protein of coxsackie B virus. Antibodies to this protein cross react with GAD 65 and vice versa, suggesting that molecular mimicry might be responsible for the disease.”5 Herpes Simplex Virus 1 and Epstein-Barr Virus “Another islet cell antigen, ICA 512 has similarities with peptides in human herpes virus 1 (herpes simplex virus 1) and 4 (Epstein-Barr virus)”.6 Celiac Disease and Adenovirus Antibodies “89% of untreated celiac patients had antibodies to adenovirus 12, and these antibodies were also raised in treated children with celiac disease (31%) compared with controls (0-13%)” “It is possible that infection with adenovirus sensitizes the genetically predisposed host to A-gliadin by molecular mimicry, with resultant gluten sensitive enteropathy, using the hit and run mechanism.”7 Protozoan Infection and Intestinal Permeability Certain protozoan infections, such as giardia and Blastocystis hominis, have been linked with the development of intestinal permeability: “39 patients with protozoan infections were compared to 10 healthy controls. Intestinal permeability was found to be increased in patients with protozoan infections compared with the control patients. Specifically, intestinal permeability was increased in the Giardia and Blastocystis groups, although not in the Entamoeba coli group. The increase in intestinal permeability in patients with Blastocystis hominis suggests that it can be a pathogenic protozoal infection and have systemic consequences.”8 What are Some of the Mediators/ Modulating Factors that Contribute to Autoimmunity? Drugs and Environmental Compounds “Autoimmune reaction or autoimmune disease may be induced by drugs and chemical xenobiotics, which have the potential to form complexes with or otherwise alter self-proteins such that they become immunogenic (targets of immune attack).”9 Persistent Organic Pollutants (POPs) and Autoimmune Disease “Persistent organic pollutants (POPs) include hundreds of different chemical compounds with common properties, such as long-term persistence, widespread diffusion in the environment and bioaccumulation through the food chain.”10 “Exposure to relatively high levels of POPs during pancreatic development in utero or in early infancy may lead to the development of type 1 diabetes among children.”11 Bisphenol A (BPA) and Autoimmune Disease One of the most well-known and toxic of these POPs is bisphenol A (BPA). BPA is commonly used by the food industry in plastic food and bevarage containers and in the lining of canned foods. “The precise mechanism underlying the immunomodulatory effects of Endocrine Disrupting Chemicals (EDCs), especially BPA, has not been clarified, and multiple mechanisms are considered.”12 “Some of these studies were prompted by concern that xenoestrogens may contribute to development of autoimmune disease.”13 “BPA is not only an estrogen mimic but also may exhibit a mechanism of action similar to that of the sex hormone at the receptor. Therefore, considerable attention has focused on this environmental estrogen-like chemical, which may affect reproductive organs.”14 “The ubiquitous estrogenic chemical bisphenol A (BPA) is the base chemical used to make polycarbonate plastic food and beverage containers, the resin lining of cans, and dental sealants; it also is found in &#8216;carbonless’ paper used for receipts as well as a wide range of other common household products.”15 “It appears to be undeniable that at least part of the immune system, especially Th1 responses, may be modulated by either prenatal or postnatal exposure to the environmental estrogen-like chemical, BPA.”16 “The effects of BPA on cells confirm that BPA acts as a potent estrogen via this recently discovered estrogen response pathway.”17 “BPA and estradiol are also equipotent at inhibiting adiponectin release from human adipocytes, further implicating BPA at current human exposure levels in insulin resistance and the metabolic syndrome.”18 “The decrease of T reg cells would predispose to immune dysfunction in aged individuals, explaining their higher risk of immune-mediated diseases, cancer, and infections. Our data also suggest the possibility that BPA might cause these diseases.”19 “Thus, avoiding exposure to or promoting the excretion of BPA and other EDCs would help in preventing diseases and adverse health effects.”20 Environmental Compounds and Glutathione Depletion The other thing we know is that an environmental compound activates the immune system only after glutathione levels are depleted in the body. Glutathione, which is produced by the liver, is considered the body\u001as most important antioxidant. Glutathione is the main antioxidant that protects cellular mitochondria. Glutathione “takes the bullet” from the free radical to protect the mitochondria. If this system fails and you don\u001at have this system to take the bullet, then you get immune activation. “Environmental exposures start depleting glutathione which leads to immune activation which activates iNOS and promotion of autoimmunity. These results suggest that TBT (an environmental pollutant), selectively induces apoptosis and T helper polarity via generation of hydrogen peroxide because of low GSH (glutathione) levels.”21 A healthy glutathione system is a prerequisite in order to prevent autoimmunity. We all have this glutathione system that allows us to not respond to, or end up responding to, an environmental hapten (chemical) exposure. If this system fails, then you get immune activation. Immune activation then triggers inducible nitric oxide synthase (iNOS) which causes tissue destruction and promotes autoimmunity. We will discuss these systems in more depth in the next segment. Content provided by Datis Kharrazian, D.C., Autoimmune Regulation of the Nitric Oxide and Glutathione Systems, 11/4/10 In part 5 of this 6-part series , we answer the following questions: How do we modulate the autoimmune response? What role do the glutathione and nitric oxide synthase (NOS) systems play in preventing and modulating AI disease? What role does vitamin D play? Continue to part 5 of series References: 1. Arch Dis Child 1998;79:448-451 2. Arch Dis Child 1998;79:448-451 3. Expert Opin. Med. Diagn. (2008) 2(6):1-13 4. Expert Opin. Med. Diagn. (2008) 2(6):1-13 5. Arch Dis Child 1998;79:448-451 6. Arch Dis Child 1998;79:448-451 7. Arch Dis Child 1998;79:448-451 8. Acta Trop. 2002 Jan;81(1):1-5 9. Expert Opin. Med. Diagn. (2008) 2(6):1-13 10. J. Epidemiol. Comm Health 2006;60;1006-08 11. J. Epidemiol. Comm Health 2006;60;1006-1008 12. Environ Health Perspect 116:514-519, 2008 13. Journal of Toxicology and Environmental Health, Part B, 11:69-146, 2008 14. Immunology 2004 112 489-495 15. JAMA, Sept 17, 2008. Vol 300, No. 11 1353 16. Immunology 2004 112 489-495 17. JAMA, Sept 17, 2008. Vol 300, No. 11 1353 18. JAMA, Sept 17, 2008. Vol 300, No. 11 1353 19. Environ Health Perspect 116:514-519, 2008 20. Environ Health Perspect 116:514-519, 2008 21. Critical role of hydrogen peroxide in the differential susceptibility of TH1 and TH2 cells to tributyltin-induced apoptosis. Biochem Pharmacol. 2008 Jan 15;75(2):552-61. Epub 2007 Sept 18","date_published":"2012-05-25T01:24:16","date_modified":"2020-04-17T16:39:54","authors":[{"name":"Dr. Richard Esquivel","url":"https://sanjosefuncmed.com/about/"}],"tags":["Autoimmune Health"]},{"id":"https://sanjosefuncmed.com/autoimmune-disease-u-s-part-5-6-part-series/","url":"https://sanjosefuncmed.com/autoimmune-disease-u-s-part-5-6-part-series/","title":"Autoimmune Disease in the U.S.- Part 5 in 6-Part Series","summary":"How do we modulate the autoimmune response? What role do the glutathione and nitric oxide synthase (NOS) systems play in preventing and modulating AI disease?","content_text":"How do we modulate the autoimmune response? What role do the glutathione and nitric oxide synthase (NOS) systems play in preventing and modulating AI disease? What role does vitamin D play? Main points of this issue: Glutathione is the body’s most important anti-oxidant Glutathione plays a significant role in preventing and modulating autoimmune disease The lower the glutathione status, the more tissue destruction occurs in autoimmunity When the glutathione recycling system fails, there is increased flare ups of autoimmune disease Nitric oxide is important in autoimmune modulation There are different isomers (forms) of nitric oxide Some of these isomers are protective of tissue and some are destructive The modulation of these isomers determines how much tissue damage takes place and the recovery of the tissue Upregulation of iNOS (inducible nitric oxide synthase)increases intestinal permeability Vitamin D is an important modulator of autoimmunity and intestinal permeability Vitamin D regulates immune function and acts on the immune system in many ways to suppress systemic inflammation The Role of Glutathione in Autoimmune Modulation As we discussed in the previous issue, a healthy glutathione system is a prerequisite in order to prevent autoimmunity. Glutathione, which is produced by the liver, is considered the body’s most important antioxidant and is the main antioxidant for protecting the cellular mitochondria. Glutathione is the antioxidant that “takes the bullet” from the free radical. If this system fails and you don’t have this system to take the bullet, then you get immune activation. Immune activation then triggers inducible nitric oxide synthase (iNOS) which causes tissue destruction and promotes autoimmunity. Evidence supports the body’s available glutathione stores play a significant role in modulating autoimmune disease: “A significant correlation between plasma glutathione and SLE severity exists that may aid evaluation of the disease severity and usefulness of the management of SLE.”1 Here’s what this study found: The lower the glutathione status, the greater destruction of tissue they had. The ones that had highest amount of glutathione activity had the least amount of tissue destruction. Glutathione helps recover tissue and helps support regulatory T cells. This system is absolutely critical for overall modulation of autoimmunity. When this glutathione recycling system fails, we lose the ability to enhance regulatory T-cells which modulate the attacks and flare-ups in these systems. We can’t regenerate the intestinal lining properly leading to increased intestinal permeability and increased autoimmunity. The Role of Nitric Oxide in Autoimmune Modulation The other system that is important in autoimmune modulation is the nitric oxide system. Nitric oxide is an important messenger molecule involved in many physiological and pathological processes. It plays both destructive and protective roles in autoimmunity, depending on which isomer is expressed. It can be a compound that helps with tissue recovery or a compound that causes tissue inflammation. There are different isomers of nitric oxide that have different effects on the body. Nitric Oxide Synthase Isomers nNOS \u001a-Optimizes neuronal synapses -Protects the neurons eNOS \u001a -Helps tissue recover and regenerate \u001a -Enhances blood flow \u001a -Dissolves endothelium plaques \u001a -Dilates blood vessels iNOS \u001a -Promotes tissue destruction \u001a -Promotes inflammation \u001a -Promotes AI attack In AI disease, there is destruction of tissue due to: \u001a Increased iNOS (increased tissue destruction) \u001a Decreased eNOS (cold hands, feet, decreased blood flow) \u001a Decreased nNOS (decreased brain function) How these isomers are manipulated or modulated will determine how much destruction of tissue or ability to recover from autoimmune flare-ups a person has. “Based on these data, it appears that the isoforms of NOS contribute to pathophysiology, and that induced NOS and NO may function, in part, in a protective pathway.”2 “Collectively, these data implicate discrete roles for the NOS isoforms in the emergence of local tissue pathology and underscore the need to define the specific pathways that are being targeted.”3 Upregulation of iNOS increases intestinal permeability The literature indicates that increased amounts of the iNOS isomer causes increased intestinal permeability: “iNOS up-regulation and oxidation/nitration of intestinal cytoskeletal proteins, promotes intestinal leakiness. We hypothesized that iNOS inhibitors will inhibit the liver and intestinal barrier cascade.”4 “We conclude that NO plays a critical immunoregulatory role and NO modulation may prevent the onset of autoimmune reactions.”5 “Together, these data indicate that antioxidant modulation of nitric oxide might be a feasible therapeutic tool to interfere with development of autoimmune diabetes.”6 “Interleukin-17 is a proinflammatory cytokine involved in autoimmune disorders. The proinflammatory action of IL-17 depends considerably on its ability to trigger the expression of inducible nitric oxide (iNOS). We propose IL-17 and NO modulation could be relevant forms of therapy for autoimmune disorders.”7 Vitamin D as a Modulator of Autoimmunity and Intestinal Permeability Vitamin D is also a very important regulator of immune function. Deficiency of vitamin D has been associated with development of intestinal permeability and autoimmune disease. “Vitamin D deficiency may compromise the mucosal barrier, leading to increased susceptibility to mucosal damage and increased risk of IBD (inflammatory bowel disease)”8 “There is growing appreciation of the importance of the pleiotropic hormone vitamin D in the development of tolerance, immune system defenses, and epithelial barrier integrity.”9 “These observations suggest that vitamin D plays a critical role in mucosal barrier homeostasis by preserving the integrity of junction complexes and the healing capacity of the colonic epithelium.”10 There is also growing evidence that vitamin D regulates immune function and acts on the immune system in many ways to suppress systemic inflammation: “The common denominator that rises from these studies is that vitamin D affects the immune system at many levels and by a number of mechanisms. It takes part in the genetic regulation of cytokine production, VDR expression and affects important biological processes by which these cells interact. On the whole, vitamin D confers an immunosuppressive effect.”11 Content provided by Datis Kharrazian, D.C., Autoimmune Regulation of the Nitric Oxide and Glutathione Systems, 11/4/10 In part 6 of this 6-part series , we answer the following questions: What is the Functional Medicine approach to the treatment of AI disease? Why do we support the glutathione and nitric oxide synthase (NOS) systems? Why do we address intestinal permeability and the GI tract? The role of vitamin D. Continue to part 6 of series References: 1. Correlation of lipid peroxidation and glutathione levels with severity of systemic lupus erythmatosus: a pilot study from single center. J Pharm Pharm Sci. 2008;11(3):30-4 2. Nitric oxide in experimental joint inflammation. Benefit or detriment? Cells Tissues Organs. 2003;174(1-2):26-33 3. Nitric oxide in experimental joint inflammation. Benefit or detriment? Cells Tissues Organs. 2003;174(1-2):26-33 4. Nitric oxide-mediated intestinal injury is required for alcohol-induced gut leakiness and liver damage. Alcohol Clin Exp Res. 2009 Jul;33(7):1220-30. Epub 2009 Apr 9 5. Immunoregulatory role of nitric oxide in Kilham rat virus-induced autoimmune diabetes in DR-BB rats. J Immunol. 2004 Jul 15;173(2):1327-35 6. Immunosuppressive and anti-inflammatory action of antioxidants in rat autoimmune diabetes. J Autoimmun. 2004 Jun;22(4):267-76 7. Inducible nitric oxide synthase activation by interleukin-17. Cytokine Growth Factor Rev. 2004 Feb;15(1):21-32 8. Am J Physiol Gastrointest Liver Physiol. 2008 Jan;294(1):G208-16 9. Potential mechanisms for the hypothesized link between sunshine, vitamin D, and food allergy in children. J Allergy Clin Immunol. 2010 Aug;126 (2):217-22 10. Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal barrier. Am J Physiol Gastrointest Liver Physiol. 2008 Jan; 294(1):G208-16 11. The Journal of Immunology, 2005, 175: 4119\u001a4126.","date_published":"2012-05-25T01:31:02","date_modified":"2020-04-17T16:39:54","authors":[{"name":"Dr. Richard Esquivel","url":"https://sanjosefuncmed.com/about/"}],"tags":["Autoimmune Health"]},{"id":"https://sanjosefuncmed.com/autoimmune-disease-u-s-part-6-6-part-series/","url":"https://sanjosefuncmed.com/autoimmune-disease-u-s-part-6-6-part-series/","title":"Autoimmune Disease in the U.S.- Part 6 in 6-Part Series","summary":"What is the Functional Medicine approach to the treatment of AI disease? The importance of supporting the glutathione and nitric oxide systems. The importance","content_text":"What is the Functional Medicine approach to the treatment of AI disease? The importance of supporting the glutathione and nitric oxide systems. The importance of addressing intestinal permeability and the GI tract. The role of vitamin D. Main points of this issue: The primary medications being used by conventional medicine to treat autoimmune disease are immune-suppressing medications Functional medicine treatment of AI disease focuses on modulating the autoimmunity, dampening immune response, decreasing tissue destruction and enhancing patient’s ability to recover There are two systems that regulate all of these aspects of the immune response: the Glutathione Recycling and Nitric Oxide Systems Glutathione is one of the most critical immune-modulating substances that we know of Glutathione prevents leaky gut There are several natural compounds that ave been shown to support the glutathione recycling system Nitic oxide plays both destructive and protective roles in autoimmunity, depending on which isomer is expressed How these isomers are manipulated or modulated will determine how much destruction of tissue or ability to recover from autoimmune flare-ups a person has Vitamin D and EPA-DHA help decrease inflammation and minimize tissue destruction Zince carnosine and turmeric help repair the intestinal lining and decrease gastrointestinal inflammatory responses How is AI disease treated? Let’s first look at how autoimmune disease is treated by conventional medicine. We will then look at the goals of treatment in functional medicine and the systems that are targeted in the modulation of the autoimmune response. Conventional medicine: steroids and other immune-suppressing medications The primary medications still being used by conventional medicine to treat autoimmune disease are immune-suppressing medications, such as prednisone and immune-suppressing medications. However, there are many known side-effects of these medications. Some of the side effects of steroids include: immune suppression, bone loss, neurodegenerative impacts on the brain, insulin-related issues, epithelial thinning, and catabolic states so they cannot recover from flare-ups. “Drugs developed by the pharmaceutical industry have thus far been associated with toxicity and side effects, which is why natural substances are of increasing interest”1 “Current Western therapies for inflammatory diseases are suboptimal; increasingly, patients are turning to complementary and alternative medicine for symptom relief and improved quality of life”2 “There is emerging evidence that many of these therapies have the ability to modulate the immune system and disrupt the proinflammatory cascade through a variety of mechanisms, including antioxidant effects, alterations in cell signaling (in particular the nuclear factor (NF)-B pathway), cytokines, proinflammatory mediators, and disruption of bacterial flora”3 “Finding therapeutic agents which can modulate the inflammatory reaction is the highest priority in medical research today”4 The Functional Medicine Approach to Treatment of AI Disease: Modulate the autoimmunity Dampen immune response Decrease tissue destruction Enhance patient\u001as ability to recover To be successful at managing AI disease, you need to address the following: Enhance integrity of mucosal membrane Balance TH1 and TH2 systems Enhance the TH3 regulatory system Decrease the TH-17 response The Role of Glutathione and Nitric Oxide Systems in Autoimmunity There are two systems that regulate all of these aspects of the immune response: Glutathione recycling system Nitric oxide isomer system The Role of Glutathione in Autoimmune Modulation A study published in 2008 showed a significant correlation between the amount of available glutathione in the blood and the severity of the disease of SLE (systemic lupus erythematosus): “A significant correlation between plasma glutathione and SLE severity exists that may aid evaluation of the disease severity and usefulness of the management of SLE”5 Here’s what they found: The lower the glutathione status, the greater destruction of tissue they had. The ones that had the highest amount of glutathione activity had the least amount of tissue destruction. Glutathione helps recover tissue, helps support regulatory T cells, and helps stop hapten-induced immune responses. This system is absolutely critical for overall modulation of autoimmunity. “These data indicate that glutathione peroxidase dependent control of intracellular reactive oxygen species accumulation is important not only for regulatiojn of Th-cell proliferation, but also for modulation of differentiation into TH1, TH2 and TH17 cells.”6 Glutathione is one of the most critical immune-modulating substances that we know of “Accumulation of evidence suggests that intracellular GSH (glutathione) levels in antigen-presenting cells such as macrophages, influence the TH1/TH2 cytokine response pattern. The observations reported herein show that pro-GSH molecules represent new therapeutic agents to support immune modulation.”7 In other words, one of the ways we can modulate these TH1/TH2 shifts is through the glutathione system. Glutathione prevents leaky gut When a person loses their glutathione recycling system, they also cannot prevent intestinal lining inflammation which then leads to leaky gut. The glutathione recycling system is one of the main systems that prevents leaky gut onset. “Glutathione is suggested to play an important role in gut barrier function and prevention of intestinal inflammation”8 This whole glutathione system does several things: It prevents environmental compounds from triggering autoimmunity When it is depleted, it causes TH1/TH2 flare-ups When this glutathione recycling system fails: We lose the ability to enhance regulatory T-cells which modulate the attacks and flare-ups in these systems We cannot regenerate the intestinal lining properly Clinical Strategies to Support Glutathione Recycling If you look at the literature, there are several compounds that help raise intracellular glutathione, activate the glutathione peroxidase and reductase enzymes, and make this process work more efficiently: Cordyceps: within minutes has been found to raise glutathione levels and has a powerful effect on the enzymes that increase glutathione (used in Chinese medicine for thousands of years) Centella asiatica Silybum marianum N-acetyl-cysteine Alpha lipoic acid L-glutamine Selenium Strategy for Glutathione Recycling Modulates TH-1 and TH-2 polarization which dampens AI tissue destruction Activates TH-3 regulatory T-cells which dampens AI tissue destruction Dampens TH-17 activity which dampens AI tissue destruction Enhances tissue and intestinal regeneration which enhances AI tissue destruction recovery Protects cell mitochondria which enhances AI tissue destruction recovery Prevents activation of iNOS which dampens AI tissue destruction The Role of Nitric Oxide in Autoimmune Modulation The other system that is important in autoimmune modulation is the nitric oxide system. Nitric oxide (NO) can be a compound that helps with tissue recovery or a compound that causes tissue inflammation. NO is an important messenger molecule involved in many physiological and pathological processes. It plays both destructive and protective roles in autoimmunity, depending on which isomer is expressed. Nitric Oxide Synthase Isomers nNOS eNOS iNOS In AI disease, there is destruction of tissue due to: Increased iNOS (increased tissue destruction) Decreased eNOS (cold hands, feet, decreased blood flow Decreased nNOS (decreased brain function) How these isomers are manipulated or modulated will determine how much destruction of tissue or ability to recover from autoimmune flare-ups a person has. “Based on these data, it appears that the isoforms of NOS contribute to pathophysiology, and that induced NOS and NO may function, in part, in a protective pathway.”9 “Collectively, these data implicate discrete roles for the NOS isoforms in the emergence of local tissue pathology and underscore the need to define the specific pathways that are being targeted.”10 “We conclude that NO (nitric oxide) plays a critical immunoregulatory role and NO modulation may prevent the onset of autoimmune reactions”11 “We propose IL-17 and NO modulation could be relevant forms of therapy for autoimmune disorders”12 Compounds Shown in Literature to Modulate Nitric Oxide Isomers: Adenosine Huperzine A Vinpocetine L-alpha-glycerylphosphosphorylcholine Alpha-ketogluteric acid Xanthinol niacinate L-acetylcarnitine Vitamin D “Vitamin D down-regulates nuclear factor-kB (NF-kB) activity, increases IL-10 production and decreases IL-6, IL-12, IFN-c, and TNF-a production, leading to a cytokine profile which favors less inflammation”13 “VDR plays a critical role in mucosal barrier homeostasis by preserving the integrity of junction complexes and the healing capacity of the colonic epithelium”14 EPA-DHA Essential Fatty Acids (Fish Oils) “EPA appears to exert much of its anti-inflammatory benefit by suppressing NF-kappaB activation via activation of PPAR-alpha and thus reducing elaboration of proinflammatory mediators”15 “When endoscopic endpoints were used to evaluate the role of fish oil in the treatment of ulcerative colitis, 3 of 3 studies showed statistically significant improvement in the study group that received fish oil supplementation”16 Other compounds that help regenerate and repair intestinal lining (and decrease risk of AI flare-ups and onset): Zinc Carnosine “Regarding intestinal permeability, Zinc Carnosine caused an approximate threefold increase in gut integrity and repair”17 Turmeric “Curcumin, a component of turmeric, has been shown to be non-toxic, to have antioxidant activity, and to inhibit such mediators of inflammation as NFB, cyclooxygenase-2 (COX-2), lipooxygenase (LOX), and inducible nitric oxide synthase (iNOS)”18 “In a larger, randomized, double-blind, multicenter trial involving patients with quiescent ulcerative colitis, administration of 1 g of curcumin twice daily resulted in both clinical improvement and a statistically significant decrease in the rate of relapse”19 “In various chronic illnesses in which inflammation is known to play a major role, curcumin has been shown to exhibit therapeutic potential. These diseases include Alzheimer’s disease (AD), Parkinson’s disease, multiple sclerosis, epilepsy, cerebral injury, CVDs, cancer, allergy, asthma, bronchitis, colitis, rheumatoid arthritis, renal ischemia, psoriasis, diabetes, obesity, depression, fatigue, and AIDS”20 Content provided by Datis Kharrazian, D.C., Autoimmune Regulation of the Nitric Oxide and Glutathione Systems, 11/4/10 References: 1. J OF PAR AND ENT NUTRITION Vol. 30,no.1, 2006,45-51 2. Nutrition in Clinical Practice 23:49\u001a62, Feb 2008 3. Nutrition in Clinical Practice 23:49\u001a62, Feb 2008 4. J OF PAR AND ENT NUTRITION Vol. 30, no.1, 2006,45-51 5. Correlation of lipid peroxidation and glutathione levels with severity of systemic lupus erythmatosus: a pilot study from single center. J Pharm Pharm Sci. 2008;11(3):30-4 6. Glutathione peroxidase 1 deficiency attenuates allergen-induced airway inflammation by suppressing TH2 and TH17 cell development. Antioxid Redox Signal. 2010 Jun 6. 7. Antiviral and immunomodulatory properties of new pro-glutathione (GSH) molecules. Curr Med Chem. 2006:13(15): 1749-55 8. Intestinal barrier function in response to abundant or depleted mucosal glutathione in Salmonella-infected rats. BMC Physiol. 2009 Apr 17:9:6 9. Nitric oxide in experimental joint inflammation. Benefit or detriment? Cells Tissues Organs. 2003;174(1-2):26-33 10. Nitric oxide in experimental joint inflammation. Benefit or detriment? Cells Tissues Organs. 2003;174(1-2):26-33 11. Immunoregulatory role of nitric oxide in Kilham rat virus-induced autoimmune diabetes in DR-BB rats. J Immunol. 2004 Jul 15;173(2):1327-35 12. Inducible nitric oxide synthase activation by interleukin-17. Cytokine Growth Factor Rev. 2004 Feb;15(1):21-32 13. Kidney International, Vol. 68 (2005), pp. 1973\u001a1981 14. Am J Physiol Gastrointest Liver Physiol. 2008 Jan;294(1):G208-16 15. Nutritional Perspectives, Vol. 28, no. 1, 1-16 16. Nutr. in Clinical Practice 23:49\u001a62, Feb 2008 17. Gut.2007 Feb ;56(2):168-75 18. J OF PAR AND ENT NUT Vol. 30,no.1, 2006,45-51 19. Nutrition in Clinical Practice 23:49\u001a62, Feb 2008 20. Int J Biochem Cell Biol. 2009 Jan;41(1):40-59","date_published":"2012-05-25T01:42:36","date_modified":"2020-04-17T16:39:54","authors":[{"name":"Dr. Richard Esquivel","url":"https://sanjosefuncmed.com/about/"}],"tags":["Autoimmune Health"]},{"id":"https://sanjosefuncmed.com/autoimmune-summit-highlights-2/","url":"https://sanjosefuncmed.com/autoimmune-summit-highlights-2/","title":"Autoimmune Summit Highlights","summary":"Wow! I hope all of you got a chance to listen to some of the speakers from this online event which took place Nov. 10-18. Dr. Amy Myers did an excellent job i","content_text":"Experts Convene in Autoimmune Summit Wow! I hope all of you got a chance to listen to some of the speakers from this online event which took place Nov. 10-18. Dr. Amy Myers did an excellent job in gathering some of the leading experts, including researchers and clinicians from the fields of immunology, neurology, gastroenterology, and pioneers in the field of functional medicine for this free educational event. Topics ranged from likely causes for this epidemic of autoimmune disease we are now seeing to genetics and environmental triggers of autoimmunity as well as diagnostic testing methods and management of these conditions through dietary and nutrient intervention. For those of you that did not have a chance to hear all of these speakers, I have good news: you can still hear any of these talks that you missed! San Jose Functional Medicine has purchased the entire set of presentations and offering direct access of all these talks to our patients, just like we did for the Gluten Summit! Just let us know by email that you are interested in hearing these talks and enter “Autoimmune Summit” in the subject of the email! We will send you a link that you can use to access the entire set of talks so you don’t miss a thing! You can also purchase the entire set of talks directly from the Autoimmune Summit website . Here are some excerpts from the talks of my personal Fab Five speakers from this amazing summit: 1. Mark Hyman, MD: A Functional Medicine Approach to Autoimmunity Dr. Amy Myers: I am thrilled with today’s speaker: we have Dr. Mark Hyman, who is effectively one of my most favorite people on the planet…and really probably does not need an introduction for the listeners out there, but I will give him one as it is. He has eight New York Times bestsellers, his most recent one, The 10-Day Detox Diet. He’s the chairman of the Institute of Functional Medicine. He has a clinic, The Ultra Wellness Center in Lenox, Massachusetts. He’s been on The Katie Couric Show and now I think is going to be part of The Dr. Oz Show, unless that’s a big secret I hope to not be spoiling…Editor of the Huffington Post, and the list goes on and on… Linus Pauling award winner, really the person who I believe has helped bring functional medicine to the mainstream and really is the pioneer leader of getting the message out. So we appreciate you. You have helped me personally and professionally, so absolutely one of my most favorite people. So I know that you have a personal story, and most of us do in functional medicine of how we got here. So I would love it if you could just share that quickly before we dive into autoimmunity. Dr. Mark Hyman: Well actually, in fact, I had a version of an autoimmune disease, an inflammatory condition where I had autoimmune antibodies and my body had broken down. And I had gone from being super healthy—I was a yoga teacher, I was a trainer for 10 years, I ran five miles a day, I’d ride my bike 100 miles a day. And literally, from one day to the next, my body just fell apart, and I developed severe fatigue, cognitive dysfunction, muscle pain—my muscle enzymes went up, my autoimmune antibodies went up, my ANA went up. Liver function tests went up, white count went down, and my digestion went completely upside down. I couldn’t digest food; I had bloating, diarrhea, and gas for years. My whole system just collapsed. Rashes, sores on my tongue, I mean nothing like ever before. I was super healthy. And I was going to have to go on disability, and I could just barely function. And it was through that disease that I discovered functional medicine. And the disease—whatever we call it, it sort of doesn’t matter—but maybe people would say it was chronic fatigue syndrome, it was whatever. What happened was that I got a huge load of mercury when I was in China which triggered an immune inflammatory process, destroyed my gut, and led to severe symptoms and muscle damage and mitochondrial injury. And so I had to literally figure out how to fix myself from the ground up, and no one had really mapped this out very well. And I sort of discovered a couple of pioneers in functional medicine: Sidney Baker, Leo Galland, Jeff Bland. I began to learn from them and sit at their feet, go to their clinic, and try and ask for their help, and I slowly started to put myself back together like Humpty Dumpty. And I didn’t really have a good map, and then through the process, I realized functional medicine was evolving, and I became the chairman of the Institute, and we really developed a whole institute of training, certification, and text books. We’re now partnering with the Cleveland Clinic, and we’re doing research in autoimmune disease, so we’re really taking this forward. Through my own journey I figured out how the body works, how it breaks down, what the causes of disease are—not just from a theoretical perspective, but from a cellular perspective. My own body was the living experiment that I used to actually try all this stuff out, and see it work! So many people suffer needlessly, and that’s what drives me. I see people not getting answers to problems that they have. Often autoimmunity is one of the biggest issues people suffer from. It has the worst treatments, and we have the best outcomes, and it just drives me crazy that people don’t know about this. Dr. Amy Myers: So, in your 15 plus years practicing functional medicine now…have you seen a rise in autoimmunity in your clinic? Dr. Mark Hyman: Oh yeah. At least, we treat a lot of it. And I think there’s a whole continuum. We often think, you know—and this is kind of weird in medicine, you have this sort of on-and-off diagnosis. You fit these criteria, and you have lupus. You fit these criteria, and you have rheumatoid arthritis. You fit these criteria, you have MS, or whatever, or inflammatory bowel. But we realize now there’s a continuum, and there’s even something called pre-autoimmune disease, which I think is a stupid name, beca use there’s no “pre” anything. It’s all a continuum of imbalances that go from mild, to moderate, to severe, to deadly. So I think that my role is to really look at that whole spectrum. You’re looking at the whole spectrum and it’s dramatically on the rise, in fact. There are about 9 million people with cancer, 22 million people with heart disease. There are 24 million people with autoimmune disease, and it’s on the rise. So when you take it as a collective problem and you look at them together, there are 80 autoimmune diseases. It’s a huge issue. Whether it’s arthritis, lupus, inflammatory bowel, MS, Sjögren’s, or vitiligo, or all sorts of autoimmune things… psoriasis…it’s such a huge problem that people haven’t seen it as one problem. And there’s no sort of autoimmune society, there’s no autoimmune institute. There’s like all these different pieces that are treated and looked at by different people, and nobody’s looking at the problem as one whole continuing issue. Dr. Amy Myers: So, based on the statistics you were just giving—and I’ve heard it’s the third leading chronic disease—but based on the statistics you just gave, it sounds like it’s actually the leading chronic disease. Dr. Mark Hyman: Well, yeah. It really is. I think when we look at the number of people affected by it, yes. I mean, it’s huge. I mean, diabetes is up there, it’s like 27 million. But it’s in there. It’s in the range. It’s such a heterogeneous group of diseases, right? It affects 8% of our population—the problem is that less than a third are diagnosed. So we’ve got 17 million people maybe who actually have it. And it affects hundreds of millions worldwide, rates are increasing dramatically. There’s a latent period of 7-14 years where it’s not even diagnosed and it’s sort of “pre-autoimmunity.” And often it’s only diagnosed after there’s tissue destruction instead of when there are imbalances that can be picked up early. So I really think it’s important to identify the trends in people’s bodies and see… I screen for that routinely. It’s really the third leading cause of morbidity and mortality after heart disease and cancer. Heart disease and cancer kill people and make people really sick, but autoimmune disease is right up there. And the healthcare costs are twice that of cancer. Dr. Amy Myers: Yeah. And so why is that? Why is it not getting diagnosed? Why is it so fractured? Why are the healthcare costs so expensive? Dr. Mark Hyman: Well it’s not getting diagnosed because most doctors are not aggressively looking for it, and they often wait until the symptoms are dramatic or extreme. So we don’t diagnose it, and I think that’s a problem. We have to get smarter about diagnosing it and seeing how to identify the root causes. Dr. Amy Myers: Do you think part of that is also because they don’t really have effective treatments? I mean, a lot of people say with underactive thyroid that the doctor doesn’t really care if it’s Hashimoto’s or not, because they’re not going to treat it differently. Whereas you and I…that puts someone in a completely different category for us. Dr. Mark Hyman: Right. I mean, here’s the thing. What is autoimmune disease? It’s an inflammatory disease. And the question then becomes not “How do I shut off inflammation?” but “How do I find the root cause of inflammation? Why is the immune system so pissed off?” That’s a question that most doctors don’t ask, so what we do in conventional care is we block, antagonize, suppress, and inhibit the immune system. We use anti-inflammatory drugs like nonsteroidals, whether it’s Aleve or Advil. We use steroids, we use drugs called TNF-alpha blockers which are called “disease modifying drugs” that suppress immunity and cause cancer, or an overwhelming infection. We’ll use chemo drugs—methotrexate, Imuran, cyclosporine—we’ve been using bone marrow transplants for some people. These are extremely aggressive, extremely intense drugs with tons of side effects. I mean, listen, if you could take a pill like a vitamin or like a mild drug that didn’t really have all these side effects and it cured autoimmune disease, great! But we don’t have that. So the problem is that there are a lot of approaches that are being missed, and doctors don’t really think there is a cure. In fact, I just saw a patient yesterday who I’ve been seeing for almost a decade. And when she came to see me, she had severe rheumatoid arthritis, her auto-antibodies were like—her ANA was 1 to 1280, which is a very high number&#8211; she had severe joint pains and rheumatoid arthritis, she had migraines, she had irritable bowel syndrome, she had terrible fatigue, and she was really quite sick. She had sinus issues and all sorts of issues, right? And this is common for these people, but they just treat everything separately, so they see a neurologist for the migraine, a G.I. guy for the irritable bowel, the rheumatologist for the autoimmune disease, and they’re really all connected. So we found out she in fact had very high anti-gliadin antibodies in her blood, which is a sign of gluten sensitivity. She didn’t have true celiac, but close. And she had super high levels of mercury like 120, and she also had immune response to mercury. So we looked at the causes, and we said, “Gee, it’s mercury and gluten, leaky gut…” she had tremendous overgrowth of yeast in her gut, so we had to kind of fix her gut. We had to get rid of the gluten, we had to get rid of the mercury, and over time, she has completely normalized. She’s 65 now, and she’s as healthy as she’s ever been. She has no auto-antibodies—she went from 1,280 to 0. Her gluten antibodies went down completely to normal. Her mercury went from 120 to 5, and her symptoms are completely better. She’s had no migraines in years and years and no irritable bowel. She’s full of energy and has no autoimmunity at all! So most doctors don’t even think that that’s possible, and they don’t even bother checking the autoantibodies if they’ve been diagnosed initially, because they figure they’re just never going to go down. But they do go away if you do the right thing, if you get to the cause. Dr. Amy Myers: So what are you seeing in your clinic as the top causes for autoimmunity? Dr. Mark Hyman: I think, Amy, it’s really important to think about the framework of functional medicine. So that’s a method we have for figuring out what the causes are. And it’s really a simple process. We say, “What is it that could be bugging you that’s triggering inflammation?” And we need to get rid of that. “What is it that you need for your immune system to work properly, for your body to work properly?” And we try to give you those things. So we get rid of the bad stuff, and we put in the good stuff. The bad stuff is a short list, and I think it’s really important to understand what those causes are, and they’re different for different people, so you can have 10 people with exactly the same autoimmune disease, and each one of those 10 people might have a different set of causes. So you can’t treat them all the same, right? And that’s really important. One person might have an autoimmune disease from eating gluten, and another person might be from mercury, and another person might be from a parasite in their gut, and the list goes on and on. Other people with strongyloides, which is a weird worm that people get, causes autoimmunity. But like, who knew that? You have to treat that person with a worm pill, another person you have to do chelation, and for another person you have to change their diet. Very different treatments for the exact same disease. And that’s the beauty of functional medicine—it allows you to figure that out. And I think the things we really think about are, “What are the toxins?” Like this woman I mentioned, she had high levels of mercury, there was this immunotoxin that caused inflammation. We measured how her cells—her lymphocytes—were responding to mercury, and we saw that they were really upset that the mercury was around. They were creating a trigger. But there are also other toxins, all the chemicals and pesticides, the plastics we’re exposed to—they’re what we call autogens. There are triggers that are chemicals that cause an autoimmune response. They’re called autogens . They’re also called obesogens because they cause obesity, too. They do everything. And then there are allergens we’re exposed to. They can be things we’re eating, and that’s the biggest source. Gluten, dairy, grains, are often a big trigger. Mold, environmental allergens, even chemical allergens can trigger a problem. Microbes, bugs—not just bugs in your gut, abnormal gut flora, which we have like parasites, yeast, bad bugs—but also things like tick-borne diseases and other weird viruses and chronic viral infections. These are things that your immune system starts reacting to. So there’s a process called molecular mimicry where our bodies start to react to these various triggers that are infectious. And then of course there’s stress. Both physical and psychological stress will trigger inflammation and autoimmunity. And poor diet. When you eat a bad diet, you’re actually affecting your gut flora. You’re creating inflammation just from the sugar. So there are a lot of things in your diet that can actually change the equation and push you toward autoimmunity. 2. David Perlmutter, MD: The Brain, Gut, and Autoimmunity Dr. Amy Myers: Today, we have Dr. David Perlmutter with us. I’m sure many of you know who he is. He’s the author of “Grain Brain,” which I know has really kind of catapulted him into mainstream, which is awesome, and also the author of “The Grain Brain Cook­book” that I think will be out in two weeks? And Grain Brain is now on its 17th publishing and is in 28 countries, and has been on the New York best seller list for 44 weeks. Besides all that, he also actually has a very active practice in Florida. And you’re on the faculty of Institute of Functional Medicine and you are a board-certified neurologist. I think I heard you in another interview and somebody said, “We all know we refer to the gut as the second brain,” and you said that it actually may be the first brain. Dr. David Perlmutter: Might well be. If you think of what’s going on in the gut in terms of its genetic potential, in terms of what the gut bacteria can do in terms of human metabolism, obesity, inflammation, autoimmunity, that’s where it starts. Those are the key players in brain d egenerative conditions like Parkinson’s and multiple sclerosis, Alzheimer’s, and even things like autism, and to some degree, even ADHD so prevalent in Western cultures , and we’re now really getting a handle on the notion that the gut has a huge influence on what goes on in the brain. And I’m sure that you and I will talk about that. Dr. Amy Myers: Absolutely. Well, let’s first get into kind of what is brain inflammation? Dr. David Perlmutter: Well, it’s nothing different than anyone else is familiar with. It’s the same process of creating life-sustaining inflammatory chemicals—there’s a good side to inflammation. It helps us deal with infection, it helps us immobilize a damaged part, but the downside is when it’s chronic, it increases free radicals, it damages our DNA, our fat, our protein, and leads to tissue destruction. It’s why the arthritic joint becomes destroyed; it’s why the inflamed coronary arteries become narrow; and it’s the same causes that underlies why a person’s brain will shrink when he or she is becoming demented. So, in the brain, we don’t re ally appreciate inflammation as readily because when your brain is inflamed, it doesn’t hurt, it doesn’t become red, it doesn’t get swollen. We don’t really get the opportunity to appreciate the simple fact that inflammation underlies things like Alzheimer’s now affecting 5.4 million Americans and inflammatory disorders really for the most part, not a genetic disorder, not a genetic inheritance issue, but perhaps some genetic predisposition, but more importantly, absolutely, fundamentally related to our lifestyle choices that increase inflammation, and these are centered upon, for example, the very foods that we eat, leading to inflammation throughout the body, and clearly, being related to developing an incurable disease, at least, as you and I have this conversation, called “Alzheimer’s,” related to the foods that we eat. That’s an important conversation to have. Dr. Amy Myers: And what really is that role? So, inflammation is, you’re saying, is leading to these diseases. How is it really doing that? Dr. David Perlmutter: Well, I guess what you’re asking is the mechanism. Until recently, I think a lot of interest has been focused on what is called “glycation of proteins,” meaning that the higher your blood sugar is, the more your blood sugar will bind to proteins in a process called glycation. We measure that, for example, with the playing old-fashioned HbA1c test –the diabetics use to measure their average blood sugar. Well, it turns out that as a metric, HbA1c—a measurement of your average blood sugar (let’s just say “glycated protein”)—powerfully relates to the rate at which your brain shrinks. Higher A1c, even well below the levels that are qualified for diagnosing diabetes, directly correlate with the rate at which your brain shrinks, so that’s something you don’t want to have. That said, the mechanism is that when proteins become glycated, it turns on genetic pathways that amp up the production of these inflammatory chemicals called “cytokines.” Now, beyond that, a newer mechanism that is becoming really quite exciting for those of us who are looking beyond the brain, has to do with the role of these glycated proteins—again, brought on by having high blood sugar—in terms of their increased permeability events in terms of the gut. In other words, glycated proteins, these things called “AGEs (advanced glycosylated end-products)” or AGEs, protein bound to sugar, increases the leakiness of the gut. When the gut is leaky, that is just like turning on gasoline to the flames of inflammation. When the gut be­comes leaky—to be technical about it—what happens is there is a coating over what are called “gram-negative bacteria,” which are hugely represented in the gut. When that coating, that goes by the initials “LPS” makes its way to the systemic circulation, it just causes inflammation to go haywire. Elevated levels of this LPS, which correlate to dramatic increased inflammation, are strongly correlated with Alzheimer’s, even Lou Gehrig’s disease for that matter. Depression, for example, is now looked upon as a smoldering inflammatory event in the human brain brought on by leakiness of the gut. So, how incredible it is, Dr. Myers that you and I are having a conversation about things that go on in the brain and we are exploring the health of the gut as it relates to the brain. So, it’s all about maintenance of the integrity of the gut lining, whether we’re talking about coronary artery disease, lupus, diabetes type 1, any autoimmune phenomenon, or any inflammatory condition in human physiology, we’ve got to pay very strict attention to all of the factors that play a role in maintaining the gut wall integrity. And understand that this lining of the gut that is the focus of so much research that really mediates whether things get in or not is one cell thick. Can you imagine? One cell thick with the surface area of a tennis court—not the one the cell, but the whole gut lining. This mediates what gets in and what gets out. There are obviously pathways that selectively allow things to get in that we need, but when those junctions have been traumatized by, in this case, glycation of proteins from having too high of a blood sugar, then things like proteins, and as I mentioned before, LPS (which is the covering of the gram-negative bacteria) get in to the systemic circulation and just beef up inflammation, and that basically sets the stage for things going on fire. And unfortunately, our efforts to take care of these diseases don’t focus on the fire of inflammation. We basically tend, in modern medicine, to focus only on the smoke. So, if you’re suffering from an inflammatory condition, you’re given an anti-inflammatory medication like, for example, a non-steroidal anti-inflammatory medicine, which are used by millions of Americans to treat inflammatory disorders like arthritis, and what these drugs do in the long run is they further damage the gut lining making the fire worse while people, moment to moment, feel a little bit better, but the problem worsens. So, we’ve got to really start pay strict attention if we’re going to have leverage points in neurological conditions like ADHD and autism, Parkinson’s, multiple sclerosis, and Alzheimer’s. We’ve got to pay attention to what is going on in the gut, and that means we’ve got to pay attention to the overusage of antibiotics that damage the gut bacteria. The explosive overusage of antibiotics in cattle that are then consumed by us—that’s where 70-80% of the antibiotics in America are used. We’ve got to understand that the very medication we are using to treat inflammation are damaging the gut lining, and we’ve even got to take this back to how you were born. The method of fetal delivery is how we inoculate the gut bacteria from the get-go—that when that child passes through the mother’s birth canal, the bacteria are invested into the mouth to begin populating the gut and that sets the stage for inflammation for that child for the rest of his or her lifetime. That either sets the stage for an autoimmune condition like type-1 diabetes or celiac disease, or it sets the stage for that immune system to be perfectly balanced and adaptable and able to confront changes in the environment as that individual grows up. Dr. Amy Myers: I don’t know if you’ve ever seen that movie, “The Business of Being Born,” but anybody watching this if they haven’t and they’re anticipating getting pregnant or are pregnant, I highly recommend it. It’s talking about the rise of C-sections in the United States now, and even if you’re not wanting it for just convenience, just how it got into somehow being in labor for 10 hours or 12 hours became unacceptable, and that was too long, or your baby wasn’t delivered right at 40 weeks and you’ve gone to 41 or 42 and suddenly, they have to induce and then when they do, giving that Pitocin then stimulates contractions, get the baby in distress and then it’s creating the C-section. Dr. David Perlmutter: In America, about 33-34% of births right now are via C-section. In other countries, it may be as high as even—in one city in Rome, 80% of births are via C-section. You’ve got to understand that the process of being born, passing through the birth canal is probably one of the most fundamental events in developing a person’s immune system. That lifelong consequences of being born by cesarean section are, in fact, very real. The risk, for example, of becoming autistic doubles if an individual is born via cesarean section. The risk, for example, of developing an autoimmune celiac disease is increased by about 80%. So, these are real issues. Type-1 diabetes risk is 70% increased. ADHD risk is tripled. The risk of having a child with ADHD is tripled if that child doesn’t pass through the birth canal and becomes inoculated with mother’s vaginal bacteria. Now, maybe this is a discussion that people might be uncomfortable with, but we’ve got to get over that because this is marking that child for the rest of his or her life. These are real statistics from peer-reviewed medical literature that are really raising a red flag. These are the types of numbers that women need to understand before they get penciled in for a C-section next Thursday at noon. Clearly, cesareans are lifesaving for a mother and a baby—no question there’s a need for that—but that might occur in up to 10% of births, and the fact that there are 33% or 1/3 of all births in America happening via C-section, I think it’s because women and their husbands need to become better informed. As that happens, these statistics will improve. Now, there is also research that indicates that you don’t undo the damage to the microbiome or the gut bacteria by breastfeeding. While breastfeeding is also clearly critically important in the development of the gut bacteria, it doesn’t fully offset those changes that are imparted by a cesarean section. And even to take it further, the mother’s prenatal diet changes the bacteria in the birth canal, whether she is overweight or not has a dramatic effect on the bacteria in the birth canal, and therefore, that is passed on to the newborn baby. That said, we know that women who are overweight give birth to babies who have a higher tendency to become obese. These babies inherit, if you will—it’s not Mendelian inheritance, it’s not sperm-and-egg, gene-DNA inheritance—but they inherit the microbiome of mother that does tend to coat for weight gain, gives them bacteria that tend to be more thrifty, that hold on to calories, and that’s a heck of a thing to saddle a kid with. Rewriting his or her destiny towards obesity just because of the changes that have happened to his or her gut bacteria—the microbiome. I think, more information remains (to be discovered) with the topic of this summit that is autoimmunity, and to be super clear, autoimmunity is a delicate balance between a malfunctioning immune system that’s either too active or one that is underactive, in which case we’re susceptible to all kinds of infection. Overactivity of the immune system to the extent that the body fails to differentiate between self and non-self—the cornerstone of autoimmunity—is really set by what goes on the gut bacteria. So, these factors of early life exposure to antibiotics for every sniffle or sore ear that a child might have, the continued push for women to use formula when they’re given samples right when they get out of the delivery room before they leave the hospital, the continued overusage of antibiotics in the production of food, meat, and even as mentioned, this overusage of cesarean section is setting up a generation of newborns for conditions that are life-threatening and in my business, for conditions that threaten brain health, and it’s preventable by getting this information to the population in general. 3. Alessio Fasano, MD: The Role of Gut Permeability in Autoimmune Diseases: How to Distinguish Facts From Fantasies Dr. Amy Myers: I could not be more pleased about our guest today. This is really one of the top interviews I’ve been waiting for this entire summit. You’ve heard his name come up left and right in pretty much everybody’s talk about gluten and leaky gut. We have Dr. Alessio Fasano here, who is a world-renowned pediatric gastroenterologist. He is the man who really has done the research behind leaky gut, zonulin, autoimmunity, celiac, and he has founded the Center for Celiac Research, which is now at Massachusetts General Hospital. He’s also a visiting professor at Harvard, and recently, wrote a book called “Gluten Freedom,” which I have been reading. So, you wrote in a very, sort of groundbreaking article that was the cover of Scientific American…I don’t know if that was five years or six years ago, but you kind of talked about this stool and having three legs of a stool in order to get celiac disease and then we can extrapolate that out to all autoimmune diseases about sort of genetics, the environment, and the gut. Can you speak to that? Dr. Alessio Fasano: Sure. You know, you also have to appreciate that this has been very challenging to put this concept forward so we were really kind of current, and it was an uphill battle, starting with the concept to convince the colleagues in the scientific community in general that celiac disease is an autoimmune disease. Again, there was very reluctant acceptance to the concept because the paradigm was, in autoimmunity, it’s something you cannot treat. It’s a one-way direction; when you got it, that’s it. With celiac disease being treatable with the diet—people, they really had a hard time to grasp the concept that this indeed was an autoimmune disease. Now, nobody would dispute that. But because this was a one of a kind autoimmune disease, we were able to really study in great detail what are the tools, what are the ingredients of this recipe, if you wish, and that’s how we learned that indeed, there are three pillars that you need to have in order to develop autoimmunity. One is you have to be genetically predisposed, and nobody would dispute that. You have to have many genes involved. With great frustration, we’ve focused lot of attention to find “the genes of autoimmunity,” just to find ourselves with empty hands because the more you search, the more genes come out. The Human Genome Project taught us that that’s definitely not the way to go to learn what is the genetic composition of autoimmunity because there’s a lot of variability, and so on and so forth, but definitely, there are many genes that you need to have in order to develop an autoimmune disease. The second component is an environmental trigger, something that is mismanaged by the immune system because of its genetic makeup. The immune system, in general, is all there to defend us against these enemies that can harm our body, but in people with genetic disposition to autoimmunity, the weapons of the immune system, rather to be directed against the enemy, is directed against your own body. A different target organ can develop into a different disease, such as diabetes, MS (multiple sclerosis), or celiac disease. Celiac disease is unique, because we know the enemy that we don’t know for any other autoimmune disease (that is gluten), and therefore we know that if there’s any way to stop this interplay between the genes and the environment, in this case, by eliminating one of the two ingredients, you can stop autoimmunity. We start really to get more insights of what it takes to develop autoimmunity and that would allow us to learn the third pillar—loss of barrier function by the intestine—that becomes more permeable and therefore allows these enemies to more easily gain access in our body and therefore to be exposed to the immune system that can react in an inappropriate way. So again, this concept—others say unforeseen, not really generally accepted, or fully-formed thinking of concepts—was put out there, and the Scientific American article that was published roughly five years ago was indeed, the stone in the pond, and the waves started to move, and nevertheless there was mixed feeling in terms of accepting this concept mainly because this increased permeability, this leaky gut syndrome had been vilified according to the scientific establishment. Complementary alternative medicine seems to claim that everything that goes wrong is due to the leaky gut, and people have a hard time believing that, and therefore, people had a really hard time to accept the concept. But now, I think that the evidence, not only from our group, but from many other people that studied it, is pretty overwhelmingly clear that there you need all three elements to develop autoimmunity. Dr. Amy Myers: And so, do you feel that gluten is a problem for all autoimmune diseases or only for celiac disease? Dr. Alessio Fasano: Oh no, I don’t think that gluten is the culprit for all autoimmune diseases at all. And matter of fact, while we have an undisputable law for celiac disease and we know because factually we take gluten out of the diet and people with celiac disease will have symptoms resolved, will have the alpha antibodies gone and will have the autoimmune insult that was first defined by the damage, repaired. We don’t have that strong evidence with anything else. We have some hints that gluten may have a role in type-1 diabetes, may have a role in multiple sclerosis, maybe that is a tangential and not the principal role like in celiac disease, but definitely, we don’t have the undisputable evidence that it can be really responsible for all of this. Dr. Amy Myers: But leaky gut, you would say, is something that does need to be present in other autoimmune diseases or not necessarily as well? Dr. Alessio Fasano: I think that that’s a must. I’m very biased here because I’m not an expert immunologist, so again, I trust and respect deeply the opinion of my colleague immunologists. I am an expert in gut physiology and biology, and if you accept, and everybody does, that the main port of entry of this instigator of autoimmunity is the gut…if you don’t have a loss of this barrier function, I just can’t see how molecules—that need to be large, these proteins, that are instigating the immune response—can get access and be seen by the immune system, because under normal circumstances, the gut has this formidable capability to keep at bay large molecules, potential enemies outside our body. Therefore, I don’t see how you can instigate an immune response unless physically, the immune system that is within our body and these enemies that are outside are body, see each other, touch each other, and are physically interacting. And again, the reason why, for example, there are a lot of medications that we cannot give by mouth is because they are too large, we have to give by injection like insulin. By the same token how can you permit that a molecule like gluten, for example, that’s much larger than what can come into our body, get access, and induce an immune response, unless something goes wrong in terms of gut permeability? And again, this theory has been supported by the Human Genome Project, in which some of the genes that have been discovered to be wrong with autoimmunity are genes that control gut permeability. So, I think that now this is not something that people will see as esoteric as before, so this is taking more and more ground in terms of key elements that you have to have in order to develop autoimmunity. Dr. Amy Myers: So, we’ve talked a ton about leaky gut in this summit and every time, your name comes up, but I would love to hear from the man himself, your explanation of what is leaky gut. Dr. Alessio Fasano: The intestine is a very long tube. In adults, it’s roughly 20 ft. long and it’s not smooth; it has valleys and hills, and that increase the surface. If you stretch the guts of an adult on the floor, you cover a double tennis court, 3,000 sq. ft. So, until the recent past, we thought that we need that to really maximize the capability to digest and sort foodstuff, but we overlooked these other key functions, one of being communicating with the environment. This is an extremely important function; it shapes who we are because you as an individual when you were born can be considered as a marble block that is the shape, and the size, and the color is determined by your genetic makeup. But what comes out of this marble block depends on from the environment that is the sculptor that carves these blocks and whatever final product will be. Even identical twins where they were split at birth and live in two different environments, they will look very differently, meaning that the environment does a great deal in terms of determining who we are, physically or socially and in terms of activities, and so on and so forth. To do that, you need to have this continued exchange with the environment. You need to continuously have exchange of information and that exchange of molecules. The intestine being the largest interface with the environment is where most of this crosstalk occurs, and this long tube is covered by single-layer cells that represent this interface with the environment. One more function that again we’ve been overlooking other than to digest and sort the foodstuff is the intestine is in charge of this trafficking of molecules, not through the cell as we believed before, but in between cells. Until the recent past, the space in between cells we thought was completely sealed by sort of cement and then in the mid-80s, the Japanese groups said that’s not the case, there are doors, but they are almost always closed. Only rarely they open to allow short time to make these molecules to go back and forth, and then would be immediately closed. When they discovered zonulin, they discovered this could be the key of these doors if and when it’s in the picture, then we start to appreciate more and more the physiology of the mechanism. Why we do that, how this works, how we really open these doors and then we close again, and what typically happens when the physiology’s pushed to the limit, you spin into pathology. That’s when we learned that when this system is out of control, one of the most frequent conditions that you can have is indeed autoimmunity. And that’s how pretty much the field of leaky gut and its role in autoimmunity really stem into the new concept, this new mission, in which again, we have these three pillars to develop autoimmunity. Because without inappropriate antigen trafficking, that continue to bombard your body, there isn’t physically, GI-wise, a way (to develop autoimmunity)—it’s an impossible task. It’s like to pretend that you leave your room without opening the door. You need what? A way to get out or a way to get in, in this case. Again, the reason why this (idea) has really been hard to accept, is because this completely revolutionized the concept of autoimmunity. The classical theories of antigen mimicry—you develop autoimmunity because you are exposed to microorganisms (bacteria, viruses, there are some molecules, there are structures similar but not identical to our own molecules) and the immune system that is not really focused and capable to distinguish similar but not identical molecules meant to get after this enemy and actually kills its own cells, or the bystander effect: the infection that destroy your cell’s molecules leaks out and now you attack these molecules that are your own body—would imply that once you got it, that’s it; there’s nothing you do about it. Once again, celiac disease taught us otherwise. If there’s any way that you can stop this interplay between the genes and the environment, you can eventually stop and treat autoimmunity. 4. Datis Kharrazian, DC, DABCN, CNS: Understanding Hashimoto’s and Other Thyroid Conditions Dr. Amy Myers: I’m really excited about our guest today. I have Dr. Datis Kharrazian with us today, who many of you probably know if you’re suffering with thyroid disease. He’s the author of, “Why Do I Still Have Thyroid Symptoms When My Labs Are Normal?” which is an incredible book. He’s also written, “Why Isn’t My Brain Working?” He’s a chiropractor and has a thriving practice in San Diego, helps train physicians and chiropractors around the world. In fact, I went to one of his seminars called “The Gut-Autoimmune-Gluten Connection,” and it was a fabulous seminar. I’m really excited to have him here today. Since thyroid disease is really one of the biggest subsets of autoimmunity and given your background in writing the book that you did, I thought it’d be great if we talk specifically about thyroid. Why don’t we just kind of go over autoimmune thyroid and how does that happen? Dr. Datis Kharrazian: Well, one of the most common autoimmune diseases worldwide is autoimmune thyroid. Unfortunately, most people that have hypothyroidism never actually get diagnosed as being autoimmune because the standard of care is basically once you identify a high TSH, you’ll just be on thyroid replacement forever. The next follow-up step would be thyroid antibodies. That test is never done because it doesn’t change treatment. The treatment is still: you’re going to go back every year and then get your replacement adjusted if your TSH is up. What people tend to forget is that the model for that type of therapy is that there is an assumption that since most people that have hypothyroidism have autoimmunity, there’s no reason to test the antibodies, and that the thyroid is going to get destroyed every year more. So, every year, you need to come in and get that adjustment. What happens is the practitioners and insurance companies don’t really authorize or perform the thyroid antibodies, and the patient then leaves thinking they have a metabolic disease and not knowing they really have an autoimmune disease. So, thyroid antibodies really confirm that the person has an autoimmune disease. For many people, autoimmune diseases are pretty prevalent. They don’t really realize that when they have hypothyroidism, they’re actually suffering from one autoimmune disease, and it’s pretty likely that they have others and different variations of it, and things associated with autoimmunity like celiac disease or other variations. What we find is people that have hypothyroidism don’t really get their thyroid under control until they can actually address their autoimmunity. Dr. Amy Myers: One of the biggest things of why people love your book so much is you really talk about people that go on and get (thyroid) medicine, and they’re still not getting better, or their labs are totally normal, but they’re still having a lot of these hypothyroid symptoms. So, what’s going on there when that happens? Dr. Datis Kharrazian: Well, there are lots of different triggers for autoimmunity, and gluten has become very popular. That’s great because we’re already used to that, but there are other foods that cross-react to gluten, and things like rice, things like corn—they can also cause the entire gluten response because they have cross-reactive responses. I really talked about that in my brain book and in my third book. The other thing that we see is simple things like blood sugar stability issues. When people have blood sugar spikes, they get IL-6 surge which stimulates the Th-17 pathway, whether they have a drop in blood sugar or have insulin surges from eating too much glucose. Those are autoimmune-promoting mechanisms, so a lot of times when we see Hashimoto’s people, it’s not just about being gluten-free or avoiding foods, it’s about stabilizing blood sugar levels. There’s less than nutritional things you can do specifically for some of these pathways, and just recently, in the laboratory, we’ve really discovered something really profound and we’re waiting to publish it, but we’ve been checking monoclonal antibodies to TSH receptor—TSH, T4, T3, 5’deionase—and we cross-reacted with 200 different foods. So, we just got 40 new foods that we know cause molecular mimicry with thyroid, and we’re readying the manuscript to get it published. In the near future, we’re going to have a very specific autoimmune Hashimoto’s diet because we’re able to identify multiple foods that cross-react. Some cross-react with 5’deionase and now we have mechanisms for T3 conversion other than cortisol and selenium and inflammatory mechanisms, and then we’ve found specific foods that directly cross-react with T3, which would explain why some people don’t do well or don’t respond to the medications they’re taking from a molecular mimicry mechanism. So, we’re finalizing the manuscript, double-checking results, and then we’ll publish it. I think we’ll have a whole new Hashimoto’s diet beyond just gluten because many of the foods that we found are within the Paleo diet. Dr. Amy Myers: Many of the foods (that cross-react) are foods that people are eating on a Paleo diet? Dr. Datis Kharrazian: Yes. And they cross-react with the thyroid. I’m giving you one example: tuna cross-reacted, but only when it’s raw, and when it’s cooked, it doesn’t cross-react. So, the protein denatures. So, when you look at tuna, and we found some foods that are high in iodine and really cross-react with T3 and T4, but when they were cooked, there’s no cross-reactivity. We found, for example, soy didn’t cross-react unless it was processed soy. We found latex—it was one of the most devastating exposures to Hashimoto’s people—every path of the pathway: TSH, 5’deionase. These are usual things because you can package your food with latex and then you can get a reaction. You can be eating sashimi thinking it’s okay and have a cross-reactivity. These cross-reactive foods really only matter if you have antibodies against those foods. Not everyone with Hashimoto’s will, let’s say, have a reaction, but if they have, let’s say, tuna antibodies that are elevated, those tuna antibodies can cross-react with T3 due to molecular mimicry. So, some people would be very sensitive to some of those cross-reactive foods based on if they have antibodies to them, and some won’t. The point is that we’re doing some research now that’s really going to cause some breakthrough in our understanding, but we’ve also done monoclonal antibody testing now with various chemicals. Now, we’re getting very specific which chemicals cross-react with which part of the thyroid, and we’re now identifying certain celiac markers versus the transglutaminase 2, 3 and 6 and what part of the thyroid they impact because they impact different parts of the circuit. So, in the near future or through the next year, we will have discovered multiple mechanisms that impact conversion patterns and then receptor pathways and then the use of hormones themselves as part of being available in getting the cross-reactivity from an immune response. Dr. Amy Myers: Can you tell us about why certain people might not do well with say, Synthroid which is just T4 versus Armour’s T4 and T3 or any particular medication and how conventional medicine is typically checking only the TSH or the TSH and the free T4, not all the other components of the thyroid? Dr. Datis Kharrazian: Yes. When you look at the patients that suffer from thyroid disease, one of the key things is that at some point if their TSH gets tight, it’s really important for them to be on a replacement, and if they are not on replacement, they can accelerate brain degeneration and they can accelerate bone loss, they can develop gallstones. So, a lot of ugly things happen if they’re actually deficient in thyroid hormone. If someone has autoimmunity to their thyroid, at some point, the thyroid gland will be destroyed and they need to get on thyroid replacement; however, the question is, “Which type of replacement?” And you have kind of a spectrum where you have really orthodox conventional people only wanting things like levothyroxines, synthetic T4, and then we have the other side of the spectrum, we have alternative people really wanting natural bioidentical things like Nature-Throid or Armour and things like that. A lot of times, what patients get is really what the practitioner likes, and it’s not really unique to the patient and this creates some problems. So, we found that a lot of Hashimoto’s people, for example, can’t take a bioidentical source like Armour or Nature-Throid because they can’t handle the T3 in it. We know these natural bioidenticals have some T3 in them. Some of them have such an underlying autoimmunity that as your autoimmunity destroy the thyroid gland, the tissue that’s broken down causes release of thyroid hormones and any additional T3 can make them have more anxiety and nervousness and insomnia. So, those people really don’t fall within what everyone wants them to really work which is like a bioidentical hormone with T3. Also, we have some filler issues. The filler of most of these is cornstarch, and many people that are gluten-sensitive cross-react with corn so they end up having filler issues, and there are some people that actually do better with just T4, even synthetic T4; they do better with it. Dr. Amy Myers: So, you keep bringing up sort of this brain Hashimoto’s or brain thyroid autoimmune connection. Can you tell us more about that? Dr. Datis Kharrazian: Yes, I’d love to. One of the things that we see in my office, is we see most people that have Hashimoto’s have a pretty devastating decline in brain health, and part of it could be because I just love brain and I like to do brain evaluations on my patients. One paper was published in the Journal of Neurology back in 2007 and they found that thyroid antibodies can bind to cerebellar astrocytes. There is actually molecular mimicry, and recently, we found similar things in our laboratory and through our research, and what we’re finding is that many people that have thyroid antibodies, those antibodies aren’t just attacking the thyroid, but they’re also attaching to the brain; they’re attaching to the cerebellum. We also know that many people that have Hashimoto’s have gluten sensitivity, and gluten itself—gluten antibodies have been shown to cross-react with the cerebellum as well. So, what we see for the most part is we see a lot of Hashimoto’s patients develop cerebellar degeneration, and what happens to them is the cerebellum starts to get degraded through this autoimmune process. They start to get balance issues, they start to get maybe occasional vertigo, trivial types of movements in their background like things flashing really upset them, they get really sensitive to light, sound, they get all these different types of neurological impairment symptoms. If it gets worse, they get ataxia, where they can’t walk straight with their eyes closed. Some of them eventually develop tremor. So, for the most part, what we’re seeing is we’re seeing a lot of thyroid patients end up with poor brain health. And here’s the thing: when the brain declines, people will get fatigue; they get brain-based fatigue, which means when they try to use their brain, they get tired, so when they try to read and they try to drive, they get tired. That’s brain-based fatigue. That’s non-metabolic fatigue; it’s using your brain with no endurance for your brain and then getting exhausted. People that have brain-based issues usually have everything blamed on their thyroid and they don’t do anything to support the brain health. So for me, when I wrote “Why Isn’t My Brain Working?”, it’s really part two of my thyroid explanation and some people haven’t really understood that. And for most people that have thyroid dysfunction, they’re still having depression and they’re still having fatigue, especially fatigue that’s induced by using their brain. There could be a brain component to it and doing strategies just for autoimmunity and leaky gut may not be enough. You actually may need to do interventions specific for the brain. So, this is one of the things we’ve noticed. We’re trying to contribute to the knowledge base. Dr. Amy Myers: And what would some of the interventions be that would be specific to the brain? Dr. Datis Kharrazian: One of the things that I’ve done is write my book. I try to go into each mechanism and explain symptoms for each major mechanism. So, lack of oxygen to the brain is a mechanism, hypoxia of the brain is a mechanism, microglial activation is a mechanism, breach to the blood-brain barrier is a mechanism, impairments in dopamine, GABA, and acetylcholine—these are all various mechanisms. So, we go through multiple mechanisms. In the beginning of each chapter, I give lists of symptoms, and if the patient has those symptoms, that chapter’s really important for them, and then we try to get some strategies. So at the end of the day, you’re trying to see which of these mechanisms there are and really understand why a person that has a thyroid issue—if you are a thyroid patient or if you work with thyroid patients as the practitioner—why are some of these people having such severe impairments in their function? And part of this is because they’re having neurodegenerative changes. There needs to be, once the autoimmunity is somewhat managed with diet and lifestyle, an approach to really improve brain health for thyroid patients. 5. Aristo Vojdani, PhD: Understanding Advanced Assessment and Diagnostic Tools to Track Autoimmune Disease Recovery Dr. Amy Myers: Today’s guest, I have Dr. Aristo Vojdani. I normally don’t read somebody’s bio, but I think you all maybe a little more familiar with perhaps some of the other speakers, and I don’t want you all to miss out on all the goodness of this gentleman’s background. It is amazing, so forgive me for having to read this a little bit. He is currently a professor of neuroimmunology at the Carrick Institute for Graduate Studies. Previously, he was with UCLA School of Medicine. He has a PhD in microbiology and clinical immunology, with postdoctoral studies in tumor immunology at UCLA. His research focuses on the predictive antibodies resulting in the development of numerous antibody assays. So, a lot of people are talking about these Cyrex Labs as we’ve gone through this summit, and he is actually the chief scientific advisor, and also developing a lot of these arrays for the testing. He has 15 U.S. patents. He’s published more than 140 articles, and he’s also the CEO and technical director of Immunoscience Labs. So privileged to have you here with us. You are definitely an expert in the world of autoimmunity. So, tell me. What is autoimmunity to you? Dr. Aristo Vojdani: Well, there is a classical definition of autoimmunity in the textbook. They tell us that autoimmunity is the process by which the immune system of an individual cannot differentiate between self and non-self, and thereby, produces antibodies against its own antigens. However, I’m going to add to that by saying that autoimmunity is a process by which the immune system of an individual, due to exposure to environmental triggers (this is the heart of the matter), cannot differentiate between self and non-self, and therefore produces antibodies against its own tissue. Dr. Amy Myers: And what are some of these environmental triggers? Dr. Aristo Vojdani: Well, we have three very famous environmental triggers. Number 1, toxic chemicals or xenobiotics. Number 2, dietary components; there are many of them; and thirdly, infections. These three, plus stress, and some additional factors play a significant role in the development of autoimmunity. Dr. Amy Myers: Before we get in to all that, I think you have a personal story about how you actually even got involved in autoimmunity and why that became an interest of yours? Is that true? Dr. Aristo Vojdani: Yes, absolutely. I was about six years old when my mother had severe infection in the gut, where she was going to so-called a dental technician without having any knowledge that we should not remove any teeth. During the infection, he was removing three or four each day. And so, today, we know he exposed her to many bacterial toxins. Six years later, she started having symptoms of rheumatoid arthritis. Fifteen years later, she had full-blown rheumatoid arthritis, osteoarthritis, and then a couple of years after that, she needed total knee replacement. So, after having the knee replacement, she lived with this painful disease for additional 40-42 years of suffering with this devastating disease. During my graduate studies, I proved, indeed, her illness was initiated by toxic material released by porphyromonas gingivalis or streptococcus mutan, which is involved in oral infection. By looking at antibodies in her blood, she had 10 times higher levels of antibodies against these two bacterial toxins, compared to any other individual who had the same age, and they were healthy at that time. So, that was my personal interest—to look and find the causes. So therefore, today, it’s very important to talk about the causes of autoimmune disease because when we learn about the causes of autoimmune disease, we can make huge difference in preventing autoimmune diseases. Dr. Amy Myers: Yes, and they are on the rise, so we definitely need to get people educated, so that they can help reverse what they have going on or prevent one from coming. So, back to what you were saying, it sounded like it was toxins, infections, and the diet, or what you’re saying the leading factors to autoimmunity. Shall we touch on each one of those individually? Dr. Aristo Vojdani: Yes, but let me read a couple of statements by two most prominent scientists from Johns Hopkins University if you don’t mind. I’m sure you know about the book by Donna Jackson Nakazawa, “The Autoimmune Epidemic.” Two people forwarded her book, and these are the two scientists I admire significantly. One of them is Dr. Hoke, MD, Ph.D., director of neuromuscular division of Johns Hopkins Hospital Institution, and he’s saying that: “It takes the human body thousands of years to adapt to new environmental stress, yet in a hundred years, we have dumped so many toxic substances into our environment that our immune system is being asked to differentiate between our own body and unrecognizable invaders nonstop, and which our body is much more likely to make a mistake than it was, say, a century ago. There are just so many opportunities to make mistakes.” The second professor is Dr. Noel Rose. He was the first one in the 1950s to actually demonstrate an animal model of thyroid autoimmunity. So, he’s the father of autoimmunity. And so, this is what Dr. Rose is saying: “We have no other good explanation as to why there should be an increase in autoimmune diseases except for the things to which we are exposed in the environment. Autoimmunity is our immune system’s effort to adapt to all the new environmental agents and shifts that we are being bombarded with. It is an unsuccessful adaptation, but it is our body’s way of trying to fight back.” So, when so many chemicals enter the human system, it’s wrong to think that these chemicals get in and out (unchanged). Some of these chemicals get metabolized; some of these chemicals directly combine to human tissue, and therefore the immune system is going to make that mistake and cannot differentiate between self and not self, and therefore is attacking the tissue plus the chemicals, which are bound to the tissue antigens. So therefore, No. 1 importance, out of the three factors, is the chemicals—xenobiotics and toxic chemicals, and their role in autoimmunity. Dr. Amy Myers: And what can somebody do? I mean, I read that book, (The Autoimmune Epidemic by Donna Jackson Nakazawa). It’s an excellent book, and if it doesn’t make you want to race out and get a water filter or air filter and eat only organic food out of nothing plastic…but we live in the real world, so we have (I think it’s something like) 80,000 chemicals, only a fraction of which are actually being studied by the EPA to say that they’re safe, and then they’re not even testing them in combination. They’re testing them in isolation, not with the other chemicals. What can somebody do? Dr. Aristo Vojdani: I think education, education, education. You educate people that chemicals, most of them, are toxins. Chemicals are estrogenic compounds, that can interfere with our hormones, and so therefore, education is the most important tool that we can teach people about. For example, again, plastics—bisphenol A and many other chemicals; herbicides; pesticides. These chemicals are major contributors of autoimmunity and if we teach them, and there is a lot we can do. I was reading this article in Journal of Environmental Health Perspective. They took few children and they put them up on a normal diet—normal classical diet. They measured levels of the chemicals in blood and urine. It was, let’s say, 100 units. Then they changed their diet to organic food, and measured the same chemicals in blood and urine. The level dropped from 100 to almost undetectable levels. Of about, let’s say, 10 units. Five days later, they put them back on the normal diet, and chemicals went back again to 100 units. This is a classical example that indeed, we can do something about it, and organic diet can help to reduce the body load of toxic chemicals. Dr. Amy Myers: I think you were credited by one of our other speakers, as saying that the Starbucks lids when you drink a hot coffee, is one of, maybe besides receipts, the biggest exposures to bisphenol A. Is that you that we need to attribute knowing that knowledge to? Dr. Aristo Vojdani: Yes, thank you so much. That’s one of them, but the most important one also is the sodas that we drink every day. I took the time and measured the pH of all the soda drinks. Believe me, Dr. Myers, the pH of soda is as acidic as vinegar, and so imagine, you’re putting this liquid in plastic bottles, whether it’s bisphenol A or bisphenol A-free; for me, plastic is plastic. Now, we have put that for months or years in the warehouses, supermarkets, and then we drink it. You think the pH of 2.2—that acidic like vinegar—is not going to eat up a little bit of this bisphenol A? And then we drink it every day. That’s one example. A second example which also is bothering me a lot is aluminum. An article published in a journal called Mucosal Immunology three months ago, showed in animal models, by introducing aluminum, it could induce an IBD (inflammatory bowel disease)-like syndrome, and then they wanted to find what is the mechanism of action because before that, we knew that aluminum accumulated in the muscle and in the brain, that’s why the connection with Alzheimer’s disease. This time, they found actually about 40-60% of aluminum get into the epithelial cells, which are the protective layer of the GI tract. And so, therefore, here we are talking so much about gluten, we are talking about so much dairy product &#8211; their proteins—but how many people know that aluminum is as toxic to some individual as gluten or other dietary protein. Also, unfortunately, when they stopped putting mercury in the vaccines, now, aluminum is used as an adjuvant. An adjuvant is a material which can enhance the immune system, in this case, to produce more antibodies, but as you know, that when the body makes more antibodies, it can make more mistakes also. And possibly, autoimmunity down the road. There are many other heavy metals. Lots of toxic chemicals are contributing to environmentally induced autoimmunity. In fact, I did share with you one of my articles from Journal of Autoimmune Disease. That special issue of the journal was put together by myself as the editor-in-chief of that issue only. I highly recommend it for those who are interested. They can download and read this article. My particular article is about the potential link between environmental triggers and autoimmunity, and for each environmental trigger, I’m giving the mechanism of action. So when we learn about mechanism of action, then we can also plan some kind of strategies to prevent autoimmune diseases. Number one are the toxic chemicals. If I were to give you a statistic based on my own personal experience from working in the lab for more than 40 years, and in clinical immunology level more than 30 years, and handling blood samples of patients exposed to toxic chemicals, I would say, out of the three factors, the most important one that are contributing to autoimmune diseases are toxic chemicals in about 50-60% of the cases, dietary components in about 30-40% of the cases; and infections in only about 10% of the cases. Dr. Amy Myers: Cyrex has a new array, Array 11, that looks at antibodies to certain toxins. Is that correct? Dr. Aristo Vojdani: Yes, correct, and those who are interested to read the science behind this array, Array 11, which are measuring IgG and IgA antibodies against 12 most common chemicals including heavy metals and bisphenol A, fire retardants, formaldehyde, and so forth, they can read my recent article, which was published this week in the Journal of Applied Toxicology. The title of this article is “Elevated Levels of Antibodies Against Xenobiotics in a Subgroup of Healthy Subject.” Why was I interested in healthy subjects? Because all of us are exposed to toxic chemicals on daily basis. I wanted to see what is the percentage of population, which chemicals bind to their tissue and results in antibody production against, for example, human serum albumin, which is the most prominent protein in the blood, plus some of these chemicals. And we found about 20-25% of the healthy population make antibodies against their own tissue antigens plus these toxic chemicals. So, if it continues like this, these individuals, in my opinion, will be more prone to autoimmune diseases in the future. So, it is highly important to test for antibodies against these chemicals, and based on this, to implement some kind of programs to eliminate these chemicals from the environment of those patients, even if they do not yet have autoimmune disease. They may be in the process of developing autoimmune disease—maybe they have autoimmune reactivity. Additionally, testing for Array 5, which is measuring antibodies against 24 different tissue antigens to different organ tissues (can be very useful).","date_published":"2014-11-25T05:35:41","date_modified":"2020-04-23T00:53:38","authors":[{"name":"Dr. Richard Esquivel","url":"https://sanjosefuncmed.com/about/"}],"tags":["Autoimmune Health"]},{"id":"https://sanjosefuncmed.com/brain-body-separation-myth-autism-systemic-disorder-affects-brain-blood-sugar-alzheimers-disease-connection/","url":"https://sanjosefuncmed.com/brain-body-separation-myth-autism-systemic-disorder-affects-brain-blood-sugar-alzheimers-disease-connection/","title":"The Brain-Body Separation Myth, Autism: A Systemic Disorder that Affects the Brain, The Blood-Sugar and Alzheimer’s Disease Connection","summary":"The Brain-Body Separation Myth: Your brain is protected from your body Many doctors and patients view the blood-brain barrier as an impenetrable wall that pro","content_text":"The Brain-Body Separation Myth: Your brain is protected from your body Many doctors and patients view the blood-brain barrier as an impenetrable wall that protects the brain from any problems in any of the other organs or anything that circulates throughout the bloodstream. However, we now know that the blood-brain barrier is just a partial barrier, not a complete barrier. The blood-brain barrier is actually a very thin (one cell thick) layer of epithelial cells that protects the brain from potentially harmful agents circulating in the blood. However, the brain-brain barrier can become “leaky” and the barrier permeable to different substances under many different types of conditions—poor nutrition, stress, infection, digestive imbalances, toxic injury, allergy and systemic inflammation. (1) Just as the gut can become leaky and lead to “leaky gut” syndrome, the blood brain barrier can become leaky. This is known as “leaky brain”. This can lead to major problems for the brain, depending on what type of substance is able to penetrate. The brain, in fact, “reads” what is happening in the rest of the body even under normal conditions of life. Let’s take a look at autism and Alzheimer’s disease to illustrate the frailty of the myth the brain is walled off from the body. Autism: A Systemic (Body) Disorder that Affects the Brain Dr. Martha Herbert is an assistant professor of neurology at Harvard Medical School and the director of TRANSCEND (Treament, Research and Neuroscience Evaluation of Neurodevelopmental Disorders). She is one of the leading experts in the world on autistic disorders. Her work in autism is considered paradigm-shifting scientific research and thinking. In her groundbreaking article in Clinical Neuropsychiatry entitled, “Autism: A brain disorder or a disorder that affects the brain?” she explains how the incoherent brain connections found in children with autism which show up as the inability to talk, connect with other people, or produce odd repetitive behaviors, have their root not in the brain but in problems with the digestive system and the immune system.(2) According to Dr. Herbert, these breakdowns in the body occur because of genetic susceptibilities which are amplified by environmental stresses, exposures and toxins. She had the foresight to ask the question: “Why do 95 to 100% of autistic children have GI dysfunction and 70% of them have immune system abnormalities?” After evaluating all the accumulated research on autism she concludes that autism is not a brain disorder, but a systemic disorder that affects the brain. She believes there may be many “autisms” because each child has unique genetic and environmental factors that can lead to the same symptoms and behaviors. Dr. Herbert noticed that the brains of autistic children are bigger and appeared swollen. These swollen brains are filled with activated immune cells and inflammatory molecules that should not be in such a high amounts in young children’s brains. Where is this inflammation coming from? She concluded based on her research that it starts outside the brain. She describes autism as a “metabolic encephalopathy” (metabolic disease of the brain). This is a 180-degree turn from conventional medical thinking in the field of neurology. If an altered response to a microbe or bug in the body by the immune system can affect brain function, or if a molecule made in the gut can change behavior or perception, then of course the brain is in communication with the rest of the body. In autism, we can clearly see the effects of systemic imbalances in the body on the brain and cognitive and behavioral abilities. The Blood-Sugar and Alzheimer’s Disease Connection Also out of Harvard is the pioneering work of neurologist Dennis Selkoe, who has linked sugar and its ability to create insulin resistance, metabolic syndrome and diabetes to Alzheimer’s disease, which is considered by many experts to be the next epidemic we will see in this country within the next 20-30 years. (3) Some researchers are calling Alzheimer’s disease “type 3 diabetes” due to recent evidence showing a startling similar relationship between the development of diabetes in the body and the development of Alzheimer’s disease in the brain. They both arise from the same mechanism: insulin resistance. Consider the following: People with type 2 diabetes have 4x the risk of developing Alzheimer’s disease than those without diabetes Even people with prediabetes have a higher risk of cognitive decline, poor memory and loss of brain function This pioneering new research out of Harvard and Brown universities by Dr. Selkoe and Dr. de la Monte has proven that insulin resistance (pre-diabetes) is a major factor in starting the cascade of brain damage that leads to Alzheimer’s disease. These researchers have shown that the same process that leads to type 2 diabetes in the body (insulin resistance) leads to the development of Alzheimer’s disease in the brain.(4) Epidemiologists now expect to see an epidemic of Alzheimer’s disease in the near future to follow the epidemic of diabetes and obesity that we are currently experiencing in the U.S. Who is going to pay for this expected sharp increase in medical costs? In the next article, we consider the brain as the master organ and discuss how the brain is often overlooked in medicine. We also look at how little conventional medicine has to offer patients with neurodegenerative disease. References: The UltraMind Solution. Mark Hyman, MD. Simon and Shuster. 2008 Herbert, M. R. 2005. Autism, a brain disorder, or a disorder that affects the brain? Clin Neuropsychiatry 2 (6):354-79. Kinoshita, J.: Alzheimer Research Forum. 2006. Alzheimer Research Forum live discussion: Insulin resistance: a common axis linking Alzheimer’s, depression, and metabolism: J Alzheimers Dis 9 (1):89-93. Kinoshita, J.: Alzheimer Research Forum. 2006. Alzheimer Research Forum live discussion: Insulin resistance: a common axis linking Alzheimer’s, depression, and metabolism: J Alzheimers Dis 9 (1):89-93.","date_published":"2012-06-27T07:44:53","date_modified":"2020-04-16T14:09:55","authors":[{"name":"Dr. Richard Esquivel","url":"https://sanjosefuncmed.com/about/"}],"tags":["Brain & Neurologic Health"]},{"id":"https://sanjosefuncmed.com/brain-health-article/","url":"https://sanjosefuncmed.com/brain-health-article/","title":"Brain Health","summary":"“Your brain is the hub of your nervous system. It is made of 100 billion neurons, about the same as the number of trees in the Amazon rainforest. Each cell is","content_text":"“Your brain is the hub of your nervous system. It is made of 100 billion neurons , about the same as the number of trees in the Amazon rainforest. Each cell is connected to around 10,000 others. So the total number of connections in your brain is about 1000 trillion —about the same as the number of leaves in the rainforest” “The human brain is highly complex and for normal function relies on the interaction of over 100 neurotransmitters (brain chemical messengers) with 300 types of receptors ”(1) “Everything you have ever experienced, felt or conducted in life is due to brain function. The ability to enjoy, perceive, sense and experience life is dictated by the firing rate of your brain. It is impossible for a person to become healthy mentally or physiologically without a healthy brain.”(2) Do You Have a Healthy Brain? Do you have mental fatigue, lack of drive or depression? Do you have difficulty focusing and completing tasks? Do you have difficulty remembering names, phone numbers or where you put your keys? Do you have anxiety, nervousness or difficulty “winding down”? Do you have unclear thinking or “brain fog”? If your answer to any of these questions is “yes”, you may be suffering from the new 21 st century epidemic of “broken brains”.(3) If so, read on. You may be surprised to find out how common these conditions are. The 21st Century Epidemic of Broken Brains We are now seeing an epidemic of brain disorders affecting 1.1 billion people worldwide. Depression is now the leading cause of world-wide disability affecting 120 million people worldwide.(4) Mental disorders affect 1 in 6 children, 1 in 2 elderly people and will cripple 1 in 4 people during their lifetime.(5) Consider the following: Psychiatric disorders affect 26% of our adult population, over 60 million Americans More than 20% of children have some type of psychiatric disorder(6, 7) More than 40 million people have anxiety More than 20 million people have depression The use of antidepressants has tripled in the last decade 1 in 10 Americans now takes an antidepressant In 2006, expenditures on antidepressants soared to over $1.9 billion The cost of psychiatric disorders on our healthcare system exceeds $200 billion/year, 12% of total healthcare spending(8) Alzheimer’s disease will affect 30% (some experts say 50%) of people over 85 years old and will affect 16 million people by 2050 8.7% of children between 8 and 15 have been diagnosed with ADHD(9) More than 8 million children, or 1 in 10, now take stimulant medications like Ritalin(10) Autism rates increased from 3 in 10,000 children to 1 in 166 children (a 20-fold increase) from 1997 to 2007(11) and now affects 1 in 88 children (38-fold increase since 1997) Learning disabilities affect between 5 and 10% of schoolchildren(12) The indirect cost to society of all these broken brains is unimaginable Broken brains show up in two major ways: Psychiatric disorders (emotional disturbance) Neurological disorders (neurological impairment) Examples of broken brains: Anxiety Depression Bipolar disease Personality disorders Eating disorders Addictions Obsessive-compulsive disorders ADD Autism Asperger’s Learning disabilities Dyslexia Alzheimer’s Dementia Parkinson’s Psychiatric or psychotropic medications are the #2 selling class of prescription drugs, after cholesterol medication.(13) Psychotropic medications are among the most widely prescribed medications in the United States. As a class, they represented 8.8% of the prescription drug market in 1994, and their use has been increasing rapidly in recent years.(14) In fact, antidepressants are one of the fastest growing classes of prescribed drugs. In 2010, more than 253.6 million prescriptions were filled for antidepressants , according to a report published by IMS Institute for Healthcare Informatics on the use of medicine in the U.S. in 2010. (15) The antipsychotic aripiprazole ( Abilify ) continues to have the highest sales, at nearly $6.9 billion, according to the latest data from research firm IMS Health.(17) A 1998 article published in the Journal of the American Medical Association (JAMA) concluded the patterns of psychotropic medication use in outpatient medical practice changed dramatically between 1985 and 1994, especially in psychiatric practice. It went on to say: “There have been a number of changes in the prescription patterns of psychotropic medications among office-based physicians. Recent years have seen enormous changes in the health care system and in the availability and applications of new and older psychotropic drugs.” “There have been additional indications approved for other marketed medications (eg, in 1990, alprazolam was approved for panic disorder). Much of this information has been systematically integrated into practice guidelines, which also affect the selection of medication.”(18) The Modern Scourge of Depression Depression disrupts the lives of approximately 1 in 10 Americans&#8211;and women in particular. Approximately 1 in 25 Americans fit the criteria for major depression according to the Centers for Disease Control.(19) It is a leading cause of disability and suicide in the U.S. Suicide was the tenth leading cause of death for all ages in 2010. There were 38,364 suicides in 2010 in the United States&#8211;an average of 105 each day. Suicide results in an estimated $34.6 billion in combined medical and work loss costs.(20) As many as two thirds of people with depression do not realize that they have a manageable illness and do not seek help. Only 50% of persons diagnosed with major depression receive any kind of help.(21) Poorer Quality of Life People suffering from depression experience a worse quality of life than people suffering from other health problems such as diabetes, arthritis and back pain. They lose pleasure in doing the things they used to love doing. They lose the ability to enjoy their favorite food, hobbies or music. They lose the ability to appreciate and enjoy being with family and friends. They often feel overwhelmed with ideas to manage and feelings of inner rage or unprovoked anger. They have feelings of sadness for no reason. And they often have poor and restless sleep which makes them even more miserable. Depression is Not a Prozac Deficiency Is medication the answer to our brain disorders? Do we really need more anti-depressants, stimulants, anti-psychotics and memory medications? Is depression really a Prozac deficiency? Hardly. But these types of medications are the only therapies known to most medical doctors. The drug companies are well aware of trends in healthcare, particularly the increased incidence and diagnosis of psychiatric health issues, and are manufacturing more and more drugs which impact brain chemistry which target some of these biochemical pathways. As a result, the use of these drugs is sky-rocketing. The Epidemic of Autism Many experts believe we are facing the largest childhood epidemic in history. The meteoric rise in autism may be the most pressing social issue of our time. Just two decades ago, the likelihood of having a child with autism was 1 in 10,000. Today it is 1 in 88, and 1 in 54 in boys and there is new evidence indicating the gap in total prevalence is closer to 1 in 40!(22) Here in Silicon Valley, home to the highest percentage of high-technology firms, the rates are much higher. It is estimated that the incidence of autism in Silicon Valley is 1 in 15!(23) Having one or both parents with strong left-brain skills is a well-documented risk factor of having an autistic child.(24) Why is that? Functional Disconnection Syndrome Well, we don’t know for sure but Dr. Robert Melillo, a leading researcher in this field believes it is related to the pathology and neurological imbalances that have been associated with autism, namely left-brain dominance and abnormal or relatively slower development of the right hemisphere of the brain, which he terms “functional disconnection syndrome”.(25) This theory holds that the functional disconnect between the two hemispheres of the brain disrupts the communication between regions of these two sides of the brain. This explains the unevenness of skills that are the hallmark of autism. It is why a child may be great at math which is left-brain-based but find reading difficult. It explains why autistic children appear to be drawn into their own world and are challenged in the area of social skills, which are right-brain-based. It also explains why autistic children are commonly fixated on repetitive tasks such as counting, or repetitive movements such as arm-flapping, which are left-brain based activities.(26) Silicon Valley: A “Breeding Ground” for Autism? This theory explains why we see such an increased rate of autism in areas that have a high rate of parents in the sciences and technologies, such as here in Silicon Valley. The Valley is a “hotbed” of left-brained thinkers, which attracts computer scientists, engineers and programmers from all over the world. Other documented risk factors for the development of an autistic child are increased age of parents at conception (especially the mother), a history of psychiatric illness or undetected brain imbalances of one or more parents, maternal stress during pregnancy, the health of the mother-to-be, certain autoimmune diseases, smoking, fetal exposure to certain medications, chemicals (such as certain pesticides), heavy metals, a sedentary lifestyle and vitamin D deficiency.(27) American Children Using Far More Psychotropic Drugs Than European Counterparts “ The annual prevalence of any psychotropic medication in youth was 6.7% in the U.S., significantly greater than in the Netherlands (2.9%) and in Germany (2.0%).”(28) This means 1 in 15 kids in the U.S. is now medicated for some type of mental condition! Why do our kids need psychotropic medications? Are our kids being targeted by pharmaceutical companies as potential users of their medications? Are these medications even effective? Sometimes, but often not. What are the side-effects to these medications? Let’s look at some of the recent evidence on the efficacy of one of the most commonly-prescribed class of psychotropic medications: antidepressants. Antidepressant Medications Shown Not to be Effective for Mild to Moderate Depression Most people taking anti-depressants either don’t respond or have only a partial response to medication. Success is considered a 50% improvement in half of the symptoms . This minimal result is achieved in less than half the patients taking these medications. 86% of those who do find some relief have one or more side effects, including: sexual dysfunction fatigue insomnia loss of mental abilities nausea weight gain increased risk of suicide A recent study published in the New England Journal of Medicine discovered that drug companies selectively published studies on antidepressants. They published nearly all the studies that showed benefit and almost none of the studies that showed they don’t work!(29) This kind of selective reporting warps our view and leads us to think that antidepressants (and other psychiatric medications) work when they don’t. The real problem is actually worse than it sounds because the positive studies often show hardly any benefit in the first place! However, one of the most interesting studies on antidepressants was recently published in the prestigious Journal of American Medical Association . This was a meta-analysis study which concluded that anti-depressants are no more effective than placebo for mild to moderate depression.(30) Meta-analysis studies are “super-studies”: they are comprehensive studies that look at the data of all the other studies available on a particular topic that meet the inclusion criteria, analyze this data and draw conclusions based on all the data available. This recent meta-analysis published in JAMA concluded that the antidepressant class of medications are no more effective than sugar-pills for the majority of depression. In the last year alone, 30 million patients in the U.S. spent over $12 billion on antidepressants. Who has benefitted from Americans spending all this money on antidepressant medication? But the real question that needs to be asked in order to fix this epidemic of broken brains is: Why is there a chemical imbalance in the first place? Why Traditional Psychiatry Typically Doesn’t Work Psychiatry has its roots in the notion that previous life experiences or traumas control mood and behavior. Yet most of these disorders we see today are the result of imbalances in the body that relate to other organs and organ systems, including the endocrine system, immune system, gastrointestinal tract, and liver detoxification capacity. Psychoanalysis or therapy will not reverse the depression that comes from profound omega-3 fatty acid deficiencies(31), a lack of vitamin B12(32), a low functioning thyroid(33) or chronic mercury toxicity.(34) Modern psychiatry has progressed into an elaborate field of science that attempts to control brain chemistry with drugs, as if all mental illness can be reduced to a brain chemistry imbalance and all we have to do is match the right drug to the mental illness. It’s definitely not as simple as that. Why do people have brain chemical imbalances? How can we restore this state of balance? Like most other drugs, psychoactive drugs don’t cure the problem. They only suppress the symptoms and tendencies. There is a reason why there are imbalances in neurotransmitters in the brain. These medications do not address the causes of these imbalances. To cure the epidemic of broken brains we have to ask a new set of questions: What is the cause of this epidemic? Are we defectively designed? Is it the result of imbalances in our body? Are more drugs really the answer? Is there a way to address the underlying causes of this epidemic so that we regain our mental (and physical) health without the use of medication? It’s shouldn’t be a surprise to learn that the answer of how to fix our broken brains lies in the health of our body. The best way to improve the health of your brain is by addressing the issues that affect the health of the body. Improve the health of your body and you will fix your broken brain The solution to the epidemic of broken brains is not found in more psychoactive medications or better psychotherapy. The brain is mostly downstream from the real causes, which are found in the biology of your whole body. Brain problems, or “disorders” are almost always systemic disorders (that affect the entire body), and the cure will be found outside the brain—in your body. The brain can be affected by many types of underlying causes, including hormonal imbalances (such as hypothyroidism or blood sugar problems), liver detoxification problems or excessive chemical or heavy metal exposure, gastrointestinal problems or dysbiosis (imbalances in the gut flora), food sensitivities, nutritional deficiencies, lack of sleep, lack of physical exercise and stress. All of these things can lead to brain disorders. Each of these imbalances has to be considered by the clinician in order to have a long-lasting positive outcome. The successful resolution of brain disorders is much more complex than taking a medication. “Mental disorders” or “brain disorders” are simply the names of common responses our bodies have to a variety of insults and deficiencies. Fixing those underlying problems in the body may allow the brain to heal, and bring the neurotransmitters and other brain chemicals back into balance. As we begin to discover the nature of how the brain works and how its function is intimately connected to the rest of the organ systems of the body, the medical myths that we have been taught are falling apart. Read on to learn more about these medical myths… In the other articles in this series, you will discover why so many people suffer from brain disorders, how the brain is intimately connected to all the organ systems of the body, why conventional medicine doesn’t work very well for most of these brain conditions and other myths of conventional medicine. You will also discover how you can fix your broken brain by addressing your health issues and nutritional deficiencies that are at the root of this problem naturally, without medications, plus a lot more! Related Articles: The Myth of Diagnosis, One Disease, Many Causes—One Cause, Many Diseases, Gluten: One Food Compound That Causes Many Problems The Myth of Medication, The Rapid Increase in Prescriptions for Mood-Altering Drugs and their Side Effects The Brain-Body Separation Myth, Autism: A Systemic Disorder that Affects the Brain, The Blood-Sugar and Alzheimer’s Disease Connection The Brain is the Master Organ, The Health of the Brain is Often Overlooked in Medicine, Conventional Medicine Offers Little for Neurodegenerative Disorders We Really Don’t Have an Evidence-Based Model of Medicine, What People Consider “Aging” is Really Neurodegeneration, Neurodegeneration is Always Progressive, Preserving Brain Plasticity References: Author unknown, Stanford wellsphere.com mental health article: Reviving Emotional and Cognitive Health p.5-6 Datis Kharrazian, D.C., Brain and Neurotransmitters Seminar, San Francisco, CA, Nov. 22-23, 2008 The UltraMind Solution. Mark Hyman, MD. Simon and Shuster. 2008 Demyttenaere, K., et al. WHO World Mental Health Survey Consortium. 2004. Prevalence,severity and unmet needs of mental disorders in the World Health Organization, World Mental Health Surveys. JAMA 21:2581-90. World Health Initiative on Depression in Public Health. www.who.int/mental_health/management/depression/depressioninph/en/ Mental Health: A Report of the Surgeon General. Rockville, MD. U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Mental Health Services, National Institutes of Health, National Institute of Mental Health, 1999. Belfer, M. L. 2008. Child and adolescent mental disorders: the magnitude of the problem across the globe. J Child Psychol Psychiatry 49 (3):226-36. Serafetinides, E. A. 1971. Cost of psychiatric illness versus cost of psychiatric research. Am J Psychiatry 148:951. Froehlich, T. E., et al. 2007. Prevalence, recognition, and help for Attention-Deficit/Hyperactivity Disorder in a national sample of U.S. children. Arch Pediatr Adolesc Med 161 (9):857-64. Zuvekas, S.H., B Vitiello, G.S. Norquist. 2006. Recent trends in stimulant medication use among U.S. children. Am J Psychiatry 63 (4):579-85. Wazana, A., M. Bresnahan, and J. Kline. 2007. The autism epidemic: Fact or artifact? J Am Acad Child Adolesc Psychiatry 46 (6):721-30. Grizzle, K. L. 2007. Developmental dyslexia. Pediatr Clin North Am 54 (3):507-523, vi. Paulose-Ram, R. et al. 2007. Trends in psychotropic medication use among U.S. adults. Pharmacoepidemiol Drug Saf 16(5):560-70. Pincus HA, Tanielian TL, Marcus SC, Olfson M, Zarin DA, Thompson J, Magno Zito J. Prescribing trends in psychotropic medications: primary care, psychiatry, and other medical specialties. JAMA. 1998 Feb 18;279(7):526-31. “The Use of Medicines in the United States: Review of 2010”. IMS Institute for Healthcare Informatics. April, 2011. http://content.healthaffairs.org/content/30/8/1434.abstract http://www.medscape.com/viewarticle/825053 Pincus HA, Tanielian TL, Marcus SC, Olfson M, Zarin DA, Thompson J, Magno Zito J. Prescribing trends in psychotropic medications: primary care, psychiatry, and other medical specialties. JAMA. 1998 Feb 18;279(7):526-31. http://www.cdc.gov/features/dsdepression/ http://www.cdc.gov/violenceprevention/pdf/suicide_datasheet-a.pdf http://emedicine.medscape.com/article/805459-overview The Scientific Truth about Preventing, Diagnosing and help for Autism Spectrum Disorders&#8211;and What Parents Can Do Now. Robert Melillo. A Perigee Book. Penguin Publishing. 2012. The Scientific Truth about Preventing, Diagnosing and help for Autism Spectrum Disorders&#8211;and What Parents Can Do Now. Robert Melillo. A Perigee Book. Penguin Publishing. 2012. Baron-Cohen S. Autism and the technical mind: children of scientists and engineers may inherit genes that not only confer intellectual talents but also predispose them to autism. Sci Am. 2012 Nov;307(5):72-5. No abstract available. The Scientific Truth about Preventing, Diagnosing and help for Autism Spectrum Disorders&#8211;and What Parents Can Do Now. Robert Melillo. A Perigee Book. Penguin Publishing. 2012. The Scientific Truth about Preventing, Diagnosing and help for Autism Spectrum Disorders&#8211;and What Parents Can Do Now. Robert Melillo. A Perigee Book. Penguin Publishing. 2012. The Scientific Truth about Preventing, Diagnosing and help for Autism Spectrum Disorders&#8211;and What Parents Can Do Now. Robert Melillo. A Perigee Book. Penguin Publishing. 2012. Child Adoles Psychiatry Ment Health. 2008 Sep 25;2(1):26. PMID: 18817536 Turner, E. H., et al. 2008. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 358 (3):252-60. Fournier JC , DeRubeis RJ , Hollon SD , Dimidjian S , Amsterdam JD , Shelton RC , Fawcett J . Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA. 2010 Jan 6;303(1):47-53. http://www.ncbi.nlm.nih.gov/pubmed/20051569 Hibbeln, J. R. 2007. From homicide to happiness-a commentary on omega-3 fatty acids in human society. Cleave Award Lecture. Nutr Health 19 (1-2):9-19. Tiemeir, H., et al. 2002. Vitamin B 12 folate, and homocysteine in depression: the Rotterdam Study. Am J Psychiatry 159 (12):2099-101. Davis, J. D., and G. Tremont. 2007. Neuropsychiatric aspects of hypothyroidism and reversibility. Minerva Endocrinol 32 (1):49-65. Review. Zachi, E.C., et al. 2007. Neuropsychological dysfunction related to earlier occupational exposure to mercury vapor. Braz J Med Biol Res 40 (3):425-33. [/vc_column_text][/vc_column][/vc_row]","date_published":"2012-05-24T18:48:19","date_modified":"2025-12-26T03:57:06","authors":[{"name":"Dr. Richard Esquivel","url":"https://sanjosefuncmed.com/about/"}],"tags":["Brain & Neurologic Health"]},{"id":"https://sanjosefuncmed.com/bridging-lifestyle-medicine-and-systems-biology/","url":"https://sanjosefuncmed.com/bridging-lifestyle-medicine-and-systems-biology/","title":"Bridging Lifestyle Medicine and Systems Biology","summary":"San Jose Functional Medicine specializes in Functional Medicine, an emerging science-based medicine that approaches the body from a &#8216;systems biology’ pe","content_text":"San Jose Functional Medicine specializes in Functional Medicine, an emerging science-based medicine that approaches the body from a &#8216;systems biology’ perspective. The focus is on identifying the key physiologic mechanisms in the body that result in the patient’s signs and symptoms and directing the treatment towards these underlying mechanisms with science-based nutritional (ie: herbal or botanical) substances. This is accomplished through extensive laboratory testing, and various health assessment questionnaires. Our friendly and caring office staff takes care of all the details &#8212; ensuring that each visit is a pleasant experience. Please do not hesitate to contact us with any questions or concerns you may have.","date_published":"2012-05-15T19:25:03","date_modified":"2017-04-25T23:35:53","authors":[{"name":"Dr. Richard Esquivel","url":"https://sanjosefuncmed.com/about/"}],"tags":["Functional Medicine"]},{"id":"https://sanjosefuncmed.com/common-chemical-exposures-and-impacts-on-human-health/","url":"https://sanjosefuncmed.com/common-chemical-exposures-and-impacts-on-human-health/","title":"Common Chemical Exposures and Impacts on Human Health","summary":"What chemicals are you exposed to on a daily basis? What is your chemical load? Does it matter? Are you exposed to harmful chemicals right now? Are your kids ","content_text":"What is your chemical load? Does it matter? Are you exposed to harmful chemicals right now? Are your kids being exposed? What can you do about it? In this 4-segmented series of part 7, we examine the effects of common environmental chemicals and toxins on human health according to the most recent research, focusing on impacts on the immune system. In this first segment, we briefly review the increasing amounts of environmental pollutants we are exposed to on a daily basis and how they may be contributing to the escalating pandemic of allergy, immune disorders and inflammatory and neurodegenerative diseases. We examine the most important chemicals and toxins in our environment, according to the U.S. government, and review their potential health impacts according to the most recent literature available. In the next segment, we review the 12 most common endocrine disruptors according to the Environmental Working Group and 4 other important environmental toxins and summarize the potential health effects of these compounds according to the most recent research. We review the evidence showing how these compounds may be contributing to various hormonal and reproductive disorders, cognitive and neurological disorders, kidney and liver disease, immunological disorders and cancer. We also make recommendations on how you can protect you and your family against exposure to each of these toxic compounds. Key concepts for this issue Environmental Toxicity and Potential Impacts on Human Health Increasing Prevalence of Allergies and Immune-Related Disorders Polypharmacy in the U.S. The Environmental Pollutant-Neuro-Endocrine-Immune Connection Have These Chemicals Been Shown To Be Safe? Are Our Kids Being Exposed? Top 10 U.S. Government Priority List of Hazardous Substances Environmental Toxicity and Potential Impacts on Human Health We are living in a world that has changed dramatically just within our lifetimes. We are now exposed to countless chemicals, hybridized foods, genetically-modified foods, all of which are very immune-activating. There are now more than 84,000 different chemicals used in making products such as food, clothes, furniture, electronics and toys that we are potentially exposed to on a daily basis and about 1,500 new chemicals are introduced each year.[1] Environmental chemicals are linked with various cancers, obesity, diabetes, heart disease, brain degeneration, neurological disorders and almost every known health issue. But these links can be difficult to identify and the published data difficult for the average person to understand. Unless there is an acute exposure, exposure to chemical pollutants usually occurs gradually over a long period of time and effects tend to be cumulative. Since most people are exposed to a number of toxic chemicals simultaneously throughout their lives and the effects are cumulative, effects of specific environmental chemicals or toxins on human health are difficult for researchers to isolate. The exception to this is fetal exposure to toxins during critical periods of development, particularly during development of the brain and nervous system. As you can imagine, it is unethical to conduct human trials on the effects of toxic chemical exposure on humans, as is often done when studying the effects of pharmaceuticals, for example. Therefore, researchers tend to rely two types of studies: animal studies (often using rats or other rodents) which may be exposed to high amounts of toxins and epidemiological studies , meaning they look at populations of people in specific areas who are likely to have or are known to have had higher amounts of exposures to a specific type of chemical or toxin than the normal population. The other type of study that is being done more recently is looking at the developmental effects of chemical exposure of the pregnant mother to the developing fetus and how it impacts child development. Increasing Prevalence of Allergies and Immune-Related Disorders Studies show that food allergy among children in the U.S. is becoming more common over time. During the 10-year period from 1997 to 2006, food allergy rates increased significantly among both preschool-aged and older children.[2] A more recent large-scale study showed that prevalence of food allergy was 8.0% in 2011.[3] This means that food allergies affected approximately 1 in 12 children in 2011! Among children with food allergy, over 38% had a history of severe reactions, and over 30% had multiple food allergies. The most common food allergens were: peanut (25%), followed by milk (21%) and shellfish (17%).[4] The researchers of this 2011 study concluded the following: “Findings suggest that the prevalence and severity of childhood food allergy is greater than previously reported.”[5] Children with food allergy are more likely to have asthma or other allergic conditions Children with food allergy are two to four times more likely to have other immune-mediated related conditions such as asthma and other allergies, compared with children without food allergies. This is of great importance as children with coexisting food allergy and asthma may be more likely to experience anaphylactic reactions to foods and be at higher risk of death.[6] Recent data also shows hospitalizations with diagnoses related to food allergies have also increased among children. Hospital discharges with a diagnosis related to food allergy increased significantly (almost 4 times) over time from 1998–2000 through 2004–2006. From 2004 to 2006, there were an average of 9,537 hospital discharges per year with a diagnosis related to food allergy among children 0 to 17 years![7] Dietary Impacts on Our Health When we look at our diets, there are two startling trends. The first is our increasing exposure to pesticides, herbicides, antibiotics, pharmaceuticals and other chemicals and toxins in our food and water supply . The second is our increased consumption of processed foods, fast food and food no longer in a natural state. The standard American diet is not only very inflammatory but very immune-activating. Many Americans turn to fast food and processed foods on a regular basis and there are increasing amounts of genetically-modified foods (which are still not labelled as GMO in most states) and food products that are composed of very inexpensive low nutrient-dense food such as wheat and other grains which are attractive to many low-budget consumers. The focus of this article will be on the trend of increasing environmental chemical and toxic exposures and the impacts on our health. Polypharmacy in the U.S. In addition to environmental exposures, the increased use of pharmaceutical drugs is absolutely shocking. Among the startling statistics, the United States now consumes 80% of the world’s opioid pain medications and 99% of the world’s hydrocodone (semi-synthetic opioid). The milligram per person use of prescription opioids in the United States increased 402% (more than 4 times), between 1997 and 2007.[8a] According to the Centers for Disease Control (CDC) National Center for Health Statistics’ Data Brief, the percentage of Americans who took at least one prescription drug in the past month increased from 44% to 48% over the last 10 years. The use of two or more drugs increased from 25% to 31%. The use of five or more drugs increased from 6% to 11%. In 2007-2008, 1 out of every 5 children and 9 out of 10 older Americans reported using at least one prescription drug in the past month. [8b] The most commonly used types of drugs included: central nervous system (brain) stimulants for children, antidepressants for middle-aged adults, and cholesterol lowering drugs for older Americans. Spending for prescription drugs in the U.S. was $234.1 billion in 2008, which was more than double what was spent in 1999.[8c] Overall, the number of Americans on medications used to treat psychological and behavioral disorders has substantially increased since 2001; more than one‐in‐five adults was on at least one of these medications in 2010, up 22 percent from ten years earlier.[8d] According to the World Health Organization, in 1999, the 15% of the world’s population who live in high-income countries (like the U.S.) purchased and consumed about 90% of total medicines, by value. The market share of the USA alone rose from 18.4% of the world total in 1976 to over 52% in 2000![8e] This means that Americans are now consuming over one-half of the medications being used worldwide, by value! This polypharmacy model of various drugs has potentially diverse impacts on human physiology beyond known adverse reactions. But the potentially harmful effects of medications don’t stop there. Healthy animals used for human consumption are often treated with antibiotics to prevent disease and hormones to increase growth rate which have potential consequences on the health of the consumer. Additionally, studies show that many of these pharmaceutical drugs are making their way into our tap water along with environmental heavy metals, chemicals and toxins while standards of testing of these compounds and water quality varies significantly in each municipality across the country. The totality of these environmental chemicals, pollutants and synthetic compounds are unquestionably having an impact on our health. The Environmental Pollutant-Neuro-Endocrine-Immune Connection The combination of chronic exposure to immune-triggering pollutants, toxins and inflammatory foods has undoubtedly contributed to various endocrine-related (hormonal) disorders and affected our ability to reproduce healthy offspring. But there is increasing evidence that environmental compounds are contributing to the increase in chronic inflammatory conditions that people suffer from today. Many have theorized that the growing development of autoimmune disease, autism, neurodegenerative disease and other chronic inflammatory conditions may be the result of our recent immunoreactive environment.[8f-10] Environmental toxins are now being linked with neurodegenerative conditions such as Alzheimer’s and Parkinson’s disease.[11] The unprecedented levels of chemicals and heavy metals today, as well as hybridized, genetically-modified and industrially-processed foods, all activate the immune system toward a pro-inflammatory state. Have These Chemicals Been Shown To Be Safe? Another major problem we face in the U.S. is that only a minority of the synthetic compounds introduced to our environment have been researched individually, much less in conjunction with one another. The Environment Protection Agency (EPA) does not require testing on chemicals introduced to the market unless evidence of potential harm exists, which means testing seldom happens. “Once substances are suspected of contributing to harm, an administration agency has the burden to show risks or harms and their causes, which is an increasingly difficult demonstration. In the USA, the vast majority of substances enter commerce without any legally required testing (under the so-called ‘post-market’ laws). In 1984, less than 20% of all substances had been subject to pre-market testing and there has been little change since. The EPA approves about 90% of new chemicals and only a quarter of more than 80,000 chemicals have been tested for toxicity.” [12] Lax policies and regulations on commercially available chemicals and toxins in the U.S. have allowed for an environment that has potentially disastrous consequences on human health. “The legal system and government agencies are not effective in addressing the role of hazardous chemicals and human health”[13] “Concerns regarding potential risk to the human population from environmental sources are growing at a steady rate”[14] Are Our Children Being Exposed? No doubt our children are being exposed to chemicals and toxic compounds at an early age and these are impacting their development before they are even born. Studies are showing startling amounts of environmental chemicals and toxins in the blood supply of embryos during pregnancy! “Of the 287 chemicals we detected in umbilical cord blood, we know that 180 cause cancer in humans or animals, 217 are toxic to the brain and nervous system and 208 cause birth defects or abnormal development in animal tests”[15] More and more evidence is showing our children are not only exposed to these hazardous chemicals in their environment and food supply but are even exposed to extremely high amounts of them through the mother’s breast milk! “In the first nationwide tests for chemical fire retardants in the breast milk of American women, the Environmental Working Group (EWG) found unexpectedly high levels of these little-known neurotoxic chemicals in every participant tested” “The average level of brominated fire retardants in the milk samples was 75 times higher than the average for Swedish women and were at levels associated with toxic effects in several studies using laboratory animals.”[16] Laboratory tests—conducted by one of the world’s leading scientific authorities on fire retardants—found that in 19 of 20 U.S. families, concentrations of toxic fire retardants (PBDEs) were significantly higher in 1.5- to 4-year-old children than their mothers! In total, 11 different flame retardants were found in these children, and 86% of the time the chemicals were present at higher levels in the children than their mothers![17] In a 2004 paper entitled “A Dialogue on Chemicals and Children”, the World Health Organization made the following statement: “It is clear that children may be particularly at risk. Developing organisms, especially during embryonic and fetal periods, early years of life and puberty, go through “windows of susceptibility” during which they are particularly vulnerable to specific environmental stressors. Many of the chemicals known to cause adverse effects easily cross the placenta and can interfere with the growth and development of the fetus. Studies have documented that some solvents and pesticides can cause cancer and that lead, methyl mercury, polychlorinated biphenyls and some pesticides cause neurodevelopmental disorders. We may be conducting a large-scale experiment with children’s health.”[18] Most recently, in September 2013, two prestigious medical organizations – the American Congress of Obstetricians and Gynecologists and the American Society for Reproductive Medicine – said in a joint statement that “toxic chemicals in our environment harm our ability to reproduce, negatively affect pregnancies and are associated with numerous long-term health problems.” “Toxic chemicals have long-lasting reproductive health effects…prenatal exposure to certain chemicals is associated with stillbirth, miscarriage, birth defects, childhood cancers and impaired brain development in children.” [19] The focus of the remainder of this segment will be examining the top 10 environmental chemicals and toxins taken from the Center for Disease Control and Prevention’s (CDC’s) Agency for Toxic Substances and Disease Registry’s (ATSDR) 2011 Priority List of Hazardous Substances. This represents a list of substances “ which are determined to pose the most significant potential threat to human health due to their known or suspected toxicity and potential for human exposure”.[20] We will focus on common exposures of these hazardous compounds and potential impacts on human health. We will also provide simple things you can do immediately to reduce your and your family’s exposure to these hazardous compounds. Top 10 U.S. Government Priority List of Hazardous Substances Arsenic Lead Mercury Vinyl chloride Polychlorinated biphenyls (PCB) Benzene Cadmium Benzopyrene Polycyclic aromatic hydrocarbons Benzofluoranthene 1. Arsenic (As) Arsenic is a naturally occurring mineral that is found in high amounts in a variety of foods, particularly rice and poultry, due to human agricultural and farming practices. It is considered #1 in the “Top 10 U.S. Government Priority List of Hazardous Substances”. The U.S. Environmental Protection Agency maximum contaminant level (MCL) in drinking water is 10 µg/L; however, concentrations of over 3,000 µg/L (300 times this limit) have been found in water wells in the United States![21] In 2001, the National Academy of Sciences estimated that people drinking arsenic-contaminated water at 10 parts per billion would have a 1-in-300 risk of developing cancer over their lifetimes. Recent research suggests that people ingest about that much arsenic in a just a half-cup serving of rice, not an unusual amount for millions of Americans! [22] What are the health effects of arsenic? Arsenic is not only a potent human carcinogen (cancer-causing agent) but can also set up children for other health problems later in life. Inorganic arsenic is ranked by the International Agency for Research on Cancer (IARC) as a Group 1 carcinogen. Arsenic is a known carcinogen associated with skin, lung, bladder, kidney, and liver cancer. Dermatological, neurological, respiratory, cardiovascular, immunological, endocrine (hormonal) and childhood developmental effects have also been associated with arsenic exposure. Early-life exposure may be related to increased risks for several types of cancer and other diseases during adulthood. [23] Studies show exposures of low-to-moderate levels of arsenic (through contaminated tap water, for example) increase risk for the development of pre-malignant skin lesions, high blood pressure, neurological dysfunctions, and all-cause and chronic disease mortality. Arsenic exposure has also been linked to increased risks of internal cancers (described above), diabetes, cardiovascular disease, adverse pregnancy outcomes, and a decrease in children’s intellectual function. [24] The good news is the research also indicates that the risk of skin lesion due to arsenic exposure is modifiable by nutritional factors, such as folate and selenium status, lifestyle factors, including cigarette smoking and body mass index, and genetic polymorphisms in genes related to arsenic metabolism. This means you can decrease your risk of skin cancer by supplementing with folic acid and selenium and adopting healthy lifestyle habits such as quitting smoking and maintaining a healthy body weight.[25] Arsenic in baby food? Many rice-based foods, such as organic rice baby cereal, rice breakfast cereals, brown rice, white rice and some fruit juices have arsenic levels much higher than are allowed in drinking water. Rice absorbs arsenic from soil or water much more effectively than most plants. That’s in part because it is one of the only major crops grown in water-flooded conditions, which allows arsenic to be more easily taken up by its roots and stored in the grains.[26] Where does arsenic come from? The U.S. is the world’s leading user of arsenic, and since 1910 about 1.6 million tons have been used for agricultural and industrial purposes. Residues from the decades of use of lead-arsenate insecticides linger in agricultural soil today, even though their use was banned in the 1980s. Other arsenic-containing ingredients in animal feed to prevent disease and promote growth are still permitted. Moreover, fertilizer made from poultry waste can contaminate crops with inorganic arsenic.[27] It turns out that poultry feed is a major ongoing source of arsenic in the environment. While it might sound alarming that there’s arsenic in your chicken and turkey sandwiches, it’s just one consequence of the use of arsenic in the current poultry industry. Poultry producers often feed their birds antibiotics to combat parasites and enhance the bird’s pink color (for eye appeal to consumers), and one antibiotic commonly used contains arsenic. In addition, poultry waste is widely used as fertilizer, which of course finds its way right into nearby waterways, contaminating them as well as the food grown on those fields.[28] How to Avoid Exposure: Limit rice consumption and try out alternatives to rice such as quinoa, barley, grits/polenta, couscous or bulgur wheat. Limit poultry consumption and eat organic food whenever possible which may decrease but not eliminate arsenic exposure. What parents can do to reduce children’s exposure: For babies, try orange vegetables such as sweet potatoes and squash, bananas and avocados as first solid foods. Limit rice consumption. Do not drink rice milk in excess. Eliminate or limit fruit juices to a maximum of one-half cup a day.[29] 2. Lead (Pb) Lead is a naturally occurring heavy metal found in small amounts in the earth. Industrial activities such as mining, manufacturing, and the burning of fossil fuels are the major sources of environmental lead. Lead was previously used but banned in the U.S. in the manufacture of household paints in 1978 and in gasoline in 1996, which has dramatically reduced exposure. However, environmental exposure to lead in water, soil, and the food supply persists. The major sources of lead in drinking water are lead plumbing, contaminated soil carried into water by rain and wind, and wastewater from industries that use lead. Where does lead come from? Lead in soil can be deposited on or absorbed by plants from air pollution. Food can contain lead if these plants are consumed by humans or livestock or during food processing. Lead that gets in or on the plant cannot always be completely removed by washing or other steps in the processing of the food. The major exposure of lead in food is through fruits and grains, according to the Agency for Toxic Substances and Disease Registry. Lead can also get into food through food containers such as older pieces of china and pottery dishes, which are fairly rare.[30] What are the health effects of lead? According to a recent review on the effects of lead: “Lead, a systemic toxicant affecting virtually every organ system, primarily affects the central nervous system, particularly the developing brain. Consequently, children are at a greater risk than adults of suffering from the neurotoxic effects of lead. The ability of lead to pass through the blood-brain barrier is due in large part to its ability to substitute for calcium ions. Within the brain, lead-induced damage in the prefrontal cerebral cortex, hippocampus, and cerebellum can lead to a variety of neurological disorders, such as brain damage, mental retardation, behavioral problems, nerve damage, and possibly Alzheimer’s disease, Parkinson’s disease, and schizophrenia. Experimental studies have also shown that lead exposure may have genotoxic effects, especially in the brain, bone marrow, liver, and lung cells.”[31] In children, prenatal and postnatal exposure to lead, even at low levels, is associated with impaired cognitive function and mental development in infants and young children, including reduced IQ and academic achievement [32-36], behavior difficulties such as attention-deficit hyperactive disorder (ADHD)[37,38], and depression and anxiety[39]. Studies have also shown these effects may persist into adulthood.[40,41] Childhood lead exposure has also been associated with decreased brain volume in specific regions of the adult brain responsible for decision-making and mood regulation many years later after exposure.[42] How to Avoid Exposure: Wash your food before consumption. Avoid lead in paint (pre-1978). If you aren’t sure about the lead in your dishes, you should not use them for storing food. 3. Mercury (Hg) Mercury (Hg) is a common contaminant of fish and other seafood. A 1997 analysis of federal health warnings published by the Environmental Working Group (EWG) concluded that fish from more than 1,660 U.S. waterways are so contaminated with mercury that they should not be eaten or eaten only in limited amounts. It found that children and mothers-to-be are at highest risk, not only from fresh fish but from mercury contamination of supermarket products such as canned tuna, shrimp, fish sticks, even instant oatmeal! [43] On top of this, we may not be getting the most accurate safety information from our governmental agencies’ recommendations. According to a new EWG analysis of fish contaminant and nutrient data published two months ago (January, 2014), people who follow the federal government’s current guidelines on seafood consumption are likely to consume too much mercury or too few beneficial omega-3 fatty acids. [44] Why are fish so contaminated with mercury? Decades of industrial mercury emissions around the world have contaminated certain fish and seafood, particularly larger, long-lived, deep-water species. A landmark 2009 study by scientists from the U.S. Geological Survey (USGS) has documented how escalating mercury-laden air emissions, chiefly from coal-fired electrical power plants in Asia, are being transformed into methylmercury, which is increasingly polluting the North Pacific Ocean and contaminating tuna, swordfish and other seafood. The study predicts a 50% increase in the Pacific’s mercury level by the year 2050 if mercury emissions from power plants increase according to current projections! [45] What are the health effects of mercury exposure? Many studies show that high exposure to mercury induces changes in the central nervous system (brain), potentially resulting in irritability, fatigue, behavioral changes, tremors, headaches, hearing and cognitive loss, dysarthria (speaking disorder), incoordination, hallucinations, and death. In the cardiovascular system, mercury induces hypertension in humans and animals that has wide-ranging consequences, including alterations in endothelial function. Mercury exposure, even at low doses, affects endothelial and cardiovascular function.[46] Chronic exposure to mercury vapor can lead to toxic effects to the central nervous system (brain) and the kidneys. Tremor is considered to be the early neurological sign of poisoning by elemental mercury. In addition, damage to peripheral nerves may also occur. Workers exposed to mercury vapor may have abnormalities in sensory and peripheral nerve conduction. Elemental mercury vapor may affect the human immune system and can result in a decreased resistance to infection, cancers, or immune dysregulation that can induce the development of allergy or autoimmune disease.[47] Mercury exposure and children’s health Acute or chronic mercury (Hg) exposure can cause adverse effects during any period of childhood development. Mercury exposure is especially dangerous to the fetus, newborn infants and young children during critical windows when the brain and other organs are rapidly developing.[48] Studies show that mercury exposure can alter brain development in the fetus, leading to learning problems, reduced performance on intelligence tests and other health problems later in life. According to the CDC, 8% of U.S. women of childbearing age have levels of mercury in their blood that present developmental risks for their babies.[49] Here are some of the organ systems that have been shown to be impacted in children and infants from prenatal and postnatal mercury exposure. Neurological Effects In two large epidemiological studies in New Zealand [50,51] and the Faroe Islands [52-54] associations between prenatal mercury exposure and the neurological development of the children were demonstrated. Outcomes associated with prenatal mercury exposure included the loss of IQ points, and decreased performance of tests, including memory, attention, language, and spatial cognition.[55] Nephrotoxicity Inorganic mercury compounds are nephrotoxic (toxic to the kidneys) and can cause kidney damage in children.[56] Cardiovascular Toxicity Heart function alteration has been described in children associated with methylmercury exposure from seafood.[57] Carcinogenity High exposure to methylmercury is associated with leukemia among adults.[58] Methylmercury compounds are classified as possible carcinogens (cancer-causing agents) to humans (group 2B). Reproductive Toxicity One retrospective study examined the effect of methylmercury contamination on the sex ratio of offspring at birth and of fetuses at stillbirth. Due to the severe methylmercury pollution in Minamata, lower numbers of male offspring at birth were found as well as an increase in the quantity of male stillborn fetuses.[59] Immunotoxicity Mercury is likely to be immunotoxic, as shown in animal models.[60] The New England children’s Amalgam trial showed an immunotoxic effect in the form of a decline in responsiveness of T cells and monocytes (white blood cells of the immune system).[61] How to Avoid Exposure: Deep water fish are the most common sources of mercury in food. Limit your consumption of tuna (including canned tuna), swordfish, shrimp and fish sticks. Make sure your fish oil supplements are checked for mercury levels. Visit http://www.ewg.org/ for more information. 4. Vinyl Chloride (PVC) Vinyl chloride is a colorless organic gas with a sweet odor, and is used to make polyvinyl chloride (PVC) plastic and vinyl products. It is used in the manufacture of numerous products in building and construction, the automotive industry, electrical wire insulation and cables, piping, industrial and household equipment, medical supplies, and is depended upon heavily by the rubber, paper, and glass industries. Over 15 billion pounds were produced in the U.S. in 1995 alone! Vinyl chloride is a known human carcinogen Vinyl chloride is also a known genotoxicant, causing chemical alterations of DNA in tissues that may lead to cancer following exposure of humans and experimental animals. The primary target organ for vinyl chloride exposure is the liver. The association between liver cancer and vinyl chloride exposure is well documented for occupational exposures.[62] Noncancer liver pathologies have also been associated with vinyl chloride exposure. [63] Several studies in experimental animal models have demonstrated that early life exposure to vinyl chloride can increase susceptibility to cancer later in life. [64] Based on these data, the U.S. ATSDR has characterized fetuses, infants, and young children as a “highly susceptible population” for vinyl chloride exposure. Children are at high risk for exposure to vinyl chloride from air contaminated with vinyl chloride by emissions released from polyvinyl chloride (PVC) plastics production and manufacturing facilities, as well as some incinerators. Contamination of groundwater and drinking water with vinyl chloride-contaminated run-off from such manufacturing facilities is also a concern for exposure of children.[65] Vinyl, the most toxic plastic for children’s health Vinyl chloride, also known as vinyl plastic, is considered the most toxic plastic for children’s health and the environment. From production to use and disposal, vinyl releases a toxic cocktail of chemicals including dioxins, phthalates, mercury, PCBs, vinyl chloride, chlorine gas and numerous other substances harmful to our health, some of which are building up in our children’s bodies and food supply. Scientists have found certain vinyl chemicals linked to asthma, cancer, birth defects, learning and developmental disabilities, obesity, diabetes and other preventable chronic diseases. [66] How to Avoid Exposure: Remove all vinyl from your household, if any, including vinyl flooring or shower curtains, especially if you have children at home. This substance can evaporate into the air at home, unnecessarily exposing you and your family. Drink filtered water to avoid vinyl chloride in drinking water. 5. Polychlorinated Biphenyls (PCBs) Polychlorinated biphenyls (PCBs) are persistent organic pollutants (POPs) that have entered the environment through both use and disposal of these compounds. The environmental transport of PCBs is complex and nearly global in scale. For decades, PCBs were widely used as coolants and insulating fluids (transformer oil) for transformers and capacitors, such as those used in old fluorescent light ballasts, and electric motors. Due to PCBs’ environmental toxicity and classification as a persistent organic pollutant, PCB production was banned by the U.S. Congress in 1979 and by the Stockholm Convention on Persistent Organic Pollutants in 2001. However, despite active research spanning five decades, extensive regulatory actions, and an effective ban on their production since the 1970s, PCBs still persist in the environment and remain a focus of attention. [67] Health effects of PCBs According to the Environmental Protection Agency (EPA) website: “PCBs have been demonstrated to cause a variety of adverse health effects. PCBs have been shown to cause cancer in animals. PCBs have also been shown to cause a number of serious non-cancer health effects in animals, including effects on the immune system , reproductive system , nervous system , endocrine system and other health effects . Studies in humans provide supportive evidence for potential carcinogenic and non-carcinogenic effects of PCBs. The different health effects of PCBs may be interrelated, as alterations in one system may have significant implications for the other systems of the body. The body’s regulation of all of these systems is complex and interrelated. As a result, it is not surprising that PCBs can exert a multitude of serious adverse health effects.” [68] Endocrine-disrupting effects of persistent organic pollutants Here is an excerpt from one recent 2013 study on the endocrine-disrupting and neurological effects of persistent organic pollutants, such as PCBs: “Even though high doses of organic pollutants are toxic, relatively low concentrations have been reported to cause long-term alterations in functioning of individual organisms, populations and even next generations. Among these pollutants are dioxins, polychlorinated biphenyls (PCBs), pesticides, brominated flame retardants, plasticizers (bisphenol A and phthalates). In addition to toxic effects, they are able to interfere with hormone receptors, hormone synthesis or hormone conversion. Because these chemicals alter hormone-dependent processes and disrupt functioning of the endocrine glands, they have been classified as endocrine-disrupting chemicals (EDCs). Because certain EDCs are able to alter neural transmission and the formation of neural networks, the term neural-disrupting chemicals has been introduced, thus implicating EDCs in the etiology of neurological disorders. Recently, public concern has been focused on the effects of EDCs on brain function, concomitantly with an increase in neuropsychiatric disorders, including autism, attention deficit and hyperactivity disorder as well as learning disabilities and aggressiveness. Several lines of evidence suggest that exposure to EDCs is associated with depression and could result in neural degeneration.” (69) Neurological effects Several epidemiological studies provide evidence that PCB exposure during utero alters brain development and the onset of neurological disorders in the developing fetus.[70-73] Multiple studies in human populations have linked exposure to PCBs prior to birth and lower scores on tests of neurological function into infancy and childhood.[74-77] PCB exposure has also been implicated in the development of autism.[78] In a 2002 Michigan study that tested children at 11 years who were born to women who had eaten relatively large quantities of PCB-contaminated fish, the children most highly exposed to PCBs prior to birth suffered from neurologic deficits which included poorer recognition memory in infancy, lower scores on a preschool IQ test, and poorer verbal IQ and reading comprehension.[79]. Thyroid and endocrine-disrupting effects Many studies have shown the endocrine-disrupting effects of PCBs, particularly related to the thyroid.[80-83] A 2012 review of the literature concluded “there is now reasonably firm evidence that PCBs have thyroid-disrupting effects”. [84] Immunological effects Several epidemiological studies have shown evidence of immunological impacts of PCB exposure on developing fetuses.[85-88] One recent 2013 systematic review concluded: “Current epidemiological evidence suggests that early-life exposure to POPs can adversely influence immune and respiratory systems development.”[89] Cancer According to the U.S. Environmental Protection Agency: “Studies in animals provide conclusive evidence that PCBs cause cancer. Studies in humans raise further concerns regarding the potential carcinogenicity of PCBs. Taken together, the data strongly suggest that PCBs are probable human carcinogens.” [90] Exposure to PCBs There are two common sources of PCB exposure: farmed salmon and mother’s breast milk. Farmed salmon In 2003, the Environmental Working Group (EWG) released results of the most extensive tests to date of polychlorinated biphenyl (PCBs) levels in farmed salmon consumed in the United States. EWG found that the salmon purchased at 7 of 10 local grocery stores was so contaminated with PCBs that they raise cancer-risk concerns, relative to health standards of the U.S. Environmental Protection Agency (EPA).[91] The EWG analysis of government data also found that farmed salmon are likely the most PCB-contaminated protein source in the current U.S. food supply. Farmed salmon are fattened with ground fishmeal and fish oils that are high in PCBs. As a result, salmon farming operations that produce inexpensive fish unnaturally, concentrate PCBs and have a higher fat content. Farmed salmon contains 52 percent more fat than wild salmon, according to USDA data. EWG analysis of state-of-the-art fish consumption data shows that roughly 800,000 US adults are 100 times over their lifetime allowable cancer risk by eating this contaminated salmon![92] Mother’s breast milk Mother’s breast milk is known to be a major source of PCBs for infants but PCB exposure from breast milk in infants after birth does not appear to cause significant neurological effects. The risks of neurological effects due to PCB exposure are attributed to fetal exposure to PCBs during fetal development, not after birth. Therefore, breastfeeding is still recommended. “…nor is there any evidence demonstrating a clinically significant negative effect of postnatal exposure to PCBs via breast milk. To date the majority of studies conclude that despite substantially higher PCB loads among breastfed infants, breastfeeding is still preferable to formula feeding.”[93] How to Avoid Exposure: Choose wild and canned salmon instead of farmed, and eat an eight-ounce serving of farmed salmon no more than once a month. Make sure your fish oil supplements are checked by the manufacturer for PCB levels. Trim fat from fish before cooking, and choose broiling, baking, or grilling over frying, as these cooking methods allow the PCB-laden fat to cook off the fish.[94] 6. Benzene Benzene is a natural constituent of crude oil, and is one of the most elementary petrochemicals. Benzene is mainly used as a precursor to heavy chemicals, such as ethylbenzene and cumene, which are produced on a billion kilogram scale. Because it has a high octane number, it is an important component of gasoline, comprising a few percent of its mass. Most non-industrial applications have been limited by benzene’s carcinogenicity. Benzene is used mainly as an intermediate to make other chemicals. About 80% of benzene is consumed in the production of three chemicals, ethylbenzene, cumene, and cyclohexane. Its most widely produced derivative is ethylbenzene, precursor to styrene, which is used to make polymers and plastics.[95] Vapors from products that contain benzene, such as glues, paints, furniture wax, and detergents, can also be a source of exposure, although many of these have been modified or reformulated since the late 1970s to eliminate or reduce the benzene content. Air around hazardous waste sites or gas stations may contain higher levels of benzene. The petroleum constituents of primary interest to human health have been the aromatic hydrocarbons (i.e.: benzene, ethylbenzene, toluene, and xylenes). Outdoor air may contain low levels of benzene from automobile service stations, wood smoke, tobacco smoke, the transfer of gasoline, exhaust from motor vehicles, and industrial emissions. About 50% of the entire nationwide exposure to benzene results from smoking tobacco or from exposure to tobacco smoke.[96] Benzene is widely used to make other chemicals such as styrofoam, dyes, detergents, drugs, pesticides, and chemicals used in nylon and other synthetic fibers. In 2006, the Food and Drug Administration (FDA) announced it found high levels of benzene in several samples in a test of a small number of sodas and juice drinks. In a very limited sample of products, FDA found two popular drinks—Safeway Diet Orange and Crystal Light Sunrise Classic Orange—with up to 17 times more benzene than allowed in tap water, and three other products with benzene levels up to four times the drinking water limit. Many other products had detectable levels of the carcinogen.[97] This is particularly disturbing given that in 1990, the FDA learned that certain soft drinks marketed to children contain two ingredients, ascorbic acid (vitamin C) and either sodium benzoate or potassium benzoate, that can mix in the soda to form benzene.[98] Health effects of benzene Acute (short-term) inhalation exposure of humans to benzene may cause drowsiness, dizziness, headaches, as well as eye, skin, and respiratory tract irritation, and, at high levels, unconsciousness. Chronic (long-term) inhalation exposure has caused various disorders in the blood, including reduced numbers of red blood cells and aplastic anemia. Reproductive effects have been reported for women exposed by inhalation to high levels, and adverse effects on the developing fetus have been observed in animal tests. Increased incidence of leukemia (cancer of the tissues that form white blood cells) have been observed in humans occupationally exposed to benzene. Benzene has been classified by the EPA as a known human carcinogen for all routes of exposure. [99] How to Avoid Exposure: Avoid tobacco and inhalation of all smoke. Avoid inhalation of gasoline exhaust or emissions. Avoid unnecessary air pollution. Buy simple and natural cleaning products when possible. Eat organic whenever possible. 7. Cadmium Human exposures to environmental cadmium are primarily the result of fossil fuel combustion, phosphate fertilizers, natural sources, iron and steel production, cement production and related activities, nonferrous metals production, and municipal solid waste incineration. The use of cadmium is generally decreasing due to its toxicity and the replacement of nickel-cadmium batteries with nickel-metal hydride and lithium-ion batteries.[100] Tobacco smoking is the most important single source of cadmium exposure in the general population. On average, smokers have 4–5 times higher blood cadmium concentrations and 2–3 times higher kidney cadmium concentrations than non-smokers. Despite the high cadmium content in cigarette smoke, there seems to be little exposure to cadmium from passive smoking.[101] Many foods contain cadmium and contribute to the cadmium in modern populations including leafy vegetables, grains, breads, legumes, and kidney meat. Other foods that are rich in cadmium which can greatly increase the cadmium concentration in human bodies are liver, mushrooms, shellfish, mussels, cocoa powder and dried seaweed.[102] Health effects of cadmium Cadmium exposure is a risk factor associated with early atherosclerosis and hypertension, which can both lead to cardiovascular disease.[103] According to the Center for Disease Control and Prevention’s (CDC) Agency for Toxic Substances and Disease Registry (ATSDR), cadmium is a known human carcinogen and affects the following organ systems: cardiovascular (heart and blood vessels), developmental (effects during periods when organs are developing), gastrointestinal (digestive), neurological (nervous system), renal (urinary system or kidneys), reproductive (producing children), respiratory (from the nose to the lungs). [104,105] How to Avoid Exposure: Avoid tobacco and inhalation of all smoke. Be aware of cadmium-rich foods and over-consuming contaminated sources of these. 8., 9., 10. Benzopyrene, Benzofluoranthene and Polycyclic Aromatic Hydrocarbons (PAHs) Polycyclic aromatic hydrocarbons (PAHs) occur in oil, coal, and tar deposits, and are produced as byproducts of fuel burning (whether fossil fuel or biomass). They are potent atmospheric pollutants. PAHs are one of the most widespread organic pollutants. In addition to their presence in fossil fuels they are also formed by incomplete combustion of carbon-containing fuels such as wood, coal, diesel, fat, tobacco, and incense. Different types of combustion yield different distributions of PAHs in both relative amounts of individual PAHs and in which isomers are produced. PAH chemicals are often linked to oil spills. Following the massive Deepwater Horizon oil spill, scientists found PAH levels to be 40 times higher than before the area was affected. The researchers said that the compounds can enter the food chain through organisms such as plankton or fish. One PAH compound, benzopyrene , is notable for being the first chemical carcinogen to be discovered (and is one of many carcinogens found in cigarette smoke). The EPA has classified seven different PAH compounds as probable human carcinogens, including benzofluoranthene .[106] Health effects of polycyclic aromatic hydrocarbons (PAHs) High prenatal exposure to PAHs is associated with lower IQ and childhood asthma. [107] The Center for Children’s Environmental Health reports studies that demonstrate that exposure to PAH pollution during pregnancy is related to adverse birth outcomes including low birth weight, premature delivery, and heart malformations. Cord blood of exposed babies shows DNA damage that has been linked to cancer.[108] In a 2009 study, researchers from the University of Cincinnati and Columbia University, NY reported that traffic pollution causes genetic changes in the womb that increase a child’s risk of developing asthma. The culprit is prenatal exposure to polycyclic aromatic hydrocarbons (PAHs), which are created as byproducts of incomplete combustion of carbon-containing fuels such as gasoline. PAH levels are high in the air in heavy-traffic areas, posing health risk for inner-city neighborhoods and residential communities in proximity to major highways.[109] In addition, a 2012 Columbia University study in Environmental Health Perspectives linked prenatal exposure to these pollutants and eventual child behavioral outcomes. The study found that exposure to higher levels of PAHs was associated with a 24% higher score of anxiety/depression for children ages 6 to 7 than those with low exposure levels. Infants found to have elevated PAH levels in their umbilical cord blood were 46% more likely to eventually score highly on the anxiety/depression scale than those with low PAH levels in cord blood. [110] How to Avoid Exposure: Avoid tobacco and all smoke. Avoid inhalation of gasoline exhaust or emissions. Avoid unnecessary air pollution. References 1. Moreno MA, Furtner F, Rivara FP. Children’s environmental health. Arch Pediatr Adolesc Med . 2012 Oct;166(10):976. doi: 10.1001/2013.jamapediatrics.8. 2. Amy M. Branum, Susan L. Lukacs. Food Allergy Among U.S. Children: Trends in Prevalence and Hospitalizations. NCHS Data Brief . No.10. October 2008 3. Gupta RS 1 , Springston EE , Warrier MR , Smith B , Kumar R , Pongracic J , Holl JL . The prevalence, severity, and distribution of childhood food allergy in the United States. Pediatrics . 2011 Jul;128(1):e9-17. doi: 10.1542/peds.2011-0204. Epub 2011 Jun 20. 4. Gupta RS 1 , Springston EE , Warrier MR , Smith B , Kumar R , Pongracic J , Holl JL . The prevalence, severity, and distribution of childhood food allergy in the United States. Pediatrics . 2011 Jul;128(1):e9-17. doi: 10.1542/peds.2011-0204. Epub 2011 Jun 20. 5. Gupta RS 1 , Springston EE , Warrier MR , Smith B , Kumar R , Pongracic J , Holl JL . The prevalence, severity, and distribution of childhood food allergy in the United States. Pediatrics . 2011 Jul;128(1):e9-17. doi: 10.1542/peds.2011-0204. Epub 2011 Jun 20. 6. Amy M. Branum, Susan L. Lukacs. Food Allergy Among U.S. Children: Trends in Prevalence and Hospitalizations. NCHS Data Brief. No.10. October 2008 7. Amy M. Branum, Susan L. Lukacs. Food Allergy Among U.S. Children: Trends in Prevalence and Hospitalizations. NCHS Data Brief. No.10. October 2008 8a. http://www.theguardian.com/commentisfree/cifamerica/2011/jun/10/prescription-drug-abuse 8b. http://www.cdc.gov/nchs/data/databriefs/db42.htm 8c. http://www.cdc.gov/nchs/data/databriefs/db42.htm 8d. http://apps.who.int/medicinedocs/en/d/Js6160e/6.html 8e. http://apps.who.int/medicinedocs/documents/s19032en/s19032en.pdf 8f. Volk HE, Lurmann, F, Penfold B, Hertz-Picciotto I, McConnell R. Traffic-related air pollution, particulate matter and autism. JAMA Psychiatry. 2013 Jan;70(1):71-7 9. Calderon-Garcidenuas L, Mora-Tiscareno A, et al. White matter hyperintensities, systemic inflammation, brain growth and cognitive functions in children exposed to air pollution. J Alzheimer’s Dis. 2012;31(1):183-191 10. Powell JJ, Van de Water, Gershwin ME. Evidence for the role of environmental agents in the initiation or progression of autoimmune conditions. Environ Health Perspect. 1999 Oct;107 Suppl 5:667-72 11. Stein J, Schettler T, Rohrer B, Valenti M. Environmental threats to healthy aging. Greater Boston Phys for Soc. Respons.and Science and Environ. Health Network. July, 2008. http://www.agehealthy.org/pdf/GBPSRSEHN_HealthyAging1017.pdf 12. Cranor C. The legal failure to prevent subclinical developmental toxicity. Basic Clin Pharmacol Toxicol. 2008 Feb;102(2):267-73 13. Cranor C. The legal failure to prevent subclinical developmental toxicity. Basic Clin Pharmacol Toxicol. 2008 Feb;102(2):267-73 14. Jan AT, Ali A, Haq Q. Glutathione as an antioxidant in inorganic mercury induced nephrotoxicity. J Postgrad Med. 2011 Jan-Mar;57(1):72-77 15. Houlihan J, et al. Body burden: the pollution in newborns. July 14, 2005. Environmental Working Group. http//www.ewg.org/research/body-burden-pollution-newborns 16. Lunder S, Sharp R. Toxic fire retardants in human breast milk. Sept 23, 2003. Environmental Working Group. http//www.ewg.org/research/mothers-milk-0 17. http://www.ewg.org/research/fire-retardants-toddlers-and-their-mothers 18. http://www.who.int/bulletin/volumes/82/11/editorial31104html/en/ 19. http://www.acog.org/About_ACOG/ACOG_Departments/Health_Care_for_Underserved_Women/Toxic_Environmental_Agents_Infographic 20. http://www.atsdr.cdc.gov/SPL/index.html 21. Marisa F. Naujokas, Beth Anderson, Habibul Ahsan, H. Vasken Aposhian, Joseph H. Graziano, Claudia Thompson, William A. Suk. The Broad Scope of Health Effects from Chronic Arsenic Exposure: Update on a Worldwide Public Health Problem . Environ Health Perspect. 2013 March; 121(3): 295–302. Published online 2013 January 3. doi: 10.1289/ehp.1205875 22. http://www.ewg.org/enviroblog/2012/09/getting-arsenic-out-your-and-your-kids-diet 23. Marisa F. Naujokas, Beth Anderson, Habibul Ahsan, H. Vasken Aposhian, Joseph H. Graziano, Claudia Thompson, William A. Suk. The Broad Scope of Health Effects from Chronic Arsenic Exposure: Update on a Worldwide Public Health Problem . Environ Health Perspect. 2013 March; 121(3): 295–302. Published online 2013 January 3. doi: 10.1289/ehp.1205875 24. Yu Chen, Faruque Parvez, Mary Gamble, Tariqul Islam, Alauddin Ahmed, Maria Argos, Joseph H. Graziano, Habibul Ahsan. Arsenic Exposure at Low-to-Moderate Levels and Skin Lesions, Arsenic Metabolism, Neurological Functions, and Biomarkers for Respiratory and Cardiovascular Diseases: Review of Recent Findings from the Health Effects of Arsenic Longitudinal Study (HEALS) in Bangladesh . Toxicol Appl Pharmacol. Author manuscript; available in PMC 2014 January 28. Published in final edited form as: Toxicol Appl Pharmacol. 2009 September 1; 239(2): 184–192. Published online 2009 January 27. 25. Yu Chen, Faruque Parvez, Mary Gamble, Tariqul Islam, Alauddin Ahmed, Maria Argos, Joseph H. Graziano, Habibul Ahsan. Arsenic Exposure at Low-to-Moderate Levels and Skin Lesions, Arsenic Metabolism, Neurological Functions, and Biomarkers for Respiratory and Cardiovascular Diseases: Review of Recent Findings from the Health Effects of Arsenic Longitudinal Study (HEALS) in Bangladesh . Toxicol Appl Pharmacol. Author manuscript; available in PMC 2014 January 28. Published in final edited form as: Toxicol Appl Pharmacol. 2009 September 1; 239(2): 184–192. Published online 2009 January 27. 26. http://www.ewg.org/enviroblog/2012/09/getting-arsenic-out-your-and-your-kids-diet 27. http://www.consumerreports.org/cro/magazine/2012/11/arsenic-in-your-food/index.htm 28. http://www.ewg.org/enviroblog/2010/11/turkeys-arsenic-arsenic-out 29. http://www.ewg.org/release/reducing-arsenic-your-diet 30. http://extoxnet.orst.edu/faqs/foodcon/lead.htm 31. Talia Sanders, Yiming Liu, Virginia Buchner, Paul B. Tchounwou. Neurotoxic Effects and Biomarkers of Lead Exposure: A Review . Rev Environ Health. Author manuscript; available in PMC 2010 April 22. Published in final edited form as: Rev Environ Health. 2009 Jan–Mar; 24(1): 15–45. 32. Wieslaw Jedrychowski, Frederica P. Perera, Jeffery Jankowski, Dorota Mrozek-Budzyn, Elzbieta Mroz, Elzbieta Flak, Susan Edwards, Anita Skarupa, Ilona Lisowska-Miszczyk. Very Low Prenatal Exposure to Lead and Mental Development of Children in Infancy and Early Childhood: Krakow Prospective Cohort Study . Neuroepidemiology . 2009 April; 32(4): 270–278. Published online 2009 February 18. doi: 10.1159/000203075 33. Meeyoung O. Min, Lynn T. Singer, H. Lester Kirchner, Sonia Minnes, Elizabeth Short, Zehra Hussain, Suchitra Nelson. Cognitive Development and Low-Level Lead Exposure in Poly-Drug Exposed Children Neurotoxicol Teratol. Author manuscript; available in PMC 2010 July 1. Published in final edited form as: Neurotoxicol Teratol . 2009; 31(4): 225–231. Published online 2009 April 2. doi: 10.1016/j.ntt.2009.03.002 34. Roberto G Lucchini, Silvia Zoni, Stefano Guazzetti, Elza Bontempi, Serena Micheletti, Karin Broberg, Giovanni Parrinello, Donald R Smith. Inverse association of intellectual function with very low blood lead but not with manganese exposure in Italian adolescents . Environ Res. Author manuscript; available in PMC 2013 October 1. Published in final edited form as: Environ Res. 2012 October; 118: 65–71. Published online 2012 August 24. doi: 10.1016/j.envres.2012.08.003 35. Canfield RL, et al. Intellectual impairment in children with blood lead concentrations below 10 microg per deciliter. N Engl J Med. 2003;348:1517–26. 36. Lanphear BP, et al. Low-level environmental lead exposure and children’s intellectual function: an international pooled analysis. Environ Health Perspect. 2005;113:894–9. 37. Paul A. Eubig, Andréa Aguiar, Susan L. Schantz. Lead and PCBs as Risk Factors for Attention Deficit/Hyperactivity Disorder . Environ Health Perspect. 2010 December; 118(12): 1654–1667. Published online 2010 September 9. doi: 10.1289/ehp.0901852. 38. Nigg JT, et al. Low blood lead levels associated with clinically diagnosed attention-deficit/hyperactivity disorder and mediated by weak cognitive control. Biol Psychiatry . 2008;63:325–31. 39. Ki-Do Eum, Susan A. Korrick, Jennifer Weuve, Olivia Okereke, Laura D. Kubzansky, Howard Hu, Marc G. Weisskopf. Relation of Cumulative Low-Level Lead Exposure to Depressive and Phobic Anxiety Symptom Scores in Middle-Age and Elderly Women . Environ Health Perspect . 2012 June; 120(6): 817–823. Published online 2012 February 29. doi: 10.1289/ehp.1104395 40. Mazumdar M, et al. Prenatal Lead Levels, Plasma Amyloid beta Levels and Gene Expression in Young Adulthood. Environ Health Perspect 2012 41. Needleman HL, et al. The long-term effects of exposure to low doses of lead in childhood. An 11-year follow-up report. N Engl J Med . 1990;322:83–8. 42. Kim M Cecil, Christopher J Brubaker, Caleb M Adler, Kim N Dietrich, Mekibib Altaye, John C Egelhoff, Stephanie Wessel, Ilayaraja Elangovan, Richard Hornung, Kelly Jarvis, Bruce P Lanphear. Decreased Brain Volume in Adults with Childhood Lead Exposure . PLoS Med. 2008 May; 5(5): e112. Published online 2008 May 27. doi: 10.1371/journal.pmed.0050112 43. http://www.ewg.org/research/catching-limit/news-release-epa-16-million-kids-moms-risk 44. http://www.ewg.org/research/us-gives-seafood-eaters-flawed-advice-on-mercury-contamination-healthy-omega-3s 45. http://www.ewg.org/news/news-releases/2009/05/06/mercury-fish-predicted-soar 46. Bruna Fernandes Azevedo, Lorena Barros Furieri, Franck Maciel Peçanha, Giulia Alessandra Wiggers, Paula Frizera Vassallo, Maylla Ronacher Simões, Jonaina Fiorim, Priscila Rossi de Batista, Mirian Fioresi, Luciana Rossoni, Ivanita Stefanon, María Jesus Alonso, Mercedes Salaices, Dalton Valentim Vassallo. Toxic Effects of Mercury on the Cardiovascular and Central Nervous Systems . J Biomed Biotechnol . 2012; 2012: 949048. Published online 2012 July 2. doi: 10.1155/2012/949048 47. Jung-Duck Park, Wei Zheng. Human Exposure and Health Effects of Inorganic and Elemental Mercury . J Prev Med Public Health. 2012 November; 45(6): 344–352. Published online 2012 November 29. doi: 10.3961/jpmph.2012.45.6.344 48. Stephan Bose-O’Reilly, Kathleen M. McCarty, Nadine Steckling, Beate Lettmeier. Mercury Exposure and Children’s Health . Curr Probl Pediatr Adolesc Health Care. Author manuscript; available in PMC 2011 May 17. Published in final edited form as: Curr Probl Pediatr Adolesc Health Care. 2010 September; 40(8): 186–215. doi: 10.1016/j.cppeds.2010.07.002 49. http://www.ewg.org/news/news-releases/2003/12/09/fda-advisory-panel-discuss-whether-tell-women-about-mercury 50. Kjellstrom T, Kennedy P, Wallis S, Mantell C. Physical and Mental Development of Children with Prenatal Exposure to Mercury from Fish. Stage I: Preliminary Tests at Age 4. National Swedish Environmental Protection Board; Solna, Sweden: 1986. 51. Kjellstrom T, Kennedy P, Wallis S, Stewart A, Friberg L, Lind B. Physical and Mental Development of Children with Prenatal Exposure to Mercury from Fish. Stage II: Interviews and Psychological Tests at Age 4. National Swedish Environmental Protection Board; Solna, Sweden: 1989. 52. Grandjean P, Weihe P, Jorgensen PJ, Clarkson T, Cernichiari E, Videro T. Impact of maternal seafood diet on fetal exposure to mercury, selenium, and lead. Arch Environ Health. 1992;47:185–95. 53. Grandjean P, Weihe P, White RF. Milestone development in infants exposed to methylmercury from human milk. Neurotoxicology . 1995;16:27–33. 54. Grandjean P, Weihe P, White RF, Debes F, Araki S, Yokoyama K, et al. Cognitive deficit in 7-year-old children with prenatal exposure to methylmercury. Neurotoxicol Teratol. 1997;19:417–28. 55. Stephan Bose-O’Reilly, Kathleen M. McCarty, Nadine Steckling, Beate Lettmeier. Mercury Exposure and Children’s Health . Curr Probl Pediatr Adolesc Health Care. Author manuscript; available in PMC 2011 May 17. Published in final edited form as: Curr Probl Pediatr Adolesc Health Care. 2010 September; 40(8): 186–215. doi: 10.1016/j.cppeds.2010.07.002 56. Stephan Bose-O’Reilly, Kathleen M. McCarty, Nadine Steckling, Beate Lettmeier. Mercury Exposure and Children’s Health . Curr Probl Pediatr Adolesc Health Care. Author manuscript; available in PMC 2011 May 17. Published in final edited form as: Curr Probl Pediatr Adolesc Health Care. 2010 September; 40(8): 186–215. doi: 10.1016/j.cppeds.2010.07.002 57. Grandjean P, Murata K, Budtz-Jorgensen E, Weihe P. Cardiac autonomic activity in methylmercury neurotoxicity: 14-year follow-up of a Faroese birth cohort. J Pediatr. 2004;144:169–76. 58. Yorifuji T, Tsuda T, Kawakami N. Age standardized cancer mortality ratios in areas heavily exposed to methyl mercury. Int Arch Occup Environ Health. 2007;80:679–88. 59. Sakamoto M, Nakano A, Akagi H. Declining Minamata male birth ratio associated with increased male fetal death due to heavy methylmercury pollution. Environ Res. 2001;87:92–8. 60. World Health Organization Principles and methods for assessing autoimmunity associated with exposure to chemicals. Environmental Health Criteria. 2006;236:1–333. 61. Shenker BJ, Maserejian NN, Zhang A, McKinlay S. Immune function effects of dental amalgam in children: a randomized clinical trial. J Am Dent Assoc. 2008;139:1496–505. 62. Sherman M . Vinyl chloride and the liver. J Hepatol. 2009 Dec;51(6):1074-81. doi: 10.1016/j.jhep.2009.09.012. Epub 2009 Oct 1. 63. Sherman M . Vinyl chloride and the liver. J Hepatol. 2009 Dec;51(6):1074-81. doi: 10.1016/j.jhep.2009.09.012. Epub 2009 Oct 1. 64. http://www.epa.gov/teach/chem_summ/VC_summary.pdf 65. http://www.epa.gov/teach/chem_summ/VC_summary.pdf 66. http://chej.org/backtoschool2013/ 67. http://en.wikipedia.org/wiki/Polychlorinated_biphenyls#United_States 68. http://www.epa.gov/epawaste/hazard/tsd/pcbs/pubs/effects.htm 69. Kajta M, Wójtowicz AK. Impact of endocrine-disrupting chemicals on neural development and the onset of neurological disorders. Pharmacol Rep. 2013;65(6):1632-9. 70. Crinnion WJ. Polychlorinated biphenyls : persistent pollutants with immunological, neurological, and endocrinological consequences. Altern Med Rev . 2011 Mar;16(1):5-13. Review. 71. Faroon O, Jones D, de Rosa C. Effects of polychlorinated biphenyls on the nervous system. Toxicol Ind Health. 2000 Sep;16(7-8):305-33. Review. 72. Jones DC, Miller GW. The effects of environmental neurotoxicants on the dopaminergic system: A possible role in drug addiction. Biochem Pharmacol . 2008 Sep 1;76(5):569-81. doi: 10.1016/j.bcp.2008.05.010. Epub 2008 May 20. Review. 73. Carpenter DO. Polychlorinated biphenyls (PCBs): routes of exposure and effects on human health. Rev Environ Health. 2006;21:1–23. 74. Schantz SL, Widholm JJ, Rice DC. Effects of PCB exposure on neuropsychological function in children. Environ Health Perspect. 2003;111:357–576. 75. Stewart P, Reihman J, Gump B, Lonky E, Darvill T, Pagano J. Response inhibition at 8 and 9 1/2 years of age in children prenatally exposed to PCBs. Neurotoxicol Teratol. 2005;27:771–80. 76. Jacobson JL, Jacobson SW. Prenatal exposure to polychlorinated biphenyls and attention at school age. J Pediatr. 2003;143:780–788. 77. Ribas-Fitó N, Sala M, Kogevinas M, Sunyer J. Polychlorinated biphenyls (PCBs) and neurological development in children: a systematic review. J Epidemiol Community Health. 2001 Aug;55(8):537-46. Review. 78. Pessah IN, Seegal RF, Lein PJ, LaSalle J, Yee BK, Van De Water J, Berman RF. Immunologic and neurodevelopmental susceptibilities of autism. Neurotoxicology . 2008 May;29(3):532-45. doi: 10.1016/j.neuro.2008.02.006. Epub 2008 Feb 23. Review. 79. Jacobson JL, Jacobson SW. Association of prenatal exposure to an environmental contaminant with intellectual function in childhood. J Toxicol Clin Toxicol. 2002;40(4):467-75. 80. Crinnion WJ. Polychlorinated biphenyls : persistent pollutants with immunological, neurological, and endocrinological consequences. Altern Med Rev . 2011 Mar;16(1):5-13. Review. 81. Jugan ML, Levi Y, Blondeau JP. Endocrine disruptors and thyroid hormone physiology. Biochem Pharmacol. 2010 Apr 1;79(7):939-47. doi: 10.1016/j.bcp.2009.11.006. Epub 2009 Nov 12. Review. 82. Boas M, Main KM, Feldt-Rasmussen U. Environmental chemicals and thyroid function: an update. Curr Opin Endocrinol Diabetes Obes. 2009 Oct;16(5):385-91. doi: 10.1097/MED.0b013e3283305af7. Review. 83. Massart F, Meucci V. Environmental thyroid toxicants and child endocrine health. Pediatr Endocrinol Rev. 2007 Sep;5(1):500-9. 84. Boas M, Feldt-Rasmussen U, Main KM. Thyroid effects of endocrine disrupting chemicals. Mol Cell Endocrinol. 2012 May 22;355(2):240-8. doi: 10.1016/j.mce.2011.09.005. Epub 2011 Sep 10. Review. 85. Crinnion WJ. Polychlorinated biphenyls : persistent pollutants with immunological, neurological, and endocrinological consequences. Altern Med Rev . 2011 Mar;16(1):5-13. Review. 86. White SS, Birnbaum LS. An overview of the effects of dioxins and dioxin-like compounds on vertebrates, as documented in human and ecological epidemiology. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev . 2009 Oct;27(4):197-211. doi: 10.1080/10590500903310047. Review. 87. Pessah IN, Seegal RF, Lein PJ, LaSalle J, Yee BK, Van De Water J, Berman RF. Immunologic and neurodevelopmental susceptibilities of autism. Neurotoxicology . 2008 May;29(3):532-45. doi: 10.1016/j.neuro.2008.02.006. Epub 2008 Feb 23. Review. 88. Nagayama J, Tsuji H, Iida T, Nakagawa R, Matsueda T, Hirakawa H, Yanagawa T, Fukushige J, Watanabe T. Immunologic effects of perinatal exposure to dioxins, PCBs and organochlorine pesticides in Japanese infants. Chemosphere. 2007 Apr;67(9):S393-8. Epub 2007 Jan 11. 89. Gascon M, Morales E, Sunyer J, Vrijheid M. Effects of persistent organic pollutants on the developing respiratory and immune systems: a systematic review. Environ Int. 2013 Feb;52:51-65. doi: 10.1016/j.envint.2012.11.005. Epub 2013 Jan 3. Review. 90. http://www.epa.gov/wastes/hazard/tsd/pcbs/pubs/effects.htm 91. http://www.ewg.org/news/news-releases/2003/07/30/first-ever-us-tests-farmed-salmon-show-high-levels-cancer-causing-pcbs 92. http://www.ewg.org/news/news-releases/2003/07/30/first-ever-us-tests-farmed-salmon-show-high-levels-cancer-causing-pcbs 93. Jorissen J. Literature review. Outcomes associated with postnatal exposure to polychlorinated biphenyls (PCBs) via breast milk. Adv Neonatal Care. 2007 Oct;7(5):230-7. Review. 94. http://www.ewg.org/research/pcbs-farmed-salmon/recommendations 95. http://en.wikipedia.org/wiki/Benzene 96. http://www.ewg.org/research/stolen-inventory/chemicals-concern 97. http://www.ewg.org/news/news-releases/2006/05/19/fda-finds-high-benzene-levels-limited-test-drinks 98. http://www.ewg.org/news/news-releases/2006/02/28/childrens-drinks-contain-ingredients-can-form-benzene 99. http://www.epa.gov/ttn/atw/hlthef/benzene.html 100. http://en.wikipedia.org/wiki/Cadmium 101. Jarup, L. Health effects of cadmium exposure—a review of the literature and a risk estimate. Scandinavian Journal of Work, Environment and Health . 1998. 24 : 11–51. 102. http://www.lenntech.com/periodic/elements/cd.htm 103. Cadmium Exposure can Induce Early Atherosclerotic Changes , Medinews Direct, 7 September 2009 104. http://www.atsdr.cdc.gov/substances/toxsubstance.asp?toxid=15 105. Soisungwan Satarug, Scott H. Garrett, Mary Ann Sens, Donald A. Sens. Cadmium , Environmental Exposure, and Health Outcomes . Environ Health Perspect. 2010 February; 118(2): 182–190. Published online 2009 October 5. doi: 10.1289/ehp.0901234 106. http://en.wikipedia.org/wiki/Polycyclic_aromatic_hydrocarbon 107. http://health.usnews.com/health-news/family-health/womens-health/articles/2009/07/20/exposure-to-common-pollutant-in-womb-might-lower-iq 108. http://www.ccceh.org/pdf-press/Time10-4-10.pdf 109. http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0004488 110. Perera, Frederica P.; Tang, Deliang; Wang, Shuang; Vishnevetsky, Julia (2012). Prenatal Polycyclic Aromatic Hydrocarbon (PAH) Exposure and Child Behavior at age 6-7. Environmental Health Perspectives . doi : 10.1289/ehp.1104315","date_published":"2014-04-02T05:42:41","date_modified":"2020-04-24T02:45:17","authors":[{"name":"Dr. Richard Esquivel","url":"https://sanjosefuncmed.com/about/"}],"tags":["Environmental Health"]},{"id":"https://sanjosefuncmed.com/common-symptoms-lab-markers-insulin-resistance/","url":"https://sanjosefuncmed.com/common-symptoms-lab-markers-insulin-resistance/","title":"Common Symptoms and Lab Markers of Insulin Resistance","summary":"Insulin resistance and diabesity are often accompanied by: Belly fat Fatigue after meals Sugar cravings (which may not be relieved by eating sweets) High trig","content_text":"Insulin resistance and diabesity are often accompanied by: Belly fat Fatigue after meals Sugar cravings (which may not be relieved by eating sweets) High triglycerides Low HDL High blood pressure Problems with blood clotting Increased inflammation These clues can often be picked up long before you ever get diabetes and may help you prevent the disease entirely. Why is this important? Because insulin resistance can cause substantial health risks even in the absence of full blown diabetes. Many people with pre-diabetes never get diabetes, but they are at high risk of many chronic diseases just the same. We could eliminate many of the long-term complications of diabesity if we simply addressed these symptoms and lab markers and diagnosed the problem much earlier in the disease process—that is to say, earlier in the continuum of diabesity. The Continuum Concept of Diabesity There are many stages of diabesity. Diabesity, like all disease, is a continuum that stretches from optimal health to full-blown illness. This is essential for you to understand if you want to fully grasp the concept of the development of diabesity and how to prevent or reverse this disease. Most medicine is based on clear-cut, on-or-off, yes-or-no diagnoses. Most conventional doctors are taught that you have a disease or you don’t, you have diabetes or you don’t. There are no gray areas. This approach is not only misguided, it is dangerous, because it misses the underlying causes and more subtle manifestations of illness. Practicing medicine this way completely ignores one of the most fundamental laws of physiology, biology, and disease: the continuum concept . There is a continuum from optimal health to hidden imbalance to serious dysfunction to disease. Anywhere along that continuum, we can intervene and reverse the process. The sooner we address the imbalance, the better, in almost all cases. When it comes to diabesity most doctors just follow blood sugar, which actually rises very late in the disease process. Conventional medicine tells us if your blood sugar is 90 or 110, you don’t have diabetes; if it is over 126, you do have diabetes. But these distinctions are completely arbitrary, and they do nothing to help treat impending problems. Given our current level of scientific understanding of diabesity , this concept of watching and waiting until more serious disease occurs is very unfortunate, misguided, and in some cases it’s deadly. It is also why diabesity is so woefully and inadequately diagnosed and treated. Millions of Americans are suffering needlessly from chronic symptoms, including chronic pain. Remember that hyperinsulinemia (elevated insulin in the blood) results in chronic inflammation, which manifests as chronic pai n. Nearly half of all diabetics are undiagnosed. Nearly all of the 100 million Americans with pre-diabetes are undiagnosed. Most Doctors Take a “Wait and See” Attitude Why are all these patients undiagnosed? Most doctors are not diagnosing it, or when they do, they don’t know what to do about it in the early stages, because there is no good drug treatment. Most doctors just take a “wait and see” attitude and wait until the patient requires medications. They know that diet and exercise are important but don’t know what else to do with them except to recommend a weight loss program. As the problem advances, these patients require more and more medications because the medications they are on are not addressing the underlying problem. And they don’t tell their patients they should plan to be on these medications the rest of their life unless they change their diet or lifestyle. The truth is the road to diabetes starts as early as childhood.(1) We now know that there is an epidemic of type 2 diabetes in children as young as eight years old (2), and pediatric diabetic specialists who used to only care for type 1 diabetes, now find their offices are overwhelmed with cases of type 2 diabetes. Research is now showing by the time you get diagnosed with diabetes, your problems with insulin and blood sugar could have been detected twenty to thirty years earlier.(3) That is, if you knew where to look, which most doctors are not trained to do. The other problem with conventional medicine is, even after the disease is diagnosed, the focus of the treatment is directed toward suppressing the symptoms and risk factors, rather than addressing the underlying cause. References (1) Nelson RA, Bremer AA. Insulin Resistance and Metabolic Syndrome in the Pediatric Population. Metab Syndr Relat Disord. 2009 Nov 29. (2) Silverstein JH, Rosenbloom AL. Type 2 diabetes in children. Curr Diab Rep. 2001 Aug;1(1):19-27. Review. (3) http://drhyman.com/blog/conditions/the-diabesity-epidemic-part-ii-why-conventional-medicine-makes-things-worse/","date_published":"2012-06-12T06:55:59","date_modified":"2020-04-19T22:13:31","authors":[{"name":"Dr. Richard Esquivel","url":"https://sanjosefuncmed.com/about/"}],"tags":["Metabolic Health"]},{"id":"https://sanjosefuncmed.com/delaying-degenerative-diseases-aging/","url":"https://sanjosefuncmed.com/delaying-degenerative-diseases-aging/","title":"Delaying the Degenerative Diseases of Aging","summary":"“The future of healthcare will be focused on, not anti-aging research, but genomic protection with lifestyle medicine” Jeffrey Bland, Ph.D. Have you ever noti","content_text":"“The future of healthcare will be focused on, not anti-aging research, but genomic protection with lifestyle medicine” Jeffrey Bland, Ph.D. Have you ever noticed that some people look young for their age? Have you seen people that look much older than they actually are? Why is that? Are there internal mechanisms in the body that promote accelerated aging? If so, can we influence these mechanisms through our diet and lifestyle choices or are they genetically determined? Researchers are now studying the aging process in living organisms and the factors that influence those mechanisms that lead to accelerated aging and the degenerative diseases of aging, such as heart disease, diabetes, stroke, osteoarthritis, osteoporosis, autoimmune disease, dementias and cancer . What researchers are finding is that these mechanisms that are driving these disease processes are largely related to diet and lifestyle choices and environmental factors . Genetics alone plays a much smaller role in one’s risk of developing most degenerative diseases than previously believed. It is estimated that only 10% of the chronic diseases seen in the U.S. (heart disease, diabetes and arthritis) which occur in the adult populations have a significant genetic component.(1) There are genetic diseases but in 90% of all chronic disease, it is the interaction between diet, lifestyle and environmental factors on our genes that determine health or disease development. The focus of this research is ultimately aimed at identifying these mechanisms that lead to accelerated aging and how these mechanisms can be slowed down through dietary and lifestyle choices. This is the concept of biological aging . Delaying the Degenerative Diseases of Aging Bruce Ames, Ph.D., is a professor of biochemistry and molecular biology at U.C. Berkeley. He has been studying the aging process for over 4 decades. His research focuses on cancer and aging and he has authored over 500 scientific publications. He is among the few hundred most-cited scientists in all fields. His focus has been on mitochondrial dysfunction and genomic stability and how these concepts affect biological aging. His research has shown that mitochondrial decay or dysfunction leads to accelerated aging and the degenerative diseases we see in the elderly. He has also pioneered the field of genomic stability (the ability to maintain the genome and prevent damage to the DNA). Damage to DNA is associated with many of the degenerative diseases associated with aging. Let’s take a closer look at what these fields of study are all about and what Dr. Ames’ and his colleagues’ research is showing. For those that are interested in this topic, here is an interesting 30 min. video of Dr. Ames lecturing on the topic of delaying the degenerative diseases of aging: Bruce Ames, Ph.D. Lectures on Aging The Mitochondria “The mitochondria, often referred to as “the power house of the cell”, are the source of at least 90% of the energy generated in the cell. The majority of this energy (80%) is produced as ATP by oxidative phosphorylation. A single cell can contain from 200 to 2,000 mitochondria. The number of mitochondria in specific cell types varies considerably, although within a given cell type the number is closely regulated.” (2) Mitochondria are the organelles of the cell that produce the majority of the body’s energy. Think of the mitochondria as the “energy-producing factories” of the body. This is where ATP is generated, which is the body’s energy “currency”. ATP is then used by the cells to fuel cellular processes. Oxygen “accepts” free electrons as part of cellular metabolism in the production of ATP. As a result of this process oxygen radicals or reactive oxygen species (ROS) are formed which have the potential of causing damage to the mitochondria and the organelles of the cell, including the DNA. Fortunately, our bodies have an antioxidant system built in, which works to neutralize these free oxygen radicals and prevent damage to the cell (when they are provided with the necessary micronutrients). Mitochondrial Decay Dr. Ames’ research found as the mitochondria age, they give out more and more oxygen radicals. These reactive oxygen species (ROS) are more prone to damage the mitochondria and the DNA as we age. Mitochondria are very vulnerable to oxidative damage. Increasing evidence is showing that mitochondrial decay drives the biological aging process. As the mitochondria become damaged, they are unable to produce ATP to fuel the cellular processes of other cells, tissues and organs. This leads to organ dysfunction and accelerated aging . Protecting ourselves against damage to the mitochondria and DNA is key to slowing down the aging process. Dr. Ames research has been focused on identifying nutrients in our diet that are necessary to prevent mitochondrial damage. We will take a look at these micronutrients that have been identified to slow down aging later in this series. Genomic Stability “The results of this study illustrate the strong impact of a wide variety of micronutrients and their interactions on genome health, depending upon their level of intake” Michael Fenech, Ph.D. The genome (DNA where our genes are coded) is fairly stable but can become unstable under certain conditions of DNA damage. When DNA becomes damaged or defective, it is usually not a big problem. Again, our bodies have the capacity to repair damaged DNA when this occurs or “silence” genes which are defective so that DNA defects don’t continue to be replicated. The DNA repair ability of a cell is vital to the integrity of its genome and to its normal functioning and the functioning of the organism. This is the concept of genomic stability . However, this DNA repair system can become inadequate when DNA damage is excessive or when the micronutrients that are necessary for DNA repair are deficient. The replication of damaged or defective DNA leads to degenerative disease, according to Dr. Ames’ research. After his years of research, he has found, essentially, the reason why we are aging faster than we otherwise would, is because of our nutrient-deprived diets and consumption of low-quality food. We will see later that micronutrients play an important role in genomic stability . We will look at specific micronutrients that have been shown to protect the genome and delay or prevent the onset of degenerative disease later in this series. We will also take a look at the new field of nutrigenomics , which looks at how nutrients in food interact with our genes to produce healthy states or promote disease . How do we know how fast we are aging biologically? In part 2 of this series we will examine the c haracteristics and key biomarkers of biological aging. Stay tuned… References 1. Weatherall DJ. 1985. The New Genetics and Clinical Practice, Second Edition. Oxford: Oxford University Press 2. Lamson DW, Plaza SM. Mitochondrial factors in the pathogenesis of diabetes: A hypothesis for treatment. Alternative Medicine Review 2002;7(2):94-111","date_published":"2012-07-12T08:32:22","date_modified":"2020-04-16T10:05:03","authors":[{"name":"Dr. Richard Esquivel","url":"https://sanjosefuncmed.com/about/"}],"tags":["Functional Medicine"]},{"id":"https://sanjosefuncmed.com/diabetes-medication-increase-risk-death/","url":"https://sanjosefuncmed.com/diabetes-medication-increase-risk-death/","title":"Diabetes Medication Can Actually Increase Your Risk of Death","summary":"If you are diabetic, overweight, or suffer from insulin resistance, metabolic syndrome, or any of the other conditions conventional medicine associates with “","content_text":"If you are diabetic, overweight, or suffer from insulin resistance , metabolic syndrome, or any of the other conditions conventional medicine associates with “elevated blood sugar,” I want to share a startling new discovery with you: Lowering your blood sugar may increase your risk of death. These are the findings from an extraordinary new study that was recently published in The New England Journal of Medicine. This should have profound implications for the treatment of obesity, diabetes, and other related conditions but unfortunately, it probably won’t. The ACCORD Study: Revolutionizing Our Understanding of Diabesity In 2008, an extraordinary study was published in The New England Journal of Medicine. It is called the ACCORD study (1), and it is one of the most profound pieces of literature that exists regarding why conventional treatments for diabetes simply do not work and how they can actually lead to increased risk of death. In the study 10,000 patients with diabetes were designated to receive intensive or regular therapy to lower blood sugar. These patients were monitored and their risks of heart attack, stroke, and death were evaluated. The patients who had their blood sugar lowered the most had a higher risk of death. The patients who had their blood sugar lowered the most had a higher risk of death. How could this happen if, as we believe, elevated blood sugar is the cause of all the evils of diabetes? Why would lowering blood sugar lead to worse outcomes? Amazingly, the study had to be stopped after three and a half years because it was evident that the aggressive blood sugar lowering led to more deaths and more heart attacks. This completely debunks the way conventional medicine understands and treats diabetes. It’s a revolutionary study. Yet for those of us who have been working to understand the real causes of diabesity, it isn’t all that surprising. How could lowering blood sugar increase your risk of death? The reason is simple: Elevated blood sugar is actually a symptom of underlying metabolic, physiologic, and biochemical processes that are out of balance … and lowering blood sugar with medications does not address the underlying issues that gave rise to the high blood sugar in the first place. This may surprise you, but many of the methods used to lower blood sugar such as insulin or oral hypoglycemic drugs actually make the problem worse by increasing insulin levels. The higher levels of insulin in the blood (hyperinsulinemia) cause systemic inflammation and hormonal balances in the body which increase your risk of developing many other chronic diseases. Type 2 diabetes is a disease of too much , not too little, insulin. Insulin is the real driver of problems with diabesity. That means you don’t simply need more insulin in your blood to lower your blood sugar. Instead, what you need to do is treat the underlying causes that gave rise to the high blood sugar and insulin in the first place. The problem of insulin resistance must be addressed. This leaves us with a final question: How can we address the fundamental underlying problem of our bodies resisting the effects of our own insulin? Any hope we have for resolving this pandemic must use a new approach to the diagnosis and treatment of diabesity. That approach is called Functional Medicine . References (1) Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008 Jun 12;358(24):2545-59.","date_published":"2012-06-12T07:20:01","date_modified":"2020-04-19T22:17:08","authors":[{"name":"Dr. Richard Esquivel","url":"https://sanjosefuncmed.com/about/"}],"tags":["Metabolic Health"]},{"id":"https://sanjosefuncmed.com/diabetes-obesity/","url":"https://sanjosefuncmed.com/diabetes-obesity/","title":"Diabetes & Obesity","summary":"The diabesity epidemic: diabetes and obesity are now the #1 health problem in america today WHAT IS DIABESITY? Diabesity is the disturbance of metabolic healt","content_text":"The diabesity epidemic: diabetes and obesity are now the #1 health problem in america today WHAT IS DIABESITY? Diabesity is the disturbance of metabolic health that results from having a problem with blood sugar balance and an excess percentage of body fat. It can range from mild to severe, depending on the stage of the disease. Mild forms of this result from having slight or no apparent blood sugar problems and being “a little” overweight. Severe forms result in full blown diabetes and obesity. The term diabesity was coined due the close relationship between diabetes and obesity.(1) We are talking here about type 2 diabetes , as opposed to type 1 diabetes, which is an autoimmune disease and affects people from an early age, usually childhood. Being overweight significantly increases your risk for developing diabetes and diabetics are almost always overweight (except in type 1 diabetes). Nearly all people that are overweight (over 70% of adult Americans) already have pre-diabetes and have significant risks of disease and death simply from being overweight.(2) [/text_output][/vc_column_inner][/vc_row_inner][vc_row_inner padding_top=”0px” padding_bottom=”0px”][vc_column_inner fade_animation_offset=”45px” width=”2/3&#8243;][columnize id=”” class=”” style=””] Diabesity affects over 1.7 billion people worldwide. It is the single biggest global health epidemic of our time. The prevalence of type 2 diabetes in America has tripled since the 1980s. In 2010, there were 27 million Americans with diabetes (25% of whom were not diagnosed) and 67 million with pre-diabetes (90% of whom were not diagnosed). By 2015, researchers estimate 2.3 billion people worldwide will be overweight and 700 million will be obese. Researchers estimate pre-diabetes will affect 1 in 2 Americans by 2020, 90% of whom will not be diagnosed . The number of diabetics will increase from 1 in 10 Americans today to 1 in 3 by 2050! Our current approach to prevention and management is obviously not working because millions more are affected every year. Not too long ago, this health condition was extremely rare. How does this condition affect our overall health?[/columnize][/vc_column_inner][vc_column_inner fade_animation_offset=”45px” width=”1/3&#8243;][image src=”7469&#8243; alt=”” href=”” title=”” info_content=”” lightbox_caption=”” id=”” class=”” style=””][/vc_column_inner][/vc_row_inner][vc_row_inner padding_top=”0px” padding_bottom=”0px”][vc_column_inner fade_animation_offset=”45px” width=”1/1&#8243;][feature_headline type=”center” level=”h4&#8243; looks_like=”h4&#8243; id=”” class=”” style=””]DIABESITY: THE LEADING CAUSE OF CHRONIC DISEASE IN THE 21ST CENTURY[/feature_headline][/vc_column_inner][/vc_row_inner][vc_row_inner padding_top=”0px” padding_bottom=”0px”][vc_column_inner fade_animation_offset=”45px” width=”1/2&#8243;][text_output] Diabesity is the leading cause of most chronic disease we are now seeing in the 21st century. (3) Those with diabesity are at an increased risk of heart disease (4)(5), stroke, dementia (6), cancer (7), high blood pressure, blindness, and kidney failure. Diabetes is the most common cause of kidney failure. Damage to the peripheral nervous system (peripheral neuropathy) affects 60 to 70% of people with diabetes and can lead to permanent nerve damage of the hands and feet, poor digestion, carpal tunnel syndrome, erectile dysfunction, and other peripheral nerve problems. So this is a very serious disease which leads to other very serious conditions. [/text_output][/vc_column_inner][vc_column_inner fade_animation_offset=”45px” width=”1/2&#8243;][image src=”7497&#8243; alt=”” href=”” title=”” info_content=”” lightbox_caption=”” id=”” class=”” style=””][/vc_column_inner][/vc_row_inner][/vc_column][/vc_row][vc_row padding_top=”0px” padding_bottom=”0px”][vc_column fade_animation_offset=”45px” width=”1/2&#8243;][image src=”7502&#8243; alt=”” href=”” title=”” info_content=”” lightbox_caption=”” id=”” class=”” style=””][/vc_column][vc_column fade_animation_offset=”45px” width=”1/2&#8243;][text_output]Given all of this, you would think everyone would be asking the questions: Why is this happening? What has caused this diabesity epidemic? Why are our current approaches to the problem failing so miserably? And what new approaches can we take that would more effectively manage the problem?(1) These are the questions that everyone needs to know the answers to. Unfortunately, most conventional doctors today are not asking these questions. Whether you are suffering from a little extra weight around the middle or you have been diagnosed with metabolic syndrome or even type 2 diabetes, the fundamental underlying mechanism of all of these conditions is the same: insulin resistance .[/text_output][/vc_column][/vc_row][vc_row padding_top=”0px” padding_bottom=”0px”][vc_column fade_animation_offset=”45px” width=”1/1&#8243;][feature_headline type=”center” level=”h4&#8243; looks_like=”h4&#8243; id=”” class=”” style=””]DIABESITY: THE LEADING CAUSE OF CHRONIC DISEASE IN THE 21ST CENTURY[/feature_headline][/vc_column][/vc_row][vc_row padding_top=”0px” padding_bottom=”0px”][vc_column fade_animation_offset=”45px” width=”1/2&#8243;][text_output]You may be one among the millions of Americans who are suffering from this health condition that is now epidemic in our country. Your doctor might have diagnosed you with one of many seemingly different disorders, such as: Insulin resistance Pre-diabetes Metabolic syndrome Obesity Syndrome X Adult onset diabetes Type 2 diabetes [/text_output][/vc_column][vc_column fade_animation_offset=”45px” width=”1/2&#8243;][image src=”7511&#8243; alt=”” href=”” title=”” info_content=”” lightbox_caption=”” id=”” class=”” style=””][/vc_column][/vc_row][vc_row padding_top=”0px” padding_bottom=”0px”][vc_column fade_animation_offset=”45px” width=”1/1&#8243;][text_output] What he or she likely didn’t tell you is that all of these conditions are due to the same mechanism of disease–just with varying degrees of severity. The underlying cause of all these conditions is the same: insulin resistance . And because this condition results from the body’s inability to respond to insulin (the hormone that regulates blood sugar), the solution for all of them is also the same (and it’s not a drug). But first, let’s look at how people develop this condition.[/text_output][/vc_column][/vc_row][vc_row padding_top=”0px” padding_bottom=”0px”][vc_column fade_animation_offset=”45px” width=”1/1&#8243;][feature_headline type=”center” level=”h4&#8243; looks_like=”h4&#8243; id=”” class=”” style=””]HOW DO YOU DEVELOP INSULIN RESISTANCE?[/feature_headline][/vc_column][/vc_row][vc_row padding_top=”0px” padding_bottom=”0px”][vc_column fade_animation_offset=”45px” width=”1/2&#8243;][text_output] Insulin resistance occurs when your diet is full of empty calories and processed carbohydrates (which get broken down to glucose rapidly), sugar-sweetened beverages (sodas), and excess starches (like bread, pasta, rice, and potatoes), especially in the absence of protein. Insulin is the hormone produced by the pancreas in response to elevations of glucose in the blood, which directs the cells to absorb the excess glucose removing it from the blood. This has the effect of lowering glucose in the blood (blood glucose). Remember, the blood stream is the circulatory system which permeates and supplies every organ, tissue and cell of the body with the oxygen and nutrients they need to function. The proper regulation of blood sugar in the body is critical. Since every cell relies on adequate levels of glucose in the blood to function normally. If they fluctuate often or if they are high or low, this affects cellular metabolism and can have tremendous influence over human physiology and pathology (the development of disease).[/text_output][/vc_column][vc_column fade_animation_offset=”45px” width=”1/2&#8243;][image src=”7518&#8243; alt=”” href=”” title=”” info_content=”” lightbox_caption=”” id=”” class=”” style=””][/vc_column][/vc_row][vc_row padding_top=”0px” padding_bottom=”0px”][vc_column fade_animation_offset=”45px” width=”1/2&#8243;][image src=”7520&#8243; alt=”” href=”” title=”” info_content=”” lightbox_caption=”” id=”” class=”” style=””][/vc_column][vc_column fade_animation_offset=”45px” width=”1/2&#8243;][text_output]When you frequently eat carbohydrates that are rapidly broken down into glucose in the digestive tract and absorbed into the bloodstream, this causes elevations in insulin on a regular basis. When this happens, your cells slowly become resistant to the effects of insulin, sort of like how your kids become when you are constantly yelling at them to clean up their room. They start tuning you out and paying less attention to your calls. Sound familiar? The cells of the body respond similarly to insulin when it is constantly in the blood trying to get the cells to uptake the glucose and lower blood glucose levels. Over time, your pancreas needs to produce more and more insulin to do the same job of keeping your blood sugar within a certain range. This is how you develop insulin resistance.(8) [/text_output][/vc_column][/vc_row][vc_row padding_top=”0px” padding_bottom=”0px”][vc_column fade_animation_offset=”45px” width=”1/4&#8243;][image src=”7527&#8243; alt=”” href=”” title=”” info_content=”” lightbox_caption=”” id=”” class=”” style=””][/vc_column][vc_column fade_animation_offset=”45px” width=”3/4&#8243;][text_output] WHAT’S THE PROBLEM WITH HIGH AMOUNTS OF INSULIN? High insulin levels are the first sign of a problem. The higher your insulin levels are, the worse your insulin resistance. Excess insulin in the body causes chronic inflammation and as a result, your body ages and deteriorates more rapidly. Chronic hyperinsulinemia (excess insulin in the blood), accelerates biological aging. In fact, insulin resistance is the single most common health problem that leads to rapid and premature aging and all its resultant diseases including heart disease , stroke, dementia, and cancer.(9),(10) It is also leads to the #1 cause of infertility, called PCOS. [/text_output][/vc_column][/vc_row][vc_row padding_top=”0px” padding_bottom=”0px”][vc_column fade_animation_offset=”45px” width=”1/1&#8243;][columnize id=”” class=”” style=””] As your insulin levels increase it leads to symptoms such as: fatigue after meals cravings for sweets (and often even eating sweets does not relieve the cravings) increasing weight gain around the belly difficulty losing weight increased thirst increased appetite frequent urination [/columnize][/vc_column][/vc_row][vc_row padding_top=”0px” padding_bottom=”0px”][vc_column fade_animation_offset=”45px” width=”1/2&#8243;][image src=”7554&#8243; alt=”” href=”” title=”” info_content=”” lightbox_caption=”” id=”” class=”” style=””][/vc_column][vc_column fade_animation_offset=”45px” width=”1/2&#8243;][text_output] WHAT’S THE PROBLEM WITH HIGH AMOUNTS OF INSULIN? High insulin levels are the first sign of a problem. The higher your insulin levels are, the worse your insulin resistance. Excess insulin in the body causes chronic inflammation and as a result, your body ages and deteriorates more rapidly. Chronic hyperinsulinemia (excess insulin in the blood), accelerates biological aging. In fact, insulin resistance is the single most common health problem that leads to rapid and premature aging and all its resultant diseases including heart disease , stroke, dementia, and cancer.(9),(10) It is also leads to the #1 cause of infertility, called PCOS. [/text_output][/vc_column][/vc_row][vc_row padding_top=”0px” padding_bottom=”0px”][vc_column fade_animation_offset=”45px” width=”1/1&#8243;][text_output]RELATED ARTICLES: Common Symptoms and Lab Markers of Insulin Resistance and the Continuum Concept of Diabesity The Problem with Diabesity – Symptoms, Not Causes and The Diabesity Solution: Therapeutic Lifestyle Change Diabetes Medication Can Actually Increase Your Risk of Death The Functional Medicine Approach to Diabesity The Dietary Shifts that are Leading to Diabesity Obesity Trends Among U.S. Adults Between 1985 and 2010 The Science of Nutrigenomics: How Nutrients in Food Interact with our Genes References (1) http://drhyman.com/blog/conditions/the-diabesity-epidemic-part-i-how-diabetes-and-obesity-are-ravaging-america-today/ (2) Mark Hyman. The Blood Sugar Solution; Little, Brown and Company. 2012 (3) http://apps.nccd.cdc.gov/DDTSTRS/FactSheet.aspx (National Diabetes Fact Sheet 2007) (4) http://www.cdc.gov/diabetes/statistics/cvd/fig5.htm (5) Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002 Dec 4;288(21):2709-16. (6) Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology. 1999 Dec 10;53(9):1937-42. (7) Key TJ, Spencer EA, Reeves GK. Symposium 1: Overnutrition: consequences and solutions Obesity and cancer risk. Proc Nutr Soc. 2009 Dec 3:1-5. (8) http://drhyman.com/blog/conditions/the-diabesity-epidemic-part-ii-why-conventional-medicine-makes-things-worse/ (9) Bhashyam S, Parikh P, Bolukoglu H, Shannon AH, Porter JH, Shen YT, Shannon RP. Aging is associated with myocardial insulin resistance and mitochondrial dysfunction. Am J Physiol Heart Circ Physiol. 2007 Nov;293(5):H3063-71. (10) Ryan AS. Insulin resistance with aging: effects of diet and exercise. Sports Med. 2000 Nov;30(5):327-46. Review. (11) Gaziano JM, Hennekens CH, O’Donnell CJ, Breslow JL, Buring JE. Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. Circulation. 1997 Oct 21;96(8):2520-5. (12) Chen L, Appel LJ, Loria C, Lin PH, Champagne CM, Elmer PJ, Ard JD, Mitchell D, Batch BC, Svetkey LP, Caballero B. Reduction in consumption of sugar-sweetened beverages is associated with weight loss: the PREMIER trial. Am J Clin Nutr. 2009 May;89(5):1299-306.[/text_output][/vc_column][/vc_row]","date_published":"2012-05-24T18:47:51","date_modified":"2024-01-29T12:17:29","authors":[{"name":"Dr. Richard Esquivel","url":"https://sanjosefuncmed.com/about/"}],"tags":["Metabolic Health"]},{"id":"https://sanjosefuncmed.com/dietary-shifts-leading-diabesity/","url":"https://sanjosefuncmed.com/dietary-shifts-leading-diabesity/","title":"The Dietary Shifts that are Leading to Diabesity","summary":"The #1 dietary shift that leads to diabesity is sugar in all its forms. The average American today eats 150-180 pounds of sugar per year. That’s over half a p","content_text":"The #1 dietary shift that leads to diabesity is sugar in all its forms. The average American today eats 150-180 pounds of sugar per year. That’s over half a pound of sugar a day! We evolved eating 22 teaspoons of sugar per year.(1) So we are no longer eating in harmony with our genes. In the last 30 years our sugar calories increasingly come from high-fructose corn syrup (HFCS). This comes mostly in the form of liquid calories from sodas, soft drinks and sweetened beverages. In fact, Dr. Walter Willett from the Harvard School Public Health stated at a recent White House meeting on Prevention and Wellness that the two most important factors driving our obesity epidemic are sugar-sweetened drinks (2) and the number of hours of television watched per day.(3) These correlate more with obesity than any other factors in the research. We need to stop eating (and drinking) so much sugar. It’s killing us. The #2 dietary shift that leads to diabesity is our low-fiber diet. As our sugar consumption has increased, our fiber consumption has decreased. We now eat less than 8 grams per day. Yet our Paleolithic ancestors ate 100 grams of fiber per day.(4) This is another indication of how we are no longer eating in harmony with our genes … Fiber is important because it slows the absorption of sugar into the bloodstream from our gut and reduces cholesterol . It mostly comes from fruits, vegetables, nuts, seeds, and beans. Those who eat a refined, processed, diet that comes from boxes, packages, or cans get less fiber than those who eat whole, real foods. The lack of fiber in our diet has enormous implications for our health. It causes heart disease , diabetes, obesity, cancers and many other chronic diseases.(5) In fact, studies show that adding high levels of fiber to the diet is as effective as diabetes medication without any of the side effects.(6) The #3 dietary shift that leads to diabesity is our epidemic of nutritional deficiencies. A number of nutrients are particularly important to prevent and treat diabesity. These include vitamin D,(7) chromium,(8),(9) magnesium,(10) zinc,(11) biotin,(12) omega-3 fats,(13) and antioxidants such alpha lipoic acid.(14) These nutrients are necessary for proper control and balance of insulin and blood sugar. When these are deficient, our biochemical machinery slows down and grinds to a halt. And these happen to be the very nutrients most of us are deficient in. What’s critical to understand is that the solution to the whole diabesity epidemic can be found at the end of your fork! What you put on your fork is the most powerful medicine you have to correct the fundamental underlying causes of chronic disease and diabesity. That is true for one simple reason: Food is more than calories; it is information . This is what the exciting new field of nutrigenomics is now showing us. References (1) Cordain L., et al. 2005. Origin and evolution of the Western diet: Health implications for the 21st century. Am J Clin Nutr. 8 (2):341-54. Review. (2) Ludwig DS, Peterson KE, Gortmaker SL. Relation between consumption of sugar-sweetened drinks and childhood obesity: a prospective, observational analysis. Lancet. 2001 Feb 17;357(9255):505-8 (3) Hu FB, Li TY, Colditz GA, Willett WC, Manson JE. Television watching and other sedentary behaviors in relation to risk of obesity and type 2 diabetes mellitus in women. JAMA. 2003 Apr 9;289(14):1785-91. (4) Eaton SB, Konner M. Paleolithic nutrition. A consideration of its nature and current implications. N Engl J Med. 1985 Jan 31;312(5):283-9. Review. (5) Robson AA. Preventing diet induced disease: bioavailable nutrient-rich, low-energy-dense diets. Nutr Health. 2009;20(2):135-66. Review. (6) Chandalia M, Garg A, Lutjohann D, von Bergmann K, Grundy SM, Brinkley LJ. Beneficial effects of high dietary fiber intake in patients with type 2 diabetes mellitus. N Engl J Med. 2000 May 11;342(19):1392-8. (7) Reis JP, von Mühlen D, Miller ER 3rd, Michos ED, Appel LJ. Vitamin D Status and Cardiometabolic Risk Factors in the United States Adolescent Population. Pediatrics. 2009 Aug 3. (8) A scientific review: the role of chromium in insulin resistance. Diabetes Educ. 2004;Suppl:2-14. Review. (9) Lau FC, Bagchi M, Sen CK, Bagchi D. Nutrigenomic basis of beneficial effects of chromium(III) on obesity and diabetes. Mol Cell Biochem. 2008 Oct;317(1-2):1-10. Epub 2008 Jul 18. Review. (10) Chaudhary DP, Sharma R, Bansal DD. Implications of Magnesium Deficiency in Type 2 Diabetes: A Review. Biol Trace Elem Res. 2009 Jul 24. (11) Masood N, Baloch GH, Ghori RA, Memon IA, Memon MA, Memon MS. Serum zinc and magnesium in type-2 diabetic patients. J Coll Physicians Surg Pak. 2009 Aug;19(8):483-6. (12) Albarracin CA, Fuqua BC, Evans JL, Goldfine ID. Chromium picolinate and biotin combination improves glucose metabolism in treated, uncontrolled overweight to obese patients with type 2 diabetes. Diabetes Metab Res Rev. 2008 Jan-Feb;24(1):41-51. (13) Flachs P, Rossmeisl M, Bryhn M, Kopecky J. Cellular and molecular effects of n-3 polyunsaturated fatty acids on adipose tissue biology and metabolism. Clin Sci (Lond). 2009 Jan;116(1):1-16. Review. (14) Shay KP, Moreau RF, Smith EJ, Smith AR, Hagen TM. Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential. Biochim Biophys Acta. 2009 Oct;1790(10):1149-60. Epub 2009 Aug 4.","date_published":"2012-06-12T07:41:43","date_modified":"2020-04-19T22:32:24","authors":[{"name":"Dr. Richard Esquivel","url":"https://sanjosefuncmed.com/about/"}],"tags":["Metabolic Health"]},{"id":"https://sanjosefuncmed.com/dont-evidence-based-model-medicine-people-aging-neurodegeneration-neurodegeneration-progressive-preserving-brain-plasticity/","url":"https://sanjosefuncmed.com/dont-evidence-based-model-medicine-people-aging-neurodegeneration-neurodegeneration-progressive-preserving-brain-plasticity/","title":"Neurodegeneration and Preserving Brain Plasticity","summary":"We Really Don’t Have an Evidence-Based Model of Medicine According to the literature, nutritional medicine is the most powerful and effective treatment availa","content_text":"We Really Don’t Have an Evidence-Based Model of Medicine According to the literature, nutritional medicine is the most powerful and effective treatment available for brain and neurodegenerative disorders. Do you know how many papers are now published supporting the use of essential fatty acids for brain function? And there are still doctors that refuse to recommend these for their patients. We still have a healthcare system that is so disconnected and fragmented, they don’t even consider it. There are many flavanoids that have been shown to dampen microglial cell activation that are never used. There are plant compounds that slow down dementia and Alzheimer’s that are not being used. There are botanicals that increase blood flow to the brain by 300-400% published over and over in the literature that are never used. Taking all the research into consideration that is available on natural compounds, we can only conclude that we really don’t have an evidence-based model of medicine. What People Consider “Aging” is Really Neurodegeneration We have all been conditioned to ignore neurodegeneration. We have all been conditioned to correlate loss of memory, loss of sensory function, low energy, loss of motivation and drive, loss of digestive function and depression with the aging process. However, these changes are not a normal part of the aging process . If you (or a loved one) can’t focus or concentrate like you used to, can’t remember things you used to, can’t move or exercise like you used to, or do not have the same joy in life as you used to, this is not normal . We are taught to correlate aging with neurodegenerative processes. As the brain degenerates, memory declines, you can’t focus, you can’t concentrate, you can’t taste, you can’t smell, you develop poor posture, and poor facial tone. The autonomic nervous system is also affected, which controls digestion, enzyme production (to digest and absorb food), gut motility (to move food through the GI tract), and large bowel function (to excrete waste). As the brain degenerates, you also suffer from gastrointestinal problems: you can’t digest your food (poor digestion), absorb your food properly (malabsorption) or excrete waste (constipation). What is going on? These are all signs of potential neurodegeneration. If you think this is normal, you may be dead wrong. All these processes are controlled by the brain. What is thought to be “aging” is really neurodegeneration. What’s the ultimate anti-aging therapy? The ultimate anti-aging is preservation of the brain! Neurodegeneration is Always Progressive Neurodegeneration only gets worse if you do nothing to slow it down. The average person loses 3,500 neurons per hour or 84,000 neurons per day. This equates to over 30 million neurons per year. How has the health of your brain changed over the last 5 years? How is your learning and memory? How is your clarity of thought? How is your energy? How is your digestion? How is your ability to handle stress or new tasks? If it’s worse, your brain is probably degenerating. Preserving Brain Plasticity You can’t do much to increase the number of neurons you have, but you can do a lot to improve the signaling between these neurons. Plasticity refers to the efficiency of signaling between neurons to accomplish a task. This means you may lose neurons but still improve brain function. If you have more plasticity than neurodegeneneration , you will be able to do new things. We all have the capacity for either plasticity or neurodegeneration as we get older. We are all having both processes that occur simultaneously. It’s just a matter of which one happens more. If you have more neurodegeneration than plasticity , you will lose brain function . If you have more plasticity than neurodegeneration , you will gain brain function. “Synaptic activity is not isolated to learning, but also to the central nervous system modulation of the endocrine, immune, and other physiological interactions. As synaptic activity declines, so does health in every respect.”(1) This means that our brain health not only affects learning and memory, but directly affects the health of our endocrine and immune systems as well. If we have an unhealthy brain, we will probably have an unhealthy endocrine (hormonal) system and a weak immune system (and be prone to infections). The next series of article will be on the most common causes of an unhealthy brain, including toxic foods, including gluten, sedentary lifestyle, stress, toxic drugs, medications, household and environmental toxins, toxic molds and heavy metals. We will also discuss the Brain-Gut Connection and the Thyroid-Brain-Immune Connection. Stay tuned! References: 1. Datis Kharrazian, D.C., Brain and Neurotransmitters Seminar, San Francisco, CA, Nov. 22-23, 2008","date_published":"2012-06-27T07:22:45","date_modified":"2020-04-19T22:44:51","authors":[{"name":"Dr. Richard Esquivel","url":"https://sanjosefuncmed.com/about/"}],"tags":["Brain & Neurologic Health"]},{"id":"https://sanjosefuncmed.com/functional-medicine-approach-diabesity/","url":"https://sanjosefuncmed.com/functional-medicine-approach-diabesity/","title":"The Functional Medicine Approach to Diabesity","summary":"In the last 20 years an emerging body of scientific knowledge points to a number of factors that are the true drivers of diabesity and most chronic disease. W","content_text":"In the last 20 years an emerging body of scientific knowledge points to a number of factors that are the true drivers of diabesity and most chronic disease. While genetic predisposition may play a role in diabesity , what we now know is that it is the ways in which your diet, lifestyle and environment interact with your genes to create changes in your moment to moment biological functioning that leads to health or disease. These changes in gene expression or function are what result in the symptoms we see in diabetes. But your symptoms — your high blood sugar, high blood pressure, high cholesterol, and the rest — are not the cause of diabesity. They are simply clues to help us find the real underlying causes . The fundamental causes of diabesity are imbalances in key systems of the body that result in insulin resistance, problems with blood sugar control, and all the other complications and associated problems. Understanding these basic systems, how they get out of balance, and how to get them back in balance, allows us to create a personalized medicine program for each person. This is what is known as Functional Medicine . If we want to effectively treat this epidemic of diabesity, we must start focusing on the underlying causes that are driving these problems in the first place. The main driving factor of our diabesity epidemic is our nutrient-poor, calorie-rich diet which has led to a nation of overfed but undernourished people. In fact, there are so few nutrients in our diet that we now have an epidemic of nutritional deficiencies that promote the development of diabetes in including vitamin D, magnesium, chromium, zinc, and antioxidant deficiencies.(1),(2). The Solution: Therapeutic Lifestyle Change The solution is simple. Spend time shopping and cooking whole, real, fresh food. Don’t eat fast food or junk food. Don’t eat food from a bag, box or package. Don’t drink sodas or sweetened beverages. Eat lots of fruit and vegetables (organic whenever possible) and whole grain (but stay away from gluten in wheat). Don’t eat fried foods (especially deep-fried foods). Eat lots of fish and fresh, healthy oil, such as olive oil, avocado and plant-based sources of protein such as raw nuts, seeds and beans. “All patients diagnosed with metabolic syndrome should be encouraged to change their diet and exercise habits as primary therapy.”(3) “National clinical guidelines recommend therapeutic lifestyle changes as a standard of care in the management of conventional risk factors (for coronary heart disease).” “…the findings clearly show that many patients who have conventional risk factors for coronary heart disease can achieve goal levels without medications within 12 weeks of initiating therapeutic lifestyle changes…” “Moreover, therapeutic lifestyle changes can generally be implemented less expensively than most medications and, unlike single drug therapy, favorably impacts multiple cardiovascular disease risk factors.”(4) Introducing FirstLine Therapy®—Reversing Diabesity With Lifestyle Medicine FirstLine Therapy® is a therapeutic lifestyle change, or lifestyle modification, program. Designed by health care professionals, FirstLine Therapy® has been shown to be remarkably successful in helping individuals like you return to a path of extended health. This is not a weight reduction program—it’s a disease reduction program. While weight loss often occurs, it’s only secondary to the primary goal of addressing insulin resistance at its root and helping you achieve and maintain a healthy body composition (lean-muscle-to-fat ratio) to improve health, manage disease, feel better, and reduce your risk to more serious conditions. For more information on this unique 12-week program, visit our FirstLine Therapy® page. References (1) Kligler B, Lynch D. An integrative approach to the management of type 2 diabetes mellitus. Altern Ther Health Med. 2003 Nov-Dec;9(6):24-32; quiz 33. Review. (2) Kelly GS. Insulin resistance: lifestyle and nutritional interventions. Altern Med Rev. 2000 Apr;5(2):109-32. Review. (3) Metabolic Syndrome: Time for Action. Am Fam Physician 2004;69:2875-82, 2887-8 (4) Effectiveness of Therapeutic Lifestyle Changes in Patients With Hypertension, Hyperlipidemia, and/or Hyperglycemia. American Journal of Cardiology 2004;94: 1558-1561","date_published":"2012-06-12T07:28:50","date_modified":"2020-04-19T22:33:12","authors":[{"name":"Dr. Richard Esquivel","url":"https://sanjosefuncmed.com/about/"}],"tags":["Metabolic Health"]},{"id":"https://sanjosefuncmed.com/gluten-summit-recap/","url":"https://sanjosefuncmed.com/gluten-summit-recap/","title":"Gluten Summit Recap","summary":"Wow! I hope all of you got a chance to listen to some of the experts that spoke in the Gluten Summit last month. Dr. Tom O’Bryan did an excellent job in gathe","content_text":"Experts Convene in First Gluten Summit Wow! I hope all of you got a chance to listen to some of the experts that spoke in the Gluten Summit last month. Dr. Tom O’Bryan did an excellent job in gathering some of the world’s leading researchers and medical experts in the field of gluten sensitivity (now termed “non-celiac gluten sensitivity” in the medical literature) and “gluten-related disorders”. These researchers and medical specialists, representing the fields of immunology, neurology, pediatrics, cardiology and gastroenterology, spoke on various health disorders linked to wheat consumption and the potential consequences on our health and the health of our children. One thing is certain: problems with wheat consumption are not limited to the gastrointestinal tract, as many medical doctors still believe. There is an overwhelming amount of evidence showing that wheat consumption is contributing to systemic chronic disease including various inflammatory and autoimmune diseases and wreaking havoc on the health of Americans and our children. For those of you that did not have a chance to hear all of these speakers, I have good news: you can still hear any of these talks that you missed! San Jose Functional Medicine has purchased the entire set of presentations and offering direct access of all these talks to our patients! Just let us know by email that you are interested in hearing these talks and enter “Gluten Summit” in the subject of the email ! We will send you a link that you can use to access the entire set of talks so you don’t miss a thing! You can also purchase the entire set of talks directly from the Gluten Summit website . Here is a summary of my personal Fab Four speakers from this amazing summit: 1. Alessio Fasano, M.D. (Bio) Why Creating the Healthiest Intestinal Environment Possible Can Arrest Your Vulnerability to the #3 Cause of Getting Sick and Dying Did Humans Evolve to Consume Wheat? According to Dr. Fasano, wheat is not digestible by the human gastrointestinal tract. He explained how wheat protein (gluten) has an unusual sequence of amino acids that our digestive enzymes are not capable of digesting and therefore gluten cannot be completely broken down. This poor digestibility of wheat may not be a problem for the majority of people but this leaves a percentage of people at risk of health problems potentially causing a variety of symptoms. He states the reason for the undigestibility of wheat is that for approximately 99.9% of human evolution, our ancestors were gluten-free. Humans only recently started to consume grains about 10,000 years ago with the event of agriculture when humans changed their nomadic lifestyle from migrating from place to place which offered animals for food and seasonal crops to settlers who began to domesticate animals and grow crops. This is when grains (wheat, barley, rye) came into the picture in terms of human evolution. He also stated that due to the hybridization of wheat over the years, the wheat we are presently consuming is very different than the wheat our ancestors ate. The amount of modern gluten content per dry wheat of the grain is much higher than it used to be (ie: 30-40% vs 15-20%) and this could partly explain why we are now seeing so many health problems related to gluten consumption. At What Age Is It Safe To Give Our Kids Wheat? There is a lot of research going on in this field right now and we cannot answer this question, but we do know if you introduce gluten too early in childhood, it can cause problems. “If we introduce gluten too early, we dramatically increase the risk of developing celiac disease in genetically-predisposed kids” The current pediatric recommendations are to introduce gluten from 4-6 months of age but recent evidence shows there is decreased risk of celiac disease (CD) by postponing introduction of gluten. Recent studies, including a study by Dr. Fasano himself which followed 700 kids at risk of CD since birth, has shown decreased risk of celiac disease if gluten is introduced after 1 year of life in order to allow the immature immune system of the GI tract to develop properly and deal sufficiently with this unusual protein. Recent data also clearly indicates there is no risk of introducing gluten later in life. What Is Intestinal Permeability And How Does It Affect Our Health? Dr. Fasano states one of the most-overlooked functions of the gastrointestinal (GI) tract is to act as a barrier between the environment and our internal body. The GI tract acts as an interface between harmful compounds from the outside world and our internal environment. A single layer of cells (the epithelial lining of the GI tract) keeps the enemy outside and ensure that these harmful compounds (such as bacteria, toxins and undigested food molecules) do not enter the body (bloodstream). However, there are “checkpoints” along the GI tract which allow passage of some special molecules. These checkpoints are called “tight junctions”. When the checkpoints are breached, there is uncontrolled passage of “instigators” which can cause significant health consequences. The permeability of the gut determines our biologic and physiologic health. Characteristics of the GI tract: The greatest possible interface with the environment so we can digest as much food as possible An efficient system of digestion and absorption The most sophisticated immunological component of our body Controlled by a sophisticated neuroendocrine network Causes of Intestinal Permeability/Leaky Gut Syndrome: Dr. Fasano summarizes the factors that have been shown in the literature to lead to uncontrolled traffic of molecules across the GI lining: Infections Dysbiosis Pollutants Chemicals GMO foods Consquences of Intestinal Permeability/Leaky Gut Syndrome: The consequences of uncontrolled trafficking of molecules may include the following, depending on our genetics: Food allergies Chronic inflammation Autoimmune disease Cancer The Epidemic of Autoimmune Disease Dr. Fasano describes an epidemic of autoimmune disease that has been taking shape the last 40-50 years. The autoimmune disease epidemic has coincided with the introduction of antibiotics. Using antibiotics is like dropping a bomb on our gut. The susceptible bacteria are killed and the non-susceptible ones grow and take over. This creates an imbalance of good and bad bacteria of the gut. We are all exposed to antibiotics in vegetables and animal products. We always need to consider the food we are feeding our gut bacteria. He compares our genetic information of our DNA to a block of precious marble and all of our genetic potential is directly influenced by our environment. We cannot blame our genetics for this epidemic because changes in genetics takes centuries, not years. This epidemic we are seeing must be directly related to our inability to adapt to our rapidly-evolving environment. Key factors for the development of autoimmune disease: Genetics Environmental trigger Intestinal permeability Human Beings are Genetically Rudimentary as a Species Dr. Fasano points out that one of the things the Human Genome Project discovered is that humans only have 25,000 genes. At the same time, a certain species of worm has been found to have approximately 90,000 genes. How can such a simple life form have more genes than humans? How did humans become so sophisticated with such few genes? The answer may lie in the fact that humans are really made from two genomes: our genetics and our microbiome (living organisms of the gut). Our microbiome is 100 times more complex in terms of genetics than human DNA. This helps to explain how humans evolved into such complex living organisms. The Complexity of the Gut Microbiome and Why We Need This Technology is now allowing us to understand the complexity of the microbiome. The microbiome helps the intestinal immune function to mature. We need gut bacteria for proper immune function and to minimize inflammation. When these bacteria live in harmony, we have good immune health. Roughly 1,000-1,200 different species of bacteria live in the gut. Our Microbiome Plays a Key Role in How Our Genes Are Expressed and is Highly Influenced By Our Environment Regarding a person’s risk in developing autoimmune disease, Dr. Fasano states: “Even if you are genetically skewed to develop these problems, it’s not definite that you will. It depends on the microbiome. And the microbiome composition is highly, highly influenced by our environment.” Environmental Influences on our Microbiome: Nutrition: our microbiome eat our leftovers Pollution Chemicals Radiation “The autoimmune epidemic is linked to changes in the composition of the microbiome due to environmental stimuli” “The foods we select on a daily basis has a direct impact on the development and maintenance of the healthy bacteria of our gut” Steps Leading To Inflammation In The Tissue: Dr. Fasano summarizes the steps that lead to autoimmunity and chronic inflammation: Consumption of gluten Gluten is only partially digested and inflammation will be instigated if the immune system sees the peptides The intestinal barrier is breached after zonulin is released These things happen in all of us to some degree but about 70-80% of us will suffer no consequences as a result Others will suffer consequences from the encounter between the instigator and the immune system Cytokines are fired against the enemy and lead to tissue destruction “The gut is not like Las Vegas. What happens in the gut doesn’t stay in the gut.” Dr. Fasano emphasizes that inflammation in the gut can spread to any tissue in the body. In classic celiac disease, tissue damage occurs in the intestines. However, immune cells can go anywhere in the body and cause arthritis (joints), peripheral neuropathy (nerves) or dermatitis herpetiformis (skin). He believes it is reductive to say that celiac disease is a GI condition. The GI tract is simply the battlefield of the first encounter of the enemy and our immune soldiers. But the war can continue in other parts of the body causing ravaging effects on our brain and peripheral nervous system, our skin, our joints and many of our internal organs. 2. Natasha Campbell-McBride, MD (Bio) The Critical Nature of Gut Health and its Impact on Children’s Brains Gut and Psychology Syndrome (GAPS): Natural Treatment for Autism, ADHD, Dyslexia, Dyspraxia, Depression and Schizophrenia Dr. Campbell tells a fascinating personal story of how she learned firsthand the close connection that exists between the health of the gut and the health of the brain. Dr. Campbell was trained in Russia and practiced as a neurologist for 5 years and then a neurosurgeon for 3 years. She observed that most of her degenerative neurological patients (ie: MS, ALS) also had digestive issues and wondered if this could be related to their neurological issues. Conventional medicine sees no relationship between these two types of problems. Her first child was diagnosed with autism by age 3. She took him to the best convention medicine doctors she knew but conventional medicine offered no help for her and her son. She returned to university to study nutrition and gathered all the information she could on how nutrition impacts brain health and the health of the body. She implemented her new knowledge with dietary and lifestyle changes and nutritional supplements for her son and his condition started to improve for the first time. Her son now shows no sign of autism and she believes this is because of early intervention in nutritional and dietary needs of these types of children. She believes the younger the child starts treatment, the greater the chance of recovery. She states if the child starts treatment by 4 or 5 years of age, it is very possible to obtain a full recovery from autism or any of these learning and behavioral disorders. The older the child is before treatment is started, the more difficult it is to obtain a full recovery. But there are improvements in all ages, even adults, so she is always hopeful. She began working more and more with autism as well as ADD/ADHD, dyslexia, dyspraxia, OCD and other neurological disorders after she saw the results with her son. She discovered there is a connection between the physical health of these children and their mental health. Neurological Patients are Usually Physically Ill Dr. Campbell has written two books on how the health of the gastrointestinal (GI) tract affects both psychological and physical health conditions. Gut and Psychology Syndrome (GAPS) focuses on mental conditions and Gut and Physiology Syndrome focuses on physical conditions. She states that all of these syndromes boil down to what is happening in the digestive tract of these people. “All disease begins in the gut”—Hippocrates The Significance of the Gut Flora Dr. Campbell explains that about 90% of all the cells in the human body are contained in the gut flora. There are 10 times as many bacteria in the gut than there are cells in the human body. “Our bodies are just a shell, a habitat for this mass of microbes which live inside us. And we ignore these microbes at our peril because their effect on the rest of the body, on every aspect of health in the human body, is absolutely monumental.” What happens in Gut and Psychology Syndrome (GAPS) patients? They have abnormal gut flora. In healthy patients, our gut flora is dominated by beneficial microbes. These beneficial microbes include beneficial bacteria, fungi, parasites, worms and viruses. If they dominate, they control disease-causing microbes. In this GAP group of people, their gut flora gets wiped out and becomes overrun by pathogenic flora (bacteria) and other disease-causing pathogens. These pathogens digest your food and convert it into disease-causing substances. These toxic substances can be absorbed through the gut lining (in leaky gut) and distributed around the body where they cause disease. Wherever these toxins accumulate, they will cause disease. If it’s the joints, they will get arthritis. If it’s the brain, they will suffer a mental disorder. The Gut Flora and Learning Disabilities Dr. Campbell is convinced that GAP children are born with a normal, healthy brain. They develop abnormal gut flora within the first two years of life which produce toxic substances. These toxic substances are absorbed into the blood and can enter the brain. This causes brain dysfunction and mental disorders. How Do Babies Learn The First Few Years Of Life? Babies learn by listening to everyone, smelling everything and touching everything in their environment. They learn by using their sense organs to collect information from their environment. A healthy brain is able to process all this information. Toxicity in the brain makes processing information difficult. All this information turns into a noise or a “mush” and the child cannot decipher anything useful. As a result, they don’t know who their mother or father is and they are likely to grab anyone’s hand and walk away with away with them because “mommy” doesn’t mean any more than another stranger. They don’t know what to do with their toys or other children that they play with. Other Manifestations of Toxicity in the Brain Depending on the type and amount of toxins that children’s brains are exposed to, they may develop any of the following conditions: Hyperactivity ADD Dyslexia Dyspraxia Oppositional defiance Undiagnosed symptoms Dr. Campbell is afraid this last category is the most common and fits the majority of children. No Time to Waste Dr. Campbell believes that medical doctors often procrastinate before giving a diagnosis and precious time is wasted. The younger the child is, the quicker we can make a change in their gut flora and heal the gut. She states the most important thing for doctors to focus on is to: “Heal and seal the gut lining” Dr. Campbell says the quicker we can heal and seal the gut and stop the river of toxins from going to the brain, the faster the child can recover. The child’s brain will take care of eliminating the toxins which are currently there. You just have to stop the flow of additional toxins into their brain. The younger the child is, the quicker we can make a change in their gut flora and the more likely to have a full recovery. The older the child is, the slower the recovery and less likelihood of a full recovery. Seizures Are Signs of Toxicity Dr. Campbell says when toxicity builds up too high in the brain, this becomes very damaging to the brain so the brain sends one discharge through the brain to “clear toxins” in the brain. This manifests as a seizure seen in epilepsy. The vast majority of epileptic seizures are born in the digestive tract of the child from toxins penetrating from the digestive tract into the blood. These toxins can then penetrate from the blood into the brain causing toxicity in the brain. The brain uses seizures as a way to discharge toxicity. If the gut issues are not resolved, then the brain will accumulate toxins again. Psychiatrists have observed that psychosis often disappears for a short period of time after an epileptic seizure which supports this view of seizures clearing toxins from the brain. The person becomes normal, lucid and you can reason with this person. An epileptic seizure can be considered a “safety valve” for the brain. Psychiatric Disorders in Adults Linked to Abnormal Gut Flora Dr. Campbell is convinced that most psychiatric disorders in adults are linked to abnormal gut flora including: Schizophrenia Depression Bipolar disorder Addictive behaviors and personalities According to Dr. Campbell, adult epilepsy can also be linked to gut toxicity. Leaky Gut According to Dr. Campbell, pathogenic microbes in the gut make the gut porous and leaky. If food, including all protein, is incompletely digested, then these partially digested proteins can penetrate into the blood causing immune responses. Allergies or intolerances to various foods can develop when the immune system does not recognize the food antigens coming into the bloodstream. This is not a ‘true’ allergy so they are often not recognized by allergists. These reactions can manifest as ‘any symptom under the sun’. Reactions to food can be delayed from two hours to two weeks after the intake of the food, which makes detection very difficult. Also, reactions to different foods can overlap. The more damaged the gut lining, the more severe the symptoms. The Gut and Immunity Dr. Campbell states that 85% of our immune system is located in the gut wall. The gut is the largest immune organ of the body. It contains 90% of the cells and genetic material of the body. “ There is a significant amount of information exchange that occurs between the gut flora and the immune system of the gut. If the gut flora is abnormal, the immune system cannot function normally.” Abnormal gut flora leads to impaired immune response to environmental stimuli causing allergy and allergic reactions. Allergic Reactions Asthma Eczema Hay fever Skin rashes Urticaria Other atopic responses Gut and Physiology Syndrome (GAPS) Patients Dr. Campbell believes a person with neurological problems is probably maldigesting most foods. The problem is with the gut lining. The focus should be on healing and sealing the gut lining. Then the food will have a chance to be digested properly before it is absorbed. This is exactly what the GAPS nutritional protocol is all about. GAPS patients have abnormal gut flora and leaky gut which triggers immune responses Leaky gut leads to food sensitivities, malabsorption and nutritional deficiencies Pathogenic flora converts food into toxic chemicals which gets distributed around the body Autoimmunity is Born in the Gut Improperly digested foods with immune cells attached to them can enter any tissue in the body. Whatever tissue they enter, they can cause damage to that tissue and physical conditions develop. Dr. Campbell believes all autoimmunity is born in the gut. Pathogenesis of Autoimmunity Antibodies develop against partially digested food proteins Food proteins resemble proteins in our body Antibodies mistakenly target the body’s own proteins This leads to autoimmune disease Common Autoimmune Conditions Rheumatoid arthritis (RA) Osteoarthritis (OA) Multiple sclerosis (MS) Amyotrophic lateral sclerosis (ALS) Nephropathy Neuropathy Psoriasis Alopecia “I’m absolutely convinced that autoimmunity begins in the gut” Treating Autoimmunity Focus on the gut Drive out pathogenic microbes Replace them with beneficial microbes Heal and seal the gut lining Fermented Foods to Strengthen and Heal the Gut Our ancestors fermented food to preserve them Fermentation produces billions of bacteria that strengthen and heal the gut Fermented foods are also predigested by bacteria to make food easier to digest and vitamins and minerals easier to absorb Using Probiotic Bacteria Introduce and increase probiotics gradually since this leads to death of pathogenic bacteria Pathogens release toxins as they die Die-off reaction can worsen symptoms and make someone quite ill (ie: headaches, migraines, fatigue, etc.) Dr. Campbell closes with the following statement: “The fact that your doctor doesn’t know that something is curable doesn’t mean the knowledge doesn’t exist somewhere” 3. William Davis, MD (Bio) Modern Wheat: It’s MORE Than Wheat Wheat-Free to Reduce Blood Sugar In an effort to reduce blood sugar, and based on the fact that wheat products increase blood sugar more than nearly any other food, Dr. Davis asked his patients to eliminate wheat, including whole grain products, from their diets. The results his patients experienced went beyond anyone’s expectations: incredible weight loss; relief from acid reflux and the gas, cramping, and diarrhea of irritable bowel syndrome; increased energy, more stable moods, and deeper sleep; relief from arthritis, including rheumatoid arthritis; dramatically improved cholesterol values; reduced blood pressure and inflammatory measures, and more. On a wheat-free diet, his patients experienced: Weight loss Relief from acid reflux and IBS Increased energy More stable moods Deeper sleep Relief from arthritis Improved cholesterol values Reduced blood pressure Reduced inflammatory markers Based on his clinical evidence, Dr. Davis has come to view wheat consumption as a widespread societal problem causing obesity, illness and suffering. He is author of “Wheat Belly: Lose the weight and Find Your Path Back to Health”. He has an upcoming book coming out soon: “Heart Scam: The multi-billion dollar medical rip-off that is exploiting America, hiding cures, and bankrupting healthcare”. Finding the Cause of Heart Disease Dr. Davis explains that CT heart scans are imaging devices developed to detect coronary atherosclerosis in individuals (actual heart disease, not just risk factors like high cholesterol or high blood pressure). This produces a calcium score based on the amount of calcium deposited in coronary arteries (plaque). Once you have plaque, it grows like mad, at average rate of 30% per year. Statin drugs have been shown to have no effect on atherosclerosis or calcium scores. Many doctors thought that the calcium scores were not reliable. Dr. Davis took a different approach. He and his colleagues did research showing that you have to control blood sugar to control atherosclerosis. If you don’t control blood sugar, you will develop coronary plaque and lose control of cardiovascular risks. That’s when he asked himself how he could help his patients nutritionally to reduce cardiovascular risk without using drugs. How Do You Control Blood Sugar Nutritionally? There are lots of drugs that control blood sugar. Dr. Davis wanted to take a nutritional approach and remove foods that are highest on the glycemic index (GI) . The glycemic index is a measurement of how rapidly food is broken down to glucose which causes elevations in blood sugar (see below). He discovered the glycemic index of two slices of wheat bread is 72, higher than a tablespoon of sugar! When patients ditched wheat and junk food, the following blood markers improved: Blood sugar lowered HbA1C lowered Triglycerides lowered LDL decreased These Patients Experienced The Following Unexpected Health Transformations: Weight loss Low blood pressure Asthma disappeared Rashes cleared up Migraines vanished Acid reflux alleviated IBS improved or cleared up Joint pain relieved Moods improved The Glycemic Index of Foods Very few foods have a glycemic index above 70, including: Dates Figs Gluten-free foods (cornstarch, rice flour, tapioca starch, potato starch) Whole wheat White flour Dr. Davis found that the glycemic index of wheat is among the highest of all foods (72). Almost every official U.S. government agency recommends a grain-dominated diet and he feels this is contributing to our high rates of diabetes and cardiovascular disease. 50% of all calories consumed worldwide come from grains. What Exactly is the Glycemic Index? The glycemic index is a measure of how high blood sugar goes 90 minutes after eating that food. Increased blood sugar triggers increased insulin release. Chronic high insulin levels lead to poor responsiveness to insulin (insulin resistance). High blood sugar also leads to glycation (glucose modification of proteins). Glycation leads to: Cataracts (glycation of the lenses of the eyes) Hypertension, arteriosclerosis and coronary atherosclerosis (glycation of blood vessels) Arthritis (glycation of cartilage) “Glycation is a fundamental process underlying multiple disease states and aging” Benefits from Removing Wheat from the Diet Eliminate high blood sugar Eliminate risk for glycation Eliminate low blood sugar Beware the Vicious Blood Sugar Cycle Dr. Davis explains that high blood sugar leads to low blood sugar. Hunger kicks in two hours later after having high blood sugar. Peptides from gliadin from wheat (gluteomorphins) act like opiates, further stimulating appetite and cravings for carbs. People consume an average of 400 calories of carbs more per day due to gluteomorphins! Dr. Davis estimates that high glycemic foods are 80-90% responsible for the diabetes epidemic we are now seeing. Primitive societies do not suffer from diabetes. Modern Wheat Dr. Davis explains that modern wheat has the following characteristics which can impact our health: High-yield, semi-dwarf strain Concoction of agricultural genetics Modern wheat has 42 chromosomes whereas wheat preceding biblical times had 14 chromosomes Very different biochemically and genetically from wheat only 40-50 years ago Celiac disease rates have quadrupled during this period of time Contains GLIA-alpha 9 gene which likely triggers celiac disease Consumption of Grains Represent Commoditization of the Human Diet Dr. Davis explains that the modern consumption of wheat came about because of agricultural and food industry interests in producing an inexpensive food commodity that could be easily stored and transported. Mass production of wheat offered the following conveniences: A product that can be easily transported Extended shelf life measured in years (yes, years , not months ) People are indifferent to quality differences Worldwide price differential Control the diet from the top down by food industry and government How Blood Sugar Affects Your Cholesterol and Risk for Heart Disease Dr. Davis explains that high blood sugar leads to elevations in small LDL particles, the worst of the “bad cholesterol”. These small LDL particles can become oxidized and lead to coronary artery disease (CAD). He makes the following points on how eating excess grains leads to the formation of excess LDLs and accounts for the increase in heart disease in the U.S.: Small LDL Particles Excess of small LDL particles are the most common abnormality in coronary disease Small LDLs have a different shape and different conformation They are more adherent to connective tissue They linger in the bloodstream for at least a week High blood sugar leads to formation of small LDLs Small LDLs become more glycated and oxidized (glycoxidized) Small LDLs and Heart Disease Glycoxidized (glycated and oxidized) LDL particles can cause heart disease High blood sugar causes glycation of LDL LDL are very glycation-prone Grains, sugars and starchy legumes lead to small LDL formation If you reduce grains, sugars and starchy legumes, LDLs will “drop like a stone” How Grains Contribute to Heart Disease Trigger formation of small LDLs Increase blood sugar Lead to glycation and oxidation of the arteries Lead to high triglycerides (TG) due to de novo lipogenesis in liver What’s the Effect of Complete Grain Removal? Drop in appetite Drop in caloric intake Weight loss (avg 26 lbs in 6 months) Drop in HbA1C and fasting glucose Drop in insulin Drop in small LDLs Drop in TGs Drop in postprandial lipoproteins Rise in HDL (“good” cholesterol) Reducing Cardiovascular Risks Follow a diet that gets rid of small LDLs Eliminate grains and sugars Raise 25-hydroxy vitamin D to 60-70 ng/ml Supplement with 3,000-3,600 mg EPA-DHA omega-3 fatty acids/day TSH &lt; 1.5, free T3, T4 in upper half of normal Identify hidden genetic causes (LipoA, Apo E4) “Statin drugs are a detour that the world has taken. The vast majority of people do not need statin drugs. What they are treating is an excess of LDL particles because they consume grains.” Wheat Withdrawal Dr. Davis has observed that a percentage of patients will have withdrawal symptoms from stopping consumption of wheat, AKA “Atkins flu” or “Paleo flu”. This is because in some people who consume wheat, their bodies create gluten-derived opiates (gluteomorphins) which act on the opiate receptors of the brain. Symptoms may include: Fatigue Depression Nausea Unable to exercise Headaches Some people will experience these symptoms when they stop wheat consumption. This is withdrawal from gluten-derived opiates and will last 3-7 days following withdrawal from wheat. They need to understand that this is normal and symptoms will only last for a brief period of time. Gut Flora and Heart Disease Dr. Davis explains that insufficient beneficial flora of the gut leads to increased risk of heart disease. Disrupted gut flora causes increased LDL which can become oxidized leading to heart disease. He recommends correcting the gut flora to minimize this risk. Helpful Strategies for Starting a Gluten-Free Diet (GFD) Choose a non-stressful time Hydrate Use sea salt Use magnesium malate (1,200 mg 2x/day) High potency probiotic (50 billion CFUs/day) This protocol can be implemented before starting a GFD Are Gluten-Free Diets Bad for You? Dr. Davis emphasizes not to replace something bad with something else bad. Don’t consume gluten-free (GF) junk carbohydrates such as corn starch, rice flour, tapioca starch, potato starch when starting on a GF diet. These increase blood sugar more than whole wheat. GF food manufacturers often put taste before nutrition. GF junk food can cause weight gain and negative health consequences. Points of Consideration Protein in corn can be problematic Corn is genetically modified in the U.S. Consider glyphosate residues (from chemically-treated foods) Consider Bt Toxins (from chemically-treated foods) Always choose organic (non-GMO) whenever possible Indulge More Healthily He tells patients they can have sandwiches, pasta, pizza, muffins, and cake but they have to be grain-free. They can use the following for the flour: Ground almonds Almond meal Almond flour Walnuts Pecans Sunflower seeds Pumpkin seeds Coconut flour Golden flaxseed 4. Jeffrey Smith (Bio) OMG–GMO and its Connection to Gluten Wheat: Genetically Modified or Hybridized? Mr. Smith explains that wheat is not currently genetically modified or genetically engineered (involving splicing and inserting genes into DNA). But wheat is selectively bread for certain traits, involving taste, texture, rise, high-yield and drought tolerance. Monsanto’s Roundup Ready Crops According to Mr. Smith, Monsanto wants to introduce genetically-engineered Roundup Ready wheat that doesn’t die when sprayed with Roundup herbicide. The food stores this herbicide so we get a heavy dose of Roundup herbicide in every bite. They want to genetically engineer wheat the same way as they have done for these crops: Existing Roundup Ready crops: Corn Soy Cotton and cottonseed oil Canola oil Sugar beets Alfalfa Little zucchini Little crookneck squash Hawaiian or Chinese papaya GMOs and Gluten Sensitivity The moderator asks if GMOs are causing people to become more reactive to gluten and other substances? Mr. Smith thinks GMOs are causing people to become more reactive to wheat and other foods for reasons that will be explained below. What are some of the impacts you have seen in the digestive tract from these GMO foods? There is growing evidence that Bt toxin damages the lining of the human GI tract by “punching holes in the gut” just as it does in insects. This is the mechanism by which Bt toxin acts as an insecticide to kill insects. All About Bt Toxin Mr. Smith explains there are 2 main categories of GMO foods: Round-Up Ready foods Those foods that produce their own insecticide (Bt toxin) Bt toxin comes from soil bacteria which pokes holes in the guts of insects. Bt toxin kills bugs by allowing macromolecules from their gut to enter the bloodstream. Genetic modification involves inserting a gene from soil bacteria into GMO foods. These foods are registered pesticides. Every cell of the plant contains Bt toxin. Monsanto, the biotech industry and the Environmental Protection Agency (EPA) has sworn that this is safe for human consumption because it doesn’t interact with humans or mammals, only certain insects. However, the Journal of Applied Toxicology overturned these claims in 2012 and stated that the same mechanism that was poking holes in insect guts was also poking holes in human guts as well. The biotech industry and the EPA claimed Bt toxin is destroyed by human stomach acid. However, Sherbrook University Hospital overturned this claim in 2011. Bt Toxin and Fetal Development According to Mr. Smith, Sherbrook University Hospital found Bt toxin in the placental cord blood of 93% of pregnant women in a study done in 2011. This means Bt toxin survived digestion through the stomach and entered the blood (presumably by poking holes in the maternal gut) and made its way into cord blood. Could it reach the brain and cause developmental problems? Could this be related to risk of autism? These are questions that have not yet been answered that he feels are critical questions that need to be addressed. GMOs and the Intestines Mr. Smith believes that intestinal permeability (leaky gut) may be increased by Bt toxin poking holes in the gut. A study found that genes can transfer from GMO crops into the gut bacteria where they might to continue to function. It’s possible that Bt toxin could be produced 24/7 in the gut! How is Bt Toxin Staying in the Body? Mr. Smith states that we don’t know this answer yet. It may be from eating animals that ate Bt crops. Another possibility is that our own bacteria are acting as living pesticide factories for Bt toxin. More research is needed to clarify this issue. But there are some interesting developments related to this question. Unidentified bacteria have been found in intestines of celiac disease (CD) children. 39% of CD kids have bacteria in the gut that shouldn’t be there. 18% of these bacteria have never been identified in humans before. Where is it coming from? We don’t know. What is Glyphosate ? The active ingredient of Round-up is glyphosate , a broad-spectrum antibiotic. Glyphosate kills beneficial bacteria but not pathogenic bacteria such as salmonella, E. coli and the bacteria that causes botulism. Glyphosate is being blamed for the epidemic of botulism we are now seeing. It creates gut dysbiosis in poultry and cows and has been related to sudden death syndrome. Dysbiosis is linked to leaky gut and gluten-related disorders. A Chain of Events Mr. Smith explains GMOs may contribute to suppressed digestive capacity by causing dysbiosis and affecting digestive enzymes. Excess undigested proteins putrefy which feed pathogenic gut bacteria causing more leaky gut and more undigested proteins. This leads to more food allergies, inflammation and risk of autoimmunity. Butyrate is the main fuel source for the regeneration of epithelial cells in the lining of the gut. Butyrate is produced by the action of good bacteria on vegetable fiber. If you don’t have sufficient beneficial bacteria, you won’t produce sufficient butyrate and this leads to a much higher risk of colon cancer, among other health problems. FDA: A Captive Regulatory Agency The FDA determined that no safety studies were necessary to put GMO foods on the market. Scientists warned against allergies, toxins, new diseases, and requested long-term studies but these opinions were disregarded. In fact, Mr. Smith points out that the current FDA head czar is ex-attorney and lobbyist for Monsanto. Limited GMO Studies We only have a handful of studies on GMOs. Mice fed GMO soybeans for 8 months had damaged testicular, pancreatic and liver cells and had reduced amylase and protease enzymes and a seven-fold increase in a trypsin inhibitor (a molecule that inhibits an enzyme that digests protein). This interferes with digestive capability and decreased ability to digest protein, gas and bloating and bad breath/odor. GMO-Free Diets Improve Gastrointestinal Disorders The following GI disorders have been shown to improve on a GMO-free diet: IBD, Crohn’s IBS Bloating, gas, abdominal pain Diarrhea Constipation Animals also improve on non-GMO diets. Bt Toxin and Allergies Mr. Smith explains that significant immune reactions have been observed in mice and farm workers who consume Bt toxin, leading to increased allergies and sensitivities. He states that the most vulnerable population appears to be the very young and very old. He believes this could increase immune load and increase sensitivity to other foods, causing an “adjuvant response”. He notes that food allergies have skyrocketed since the introduction of GMOs. Glyphosate-Sprayed Crops Glyphosate (the active ingredient in Round-Up) which kills beneficial flora, is sprayed on the following grains before harvest because it dries down the crops to make harvest easier and more uniform: Wheat Barley Rye Lentils Citrus Sweet potatoes It has been shown to penetrate the food portion of the crop. Non-GMO crops are also sprayed with glyphosate, which means that you may be exposing yourself and your family to this antibiotic every time you buy fruits and vegetables at your neighborhood supermarket. The only way to avoid exposure to this chemical is to buy organic food. Shopping Non-GMO Mr. Smith explains that organic means non-GMO by definition. In order to meet organic certification, food must not by genetically modified. Look for products verified non-GMO by the “Non-GMO Project”. Over 10,000 products have been verified non-GMO. Go to: www.nongmoshoppingguide.com Mr. Smith notes that the EPA just recently increased allowable residue levels to levels that are a million times higher than the level which has been shown to cause damage and health effects. Other Issues with Roundup According to Mr. Smith, Roundup is also an endocrine disruptor. This means that the enzyme aromatase gets disrupted leading to feminizing in males and virilizing (masculinization) in females. Roundup also leads to decreased vitamin and mineral absorption. In addition, glyphosate is a broad-spectrum chelator and makes vitamins and minerals unavailable for digestion and absorption leading to nutrient deficiencies. Glyphosate has been shown to lead to deficiencies in the following vitamins and minerals: Calcium Cobalt Vitamin B12 Manganese Magnesium Mr. Smith recommends choosing organic non-GMO vegetables to optimize absorption of vitamins and minerals. He gives the following websites as useful resources for more information on non-GMO foods: www.responsibletechnology.org www.nongmoshoppingguide.com","date_published":"2013-12-09T08:23:48","date_modified":"2020-05-22T00:35:47","authors":[{"name":"Dr. Richard Esquivel","url":"https://sanjosefuncmed.com/about/"}],"tags":["Functional Medicine"]},{"id":"https://sanjosefuncmed.com/insulin-resistance-dysglycemia-and-diabetes/","url":"https://sanjosefuncmed.com/insulin-resistance-dysglycemia-and-diabetes/","title":"Insulin Resistance, Dysglycemia and Diabetes","summary":"In part 2, we learned that the same physiologic processes that drive biological aging are the same processes that lead to chronic disease, increased risk of p","content_text":"In part 2, we learned that the same physiologic processes that drive biological aging are the same processes that lead to chronic disease, increased risk of poor quality of life and shorter lifespan. In order to slow down biological aging, we need to reduce our risk of developing chronic disease. In the next few articles in this series, we will review the major mechanisms of chronic and degenerative disease. Take the Insulin Resistance Quiz: Do you suffer from any of the following? Fatigue or drowsiness after eating? Need for coffee in the afternoon? Crave sweets after eating and during the day? Eating sweets does not relieve sugar cravings? Difficulty losing weight? Increased waist-to-hip ratio Frequent urination? Increased thirst and appetite? If you have any of the above symptoms or signs, you probably have some degree of insulin resistance . But you’re not alone. Over 100 million Americans suffer from this condition. [1] That is about 1 of 3 adult Americans. The effects of insulin resistance are not the same in everyone but the ultimate consequences are the same: diabetes, [2] heart attack and stroke, [3] depression, [4] Alzheimer’s disease, [5] sleep apnea, [6] hormone imbalances, [7] obesity [8] and certain types of cancer [9] . Studies have shown almost all the chronic diseases related to aging are directly or indirectly caused by this condition. [10] [11] What is insulin resistance? Insulin resistance is a condition that develops when we eat too much sugar or refined carbohydrates, don’t exercise, are under high amounts of stress on a regular basis and gain excess weight, especially abdominal fat. Obesity is now considered to be the largest contributor to insulin resistance. [12] No wonder why this is a national health problem! At first, our bodies are able to cope with these problems by having the pancreas produce extra insulin to lower our elevated blood sugar. But if this continues for a long period of time our bodies become resistant to the insulin being produced and the cells of the body no longer respond as efficiently to the insulin in the bloodstream. So the pancreas secretes even more insulin in order to get the same job done (lower blood sugar). This leads to hyperinsulinemia (excess insulin in the blood) and dysglycemia (blood sugar imbalances) and all the negative consequences on our health. Hyperinsulinemia and dysglycemia increase the risk of developing many chronic conditions related to aging affecting the heart, circulatory system, brain, liver, gastrointestinal tract, endocrine (hormonal) system, and the immune system as you will see. What are the health impacts of insulin resistance? Excess insulin causes the following negative impacts on human physiology: Type 2 Diabetes Cardiovascular Disease Hormone Imbalances Obesity Impaired Liver Detoxification Intestinal Permeability/Leaky Gut Alzheimer’s Disease Depression Cancer Insulin Resistance and Diabetes Everyone knows that diabetes is a major health problem in the U.S. today but did you know that diabetes affects over 1.7 billion people worldwide? It is the single biggest global health epidemic of our time. [13] The prevalence of type 2 diabetes in America has tripled since the 1980s. In 2010, there were 27 million Americans with diabetes (25% of whom were not diagnosed) and 67 million with pre-diabetes (90% of whom were not diagnosed). Researchers estimate pre-diabetes will affect 1 in 2 Americans by 2020, 90% of whom will not be diagnosed . The number of diabetics is expected to increase from 1 in 10 Americans today to 1 in 3 by 2050! [14] “Obesity-induced insulin resistance is the major determinant of metabolic syndrome, which precedes the development of type 2 diabetes mellitus and is thus the driving force behind the emerging diabetes epidemic.” [15] Diabesity is a term used to describe the disturbance of metabolic health that results from having a problem with blood sugar balance and an excess percentage of body fat. It can range from mild to severe, depending on the stage of the disease. Mild forms of this result from having slight or no apparent blood sugar problems and being “a little” overweight. Severe forms result in full blown diabetes and obesity. The term diabesity was coined due the close relationship between diabetes and obesity. Our current approach to prevention and treatment is obviously not working because millions more are affected every year. Not too long ago, this health condition was extremely rare. How does diabetes impact our health? Diabetes: The Leading Cause of Chronic Disease in the 21st Century Diabetes and its direct impact on physiology is the leading cause of most chronic disease we are now seeing in the 21st century. [16] Those with diabetes are at an increased risk of heart disease and stroke, [17] [18] [19] dementia, [20] blindness, peripheral neuropathy, kidney failure and many types of cancer. [21] [22] [23] [24] [25] [26] Diabetes is the most common cause of kidney failure. Damage to the peripheral nervous system (peripheral neuropathy) affects 75% of people with diabetes [27] and can lead to permanent nerve damage of the hands and feet, poor digestion, carpal tunnel syndrome, erectile dysfunction, and other peripheral nerve problems. Mortality rates are significantly increased in patients with type 2 diabetes. [28] So this is a very serious disease which leads to other very serious health conditions. How does diabetes impact the aging process? Diabetes makes you older before your time According to a recent study, people in their 50’s with diabetes may age before their time compared with their diabetes-free counterparts! This study showed that adults aged 51-70 with diabetes developed age-related ailments such as cognitive impairment, incontinence, falls, dizziness, vision impairment and pain at a faster rate than those without diabetes. For adults aged 51-60 with diabetes, the odds of developing new geriatric conditions were nearly double those who didn’t have diabetes! “Because diabetes affects multiple organ systems, it has the potential to contribute significantly to the development of a number of issues that we associate with aging.” [29] Although insulin resistance is most closely associated with the development of type 2 diabetes and its associated age-related health problems as described above, unfortunately, it doesn’t stop there. Insulin resistance also increases your risk of developing all of the following health conditions as well. Insulin Resistance and Cardiovascular Disease Excess insulin itself has major impacts on cardiovascular disease. Insulin has dramatic impacts on lipid metabolism and promotes inflammation. Insulin promotes sodium retention, causing hypertension (high blood pressure). [30] Insulin resistance upregulates HMG co-reductase, which is responsible for creating cholesterol so you get higher cholesterol levels [31] and alters the activity of cholesterol ester transfer protein, causing decreased HDL (protective cholesterol). [32] This condition also leads to the inability to breakdown clotting proteins leading to increased risk of clotting and heart attack and stroke. [33] [34] Therefore, insulin resistance leads to elevated cholesterol, decreased HDL, elevated blood pressure, and increased risk of clotting. This condition is known as metabolic syndrome, also referred to as “pre-diabetes”. This condition is called a “syndrome” because it is identified by having any 3 of 5 cardiometabolic risk factors. It doesn’t meet the strict criteria for diabetes but damage occurs in the heart, circulatory system, endocrine system and brain before you get diabetes. Diagnostic criteria for metabolic syndrome: The diagnosis of metabolic syndrome is applied when 3 of the following 5 criteria are met: Abdominal obesity (men &gt;40 in., women &gt;35 in.) Fasting glucose &gt;110 to 126 BP &gt; 130/80 Triglycerides &gt;150 HDL (men &lt;40, women &lt;50) Insulin Resistance and Hormone Imbalances Elevated Testosterone in Females Excess insulin in females is a major driver of testosterone which leads to polycystic ovarian syndrome (PCOS). [35] Insulin upregulates an enzyme of the ovaries (17,20 lyase of the theca cells) causing increased testosterone production in females. [36] These upregulated testosterone pathways and its consequences result in polycystic ovarian syndrome (PCOS). PCOS is the #1 cause of infertility in U.S. [37] [38] PCOS is primarily characterized by signs of excess androgens (ie: testosterone), insulin resistance and chronic anovulation (no ovulatory cycles). Symptoms range from mild to severe. Insulin resistance in females leads to the following symptoms: Irregular periods Infertility Thinning of hair and hair loss Growth of facial hair Acne Weight gain Inability to burn body fat Fluid retention Fatigue Mood swings Depression This syndrome is also associated with estrogen proliferative cancers (ie: breast and uterine), [39] skin discoloration (acanthosis nigricans), [40] and increased cardiovascular risks. [41] Elevated Estrogen in Males In males , insulin upregulates the enzyme aromatase found in body fat, causing conversion of testosterone to estradiol. This throws off the testosterone to estradiol ratio, promoting further insulin resistance. [42] Low testosterone levels have been correlated with increased obesity, an increased waist-to-hip ratio, insulin insensitivity with higher concentrations of glucose and insulin, and increased cardiovascular risk factors including: an increase in low-density lipoproteins (LDL), a decrease in high-density lipoproteins (HDL), increased fibrinogen levels and an increase in apolipoprotein B. [43] [44] [45] [46] [47] Insulin resistance also causes increased cytokine activity (low-grade chronic inflammation) putting these men at additional risk for heart attack and other chronic diseases. [48] “There is a common pathophysiology of insulin resistance, cytokines, and testosterone all engaged together” [49] Insulin resistance in males leads to the following symptoms: low libido depression irritability and easily angered become emotionally sensitive feel warm all the time and preference for cool temperatures have frequent sweating attacks Insulin Resistance and Obesity Insulin resistance plays a major role in the current obesity trends in the U.S. In insulin resistance, the cells are unable to transport glucose into the cells to be used for energy. Glucose is then forced to take an alternative pathway into lipogenesis (the creation of fats in the form of adipose tissue). This pathway is heavily dependent on ATP (your body’s primary source of fuel). This may explain why people with this condition often have fatigue after meals. There is also accumulating evidence that obesity induces insulin resistance. [50] [51] So there appears to be a “vicious cycle” that occurs between the development of obesity and insulin resistance. Secondly, there are relationships that exist between insulin, cortisol and leptin which contribute to obesity. Leptin is a hormone produced by adipose tissue that is responsible for decreasing appetite and regulating fat storage. Insulin is an adrenal stimulant and drives up cortisol levels. This elevation of cortisol causes leptin resistance by increasing leptin to very high levels and inhibiting leptin receptors. This leads to decreased potential to burn fat and increased potential to store fat and be hungry all the time. [52] [53] [54] Insulin Resistance and Impaired Liver Detoxification Dysglycemia and insulin resistance also leads to compromised phase I and phase II liver detoxification pathways. [55] [56] These are important pathways of the liver involved in eliminating certain drugs, toxins and hormones from the body. Insulin surges downregulate one of the enzymes (G6PD) involved in glutathione production. [57] [58] When glutathione levels are suppressed, phase I and phase II detoxification will be compromised. Glutathione is the main antioxidant for our cells and is important for both phase I and phase II pathways of detoxification . When glutathione levels drop, inflammatory processes associated with aging such as neuropathies, [59] vascular disease, [60] autoimmune disease, [61] neurodegenerative disease, [62] and many other problems develop as documented in numerous studies. [63] [64] [65] Chronic dysglycemia causes compromised liver pathways and ability to clear drugs and toxins from the body leading to symptoms associated with toxicity, such as acne, constipation, bloating and drug or chemical sensitivities. Insulin Resistance and “Leaky Gut” Elevated cortisol levels seen in insulin resistance have adverse effects on the gastrointestinal tract by suppressing secretory IgA (SIgA), delaying mucosal cell regeneration and by promoting a pro-inflammatory environment. [66] [67] [68] SIgA cells are the barrier defense cells of the gastrointestinal (GI) lining and protect against GI infection. “Leaky gut” (intestinal permeability) patterns develop when SIgA levels drop. “Leaky gut” is a condition in which the barrier of the intestinal tract becomes compromised and there is increased penetration of large molecules, such as undigested protein molecules, bacteria and toxins. [69] This leads to chronic inflammation and increased risk of autoimmune disease. [70] “There is growing evidence that increased intestinal permeability plays a pathogenic role in various autoimmune diseases. Therefore, we hypothesize that loss of intestinal barrier function is necessary to develop autoimmunity” [71] Insulin Resistance and Depression, Dementia and Neurodegenerative Disease Pioneering new work out of Harvard and Brown universities from Dr. Denis Selkoe and Suzanne de la Monte has proved that insulin resistance is a major factor in starting the cascade of brain damage that steals the memory of over half of people in their eighties, leading to a diagnosis of Alzheimer’s disease . The reason is that insulin resistance leads to a cascade of damage, which produces the inflammation so characteristic of brain problems, especially dementia and depression. [72] Recent studies have shown that diabetics have a fourfold increased risk of developing Alzheimer’s disease. There is such a close association between insulin resistance of the brain and the development of Alzheimer’s disease, that this disease is now being called “type 3 diabetes”. [73] One study of 2,632 men and women over five years recently published in JAMA found that those with metabolic syndrome and inflammation had dramatic declines in cognitive function. [74] It is called mild cognitive impairment. This is a prelude to dementia. PET scans which look at brain metabolism have found altered and damaged brain function that occurs far in advance of the diagnosis of dementia. [75] Some experts say that changes can be identified decades before diagnosis. This process of decline starts in childhood and adolescence. Given the epidemic of childhood obesity and the fact that we are seeing heart disease in twenty-year-olds, we may soon see an epidemic of Alzheimer’s when these kids enter their forties and fifties. It is well known that depression is more common in diabetes, but a Finnish study of young men found that those who had the worst insulin resistance had an almost 3-fold risk of having severe depression. [76] Insulin Resistance and Cancer There is increasing evidence in the literature regarding the role excess insulin plays in carcinogenesis (initiation of cancer) for various types of cancer. [77] [78] The studies are becoming more conclusive on insulin’s role in promoting inflammatory responses and its numerous adverse impacts on human metabolism. Insulin and Chronic Inflammation As individuals develop insulin resistance and obesity, increased inflammatory cytokines (chemical messengers/mediators) are produced. [79] [80] [81] [82] Many of these cytokines fire each other up initiating further inflammatory processes. Increased inflammation promotes increased tissue destruction and catabolic (breakdown of tissue) processes in the body and many of the chronic diseases associated with aging as we will learn in the next article. Stay tuned! References: [1] Grimm JJ. Interaction of physical activity and diet: implications for insulin-glucose dynamics- Public Health Nutr 1999;2:363-368. [2] Moore MA, et al. Implications of the hyperinsulinemia -diabetes-cancer link for preventative efforts. Eur J Cancer Prev 1998;7:89-107 [3] Despres JP, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Eng J Med 1996;334:952-957. [4] Timonen, M. et al. 2007. Insulin resistance and depressive symptoms in young adult males: Findings from Finnish military conscripts. Psychosom Med 69(8):723-28 [5] Kinoshita, J.; Alzheimer Research Forum. 2006. Alzheimer Research Forum live discussion: Insulin resistance: a common axis linking Alzheimer’s, depression and metabolism? J Alzheimers Dis 9 (1):89-93 [6] Tiihonen M, Partinen M. Narvanen S. The severity of obstructive sleep apnea is associated with insulin resistance. J Sleep Res 1993;2:56-61. [7] Arthur LS, Selvakumar R, Seshardir MS. Hyperinsulinemia in polycystic ovary disease. J Reprod Med 1999;44:783-787. [8] Benzi L, et al. Intracellular hyperinsulinemia: a metabolic characteristic of obesity with and without type 2 diabetes: intracellular insulin in obesity and type 2 diabetes. Diabetes Res Clin Pract 1999:46:231-237. [9] Stoll BA. Essential fatty acids, insulin resistance and breast cancer risk Nutr Cancer 1998;31:72-77. [10] Bhashyam, S, et al. Aging is associated with myocardial insulin resistance and mitochondrial dysfunction. Am J Physiol Heart Circ Physiol. 2007 Nov;293(5):H3063-71. [11] Ryan AS. Insulin resistance with aging: effects of diet and exercise. Sports Med. 2000 Nov;30(5):327-46. Review [12] Johnson AM , Olefsky JM . The origins and drivers of insulin resistance. Cell. 2013 Feb 14;152(4):673-84. doi: 10.1016/j.cell.2013.01.041. [13] Ginter E , Simko V . Type 2 diabetes mellitus, pandemic in 21st century. Adv Exp Med Biol. 2012;771:42-50. [14] Mark Hyman. The Blood Sugar Solution; Little, Brown and Company. 2012 [15] Johnson AM , Olefsky JM . The origins and drivers of insulin resistance. Cell. 2013 Feb 14;152(4):673-84. doi: 10.1016/j.cell.2013.01.041. [16] http://apps.nccd.cdc.gov/DDTSTRS/FactSheet.aspx (National Diabetes Fact Sheet 2007) [17] http://www.cdc.gov/diabetes/statistics/cvd/fig5.htm [18] Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002 Dec 4;288(21):2709-16. [19] Kuwahara M, et al. Type II diabetes mellitus is a risk factor for heart failure in pre-dialysis patients. Ther Apher Dial. 2012 Dec;16(6):541-7. doi: 10.1111/j.1744-9987.2012.01090.x. Epub 2012 Aug 13. [20] Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology. 1999 Dec 10;53(9):1937-42. [21] Yoon JM, et al. Pre-existing diabetes mellitus increases the risk of gastric cancer: A meta-analysis. World J Gastroentero l. 2013 Feb 14;19(6):936-45. doi: 10.3748/wjg.v19.i6.936. [22] Fujii M, et al. A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma. Med Mol Morphol. 2013 Feb 22. [Epub ahead of print] [23] Bao C, et al. Diabetes mellitus and incidence and mortality of kidney cancer: A meta-analysis. J Diabetes Complications. 2013 Feb 20. pii: S1056-8727(13)00005-6. doi: 10.1016/j.jdiacomp.2013.01.004. [Epub ahead of print] [24] Zhu Z, et al. Diabetes mellitus and risk of bladder cancer: a meta-analysis of cohort studies. PLoS One. 2013;8(2):e56662. doi: 10.1371/journal.pone.0056662. Epub 2013 Feb 20. [25] Amudhan S , Krishnan A . Diabetes mellitus: a risk factor for cancer and non-vascular disease deaths too. Natl Med J India. 2011 Jul-Aug;24(4):222-4. [26] Pandey A , et al. Diabetes mellitus and the risk of cancer. Minerva Endocrinol. 2011 Sep;36(3):187-209. [27] Ugoya SO , et al. Clinically diagnosed diabetic neuropathy: frequency, types and severity. J Natl Med Assoc. 2006 Nov;98(11):1763-6. [28] Barkoudah E et al. Mortality rates in trials of subjects with type 2 diabetes. J Am Heart Assoc. 2012 Feb;1(1):8-15. doi: 10.1161/JAHA.111.000059. Epub 2012 Feb 20. [29] Cigolle CT et al. Geriatric conditions develop in middle-aged adults with diabetes. J Gen Intern Med. 2011 Mar;26(3):272-9. doi: 10.1007/s11606-010-1510-y. Epub 2010 Sep 29. [30] Zavaroni I, Mazza S, Dall’aglio E, et al. Prevelance of hyperinsulinemia in patients with high blood pressure. J int Med 1992;231:235-240. [31] Dietschy JM, Brown MS. Effect of alterations of the specific activity of the intracellular acetyl CoA pool apparent rates of hepatic cholesterogenesis. J Lipid Res 1974;15:508-516. [32] Swensen TL. The role of cholesteryl ester transfer protein in lipoprotein metabolism. Diabetes Metab Res 1991;7:139-153. [33] Potter van Loon, et al. The cardiovascular risk factor plasminogen activator inhibitor type I is related to insulin resistance. Metabolism 1993;42:945-949. [34] Juhan-Vague, et al. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. Circulation 1996;94(9):2057-2063. [35] Stepto NK , et al. Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp. Hum Reprod. 2013 Mar;28(3):777-84. doi: 10.1093/humrep/des463. Epub 2013 Jan 12. [36] Jakubowski L . Endokrynol Pol. 2005 May-Jun;56(3):285-93. Review. [Genetic aspects of polycystic ovary syndrome]. [37] Sozen I, Arici A. Hyperinsulinism and its interaction with hyperandrogenism in polycystic ovary syndrome. Obest Gynecol Surv 2000;55:321-328. [38] Nestler J. Insulin resistance effects on sex hormones and ovulation in the polycystic ovary syndrome. In:Reaven G, Laws A, eds. Contemporary Endocrinology; Insulin Resistance . Totowa NJ: Humana Press; 1999.347-365. [39] Dahlgreen E, et al. Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long term follow-up focusing on natural history and circulating hormones. Fertil Steril 1992;57:505-513. [40] Oberfiled S. Metabolic lessons from the study of young adolescents with polycystic ovary syndrome, is insulin indeed the culprit. J Clin Endocrinol Metab 2000;85:3520-3525. [41] Wild RA. Obesity, lipids, cardiovascular risk and androgen excess. Am J Med 1995;98:27S-32S. [42] The promoters of the aromatase gene in male testicular cells. Reprod Biol . 2004 Mar;4(1):23-34 [43] Phillips GB, Pinkernall BH, Jing TY. The association of hypotestosteronemia with coronary artery disease in men. Arterioscler Thromb 1994;14:701-706 [44] Zgliczynski S, et al. Effects of testosterone replacement thereapy on lipids and lipoproteins in hypogonadic and elderly men. Atherosclerosis . 1996:121(1):35-43 [45] Chou T, et al. Testosterone induces dilation of canine coronary conductance and resistance arteries in vivo. Circulation . 1996:94(10):2614-2619 [46] Phillips G, et al. Sex hormones and hemostatic risk factors for coronary heart disease in men with hypertension. J of Hypertension. 193:11(7):699-702 [47] Jepsen L, et al. Decreased serum testosterone in men with acute ischemic stroke. Arterioscler Thromb Basc Biol, 1996:16(6):749-754 [48] Hypogonadotrophic hypogonadism in type 2 diabetes Aging Male . 2008 Sep;11(3):107-117 [49] Testosterone deficiency, insulin resistance and the metabolic syndrome. Nat Rev Endocrinol . 2009 Dec;5;(12):673-681 [50] Johnson AM , Olefsky JM . The origins and drivers of insulin resistance. Cell. 2013 Feb 14;152(4):673-84. doi: 10.1016/j.cell.2013.01.041. [51] Galgani J , Díaz E . Rev Med Chil. 2000 Dec;128(12):1354-60. [Obesity and fatty acids in the etiology of insulin resistance]. [52] Zakrzewska KE, et al. Glucocorticoids as counterregulatory hormones of leptin: toward an understanding of leptin resistance. Diabetes 1997;46:717-719. [53] Zakrzewska, et al. Induction of obesity and hyperleptinemia by central glucocorticoid infusion in the rat. Diabetes 1999;48:365-370. [54] Bermeis K, Vosmeer S, Kelly U. Effects of glucocorticoids and of growth hormone on serum leptin concentrations in man. Eur J Endocrinol 1996;663-665. [55] Vávrová L , et al. Altered Activities of Antioxidant Enzymes in Patients with Metabolic Syndrome. Obes Facts. 2013 Feb 21;6(1):39-47. [Epub ahead of print]. [56] Ozgen IT , et al. Oxidative stress in obese children and its relation with insulin resistance. J Pediatr Endocrinol Metab. 2012;25(3-4):261-6. [57] Xu, Y, et al. Diabetes causes inhibition of glucose-6-phosphate dehydrogenase via activation of PKA, which contributes to oxidative stress in rat kidney cortex. Am J Physiol Renal Physiol. 2005 Nov;289(5):F1040-7. Epub 2005 Jun 14. [58] Iwakiri, R, et al. Determinants of hydroperoxide detoxification in diabetic rat intestine: effect of insulin and fasting on the glutathione redox cycle. Metabolism . 1995 Nov;44(11):1462-8. [59] Cameron NE, Cotter MA. Metabolic and vascular factors in the pathogenesis of diabetic neuropathy. Diabetes. 1997 Sep;46 Suppl 2:S31-7. [60] Weldy CS, et al. Glutathione (GSH) and the GSH synthesis gene Gclm modulate vascular reactivity in mice. Free Radic Biol Med. 2012 Sep 15;53(6):1264-78. doi: 10.1016/j.freeradbiomed.2012.07.006. Epub 2012 Jul 21. [61] Shah D, et al. Altered redox state and apoptosis in the pathogenesis of systemic lupus erythematosus. Immunobiology . 2012 Aug 4. [Epub ahead of print] [62] Lee M, et al. Depletion of GSH in glial cells induces neurotoxicity: relevance to aging and degenerative neurological diseases. FASEB J. 2010 Jul;24(7):2533-45. doi: 10.1096/fj.09-149997. Epub 2010 Mar 12. [63] Mari M, et al. Mitochondrial glutathione: Features, regulation and role in disease. Biochim Biophys Acta. 2012 Oct 30. pii: S0304-4165(12)00304-2. doi: 10.1016/j.bbagen.2012.10.018. [Epub ahead of print] [64] Droge W and Breitkreutz R. Glutathione and immune function . Proc Nutr Soc . 2000. 59 (4):595-600. Review [65] Faut M, et al. Alterations of the redox state, pentose pathway and glutathione metabolism in an acute porphyria model. Their impact on heme pathway. Exp Biol Med (Maywood). 2013 Feb 6. [Epub ahead of print] [66] Guhad, FA, et al. Salivary IgA as a marker of social stress in rats. Neurosci Lett , 216(2). 137-140, 1996. [67] Cunningham-Rundies, C., et al. Proc. Nat Acada. Sci USA. 75:3387, 1978. [68] Cunningham-Rundies, C., et al. J Clin Invest . 64:270, 1979. [69] Liu Z, et al. Tight junctions, leaky intestines, and pediatric diseases. Acta Paediatr . 2005 Apr;94(4):386-93. [70] Mechanisms of disease: the role of intestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases. Nat Clin Pract Gastroenterol Hepatol. 2005 Sep;2(9): 416-22 [71] Tight junctions, intestinal permeability, and autoimmunity: celiac disease and type 1 diabetes paradigms. Ann N Y Acad Sci. 2009 May;1165:195-205 [72] Kinoshita, J.; Alzheimer Research Forum. 2006. Alzheimer Research Forum live discussion: Insulin resistance: a common axis linking Alzheimer’s, depression and metabolism? J Alzheimers Dis 9 (1):89-93 [73] De la Monte SM, Wands JR. Alzheimer’s disease is type 3 diabetes—evidence reviewed. J Diabetes Sci Technol. 2008 Nov;2(6):1101-13. [74] Yaffe, K. et al. 2004 The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA 292 (18):2237-2242. [75] Silverman, DH, et al. 2001. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA 286(17):2120-127. [76] Timonen, M. et al. 2007. Insulin resistance and depressive symptoms in young adult males : Findings from Finnish military conscripts. Psychosom Med 69(8):723-28 [77] Perseghin G et al. Insulin resistance/hyperinsulinemia and cancer mortality: the Cremona study at the 15th year of follow-up. Acta Diabetol. 2012 Dec;49(6):421-8. doi: 10.1007/s00592-011-0361-2. Epub 2012 Jan 4. [78] Faulds MH , Dahlman-Wright K . Metabolic diseases and cancer risk. Curr Opin Oncol. 2012 Jan;24(1):58-61. doi: 10.1097/CCO.0b013e32834e0582. [79] Ojeda-Ojeda M, et al. Mediators of Low-Grade Chronic Inflammation in Polycystic Ovary Syndrome (PCOS). Curr Pharm Des. 2013 Feb 20. [Epub ahead of print] [80] Boden G, Salehi S. Why Does Obesity Increase the Risk for Cardiovascular Disease? Curr Pharm Des. 2013 Feb 20. [Epub ahead of print] [81] Mauvais-Jarvis F . Novel link between inflammation, endothelial dysfunction, and muscle insulin resistance. Diabetes. 2013 Mar;62(3):688-90. doi: 10.2337/db12-1434. [82] Vávrová L , et al. Altered Activities of Antioxidant Enzymes in Patients with Metabolic Syndrome. Obes Facts. 2013 Feb 21;6(1):39-47. [Epub ahead of print]","date_published":"2013-03-04T04:52:53","date_modified":"2020-04-16T14:15:17","authors":[{"name":"Dr. Richard Esquivel","url":"https://sanjosefuncmed.com/about/"}],"tags":["Metabolic Health"]},{"id":"https://sanjosefuncmed.com/intestinal-permeability-chronic-disease-connection/","url":"https://sanjosefuncmed.com/intestinal-permeability-chronic-disease-connection/","title":"The Intestinal Permeability and Chronic Disease Connection","summary":"The intestinal permeability and chronic disease connection: (type 1 diabetes, autoimmune hepatitis, chronic fatigue syndrome, heart failure, depression and ch","content_text":"The intestinal permeability and chronic disease connection: (type 1 diabetes, autoimmune hepatitis, chronic fatigue syndrome, heart failure, depression and chronic pain) This is part 2 of a 5-part series on Intestinal Permeability (Leaky Gut) Main points of this issue: Intestinal permeability is a precondition for the development of autoimmune disease The connection between intestinal permeability and type I diabetes The connection between intestinal permeability and autoimmune hepatitis The connection between intestinal permeability and chronic fatigue syndrome The connection between intestinal permeability and heart failure The connection between intestinal permeability and depression Patients with intestinal permeability will have symptoms of fatigue, depression, and pain (inflammation) Intestinal Permeability and Autoimmune Disease As we learned in Part 1, there is a growing amount of evidence establishing the connection between intestinal permeability and the development of autoimmune disease. This review paper was published in 2009 in the Annals of New York Academy of Science . This journal is one of the top-rated, most powerful scientific journals available: “There is growing evidence that increased intestinal permeability plays a pathogenic role in various autoimmune diseases. Therefore, we hypothesize that loss of intestinal barrier function is necessary to develop autoimmunity.”1 Basically, what this paper is saying, is that the research is pointing to intestinal permeability, or leaky gut, as a precondition for the development of autoimmune disease . Let’s take a closer look at the evidence supporting this connection. Intestinal Permeability and Autoimmune (Type 1) Diabetes “Increased intestinal permeability has also been observed in animal models of type 1 diabetes as well as in humans with or at increased risk for the disease. An altered mucosal immune system has been associated with the disease and is likely a major contributor to the failure to form tolerance. This results in the autoimmunity that underlies type 1 diabetes.”2 This paper is stating that intestinal permeability is “likely a major contributor” to loss of immune tolerance to self-tissue and the development of autoimmune diabetes. Here is another paper that supports the connection between intestinal permeability and the development of type I diabetes: “These findings indicate the presence of an intestinal permeability associated with type 1 diabetes that is already detectable before clinical onset of the disease. The findings also suggest that the small intestine is an organ participating in the pathogenetic process of type 1 diabetes.”3 Intestinal Permeability and Autoimmune Hepatitis This paper reviews the evidence in support of the connection between intestinal permeability and autoimmune hepatitis: “In this paper, we review the evidence for microbial infection and leaky gut syndrome that might give rise to chronic hepatic inflammatory disorders with features of autoimmunity.”4 Intestinal Permeability and Chronic Fatigue Syndrome Research is now linking leaky gut with CFS. This is a great paper published in 2008: “The results show that normalization of the IgA and IgM responses to translocated LPS may predict clinical outcome in chronic fatigue syndrome (CFS). The results support the view that a weakened tight junction barrier with subsequent gut-derived inflammation is a novel pathway in CFS, and that it is a new target for drug development in CFS. Meanwhile, CFS patients with leaky gut can be treated with specific natural anti-inflammatory and anti-oxidative substances and a leaky gut diet.”5 This paper is a great example of evidence-based medicine. The researchers identify the mechanism involved and since there is no drug available to treat this, they recommend diet and natural supplements. The fact that there is no drug available to treat this is one of the reasons this condition is being ignored by the healthcare model. Intestinal Permeability and Heart Failure Here are two studies suggesting a connection between gut permeability and the development of chronic heart failure: “Recent studies suggest an altered morphology, permeability, and absorption of the digestive tract in chronic heart failure. Both lack of mucosal integrity with consecutive local and systemic inflammation, and dysfunction of transport proteins may worsen the clinical symptoms of chronic heart failure. Therefore, future studies need to address the pathophysiology of the intestinal barrier whose reactivity seems to be crucial for heart function.”6 “There is increasing evidence to suggest that a &#8216;leaky’ bowel wall may lead to translocation of bacteria and/or endotoxin, which may be an important stimulus for inflammatory cytokine activation in chronic heart failure.”7 Intestinal Permeability and Depression There is growing evidence linking gut permeability with depressive disorders. Here are three papers supporting this connection. “The above-mentioned results indicate that both chronic fatigue syndrome and major depressive disorder are accompanied by an increased gut permeability, which has allowed an exaggerated passage of proteins through a compromised epithelial barrier.”8 “This paper hypothesizes that inflammatory, oxidative and nitrosative pathways, and an increased translocation of LPS from gram-negative bacteria from leaky gut are causally related to depression and novel targets for antidepressant development.”9 Here is an interesting study. Basically, this paper concludes that patients with major depression should be checked for leaky gut and treated for this, if found! “The results show that intestinal mucosal dysfunction, characterized by an increased translocation of gram-negative bacteria known as leaky gut, plays a role in the inflammatory pathophysiology of depression. It is suggested that patients with major depression should be checked for leaky gut and accordingly, should be treated for leaky gut.”10 Review of Concepts and Discussion: Intestinal permeability has been linked to several chronic diseases in the literature, including autoimmune disease, chronic fatigue syndrome, heart disease and depression. The real question is: “What role does intestinal permeability play in the development of these diseases?” The research is pointing to an understanding of intestinal permeability as a mechanism for the development of autoimmunity and other chronic disease. This means, from a clinical standpoint, the restoration of the integrity of the gut barrier should be made a priority and opens up a new and potentially significant therapeutic approach to the management of these chronic health conditions. As we will see in upcoming issues, this can be done through dietary modification and intake of nutritional compounds that have been shown to improve the health of the gastrointestinal lining. These changes can have a profound effect on the symptomology of these individuals. Content provided by Datis Kharrazian, D.C., Breaking the Complex Web of Leaky Gut Syndrome, 2/10/11 In part 3 of this 5-part series , we answer the following questions: What are the most common symptoms and signs associated with intestinal permeability? When do we suspect it? How do we test for it? Continue to part 3 of series References: 1. Tight junctions, intestinal permeability, and autoimmunity: celiac disease and type 1 diabetes paradigms. Ann N Y Acad Sci. 2009 May;1165:195-205 2. The “perfect storm” for type 1 diabetes: the complex interplay between intestinal microbiota, gut permeability, and mucosal immunity. Diabetes. 2008 Oct;57(10):2555-62 3. Increased intestinal permeability precedes clinical onset of type 1 diabetes Diabetologia. 2006 Dec;49(12):2824-7. Epub 2006 Oct 7 4. Atypical p-ANCA in PSC and AIH: a hint towards a \u001aleaky gut\u001a? Clin Rev Allergy Immunol. 2009 Feb;36(1):40-51 5. Normalization of leaky gut in chronic fatigue syndrome is accompanied by a clinical improvement: effects of age, duration of illness and the translocation of LPS from gram-negative bacteria. Neuro Endocrinol Lett. 2008 Dec;29(6):902-10 6. The emerging role of the gut in chronic heart failure. Curr Opin Nutr Metab Care. 2008 Sep;11(5):632-9 7. The importance of the gastrointestinal system in the pathogenesis of heart failure. Eur Heart J. 2005 Nov;26(22):2368-74 8. An IgM-mediated immune response directed against nitro-bovine serum albumin (nitro-BSA) in chronic fatigue syndrome (CFS) and major depression: evidence that nitrosative stress is another factor underpinning the comorbidity between major depression and CFS. Neuro Endocrinol Lett. 2008 Jun;29(3):313-9 9. The cytokine hypothesis of depression: inflammation, oxidative and nitrosative stress (IO&NS) and leaky gut as new targets for adjunctive treatments in depression. Neuro Endocrinol Lett. 2008 Jun;29(3):287-91 10. The gut-brain barrier in major depression: intestinal mucosal dysfunction with an increased translocation of LPS from gram-negative enterobacteria (leaky gut) plays a role in the inflammatory pathophysiology of depression. Neuro Endocrinol Lett. 2008 Feb;29(1):117:24","date_published":"2012-05-25T01:51:38","date_modified":"2020-04-19T22:34:05","authors":[{"name":"Dr. Richard Esquivel","url":"https://sanjosefuncmed.com/about/"}],"tags":["Digestive Health"]},{"id":"https://sanjosefuncmed.com/intestinal-permeability-clinical-unwinding-leaky-gut/","url":"https://sanjosefuncmed.com/intestinal-permeability-clinical-unwinding-leaky-gut/","title":"Intestinal Permeability: Clinical Unwinding of Leaky Gut","summary":"How do we address the treatment of intestinal permeability? Clinical unwinding of leaky gut. Is diet important in the treatment of leaky gut? Glutathione, Vit","content_text":"How do we address the treatment of intestinal permeability? Clinical unwinding of leaky gut. Is diet important in the treatment of leaky gut? Glutathione, Vitamin D and Leaky Gut This is part 5 of a 5-part series on Intestinal Permeability (Leaky Gut) Main points of this issue: Leaky gut is a condition that responds well to dietary modification and targeted nutritional supplements Our leaky gut treatment protocol is an aggressive and complete program designed to break the vicious cycle of leaky gut This protocol consists of a restricted dietary program and nutritional supplements that have been shown in the literature to reduce intestinal inflammation and repair the intestinal lining This protocol may need to be conducted for an extended period of time for more progressed cases, or for cases of systemic inflammation or autoimmunity The length of time required to make improvement in this condition depends on the mechanisms that are causing the leaky gut There will be some people that will have chronic leaky gut for the rest of their life, such as severe autoimmune patients, or systemic inflammatory conditions The nitric oxide synthase system must be addressed in the treatment of leaky gut The glutathione recycling system must be addressed in the treatment of leaky gut Vitamin D supplementation is important in the treatment of leaky gut Leaky Gut Treatment Protocol The treatment of leaky gut includes an aggressive and complete program designed to break the vicious cycle of leaky gut. This consists of a restricted dietary regimen and nutritional supplements that have been shown to help reduce intestinal inflammation and help repair the intestinal lining. This dietary program may need to be conducted for an extended period of time for more progressed cases, depending on the factors involved in promoting leaky gut. It can also be conducted for as little as a few days for quick recovery after exposure to intestinal food sensitivities. Length of Program Average leaky gut program: 10 days Moderate leaky gut program: 20 days Severe leaky gut program: 30-90 days Chronic leaky gut program: as needed Acute repair program: 3 days One of the things that will create variables for how long this will take are the mechanisms involved that are causing the leaky gut. If you are still consuming alcohol or consuming inflammatory foods or have hormonal deficiencies or have blood sugar issues, this will take longer to correct. There will be some people that will have chronic leaky gut for the rest of their life, such as severe autoimmune patients and systemic inflammatory conditions. Foods to Avoid Sugars: including corn syrup, high fructose corn syrup, molasses, honey, chocolate candy, etc. High glycemic fruits: watermelon, mango, pineapple, raisins and canned fruit Grains: including gluten, wheat, oats, rice, barley, buckwheat, soy, corn, wheat germ, spelt, amaranth, kamut, millet, and quinoa, etc. Gluten-containing compounds: including processed salad dressings, ketchup, soy sauce, barbecue sauce, condiments, modified starches, etc. Dairy: including milk, whey, eggs, cheeses, creams, and mayonnaise, etc. Soy: including soy milk, soy sauce, soy protein, etc. Alcohol: including beer, wine, sake, cognac, liquors, etc. Lectins: including nuts, beans, soy, potatoes, tomato, eggplant, pepper, peanut oil, soy oil, etc. Coffee Processed foods Canned foods Foods to Eat Most vegetables (except tomato, potatoes and mushrooms): including asparagus, spinach, lettuce, broccoli, beets, cauliflower, carrots, celery artichokes, garlic, onions, zucchini, squash, rhubarb, cucumbers, turnips, watercress, etc. Fermented foods: including sauerkraut, kimchi, pickled ginger, mixed pickle, coconut yogurt, kombucha tea, etc. Meats: including fish, chicken, beef, lamb, organ meats, etc. Low glycemic foods: apricot, plum apple, peach, pear, cherries, berries, etc. Coconut: including coconut oil, coconut bitter, coconut milk, etc. Herbal teas Olives and olive oil Avoid Gluten It is important to avoid gluten if you have intestinal permeability. Once intestinal permeability develops, gluten sensitivity will develop in almost all cases. Gluten sensitivity will also promote intestinal permeability by activating zonulin (the protein that binds the epithelial cells together). Gluten has been shown to activate the zonulin system directly and continue to promote leaky gut. “Gliadin binds to chemokine receptor CXCR3 and leads to MyD88-dependent zonulin release and increased intestinal permeability.”1 Key Nutritional Supplements in the Treatment of Leaky Gut Syndrome When it comes to the treatment of leaky gut, there are two critical systems that need to be addressed: The Nitric Oxide Synthase system The Glutathione Recycling system The Role of the Nitric Oxide System in Leaky Gut Syndrome When you look at the nitric oxide system, there are 3 different forms of nitric oxide nNOS eNOS iNOS Forms of Nitric Oxide Synthase: nNOS optimizes neuronal synapses protects the neurons eNOS helps tissue recover and regenerate dissolves endothelium plaques dilates blood vessels iNOS Promotes tissue destruction Promotes inflammation Promotes AI attack People that have autoimmunity have poor eNOS and nNOS and very high iNOS, which means they are inflamed but cannot get blood flow or neurologic activity going. When people have nitric oxide system dysfunction, they end up with breakdown of their intestinal barrier. “iNOS up-regulation and oxidation/nitration of intestinal cytoskeletal proteins, promotes intestinal leakiness.”2 Large amounts of iNOS can increase gut permeability, induce apoptosis and stimulate intestinal secretion.”3 It is known that the overproduction of iNOS is related to intestinal destruction and inflammation. iNOS inhibitors should be considered as potential anti-inflammatory agents for intestinal injury.”4 One of the goals of treatment of intestinal permeability is to provide compounds that are used to support the expression of eNOS and nNOS, while dampening the expression of iNOS. Compounds that have been shown to modulate the Nitric Oxide System Adeniosine Huperzine A Vinpocetine L-alpha-glycerylphosphosphorylcholine Alpha-ketogluteric acid (AKG) Xanthinol niacinate L-acetylcarnitine (LAC) The Role of the Glutathione Recycling System in Leaky Gut Syndrome Glutathione is the main antioxidant that protects cellular mitochondria. Glutathione exists in reduced (GSH) and oxidized (GSSG) states. GSH (reduced glutathione) becomes GSSG (oxidized glutathione) by an enzyme called glutathione peroxidase. GSH can be regenerated from GSSG by the enzyme glutathione reductase. As long as these enzymes are working efficiently, your body is able to maintain this glutathione recycling system and you are fine. When this enzyme system fails, you get activation of iNOS and autoimmunity. The ability to activate these enzymes is critical for autoimmunity. You don’t get leakiness of gut until glutathione stores are depleted “Glutathione depletion aggravated ileal inflammation after infection.” “Glutathione is suggested to play an important role in gut barrier function and prevention of intestinal inflammation.” “Intestinal barrier destruction occurs once glutathione is depleted.”5 In other words, if your glutathione levels are healthy, you will not get intestinal destruction. “A recent study investigated the role of reactive oxygen species (ROS) modulation with intestinal mucosal permeability damage.” “Treatment with glutathione precursors prevented the MTX (methotrexate)-induced ROS production and the increase of paracellular permeability.”6 “The researchers concluded that data support the hypothesis that the GSH antioxidant system plays a crucial role in gut barrier protection.”7 If you look at the literature, there are several compounds that help raise intracellular glutathione, activate the glutathione peroxidase and reductase enzymes, and make this process work more efficiently. Compounds that have been shown to modulate the Glutathione Recycling System Cordyceps: found to raise intracellular RBC glutathione levels by 300% within minutes and has a powerful effect on the enzymes that increase glutathione Centella asiatica Silybum marianum N-acetyl-cysteine Alpha lipoic acid L-glutamine Selenium Vitamin D and Leaky Gut Don\u001at forget about the importance of vitamin D for intestinal permeability and autoimmunity: “There is growing appreciation of the importance of the pleiotropic hormone vitamin D in the development of tolerance, immune system defenses, and epithelial barrier integrity.”8 “These observations suggest that vitamin D plays a critical role in mucosal barrier homeostasis by preserving the integrity of junction complexes and the healing capacity of the colonic epithelium.9 Content provided by Datis Kharrazian, D.C., Breaking the Complex Web of Leaky Gut Syndrome, 2/10/11 References: 1. Gliadin induces an increase in intestinal permeability and zonulin release by binding to the chemokine receptor CXCR3. Gastroenterology. 2008 Jul;135(1):194-204.e3 2. Nitric oxide-mediated intestinal injury is required for alcohol-induced gut leakiness and liver damage. Alcohol Clin Exp Res. 2009 Jul;33(7):1220-30. Epub 2009 Apr 9 3. Targeting nitric oxide in the GI tract. Curr Opin Investing Drug. 2004 May;5(5):529-36 4. iNOS expression in oral and gastrointestinal tract mucosa. Dig Dis Sci. 2008 Jun;53(6):1437-42 5. Intestinal barrier function in response to abundant or depleted mucosal glutathione in Salmonella-infected rats. BMC Physiol. 2009 Apr 17:9:6 6. Oxidative stress and enhanced paracellular permeability in the small intestine of methotrexate treated rats. Cancer Chemother Pharmacol. 2010 May;65(6):1117-2 7. The role of the glutathione antioxidant system in gut barrier failure in a rodent model of experimental necrotizing enterocolitis. Surgery. 2004 Sep;136(3):557-66 8. Potential mechanisms for the hypothesized link between sunshine, vitamin D, and food allergy in children. J Allergy Clin Immunol. 2010 Aug;126 (2):217-22 9. Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal barrier. Am J Physiol Gastrointest Liver Physiol. 2008 Jan; 294(1):G208-16","date_published":"2012-05-25T02:19:15","date_modified":"2020-04-19T22:21:20","authors":[{"name":"Dr. Richard Esquivel","url":"https://sanjosefuncmed.com/about/"}],"tags":["Digestive Health"]},{"id":"https://sanjosefuncmed.com/intestinal-permeability-leaky-gut-2/","url":"https://sanjosefuncmed.com/intestinal-permeability-leaky-gut-2/","title":"Intestinal Permeability (Leaky Gut)","summary":"By now, most people have heard of leaky gut syndrome but are still wondering if this is real or if this is folklore medicine. Leaky gut syndrome is very real.","content_text":"In this issue, we discuss a common clinical condition known as intestinal permeability in the literature, also known as “leaky gut”. We discuss the most common signs and symptoms associated with this condition, reliable testing methods for this and review the literature on the leaky gut—autoimmune connection. Is leaky gut syndrome real? By now, most people have heard of leaky gut syndrome but are still wondering if this is real or if this is folklore medicine. Leaky gut syndrome is very real. The immunological literature is filled with information on leaky gut syndrome. In the immunological literature, leaky gut syndrome has been linked to autoimmune disease, depression, congestive heart failure and pediatric diseases such as autism. It is called intestinal permeability compromise in the literature and is much more common than most people and doctors realize. What is intestinal permeability (or “leaky gut” syndrome)? For a more complete discussion of intestinal permeability, click here: What is Intestinal Permeability or “Leaky Gut”? The lining of the gastrointestinal (GI) tract is composed of small epithelial cells that lie side-by-side each other forming tight junctions . These tight junctions act as a barrier between the interior of the body (blood/circulatory system) and the exterior of the body (the GI tract). There are two primary functions of the epithelial lining of the GI tract: the first is to absorb small, micromolecules , such as digested food particles, which are used as fuel sources and other processes for the body. These micronutrients are absorbed directly into the epithelial cells or between the cells and enter the bloodstream after passing through the gut-associated lymphoid tissue (GALT), the underlying intestinal immune system. The GALT serves as a containment system, preventing potentially harmful antigens from reaching systemic circulation. “A more attentive analysis of the anatomic and functional arrangement of the gastrointestinal tract, however, suggests that another extremely important function of this organ is its ability to regulate the trafficking of macromolecules between the environment and the host through a barrier mechanism.”(1) The second function of the epithelial lining of the GI tract, is to prevent the absorption of larger macromolecules which should not normally penetrate through the intestinal barrier. When tight junctions of the intestinal mucosa are compromised, they become widened and permeable to large undigested food compounds, toxins and bacteria. This is known as intestinal permeability or “leaky gut”. The larger compounds of absorbed yet undigested proteins are reacted against by the GALT (gut-associated lymphoid tissue). This reaction then promotes exaggerated immune responsiveness and intestinal inflammation. The Vicious Cycle of Leaky Gut Once these tight junctions breakdown for whatever reason, the large compounds of undigested proteins that are absorbed are reacted against by the underlying intestinal immune system. This promotes exaggerated immune responsiveness which causes further destruction of the tight junctions. So the immune response which results from intestinal permeability actually perpetuates further intestinal barrier destruction. This creates a vicious cycle of further intestinal inflammation and increased intestinal permeability.(2-5) Summary of Increased Intestinal Permeability (Leaky Gut) When tight junctions of the intestinal mucosa are compromised, they become widened and permeable to large, undigested compounds, toxins and bacteria, known as “leaky gut” The large compounds of absorbed yet undigested proteins are reacted against by the underlying intestinal immune system This reaction then promotes exaggerated immune responsiveness This creates a vicious cycle of further intestinal inflammation and greater loss of intestinal permeability What are the signs and symptoms of intestinal permeability? For a more complete list of signs and symptoms of intestinal permeability, click here: Symptoms and Common Imbalances Associated with Intestinal Permeability The most common symptoms of a person suffering from leaky gut syndrome are gastrointestinal symptoms such as bloating, gas, abnormal bowel movements, systemic inflammation and food sensitivities. Additionally, the development of any inflammatory symptoms after exposure to certain foods or diets may also indicate intestinal permeability dysfunction. On the other hand, the person with intestinal permeability may not complain of intestinal symptoms but have inflammatory issues such as chronic systemic joint pain, eczema, muscle aches, etc. Other times, the person will complain only of depression, brain fog or fatigue.(6) Leaky Gut Leads to Poor Digestion and Malabsorption When the intestinal mucosa of the GI tract becomes damaged, the damaged cells become unable to properly produce the enzymes necessary for digestion and absorption . The other consequence of intestinal permeability is malabsorption of nurients . Many of these leaky gut patients have nutrient malabsorption because of damage to the microvilli of the epithelial cells that occurs in leaky gut. The microvilli are the finger-like projections on the surface of the epithelial cells where absorption of nutrients takes place. You can think of these microvilli as the shag on a carpet. Each of these ‘shags’ absorbs a different type of nutrient. These damaged microvilli are then unable to absorb micronutrients efficiently. The larger molecules are able to penetrate because of their greater mass. So you get leaky gut with poor digestion and malabsorption . This leads to malnutrition, further intestinal inflammation, further intestinal permeability and the development of food sensitivities and bacterial and yeast overgrowths in the GI tract. Food Sensitivities Are Common in Leaky Gut The literature shows a close connection between increased food sensitivities and intestinal permeability. The mechanism is believed to be due to increased penetration of large undigested food peptides through the intestinal lining that are then reacted against by the immune system. Since these large molecules are foreign to the immune cells of the gut, they become targets of the immune system, leading to food sensitivities. “Intestinal permeability is increased in patients with food allergy, suggesting that the uptake of food antigens is elevated in food-allergic patients.”(7) Most Common Symptoms Associated with Leaky Gut Syndrome: Bloating and digestive complaints Depression Fatigue Chronic pain/inflammation Multiple food sensitivities Chronic yeast overgrowth syndromes Brain fog Intestinal permeability will cause systemic inflammation Intestinal permeability will cause systemic inflammation (throughout the circulatory system). If a person has their barrier system breached, they will have an increase in inflammatory responses which increases risk of all chronic disease, including neurodegeneration, cardiovascular disease, bone loss, etc. A person’s intestinal barrier integrity will influence their inflammatory load and their potential for deteriorating mechanisms. Intestinal permeability dysfunction should always be considered and assessed by proper laboratory testing when a person has autoimmune disease, systemic inflammation, depression, fatigue or any other degenerative or inflammatory condition. Assessment of Intestinal Permeability: Intestinal Permeability Antigenic Screen The Cyrex intestinal barrier function test is the most accurate intestinal barrier permeability test available and is currently the only lab that measures the immunological response against the intestinal barrier and accepted markers of permeability. The profile includes actin/myosin network IgG, occludin/zonulin IgG, IgA, IgM and lipopolysaccharides (LPS) IgG, IgA, and IgM . Measurements of these antibodies can be used as markers for intestinal permeability. Elevations of occludin/zonulin antibodies indicate breakdown of the intestinal barrier integrity through paracellular (tight junction) pathways . Elevations of actomyosin antibodies indicate breakdown of the intestinal barrier integrity through transcellular (across the intestinal cells) pathways and may also suggest possible autoimmunity against mucosal epithelium and other tissues that contain the actomyosin cytoskeleton. Elevations of LPS antibodies indicate excess penetration of LPS into the bloodstream (leakiness) . What Causes Leaky Gut? Below are the mechanisms that have been identified in the literature to be associated with risk of development of intestinal permeability/leaky gut. For a more complete discussion of the causes of leaky gut, click here: Intestinal Permeability: Mechanisms Leading to Leaky Gut Mechanisms of Leaky Gut Diet Alcohol Gluten Casein Processed foods Excess sugar Fast food Medication Corticosteroids NSAIDs (ie: ibuprofen, aspirin, other anti-inflammatory drugs) Antibiotics Antacids (and acid-supressing medications) Xenobiotics Infections H. pylori Bacterial overgrowth Yeast overgrowth Intestinal virus Parasitic infection Stress ↑ Cortisol ↑ CRH ↑ Catecholamines Hormonal ↓ Thyroid ↓ Progesterone ↓ Estradiol ↓ Testosterone Neurologic Brain trauma Stroke Neurodegeneration Metabolic Glycosylated end products Intestinal inflammation Autoimmunity How gluten sensitivity leads to intestinal permeability (leaky gut) All of the above conditions can increase risk of leaky gut. However, one of the most well-documented cause of leaky gut is gluten sensitivity. Immune responses to gliadin have been found to initiate intestinal permeability via upregulation of zonulin: “Gliadin and its peptides interact with the intestinal epithelium increasing intestinal permeability through the release of zonulin that, in turn, enables paracellular translocation of gliadin and its subsequent interaction with macrophages within the intestinal submucosa (in celiac disease patients).”(8) The Leaky Gut—Autoimmune Connection There is increasing evidence in the literature that intestinal permeability plays a major role in immune dysregulation and the potential for the development of autoimmune disease. One of the things we need in order to prevent autoimmune disease is immune self-tolerance (tolerance to self-tissue). The research is showing once these tight junction proteins get compromised, there is such immune zealousness and activation, immune self-tolerance is lost. Any tissue is up for grabs for autoimmune destruction. “It is now apparent that tight junctions are dynamic structures that are involved in developmental, physiological, and pathological processes. As a result, particular attention is being placed on the role of tight junction dysfunction in the pathogenesis of several diseases, particularly autoimmune diseases.”(9) “Together with the gut-associated lymphoid tissue and the neuroendocrine network, the intestinal epithelial barrier, with its intercellular tight junctions, controls the equilibrium between tolerance and immunity to non-self antigens. When the finely-tuned trafficking of macromolecules is dysregulated in individuals, both intestinal and extraintestinal autoimmune disorders can occur.”(10) “In all cases, increased permeability appears to precede disease and causes an abnormality in antigen delivery that triggers the multiorgan process leading to the autoimmune response.”(11) A recent article published in a well-respected medical journal hypothesized that intestinal permeability is a necessary pre-condition for the development of autoimmunity: “There is growing evidence that increased intestinal permeability plays a pathogenic role in various autoimmune diseases. Therefore, we hypothesize that loss of intestinal barrier function is necessary to develop autoimmunity.”(12) Leaky Gut Syndrome and Autoimmune Disease The recent literature shows leaky gut syndrome to be associated with a wide variety of autoimmune diseases affecting multiple organs, including the gastrointestinal system, liver and pancreas. It has even been associated with heart disease, chronic fatigue, depression, obesity and pediatric conditions such as autism. Below is a list of health conditions associated with leaky gut syndrome and excerpts from the recent literature supporting this connection. Health Conditions Associated with Leaky Gut Syndrome: Type 1 Diabetes Inflammatory bowel Disorders Autoimmune Hepatitis Cardiovascular Disease Chronic Fatigue Syndrome (CFS) Depression Pediatric Disorders Autism Leaky Gut Syndrome and Type1 Diabetes “These findings indicate the presence of an intestinal permeability associated with type 1 diabetes that is already detectable before clinical onset of the disease. The findings also suggest that the small intestine is an organ participating in the pathogenic process of type 1 diabetes.”(13) “The origin of beta-cell specific autoimmunity is not known in type 1 diabetes. Several studies of this disease in animal models indicate that the manifestation of autoimmune diabetes can be modified by factors which influence the gut immune system. Some indirect evidence from studies in patients with type 1 diabetes also suggests that aberrant function of the gut immune system may be involved in the development of this disease. These studies have encouraged the search for treatments interfering with mucosal immunity for the prevention of this disease.”(14) “Increased intestinal permeability has also been observed in animal models of type 1 diabetes as well as in humans with or at increased risk for the disease. Finally, an altered mucosal immune system has been associated with the disease and is likely a major contributor to the failure to form tolerance resulting in autoimmunity. This results in the autoimmunity that underlies type 1 diabetes.”(15) “Therefore, understanding the interactions between the upregulation of zonulin, increased intestinal permeability, and the development of autoimmune diseases may lead to novel preventative and possibly therapeutic strategies for type 1 diabetes.”(16) Leaky Gut Syndrome and Inflammatory Bowel Disorders (IBD) “A major task of the intestine is to form a defensive barrier to prevent absorption of damaging substances from the external environment. This protective function of the intestinal mucosa is called ‘permeability’. Ample evidence indicates that permeability is increased in most patients with Crohn’s disease and in 10% to 20% of their clinically healthy relatives. Permeability measurements in Crohn’s patients reflect the activity, extent, and distribution of the disease and may allow us to predict the likelihood of recurrence after surgery or medically induced remission. Permeability is also increased in Celiac disease and by trauma, burns and nonsteroidal anti-inflammatory drugs. The major determinant of the rate of intestinal permeability is the opening or closure of the tight junctions between enterocytes in the paracellular space.”(17) “The intestinal mucosal barrier has evolved to maintain a delicate balance between absorbing essential nutrients while preventing the entry of inappropriate molecules or substances and responding to harmful contents. In IBD, disruptions of essential elements of the intestinal barrier lead to permeability defects. These barrier defects exacerbate the underlying immune system, subsequently resulting in tissue damage. The epithelial phenotype in active IBD is very similar in both CD and UC. It is characterized by…increased permeability via both transcellular and paracellular routes and increased apoptosis of epithelial cells. Therapeutic restoration of the mucosal barrier would provide protection and prevent antigenic overload due to intestinal ‘leakiness’.”(18) Leaky Gut Syndrome and Autoimmune Hepatitis “Primary sclerosing cholangitis (PCS) and autoimmune hepatitis are enigmatic chronic inflammatory diseases of the liver, which are frequently associated with chronic inflammatory bowel diseases. In this paper, we review the evidence for microbial infection and leaky gut syndrome that might give rise to chronic hepatic inflammatory disorders with features of autoimmunity.”(19) Leaky Gut Syndrome and Cardiovascular Disease “Chronic heart failure is a multisystem disease with increased sympathetic tone, an anabolic/catabolic imbalance and chronic inflammation. Recent studies suggest an altered morphology, permeability, and absorption of the digestive tract in chronic heart failure…bacterial endotoxin is thought to enter the bloodstream through the hypoperfused edematous gut wall, thereby triggering an inflammatory response. A recent study focused on specific alterations of the gastric, small intestinal and large intestinal region in chronic heart failure. It describes the leaky intestinal barrier with an augmented bacterial biofilm that may contribute to chronic inflammation and malnutrition. Both lack of mucosal integrity with consecutive local and systemic inflammation and dysfunction of transport proteins may worsen the clinical symptoms of chronic heart failure. Therefore, future studies need to address the pathophysiology of the intestinal barrier whose reactivity seems to be crucial for heart function.”(20) “Chronic heart failure (CHF) is a multi-organ disease with increasing evidence for the involvement of the gastrointestinal system in this syndrome. In recent research, the gut has received very little attention from cardiologists as its role in the pathogenesis of cardiovascular disease is poorly understood. Intestinal ischemia may play an important role in bacterial translocation by increasing bowel permeability. Decreased cardiac function can reduce bowel perfusion and so clearly impairs the function of the intestinal barrier. There is increasing evidence to suggest that a ‘leaky’ bowel wall may lead to translocation of bacterial and/or endotoxin, which may be an important stimulus for inflammatory cytokine activation in CHF.”(21) Leaky Gut Syndrome and Chronic Fatigue Syndrome “The results support the view that a weakened tight junction barrier with subsequent gut-derived inflammation is a novel pathway in CFS, and that it is a new target for drug development in CFS. Meanwhile, CFS patients with leaky gut can be treated with specific natural anti-inflammatory and anti-oxidative substances and a leaky gut diet.”(22) “…CFS is accompanied by an increased translocation of endotoxins from gram-negative enterobacteria through the gut wall, as demonstrated by increased prevalences and median values for serum IgM and IgA against the endotoxins of gram-negative enterobacteria. This condition can also be described as increased gut permeability or leaky gut and indicates intestinal mucosal dysfunction (IMD). In one study, they reported a case of a 13-year old girl with CFS who showed very high values for serum IgM against the LPS of some enterobacteria and signs of oxidative and nitrosative stress, activation of the inflammatory response system, and IgG3 subclass deficiency. Upon treatment with specific antioxidants and a leaky gut diet and intravenous immunoglobulins, the increased trasnclocation of the LPS of gram-negative enterobacteria normalized and this normalization was accompanied by a complete remission of the CFS symptoms.”(23) Leaky Gut Syndrome and Depression “The above-mentioned results indicate that both chronic fatigue syndrome and major depressive disorder are accompanied by an increased gut permeability, which has allowed an exaggerated passage of proteins through a compromised epithelial barrier.”(24) “The results show that intestinal mucosal dysfunction, characterized by an increased translocation of gram-negative bacteria known as leaky gut, plays a role in the inflammatory pathophysiology of depression. It is suggested that patients with major depression should be checked for leaky gut and accordingly, should be treated for leaky gut.”(25) “Research has found that depression is accompanied by an inflammatory reaction indicated by an increased production of pro-inflammatory cytokines, such as interleukin-1beta (IL-1β), IL-6, TNF-α, and interferon-γ (IFN-γ). These cytokines are stress sensitive and may cause depressive behaviors. This paper hypothesizes that inflammatory, oxidative and nitrosative pathways, and an increased translocation of LPS from gram-negative bacteria from leaky gut are causally related to depression and novel targets for antidepressant development.”(26) Leaky Gut Syndrome and Pediatric Disease “Tight junctions (TJs) represent the major barrier within the paracellular pathway between intestinal epithelial cells. Disruption of TJs leads to intestinal hyperpermeability (leaky gut) and is implicated in the pathogenesis of several acute and chronic pediatric disease entities that are likely to have their origin during infancy. There is evidence for the role of TJ breakdown in diseases such as systemic inflammatory response syndrome (SIRS), inflammatory bowel disease, type 1 diabetes, allergies, asthma and autism in the pediatric population.”(27) Leaky Gut Syndrome and Autism “Intestinal permeability (IPT) was investigated in patients with autism as well as in their first-degree relatives to investigate leaky gut hypothesis. IPT results, assessed by means of the lactulose/mannitol test, were compared with adult and child controls and with FC values. The results demonstrated that a high percentage of abnormal IPT values were found among patients with autism (36.7%) and their relatives (21.2%) compared with normal subjects (4.8%). Patients with autism on a reported gluten-casein-free diet had significantly lower IPT values compared with those who were on an unrestricted diet and controls. The researchers concluded that the results obtained support the leaky gut hypothesis and indicate that measuring IPT could help to identify a subgroup of patients with autism who could benefit from a gluten-free diet. The IPT alterations found in first-degree relatives suggest the presence of an intestinal (tight-junction linked) hereditary factor in the families of subjects with autism.”(28) In part 6, we will discuss the increasing prevalence of autoimmune disease and how these diseases are related to gluten sensitivity. We will also discuss the management of intestinal permeability and autoimmune disease with functional medicine. References 1. NAT CLIN PRAC GASTRO & HEP SEPT 2005 VOL 2 NO 9 2. Fasano A. Systemic autoimmune disorders in celiac disease. Curr Opin Gastroenterol. 2006 Nov;22(6):674-679. 3. Barton SH, Murray JA. Celiac disease and autoimmunity in the gut and elsewhere. Gastroenterol Clin North Am. 2008 Jun;37(2):411-28, vii. 4. Ventura A, et al. Duration of exposure to gluten and risk for autoimmune disorders in patients with celiac disease. SIGEP Study Group for Autoimmune Disoders in Celiac Disease. Gastroenterology. 1999 Aug;117(2):297-303. 5. Cosnes J, et al. Groupe D’Etude et de Recherche Sur la Maladie Coeliaque. Incidences of autoimmune diseases in celiac disease : protective effect of the gluten-free diet. Clin Gastroenterol Hepatol. 2008 Jul;6(7):753-8. 6. Kharrazian, D. The Gluten, Leaky Gut, Autoimmune Connection. Apex Energetics lecture. Mar. 16, 2013. 7. GASTROENTEROLOGY 2005;128:1089-1113 8. The Journal of Immunology, 2006, 176: 2512-2521. 9. NAT CLIN PRAC GASTRO & HEP SEPT 2005 VOL 2 NO 9 10. Mechanisms of disease: the role of intestinal barrier function in the pathogenesis of gastrointes-tinal autoimmune diseases. Nat Clin Pract Gastroenterol Hepatol. 2005 Sep;2(9): 416-22 11. DIABETES, VOL. 55, MAY 2006 12. Tight junctions, intestinal permeability, and autoimmunity: celiac disease and type 1 diabetes paradigms. Ann N Y Acad Sci. 2009 May;1165:195-205 13. Increased intestinal permeability precedes clinical onset of type 1 diabetes. Diabetologia. 2006 Dec;49(12):2824-7. Epub 2006 Oct 7 14. Vaarala O. Gut and the induction of immune tolerance in type 1 diabetes. Diabetes Metab Res Rev. 1999 Sep-Oct;15(5):353-61 15. Varaala O, Atkinson MA. The “perfect storm” for type 1 diabetes: the complex interplay between intestinal microbiota, gut permeability, and mucosal immunity. Diabetes. 2008 Oct;57 (10):2555-62 16. DIABETES, VOL. 55, MAY 2006 17. Hollander D. Intestinal permeability, leaky gut and intestinal disorders. Curr Gastroenterol Rep. 1999 Oct;1(5):410-6 18. Salim SY, Soderholm JD. Importance of disrupted intestinal barrier in inflammatory bowel diseases. Inflamm Bowel Dis. 2011 Jan;17(1):362-81 19. Terjung B, Spengler U. Atypical p-ANCA in PSC and AIH: a hint towards a “leaky gut”? Clin Rev Allergy Immunol. 2009 Feb;36(1):40-51 20. Sandek A, et al. The emerging role of the gut in chronic heart failure. Curr Opin Nutr Metab Care. 2008 Sep;11(5):632-9 21. Krack A, et al. The importance of the gastrointestinal system in the pathogenesis of heart failure. Eur Heart J. 2005 Nov;26(22):2368-74 22. Maes M. Normalization of leaky gut in chronic fatigue syndrome is accompanied by a clinical improvement: effects of age, duration of illness and the translocation of LPS from gram-negative bacteria. Neuro Endocrinol Lett. 2008 Dec;29(6):902-10 23. Maes M, et al. Normalization of the increased translocation of endotoxin from gram-negative enterobacteria (leaky gut) is accompanied by a remission of chronic fatigue syndrome. Neuro Endocrinol Lett. 2007 Dec;28(3):739-44 24. Maes M, et al. An IgM-mediated immune response directed against nitro-bovine serum albumin (nitro-BSA) in chronic fatigue syndrome (CFS) and major depression: evidence that nitrosative stress is another factor underpinning the comorbidity between major depression and CFS. Neuro Endocrinol Lett.2008 Jun;29(3):313-9 25. Maes M, et al. The gut-brain barrier in major depression: intestinal mucosal dysfunction with an increased translocation of LPS from gram-negative enterobacteria (leaky gut) plays a role in the inflammatory pathophysiology of depression. Neuro Endocrinol Lett. 2008 Feb;29(1):117:24 26. Maes M. The cytokine hypothesis of depression: inflammation, oxidative and nitrosative stress (IO&NS) and leaky gut as new targets for adjunctive treatments in depression. Neuro Endocrinol Lett. 2008 Jun;29(3):287-91 27. Liu Z, Li N, Neu J. Tight junctions, leaky intestines, and pediatric diseases. Acta Paediatr. 2005 Apr;94(4):386-93 28. de Magistris L, et al. Alterations of the intestinal barrier in patients with autism spectrum disorders and in their first-degree relatives. J Pediatr Gastroenterol Nutr. 2010 Oct;51(4):418-24","date_published":"2013-05-13T08:07:54","date_modified":"2020-05-22T01:02:04","authors":[{"name":"Dr. Richard Esquivel","url":"https://sanjosefuncmed.com/about/"}],"tags":["Digestive Health"]},{"id":"https://sanjosefuncmed.com/intestinal-permeability-leaky-gut/","url":"https://sanjosefuncmed.com/intestinal-permeability-leaky-gut/","title":"What is Intestinal Permeability or “Leaky Gut”?","summary":"What is intestinal permeability or “leaky gut”? Why haven’t I heard of this? Intestinal permeability causes systemic inflammation. Intestinal permeability as ","content_text":"What is intestinal permeability or “leaky gut”? Why haven’t I heard of this? Intestinal permeability causes systemic inflammation. Intestinal permeability as a precondition for the development of autoimmune disease. This is part 1 of a 5-part series on Intestinal Permeability (Leaky Gut) Main points of this issue What is intestinal permeability (or leaky gut)? Intestinal permeability causes systemic inflammation Leaky gut syndrome is very real Research on Intestinal Permeability/Leaky Gut Syndrome Why haven’t I heard of this? Health Conditions Associated with Leaky Gut Syndrome Intestinal permeability as a precondition for the development of autoimmune disease? Most people know that one of the primary functions of the gastrointestinal (GI) tract is to break down large macromolecules ingested as food into small micronutrients which are then absorbed through the intestinal lining and enter the bloodstream. These micronutrients then serve as fuel sources for the body. However, many people don\u001at know that the intestinal lining also serves another important function: it acts as a barrier and prevents the absorption of large molecules into the bloodstream, such as undigested protein, bacteria and toxins. These large molecules should pass through the entire GI tract and be eliminated from the body without being absorbed and entering the bloodstream. This barrier function is a very important function of the epithelial lining of the GI tract. If the intestinal barrier starts to become too permeable and “leak”, this may pose many problems for the body. Intestinal permeability will cause systemic inflammation If anything penetrates through this gastrointestinal barrier that is foreign, the immune system is activated to eliminate or destroy these unwelcome molecules. This activation of the immune system leads to an inflammatory response. If you look at the anatomy of the intestinal lining, it is mostly immune cells with a thin layer of epithelial cells protecting it. If that layer gets breached, there is no question there will be an inflammatory immune response. So it is no surprise to see systemic inflammation and autoimmunity when there is breach of this thin epithelial lining. If a person has their barrier system breached, they will have an increase in inflammatory response. Increases in inflammatory responses increase risk of all chronic disease, including depression and neurodegenerative diseases, cardiovascular disease, bone loss, autoimmune disease, inflammatory bowel disease and chronic pain. A person\u001as intestinal barrier integrity will influence their inflammatory load and their potential for deteriorating mechanisms throughout the body. Is “Leaky Gut” real? Is leaky gut a myth, like Bigfoot, or is it real? Leaky gut syndrome is very real. The immunological literature is filled with information on leaky gut syndrome. This topic has been getting more and more attention in the literature over the past 5 to 10 years. In the immunological literature, leaky gut syndrome has been linked to autoimmunity, depression, congestive heart failure and neurodegenerative disease of all types. Research on Intestinal Permeability/Leaky Gut Syndrome There has been an explosion of research on leaky gut syndrome in the past 10 years. Researchers have been able to identify the messenger protein (called \u001azonulin\u001a) that leads to leaky gut. They have been able to purify the peptide and induce leaky gut with zonulin exposure in animal models. Now they have the clinical ability to induce leaky guts in animals. One of the interesting things that has been shown in animal models is the induction of autoimmune disease, such as type I (juvenile-onset) diabetes, immediately, by inducing leaky gut! Why haven’t I heard of this? Most people in the conventional world don\u001a’t know about leaky gut syndrome or intestinal permeability. Why? Because there is no drug currently available to treat it so most doctors have not heard of it. This will change shortly because drug companies are now working on a leaky gut drug. Once they develop the drug, everyone will know about it. There is now a zonulin-blocker (called \u001aZ-100\u001a) being developed which they have given to animals and this has drastically decreased their intestinal inflammation. Zonulin is one of the peptide messengers that leads to leaky gut syndrome. In animal studies, they have been able to block zonulin and stop leaky gut. Once these drugs have been tested on humans and we have a human zonulin-blocker, everyone in the world will be looking for leaky gut. Health Conditions Associated with Leaky Gut Syndrome The following conditions have been associated with leaky gut syndrome: Autoimmune disorders Multiple food sensitivities Multiple chemical sensitivities Chronic fatigue syndrome Heart failure Depression Chronic inflammatory conditions Chronic pain Inflammatory bowel Chronic yeast overgrowth syndromes Brain fog Intestinal Permeability and Autoimmune Disease There is a growing amount of evidence establishing the connection between intestinal permeability and the development of autoimmune disease. This review paper was published in 2009 in the Annals of New York Academy of Science. This journal is one of the top-rated most powerful scientific journals available: “There is growing evidence that increased intestinal permeability plays a pathogenic role in various autoimmune diseases. Therefore, we hypothesize that loss of intestinal barrier function is necessary to develop autoimmunity.”1 Basically, what this paper is saying, is that the research is pointing to intestinal permeability, or leaky gut, as a precondition for the development of all autoimmune disease , such as type I diabetes, rheumatoid arthritis, lupus, Hashimoto\u001as, Graves, Crohn\u001as disease, ulcerative colitis, Celiac disease, etc. Here’s another paper supporting this discovery: “Together with the gut-associated lymphoid tissue and the neuroendocrine network, the intestinal epithelial barrier, with its intercellular tight junctions, controls the equilibrium between tolerance and immunity to non-self antigens. When the finely-tuned trafficking of macromolecules is dysregulated in individuals, both intestinal and extraintestinal autoimmune disorders can occur.”2 One of the things we have to have in order to prevent autoimmune disease is immune tolerance to self-tissue . This prevents our immune system from attacking one\u001as own tissue of the body. One of the things they are finding is once these tight junction proteins get compromised, there is such immune zealousness and activation, this whole immune self-tolerance is lost and the immune system is prone to attacking self-tissue. When this occurs, any tissue is up for grabs for autoimmune destruction. The type of tissue that is targeted for destruction determines the type of autoimmune disease that develops. Content provided by Datis Kharrazian, D.C., Breaking the Complex Web of Leaky Gut Syndrome, 2/10/11 In part 2 of this 5-part series , we answer the following questions: What chronic diseases have been associated with intestinal permeability? Continue to part 2 of series References: 1. Tight junctions, intestinal permeability, and autoimmunity: celiac disease and type 1 diabetes paradigms. Ann N Y Acad Sci. 2009 May;1165:195-205 2. Mechanisms of disease: the role of intestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases. Nat Clin Pract Gastroenterol Hepatol. 2005 Sep;2(9): 416-22","date_published":"2012-05-25T01:47:46","date_modified":"2020-04-19T22:46:40","authors":[{"name":"Dr. Richard Esquivel","url":"https://sanjosefuncmed.com/about/"}],"tags":["Digestive Health"]},{"id":"https://sanjosefuncmed.com/intestinal-permeability-mechanisms-lead-leaky-gut/","url":"https://sanjosefuncmed.com/intestinal-permeability-mechanisms-lead-leaky-gut/","title":"Intestinal Permeability: Mechanisms and Causes that Lead to Leaky Gut","summary":"What causes leaky gut? What are the mechanisms involved in the development of leaky gut? Diet, medication, infections, stress, hormonal imbalances, neurologic","content_text":"What causes leaky gut? What are the mechanisms involved in the development of leaky gut? Diet, medication, infections, stress, hormonal imbalances, neurologic and metabolic issues and autoimmunity can all promote leaky gut. This is part 4 of a 5-part series on Intestinal Permeability (Leaky Gut) Main points of this issue: Mechanisms leading to leaky gut There are multiple factors that contribute to leaky gut Diet can promote leaky gut Medication can promote leaky gut Infections can promote leaky gut Stress can promote leaky gut Hormonal imbalances can promote leaky gut Neurologic issues can promote leaky gut Metabolic issues can promote leaky gut Autoimmunity can promote leaky gut Mechanisms Leading to Leaky Gut Think of the cells of your intestinal lining, where absorption of micromolecules takes place, as bricks which sit side by side along the basement membrane. These “bricks” are held together by proteins that form tight junctions, which can be considered the “mortar” between the bricks. Micronutrients are absorbed into the epithelial cells and transported through the cells and basement membrane where they enter the bloodstream. If the mortar starts to break down, you get penetration of foreign molecules through the intestinal barrier which can then enter the bloodstream (hence the term “leaky gut”). These foreign molecules may include undigested food molecules, toxins or bacteria. These large molecules are reacted against by the underlying intestinal immune system. This reaction then promotes exaggerated immune responsiveness leading to systemic inflammation (inflammation throughout the bloodstream). This creates a vicious cycle of further intestinal inflammation, damage to the intestinal lining, and increased intestinal permeability. This leads to intestinal disorders and autoimmune disease: “Together with the gut-associated lymphoid tissue and the neuroendocrine network, the intestinal epithelial barrier, with its intercellular tight junctions, controls the equilibrium between tolerance and immunity to non-self antigens. When the finely-tuned trafficking of macromolecules is dysregulated in individuals, both intestinal and extraintestinal autoimmune disorders can occur.”1 What are the Causes of Leaky Gut? Diet Medication Infection Stress Hormonal Imbalances Neurologic Issues Metabolic Issues Autoimmunity Diet Can Promote Leaky Gut Gluten (wheat) Casein (milk) Processed food Excess sugar Fast food Alcohol The standard American diet (SAD) alone is sufficient to cause leaky gut. If someone is eating transfats, fried foods, deamidated gliadin (from wheat), processed casein (from milk) and other processed foods every single day, they will probably end up with leaky gut. How does food cause inflammation? Food causes an inflammatory response which activates T cells which release cytokines which then activate their joint swelling and inflammation. Alcohol consumption can cause leaky gut. Someone who drinks alcohol and eats the standard American diet is at risk for developing leaky gut.2 Medications Can Promote Leaky Gut Corticosteroids Antibiotics Antacids Xenobiotics Medications can cause leaky gut, especially prednisone and antibiotics. Infections Can Promote Leaky Gut H. pylori Bacterial overgrowth Yeast overgrowth Intestinal viruses Parasitic infection Any type of pathogenic infection can cause leaky gut. Stress Can Promote Leaky Gut Stress alone can cause leaky gut. Stress causes increased blood flow to skeletal muscles and decreased blood flow to the gut. You immediately get decreased blood flow to the gut when under stress. We know that stress responses have major influences on leaky gut. “Increased exposure to life events determines a defective jejunal epithelial response to incoming stimuli. This abnormal response may represent an initial step in the development of prolonged mucosal dysfunction.”3 “Prolonged exposure to stress can induce low-grade inflammation, cause ultra structural epithelial abnormalities, and alter bacterial-host interactions, allowing greater microbial translocation.4” Hormonal Imbalances Can Promote Leaky Gut Deficiency of the following hormones leads to leaky gut: Thyroid hormone Estrogen Progesterone Testosterone Thyroid Hormone and Leaky Gut “Lack of thyroid hormone stimulation of gastric and intestinal cells leads to ulcerations and intestinal permeability known as “leaky gut syndrome”. Additionally, endoscopic examination of gastric ulcers found low T3, low T4, and abnormal levels of reverse T3 on gastric ulcerative tissues.”5 “Both thyroxine and triiodothyronine have been shown to protect the intestinal mucosal lining from stress-induced intestinal lining injury.”6 Estradiol and Leaky Gut “Estradiol modulates paracellular permeability and tight junction (TJ) function in the intestinal epithelium.”7 Progesterone and Leaky Gut “Treatment with progesterone protected intestinal lining macroscopic injury and albumin extravasation.”8 Testosterone and Leaky Gut We propose that lack of testosterone delays intestinal healing.”9 Neurologic Conditions Can Promote Leaky Gut Brain integrity is critical in intestinal permeability. 90% of the brain’s output goes into the lower brainstem. When the brain isn’t able to fire into the enteric nervous system, you don’t have gut motility and you don’t have parasympathetic effect. When people have decreased parasympathetic activation, they get leaky gut. “Traumatic brain injury causes GI dysfunction and increased intestinal permeability. Regulation of the gut barrier may involve the central nervous system.”10 “Traumatic brain injury (TBI) can lead to several physiologic complications, including gastrointestinal dysfunction. Specifically, TBI can induce an increase in intestinal permeability.”11 “At the intestinal level, traumatic brain injury (TBI) induces profound effects, including gastrointestinal mucosa ischemia and motility dysfunction.”12 Metabolic Imbalances Can Promote Leaky Gut Then you have metabolic issues such as diabetes. Diabetes causes glycosylated-end products which causes leaky gut. Autoimmunity Leads to Leaky Gut Most people learn about leaky gut and autoimmunity in the following way: intestinal permeability allows peptides to cross, making the immune system overzealous which then triggers autoimmune expression and increased cytokine activity. In other words, leaky gut leads to autoimmunity. But we now know autoimmunity also leads to leaky gut . Cytokine explosions from autoimmunity activate iNOS which immediately destroys the tight junctions of the intestinal barrier. As the autoimmunity flares up, they will get increased permeability. Leaky Gut Vicious Cycle Loss of tight intestinal junctions leads to entry of antigens and peptides and multiple food sensitivities, which leads to intestinal inflammation and promotes further leaky gut. Content provided by Datis Kharrazian, D.C., Breaking the Complex Web of Leaky Gut Syndrome, 2/10/11 In part 5 of this 5-part series , we answer the following questions: How do we address the treatment of intestinal permeability? Clinical unwinding of leaky gut. Is diet important in the treatment of leaky gut? Vitamin D and Leaky Gut Continue to part 5 of series References 1. Mechanisms of disease: the role of intestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases. Nat Clin Pract Gastroenterol Hepatol. 2005 Sep;2(9): 416-22 2. Alcohol, intestinal bacterial growth, intestinal permeability to endotoxin, and medical consequences: summary of a symposium Alcohol. 2008 Aug 42(5):349-61. Epub 2008 May 27 3. Maladaptive intestinal epithelial responses to life stress may predispose healthy women to gut mucosal inflammation. Gastroenterology. 2008 Jul;135(1):163-172.e1. Epub 2008 Mar 22 4. Pathophysiological mechanisms of stress-induced intestinal damage. Curr Mol Med. 2008 Jun;8(4):274-81 5. The effects of stress on gastric ulceration, T3, T4, reverse T3 and cortisol in neonatal foals. Equine Vet J. 1992; 24(1):37-40 6. The effects of thyroid hormones on stress ulcer formation. Anz J Surg. 2002; 72(9):672-5 7. Estradiol decreases colonic permeability through estrogen receptor beta-mediated up-regulation of occluding and junctional adhesion molecule-A in epithelial cells. J Physiol. 2009 Jul 1;587(Pt 13):3317-28. Epub 2009 May 11 8. Dual effect of female sex steroids on drug-induced gastroduodenal ulcers in the rat Life Sci. 1999;64(25):2341-50 9. Gastric secretion, proinflammatory cytokines and epidermal growth factor (EGF) in the delayed healing of lingual and gastric ulcerations by testosterone. Inflammapharmacology; 2008 Feb; 16(1):40-7 10. Stimulating the central nervous system to prevent intestinal dysfunction after traumatic brain injury. J Trauma. 2010 May;68(5):1059-64 11. Traumatic brain injury and intestinal dysfunction: uncovering the neuro-entericaxis. J Neurotrauma. 2009 Aug;26(8):1353-9 12. Permeability to glucose after experimental traumatic brain injury: effect of gadopentetate dimeglumine administration. Basic Clin Pharmacol. 2008 Sep;103(3):247-54. Epub 2008 Jul 8","date_published":"2012-05-25T02:11:35","date_modified":"2020-04-19T22:22:11","authors":[{"name":"Dr. Richard Esquivel","url":"https://sanjosefuncmed.com/about/"}],"tags":["Digestive Health"]},{"id":"https://sanjosefuncmed.com/introduction-autoimmune-disease-it-common-it-diagnosed-managed/","url":"https://sanjosefuncmed.com/introduction-autoimmune-disease-it-common-it-diagnosed-managed/","title":"Introduction to autoimmune disease: What is it? How common is it? How is it diagnosed? How is it managed?","summary":"Main points of this issue: Rates of autoimmune (AI) diseases are increasing every year in the U.S. The diagnosis of AI disease is only made after there is deg","content_text":"Main points of this issue: Rates of autoimmune (AI) diseases are increasing every year in the U.S. The diagnosis of AI disease is only made after there is degeneration of tissue Most AI cases remain undiagnosed Most AI cases continue to progress over time Most AI patients develop more than one AI disease during their lifetime Conventional healthcare has very little to offer these patients besides steroids Autoimmune Disease in the U.S. One of the things we know for sure is that the rates of autoimmune (AI) disease in the U.S. continue to go up for all AI diseases. There is an explosion of AI disease happening now like never before. \u001aAutoimmune diseases are the third leading cause of morbidity and mortality in the industrialized world, surpassed only by cancer and heart disease.\u001a1 \u001aWhile many individual autoimmune diseases are rare, collectively they are thought to affect approximately 8 percent of the United States population \u001a 24 million persons.\u001a \u001aTo provide a context to evaluate the impact of autoimmune diseases, cancer affected approximately 9 million people and heart disease affected approximately 22 million people in the United States.\u001a2 What is Autoimmune Disease? Autoimmune disease occurs when the immune system begins targeting self-tissue causing destruction of that tissue or organ. There are many different AI diseases that have been identified, such as rheumatoid arthritis (RA), multiple sclerosis (MS), lupus (SLE), Hashimoto\u001as thyroiditis, Crohn\u001as disease, ulcerative colitis (UC), type I diabetes and Celiac disease (CD). AI disease can affect every organ and tissue in the body \u001aAutoimmune diseases can affect virtually every site in the body\u001a \u001aAt least 15 diseases are known to be the direct result of an autoimmune response, and circumstantial evidence links more than 80 conditions to autoimmunity.\u001a 3 AI disease is usually progressive over time There is no cure for most AI diseases. AI patients generally suffer more and more symptoms of tissue destruction over time. Conventional treatment is focused on suppressing the immune response and controlling symptoms but little is offered to the patient in regards to modulating the autoimmunity and avoiding triggers that cause flare-ups of the autoimmune response. As a result, AI conditions tend to cause more and more tissue destruction over time, eventually leading to severe tissue destruction and organ failure in many cases. Diagnosis of AI Disease The diagnosis of AI disease is only made after there is degeneration of the tissue In conventional healthcare, the diagnosis of AI disease is based on destruction of tissue (observable on diagnostic imaging), along with autoantibodies (antibodies against self-tissue) and other markers found in the blood along with clinical findings (signs and symptoms of patient). However, the development of tissue destruction or organ failure does not happen overnight. What about the 5-10 years of suffering the patient had before they are diagnosed with the disease? AI Reaction vs. AI Disease During the early stages of autoimmunity, the immune system is attacking tissue and initiating an AI reaction (based on the presence of antibodies) but the diagnosis of AI disease is not given until observable destruction of tissue has been identified. An AI reaction is when the immune system starts to attack self-tissue. The presence of autoantibodies indicates that the immune system is initiating an immune response against self-tissue (tissue or cellular components of the body). During an AI reaction, you may or may not have symptoms of that tissue being destroyed. Symptoms will only occur when the tissue destruction is severe enough to lead to a change in physiologic function. The AI reaction isn\u001at really a concern in the conventional model Our current healthcare system typically waits until the patient shows evidence of tissue destruction before they are given the diagnosis of autoimmune disease. For example, you may have autoantibodies against the cartilage and swelling and pain against your joints, but it isn\u001at diagnosed as rheumatoid arthritis (RA) until destruction of joints have been seen on X-ray or MRI. Or you may have myelin antibodies but you will not be given the diagnosis of multiple sclerosis (MS) until there are observable changes or lesions in the MRI of the brain or spinal cord. Most AI disease remains undiagnosed. \u001aCollectively autoimmune diseases have been identified in about 24 million people in the U.S., and only 1/3 are diagnosed. That means about 72 million people have an AI disease. It\u001as not looked for. Our system waits until the signs and symptoms are severe enough with organ failure and irreversible damage before we identify it.\u001a 4 Prevalence of Multiple Autoimmune Diseases The other thing we know is that when people have antibodies against one known tissue type, there is likely other antibodies against other tissue as well. In other words, when a person is diagnosed with AI disease, they are at high risk of developing other autoimmune diseases during their lifetime. It is very rare that only one tissue type is targeted by the immune system. When we look at people with AI disease, they may have multiple types of tissue being targeted that have not yet been identified. For example, the literature shows people with thyroid autoimmune disease have over a 50% chance of being affected by another autoimmune disease.5 Conventional treatment of AI Disease: Immune-suppressing medication People with AI reactions usually don\u001at get diagnosed and don\u001at get any management or support until they get diagnosed with AI disease in conventional medicine. Once patients suffer sufficient tissue destruction to be diagnosed with AI disease, what does conventional healthcare have to offer? The standard of care is steroids and other immune-suppressing drugs. Steroids are usually not used in the initial stages because the adverse and damaging effects on the body make it not worth the risks. Some of the side effects of steroids include: immune suppression, bone loss, neurodegeneration, insulin-related issues, epithelial thinning, catabolic states so they cannot recover, etc. So patients aren\u001at given steroids until their condition has become severe and progressed. If the tissue destruction is severe enough, doctors may use a bone marrow-suppressing drug to shut down the immune system completely or they may take out the thymus in some of the more severe conditions such as myasthenia gravis. There really is little hope in the conventional model of healthcare for these AI patients to have an impact on the progression of their autoimmunity since the focus of treatment is suppression of the immune system. These immuno-suppressive agents come with significant adverse effects. Alternative Treatment for Autoimmune Disease Not Much Better Many of these patients end up seeing an alternative healthcare practitioner. What happens then? If the practitioner doesn\u001at know it\u001as an AI reaction, they treat every symptom separately. For example, a person comes in with parietal cell antibodies, cartilage antibodies, myelin antibodies and skin epithelial antibodies and all the symptoms characteristic of each of these diseases. What would be the treatment? Most likely, the alternative practitioner would offer different treatments for each of the symptoms with no consciousness that they really only have one underlying mechanism, which is autoimmunity. They would not consider focusing treatment on the immune system. Nor would they consider focusing on finding the triggers of the autoimmunity. In addition, with many autoimmune people, you can\u001at just give them any type of treatment because some compounds will actually flare up their autoimmunity. Many of the supplements these patients are already taking are flaring them up and making them worse because they are triggering their AI mechanisms. When you look at alternative medicine, they oversimplify autoimmunity to be due to either nutritional deficiencies or caused by heavy metals, viruses or parasites. This is a very simplistic way of looking at autoimmunity. There is more to autoimmunity than just piling on supplements, hunting for viruses and parasites and eliminating metals. Heavy metal chelation is not a good idea for many of these patients, either. Sometimes doing heavy metal chelation can flare these people up and get them to a place they can never get out of. Alternative practitioners can\u001at just randomly do these types of therapies because it is not efficient patient management and can actually flare these patients up to a critical condition. Functional Medicine: A Better Option for Autoimmune Disease Autoimmune Regulation as a Therapeutic Approach When you look at the dysregulation of the immune system that occurs in autoimmunity, we know that there are different systems involved in the targeting of tissue for destruction. Autoimmunity is a multi-variant process and the goal should be to calm down the autoimmunity, specifically the immune response against self-tissue. There are several innate regulating systems of immune function that begin to dysregulate in autoimmunity. In functional medicine, we attempt to modulate the autoimmunity by regulating these various systems. When we consider treatment of autoimmunity, there are 3 things we focus on: 1. Finding the triggers causing the autoimmunity to flare up and remove them 2. Modulating the autoimmunity and decrease the tissue destruction 3. Enhancing and supporting their recovery from these flare-ups We are not talking about curing these AI conditions because we don\u001at know how to do that. But we can make it so a person has more good days than bad days. In future articles in this series on autoimmunity, we will be discussing in more detail what these systems are and how we can intervene with dietary changes and nutritional medicine to modulate immune function. References: The Journal of Immunology, 2005, 175: 4119\u001a4126. NIH. Autoimmune Diseases Coordinating Comm. Autoimmune Diseases Research Plan. 2006 NAT CLIN PRAC GASTRO & HEP SEPT 2005 VOL 2 NO 9 Jeffrey S. Bland, Ph.D.; Metagenics Educational Programs. 2006 ACTA BIO MEDICA 2003; 74; 9-33","date_published":"2012-05-24T22:34:31","date_modified":"2020-04-19T22:24:30","authors":[{"name":"Dr. Richard Esquivel","url":"https://sanjosefuncmed.com/about/"}],"tags":["Autoimmune Health"]},{"id":"https://sanjosefuncmed.com/myth-diagnosis-disease-causes-one-cause-diseases-gluten-food-compound-problems/","url":"https://sanjosefuncmed.com/myth-diagnosis-disease-causes-one-cause-diseases-gluten-food-compound-problems/","title":"The Myth of Diagnosis, One Disease, Many Causes—One Cause, Many Diseases, Gluten: One Food Compound That Causes Many Problems","summary":"The Myth of Diagnosis: If you know the name of your disease, you know what’s wrong with you This myth is pervasive throughout medicine and is the single bigge","content_text":"The Myth of Diagnosis: If you know the name of your disease, you know what’s wrong with you This myth is pervasive throughout medicine and is the single biggest obstacle to changing the way we do things and finding the answers to our health problems. The problem is we are in the “naming and blaming” business in medicine. Find the name of the “disease” then match the drug to the disease. You have “depression” so you need an “antidepressant” and so on. Unfortunately, this approach or method of thinking is outdated and sometimes dangerous. Once you have a label, you are put in the group of people that have the same label and it is assumed that you carry the same attributes of that group. The outdated method of naming the disease and then assigning a drug to fix it clearly isn’t working. The reason why is because the name of the disease bears little relationship to the cause of the disease. “ The chemical model of mental illness has too often confused association with causation. Worse still, it has failed the species.” (1) We need to get out of the “name-it and blame-it game” and start thinking about how the body works, how to personalize our approach, and how not to suppress symptoms but to restore normal function. Fortunately, there are only a few fundamental mechanisms that underlie nearly every chronic disease. These underlying mechanisms are the link between all these different diseases people develop as they age. In almost all chronic disease, the same few mechanisms go wrong. These mechanisms can lead to many different types of problems or disease states. At the same time, one disease may have multiple causes. One Disease, Many Causes—One Cause, Many Diseases One disease can have many different causes, all of which manifest the same symptoms. For example, depression may be caused by many different factors , yet the symptoms we see are the same across the board. Depression may be the result of a multitude of causes: Folate, B6 or B12 deficiency Low thyroid function “Brain allergies” to foods Autoimmune response to gluten that inflames the brain Mercury poisoning Abnormal proteins called gluteo- or caseomorphins from poorly digested food that alter brain chemistry Brain inflammation from a hidden infection Blood sugar imbalances Low testosterone or other sex hormones Omega-3 fatty acid deficiency Adrenal gland dysfunction from excessive stress These are some of the real causes of “depression” as well as many other mental illness and neurological conditions. Without addressing the root, underlying mechanisms like these, we can never have optimal brain function or mood. There is really no such thing as the “disease” of depression, just many different systemic imbalances that cause the symptoms we refer to as “depression”. Gluten: One Food Compound That Causes Many Problems Gluten, a protein found in wheat, is one common food compound that can create many illnesses and diseases A recent review paper published in the NEJM listed 55 diseases that can be caused by eating gluten.(2) These include many neurological and psychiatric diseases such as anxiety, depression, schizophrenia, dementia, migraines, epilepsy, and neuropathy.(3) Gluten in the diet has also been linked to autism.(4) Removing gluten and casein (a protein found in milk) can lead to significant improvements in the symptoms of autistic children.(5) Besides making the brain inflamed , gluten can be broken down in the gut into odd little proteins that act like psychedelic drugs (opium-like peptides called gluteomorphins ) which change brain function and behavior. Gluten also contains significant amounts of glutamate , a molecule that excites and damages brain cells through a special brain receptor or docking station called the NMDA (N-methyl-D-aspartate) receptor . Overactivation of this receptor by glutamate is implicated in many psychiatric disorders. Glutamate is called an excitotoxin (a substance which overexcites and kills or damages brain cells). So, gluten can cause brain dysfunction by three different mechanisms— inflammation, odd morphine or psychedelic proteins, and as an excitotoxin. This is how gluten is a single cause behind many different “diseases”.(6) In the next article, we discuss the myth of medication, the rapid increase in prescriptions for mood-altering drugs and some of their side-effects. References: Reducing the Brain, Ignoring the Soul. Grace E. Jackson, M.D. Farrell, R.J. and C.P. Kelly. 2002. Celiac sprue. NEJM 346 (3):180-88. Review. Bushara, K.O. 2005 Neurologic presentation of celiac disease. Gastroenterology 128 (4 Suppl 1):S92-97. Review Millward, C, et al. 2004. Gluten- and casein-free diets for autistic spectrum disorder. Cochrane Database Syst Rev 2:CD003498. Review. Millward, C, et al. 2004. Gluten- and casein-free diets for autistic spectrum disorder. Cochrane Database Syst Rev 2:CD003498. Review. The UltraMind Solution. Mark Hyman, MD. Simon and Shuster. 2008","date_published":"2012-06-27T08:01:52","date_modified":"2020-04-19T22:34:48","authors":[{"name":"Dr. Richard Esquivel","url":"https://sanjosefuncmed.com/about/"}],"tags":["Functional Medicine"]},{"id":"https://sanjosefuncmed.com/myth-medication-rapid-increase-prescriptions-mood-altering-drugs-side-effects/","url":"https://sanjosefuncmed.com/myth-medication-rapid-increase-prescriptions-mood-altering-drugs-side-effects/","title":"The Myth of Medication, The Rapid Increase in Prescriptions for Mood-Altering Drugs and their Side Effects","summary":"The Myth of Medication: Drugs are the Answer to Mental Illness One of the problems of conventional medical training is that doctors are not trained to identif","content_text":"The Myth of Medication: Drugs are the Answer to Mental Illness One of the problems of conventional medical training is that doctors are not trained to identify the root causes of health disorders, but trained more to act as clinical pharmacologists. M.D.s are trained to diagnose disease, and choose the most appropriate medication to treat it. A typical medical doctor’s only tools are pharmaceutical drugs. If all you have is a hammer, everything looks like a nail. Our goal in medicine should be to find the right “medicine” for each person, without prejudice, whether it is a drug, a therapy, a nutrient, diet change, detoxification, a hormone, or exercise. We must embrace whatever works and inquire into its effectiveness with all our scientific, economic and political resources. Let’s take a look at the main categories of medicine for the brain: Anti-depressants (SSRIs, like Prozac) Stimulants (Ritalin) Tranquilizers/Anti-psychotics (Risperdal, Zyprexa, Seroquel, Geodon) The Rapid Increase in Prescriptions for Mood-Altering Drugs These mood-altering drugs are the fastest-growing segment of the pharmaceutical market and as a group constitute the second biggest class of medication in total sales and prescriptions In children alone, over the 3-year period from 1997-2000, the use of antipsychotic medication increased 138%.(1) It has continued to increase since then. The global use of ADHD medication rose by 300% from 1993 to 2000.(2) From 2000 to 2010, the number of physician outpatient visits in which ADHD was diagnosed increased 66% from 6.2 million to 10.4 million visits.(3) Of these ADHD visits, psychostimulants have remained the dominant treatment; they were used in 96% of treatment visits in 2000 and 87% of treatment visits in 2010.(4) Use of antidepressant drugs has soared nearly 400% since 1988, making this class of medication the most frequently used by people ages 18-44.(5) 11% of Americans ages 12 years and older took antidepressants during the 2005-08 study period.(6) The use of untested and potentially unsafe combinations of psychotropic drug cocktails has increased 500% in children. The authors of the study warned that our prescribing practices are not in sync with our current knowledge.(7) Consider the increase of prescribed uses due to pharmaceutical marketing of tranquilizer/anti-psychotic medication such as Risperdal, Zyprexa, Seroquel and Geodon. This class of medications is one of the biggest-growing sectors in drug sales. Antipsychotics (tranquilizers) were originally prescribed for conditions of psychosis (ie: inability to distinguish what’s real from what’s imaginary). Now they are given to children with behavioral problems, autism and ADHD and to adults with depression, anxiety, OCD, bipolar disease, dementia and Parkinson’s disease. Antipsychotic usage has shown a 10-20% rate of increase per year over the last few years Current sales of these drugs total about $12 billion/year Psychotropic Drugs Can Lead to Serious Side Effects Besides acting like a chemical strait-jacket and making people dull, slow and stupid, they increase the risk of obesity, diabetes, stroke, blood clots, and more serious conditions known as neuroleptic malignant syndrome (where your body literally burns up with fever and your muscles are destroyed) and tardive dyskinesia (uncontrolled repetitive, involuntary, and purposeless movements such as lip-smacking, rapid eye blinking, grimacing and spasms in the legs).(8) What most consumers don’t understand is that drug testing is often very limited before drug approval. New drugs are tested on a few hundred to a few thousand people often for a very limited time (usually a few weeks to a few months). Then they are released on the market, supported by more than $30 billion in pharmaceutical advertising dollars (or about $25,000/year for each of the 737,000 physicians in America) Once approved, these drugs can be prescribed for any use. Once approved, there is no official tracking of its risks or benefits to the millions who are prescribed the drug. It’s left up to the patients or doctors to self-report problems. This leaves the public very vulnerable. Unfortunately, it appears drug companies often see any backlash or lawsuits as simply part of their “research and development” expenses of their drugs. The Pharmaceutical Companies Consider Lawsuits a Part of Drug Marketing and Development Eli Lilly, the maker of the antipsychotic drug Zyprexa , has already paid $1.2 billion to settle 30,000 lawsuits from people who claim that Zyprexa caused them to develop diabetes or other diseases, and is also alleged to have promoted Zyprexa for unapproved off-label use, which it denies. Zyprexa is approved for schizophrenia , but doctors also prescribe it for anxiety. Bloomberg News reported the following in December 2006: “Nationwide, several lawsuits accuse drug companies of engaging in deceptive marketing by overstating the effectiveness and understating the risks of new anti-psychotics. The suits also claim companies promoted the drugs for unapproved uses. Mississippi, Louisiana, Alaska and West Virginia sued Eli Lilly and Co. this year on behalf of their Medicaid health programs for the poor. They said the company fraudulently touted the antipsychotic Zyprexa for unapproved uses. Indianapolis-based Lilly settled about 8,000 personal injury complaints for $700 million in 2005 and faces 4,000 more claims.” We are a drug-addicted society and we are overprescribed medication when there are better solutions. According to the JAMA (Journal of the American Medical Association), in an average week, 81% of Americans use at least one medication, 50% take at least one prescription drug, and 7% take 5 or more drugs. Of those over 65 years old, 12% take at least 10 medications and 23% take at least 5 medications .(9) Why are Americans prescribed so many medications? In the next article, we will reveal the brain-body separation myth, take a different look at autism as a systemic disorder that affects the brain (instead of primarily a brain disorder) and look at the blood-sugar and Alzheimer’s disease connection. References: Vargas, D. L., et al. 2005. Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol 57 (1):67-81. Lenoir, M., et al. 2007. Intense sweetness surpasses cocaine reward. PLoS ONE 2 (1):e698. http://www.sciencedirect.com/science/article/pii/S1876285912000046 http://www.sciencedirect.com/science/article/pii/S1876285912000046 The data are from the National Health and Nutrition Examination Surveys, which included information from 12,637 participants about prescription-drug use, antidepressant use, length of use, severity of depressive symptoms and contact with a health professional. The data are from the National Health and Nutrition Examination Surveys. Bhatara, V, et al. 2004. National trends in concomitant psychotropic medication with stimulants in pediatric visits: Practice versus knowledge. Atten Disord 7 (4):217-26. The UltraMind Solution. Mark Hyman, MD. Simon and Shuster. 2008 Kaufman, D. W., et al. 2002. Recent patterns of medication use in the ambulatory adult population of the United States. The Slone Survey. JAMA 287:337-44.","date_published":"2012-06-27T07:53:48","date_modified":"2020-04-19T22:35:48","authors":[{"name":"Dr. Richard Esquivel","url":"https://sanjosefuncmed.com/about/"}],"tags":["Functional Medicine"]},{"id":"https://sanjosefuncmed.com/nutritional-management-chemical-sensitivity-role-plays-autoimmunity/","url":"https://sanjosefuncmed.com/nutritional-management-chemical-sensitivity-role-plays-autoimmunity/","title":"Nutritional Management of Chemical Sensitivity and its Role in Autoimmunity","summary":"What role does chemical sensitivity play in the development of autoimmunity? How do we evaluate for loss of chemical tolerance? What are other factors besides","content_text":"In the last segment, we reviewed how our bodies eliminate the toxic chemicals we are exposed to on a daily basis and introduced the concept of “toxicant-induced loss of tolerance”. We also discussed some of the mechanisms that lead to this condition, which is becoming more and more common, as well as common signs and symptoms of this condition. In this final segment of this series, we discuss the role chemical sensitivity plays in the development of autoimmunity and laboratory evaluation of immune-chemical tolerance. We also consider other factors besides chemical exposure that impact chemical sensitivity. Then we discuss nutritional management of loss of chemical tolerance from a functional medicine perspective. Key concepts for this issue: The Role Chemical Sensitivity Plays in the Development of Autoimmunity Why Does Chemical Tolerance Vary From Person to Person? Laboratory Evaluation of Immune-Chemical Tolerance Other Factors Besides Chemical Exposure That Impact Chemical Sensitivity Nutritional Management of Loss of Chemical Tolerance The Role Chemical Sensitivity Plays in the Development of Autoimmunity As discussed in previous segments, the prevalence of autoimmunity is increasing at an alarming rate. “Currently 1 in 12 women and 1 in 25 men have autoimmune disease. Over 50 million Americans now have autoimmune disease”[47] Additionally, the research points to chemicals as contributing factors to autoimmunity, cancer and neurological conditions: “There are increasing rates of autoimmunity, cancer, neurological disorders, and inflammatory conditions evoked by chemicals”[48] “Autoimmune diseases may be induced by physical and/or chemical environmental factors”[49] Somewhere along the way after the depletion of glutathione, we turn on autoimmunity causing destruction of various tissues, including the brain, gut, thyroid and a number of other tissues. When we lose this glutathione system, we lose our capacity to handle environmental compounds and self-tolerance to our own tissue. But how does this happen? Prevailing theory of how chemical sensitivity leads to autoimmunity: When environmental compounds enter the body, they often bind to proteins of human tissue such as albumin because this is how the body eliminates these compounds. A hapten is a small molecule that can elicit an immune response only when attached to a large carrier such as a protein. In some individuals, the immune system responds to this protein-bound hapten . When the immune system responds to this foreign antigen complex, it usually produces antibodies to the human tissue portion, rather than the hapten so the immune response continues even after the hapten is removed. Depending on the human tissue that becomes targeted by the immune system, various autoimmune conditions can result. “Epidemic clustering of some autoimmune diseases following xenobiotic exposure reinforces the thesis that autoimmune disease is secondary to genetic and environmental factors”[50] “Basic science and epidemiological research suggests that oxidative stress and inflammation may play a role in autoimmune disease”[51] Why Does Chemical Tolerance Vary From Person to Person? Why are most people living relatively normal, healthy lives despite all these toxic exposures while other people succumb to toxin-induced illness? If you tested random people in the U.S., including healthy people, chances are all of them would show contamination from heavy metals and environmental chemicals. Being completely free of heavy metals and environmental chemicals these days is impossible. Anthropological studies show even mummies were contaminated with heavy metals. Our bodies have the capacity to deal with chemical and heavy metal exposure by either eliminating these from the body following transformation via the liver and excretion via the urine or stool, or in some cases, sequestering heavy metals in tissue, such as bone. Some people seem to have immune responses to these environmental compounds, while others do not. In fact, one person can have very high levels of toxicity and be symptom-free, while another person who has low levels of contamination reacts severely. The issue is not how many toxins are in your system but whether your immune system reacts to them. This can cause severe reactions and symptoms and lead to chronic inflammation. This is the mechanism behind toxicant-induced loss of chemical tolerance (TILT), multiple chemical sensitivities, and toxin-induced brain degeneration mechanisms that are becoming so common today. How do we evaluate loss of chemical tolerance? Laboratory Evaluation of Environmental Chemical Tolerance Evaluating chemical immune tolerance can be done objectively with Cyrex Labs Array 11—Chemical Immune Reactivity Screen. Chemical immunoreactivity testing evaluates for immunological reactivity to environmental compounds by evaluating antigen-antibody reactivity to these compounds. The presence of elevated antibodies to common environmental compounds indicates overzealous immune reactions to chemicals and loss of immune tolerance. Chemical antibody testing has several advantages. First, it allows for a diverse array of common chemicals to be evaluated, in addition to heavy metals. Second, it measures immune responses to these chemicals, unrelated to their quantitative load, that result in immunological and inflammatory responses from these environmental chemicals. Elevated chemical antibodies indicate an exaggerated immune response to these common chemicals leading to the promotion of systemic inflammation and can occur with trace exposures of chemicals when immune integrity is compromised. Any elevation in chemical antibodies indicate loss of chemical tolerance and risk of abnormal immune reactions to everyday environmental compounds. Are There Factors Besides Chemical Exposure That Impact Chemical Sensitivity? Unrelated to environmental loads, you can lose chemical tolerance from the following immunological imbalances: Chronic stress Intestinal permeability Chronic infections Chronic inflammation Autoimmunity Poor sleep Malnutrition Chemical sensitivity can be impacted by all of these factors unrelated to toxin exposures. For example, patients exposed to chronic stress may lose the integrity of their barrier systems and develop insufficiency of their immune regulatory T-cells as a result. They may then start to react immunologically to daily chemical exposures such as cigarette smoke or gasoline fumes. The exposure may cause them to suffer migraines, skin outbreaks, sinus reactions, etc. In this case, addressing the person’s internal stress response with stress management and nutritional compounds (ie: adaptogens, etc.) is critical to minimizing the factors promoting the person’s stress physiology and chemical sensitivity. Another example of a condition that can affect chemical sensitivity is chronic infection . Chronic infection can lead to chronic inflammation and compromised immune regulatory T-cell function as well as loss of barrier system integrity. When your immune system is constantly working 24/7 to eliminate a pathogen but is unsuccessful, it is at risk of loss of regulatory T-cell function and dysfunctional immune responses. This is what happens in certain chronic infections such as chronic Lyme disease when the instigating pathogen (a bacteria called borellia burgdorferi and other concomitant co-infections) cannot be eliminated by the immune system. The individual eventually becomes at risk for chemical intolerance and autoimmune reactions. Autoimmune conditions always involve a certain degree of chronic inflammation and T-regulatory cell dysfunction as well which can then lead to loss of chemical tolerance. These types of issues must be identified and addressed in order to have a chance at improving tolerance to environmental chemicals. Otherwise, progress will be very limited and palliative at best. It is important the practitioner consider all of the potential contributors that may play a role in loss of chemical tolerance. Management of Loss of Chemical Tolerance Management of loss of chemical tolerance involves: Identification of offending chemicals/heavy metals (through laboratory evaluation) Avoidance or minimization of exposures to these offending chemicals/heavy metals from one’s environment (as much as possible) Nutritional support of the physiologic systems involved in loss of chemical tolerance Targeted nutritional support for phase I and phase II biotransformation pathways for transformation and elimination of offending chemicals (when applicable) Avoiding Exposures Knowing common environmental sources of exposure of these chemical compounds that initiate immune responses is a critical first step in order to minimize these exposures and resultant “flareups” of symptoms. Avoiding these compounds completely cannot always be done in all cases but many of these compounds can often be avoided and avoidance alone can sometimes lead to significant improvement in symptoms. For example, common sources of mercury exposures include amalgam fillings and medical implants, vaccinations and contaminated fish and shellfish and contaminated fish oils. Consideration should be given to removal of dental amalgums (by a qualified dentist in an appropriate way) and vaccination schedules. Decreased frequency or decreased regularity of vaccinations can minimize impact of exposures. Fish consumption can be a source of exposure as well, as discussed earlier. Limiting fish consumption to twice a week and consuming only wild fish rather than farm-raised fish can significantly decrease risk of mercury exposures. Quality fish oils produced by a reputable company that tests for mercury levels (which tend to cost a little more than some of the cheaper supplements) are recommended. Look for levels of detectability of heavy metals, such as mercury, lead, PCBs and dioxins in ppb (parts per billion) and ppt (parts per trillion). Nutritional Support for Chemical Tolerance Immune-chemical tolerance is dependent upon many overlapping physiological factors that include the glutathione system, regulatory T-cell function, barrier system integrity, NF-kB dysregulation and chronic inflammation and impaired hepatic biotransformation. Depletion of glutathione and inadequate glutathione system Regulatory T-cell failure Breakdown of barrier systems NF-kB dysregulation/chronic inflammation Impaired hepatic biotransformation All of these systems are compromised to some degree in loss of chemical tolerance and management of this condition must include assessment of all these areas and address all physiological imbalances that are identified or suspected. There are various natural compounds that have been shown in the scientific literature to address each of these physiologic imbalances which can have powerful effects. These are the compounds we use in functional medicine to improve chemical tolerance. Here are the primary strategies we use and a brief list of the main compounds used to support each of these systems. Optimize Glutathione and Glutathione System Glutathione helps support regulatory T cells, and differentiation of T-cells into their specific types by reducing damage from oxidative stress. This system is absolutely critical for overall modulation of immune responses. There are several compounds that have been identified in the literature to help raise intracellular glutathione, activate the glutathione peroxidase and reductase enzymes, and support the glutathione system. N-acetyl-cysteine N-acetyl-cysteine is a metabolite of the sulfur-containing amino acid, cysteine. It plays a role in the sulfation cycle, acting as a sulfur donor in phase II detoxification and as a methyl donor in the conversion of homocysteine to methionine. N-acetyl cysteine is rapidly metabolized to intracellular glutathione. It is used for acetaminophen overdose and as a nephroprotective agent for radiocontrast. [52-58] Alpha lipoic acid Alpha lipoic acid is an antioxidant that is made by the body and is found in every cell, where it helps turn glucose into energy. Unlike other antioxidants, which work only in water (such as vitamin C) or fatty tissues (such as vitamin E), alpha lipoic acid is both fat- and water-soluble. This means it can work throughout the body. Alpha lipoic acid also plays an important role in the synergism of antioxidants. It directly recycles and extends the metabolic life spans of vitamin C, glutathione, and coenzyme Q10, and it indirectly renews vitamin E, all of which are necessary for glutathione recycling. [59-68] L-glutamine L-glutamine is important for the generation of glutathione stores since glutamate is unable to be transported into cells. Glutamine is efficiently transported into the cell, converted to glutamate, and readily available for glutathione synthesis. Research has demonstrated that glutamine is important for the generation of glutathione. [69-82] Selenium Selenium is a trace element nutrient that serves as the essential cofactor for the enzyme glutathione peroxidase. Selenium-deficient humans and animals are known to be deficient in glutathione peroxidase activity in their cells and plasma. [83-94] Cordyceps Cordyceps (used in Chinese medicine for thousands of years) has been shown to activate glutathione peroxidase synthesis in the body (the enzymes that increase glutathione) and raise glutathione levels within minutes. Research has demonstrated cordyceps helps protect cells by engaging the glutathione enzyme cycle. [95-98] Centella asiatica (Gotu Kola) Research has clearly demonstrated that oral intake of gotu kola very rapidly and dramatically increases the activity and amount of glutathione peroxidase and quantity of glutathione. [99-109] Silybum marianum Administration of Silybum marianum has shown to significantly increase glutathione, increase superoxide dismutase activity, and have positive influence in the ratios of reduced and oxidized glutathione. [110-126] Broccoli extract Broccoli has a high content of glucosinolates, which are metabolized into isothiocyanates and sulforaphane [127]. These compounds exhibit chemoprotective activity through a mechanism involving inhibition of cytochrome P450 and induction of GST and other enzymes. [128,129] Optimize Regulatory T-Cell Function and TH-3 System The two most powerful ways known to support regulatory T-cell function and coordinate TH-1 and TH-2 balance involve glutathione and vitamin D. Glutathione Glutathione (GSH) is one of the most critical immune-modulating substances that we know of. Like a conductor of an orchestra, glutathione regulates various aspects of immune balance. As previously discussed, studies show that GSH has a significant impact on the immune system’s ability to activate the appropriate T-helper cell response. [130,131] Because GSH is so important in the immune system’s activation of the appropriate T-helper response, altering its levels may have significant implications in TH1/TH2-related diseases. [132] “Accumulation of evidence suggests that intracellular GSH (glutathione) levels in antigen-presenting cells such as macrophages, influence the TH1/TH2 cytokine response pattern. The observations reported herein show that pro-GSH molecules represent new therapeutic agents to support immune modulation.” [133] “These data indicate that glutathione peroxidase-dependent control of intracellular reactive oxygen species accumulation is important not only for regulation of TH-cell proliferation, but also for modulation of differentiation into TH1, TH2 and TH17 cells.”[134] See the clinical strategies described above for strategies for increasing glutathione levels. Vitamin D Numerous studies have been published establishing the critical immunoregulatory role that vitamin D plays in the prevention of immune dysfunction and the development of autoimmune disease. [135-142] Vitamin D appears to act on a number of different immune cells to promote various regulatory responses by the immune system. Vitamin D deficiency has been associated with many autoimmune disorders including multiple sclerosis, Type 1 diabetes, Crohn’s disease, rheumatoid arthritis as well as others. [143] Studies have shown a significant relation between vitamin D deficiency and allergy and an important role of vitamin D in the pathogenesis and severity of allergic disease, and its capacity to control allergic disease. [144,145] Vitamin D supplementation has been shown to reduce the occurrence of asthma in most related studies and may be useful in the prevention or adjunct treatment of chronic obstructive pulmonary disease. [146,147] Here are a few selections from the literature on the role vitamin D plays in immune health: “Increasing evidence demonstrates a strong association between vitamin D signaling and many biological processes that regulate immune responses. The discovery of the vitamin D receptor in multiple immune cell lineages, such as monocytes, dendritic cells, and activated T cells credits vitamin D with a novel role in modulating immunological functions and its subsequent role in the development or prevention of autoimmune diseases.”[148] “It is apparent that vitamin D has significant effects on the immune system and as such may contribute to the pathogenesis of autoimmune disease. Low vitamin D status is reported in many inflammatory rheumatic conditions. In some this extends to an association with disease activity. Vitamin D acts on a number of cells involved in both innate and acquired immunity biasing the adaptive immune system away from Th17 and Th1, towards Th2 and T-regs (T3). Deficiency accordingly could encourage autoimmunity. Vitamin D deficiency may well be an important factor in autoimmune rheumatic disease, including initial disease development and worsening the disease once present.”[149] Optimize Protective Barrier Systems Most people with loss of chemical tolerance have a compromised intestinal barrier. Improving the integrity of this barrier is critical to minimizing inflammatory responses. There are a number of compounds which have been shown to improve the integrity of the body’s intestinal barrier system. L-Glutamine L-glutamine is the preferred fuel source for the cells of the small intestine and has been shown in numerous studies to support the regeneration and repair of the intestinal lining. It has also been shown to increase the number of cells in the small intestine, the number of villi on those cells, as well as the height of the villi. Glutamine-reduced permeability of the lining may accompany “leaky gut” patterns that promote intestinal inflammation and the development of delayed food intolerances. [150-171] Deglycyrrhizinated Licorice Deglycyrrhizinated licorice is a popular and substantially studied natural compound that provides flavonoids that help heal the gastric and intestinal lining. Many different mechanisms have been shown with regard to its restorative properties including stimulation and differentiation of glandulars cells, protective mucous formation, protective mucous secretion, increased intestinal blood flow, and growth and regeneration of intestinal lining cells. [172-189] N-Acetyl Glucosamine N-acetyl glucosamine is a monosaccharide derivative of glucose that is used to support the intestinal glycoprotein cover of the mucosa called mucin. It is also a precursor substrate for the repair of the intestinal mucosal cells and provides support of mucosa membrane irritation. [190-193] Aloe Leaf Extract Aloe leaf extract contains natural phytochemicals and powerful antioxidant properties that reduce intestinal inflammation, soothe the intestines, aid in intestinal wound healing, and have an anti-ulcer effect. It also appears to have antifungal properties, supports cholinergic intestinal motility, and reduces intestinal pain and discomfort. [194-203] Spanish Moss Spanish moss is also known as Tillandsia and it has historically been used for intestinal irritation and allergies. Research on the plant has identified rich sources of flavonoids and other phytochemicals that provide antimicrobial activity and free radical scavenging properties. [204-209] Marshmallow Extract Marshmallow extract has high content of mucilage that can soothe and help heal compromised intestinal barrier tissue. It is also rich in antioxidants that can support healing of tissue. It also has properties that inhibit hyaluronidase, which is the enzyme involved in the production of hyaluronic acid that is involved with intestinal tissue destruction. [210-213] Methylsulfonylmethane (MSM) Methylsulfonylmethane (MSM) is a rich source of natural sulfur which helps as a substrate for antioxidant defense systems as well as support substrates for hepatic phase II sulfation pathways. It has antifungal and anti-inflammatory properties that help support the compromised liver-gut axis. [214-218] Gamma Oryzanol Gamma oryzanol is a mixture of plant sterols and ferulic acid esters from rice. It has demonstrated to be a powerful antioxidant. Numerous papers have demonstrated its effectiveness in gastrointestinal complaints, ulcers, irritable bowel syndrome and non-specific gastrointestinal conditions. It has also been shown to modulate and support the enteric nervous system in its ability to activate intestinal motility and secrete digestive enzymes. [219-226] Slippery Elm Bark Slippery elm bark is very high in natural mucilage and helpful in soothing the inflamed intestinal cells. It reduces contact of inflammatory proteins with the intestinal mucosa, thereby enhancing recovery from intestinal barrier compromise and inflammation. [227-230] German Chamomile The chief constituents of German chamomile have been shown to enhance wound-healing time, modulate prostaglandins and nitric oxide activity to provide gastric and intestinal protection. [231-238] Marigold Flower Extract Marigold flower extract constituents include saponins, carotenoids, flavonoids, mucilage, bitter principle, phytosterols, polysaccharides, and resin. It has been used historically for varied gastrointestinal complaints. It provides substrates for digestive enzyme production, helps during inflammation and provides antibacterial activity. [239-246] Glutathione When a person loses their ability to recycle glutathione and glutathione levels become depleted, they are at risk for intestinal lining inflammation which then leads to leaky gut. The glutathione recycling system is one of the main systems that prevents leaky gut onset. Glutathione is suggested to play an important role in gut barrier function and prevention of intestinal inflammation. [247-252] Zinc Carnosine “Regarding intestinal permeability, zinc carnosine caused an approximate threefold increase in gut integrity and repair”[253] Vitamin D “VDR (vitamin D receptor) plays a critical role in mucosal barrier homeostasis by preserving the integrity of junction complexes and the healing capacity of the colonic epithelium. Therefore, vitamin D deficiency may compromise the mucosal barrier, leading to increased susceptibility to mucosal damage and increased risk of IBD (inflammatory bowel disease). ” [254] “There is growing appreciation of the importance of the pleiotropic hormone vitamin D in the development of tolerance, immune system defenses, and epithelial barrier integrity” [255] “1,25(OH)2D3 (vitamin D) may play a protective role in mucosal barrier homeostasis by maintaining the integrity of junction complexes and in healing capacity of the colon epithelium. 1,25(OH)2D3 may represent an attractive and novel therapeutic agent for the adjuvant therapy of IBD (inflammatory bowel disease).”[256] Intestinal Permeability Dietary Restrictions It is important to avoid certain types of food that tend to aggravate or worsen intestinal permeability when trying to repair the gut barrier and decrease autoimmune responses. These self-promoting vicious cycles become difficult to unwind unless aggressive dietary and nutritional strategies are employed. See Intestinal Permeability Dietary Restrictions at the end of Successful Aging Part 6b for a complete list of these foods. Optimize NF-kB Activity and Minimize Chronic Inflammation NF-kB signaling needs to be downregulated in order to maintain tissue homeostasis. Overall, it appears that the two most potent natural NF-kB minimizers that researchers have discovered are curcumin and resveratrol . Curcumin is the alkaloid derived from turmeric , a spice used in Indian cooking. Resveratrol is a compound found in the skin of red grapes, peanuts and some berries. In recent studies, both curcumin and resveratrol have shown to support healthy numbers of T-cell cytokines (inflammatory messengers). These results suggest the potential use of these phytochemicals for supporting healthy immune responses. Here is what some recent literature is saying about these compounds: Curcumin “Curcumin, a dietary spice from turmeric, has outstanding anti-inflammation and neuroprotective effects. Herein, we review key features of curcumin involved in biology, pharmacology, and medicinal chemistry and discuss its potential relevance to pathophysiological progress of multiple sclerosis”[257] “Curcumin, a component of turmeric, has been shown to be non-toxic, to have antioxidant activity, and to inhibit such mediators of inflammation as NFkB, cyclooxygenase-2 (COX-2), lipooxygenase (LOX), and inducible nitric oxide synthase (iNOS)”[258] “In a larger, randomized, double-blind, multicenter trial involving patients with quiescent ulcerative colitis, administration of 1 g of curcumin twice daily resulted in both clinical improvement and a statistically significant decrease in the rate of relapse”[259] “Our results indicate that curcumin has the potential to protect against cardiac inflammation… and may provide a novel therapeutic strategy for autoimmune myocarditis” [260] “In various chronic illnesses in which inflammation is known to play a major role, curcumin has been shown to exhibit therapeutic potential. These diseases include Alzheimer’s disease (AD), Parkinson’s disease, multiple sclerosis, epilepsy, cerebral injury, CVDs, cancer, allergy, asthma, bronchitis, colitis, rheumatoid arthritis, renal ischemia, psoriasis, diabetes, obesity, depression, fatigue, and AIDS”[261] “…curcumin has received considerable interest as a potential therapeutic agent for the prevention and/or treatment of various malignant diseases, arthritis, allergies, Alzheimer’s disease, and other inflammatory illnesses. The underlying mechanisms of these effects are diverse and appear to involve the regulation of various molecular targets, including transcription factors (such as nuclear factor-kB)…”[262] Resveratrol Resveratrol has been shown in the literature to have powerful anti-inflammatory effects which involve multiple pathways including inhibiting NF-kB, inhibiting iNOS (inducible-nitric oxide synthase) expression and inhibiting inflammatory cytokines such as IL-6 in various inflammatory conditions, including multiple sclerosis [263], diabetic neuropathy [264], arthritis [265], autoimmune myocarditis [266], colitis [267], and exerts immunomodulatory effects both in vitro and in vivo in lymphocytic leukemia. [268] “These studies demonstrate that SRT501 (a pharmaceutical grade formulation of resveratrol) attenuates neuronal damage and neurological dysfunction in experimental autoimmune encephalomyelitis (the animal model of multiple sclerosis) by a mechanism involving SIRT1 activation”[269] “This study confirms the NF-kB inhibitory activity and anti-inflammatory activity of resveratrol, which may contribute to neuroprotection in diabetic neuropathy apart from its antioxidant effect”[270] “In summary, our results suggest that resveratrol suppresses apoptosis and inflammatory signaling through its actions on the NF-kB pathway in human chondrocytes”[271] “Resveratrol significantly ameliorated myocardial injury and preserved cardiac function in a rat model of autoimmune myocarditis” [272] In addition, both curcumin and resveratrol have been shown to reduce the inflammatory mediators that contribute to the low-level, chronic inflammation found in obese individuals and have been linked to the onset of cardiovascular disorders, insulin resistance and type 2 diabetes mellitus. “Curcumin and resveratrol are able to inhibit TNFalpha-activated NF-kappaB signaling in adipocytes and as a result significantly reduce cytokine expression. These data suggest that curcumin and resveratrol may provide a novel and safe approach to reduce or inhibit the chronic inflammatory properties of adipose tissue.”[273] Optimize Targeted Phase I and Phase II Hepatic Biotransformation Pathways As discussed above, both phase I and phase II hepatic biotransformation pathways are involved in transformation and elimination of environmental chemicals. Phase I reactions involve the cytochrome P450 enzyme which is responsible for converting lipophilic (fat-loving) toxins into biotransformed intermediates that are more water-soluble. In phase II, these biotransformed intermediates undergo further biotransformation in a second series of enzymes called conjugases . Each chemical we are exposed to is eliminated from the body via specific phase II pathways. This means it is most efficient to support those specific detox pathways that are involved in the elimination of the particular chemicals that are responsible for the immune reactions and increase of symptoms as identified by laboratory testing. It is important to note that heavy metals do not enter phase I and phase II biotransformation pathways. Phase I pathways are primarily dependent on the glutathione system as well as the cytochrome P450 enzyme system, therefore, the glutathione system is always supported in all chemical exposures. Phase II pathways rely on different enzymes with various coenzymes and cofactors needed to function properly. There are a number of key compounds that have been identified to support each of these specific pathways, including sulfation, methylation, glutathione conjugation, acetylation, glucoronidation and glycine (amino acid) conjugation. In addition, there are a number of natural compounds that have been shown to support bile formation and secretion and excretion of toxic compounds through the biliary system, known as phase III pathways. Dandelion (Taraxacum officinale) Dandelion root has physiologic impacts on both the liver and gallbladder. It impacts the liver by promoting the production of bile and its delivery to the gallbladder. It impacts the gallbladder by causing contraction and release of stored bile.[274-276] Milk Thistle (Silybum marianum) Milk thistle has the ability to increase the solubility of bile and its use has been shown to significantly reduce biliary cholesterol concentrations and bile saturation index.[277] It has potent antioxidant activity which supports phase I detoxification and prevents the depletion of hepatic glutathione which is important for phase II detoxification.[278-280] Silybum marianum has anti-inflammatory chemical properties that are inhibitors of inflammatory prostaglandins and leukotrienes as well as chemical properties that promote protein synthesis to replace damaged liver cells. [281-284] Gotu Kola (Centella asiatica) Gotu kola has active constituents known as triterpenoid compounds that have impacts on cells and tissues that are important in detoxification. It has shown the ability to improve histological findings of liver cirrhosis.[285,286] It also supports hepatic detoxification due to its physiological impact on enhancing venous circulation. Centella asiatica has shown the ability to improve venous disorders such as chronic venous insufficiency and venous hypertension.[287,288] Improved venous circulation has influential roles in optimizing detoxification that are generally overlooked. Panax Ginseng Panax ginseng has shown in several studies to have numerous positive impacts on hepatic function. It has shown to reverse fatty liver in animals, and demonstrate profound anti-hepatotoxic properties.[289,290] It has shown the ability to promote Kupffer cells and shown to increase nuclear, ribosomal, and messenger RNA biosynthesis. [291-293] Glutathione Conjugation Support Glutathione is a tripeptide amino acid that depends upon adequate levels of essential nutrients such as B6, riboflavin, choline, methionine, cysteine or n-acetyl-cysteine (NAC), vitamin C, betaine, glycine, glutamic acid, potassium, copper, zinc, and selenium. Numerous studies have shown that taking these essential nutrients will enhance glutathione levels. [294,295] Methylation Conjugation Support Methylation involves conjugating phase I end-products with single-carbon compounds. Methylation requires methionine, betaine, ascorbic acid, alpha tocopherol (vitamin E), choline, pyradoxyl-5-phosphate (vitamin B6), trimethlyglycine, magnesium, methylcobalamin (vitamin B12), and folic acid. Acetylation Conjugation Support Acetylation pathways conjugate toxins with acetyl-CoA and two carbon compounds. Acetylation pathways are dependent on pantothenic acid, thiamin, and vitamin C.[296] Glucuronidation Conjugation Support Glucuronidation involves combining toxins and end-products with glucuronic acid. This pathway is supported by B-vitamins, magnesium, and glycine, which help support the uronic acid pathway that synthesizes glucuronic acid. Sulfation Conjugation Support Sulfation involves combining toxins and end products with sulfur-containing amino acids. An important step in sulfation is the conversion of sulfites to sulfates by the molybdenum-dependent enzyme sulfite oxidase. Therefore, the mineral molybdenum and the sulfur-containing amino acids such as N-acetyl-cysteine, glycine, and methionine are important for sulfation conjugation support. Heavy Metal Exposure and Elimination Heavy metals are eliminated by the body via different mechanisms, which rely heavily on our body’s metallothionein and glutathione systems. Metal binding proteins, including metallothioneins, are potent chelators for heavy metals and are central to the natural response of the body to these toxic elements.[297-299] Glutathione is another potent chelator involved in cellular response, transport, and excretion of metals and is a biomarker for toxic metal overload. [300-303] But it is a type of chelator that does not redistribute to other tissues, which is a big risk in many chelation therapies.[304-308] Natural compounds such as N-acetyl L-cysteine, alpha lipoic acid and glutathione all contribute to chelation and excretion of metals in the human body with much less risk of displacement into other tissues, such as the brain, than synthetic chelating agents.[309,310] These compounds also serve as antioxidants in the tissue to protect the tissue from damage caused by interaction with heavy metals.[311-313] Oxidative stress may be considered as one of the prime contributing mechanisms in metal toxicity and thus provide a strong rationale for including antioxidants during chelation therapy.[314] Antioxidant supplementation with chelating agents has been found beneficial in increasing metal mobilization and providing improved recovery from problems associated with chelation therapy [315-317]. Combination therapies with antioxidants like N -acetylcysteine (NAC), alpha-lipoic acid (ALA), and melatonin have shown considerable promise in improving clinical recoveries in animal models.[318] Antioxidant therapy should be considered and utilized in any protocol to support elimination of heavy metals. References 47. American Autoimmune Related Diseases Association: www.aarda.com 48. Powell JJ, Van de Water J, Gershwin ME. Evidence for the role of environmental agents in the initiation or the progression of autoimmune conditions. Environ Health Perspect. 1999 Oct;107 Suppl 5:667-672 49. Yoshida S, Gershwin ME. Autoimmunity and selected environmental factors of disease induction. Semin Arthritis Rheum. 1993 Jun;22(6):399-419 50. Yoshida S, Gershwin ME. Autoimmunity and selected environmental factors of disease induction. Semin Arthritis Rheum. 1993 Jun;22(6):399-419 51. Powell JJ, Van de Water J, Gershwin ME. Evidence for the role of environmental agents in the initiation or the progression of autoimmune conditions. Environ Health Perspect. 1999 Oct;107 Suppl 5:667-672 52. Odom RY, Dansby MY, Rollins-Hairston AM, Jackson KM, Kirlin WG. Phytochemical induction of cell cycle arrest by glutathione oxidation and reversal by N-acetylcysteine in human colon carcinoma cells. Nutr Cancer. 2009;61(3):332-9. 53. Soghier LM, Brion LP. Cysteine, cystine or N-acetylcysteine supplementation in parenterally fed neonates. Cochrane Database Syst Rev. 2006 Oct 18;(4):CD004869. 54. Badaloo A, Reid M, Forrester T, Heird WC, Jahoor F. Cysteine supplementation improves the erythrocyte glutathione synthesis rate in children with severe edematous malnutrition. Am J Clin Nutr. 2002 Sep;76(3):646-52. 55. Drager LF, Andrade L, Barros de Toledo JF, Laurindo FR, Machado Cesar LA, Seguro AC. Renal effects of N-acetylcysteine in patients at risk for contrast nephropathy: decrease in oxidant stress-mediated renal tubular injury. Nephrol Dial Transplant 2004;19:1803-1807. 56. Shimada K, Murayama T, Yokode M, Kita T, Uzui H, Ueda T, Lee JD, Kishimoto C. N-acetylcysteine reduces the severity of atherosclerosis in apolipoprotein E-deficient mice by reducing superoxide production. Circ J 2009;73:1337-1341. 57. Moldeus P, Cotgreave IA, Berggren M. Lung protection by a thiol-containing antioxidant: N-acetylcysteine. Respiration 1986;50 Suppl 1:31-42. 58. Prescott LF, Park J, Ballantyne A, Adriaenssens P, Proudfoot AT. Treatment of paracetamol (acetaminophen) poisoning with N-acetylcysteine. Lancet 1977;2:432-434. 59. Shay KP, Moreau RF, Smith EJ, Smith AR, Hagen TM. Alpha-lipoic acid as adietary supplement: molecular mechanisms and therapeutic potential. Biochim Biophys Acta. 2009 Oct;1790(10):1149-60. Epub 2009 Aug 4. 60. Kinnunen S, Oksala N, Hyyppä S, Sen CK, Radak Z, Laaksonen DE, Szabó B, Jakus J, Atalay M. Alpha-Lipoic acid modulates thiol antioxidant defenses and attenuates exercise-induced oxidative stress in standardbred trotters. Free Radic Res. 2009 Aug;43(8):697-705. 61. Maczurek A, Hager K, Kenklies M, Sharman M, Martins R, Engel J, Carlson DA, Münch G. Lipoic acid as an anti-infl ammatory and neuroprotective treatment for Alzheimer’s disease. Adv Drug Deliv Rev. 2008 Oct-Nov;60(13-14):1463-70. 62. Suh JH, Moreau R, Heath SH, Hagen TM. Dietary supplementation with (R)-alpha-lipoic acid reverses the age-related accumulation of iron and depletion of antioxidants in the rat cerebral cortex. Redox Rep. 2005;10(1):52-60. 63. Hill AS, Rogers QR, O’Neill SL, Christopher MM. Effects of dietary antioxidant supplementation before and after oral acetaminophen challenge in cats. Am J Vet Res. 2005 Feb;66(2):196-204. 64. Zicker SC, Hagen TM, Joisher N, Golder C, Joshi DK, Miller EP. Safety of long-term feeding of dl-alpha-lipoic acid and its effect on reduced glutathione:oxidized glutathione ratios in beagles. Vet Ther. 2002 Summer;3(2):167-76. 65. Jones W, Li X, Qu ZC, Perriott L, Whitesell RR, May JM. Uptake, recycling, and antioxidant actions of alpha-lipoic acid in endothelial cells. Free Radic Biol Med. 2002 Jul 1;33(1):83-93. 66. Miquel J. Can antioxidant diet supplementation protect against age-related mitochondrial damage? Ann N Y Acad Sci. 2002 Apr;959:508-16. 67. Khanna S, Atalay M, Laaksonen DE, Gul M, Roy S, Sen CK. Alpha-lipoic acid supplementation: tissue glutathione homeostasis at rest and after exercise. J Appl Physiol. 1999 Apr;86(4):1191-6. 68. Han D, Handelman G, Marcocci L, Sen CK, Roy S, Kobuchi H, Tritschler HJ, Flohé L, Packer L. Lipoic acid increases de novo synthesis of cellular glutathione by improving cystine utilization. Biofactors. 1997;6(3):321-38. 69. Kul M, Vurucu S, Demirkaya E, Tunc T, Aydinoz S, Meral C, Kesik V, Alpay F. Enteral glutamine and/or arginine supplementation have favorable effects on oxidative stress parameters in neonatal rat intestine. J Pediatr Gastroenterol Nutr. 2009 Jul;49(1):85-9. 70. Fan YP, Yu JC, Kang WM, Zhang Q. Effects of glutamine supplementation on patients undergoing abdominal surgery. Chin Med Sci J. 2009 Mar;24(1):55- 71. Todorova V, Vanderpool D, Blossom S, Nwokedi E, Hennings L, Mrak R, Klimberg VS. Oral glutamine protects against cyclophosphamide-induced cardiotoxicity in experimental rats through increase of cardiac glutathione. Nutrition. 2009 Jul-Aug;25(7-8):812-7. 72. Cruzat VF, Tirapegui J. Effects of oral supplementation with glutamine and alanyl-glutamine on glutamine, glutamate, and glutathione status in trained rats and subjected to long-duration exercise. Nutrition. 2009 Apr;25(4):428-35. 73. Kaufmann Y, Todorova VK, Luo S, Klimberg VS. Glutamine affects glutathione recycling enzymes in a DMBA-induced breast cancer model. Nutr Cancer. 2008;60(4):518-25. 74. Xue H, Sawyer MB, Field CJ, Dieleman LA, Murray D, Baracos VE. Bolus oral glutamine protects rats against CPT-11-induced diarrhea and differentially activates cytoprotective mechanisms in host intestine but not tumor. J Nutr. 2008 Apr;138(4):740-6. 75. Mok E, Constantin B, Favreau F, Neveux N, Magaud C, Delwail A, Hankard R. L-glutamine administration reduces oxidized glutathione and MAP kinase signaling in dystrophic muscle of mdx mice. Pediatr Res. 2008 Mar;63(3):268-73. 76. Kaufmann Y, Klimberg VS. Effect of glutamine on gut glutathione fractional release in the implanted tumor model. Nutr Cancer. 2007;59(2):199-206. 77. Belmonte L, Coëffi er M, Le Pessot F, Miralles-Barrachina O, Hiron M, Leplingard A, Lemeland JF, Hecketsweiler B, Daveau M, Ducrotté P, Déchelotte P. Effects of glutamine supplementation on gut barrier, glutathione content and acute phase response in malnourished rats during infl ammatory shock. World J Gastroenterol. 2007 May 28;13(20):2833-40. 78. Jackson AA, Gibson NR, Lu Y, Jahoor F. Synthesis of erythrocyte glutathione in healthy adults consuming the safe amount of dietary protein. Am J Clin Nutr.2004 Jul;80(1):101-7. 79. Melis GC, ter Wengel N, Boelens PG, van Leeuwen PA. Glutamine: recent developments in research on the clinical significance of glutamine. Curr Opin Clin Nutr Metab Care. 2004 Jan;7(1):59-70. 80. Johnson AT, Kaufmann YC, Luo S, Todorova V, Klimberg VS. Effect of glutamine on glutathione, IGF-I, and TGF-beta 1. J Surg Res. 2003 May 15;111(2):222-8. 81. Manhart N, Vierlinger K, Spittler A, Bergmeister H, Sautner T, Roth E. Oral feeding with glutamine prevents lymphocyte and glutathione depletion of Peyer’s patches in endotoxemic mice. Ann Surg. 2001 Jul;234(1):92-7. 82. Le Bricon T. Effect of glutamine supplementation on protein metabolism and glutathione in tumor-bearing rats. Clin Nutr. 1996 Aug;15(4):211. 83. Wichtel JJ, Thompson KG, Williamson NB. Serum glutathione peroxidase activity reflects short-term increases in selenium intake in goats. N Z Vet J. 1996 Aug;44(4):148-50 84. Delmas-Beauvieux MC, Peuchant E, Couchouron A, Constans J, Sergeant C, Simonoff M, Pellegrin JL, Leng B, Conri C, Clerc M. The enzymatic antioxidant system in blood and glutathione status in human immunodeficiency virus (HIV)-infected patients: effects of supplementation with selenium or beta-carotene. Am J Clin Nutr. 1996 Jul;64(1):101-7. Erratum in: Am J Clin Nutr 1996 Dec;64(6):971. 85. Winnefeld K, Schirrmeister W, Thiele R, Sperschneider H, Klinger G. Selenium and antioxidant status in various diseases. Med Klin (Munich). 1995 Jan 15;90 Suppl 1:7-9 86. Bellisola G, Perona G, Galassini S, Moschini G, Guidi GC. Plasma selenium and glutathione peroxidase activities in individuals living in the Veneto region of Italy. J Trace Elem Electrolytes Health Dis. 1993 Dec;7(4):242-4. 87. Bedwal RS, Nair N, Sharma MP, Mathur RS. Selenium–its biological perspectives . Med Hypotheses. 1993 Aug;41(2):150-9. PubMed 88. Zachara BA, Mikolajczak J, Trafi kowska U. Effect of various dietary selenium (Se) intakes on tissue Se levels and glutathione peroxidase activities in lambs. Zentralbl Veterinarmed A. 1993 May;40(4):310-8. 89. Wilke BC, Vidailhet M, Favier A, Guillemin C, Ducros V, Arnaud J, Richard MJ. Selenium, glutathione peroxidase (GSH-Px) and lipid peroxidation products before and after selenium supplementation. Clin Chim Acta. 1992 Apr 30;207(1-2):137-42. 90. Bellisola G, Galassini S, Moschini G, Poli G, Perona G, Guidi G. Selenium and glutathione peroxidase variations induced by polyunsaturated fatty acids oral supplementation in humans. Clin Chim Acta. 1992 Jan 31;205(1-2):75-85. 91. Pearson DJ, Day JP, Suarez-Mendez VJ, Miller PF, Owen S, Woodcock A. Human selenium status and glutathione peroxidase activity in northwest England. Eur J Clin Nutr. 1990 Apr;44(4):277-83. 92. Michaëlsson G, Edqvist LE. Erythrocyte glutathione peroxidase activity in acne vulgaris and the effect of selenium and vitamin E treatment. Acta Derm Venereol. 1984;64(1):9-14. PubMed PMID: 6203294. 93. Doni MG, Avventi GL, Bonadiman L, Bonaccorso G. Glutathione peroxidase, selenium, and prostaglandin synthesis in platelets. Am J Physiol. 1981 May;240(5):H800-3. 94. Hafeman DG, Sunde RA, Hoekstra WG. Effect of dietary selenium on erythrocyte and liver glutathione peroxidase in the rat. J Nutr. 1974 May;104(5):580-7. 95. Ko WS, Hsu SL, Chyau CC, Chen KC, Peng RY. Compound Cordyceps TCM-700C exhibits potent hepatoprotective capability in animal model. Fitoterapia. 2010 Jan;81(1):1-7. 96. Ji DB, Ye J, Li CL, Wang YH, Zhao J, Cai SQ. Antiaging effect of Cordyceps sinensis extract. Phytother Res. 2009 Jan;23(1):116-22. 97. Wang YH, Ye J, Li CL, Cai SQ, Ishizaki M, Katada M. [An experimental study on anti-aging action of Cordyceps extract]. Zhongguo Zhong Yao Za Zhi. 2004 Aug;29(8):773-6. 98. Liu Y, Wu C, Li C. [Anti-oxidation of Paecilomyces Sinensis (S. Pnov.)]. Zhongguo Zhong Yao Za Zhi. 1991 Apr;16(4):240-2, 256. 99. Haleagrahara N, Ponnusamy K. Neuroprotective effect of Centella asiatica extract (CAE) on experimentally induced parkinsonism in aged Sprague-Dawley rats. J Toxicol Sci.2010;35(1):41-7. 100. Shinomol GK, Ravikumar H; Muralidhara. Prophylaxis with Centella asiatica confers protection to prepubertal mice against 3-nitropropionicacid-induced oxidative stress in brain. Phytother Res. 2009 Nov 26. 101. Shinomol GK, Muralidhara. Prophylactic neuroprotective property of Centella asiatica against 3-nitropropionic acid induced oxidative stress and mitochondrial dysfunctions in brain regions of prepubertal mice. Neurotoxicology. 2008 Nov;29(6):948-57. 102. Shinomol GK, Muralidhara. Effect of Centella asiatica leaf powder on oxidative markers in brain regions of prepubertal mice in vivo and its in vitro efficacy to ameliorate 3-NPA-induced oxidative stress in mitochondria. Phytomedicine. 2008 Jun 5. 103. Flora SJ, Gupta R. Benefi cial effects of Centella asiatica aqueous extract against arsenic-induced oxidative stress and essential metal status in rats. Phytother Res. 2007 Oct;21(10):980-8. 104. Ramanathan M, Sivakumar S, Anandvijayakumar PR, Saravanababu C, Pandian PR. Neuroprotective evaluation of standardized extract of Centella asciatica in monosodium glutamate treated rats. Indian J Exp Biol. 2007 May;45(5):425-31. 105. Gupta R, Flora SJ. Effect of Centella asiatica on arsenic-induced oxidative stress and metal distribution in rats. J Appl Toxicol. 2006 May-Jun;26(3):213-22. 106. Jayashree G, Kurup Muraleedhara G, Sudarslal S, Jacob VB. Antioxidant activity of Centella asiatica on lymphoma-bearing mice. Fitoterapia. 2003 Jul;74(5):431-4. 107. Gupta YK, Veerendra Kumar MH, Srivastava AK. Effect of Centella asiatica on pentylenetetrazole-induced kindling, cognition and oxidative stress in rats. Pharmacol Biochem Behav. 2003 Feb;74(3):579-85. 108. Veerendra Kumar MH, Gupta YK. Effect of different extracts of Centella asiatica on cognition and markers of oxidative stress in rats. J Ethnopharmacol. 2002 Feb;79(2):253-60. 109. Lee MK, Kim SR, Sung SH, Lim D, Kim H, Choi H, Park HK, Je S, Ki YC. Asiatic acid derivatives protect cultured cortical neurons from glutamate-induced excitotoxicity. Res Commun Mol Pathol Pharmacol. 2000 Jul-Aug;108(1-2):75-86. 110. Shaker E, Mahmoud H, Mnaa S. Silymarin, the antioxidant component and Silybum marianum extracts prevent liver damage. Food Chem Toxicol. 2010 Mar;48(3):803-6. 111. Kidd PM. Bioavailability and activity of phytosome complexes from botanical polyphenols: the silymarin, curcumin, green tea, and grape seed extracts. Altern Med Rev. 2009 Sep;14(3):226-46. 112. Kaur G, Athar M, Alam MS. Dietary supplementation of silymarin protects against chemically induced nephrotoxicity, infl ammation and renal tumor promotionresponse. Invest New Drugs. 2009 Jul 10. 113. Lu P, Mamiya T, Lu LL, Mouri A, Zou L, Nagai T, Hiramatsu M, Ikejima T, Nabeshima T. Silibinin prevents amyloid beta peptide-induced memory impairment and oxidative stress in mice. Br J Pharmacol. 2009 Aug;157(7):1270-7. 114. Gharagozloo M, Moayedi B, Zakerinia M, Hamidi M, Karimi M, Maracy M, Amirghofran Z. Combined therapy of silymarin and desferrioxamine in patients with beta-thalassemia major: a randomized double-blind clinical trial. Fundam Clin Pharmacol. 2009 Jun;23(3):359-65. 115. Kim SH, Cheon HJ, Yun N, Oh ST, Shin E, Shim KS, Lee SM. Protective effect of a mixture of Aloe vera and Silybum marianum against carbon tetrachloride-induced acute hepatotoxicity and liver fi brosis. J Pharmacol Sci. 2009 Jan;109(1):119-27. 116. Turgut F, Bayrak O, Catal F, Bayrak R, Atmaca AF, Koc A, Akbas A, Akcay A, Unal D. Antioxidant and protective effects of silymarin on ischemia and reperfusion injury in the kidney tissues of rats. Int Urol Nephrol. 2008;40(2):453-60. 117. Ligeret H, Brault A, Vallerand D, Haddad Y, Haddad PS. Antioxidant and mitochondrial protective effects of silibinin in cold preservation-warm reperfusion liver injury. J Ethnopharmacol. 2008 Feb 12;115(3):507-14. 118. Toklu HZ, Tunali Akbay T, Velioglu-Ogunc A, Ercan F, Gedik N, Keyer-Uysal M, Sener G. Silymarin, the antioxidant component of Silybum marianum, prevents sepsis-induced acute lung and brain injury. J Surg Res. 2008 Apr;145(2):214-22. 119. Song Z, Song M, Lee DY, Liu Y, Deaciuc IV, McClain CJ. Silymarin prevents palmitate-induced lipotoxicity in HepG2 cells: involvement of maintenance of Akt kinase activation. Basic Clin Pharmacol Toxicol. 2007 Oct;101(4):262-8. 120. Toklu HZ, Tunali-Akbay T, Erkanli G, Yüksel M, Ercan F, Sener G. Silymarin, the antioxidant component of Silybum marianum, protects against burn-induced oxidative skin injury. Burns. 2007 Nov;33(7):908-16. 121. Kiruthiga PV, Shafreen RB, Pandian SK, Arun S, Govindu S, Devi KP. Protective effect of silymarin on erythrocyte haemolysate against benzo(a)pyrene and exogenous reactive oxygen species (H2O2) induced oxidative stress. Chemosphere. 2007 Jul;68(8):1511-8. 122. Pradhan SC, Girish C. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Indian J Med Res. 2006 Nov;124(5):491-504. 123. Das SK, Vasudevan DM. Protective effects of silymarin, a milk thistle (Silybium marianum) derivative on ethanol-induced oxidative stress in liver. Indian J Biochem Biophys. 2006 Oct;43(5):306-11. 124. Edwards J, Grange LL, Wang M, Reyes E. Fetoprotectivity of the flavanolignan compound siliphos against ethanol-induced toxicity. Phytother Res. 2000 Nov;14(7):517-21. 125. Täger M, Dietzmann J, Thiel U, Hinrich Neumann K, Ansorge S. Restoration of the cellular thiol status of peritoneal macrophages from CAPD patients by the fl avonoids silibinin and silymarin. Free Radic Res. 2001 Feb;34(2):137-51 126. Valenzuela A, Aspillaga M, Vial S, Guerra R. Selectivity of silymarin on the increase of the glutathione content in different tissues of the rat. Planta Med. 1989 Oct;55(5):420-2. 127. Fahey JW, Talalay P. Antioxidant functions of sulforaphane: a potent inducer of Phase II detoxication enzymes. Food Chem Toxicol 1999;37:973-979. 128. Barcelo S, Gardiner JM, Gescher A, Chipman JK. CYP2E1-mediated mechanism of anti-genotoxicity of the broccoli constituent sulforaphane. Carcinogenesis 1996;17:277-282. 129. Maheo K, Morel F, Langouet S, Kramer H, Le Ferrec E, Ketterer B, Guillouzo A. Inhibition of cytochromes P-450 and induction of glutathione S-transferases by sulforaphane in primary human and rat hepatocytes. Cancer Res 1997;57:3649-3652. 130. Peterson JD, Herzenberg LA, Vasquez K, Waltenbaugh C. Glutathione levels in antigen-presenting cells modulate Th1 versus Th2 response patterns. Proc Natl Acad Sci U S A. 1998 Mar 17; 95(6):3071-6. 131. Murata Y, Shimamura T, Hamuro J. The polarization of T(h)1/T(h)2 balance is dependent on the intracellular thiol redox status of macrophages due to the distinctive cytokine production. Int Immunol. 2002 Feb; 14(2):201-12. 132. Nazzareno Ballatori, Suzanne M. Krance, Sylvia Notenboom, Shujie Shi, Kim Tieu, Christine L. Hammond. Glutathione dysregulation and the etiology and progression of human diseases . Biol Chem. 2009 March; 390(3): 191–214. 133. Antiviral and immunomodulatory properties of new pro-glutathione (GSH) molecules. Curr Med Chem. 2006:13(15): 1749-55 134. Glutathione peroxidase 1 deficiency attenuates allergen-induced airway inflammation by suppressing TH2 and TH17 cell development. Antioxid Redox Signal. 2010 Jun 6. 135. Venu Lagishetty, Nancy Q. Liu, Martin Hewison. Vitamin D metabolism and innate immunity . Mol Cell Endocrinol. 2011 December 5; 347(1-2): 97–105. 136. Cynthia Aranow. Vitamin D and the Immune System . J Investig Med. 2011 August; 59(6): 881–886 137. Bansal AS, Henriquez F, Sumar N, Patel S. T helper cell subsets in arthritis and the benefits of immunomodulation by 1,25(OH)₂ vitamin D. Rheumatol Int. 2012 Apr;32(4):845-52. 138. Jot Hui Ooi, Jing Chen, Margherita T. Cantorna. Vitamin D regulation of immune function in the gut: Why do T cells have vitamin D receptors? Mol Aspects Med. 2012 February; 33(1): 77–82. 139. Diane L. Kamen, Vin Tangpricha. Vitamin D and molecular actions on the immune system: modulation of innate and autoimmunity . J Mol Med (Berl) 2010 May; 88(5): 441–450. 140. Margherita T. Cantorna. Vitamin D, Multiple Sclerosis and Inflammatory Bowel Disease . Arch Biochem Biophys. 2012 July 1; 523(1): 103–106. 141. Sloka S, Silva C, Wang J, Yong VW. Predominance of Th2 polarization by vitamin D through a STAT6-dependent mechanism. J Neuroinflammation. 2011 May 24;8:56 142. Danny Bruce, Jot Hui Ooi, Sanhong Yu, Margherita T Cantorna. Vitamin D and host resistance to infection? Putting the cart in front of the horse . Exp Biol Med (Maywood) 2010 August; 235(8): 921–927. 143. Székely JI, Pataki Á. Effects of vitamin D on immune disorders with special regard to asthma, COPD and autoimmune diseases: a short review. Expert Rev Respir Med. 2012 Dec;6(6):683-704. Review. 144. Ozkara S, Keles E, Ilhan N, Gungor H, Kaygusuz I, Alpay HC. The relationship between Th1/Th2 balance and 1α,25-dihydroxyvitamin D₃ in patients with nasal polyposis. Eur Arch Otorhinolaryngol. 2012 Dec;269(12):2519-24. 145. Taher YA, van Esch BCAM, Hofman GA, Henricks PAJ, van Oosterhout AJ. 1 α ,25-Dihydroxy-vitamin D 3 potentiates the beneficial effects of allergen immunotherapy in a mouse model of allergic asthma: role for IL-10 and TGF- β 1 . Journal of Immunology . 2008;180(8):5211–5221 146. Székely JI, Pataki Á. Effects of vitamin D on immune disorders with special regard to asthma, COPD and autoimmune diseases: a short review. Expert Rev Respir Med. 2012 Dec;6(6):683-704. Review. 147. Maalmi H, Berraïes A, Tangour E, Ammar J, Abid H, Hamzaoui K, Hamzaoui A. The impact of vitamin D deficiency on immune T cells in asthmatic children: a case-control study. J Asthma Allergy. 2012;5:11-9. 148. Yang CY, Leung PS, Adamopoulos IE, Gershwin ME. The implication of vitamin D and autoimmunity: a comprehensive review. Clin Rev Allergy Immunol. 2013 Oct;45(2):217-26. 149. Gatenby P, Lucas R, Swaminathan A. Vitamin D deficiency and risk for rheumatic diseases: an update. Curr Opin Rheumatol. 2013 Mar;25(2):184-91. Review. 150. Noyer CM, Simon D, Borczuk A, Brandt LJ, Lee MJ, Nehra V. A double-blind placebo-controlled pilot study of glutamine therapy for abnormal intestinal permeability in patients with AIDS. Am J Gastroenterol. 1998 Jun;93(6):972-5. 151. Klimberg VS, Souba WW, Dolson DJ, Salloum RM, Hautamaki RD, Plumley DA, Mendenhall WM, Bova FJ, Khan SR, Hackett RL, et al. Prophylactic glutamine protects the intestinal mucosa from radiation injury. Cancer. 1990 Jul 1;66(1):62-8. 152. Chamorro S, de Blas C, Grant G, Badiola I, Menoyo D, Carabaño R. Effect of dietary supplementation with glutamine and a combination of glutamine-arginine on intestinal health in twenty-five-day-old weaned rabbits. J Anim Sci. 2010 Jan;88(1):170-80. 153. Amasheh M, Andres S, Amasheh S, Fromm M, Schulzke JD. Barrier effects of nutritional factors. Ann N Y Acad Sci. 2009 May;1165:267-73 154. Kul M, Vurucu S, Demirkaya E, Tunc T, Aydinoz S, Meral C, Kesik V, Alpay F. Enteral glutamine and/or arginine supplementation have favorable effects on oxidative stress parameters in neonatal rat intestine. J Pediatr Gastroenterol Nutr. 2009 Jul;49(1):85-9. 155. Azuma H, Mishima S, Oda J, Homma H, Sasaki H, Hisamura M, Ohta S, Yukioka T. Enteral supplementation enriched with glutamine, fiber, and oligosaccharide prevents gut translocation in a bacterial overgrowth model. J Trauma. 2009 Jan;66(1):110-4. 156. Maes M, Leunis JC. Normalization of leaky gut in chronic fatigue syndrome (CFS) is accompanied by a clinical improvement: effects of age, duration of illness and the translocation of LPS from gram-negative bacteria. Neuro Endocrinol Lett. 2008 Dec;29(6):902-10. 157. Tian J, Hao L, Chandra P, Jones DP, Willams IR, Gewirtz AT, Ziegler TR. Dietary glutamine and oral antibiotics each improve indexes of gut barrier function in rat short bowel syndrome . Am J Physiol Gastrointest Liver Physiol. 2009 Feb;296(2):G348-55. 158. Coëffier M, Claeyssens S, Lecleire S, Leblond J, Coquard A, Bôle-Feysot C, Lavoinne A, Ducrotté P, Déchelotte P. Combined enteral infusion of glutamine, carbohydrates, and antioxidants modulates gut protein metabolism in humans. Am J Clin Nutr. 2008 Nov;88(5):1284-90. 159. Wang WW, Qiao SY, Li DF. Amino acids and gut function. Amino Acids. 2009 May;37(1):105-10. Epub 2008 Aug 1. Review. PubMed PMID:18670730. 160. Xue H, Sawyer MB, Field CJ, Dieleman LA, Murray D, Baracos VE. Bolus oral glutamine protects rats against CPT-11-induced diarrhea and differentially activates cytoprotective mechanisms in host intestine but not tumor. J Nutr. 2008 Apr;138(4):740-6. 161. Vicario M, Amat C, Rivero M, Moretó M, Pelegrí C. Dietary glutamine affects mucosal functions in rats with mild DSS-induced colitis. J Nutr. 2007 Aug;137(8):1931-7. 162. Harsha WT, Kalandarova E, McNutt P, Irwin R, Noel J. Nutritional supplementation with transforming growth factor-beta, glutamine, and short chain fatty acids minimizes methotrexate-induced injury. J Pediatr Gastroenterol Nutr. 2006 Jan;42(1):53-8. 163. Yeh CL, Hsu CS, Yeh SL, Chen WJ. Dietary glutamine supplementation modulates Th1/Th2 cytokine and interleukin-6 expressions in septic mice. Cytokine. 2005 Sep 7;31(5):329-34. 164. Basivireddy J, Jacob M, Balasubramanian KA. Oral glutamine attenuates indomethacin-induced small intestinal damage. Clin Sci (Lond). 2004 Sep;107(3):281-9. 165. Li N, Liboni K, Fang MZ, Samuelson D, Lewis P, Patel R, Neu J. Glutamine decreases lipopolysaccharide-induced intestinal inflammation in infant rats. Am J Physiol Gastrointest Liver Physiol. 2004 Jun;286(6):G914-21. 166. Zhou X, Li YX, Li N, Li JS. Glutamine enhances the gut-trophic effect of growth hormone in rat after massive small bowel resection. J Surg Res. 2001 Jul;99(1):47-52. K60 RepairviteTM 167. Li N, Li J, Li Y. [Nutritional rehabilitation for patients with extreme short bowel]. Zhonghua Wai Ke Za Zhi. 1997 Dec;35(12):707-9. 168. Gismondo MR, Drago L, Fassina MC, Vaghi I, Abbiati R, Grossi E. Immunostimulating effect of oral glutamine. Dig Dis Sci. 1998 Aug;43(8):1752-4. 169. Ameho CK, Adjei AA, Harrison EK, Takeshita K, Morioka T, Arakaki Y, Ito E, Suzuki I, Kulkarni AD, Kawajiri A, Yamamoto S. Prophylactic effect of dietary glutamine supplementation on interleukin 8 and tumour necrosis factor alpha production in trinitrobenzene sulphonic acid induced colitis. Gut. 1997 Oct;41(4):487-93. 170. Elia M, Lunn PG. The use of glutamine in the treatment of gastrointestinal disorders in man. Nutrition. 1997 Jul-Aug;13(7-8):743-7. 171. Wu G, Meier SA, Knabe DA. Dietary glutamine supplementation prevents jejunal atrophy in weaned pigs. J Nutr. 1996 Oct;126(10):2578-84. 172. Marks IN. Site-protective agents. Baillieres Clin Gastroenterol. 1988 Jul;2(3):609-20. Review. 173. Marks IN, Boyd E. Mucosal protective agents in the long-term management of gastric ulcer. Med J Aust. 1985 Feb 4;142(3):S23-5. 174. Russell RI, Morgan RJ, Nelson LM. Studies on the protective effect of deglycyrrhinised liquorice against aspirin (ASA) and ASA plus bile acidinduced gastric mucosal damage, and ASA absorption in rats. Scand J Gastroenterol Suppl. 1984;92:97-100. 175. Bennett A. Gastric mucosal formation of prostanoids and the effects of drugs. Acta Physiol Hung. 1984;64(3-4):215-7. 176. Morgan RJ, Nelson LM, Russell RI, Docherty C. The protective effect of deglycyrrhinized liquorice against aspirin and aspirin plus bile acid-induced gastric mucosal damage, and its influence on aspirin absorption in rats. J Pharm Pharmacol. 1983 Sep;35(9):605-7. 177. Glick L. Deglycyrrhizinated liquorice for peptic ulcer. Lancet. 1982 Oct 9;2(8302):817. 135. van Marle J, Aarsen PN, Lind A, van Weeren-Kramer J. Deglycyrrhizinised liquorice (DGL) and the renewal of rat stomach epithelium. Eur J Pharmacol. 1981 Jun 19;72(2-3):219-25. 178. Datla R, Rao SR, Murthy KJ. Excretion studies of nitrofurantoin and nitrofurantoin with deglycyrrhizinated liquorice. Indian J Physiol Pharmacol. 1981 Jan-Mar;25(1):59-63. 179. Rees WD, Rhodes J, Wright JE, Stamford LF, Bennett A. Effect of deglycyrrhizinated liquorice on gastric mucosal damage by aspirin. Scand J Gastroenterol. 1979;14(5):605-7. 180. Balakrishnan V, Pillai MV, Raveendran PM, Nair CS. Deglycyrrhizinated liquorice in the treatment of chronic duodenal ulcer. J Assoc Physicians India. 1978 Sep;26(9):811-4. 181. D’Imperio N, Giuliani Piccari G, Sarti F, Soffritti M, Spongano P, Benvenuti C, Dal Monte PR. Double-blind trial in duodenal and gastric ulcers. Cimetidine and deglycyrrhizinized liquorice. Acta Gastroenterol Belg. 1978 Jul-Aug;41(7-8):427-34. 182. Bardhan KD, Cumberland DC, Dixon RA, Holdsworth CD. Proceedings: Deglycyrrhizinated liquorice in gastric ulcer: a double blind controlled study. Gut. 1976 May;17(5):397. 183. Larkworthy W, Holgate PF. Deglycyrrhizinized liquorice in the treatment of chronic duodenal ulcer. A retrospective endoscopic survey of 32 patients. Practitioner. 1975 Dec;215(1290):787-92. 184. Aarsen PN. Standardization method of deglycyrrhizinized liquorice on experimental gastric ulcers in rats. Arzneimittelforschung. 1973 Sep;23(9): 1346-8. 185. Engqvist A, von Feilitzen F, Pyk E, Reichard H. Double-blind trial of deglycyrrhizinated liquorice in gastric ulcer. Gut. 1973 Sep;14(9):711-5. 186. Håkanson R, Liedberg G, Oscarson J, Rehfeld JF, Stadil F. Effect of deglycyrrhizinized liquorice on gastric acid secretion, histidine decarboxylase activity and serum gastrin level in the rat. Experientia. 1973 May 15;29(5):570-1. 187. Whiting B, Thomson TJ. Deglycyrrhizinized liquorice in duodenal ulcer. Br Med J. 1971 Oct 2;4(5778):48. 188. Feldman H, Gilat T. A trial of deglycyrrhizinated liquorice in the treatment of duodenal ulcer. Gut. 1971 Jun;12(6):449-51. 189. Andersson S, Bárány F, Caboclo JL, Mizuno T. Protective action of deglycyrrhizinized liquorice on the occurrence of stomach ulcers in pylorus-ligated rats. Scand J Gastroenterol. 1971;6(8):683-6. 190. Baldrick P. The safety of chitosan as a pharmaceutical excipient. Regul Toxicol Pharmacol. 2010 Apr;56(3):290-9. 191. Gunn-Moore DA, Shenoy CM. Oral glucosamine and the management of feline idiopathic cystitis. J Feline Med Surg. 2004 Aug;6(4):219-25. 192. Seidman EG, Bernotti S, Levy E. Nutritional modulation of gut inflammation. Nestle Nutr Workshop Ser Clin Perform Programme. 2002;7:41-61; discussion 61-5. 193. Sharma R, Schumacher U. Carbohydrate expression in the intestinal mucosa. Adv Anat Embryol Cell Biol. 2001;160:III-IX, 1-91. 194. Fawole OA, Amoo SO, Ndhlala AR, Light ME, Finnie JF, Van Staden J. Anti-inflammatory, anticholinesterase, antioxidant and phytochemical properties of medicinal plants used for pain-related ailments in South Africa. J Ethnopharmacol. 2010 Feb 3;127(2):235-41. 196. Ozsoy N, Candoken E, Akev N. Implications for degenerative disorders: Antioxidative activity, total phenols, flavonoids, ascorbic acid, betacarotene and beta-tocopherol in Aloe vera. Oxid Med Cell Longev. 2009 Apr;2(2):99-106. 197. Kigondu EV, Rukunga GM, Keriko JM, Tonui WK, Gathirwa JW, Kirira PG, Irungu B, Ingonga JM, Ndiege IO. Anti-parasitic activity and cytotoxicity of selected medicinal plants from Kenya. J Ethnopharmacol. 2009 Jun 25;123(3):504-9. 198. Chen W, Lu Z, Viljoen A, Hamman J. Intestinal drug transport enhancement by Aloe vera. Planta Med. 2009 May;75(6):587-95. 199. Pogribna M, Freeman JP, Paine D, Boudreau MD. Effect of Aloe vera whole leaf extract on short chain fatty acids production by Bacteroides fragilis, Bifidobacterium infantis and Eubacterium limosum. Lett Appl Microbiol. 2008 May;46(5):575-80. 200. Rosca-Casian O, Parvu M, Vlase L, Tamas M. Antifungal activity of Aloe vera leaves. Fitoterapia. 2007 Apr;78(3):219-22. 201. Iena IaM. [The therapeutic properties of aloe]. Lik Sprava. 1993 Feb-Mar;(2-3):142-5. 202. t’Hart LA, van den Berg AJ, Kuis L, van Dijk H, Labadie RP. An anticomplementary polysaccharide with immunological adjuvant activity from the leaf parenchyma gel of Aloe vera. Planta Med. 1989 Dec; 55(6):509-12. 203. Brossat JY, Ledeaut JY, Ralamboranto L, Rakotovao LH, Solar S, Gueguen A, Coulanges P. [Immunostimulating properties of an extract isolated from Aloe vahombe. 2. Protection in mice by fraction F1 against infections by Listeria monocytogenes, Yersinia pestis, Candida albicans and Plasmodium berghei]. Arch Inst Pasteur Madagascar. 1981;48(1):11-34. 204. Delaporte RH, Sarragiotto MH, Takemura OS, Sánchez GM, Filho BP, Nakamura CV. Evaluation of the antioedematogenic, free radical scavenging and antimicrobial activities of aerial parts of Tillandsiastreptocarpa Baker-Bromeliaceae. J Ethnopharmacol. 2004 Dec;95(2-3):229-33. 205. de Queiroga MA, de Andrade LM, Florêncio KC, de Fátima Agra M, da Silva MS, Barbosa-Filho JM, da-Cunha EV. Chemical constituents from Tillandsia recurvata. Fitoterapia. 2004 Jun;75(3-4):423-5. 206. Arslanian RL, Stermitz FR, Castedo L. 3-Methoxy-5-hydroxyflavonols from Tillandsia purpurea. J Nat Prod. 1986 Nov-Dec;49(6):1177-8. 207. FEURT SD, FOX LE. Effects of oral administration of Spanish moss, Tillandsia usneoides L. Science. 1953 Nov 20;118(3073):626-7. 208. FEURT SD, FOX LE. The pharmacological activity of substances extracted from Spanish moss, Tillandsia usneoides L. J Am Pharm Assoc Am Pharm Assoc (Baltim). 1952 Aug;41(8):453-4. 209. WEBBER MG, LAUTER WM, FOOTE PA. A preliminary phytochemical study of Tillandsia usneoides L. (Spanish moss). J Am Pharm Assoc Am Pharm Assoc. 1952 May;41(5):230-5. 210. Hage-Sleiman R, Mroueh M, Daher CF. Pharmacological evaluation of aqueous extract of Althaea officinalis flower grown in Lebanon. Pharm Biol. 2011 Mar;49(3):327-33. 211. Deters A, Zippel J, Hellenbrand N, Pappai D, Possemeyer C, Hensel A. Aqueous extracts and polysaccharides from Marshmallow roots (Althea officinalis L.): cellular internalisation and stimulation of cell physiology of human epithelial cells in vitro. J Ethnopharmacol. 2010 Jan 8;127(1):62-9. 212. Kardosová A, Machová E. Antioxidant activity of medicinal plant polysaccharides. Fitoterapia. 2006 Jul;77(5):367-73. Epub 2006 May 24. 213. Wang DF, Shang JY, Yu QH. [Analgesic and anti-inflammatory effects of the flower of Althaea rosea (L.) Cav.]. Zhongguo Zhong Yao Za Zhi. 1989 Jan;14(1):46-8, 64. 214. Iauk L, Lo Bue AM, Milazzo I, Rapisarda A, Blandino G. Antibacterial activity of medicinal plant extracts against periodontopathic bacteria. Phytother Res. 2003 Jun;17(6):599-604. 215. Satia JA, Littman A, Slatore CG, Galanko JA, White E. Associations of herbal and specialty supplements with lung and colorectal cancer risk in the VITamins and Lifestyle study. Cancer Epidemiol Biomarkers Prev. 2009 May;18(5):1419-28. 216. Marañón G, Muñoz-Escassi B, Manley W, García C, Cayado P, de la Muela MS, Olábarri B, León R, Vara E. The effect of methyl sulphonyl methane supplementation on biomarkers of oxidative stress in sport horses following jumping exercise. Acta Vet Scand. 2008 Nov 7;50:45. 217. Brien S, Prescott P, Bashir N, Lewith H, Lewith G. Systematic review of the nutritional supplements dimethyl sulfoxide (DMSO) and methylsulfonylmethane (MSM)in the treatment of osteoarthritis. Osteoarthritis Cartilage. 2008 Nov;16(11):1277-88. 218. Parcell S. Sulfur in human nutrition and applications in medicine. Altern Med Rev. 2002 Feb;7(1):22-44. 219. Maoka T, Tanimoto F, Sano M, Tsurukawa K, Tsuno T, Tsujiwaki S, Ishimaru K, Takii K. Effects of dietary supplementation of ferulic acid and gammaoryzanol on integument color and suppression of oxidative stress in cultured red sea bream, Pagrus major. J Oleo Sci. 2008;57(2):133-7. 220. Accinni R, Rosina M, Bamonti F, Della Noce C, Tonini A, Bernacchi F, Campolo J, Caruso R, Novembrino C, Ghersi L, Lonati S, Grossi S, Ippolito S, Lorenzano E, Ciani A, Gorini M. Effects of combined dietary supplementation on oxidative and inflammatory status in dyslipidemic subjects. Nutr Metab Cardiovasc Dis. 2006 Mar;16(2):121-7. 221. Sierra S, Lara-Villoslada F, Olivares M, Jiménez J, Boza J, Xaus J. Increased immune response in mice consuming rice bran oil. Eur J Nutr. 2005 Dec;44(8):509-16. 222. Jariwalla RJ. Rice-bran products: phytonutrients with potential applications in preventive and clinical medicine. Drugs Exp Clin Res. 2001;27(1):17-26. 223. Sugano M, Tsuji E. Rice bran oil and human health. Biomed Environ Sci. 1996 Sep;9(2-3):242-6. 224. Hirose M, Ozaki K, Takaba K, Fukushima S, Shirai T, Ito N. Modifying effects of the naturally occurring antioxidants gamma-oryzanol, phytic acid, tannic acid and n-tritriacontane-16, 18-dione in a rat wide-spectrum organ carcinogenesis model. Carcinogenesis. 1991 Oct;12(10):1917-21. 225. Wheeler KB, Garleb KA. Gamma oryzanol-plant sterol supplementation: metabolic, endocrine, and physiologic effects. Int J Sport Nutr. 1991 Jun;1(2):170-7. 226. Itaya K, Kitonaga J, Ishikawa M. [Studies of gamma-oryzanol. (2) The antiulcerogenic action]. Nippon Yakurigaku Zasshi. 1976 Nov;72(8):1001-11. 227. Brown AC, Hairfield M, Richards DG, McMillin DL, Mein EA, Nelson CD. Medical nutrition therapy as a potential complementary treatment for psoriasis-five case reports. Altern Med Rev. 2004 Sep;9(3):297-307. 228. Choi HR, Choi JS, Han YN, Bae SJ, Chung HY. Peroxynitrite scavenging activity of herb extracts. Phytother Res. 2002 Jun;16(4):364-7. 229. Majchrowicz MA. Essiac. Notes Undergr. 1995 Winter;(no 29):6-7. 230. Gill RE, Hirst EL, Jones JK. Constitution of the mucilage from the bark of Ulmus fulva (slippery elm mucilage); the sugars formed in the hydrolysis of the methylated mucilage. J Chem Soc. 1946 Nov:1025-9. 231. Jarrahi M, Vafaei AA, Taherian AA, Miladi H, Rashidi Pour A. Evaluation of topical Matricaria chamomilla extract activity on linear incisional wound healing in albino rats. Nat Prod Res. 2010 May;24(8):697-702. 232. Bezerra SB, Leal LK, Pinto NA, Campos AR. Bisabolol-induced gastroprotection against acute gastric lesions: role of prostaglandins, nitric oxide, and KATP+ channels. J Med Food. 2009 Dec;12(6):1403-6. 233. Moura Rocha NF, Venâncio ET, Moura BA, Gomes Silva MI, Aquino Neto MR, Vasconcelos Rios ER, de Sousa DP, Mendes Vasconcelos SM, de França Fonteles MM, de Sousa FC. Gastroprotection of (-)-alphabisabolol on acute gastric mucosal lesions in mice: the possible involved pharmacological mechanisms. Fundam Clin Pharmacol. 2009 Aug 3. 234. Pereira RP, Fachinetto R, de Souza Prestes A, Puntel RL, Santos da Silva GN, Heinzmann BM, Boschetti TK, Athayde ML, Bürger ME, Morel AF, Morsch VM, Rocha JB. Antioxidant effects of different extracts from Melissa officinalis, Matricaria recutita and Cymbopogon citratus. Neurochem Res. 2009 May;34(5):973-83. 235. Nogueira JC, Diniz Mde F, Lima EO. In vitro antimicrobial activity of plants in Acute Otitis Externa. Braz J Otorhinolaryngol. 2008 Jan-Feb;74(1):118-24. 236. Shikov AN, Pozharitskaya ON, Makarov VG, Kvetnaya AS. Antibacterial activity of Chamomilla recutita oil extract against Helicobacter pylori. Phytother Res. 2008 Feb;22(2):252-3. 237. Capasso R, Savino F, Capasso F. Effects of the herbal formulation ColiMil on upper gastrointestinal transit in mice in vivo. Phytother Res. 2007 Oct;21(10):999-1101. 238. Mahady GB, Pendland SL, Stoia A, Hamill FA, Fabricant D, Dietz BM, Chadwick LR. In vitro susceptibility of Helicobacter pylori to botanical extracts used traditionally for the treatment of gastrointestinal disorders. Phytother Res. 2005 Nov;19(11):988-91. 239. Madisch A, Holtmann G, Mayr G, Vinson B, Hotz J. Treatment of functional dyspepsia with a herbal preparation. A double-blind, randomized, placebo-controlled, multicenter trial. Digestion. 2004;69(1):45-52. 240. Elango G, Rahuman AA, Kamaraj C, Zahir AA, Bagavan A. Studies on effects of indigenous plant extracts on filarial vector Culex tritaeniorhynchus Giles. Parasitol Res. 2010 Apr 7. 241. Aguilar HH, de Gives PM, Sánchez DO, Arellano ME, Hernández EL, Aroche UL, Valladares-Cisneros G. In vitro nematocidal activity of plant extracts of Mexican flora against Haemonchus contortus fourth larval stage. Ann N Y Acad Sci. 2008 Dec;1149:158-60. 242. Bashir S, Gilani AH. Studies on the antioxidant and analgesic activities of Aztec marigold (Tagetes erecta) flowers. Phytother Res. 2008 Dec;22(12):1692-4. 243. Wang M, Tsao R, Zhang S, Dong Z, Yang R, Gong J, Pei Y. Antioxidant activity, mutagenicity/ anti-mutagenicity, and clastogenicity/anticlastogenicity of lutein from marigold flowers. Food Chem Toxicol. 2006 Sep;44(9):1522-9. 244. Wang M, Tsao R, Zhang S, Dong Z, Yang R, Gong J, Pei Y. Antioxidant activity, mutagenicity/anti-mutagenicity, and clastogenicity/anticlastogenicity of lutein from marigold flowers. Food Chem Toxicol. 2006 Sep;44(9):1522-9. 245. Breithaupt DE, Bamedi A, Wirt U. Carotenol fatty acid esters: easy substrates for digestive enzymes? Comp Biochem Physiol B Biochem Mol Biol. 2002 Aug;132(4):721-8. 246. Garg SC, Dengre SL. Antibacterial activity of essential oil of Tagetes erecta Linn. Hindustan Antibiot Bull. 1986 Feb-Nov;28(1-4):27-9. 247. Martín-Venegas R, Brufau MT, Guerrero-Zamora AM, Mercier Y, Geraert PA, Ferrer R. The methionine precursor DL-2-hydroxy-(4-methylthio)butanoic acid protects intestinal epithelial barrier function. Food Chem. 2013 Dec 1;141(3):1702-9. 248. Flamant M, Aubert P, Rolli-Derkinderen M, Bourreille A, Neunlist MR, Mahé MM, Meurette G, Marteyn B, Savidge T, Galmiche JP, Sansonetti PJ, Neunlist M. Enteric glia protect against Shigella flexneri invasion in intestinal epithelial cells: a role for S-nitrosoglutathione. Gut. 2011 Apr;60(4):473-84. 249. van Ampting MT, Schonewille AJ, Vink C, Brummer RJ, van der Meer R, Bovee-Oudenhoven IM. Intestinal barrier function in response to abundant or depleted mucosal glutathione in Salmonella-infected rats. BMC Physiol. 2009 Apr 17:9:6 250. Maeda T, Miyazono Y, Ito K, Hamada K, Sekine S, Horie T. Oxidative stress and enhanced paracellular permeability in the small intestine of methotrexate treated rats. Cancer Chemother Pharmacol.2010 May;65(6):1117-2 251. Savidge TC, Newman P, Pothoulakis C, Ruhl A, Neunlist M, Bourreille A, Hurst R, Sofroniew MV. Enteric glia regulate intestinal barrier function and inflammation via release of S-nitrosoglutathione. Gastroenterology. 2007 Apr;132(4):1344-1358 252. The role of the glutathione antioxidant system in gut barrier failure in a rodent model of experimental necrotizing enterocolitis. Surgery. 2004 Sep;136(3):557-66 253. Mahmood A , FitzGerald AJ , Marchbank T , Ntatsaki E , Murray D , Ghosh S , Playford RJ . Zinc carnosine, a health food supplement that stabilises small bowel integrity and stimulates gut repair processes. Gut. 2007 Feb;56(2):168-75. Epub 2006 Jun 15. 254. Kong J, Zhang Z, Musch MW, Ning G, Sun J, Hart J, Bissonnette M, Li YC. Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal barrier. Am J Physiol Gastroint. Liver Physiol. 2008 Jan; 294(1):G208-16 255. Vassallo MF, Camargo CA Jr. Potential mechanisms for the hypothesized link between sunshine, vitamin D, and food allergy in children. J Allergy Clin Immunol. 2010 Aug;126 (2):217-22 256. Zhao H, Zhang H, Wu H, Li H, Liu L, Guo J, Li C, Shih DQ, Zhang X. Protective role of 1,25(OH)2 vitamin D3 in the mucosal injury and epithelial barrier disruption in DSS-induced acute colitis in mice. BMC Gastroenterol. 2012 May 30;12:57. 257. Curcumin has bright prospects for the treatment of multiple sclerosis . Int Immunopharmacol. 2011 Mar;11(3):323-330 258. Curcumin, an atoxic antioxidant and natural NFkappaB, cyclooxygenase-2, lipooxygenase, and inducible nitric oxide synthase inhibitor: a shield against acute and chronic diseases. Bengmark S. JPEN J Parenter Enteral Nutr. 2006 Jan-Feb;30(1):45-51. Review. 259. Curcumin, an active component of turmeric in the prevention and treatment of ulcerative colitis: preclinical and clinical observations. Baliga MS, Joseph N, Venkataranganna MV, Saxena A, Ponemone V, Fayad R. Food Funct. 2012 Nov;3(11):1109-17. doi: 10.1039/c2fo30097d. Review. 260. Curcumin ameliorates cardiac inflammation in rats with autoimmune myocarditis . Biol Pharm Bull. 2011;34(7):974-979 JPEN J Parenter Enteral Nutr. 2006 Jan-Feb;30(1):45-51. Review. 261. “Spicing up” of the immune system by curcumin. Jagetia GC, Aggarwal BB. J Clin Immunol. 2007 Jan;27(1):19-35. Epub 2007 Jan 9. Review. 262. The targets of curcumin. Curr Drug Targets. 2011 Mar 1;12(3):332-347. 263. Oral resveratrol reduces neuronal damage in a model of multiple sclerosis. J neuroopthalmol. 2010 Dec;30(4):328-339 264. NF-kB inhibitory action of resveratrol: a probable mechanism of neuroprotection in experimental diabetic neuropathy. Biochem Biophys Res Commun. 2010 Apr 2;394(2):360-365 265. Resveratrol suppresses IL-1β-induced inflammatory signaling and apoptosis in human articular chondrocytes: potential use for use as a novel nutraceutical for the treatment of osteoarthritis. Biochem Pharmacol. 2008 Dec 1;76(11):1426-39 266. Resveratrol ameliorates experimental autoimmune myocarditis. Circ J. 2007 Mar;71(3):397-404 267. Youn J, Lee JS, Na HK, Kundu JK, Surh YJ. Resveratrol and piceatannol inhibit iNOS expression and NF-kappaB activation in dextran sulfate sodium-induced mouse colitis. Nutrition and Cancer . 2009;61(6):847–854. 268. Li T, Fan G-X, Wei W, Li T, Yuan Y-K. Resveratrol induces apoptosis, influences IL-6 and exerts immunomodulatory effect on mouse lymphocytic leukemia both in vitro and in vivo. International Immunopharmacology . 2007;7:1221–1231. 269. Oral resveratrol reduces neuronal damage in a model of multiple sclerosis. J neuroopthalmol. 2010 Dec;30(4):328-339 270. NF-kB inhibitory action of resveratrol: a probable mechanism of neuroprotection in experimental diabetic neuropathy. Biochem Biophys Res Commun. 2010 Apr 2;394(2):360-365 271. Resveratrol suppresses IL-1β-induced inflammatory signaling and apoptosis in human articular chondrocytes: potential use for use as a novel nutraceutical for the treatment of osteoarthritis. Biochem Pharmacol. 2008 Dec 1;76(11):1426-39 272. Resveratrol ameliorates experimental autoimmune myocarditis. Circ J. 2007 Mar;71(3):397-404 273. Gonzales AM, Orlando RA. Curcumin and resveratrol inhibit nuclear factor-kappaB-mediated cytokine expression in adipocytes. Nutrition and Metabolism . 2008;5(1):17–30. 274. Faber K. The dandelion Taraxacum officinale. Pharmaize 1958;13:423-436. 275. Susnik F. Present state of knowledge of the medicinal plant Taraxacum officinale. Weber. Med Razgledi 1982;21:323-328. 276. Bohm K. Choleretic action of some medicinal plants . Arzneimittel Forsch 1959;9:376-378. 277. Nassauto G et al. Effects of silbinion on biliary lipid composition. Experimental and clinical study. J Hepatol 1991;12:290-295. 278. Wagnar H. Antihepatotoxic flavonioids. In: CodyV, Middleton E, Harbourne JB, eds. Plant flavonoids in biology and medicine: biochemical, pharmacological, and structure-activity relationships. New York, NY: Alan R Liss. 1986:p545-558 279. Adzet T. Polyphenolic compounds with biological activity and pharmacological activity. Herbs Spices Medicinal Plants 1986;1:167-184 280. Hikino H, Kiso Y, Wagner H. Antihepatotoxic actions of flavanolignans from Silybum marianum fruits. Plant Medica 1984;50:248-250. 281. Fiebrich F, Koch H. Siymarin, an inhibitor of prostaglandin synthetase . Experentia 1979;35:150-152. 282. Feibrich F, Koch H. Silymarin an inbitor of lipoxygenase. Experentia 1979;35:148-150. 283. Palasciano G, Protinacasa P, et al. The effect of silymarin on plasma levels of malonadialdehyde in patients receiving long-term treatment of psychotropic drugs. Curr Ther Res 1994;55:537-545. 284. Sonnenbicher J, Goldberg M, Hane L, et al. Stimulatory effect of silibinin on the DNA synthesis in partially hepatectomized rat livers. Non-responsive in hepatoma and other malignant cel lines. Biochem Pharm 1986;35:538-541. 285. Darnis F, Orcel L, de Saint-Maur PP, Mamaou P. Use of a titrated extract of Centella asiatica in chronic hepatic disorders. Sem Hosp Paris 1979;55:1749-1750. 286. El Zawahry MD, Kahil AM, El Banna MH. Madecassol. A new therapy for hepatic fibrosis. Bull Soc Int Chir (Belgium) 1975;34:296-297. 287. Belcaro GV, Grimaldi R, Guidi G. Improvement of capillary permeability in patients with venous hypertension after treatment with TTFCA. Angiology 1990; 41(7):533-540. 288. Pointel JP, Boccalon H, Cloarec M, et al. Titrated extract of Centella asiatca (TECA) in the treatment of venous insufficiency of the lower limbs. Angiology 1987;38(11):46-50. 289. Hikino H, Kiso Y, Sandah S, Shoji J. Antihepatotoxic actions of ginesenosides form Panax ginseng roots. Planta Medica 1985;52: 62-64. 290. Yammato M, Uemura T, Nakama S, et al. Serum HDL-cholesterol-increasing and fatty liver-improving action of Panax ginseng in high cholesterol diet-feed rats with clinical effects on hyperlipidemia in man. Am J Chin Med 1983;11:96-101. 291. Bombardelli E, Cirstoni A, Lietta A. The effect of acute and chronic (Panax) ginseng saponins treatment on adrenal function; biochemical and pharmacological. Proceedings 3rd International Ginseng Symposium.Seoul: Korean Research Institute. 1980: p 9-16. 292. Oura H, Hiai S, Seno H. Synthesis and characterization of nuclear RNA induced b Radix ginseng extract in rat liver. Chem Pharm Bull 1971;19:1598-1605. 293. Oura H, Hiai S, Nabatini S, Nakagawa H, et al. Effect of ginseng o endoplasmic reticulum and ribosome. Planta Medica 1975;28:76-88. 294. Johnston CJ, Meyer CG, Srilakshmi JC. Vitamin C elevates red blood cell glutathione levels in healthy adults. Am J Clin Nutr 1993; 58: 103-105. 295. Jain A, Buist NR, Keenaaway NG, et al. Effect of ascorbate or N-acetlycysteine treatments in patient with hereditary glutathione synthetase deficiency. J Pediatr 1994; 124: 229-233. 296. Skvortsova RI, Pzniakovski VM, Agarkova IA. Role of vitamin factor in preventing phenol poisoning. Vopr Pitan 1981; 2: 32-35. 297. Margaret E. Sears. Chelation: Harnessing and Enhancing Heavy Metal Detoxification—A Review . ScientificWorldJournal. 2013; 2013: 219840. Published online 2013 April 18. doi: 10.1155/2013/219840 298. Lynes MA, Kang YJ, Sensi SL, Perdrizet GA, Hightower LE. Heavy metal ions in normal physiology, toxic stress, and cytoprotection. Annals of the New York Academy of Sciences . 2007;1113:159–172.[ PubMed ] 299. Klaassen CD, Liu J, Diwan BA. Metallothionein protection of cadmium toxicity. Toxicology and Applied Pharmacology . 2009;238(3):215–220. [ PMC free article ] [ PubMed ] 300. Margaret E. Sears. Chelation: Harnessing and Enhancing Heavy Metal Detoxification—A Review . ScientificWorldJournal. 2013; 2013: 219840. Published online 2013 April 18. doi: 10.1155/2013/219840 301. Wang G, Fowler BA. Roles of biomarkers in evaluating interactions among mixtures of lead, cadmium and arsenic. Toxicology and Applied Pharmacology . 2008;233(1):92–99. [ PubMed ] 302. Franco R, Sánchez-Olea R, Reyes-Reyes EM, Panayiotidis MI. Environmental toxicity, oxidative stress and apoptosis: Ménage à Trois. Mutation Research/Genetic Toxicology and Environmental Mutagenesis .2009;674:3–22. [ PubMed ] 303. Geier DA, Kern JK, Garver CR, et al. Biomarkers of environmental toxicity and susceptibility in autism. Journal of the Neurological Sciences . 2009;280(1):101–108. [ PubMed ] 304. Anderson O. Chemical and biological considerations in the treatment of metal intoxications by chelating agents. Mini Rev Med Chem. 2004 Jan;4(1):11-21. 305. Ewan KB, Pamphlett R. Increased inorganic mercury in spinal motor neurons following chelationg agents. Neurotoxicaolgoy. 1996 Summer;17(2):343-349. 306. Ibim SE, Trotman J, Musey PI, Semafuko WE. Depletion of essential elements by calcium disodium EDTA treatment in the dog. Toxicology. 1992;73(2):229-237. 307. Flora SJ, Pachauri V. Chelation in metal intoxication. Int J Environ Res Public Health. 2010 Jul;7(7):2745-2788. 308. Aaseth J, Skaug MA, Cao Y, Andersen O. Chelation in metal intoxication-Principles and paradigms. J Trace Elem Med Biol. 2014 Oct 19. pii: S0946-672X(14)00180-1. doi: 10.1016/j.jtemb.2014.10.001. [Epub ahead of print] Review. 309. Margaret E. Sears. Chelation: Harnessing and Enhancing Heavy Metal Detoxification—A Review . ScientificWorldJournal. 2013; 2013: 219840. Published online 2013 April 18. doi: 10.1155/2013/219840 310. Flora SJ, Pachauri V. Chelation in metal intoxication. Int J Environ Res Public Health. 2010 Jul;7(7):2745-2788. 311. Flora SJ, Shrivastava R, Mittal M. Chemistry and pharmacological properties of some natural and synthetic antioxidants for heavymetal toxicity. Curr Med Chem. 2013;20(36):4540-74. Review. 312. Margaret E. Sears. Chelation: Harnessing and Enhancing Heavy Metal Detoxification—A Review ScientificWorldJournal. 2013; 2013: 219840. Published online 2013 April 18. doi: 10.1155/2013/219840 313. Flora SJ, Pachauri V. Chelation in metal intoxication. Int J Environ Res Public Health. 2010 Jul;7(7):2745-2788. 314. Flora SJ, Pachauri V. Chelation in metal intoxication. Int J Environ Res Public Health. 2010 Jul;7(7):2745-2788. 315. Flora SJ, Pachauri V. Chelation in metal intoxication. Int J Environ Res Public Health. 2010 Jul;7(7):2745-2788. 316. Flora SJS. Nutritional components modify metal absorption, toxic response and chelation therapy. J. Nutri. Environ. Med. 2002;12:51–65. 317. Pande M, Flora SJS. Lead induced oxidative damage and its response to combined administration of α-Lipoic acid and succimers in rats. Toxicology. 2002;177:187–196. [ PubMed ] 318. Flora SJ, Pachauri V. Chelation in metal intoxication. Int J Environ Res Public Health. 2010 Jul;7(7):2745-2788.","date_published":"2014-12-17T06:03:34","date_modified":"2024-03-26T08:13:02","authors":[{"name":"Dr. Richard Esquivel","url":"https://sanjosefuncmed.com/about/"}],"tags":["Environmental Health"]},{"id":"https://sanjosefuncmed.com/obesity-trends-u-s-adults-1985-2010/","url":"https://sanjosefuncmed.com/obesity-trends-u-s-adults-1985-2010/","title":"Obesity Trends Among U.S. Adults Between 1985 and 2010","summary":"During the past 20 years, there has been a dramatic increase in obesity in the United States. In 1985, only a few states were participating in CDC’s BRFSS and","content_text":"During the past 20 years, there has been a dramatic increase in obesity in the United States. In 1985, only a few states were participating in CDC’s BRFSS and providing obesity data. In 1990, among states participating in the Behavioral Risk Factor Surveillance System, ten states had a prevalence of obesity less than 10% and no states had prevalence equal to or greater than 15%. In 1991, 4 states had obesity prevalence rates of 15-19 percent and no states had rates at or above 20 percent. By 1999, no state had prevalence less than 10%, 18 states had a prevalence of obesity between 20-24%, and no state had prevalence equal to or greater than 25%. In 2003, 15 states had prevalence rates of 15-19 percent; 31 states had rates of 20-24 percent; and 4 states had rates of more than 25 percent. In 2008, only one state (Colorado) had a prevalence of obesity less than 20%. Thirty-two states had a prevalence equal to or greater than 25%; six of these states (Alabama, Mississippi, Oklahoma, South Carolina, Tennessee, and West Virginia ) had a prevalence of obesity equal to or greater than 30%. In 2010, no state had a prevalence of obesity of less than 20%. 36 states had a prevalence equal to or greater than 25%; 12 of these states had a prevalence equal to or greater than 30%.(5) PowerPoint Slideshow of Obesity Trends in the U.S. from 1985 to 2010 Source: The data shown in these maps were collected through CDC’s Behavioral Risk Factor Surveillance System (BRFSS).","date_published":"2012-06-13T04:23:04","date_modified":"2020-04-19T22:26:07","authors":[{"name":"Dr. Richard Esquivel","url":"https://sanjosefuncmed.com/about/"}],"tags":["Metabolic Health"]},{"id":"https://sanjosefuncmed.com/problem-diabesity-treatment-symptoms/","url":"https://sanjosefuncmed.com/problem-diabesity-treatment-symptoms/","title":"The Problem with Diabesity Treatment–Symptoms, Not Causes","summary":"The main reason our current approach to treating diabesity fails is because it focuses on treating the symptoms or risk factors of the disease rather than the","content_text":"The main reason our current approach to treating diabesity fails is because it focuses on treating the symptoms or risk factors of the disease rather than the causes . All of our attention is focused on treatments that: Lower blood sugar (diabetes drugs and insulin) Lower high blood pressure (anti-hypertensive drugs) Lower cholesterol (statins) Thin the blood (aspirin) But we never ever ask the most important question: Why is your blood sugar, blood pressure, or blood cholesterol too high and why is your blood too sticky and likely to clot in the first place? Put another way: What are the root causes of diabesity? Answering that question must be the focus of our diagnosis and treatment of this disease if we are going to solve this global epidemic. The Diabesity Solution: Therapeutic Lifestyle Change The real solution for diabesity is a comprehensive diet and therapeutic lifestyle change. In truth, diabetes, elevated blood sugar, blood pressure, and cholesterol are simply downstream symptoms that result from problems with our diet, lifestyle, and environmental toxin exposure interacting with our unique genetic susceptibilities. These are the real causes of diabesity. Unfortunately, few doctors are taking the time to address these important health issues with their patients. Understanding this has a profound impact on the whole way we think about diabesity. It’s not simply a matter of trying one type of medication or another. We need to address the underlying problems in diet and lifestyle that are leading to and perpetuating this metabolic problem. Otherwise, we will only be masking the problem with medications that don’t address the root causes. Using medication or surgery to treat symptoms like imbalanced blood sugar, high cholesterol, high blood pressure, and the other complications of diabetes is like mopping up the floor while the sink overflows. It’s too little too late. And you need to stay on the medication the rest of your life, unless you significantly change your diet and lifestyle. And if you were to stop the medication, you would be back to the same place as you were when you started. In medicine today we have a choice. We can continue to mop up this overflow, or we can deal with the source of the problem and turn off the faucet–that is, treat the root problems that are causing your illness. The real solution for diabesity is a comprehensive diet and lifestyle change program . We offer a science-based therapeutic lifestyle change program, called FirstLine Therapy ® , which is being used by thousands of doctors all over the country with excellent results. This program addresses the root causes of diabesity (insulin resistance) and therefore has long-lasting and permanent results. Our patients not only lose weight, but see improvements in their blood sugar levels and cardiovascular risk factors. There are 3 published studies on the efficacy of this program. For more information, see our FirstLine Therapy ® page.","date_published":"2012-06-12T07:06:57","date_modified":"2020-04-19T22:37:53","authors":[{"name":"Dr. Richard Esquivel","url":"https://sanjosefuncmed.com/about/"}],"tags":["Metabolic Health"]},{"id":"https://sanjosefuncmed.com/reversal-cognitive-decline-validated-functional-medicine-approach/","url":"https://sanjosefuncmed.com/reversal-cognitive-decline-validated-functional-medicine-approach/","title":"Reversal of Cognitive Decline: A Validated Functional Medicine Approach","summary":"A landmark study was published last month showing the therapeutic value of a functional medicine approach to memory loss and cognitive decline related to neur","content_text":"A landmark study by Dale E. Bredesen, MD, was published last month in the journal Aging , showing the therapeutic value of a functional medicine approach to memory loss and cognitive decline related to neurodegenerative disease, such as Alzheimer’s disease (AD) on a small group of aging patients. This is the first study of this kind which examined the therapeutic benefit of making simple dietary changes, changes in sleep and physical activity levels, stress management counseling and individualized targeted nutritional supplementation to improve metabolic pathways involved in brain function based on physiologic imbalances identified in lab work on the participants. Sound familiar? This is the same approach we use in functional medicine on each and every one of our patients who come to us for help with chronic conditions, including neurodegenerative conditions. The design of this study allowed the researchers to perform assessments and identify potential pathological mechanisms involved in the progression of these participants’ cognitive conditions prior to intervention. The goal was to intervene in as many of these mechanisms as possible with targeted nutrients as well as dietary and lifestyle changes to support these metabolic interventions, and observe the effects on their memory and cognition. What was the outcome? 9 out of 10 patients (90%) showed subjective or objective improvements in cognition within 3 to 6 months of initiation of treatment! This is a significant improvement over the pharmaceutical drugs currently used to treat AD or mild cognitive impairment (MCI) which show temporary and marginal benefits at best. “We’ve been studying the underlying mechanisms of neurodegeneration in the test tube and in transgenic mice for 25 years, and we came to the conclusion that there is an imbalance between the physiological processes that mediate plasticity in Alzheimer’s disease ― between synaptoblastic (synapse formation) and synaptoclastic (synapase breakdown) signaling — similar to what we see in osteoporosis, where osteoblastic signaling is chronically exceeded by osteoclastic signaling, resulting in bone loss,” principal investigator Dale Bredesen, MD, professor of neurology and director, Mary S. Easton Center for Alzheimer’s Disease Research, University of California, Los Angeles, told Medscape Medical News. Through this nutritional and lifestyle intervention, “it appears we can correct this network imbalance by tweaking it at multiple sites,” Dr. Bredesen added. Study Design and Results A total of 10 patients with memory loss associated with either AD, mild cognitive impairment, or subjective cognitive impairment were recruited for the study. Each participant was instructed to follow a personalized intervention program tailored to address specific metabolic deficits identified on laboratory testing believed to be affecting the plasticity of the participant’s brain, causing memory loss. Nine of the 10 patients displayed subjective or objective improvement in cognition within 3 to 6 months of initiation of treatment. The single patient who failed to respond to the intervention had late-stage AD. Six participants had discontinued working or were struggling with their jobs at study outset because of memory problems. “ All were able to return to work or continue working with improved performance, and improvements have been sustained,” said Dr. Bredesen. At the present time, one patient has been followed for 2.5 years from the initial presentation, and the patient continues to show “sustained and marked improvement.” Dr. Bredesen noted that the level of improved function required to work effectively is an important outcome of any successful therapeutic intervention. Failure of Pharmaceutical Drugs for Cognitive Disorders From the original published article: “Drug development for neurodegenerative disease has been, arguably, the field of greatest failure of biomedical therapeutics development. Patients with acute illnesses such as infectious diseases, or with other chronic illnesses, such as cardiovascular disease, human immunodeficiency virus infection, and even cancer, have access to more effective therapeutic options than do patients with AD or other neurodegenerative diseases. In the case of AD, there is not a single therapeutic that exerts anything beyond a marginal, unsustained symptomatic effect, with little or no effect on disease progression. Furthermore, in the past decade alone, hundreds of clinical trials have been conducted for AD, at an aggregate cost of billions of dollars, without success. This has led some to question whether the approach taken to drug development for AD is an optimal one. The past few decades of genetic and biochemical research have revealed an extensive network of molecular interactions involved in AD pathogenesis, suggesting that a network-based therapeutics approach, rather than a single target-based approach, may be feasible and potentially more effective for the treatment of cognitive decline due to Alzheimer’s disease.” A Systems Biology Approach to AD Earlier mouse studies suggested that the pathophysiology involved in the development of AD (ie: beta-amyloid precursor protein (APP) signaling) involved many inputs (ie: inflammatory mediators, hormonal mediators, apolipoproteins and lipid metabolism factors, etc.) and suggested that the pathology of AD dictates a system or program-type of intervention rather than a single targeted agent. The researchers described the basic tenets of the therapeutic system as the following: The goal is not simply to normalize metabolic parameters but to optimize them. Based on the hypothesis that AD results from an imbalance in an extensive plasticity network, the therapy should address as many network components as possible. The underlying network has a threshold effect, such that once enough of the network components have been impacted, the disease process would be halted or reversed. The therapy is personalized, based on the laboratory values affecting the plasticity network. The program is time-dependent, so there is continued optimization over time. For each network component, the goal is to address it physiologically, as far upstream as possible. Optimizing Metabolic Parameters “Just as for other chronic illnesses such as atherosclerotic cardiovascular disease, the goal is not simply to normalize metabolic parameters, but rather to optimize them,” the investigators write. Lab markers associated with the pathophysiology of neurodegenerative disease and cognitive decline were evaluated with the goal of moving the markers into an ideal range (functional range), rather than the standard laboratory reference range with the goal of optimizing these markers. For example, a typical lab range for homocysteine is less than 12 µmol/l, however this study’s goal was to keep this marker below 7 µmol/l (as we do in functional medicine), as research indicates an elevation above 7 µmol/l indicates compromised methylation status and increased risk of neurodegenerative disease. When homocysteine was found to be above 7 µmol/l, supplementation with methylcobalamin (vitamin B12) and folic acid (MTHF) to lower homocysteine was recommended. Another example is how 25-hydroxy vitamin D levels were interpreted. Standard lab ranges for 25-OH vitamin D are 30-100ng/ml, however, in this study, the goal was to move 25-OH vitamin D levels up to 50-100ng/ml as higher levels have been associated with improved brain function and decreased risk of dementia. The Threshold Effect Critical to the success of this hypothesis is the idea that there is a “threshold” at which multiple interventions will start to reverse the pathology leading to memory loss. As Dr. Bredesen points out, it has been shown by Dean Ornish, MD, founder and president of Preventive Medicine Research Institute, San Francisco, California, among others that with a large enough lifestyle change, buildup of atherosclerotic plaque and subsequent coronary artery disease can be reversed. Similarly, in AD, if enough of the factors that contribute to the imbalance between synaptoblastic and synaptoclastic signaling in the brain can be reversed, deficits in the network that lead to memory loss can be redressed — “and you start to see improvement, which is exactly what we saw in these patients. If they follow enough of these interventions, they are able to improve,” Dr. Bredesen said. “Based on the hypothesis that AD results from an imbalance in an extensive plasticity network, the therapy should address as many network components as possible, with the idea that a combination approach may create an effect that is more than the sum of the effects of many monotherapeutics,” the researchers add. Individualized Interventions The interventions used in the 10 patients involved in the UCLA pilot project were personalized to each individual just as we do in functional medicine, but they shared similar elements. Typically, patients were asked to eliminate all simple carbohydrates and processed foods from their diet and increase consumption of fruits, vegetables and wild fish (not farm-raised fish). They were also asked to avoid gluten (adopt a gluten-free diet) and follow a strict meal pattern with specifically timed interludes of fasting (12-hours). Exercise was a key component of all interventions, and participants were counseled on ways to reduce stress through practices such as yoga and meditation. Specific supplement recommendations were given to the participants depending on the results of the lab markers studied and symptomotology, such as vitamin D3, fish oils, methylcobalamin (vitamin B12), folic acid, curcumin, ashwagandha and probiotics. One of the main therapeutic principles for these cognitive patients was to reduce inflammation in the body and in the brain so many of these supplements were used for their studied anti-inflammatory effects, such as curcumin and fish oils. Optimizing antioxidants and mitochondrial function was emphasized so the use of mixed tocopherols (vitamin E), N-acetyl cysteine, alpha-lipoic acid, blueberries, vitamin C, coenzyme Q10, acetyl-L-carnitine, selenium, zinc and resveratrol were recommended. Hormonal imbalances in thyroid hormone, cortisol, and estrogen and progesterone were also addressed with the goal of optimizing hormone levels, just as we do in functional medicine. “The program is not easy to follow,” Dr. Bredesen acknowledged. (None of the patients in this pilot project were able to fully follow the program). “But what this program says is that we are all contributing to our own AD by the diet we choose to eat; by the way we sleep; by the stress we have in our lives; by our microbiome; and of course by our genetics. The important thing here is, we can alter cognitive decline by affecting each of these parameters.” Growing Evidence Commenting on the study for Medscape Medical News , Heather Snyder, PhD, director, medical and scientific relations, Alzheimer’s Association, Chicago, Illinois, said a number of studies have shown that lifestyle interventions can attenuate the progressive decline in cognitive function in older individuals. Most recently, the FINGER study (Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability), which was presented earlier this year at the Alzheimer’s Association International Conference 2014, showed that a multipronged lifestyle intervention had a significant beneficial effect on overall cognitive performance, including memory, executive function, and psychomotor speed, in a large cohort of older participants at high risk for cognitive decline. “The FINGER study certainly suggests that this is the kind of study we need to do in translating what Dr. Bredesen did to a much larger clinical trial,” Dr. Snyder said. Dr. Snyder also noted that it is clear the underlying pathology driving AD is already changing well before patients manifest overt memory loss and accompanying symptoms of the disease. “This presents us with an opportunity to identify those individuals at the earliest stage of AD, when we can intervene with a medication or some type of nonpharmacological intervention,” she suggested. Important Features of Study From my personal perspective, what makes this a landmark study is the design of the study . Each participant was put on an individualized dietary and nutritional protocol based on their lab markers and symptomotology. This follows the principles of functional medicine which appreciates the uniqueness of each individual’s genetics and unique physiology. This is rarely done in conventional medicine, especially in managed care, where each person is prescribed the “standard of care” which is usually a particular medication based on the person’s diagnosis , at the expense of all other considerations. Patients with the same diagnosis usually receive the same medication, with few exceptions. Genetic factors, family history, lab markers and other presenting symptoms are essentially ignored (unless they directly interfere or present a known problem with the medication). Another unique feature of this study was the multidimensional approach of the intervention. This intervention intentionally targeted multiple mechanisms simultaneously with the intention of impacting the “network” of pathophysiology that is involved in neurodegeneration and cognitive decline. The researchers called this a “threshold” that, if reached, could halt or even reverse the disease process. The concept used in this study was that if a sufficient number of biochemical pathways were targeted, then a threshold could be reached in which the pathophysiology underlying the disease process could be reversed. This is very different from the pharmaceutical approach in which usually only one or two mechanisms are targeted by the drug. These types of interventions are limited in their scope and therefore limited in their potential to have an impact on the underlying pathophysiology driving the disease process, which often involves multiple mechanisms. The third distinguishing characteristic of this study was the use of dietary and lifestyle changes and nutritional supplements as the intervention. These are safe, low-cost interventions with minimal risk of side-effects and are easily obtained by practically anyone. Of course, the quality of the food and supplements used in the study can potentially impact the outcome. However, since no particular brand of food and supplements were recommended, these particular decisions were left to the individual and significant results were still obtained. It can be assumed that even better results are possible if higher quality food and supplements are used in the intervention. The fourth distinguishing characteristic, and most obvious, is the results obtained by the participants in the study. 90% of the participants showed subjective or objective improvements within a 3 to 6 month period. All 6 of the participants whose cognitive decline had a major impact on job performance were able to return to work or continue working with increased performance. This is a tremendous improvement over the medications currently approved for the use of these conditions and considered the current standard of care. The efficacy shown in reducing symptoms of cognitive decline and potentially reversing the neurodegenerative disease process by the use of dietary and lifestyle changes is truly astounding and holds much promise for the millions of sufferers of these conditions who until now have had few viable options. Original article p ublished online in Aging, September 27, 2014 . Full text of article Excerpts of this article were taken from Medscape’s 10/3/2014 article, Novel Intervention May Reverse Alzheimer’s Memory Loss, by Pam Harrison.","date_published":"2014-10-15T07:03:19","date_modified":"2020-04-23T01:39:54","authors":[{"name":"Dr. Richard Esquivel","url":"https://sanjosefuncmed.com/about/"}],"tags":["Brain & Neurologic Health"]},{"id":"https://sanjosefuncmed.com/science-nutrigenomics-nutrients-food-interact-genes/","url":"https://sanjosefuncmed.com/science-nutrigenomics-nutrients-food-interact-genes/","title":"Nutrigenomics: How Nutrients in Food Interact with our Genes","summary":"We generally think of food as a way to get energy; a means to provide our bodies with the fuel they need to function. However, new science has shown that food","content_text":"We generally think of food as a way to get energy; a means to provide our bodies with the fuel they need to function. However, new science has shown that food literally speaks to your genes. The information your body receives from the foods you eat turn your genes on and off. This provides your body with instructions about how to control your metabolism from moment to moment and day to day, every time you take a bite of food. This is the science of nutrigenomics, or how food talks to your genes, and it is the nutritional approach that underlies our therapeutic lifestyle program. By feeding your body the right information, you can turn off the genes that lead to diabesity and turn on the genes that lead to health . The key lies in the quality and type of food you eat, not necessarily the calories you consume or the ratio of protein, fat, and carbohydrate in your diet. Dr. Dean Ornish proved that you could reverse blockages in clogged arteries and increase blood flow in the heart by simply changing the quality of the food you put in your body and engaging in some simple lifestyle changes . He also showed that you could beneficially affect over 500 genes turning off the disease-causing genes and turning on the health promoting genes by changing diet and lifestyle in just three months. This is more powerful than any medication ever invented. So what should you eat? The optimal diet to prevent and treat diabesity includes: • Fruits • Vegetables • Nuts • Seeds • Beans • Whole grains • Healthy fats such as olive oil, nuts, avocados, and omega-3 fats • Modest amounts of lean animal protein including small wild fish such as salmon or sardines. This is commonly known as a Mediterranean diet . It is a diet of whole, real, fresh food. It is a diet of food you have to prepare and cook from the raw materials of nature. And it has broad-ranging benefits for your health. Our common ideas about food as only a source of energy are very limited. Nutrigenomics and its role in diabesity is the future of medicine. It will help us both understand and successfully treat this burdensome condition that affects over 1 billion people worldwide.(1) References (1) http://drhyman.com/blog/conditions/the-diabesity-epidemic-part-iii-treating-the-real-causes-instead-of-the-symptoms-2/","date_published":"2012-06-12T07:46:22","date_modified":"2020-04-19T22:38:52","authors":[{"name":"Dr. Richard Esquivel","url":"https://sanjosefuncmed.com/about/"}],"tags":["Functional Medicine"]},{"id":"https://sanjosefuncmed.com/symptoms-common-imbalances-intestinal-permeability/","url":"https://sanjosefuncmed.com/symptoms-common-imbalances-intestinal-permeability/","title":"Intestinal Permeability: Symptoms and Common Imbalances","summary":"What are the most common symptoms and signs associated with intestinal permeability? When do we suspect it? How do we test for leaky gut syndrome? This is par","content_text":"What are the most common symptoms and signs associated with intestinal permeability? When do we suspect it? How do we test for leaky gut syndrome? This is part 3 of a 5-part series on Intestinal Permeability (Leaky Gut) Main points of this issue: Symptoms of leaky gut vary significantly and have a varied presentation Common Imbalances Associated with Leaky Gut Malabsorption is Common in Leaky Gut Lab Testing for Leaky Gut Syndrome Symptoms of Leaky Gut Symptoms of leaky gut vary significantly and have a varied presentation. There is a spectrum of severity of intestinal permeability from mild to severe forms. Here is a list of the most common symptoms associated with intestinal permeability: bloating poor digestion inflammation food sensitivities chronic pain brain fog/poor memory depression fatigue People with intestinal permeability will often react to certain types of foods, especially common food allergens such as wheat and dairy. Gluten sensitivity is very common with these patients. Digestive abnormalities such as bloating and food sensitivities are common symptoms of leaky gut. On the other side of the scale are people who never have intestinal symptoms. Another very common presentation of leaky gut is chronic pain (systemic inflammation), depression and fatigue. These patients will have brain fog, fatigue, and depression. As clinicians, when we see patients that present with these symptoms, we have to consider intestinal permeability issues. When patients come into our clinic with these sorts of complaints, it is important to assess their risk of having intestinal permeability problems. We will discuss lab testing for this condition below. In addition, their diet will clue the clinician in to their risk of having some degree of intestinal permeability. If someone has to follow a strict diet to manage or avoid symptoms of fatigue, depression or pain, then this could point to leaky gut issues. It is important to assess for leaky gut in these patients as well. Common Imbalances Associated with Leaky Gut There are a number of common imbalances that often occur together with leaky gut. This includes: Malabsorption Malnutrition Bacterial overgrowth Immune activation Yeast overgrowth Intestinal lining degeneration Impaired intestinal immune integrity Dysbiosis Food sensitivities Malabsorption is Common in Leaky Gut Many of these leaky gut patients get malabsorption because the inflammation that occurs from the penetration of peptides causes mucus formation. The mucus makes it difficult for small micronutrients to penetrate. The larger molecular weight molecules are able to penetrate but not the smaller ones. So you get leaky gut usually with malabsorption and malnutrition. This becomes a serious issue. These people end up with bacterial overgrowths due to imbalances in acidity and lack of beneficial flora. One of the most common bacterial infections they get is H. pylori. The leaky gut syndrome causes systemic immune activation and causes yeast overgrowths. Their intestinal lining continues to degenerate and they get further leaky gut. They have impaired intestinal immune integrity. Their secretory IgA get compromised and they get dysbiosis and multiple food sensitivities. The average person with leaky gut has bacterial overgrowths, yeast overgrowths, dysbiosis, a weak gut immunity and probably multiple bacterial and/or parasitic infections. How do you test for leaky gut syndrome? Cyrex Labs Panel 2: Intestinal Antigenic Permeability Screen Cyrex Labs is the only lab test available in the country that offers immunologic testing for antibodies against the gut proteins that bind the epithelial cells together (occludin-zonulin and actin-myosin). If these are positive, we know there is a compromised gut barrier. This test also assesses for bacterial lipopolysaccharides (LPS). LPS should only be found in the GI tract, not the blood. If these antibodies are found in the blood, this also indicates a breached barrier system. Bacterial endotoxin (LPS) IgG, IgM, IgA → permeability/dysbiosis Actin-myosin network IgG → epithelial cell damage Occludin/zonulin IgG, IgM, IgA → tight junction damage The Intestinal Antigenic Permeability Screen costs about $200. For more information, visit Cyrex Labs . Content provided by Datis Kharrazian, D.C., Breaking the Complex Web of Leaky Gut Syndrome, 2/10/11 In part 4 of this 5-part series , we answer the following questions: What causes leaky gut? What are the mechanisms involved in the development of leaky gut? Continue to part 4 of series","date_published":"2012-05-25T01:55:09","date_modified":"2020-04-19T22:28:47","authors":[{"name":"Dr. Richard Esquivel","url":"https://sanjosefuncmed.com/about/"}],"tags":["Digestive Health"]},{"id":"https://sanjosefuncmed.com/the-gluten-sensitivity-leaky-gut-and-autoimmunity-connection/","url":"https://sanjosefuncmed.com/the-gluten-sensitivity-leaky-gut-and-autoimmunity-connection/","title":"The Gluten Sensitivity, Leaky Gut and Autoimmunity Connection","summary":"In parts 4, 5 and 6 of this series, we examine the connection between gluten sensitivity, leaky gut and autoimmune disease. In this article, we focus on glute","content_text":"In parts 4, 5 and 6 of this series, we examine the connection between gluten sensitivity, leaky gut and autoimmune disease. In this article, we focus on gluten sensitivity . What is gluten sensitivity and how is it different from celiac disease? What are the most common symptoms and signs associated with non-celiac gluten sensitivity? How common is it? Why are we seeing such an increase in this condition? How can I find out if I am sensitive to gluten? Gluten Sensitivity Without question, there has been an explosion of three major factors of chronic inflammation which leads to many chronic diseases: gluten sensitivity, intestinal permeability and autoimmune disease. It appears that these three factors combine to create vicious cycles leading to various ailments and symptoms. For example, gluten sensitivity leads to leaky gut and leaky gut leads to gluten sensitivity. Both gluten sensitivity and leaky gut have been shown to be major contributors to various autoimmune responses. Also, the inflammatory response of autoimmunity promotes tight junction breakdown and intestinal permeability and gluten sensitivity. We don’t know where it may start in any individual. But we do know that any of these can increase the risk of developing any other. (1) In this article, we explore the important topic of gluten sensitivity. What’s all the fuss about gluten sensitivity? Gluten sensitivity is defined as an immune response to gluten; it is not to be confused with an allergy. By strict definition, an allergy is a clear IgE-mediated response to an offender and may create anaphylaxis (a severe allergic reaction to an allergen). Gluten sensitivity is a IgA, IgM or IgG-mediated response to gluten and is not typically involved in anaphylaxis. This is important, because the gluten sensitivity response will not be identified with conventional allergy tests that use skin testing or IgE responses. Gluten sensitivity promotes an immune response that increases systemic inflammation and has been associated with a multitude of health conditions in the peer-reviewed literature. (2) What’s the difference between gluten sensitivity and celiac disease? Celiac disease is a relatively rare (yet increasingly common) severe intolerance to gluten in which the immune system attacks and destroys the gastrointestinal tract on exposure to gluten. It affects approximately 1 in 100 people, or about 3 million Americans, most of whom are not diagnosed. (3) It can create a diverse range of gastrointestinal symptoms, such as bloating, gas, abdominal pain and cramping and diarrhea and may be associated with other symptoms including anemia, depression, joint pain, muscle pain, skin rashes and numbness and tingling anywhere in the body. This is diagnosed through conventional blood tests and may require intestinal biopsy. However, gluten sensitivity, which is much more common, has been associated with most of these symptoms, but others as well, including migraines, ADD/ADHD, autism, neurodegenerative disease, such as Alzheimer’s and Parkinson’s disease, autoimmune thyroid/hypothyroidism, autoimmune hepatitis, fibromyalgia, obesity and various skin problems. (4) This condition is much more difficult to diagnose because conventional lab testing is not reliable to assess risk of gluten sensitivity. Specialized testing (or a gluten-free diet) is required to assess this condition, which we will discuss later. This is why it is so underdiagnosed by doctors and other healthcare providers. Let’s first look at how celiac disease was first identified and how it is currently diagnosed. How is celiac disease diagnosed? Celiac disease was first identified in 1950 by a Dutch pediatrician, Willem-Karel Dicke. In the 1960’s, gastroenterologists further studied the disease and were able to identify characteristic destruction patterns with celiac disease by studying intestinal tissue biopsies. This research has found two genotypes associated with increased risk of celiac disease: HLA-DQ2 and HLA-DQ8. Most celiac patients have the variant HLA-DQ2 allele. Researchers also found that celiac disease has specific antibodies that could be measured in the blood, such as gluten antibodies and transglutaminase antibodies. Over time, different criteria have been developed to diagnose celiac disease. Initially, celiac disease was thought to be a gastrointestinal disorder that was only a problem for susceptible people with certain genes who ingested gluten, leading to the destruction of the intestinal tract. This initial concept has now been challenged by research studies. Gluten sensitivity affects much more than just the intestinal tract! Many people who have gluten sensitivity do not have intestinal manifestations. Instead, it can affect other tissues, such as the brain, peripheral nerves, thyroid, joints, etc. These are referred to as extraintestinal manifestations. The most common system affected by gluten is the nervous system. In fact, one study found that patients with intestinal complaints represent only a third of patients with neurological manifestations and gluten sensitivity! “Patients with an enteropathy (disease of the intestinal tract) represent only a third of patients with neurological manifestations and gluten sensitivity.”(5) In a study of 10 subjects who had headaches, walking abnormalities and elevated antigliadin antibodies, seven demonstrated complete resolution of symptoms with a gluten-free diet. The most interesting part of the study was that 6 out of the 10 subjects had no intestinal complaints! (6) Gluten sensitivity commonly causes neurological problems Gluten sensitivity may manifest in a number of neurological deficits, depending on what part of the brain or nervous system is affected, including numbness and tingling in any part of the body (peripheral neuropathy), balance problems (ataxia), migraines, attention-deficit problems or ADHD, “brain fog”, and cognitive deficits. (7, 8, 9) A recent paper entitled, “The Gluten Syndrome: a neurological disease” reported findings that gluten sensitivity that is unassociated with celiac disease or gastrointestinal destruction can cause harm to the brain and nervous system, leading to diverse neurological malfunction. (10) “My doctor says gluten is not a problem unless I have celiac disease” This is simply not true. Look at all the health problems gluten sensitivity can cause unrelated to celiac disease! In fact, as you can see, this can often be worse! Once a person develops gluten sensitivity without enteropathy (gastrointestinal disease), there is high risk of damage to the brain and nervous system. A recent paper entitled “Gluten sensitivity: from gut to brain,” concluded that non-celiac gluten sensitivity is more likely to attack the brain and nervous system than any other organ: “Thus, scientific literature now shows that gluten-immune reactions or gluten sensitivity not associated with the strict diagnostic criteria of celiac disease is more likely to attack the brain and nervous system than any other tissue”(11) Gluten sensitivity is recently being found to be involved in the pathological processes of neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, supranuclear palsy, and Huntington’s disease: “In this review, we discuss the molecular mechanisms of the transglutaminases involved in the pathological processes responsible for neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, supranuclear palsy, Huntington’s disease, and other recently identified polyglutamine diseases”(12) Unfortunately, many medical doctors and other healthcare providers are not aware of this. How can this not be considered a problem? How common is gluten sensitivity? We are currently seeing a huge explosion in gluten sensitivity in this country leading to a wide variety of symptoms affecting multiple organ systems as seen above. These symptoms can range from mild to severe. But how common is it? We don’t really know at this point how common gluten sensitivity actually is. However, we do know that problems with gluten are widely underdiagnosed. “…for every symptomatic patient with celiac disease there are eight patients with celiac disease and no gastrointestestinal symptoms” (13) We also know that approximately 1/3 of the U.S. population has the HLA-DQ2 or DQ8 genotype (the genotype associated with celiac disease). This means that incidence of gluten sensitivity may be as high as 1/3 of the American population! It has been estimated that between 35-50% of the U.S. population has some form of gluten sensitivity. (14) Unfortunately, most of these patients go years suffering from various symptoms without a clear diagnosis. “Many patients with undiagnosed celiac disease spend years seeking help for complaints such as chronic tiredness or mild abdominal symptoms” “The response to an appropriate gluten-free diet is often life-transforming for symptomatic patients”(15) Where does gluten come from? Gluten comes from wheat, barley and rye and is used extensively by the food industry because it is an extremely cheap food and can be used easily to produce a wide variety of food products. Almost anything that comes from a box or a bag contains gluten, including chips, crackers, cookies, cake, pasta, bread, cereal, frozen food, etc. Common Sources of Gluten: Wheat Spelt Kamut Oats (98% of the oats in the U.S. are contaminated with gluten) Rye Barley There are also many hidden sources of gluten: Soy sauce Food starches Food emulsifiers Food stabilizers Artificial food coloring Malt extract, flavor, syrup Dextrins Why are we seeing such an increase in gluten sensitivity? No one knows for sure why we are seeing this explosion of gluten sensitivity in the U.S. But based on the fact that many gluten intolerant individuals can consume gluten in other countries, there is strong suspicion that the increased sensitivity to gluten in the U.S. is related to the production , processing and storage of gluten that are unique to this country. (16) The following is a list of likely culprits to the dramatic increase in gluten sensitivity we are now seeing across the country: Probable factors leading to increased prevalence of gluten sensitivity: Hybridization of gluten Gluten deamidation Storage of grains Leaky gut syndrome Hybridization of Gluten The grains we consume now are not the same grains we used to consume as children or that our parents consumed: they are now hybridized foods. These are completely different grains and proteins. Hybridization involves cross-breeding various species. Gluten is not technically genetically modified, but it has been significantly hybridized and deamidated. (17, 18, 19) Hybridization is the process of creating a new protein by combining different strains of wheat together, not the process of inserting or deleting genes associated with genetic modification. This may create as much as 5% of new protein sequences in the new strain that are not found in the original sources. Many people feel that the hybridization of wheat has created a “new wheat” and one that appears to be very immunoreactive, especially to the brain and nervous system. Gluten Deamidation The other thing that has happened to our grains here in the U.S. is that the gluten we are now exposed to has undergone a process called deamidation . Deamidation of gluten is the product of chemical or enzymatic treatment of gluten used by the food-processing industry. This process is performed to make the food water soluble and easier to create food products from. However, people may have reactions to deamidated gliadin (the protein portion of gluten) but may not have reactions to gluten in its native form. (20) In one double-blinded, placebo-controlled study, subjects did not react to native wheat flour but had severe immune reactions to deamidated wheat. They concluded that gluten deamidation generates new immune-activating substances. (21) Another study published in the European Journal of Inflammation concluded that deamidated glutens are “new” food compounds and may be the major cause of hidden inflammatory responses to food: “This extensive use of wheat isolates in the food industry may be the major cause of hidden food allergies…” “The wheat isolates are used as food emulsifiers, gelling agents, film formation aid, stretchability agents in meat products, sauces, soups and as clarifying agents in red wines” “Because of food isolates or deamidated gluten are new food ingredients, when allergy to wheat is suspected, immune reaction to wheat isolates should be tested…”(22) Overall, it is clear that although wheat does not fit the strict definition of a genetically-modified food (GMO), we are not longer consuming the wheat protein we used to eat and that the hybridization and deamidation of wheat protein are causing significant immune activation. Storage of Grains The other thing that may account for this increase in gluten sensitivity is long-term storage of these grains in warehouses. The average grain is stored in bins for about 2 years before they are purchased by the food manufacturers. When it is stored in bins, enterotoxins (compounds toxic to the GI tract) tend to grow. These enterotoxins denature the proteins and are very inflammatory compounds. So the grains that are being consumed here in the U.S. are genetically-modified, deamidated, enterotoxin-filled grains. The outcome of this is that we now have a very inflammatory compound that is being used extensively throughout the food industry and is causing major problems in this susceptible population. (23) Leaky Gut Syndrome We will learn about the role that intestinal permeability or leaky gut syndrome plays in gluten sensitivity as well as the development of autoimmune disease in the next article in this series. It appears there is a vicious cycle that occurs between both gluten sensitivity and leaky gut syndrome increasing risk of autoimmune disease. How can I find out if I am gluten sensitive? Is lab testing for gluten sensitivity reliable? Many patients are wondering if they are gluten sensitive and asking their doctors to test for this. Unfortunately, the conventional labs that are used by the majority of medical doctors testing for gluten sensitivity are not reliable. There are many false negative results, meaning, the results come back negative but the person is actually reacting to gluten. They are then being told by their doctors they can go ahead and eat wheat while they continue to suffer. Why is this? This is because all of these labs are using the same limited testing methods. They are only checking antibodies to one fraction of the wheat grain (gliadin) and only one type of gliadin (alpha gliadin) which is associated with celiac disease. However, there are many components that make up wheat that are causing immunological reactions, including, the protein portion (gluten) which is composed of gliadin and glutenin , and the lectin portion, including wheat germ agglutinin. In addition, the gliadin portion can be divided into alpha, gamma and omega gliadin. You can have an immune response to any of these fractions of wheat. But all conventional labs are currently only testing for alpha gliadin, not any of the other components to the wheat grain. Some labs are starting to check deamidated gliadin but again, only the alpha gliadin fraction. These labs are not testing for the whole spectrum of these immune responses to gluten or the lectin portion of wheat so most of these immunological reactions are being completely missed by the current conventional testing methods! Gluteomorphins Another response to wheat that is common, especially in the ADD/ADHD or autistic population of children, is a gluteomorphin response. Gluteomorphin is an opioid peptide that is formed during digestion of the gluten protein. Gluteomorphin responses are very common in those that have neurological or neurochemical responses to gluten exposure. This is a common problem in the autistic community. Gluten (from wheat) and casein (from dairy) get metabolized into opioids called gluteomorphin or caseomorphin and there is an immune reaction against it with this population of children. Many of these autistic kids are actually addicted to dairy and wheat . These compounds then cause neurochemical imbalances . Gluteomorphin Withdrawal Theory One of the things that can happen with someone that has gluteomorphin antibodies , is they may have neurochemical imbalances induced and severe addiction to gluten. If they are put on a strict gluten-free diet, they are prone to develop a gluteomorphin withdrawal reaction. These individuals may feel worse and develop new symptoms when they start a gluten-free diet and symptoms may last a few days or several weeks. The reason for this is the gluteomorphin compound acts like an opioid in the brain. When this system gets disrupted, the opioid activity changes in their brain and in their enteric nervous system causing symptoms such as irregular bowel movements or severe depression or crazy thoughts. Prodynorphins In addition to a gluteomorphin responses, people can also have a prodynorphin response. Prodynorphin is an opioid that is a basic building block of endorphins. Many people that have gluten immune reactions produce prodynorphin antibodies . Prodynorphin has been shown to play a part in many processes in the brain. These include how well people feel about themselves, their memories, and their perceptions of pain. It is known that people who don’t make enough prodynorphin (or have antibodies against them) are vulnerable to drug addiction, schizophrenia, bipolar disorders, and a form of epilepsy. (24, 25, 26, 27) Gluten sensitivity is known to lead to prodynorphin antibodies and potentially lead to neurochemical disorders. A person may have prodynorphin antibodies or gluteomorphin antibodies but they don’t have alpha gliadin antibodies. This means they will test negative on conventional lab testing for gluten sensitivity but eating gluten will totally throw off their brain chemistry! Is there any lab that offers reliable testing for gluten sensitivity? Yes, fortunately there is. Cyrex Labs ( cyrexlabs.com ) specializes in immunological testing and offers comprehensive gluten sensitivity testing which tests for immune reactions to all these components of wheat. Currently, only a small percentage of doctors and healthcare practitioners are using these specialized immunological testing methods so be sure to discuss this with your healthcare practitioner. Below is a description of the comprehensive wheat/gluten sensitivity testing that is available through Cyrex Labs. Cyrex Array 3: Wheat/Gluten Proteome Sensitivity & Autoimmunity Antibody Panel 3, called: “Wheat/Gluten Proteome Sensitivity & Autoimmunity” tests for IgA and IgG antibodies to all of the following wheat fractions. Antibodies to each of these fractions of wheat are involved in different immune reactions and have been associated with various symptoms and disease processes. For example, while transglutaminase 2 is involved in various gut reactions, transglutaminase 3 tends to be involved in various skin reactions and transglutaminase 6 is involved in various neurological problems. (28) Wheat Wheat germ agglutinin Deamidated gliadin 15 Deamidated gliadin 17 Deamidated gliadin 33 Omega gliadin Glutenin Prodynorphin Gluteomorphin Transglutaminase 2 Transglutaminase 3 Transglutaminase 6 Gliadin bound to transglutaminase Immune complexes Conclusion Non-celiac gluten sensitivity is extremely common and widely underdiagnosed. Gluten sensitivity manifests in a wide range of symptoms that affect multiple organ systems of the body, not only the gastrointestinal tract. Celiac disease, which is one type of severe intolerance to gluten, was once believed to be primarily a gastrointestinal disorder, but this belief is now being challenged in the literature. Non-celiac gluten sensitivity is more likely to affect the brain and nervous system than the gastrointestinal system. Probable factors leading to the increased prevalence of gluten sensitivity include hybridization of wheat, deamidation of gluten and long-term storage of grains. Current conventional testing, although reliable for celiac disease, is not reliable for gluten sensitivity. There are reliable testing methods for gluten sensitivity available through Cyrex Labs. Be sure to discuss these testing methods with your doctor or healthcare practitioner if you suspect gluten sensitivity. In part 5, we will discuss intestinal permeability (leaky gut syndrome)and how this condition is related to gluten sensitivity and the development of autoimmune disease. References: 1. Kharrazian, D. The Gluten, Leaky Gut, Autoimmune Connection. Apex Energetics lecture. Mar. 16, 2013. 2. Murray, J. The widening spectrum of celiac disease. Am J Clin Nutr. 1999:69:354-65. 3. Increased prevalence and mortality in undiagnosed celiac disease. Gastroenterology. 2009 Jul;137(1):88-93. Epub 2009 Apr 10 4. Petersen V, Petersen R. The Gluten Effect: How “Innocent Wheat is Ruining Your Health”. True Health Publishing. 2009. 5. Hadjivassiliou M, et al. Gluten sensitivity as a neurological illness . J Neurol Neurosurg Psychiatry, 2007:72:560-563 6. Hadjivassiliou M, et al. Headache and CNS white matter abnormalities associated with gluten sensitivity. Neurology. 2001 Feb 13;56(3):385-388 7. Hernandez-Lahoz C , Mauri-Capdevila G , Vega-Villar J , Rodrigo L . [Neurological disorders associated with gluten sensitivity]. Rev Neurol. 2011 Sep 1;53(5):287-300. 8. Association between migraine and Celiac disease: results from a preliminary case-control and therapeutic study. Am J Gastroenterol. 2003 Mar;98(3)625-9. 9. A preliminary investigation of ADHD symptoms in persons with CD. J Atten Disord. 2006 Nov;10(2):200-4 10. Ford RP. The gluten syndrome: a neurological disease. Med Hypotheses. 2009 Sep;73(3):438-40 11. Hadjivassiliou M, et al. Gluten sensitivity: from gut to brain. Lancet Neurol. 2010 Mar;9(3):318-330 12. Transglutaminase-catalyzed post translational modifications of proteins in the nervous system and their possible involvement in neurodegenerative diseases. CNS Neurol Disord Drug Targets. 2008 Oct; 7(4):370-5. 13. Fasano A, Catassi C. Gastroenterology, 2001;120:636-651 14. Fine, Kenneth, “Early Diagnosis of Gluten Sensitivity: Before the Villi are Gone,” Celiac.com, http://www.celiac.com/articles/759/1/Early-Diagnosis-of-Gluten-Sensitivity-Before-the-Villi-are-Gone-By-Kenneth-Fine-MD/Page1.html . 15. Celiac disease: the great imitator. Med J Aust. 2004 May 17;180(10):524-526 16. Kharrazian, D. Understanding the Complexity of Gluten Sensitivity. Apex Energetics. Lecture. Jan. 27, 2011. 17. Yuan Z, et al. Mitototic illegitimate recombination is a mechanism for novel changes in high-molecular-weigh glutenin subunits in wheat-rye hybrids. PLoS One. 2011;6(8):e23511 18. Molnar-Lang M, et al. Identification and phenotypic description of new wheat : six-rowed winter barley disomic additions. Genome. 2012 Apr;55(4):302-311 19. Szakacs E, et al. Identification of new winter wheat—winter barley addition lines (6HS and 7H) using fluorescence in situ hybridization and the stability of the whole ‘Martonvasari 9 krl’- ‘Igri’ addition set. Genome. 2010 Jan;53(1):35-44. 20. Denery-Papini S , et al. Allergy to deamidated gluten in patients tolerant to wheat: specific epitopes linked to deamidation. Allergy. 2012 Aug;67(8):1023-32. doi: 10.1111/j.1398-9995.2012.02860.x. Epub 2012 Jun 28. 21. Anaphylaxis to wheat isolates: immunochemical study of a case proved by means of double-blind, placebo-controlled food challenge. J Allergy Clin Immunol. 2003 Apr; 111(4):897-899 22. The immunology of immediate and delayed hypersensitivity reaction to gluten. European Journal of Inflammation. 2008 Jan;6(1):1721-1727. 23. Kharrazian, D. The Gluten, Leaky Gut, Autoimmune Connection. Apex Energetics lecture. Mar.16, 2013. 24. Schwarzer C . 30 years of dynorphins&#8211;new insights on their functions in neuropsychiatric diseases. Pharmacol Ther. 2009 Sep;123(3):353-70. doi: 10.1016/j.pharmthera.2009.05.006. Epub 2009 May 28. 25. Butelman ER , Yuferov V , Kreek MJ . κ-opioid receptor/dynorphin system: genetic and pharmacotherapeutic implications for addiction. Trends Neurosci. 2012 Oct;35(10):587-96. doi: 10.1016/j.tins.2012.05.005. Epub 2012 Jun 16. 26. Hurd YL . Subjects with major depression or bipolar disorder show reduction of prodynorphin mRNA expression in discrete nuclei of the amygdaloid complex. Mol Psychiatry. 2002;7(1):75-81. 27. Peckys D , Hurd YL . Prodynorphin and kappa opioid receptor mRNA expression in the cingulate and prefrontal cortices of subjects diagnosed with schizophrenia or affective disorders. Brain Res Bull. 2001 Jul 15;55(5):619-24. 28. Cyrex Labs website. www.cyrexlabs.com","date_published":"2013-04-22T02:39:13","date_modified":"2020-05-22T01:18:08","authors":[{"name":"Dr. Richard Esquivel","url":"https://sanjosefuncmed.com/about/"}],"tags":["Digestive Health"]},{"id":"https://sanjosefuncmed.com/thyroid-brain-crosstalk-part-1-microglia-neuron-thyroid-connection/","url":"https://sanjosefuncmed.com/thyroid-brain-crosstalk-part-1-microglia-neuron-thyroid-connection/","title":"Thyroid-Brain Crosstalk-Part 1: The Microglia, Neuron and Thyroid Connection","summary":"The evidence clearly demonstrates that there is functional crosstalk between the brain and the thyroid. Thyroid hormones have very powerful influence on micro","content_text":"The evidence clearly demonstrates that there is functional crosstalk between the brain and the thyroid. Thyroid hormones have very powerful influence on microglia cells of the brain and neuronal neurotransmitter pathways. Cytokine surges (which initiate inflammatory processes) turn on microglia cells causing neural inflammation. Patients with thyroid disorders develop a vast list of neurological, mood, and cognitive symptoms. These people may not have a neurological disease but they suffer from various brain disorders, such as anxiety, depression, mood disorders and memory loss. There is clear evidence that neurotransmitters are important centrally for the modulation of the HPT axis. Long-term hypothyroidism leads to neurodegeneration (degeneration of the brain). The research shows when people have long-lasting hypothyroidism, they will have accelerated neurodegeneration. People that are not diagnosed with hypothyroidism for a long period of time after onset will have increased neurodegeneration. The brain is one of the main tissue/organ that degenerates in hypothyroidism. When the brain degenerates, there are two common symptoms patients have: Depression Fatigue (with brain activity) Hypothyroidism leads to depression People may think their depression and fatigue is thyroid-related and will focus their efforts into improving their thyroid but they will continue to have symptoms until they address their brain. When the brain loses its health and integrity, they get depression. Their brain fires less efficiently and has less endurance. Their neurotransmitter activity is decreased and the brain is less efficient in its firing rate. This leads to depression, decreased ability to motivate and concentrate. Depression from a neurological perspective results from decreased firing of the frontal cortex of the brain. Hypothyroidism leads to brain-based fatigue Hypothyroid patients will have brain-based fatigue. When hypothyroid patients perform activities that require mental activity, such as reading or driving for prolonged periods, they get tired. Even after they start taking thyroid hormones, they will continue to have these symptoms and they will think their thyroid is not managed well. Both neurons and glial cells of the brain are impacted by hypothyroidism. Their brain also has less endurance so they get tired when they use their brain for extended periods of time. If people have fatigue when they read, drive or have long conversations, this is brain-based fatigue. You cannot get brain endurance back unless you support your brain. These hypothyroid patients fail because their practitioners are not looking at the brain. Thyroid hormones dampen glial activation and brain inflammation The brain is composed of glial cells and neurons. More than half the mass of the brain is glial cells. There are 10 glial cells to every neuron. The glial cells are part of the brain-immune response and prone to inflammation. When patients become hypothyroid, the glial cells are prone to an inflammatory state. Thyroid hormones dampen glial activation. We all have some degree of brain inflammation but a person who is hypothyroid has increased brain inflammation. In addition, systemic cytokine surges also turn on glial cells toward an inflammatory state. When the brain gets inflamed, you get decreased neuron conductance. The most common way people explain decreased neuron conductance is “brain fog”. We see many brain-fog hypothyroid patients that have difficulty completing a thought. “Thyroid hormones have powerful microglia-modulating properties that are very important for brain development as well as healthy adult brain aging and neuro-immune modulation” Hypothyroidism in youth leads to developmental disorders Kids that are hypothyroid that never get diagnosed have much lower IQ scores than kids that never develop a thyroid disorder. “Congenital hypothyroidism leads to developmental disorders characterized by cognitive, sensory, and motor disorders that are correlated with the magnitude of the thyroid hormone deficiency. This reflects a variety of alterations in CNS histogenesis, including impaired dendritic and axonal development, reduced number of synapses, hypomyelination and altered astroglial development” Hypothyroidism in pregnancy leads to brain developmental disorders If the mother is hypothyroid during pregnancy, there is a very high chance of mental retardation in the child. Thyroid hormone has very powerful influences on the brain. When thyroid hormone is imbalanced, the brain is compromised. Hypothyroidism in adults increases risk of all neurodegenerative disorders People that are hypothyroid as an adult have increased risk of all neurodegenerative disorders: Alzheimer’s, vascular dementia, Parkinson’s, etc. “T3 and T4 thyroid hormones have been demonstrated to favor basic processes of neurogenesis, including precursor cell proliferation, neuronal migration, dendritic and axonal growth, meylination an synaptogenesis. In the adult brain, thyroid hormones have shown the ability to promote plasticity and promote healthy brain aging. It is suggested that thyroid hormones might influence microglial reactions that accompany lesions or neurodegenerative diseases in the CNS and could regulate microglial functions” Microglial activation…now what? One of the things we need to consider with these hypothyroid patients is the health of their brain. We always look for depression or brain-based fatigue with these patients. It is common for hypothyroid patients to have brain-based fatigue (ie: fatigue with driving, reading, etc.) If someone has thyroid deficiency and the microglial cells get activated, even after they go on thyroid hormones, the glial cells remain activated. Once the microglial cells get activated, they never completely shut off, even after going on thyroid hormone. Thyroid hormone will dampen microglial activation, but not completely stop it. The longer they have been hypothyroid, the more neurodegeneration they will have and the more microglial activation they will have. Nutritional Strategies: Dampen Glial Activation One of the strategies we use with these patients is to dampen the neural inflammation and glial activation of the brain. There are very few natural substances which have the ability to dampen microglial activation. There are only certain flavanoids that can cross the blood-brain-barrier and have an anti-glial inflammatory response. We use these flavanoids to dampen glial activation in hypothyroid patients. Article by Datis Kharrazzian, D.C., Mastering the Thyroid, Nov. 12, 2010","date_published":"2012-06-02T03:42:45","date_modified":"2020-04-19T22:39:48","authors":[{"name":"Dr. Richard Esquivel","url":"https://sanjosefuncmed.com/about/"}],"tags":["Thyroid & Hormone Health"]},{"id":"https://sanjosefuncmed.com/thyroid-brain-crosstalk-part-2-serotonin-thyroid-interactions/","url":"https://sanjosefuncmed.com/thyroid-brain-crosstalk-part-2-serotonin-thyroid-interactions/","title":"Thyroid-Brain Crosstalk-Part 2: Serotonin and Thyroid Interactions","summary":"One of the things that is common in hypothyroid patients is that many of them are on antidepressants. However, none of the antidepressant medications actually","content_text":"One of the things that is common in hypothyroid patients is that many of them are on antidepressants. However, none of the antidepressant medications actually raise the quantity of the neurotransmitter that the medication is targeting. They only allow the neurotransmitter to remain in the synaptic cleft for a longer period of time. They may have chronic brain issues because they are not getting proper serotonergic activity but the pharmaceutical model doesn’t enhance the serotonergic system, it only allows it to have a short-term effect of increasing neurotransmission. Effects of Thyroid Hormone Deficiency on Serotonin Decreases cortical serotonin concentrations Decreased quantity of peripheral serotonin Decreased 5-HT density in the brain Increased serotonin turnover in the brain stem Diminished central and peripheral serotonergic activity When people are thyroid deficient, they don’t make as much central and peripheral serotonin, the receptor sites are produced in decreased quantity in the brain and they get decreased activation of their serotonin system overall. If this happens for years and years, this will lead to permanent neurodegeneration of serotonergic neurons. There are a number of studies that support the view that the serotonergic system starts to fail in hypothyroid disorders: “Thyroid hormone has been shown to activate the serotonin receptors in the frontal cortex” When thyroid levels are low, they have decreased serotonin activity and many of these people get depressed. They continue to have depression even after going on thyroid hormone because these serotonergic systems have degenerated and they are less efficient. “Losses of cortical serotonin receptors appears to be a consequence of hypothyroidism at the level of the serotonin system of the brain” Enhancing the Serotonergic System In the natural medicine model, we can actually enhance the serotonergic system. This is well-published in the literature. Many natural compounds can actually increase the quantity of serotonin. What unfortunately happens to some of these people who have been hypothyroid for a long period of time, they not only have their glial cells activated, but their neurotransmitter pathways become less efficient. When neurons don’t get activation, they degenerate and die. Imagine this has been going on for a decade. What happens to their serotonergic pathways of their brain? They permanently degenerate. Sadly, some of these patients will have permanent neurodegeneration from undiagnosed hypothyroidism. Content provided by Datis Kharrazian, D.C., Mastering the Thyroid, Nov. 12, 2010","date_published":"2012-06-04T06:24:11","date_modified":"2020-04-19T22:41:17","authors":[{"name":"Dr. Richard Esquivel","url":"https://sanjosefuncmed.com/about/"}],"tags":["Thyroid & Hormone Health"]},{"id":"https://sanjosefuncmed.com/thyroid-immune-crosstalk-part-1-immune-activity-thyroid/","url":"https://sanjosefuncmed.com/thyroid-immune-crosstalk-part-1-immune-activity-thyroid/","title":"Thyroid-Immune Crosstalk-Part 1: Immune Activity on Thyroid","summary":"The evidence clearly demonstrates that there is functional crosstalk between the immune system and the thyroid. Thyroid hormones are not only used to support ","content_text":"The evidence clearly demonstrates that there is functional crosstalk between the immune system and the thyroid. Thyroid hormones are not only used to support immune cells basic metabolic rate, but they also exhibit influences on cellular messenger systems that promote modulation of T and B-cell activity, cellular apoptosis, cytokine release and other immunokine responses. Therefore, thyroid hormones are classified as immune system modulators and thyroid function should be considered in cases of immune dysregulation or immune challenges. Additionally, immune signaling mediators such as cytokines and adjuvants have been found to disrupt all aspects of the HPT (hypothalamic-pituitary-thyroid) axis, peripheral metabolism, and thyroid receptor site transcriptional expressions. Immune disorders have great potential to disrupt thyroid physiology and promote concomitant dysfunction in cellular metabolism. Cytokines and the HPT Axis Any type of AI disease causes increased cytokine activity. In any type of autoimmunity, there is dominance in either the TH1 or TH2 cytokine system. But the fact is that there is increased cytokine activity on either side. These cytokine are messenger proteins that have signaling effects. In either the TH1 or TH2 types of dominance, there is increased cytokine load which make the thyroid receptor sites less efficient. Any type of increased cytokine activity causes decreased receptor site response. This can result from any type of cytokine shift, including chronic infection. Anyone with chronic inflammation will have elevated cytokines. Any type of chronic inflammation will suppress the HPT axis. Cytokines have been shown to downregulate the HPT axis by suppressing TSH output. If cytokines are suppressing TSH output, TSH and T4 will be low. When you see this pattern, you need to rule out systemic inflammation or autoimmunity. Autoimmune reactions will cause suppression of TSH and T4. Cytokines and Peripheral Thyroid Hormone Conversion Cytokines also have the potential to disrupt peripheral conversion of inactive T4 into active T3 hormone. Both TH1 and TH2 cytokines have demonstrated the ability to downregulate thyroid conversion potentials of T3. Chronic inflammation will cause decreased conversion of T4 to T3. How will this look on a lab test? TSH is normal T4 is normal T3 is low RT3 is high If we see this, we suspect inflammation. Most AI patients have T4 to T3 conversion issues. These patients do better with Armor or bioidentical hormone because all bioidentical hormone contains T3. Any type of chronic inflammatory mechanism will shut down both receptor site responses and cause conversion issues Lipopolysaccarides and Thyroid Metabolism We also know chronic gut issues will impact thyroid conversion. These will cause T4 to T3 conversion issues. Gastrointestinal microorganisms which release compounds such as lipopolysaccharides (LPS) are adjuvants that impact thyroid physiology. LPS released from gram-negative bacteria are considerd endotoxins that may be used as adjuvants in the immune response. Adjuvants are agents that cannot potentiate an immune response alone, but with the orchestration of other cellular agents, can influence physiological responses. LPS has the potential to influence the thyroid at all levels of function, including reducing thyroid hormone levels, diminishing the expression of the thyroid receptor sites, increasing inactive RT3 levels, decreasing TSH and promoting AI thyroid conditions. A study of 24 healthy subjects who underwent IV injection of an LPS endotoxin demonstrated diminished levels of serum T4, serum free T3 and serum TSH and inactive RT3 was elevated when compared with controls. A similar study was conducted with 18 healthy subjects who underwent intravenous injections with an LPS endotoxin from E. coli. The LPS-challenged subjects demonstrated decreased levels of serum T4, serum free T4, T3, TSH, and a rise in inactive RT3. These studies suggest that an immune challenge and abnormal gastrointestinal microorganism environments may promote abnormal central pituitary release of TSH as well as potential peripheral thyroid hormone production. LPS has been shown to contribute to the pathogenesis of non-thyroidal illness (NTI) of the central part of the HPT axis. When the gut or lung epithelium is activated by infection, instead of just releasing cytokines, there is a LPS response which can shut down T4 to T3 conversion. When we see a T4 to T3 conversion issue, we have to consider intestinal and lung epithelial infections or chronic inflammation. We need to do labwork to see what mechanisms are involved. Cytokines and Thyroid Receptor Site Expression Inflammatory cytokines alter thyroid function and thyroid receptor site proteomic responses. This is why many people taking thyroid hormones do not necessarily feel that much better. Proinflammatory cytokines have been associated with non-thyroid illness in view of their capability to decrease D1 and thyroid hormone receptor (TR) beta1 mRNA expression. Active immune-related patterns may hinder thyroid metabolism and a careful evaluation of immune-related disorders must be provided to all individuals who present with thyroid symptomology. An example of this is the AI thyroid patient or a patient with an inflammatory disease who is taking replacement hormones but is still suffering from thyroid symptoms. In these scenarios, the elevations in inflammatory cytokines are depressing thyroid receptor site responsiveness while the hormones create a normal appearance of thyroid markers (TSH, T4, T3). Many AI patients will not notice any difference even when taking thyroid hormone b/c of decreased receptor site sensitivity and decreased conversion of T4 to T3. What would happen to an autoimmune thyroid patient who has cytokine elevations and is given T4 thyroid hormone? They can’t convert T4 into T3 and they have decreased receptor site responsiveness. Many of them feel better with Armor, but some of them don’t because they have lost receptor site sensitivity. The other we see with these patients is the have relapsing autoimmune responses. They flare up for a few days and calm down, flare up again and then calm down. When they flare up, there is destruction of the thyroid releasing more thyroid hormones and if they are taking T3, this is too much and they get nervousness, palpitations and insomnia. Many of them will not be able to tolerate bioidentical thyroid hormone at all because all the bioidenticals contain T3. Summary of Immune Activity on Thyroid Cytokine activity causes suppression of: HPT coordination TRH release T4 conversion into T3 Post-transcriptional receptor site activity Thyroid hormone uptake LPS or adjuvant causes suppression of: HPT coordination TSH production Thyroid hormone secretion Thyroid receptor site expression Active T3 LPS or adjuvant causes promotion of: RT3 production Autoimmune thyroid response Content provided by Datis Kharrazian, D.C., Mastering the Thyroid, Nov. 12, 2010","date_published":"2012-05-25T07:47:41","date_modified":"2020-04-19T22:42:02","authors":[{"name":"Dr. Richard Esquivel","url":"https://sanjosefuncmed.com/about/"}],"tags":["Thyroid & Hormone Health"]},{"id":"https://sanjosefuncmed.com/thyroid-immune-crosstalk-part-2/","url":"https://sanjosefuncmed.com/thyroid-immune-crosstalk-part-2/","title":"Thyroid-Immune Crosstalk—Part 2: Thyroid Influence on Immunology","summary":"Thyroid Influence on Immunology Thyroid hormones play critical roles in the differentiation, growth, and metabolism of immune system regulation. Every single ","content_text":"Thyroid Influence on Immunology Thyroid hormones play critical roles in the differentiation, growth, and metabolism of immune system regulation. Every single immune cell has receptor sites for thyroid hormone, including immune cells. If a person is in a thyroid-deficient state, there has to be an effect on their immune response because thyroid hormones help influence their activity. Immune cells require thyroid hormone for proper maturation and immune regulation and regulation of T and B cells. Inflammatory Modulation and Thyroid Hormones How can people modulate autoimmune dysregulation if they are thyroid deficient? Also, you cannot dampen autoimmunity if they are thyroid deficient. One study found that thyroxine has the potential to dampen inflammatory cytokines such as IFN-gamma, IL-4, IL-10. Increased cytokine activity means more inflammation, pain and destruction of tissue. What is causing the receptor sites to not respond? Cytokine load (the amount of cytokines and cytokine activity). What does thyroid hormone essentially do? Dampen cytokine activity. It is very difficult to manage autoimmunity in a thyroid hormone deficiency state. We know that thyroid hormones have the ability to dampen cytokine load which has an impact on conversion of T4 to T3 and responsiveness of the receptor site. We also know that inability to dampen inflammatory cytokine response leads to systemic inflammation. So you can see a vicious cycle going on. The autoimmunity increases cytokine load and t he cytokine load has impacts on thyroid metabolism: It can suppress TSH It can cause decreased conversion It can make the receptor sites less responsive When people become thyroid deficient, they can’t modulate autoimmunity as well and they have less potential to dampen their cytokine activity, meaning more inflammation. Thyroid and Intestinal Inflammation We also know that thyroid hormones have major impacts on intestinal inflammation. Thyroid hormones have powerful influences on the integrity of gastrointestinal mucosa tight junctions in both the stomach and small intestine. Lack of thyroid hormone stimulation to gastric and intestinal cells leads to ulcerations and intestinal permeability known as “leaky gut syndrome”. When people are thyroid deficient, they are more prone to intestinal inflammation and intestinal permeability (leaky gut). Both thyroxine (T4) and triiodothyronine (T3) have been shown to protect the intestinal mucosal lining from stress-induced ulcer formation. Additionally, endoscopic examination of gastric ulcers found low T3, low T4 and abnormal levels of RT3 on gastric ulcerative tissues. Long-term hypothyroid states lead to leaky guts We know that people who are hypothyroid for a long period of time develop leaky guts. They then develop more food allergies and chemical sensitivities and more autoimmunity. One of the things you need to consider is that these people have gut permeability issues. Even if they are taking thyroid hormone, they cannot get thyroid effects on their gut epithelium to calm down the inflammation if they have thyroid resistance. The fact that they have thyroid resistance prevents them from getting the inflammatory-calming effects of thyroid hormone. So what do they end up with? Leaky guts. Most hypothyrioid patients are gluten sensitive Even if they are on thyroid hormone, if they have inflammation and increased cytokine load, this cytokine load will prevent thyroid hormone from having an effect on the receptor sites. The overlapping thing with these Hashimoto’s patients is almost all of them have gluten sensitivity. Some of them have full-blown Celiac’s disease. Hypothyroid patients have: gluten sensitivity that destroys their gut intestinal cells that are not responding to thyroid hormone cytokine surges So they end up with leaky guts Hypothyroid patients have leaky gut susceptibilities for the rest of their life Intestinal permeability is part of their condition and the will have this susceptibility for the rest of their life. Based on the physiology of their condition, they will always be susceptible to a leaky gut. There will be times when they get stressed out and get worse, when they eat certain food for example. They have to know how to deal with it and they have to have a strategy to work through this during this period of time. Our goal with hypothyroid patients is to empower them to understand their condition and how to better cope with it. There will be times when their gut permeability improves and they are less symptomatic and there will be times when it gets worse. They have to understand that they are prone to developing leaky gut for the rest of their life. TH1/TH2 Dysregulation and Hypothyroidism When patients are thyroid deficient, they are at increased risk of TH1/TH2 dysregulation. Thyroid hormones modulate CD4 and CD8 activity and TH1 and TH2 responses. These expressions influence the potential to regulate abnormal autoimmune expression. Most hypothyroid patients are autoimmune and most have: Decreased thyroid hormone production which leads to: Immune dysregulation Increased inflammatory cytokines Leaky gut syndrome When these hypothyroid patients are managed by practitioners from a single nutrient or drug model, they don’t get very far with them. They need to have a person that understands the complexity of the condition and manage them for it and teach them what it is and empower them so they can manage it themselves. Unique characteristics of hypothyroid patients There are a couple things that are very unique about these hypothyroid patients: They shift into a TH1 or TH2 polarity and this will never change There are certain supplements that can flare them up, depending on their dominant side, or you can calm down their autoimmunity by giving them supplements from their non-dominant side We can expect that these people will have limited response to thyroid hormone but they still need it since if they don’t have the thyroid hormones, they can’t dampen the autoimmunity We can expect them to do better with a T3 source of thyroid hormone because they often have conversion problems but on the other hand, when they have flare-ups and unremitting attacks, they have excess T3 in their system, so they cannot tolerate anymore T3. The hypothyroid-gluten sensitivity connection The genotype for Hashimoto’s and the genotype for gluten sensitivity are the same. You can expect almost all these people to have both. They will have gluten sensitivity, intestinal permeability and cytokine surge issues. You will have the most clinical effect if you can: Dampen TH1/TH2 responses Get them off gluten Improve intestinal permeability Decrease cytokine load Summary of Thyroid Influence on Immunology Thyroid hormones: produce a protective influence on the intestinal lining increase the proliferation of intestinal intraepithelial lymphocytes to improve the intestinal barrier system modulate the expression of intestinal inflammation increase intestinal catecholamines and enhance intestinal blood flow enhance T-helper stimulation of nitric oxide synthase modulate immune cell cytokine release modulate lymphocyte subpopulation in mediating inflammation modulate dampening of excess inflammatory cytokine responses in inflammatory states modulate immune cell homeostasis apoptosis Article by Datis Kharrazzian, D.C., Mastering the Thyroid, Nov. 12, 2010","date_published":"2012-05-29T06:08:53","date_modified":"2020-04-19T22:42:28","authors":[{"name":"Dr. Richard Esquivel","url":"https://sanjosefuncmed.com/about/"}],"tags":["Thyroid & Hormone Health"]},{"id":"https://sanjosefuncmed.com/we-offer-research-based-therapeutic-lifestyle-change-tlc-and-detox-programs/","url":"https://sanjosefuncmed.com/we-offer-research-based-therapeutic-lifestyle-change-tlc-and-detox-programs/","title":"We offer research-based therapeutic lifestyle change (TLC) and detox programs","summary":"FirstLine Therapy® is a comprehensive therapeutic lifestyle change (TLC) program that takes a multidisciplinary approach to weight gain and metabolic abnormal","content_text":"FirstLine Therapy® is a comprehensive therapeutic lifestyle change (TLC) program that takes a multidisciplinary approach to weight gain and metabolic abnormalities, including elevated blood sugar (pre-diabetes and diabetes) and lipid (cholesterol and triglyceride) abnormalities. TLC is recommended by leading health organizations such as the National Institute Health, the American Heart Association and American Diabetes Association as an initial health intervention before resorting to the use of pharmaceutical intervention. See the “FirstLine Therapy” tab for more detailed information on this unique program! Our detoxification programs are safe, effective and science-based. They are based on years of research at the Metagenics Functional Medicine Research Center in Gig Harbor, Washington. They are being used by thousands of doctors all over the country to support the detoxification pathways of the liver by providing nutrient-focused medical foods which have been shown in the literature to support these pathways. Contact our office to find out if this is an appropriate program for you!","date_published":"2012-05-15T19:24:15","date_modified":"2017-04-25T23:35:53","authors":[{"name":"Dr. Richard Esquivel","url":"https://sanjosefuncmed.com/about/"}],"tags":["Environmental Health"]},{"id":"https://sanjosefuncmed.com/why-choose-our-detox-program/","url":"https://sanjosefuncmed.com/why-choose-our-detox-program/","title":"Why Choose our Detox Program?","summary":"It is science-based. It supports BOTH Phase I and Phase II activities by providing key ingredients such as L-glutathione, N-acetylcysteine, taurine, sodium su","content_text":"It is science-based. It supports BOTH Phase I and Phase II activities by providing key ingredients such as L-glutathione, N-acetylcysteine, taurine, sodium sulfate, and catechins from green tea. If needed, alkalizing factors such as potassium citrate can be included to enhance toxin excretion. It provides rice protein, a low-allergy-potential source of protein. It is clinically tested. It has a proven track record with over 15 years of clinical use worldwide. It is backed by published research that shows it helps relieve symptoms and conditions associated with toxicity. This research is available upon request.","date_published":"2012-05-15T19:23:43","date_modified":"2017-04-25T23:35:53","authors":[{"name":"Dr. Richard Esquivel","url":"https://sanjosefuncmed.com/about/"}],"tags":["Environmental Health"]},{"id":"https://sanjosefuncmed.com/world-health-organization-diseases-disorders-treated-acupuncture/","url":"https://sanjosefuncmed.com/world-health-organization-diseases-disorders-treated-acupuncture/","title":"Diseases and Disorders that can be treated with Acupuncture","summary":"Diseases and disorders that can be treated with acupuncture The diseases or disorders for which acupuncture therapy has been tested in controlled clinical tri","content_text":"Diseases and disorders that can be treated with acupuncture The diseases or disorders for which acupuncture therapy has been tested in controlled clinical trials reported in the recent literature can be classified into four categories as shown below. 1. Diseases, symptoms or conditions for which acupuncture has been proved-through controlled trials-to be an effective treatment: Adverse reactions to radiotherapy and/or chemotherapy Allergic rhinitis (including hay fever) Biliary colic Depression (including depressive neurosis and depression following stroke) Dysentery, acute bacillary Dysmenorrhoea, primary Epigastralgia, acute (in peptic ulcer, acute and chronic gastritis, and gastrospasm) Facial pain (including craniomandibular disorders) Headache Hypertension, essential Hypotension, primary Induction of labour Knee pain Leukopenia Low back pain Malposition of fetus, correction of Morning sickness Nausea and vomiting Neck pain Pain in dentistry (including dental pain and temporomandibular dysfunction) Periarthritis of shoulder Postoperative pain Renal colic Rheumatoid arthritis Sciatica Sprain Stroke Tennis elbow 2. Diseases, symptoms or conditions for which the therapeutic effect of acupuncture has been shown but for which further proof is needed: Abdominal pain (in acute gastroenteritis or due to gastrointestinal spasm) Acne vulgaris Alcohol dependence and detoxification Bell’s palsy Bronchial asthma Cancer pain Cardiac neurosis Cholecystitis, chronic, with acute exacerbation Cholelithiasis Competition stress syndrome Craniocerebral injury, closed Diabetes mellitus, non-insulin-dependent Earache Epidemic haemorrhagic fever Epistaxis, simple (without generalized or local disease) Eye pain due to subconjunctival injection Female infertility Facial spasm Female urethral syndrome Fibromyalgia and fasciitis Gastrokinetic disturbance Gouty arthritis Hepatitis B virus carrier status Herpes zoster (human (alpha) herpesvirus 3) Hyperlipaemia Hypo-ovarianism Insomnia Labour pain Lactation, deficiency Male sexual dysfunction, non-organic Ménière disease Neuralgia, post-herpetic Neurodermatitis Obesity Opium, cocaine and heroin dependence Osteoarthritis Pain due to endoscopic examination Pain in thromboangiitis obliterans Polycystic ovary syndrome (Stein-Leventhal syndrome) Postextubation in children Postoperative convalescence Premenstrual syndrome Prostatitis, chronic Pruritus Radicular and pseudoradicular pain syndrome Raynaud syndrome, primary Recurrent lower urinary-tract infection Reflex sympathetic dystrophy Retention of urine, traumatic Schizophrenia Sialism, drug-induced Sjögren syndrome Sore throat (including tonsillitis) Spine pain, acute Stiff neck Temporomandibular joint dysfunction Tietze syndrome Tobacco dependence Tourette syndrome Ulcerative colitis, chronic Urolithiasis Vascular dementia Whooping cough (pertussis) 3. Diseases, symptoms or conditions for which there are only individual controlled trials reporting some therapeutic effects, but for which acupuncture is worth trying because treatment by conventional and other therapies is difficult: Chloasma Choroidopathy, central serous Colour blindness Deafness Hypophrenia Irritable colon syndrome Neuropathic bladder in spinal cord injury Pulmonary heart disease, chronic Small airway obstruction 4. Diseases, symptoms or conditions for which acupuncture may be tried provided the practitioner has special modern medical knowledge and adequate monitoring equipment: Breathlessness in chronic obstructive pulmonary disease Coma Convulsions in infants Coronary heart disease (angina pectoris) Diarrhoea in infants and young children Encephalitis, viral, in children, late stage Paralysis, progressive bulbar and pseudobulbar References: World Health Organization Recommendations on Acupuncture","date_published":"2012-06-16T06:48:48","date_modified":"2020-04-19T22:47:57","authors":[{"name":"Dr. Richard Esquivel","url":"https://sanjosefuncmed.com/about/"}],"tags":["Acupuncture"]}]}